<SEC-DOCUMENT>0000950170-24-055727.txt : 20240508
<SEC-HEADER>0000950170-24-055727.hdr.sgml : 20240508
<ACCEPTANCE-DATETIME>20240508162134
ACCESSION NUMBER:		0000950170-24-055727
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240508
DATE AS OF CHANGE:		20240508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sana Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001770121
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39941
		FILM NUMBER:		24926525

	BUSINESS ADDRESS:	
		STREET 1:		188 EAST BLAINE STREET, SUITE 400
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		(206) 701-7914

	MAIL ADDRESS:	
		STREET 1:		188 EAST BLAINE STREET, SUITE 400
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sana-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-07T13:52:20.7415+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:sana="http://sana.com/20240331" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_03b3791a-af07-4998-800e-8084e61f8a12" name="dei:DocumentFiscalPeriodFocus" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d">Q1</ix:nonNumeric><ix:nonNumeric id="F_06f5dfe0-bd7e-472d-b74d-02623451c999" name="dei:AmendmentFlag" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d">false</ix:nonNumeric><ix:nonNumeric id="F_e07fcceb-2d04-43f0-bf54-bc5fa7bd2e81" name="dei:CurrentFiscalYearEndDate" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d">--12-31</ix:nonNumeric><ix:nonNumeric id="F_dd90f8af-8f09-48bf-8318-19f8252188a3" name="dei:EntityCentralIndexKey" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d">0001770121</ix:nonNumeric><ix:nonFraction id="F_89418f0f-6984-4348-b8ec-9c99d5c63b1a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_0d6428fa-d4da-42b6-8df5-341dae7d687e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_c6d507a7-6a7d-44db-b8c6-e6984e181cbc" name="us-gaap:PreferredStockValue" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_76611905-94cf-4a23-a199-66b620c77ee6" name="us-gaap:PreferredStockValue" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sana-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="C_86a65137-2789-4d83-b804-3ef4fd1ebe47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b656889-79bb-4672-bcb3-fd154c164adf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f674985-b139-480d-b274-2a0503c4dce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfb83220-389a-46ef-9749-8c6f3606deb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e77f8e79-8380-4173-9ea0-6fd155040616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_beb5b16b-6471-404e-aa6d-b2a7573c831a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_584f9a41-0e9d-44db-a47d-1be5d9acba98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81ea7889-0580-4531-870a-0c65974ac802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29744a16-e164-4459-bf1b-bc4cbfe6916d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sana:InProcessResearchAndDevelopmentIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18f3293e-df26-43da-a598-50ac321fdc65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6027cc1-7afb-4fa9-88e4-4c01cce1cb2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8a9dedd-06c5-4477-a6bb-e88883200c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42aa39ff-3900-4c5e-985b-ace73bd8d9af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cf9a87b-eed3-43a3-93f1-c8d0035536c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_784cd865-32af-4b9e-9a2d-1283b79c0fb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0650284f-37cc-47aa-8b3e-b08472cfc282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68a01da0-f0b5-45cd-b4fe-aae17edbf123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cca9dd29-2dba-4680-84e1-d43e2ddb90e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">sana:Rule10B51TradingPlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2d83e1b-1262-4dec-b6d4-df0a5108f32b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa78a347-b2c3-4998-92a1-ff2191d35b80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f9d4e78-b28f-45b8-a7ec-c2b98459dfc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c74da5e-db6b-4240-81f6-b1cc19323032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cd2c1c8-63b2-4e43-b354-bbe68ce2f425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7d54ad9-1d5e-4031-8013-d956752e48dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1fcce66-212c-4a70-9718-133d1c668a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55131829-499c-4826-bd23-4f67ee1ace9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50195858-336e-4ba8-93a6-442d74800d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d058c627-dfd8-4eb4-89d4-e773af8d23b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5f766dc-31ca-402b-9dbd-c586a549b71f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4600a476-bff3-4417-9572-0fce0dfac06c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfb14b1e-3ce3-4211-b44b-454387680bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8e330e6-05d0-41c5-9f40-ed43cee976e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad091749-d991-4041-9e16-79d0ac453e20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00b71411-02d1-4dbc-842b-d19a3cff2367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6091c139-f87a-4c94-9bf8-6b84025b7ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86dab90d-c97a-4375-b478-9bef336bc6ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6ce25b6-c626-470d-b450-ff463c8d2c46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_729027ec-b0b4-4b18-87f2-8db8ae9bdd77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d90fc972-dfb8-47f8-aecb-c44ba7bfe28d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94f4df8f-7b42-4c68-be26-534736b5d5f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sana:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdc2c79f-6027-47c6-b3d8-4dec37b42493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cc9980e-3cae-4e1d-8847-36113c44cfb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95b79823-dbbd-4370-9127-b27adbac303b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65f65e05-e779-44e5-ae6f-7877d20cf158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c347a70d-0102-4f86-9df2-224e9dde7027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dafa944e-950c-499e-8b37-2dbf29453f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fe7817f-a59d-4ee9-8d11-4a174e824ba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06a0dace-22c9-49b4-b126-d21eae97f669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_823c66ba-b506-4ca6-9d31-5351ec2592d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a55ce09-f176-4fab-a2e9-e04a6400a283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be1d75be-894d-4c8e-a248-7743778c933d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63e6b918-5acf-48a9-b764-d3dbe3d981fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cce18b1-5b05-469a-898d-954d3e894e00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49111c32-8c42-46ee-b4fc-28fe251ba44f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3855180a-7d90-426b-9874-03499729f15a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e115f01-d2f7-4c57-aad5-86133c460620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbf6b029-0470-4e87-9590-c00f1975ad8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70fd08ab-41b6-404e-b0b7-355ae3c53fbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60a4c997-ab06-4f9e-8db8-c507524ec994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18571269-31c5-4f70-a45a-3ef776d6eb61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:UnderwritersOptionToPurchaseAdditionalSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b0a8034-8cf2-4c3d-a6c4-dc826a8a63fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6da32b5-4e8e-4f22-b11e-b496dd2352a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_223e6244-4447-479e-a802-dff78ea29aef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b455bc1-d635-49ad-bf86-120e8cdbf8b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546c0313-0f3f-4820-bf29-21b1e0968e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91e4e70f-95ff-409e-9dca-3d8f020d91b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a8fc778-052c-4707-bdea-05eb75e7228d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbe6df99-60ae-4f68-a843-401a8a497361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_995d9eee-7d60-4997-aedf-118f7f6b649d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_147c1909-b56c-4e45-bb6a-2f58c5972a51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e852dc08-0bf7-4b90-9f2e-d291734160a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e95d768c-3dca-4fa7-ad61-ee5856361683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ca9ade4-b42f-4a4e-999d-db79e5fb7206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3ae50f3-372a-4d53-b386-1eaa80038130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bd66b24-e325-40b8-abb1-65a998714668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a57b1903-cab8-45b9-8d74-c152b19c7eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06e3eb5f-e863-49fa-8563-0e30982ae5cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c57b0ce6-633b-46bf-af84-70d41e43de5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16202469-4333-43bd-8ab0-185f07269735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b81110b3-94ea-476b-8d47-6401255ca2bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7135efce-efcb-4461-a247-176eda4a968d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34f78daa-46b2-4c59-83f1-782cdc0c0849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a337850-011f-419d-9b96-9745a28abc2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55b234fc-e689-4f6e-ade4-f2280aca3981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ab6eba0-d3c4-442f-bc85-efd0ea497f3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7611f40-5b1f-46ae-8564-b1292748318e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bf2bbd7-4ee7-4371-8586-07b289dc7983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04c586a3-4616-447f-9140-209061d79050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50ec5c72-5617-4171-8d33-f4ac6315d6f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:RochesterNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7474455a-fc6d-4cd3-90d2-70280da1b89f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d60103d-6496-453b-beb9-76e3514ed534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1033bd7-dfcc-4e46-b61c-7521a50f2305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06a89b0d-46d1-4a51-939b-a06edc10c59b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b65933e-d17e-4f72-8dde-db3186b43c92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ef92338-838e-468e-a513-56d2d714ed59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80adbfa4-77b0-4c43-8085-8ee94b655983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb5073c6-93d6-4f52-8309-895c393ef41f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5baaaa87-fae6-4ea1-8c7f-c6624c122de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a197803e-4cdd-43c1-9127-6f070156a3c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a379388d-c2de-4807-a894-cff2e4a56b6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12ff06ef-947f-4808-a33d-0ff97573bdf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f3c4803-a059-4ebb-ae2b-4ac87f86d07d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc66556d-71cc-4a9b-ab52-0e7d6815bf7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd00d5a3-324d-497b-a8e2-82db2e6edc2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f29e181-ea6c-400a-8ba7-6bea7dba7a7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50f28a60-d008-4a0e-9e96-e1ccac671344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43cb099f-cefc-4cc9-beab-28440d03eebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5046514-fcb5-4d24-b1c8-fa4729ff4c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sana:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e125326-33fa-46ec-a521-b916a2ec4dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_643555c3-2807-4634-8e1c-203532b68dd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_928be825-e134-4309-ace3-ac7914760235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e731ce1-98f4-4819-a7ad-0f95050b9b55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b0fcd89-81c1-4b90-a9c4-cb1922157bbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e48bacc4-19a5-4b6d-bd4a-f5ea9f59378a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">sana:Rule10B51TradingPlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b931ac74-0689-4fcf-9fd6-7716f8afe0a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b2f8dd4-c615-4c6b-b326-f49621a6eb03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70cd5777-3e29-4131-aad9-ba09ce7c693d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_641277e3-749d-4eb9-a24e-d5fc027e6183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7de50755-31cf-4120-a7ad-64811d98119c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a9d7d6d-eeb7-46e6-b7d4-e0b5c139fee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a51b0686-423c-43e8-94c5-8d8eb699f340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fdca39a-64d6-45fd-a2b0-60576cb81cf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4ec08c5-443c-43d4-9292-a4247d9af712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ccf1cdd-58e0-4408-a0fa-022aac193bde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b964641-c572-4eb4-ad43-aaa271ec731c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeLaboratoryAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfd47a7d-8c14-4eb8-8032-56ab21cc27b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ef25fb2-65c6-460a-a441-dd847f65b914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_586b0056-75c6-4ab5-8d42-c2f9ab46e617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c12ea39b-aeb0-4f12-b248-2e617e0f6530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a16970d7-1af4-4067-88b3-324a3854a541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1df77845-a1de-4f4e-81f7-0609b3956c1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e53ea5e6-c436-4396-b07d-aa29105b61ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25947cd9-a663-4cab-b957-bc7138703866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88402e74-7150-43da-a733-2aff3a7e03cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12fdc9e8-0ca8-4874-b926-71ede412b36f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4650afc1-9af0-49d7-a045-02b7cc48e08a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a1f55ec-17f1-42c1-b4cf-309cd1fd5eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0806d70-bf3c-4907-8e95-1d6b45653b32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25788be5-71c6-4519-9446-0a103addacb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17283059-11e9-44c9-8c95-9b47afc70185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ec8e97a-eeb9-43b9-a3d4-79634fa4152c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb2f913c-2539-43df-900b-bd15d965ab34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fec33127-b46e-468d-bbde-9835085b612c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70a725dd-e57a-4033-8f99-adf5043341f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae90f9dc-f66e-4ca7-9990-7e8b027d5fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65e2a512-f26e-46ac-8ba3-43bba960b76f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6118355a-f762-4887-9f8b-16f2afbc5567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94d2ec2c-37d2-474c-abc6-bc8a607c98a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bad0c086-6e01-4d43-9445-ceaacc421516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d2713f5-18c1-46f4-a590-7d2440ecea25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c1f3354-a6f1-4f78-9017-287f0a19140e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ede2c8d-756e-40dc-8c8a-ee6a66e7752d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_53a20183-aca1-42fc-96ad-318f0bd6815c" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_323d185e-d271-4dc5-8663-9340bef4638d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa7333e1-1be7-4c77-9841-cd36b0d7d1ec" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b38b945b-7d1f-413d-87af-402c1f5e8491" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from            to</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4a8171d-0e81-43cd-8bd9-d9d44c3be49e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39941</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca645344-af45-4842-93a0-1d7937bacdf9" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fb1820b6-55a7-4b87-aa4c-26bcaeb004d3" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_de92aece-ba39-4d0b-88e9-af8d8b5c509d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">83-1381173</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:16.55pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_37bd5347-37ec-4303-ab8e-e709ba817645" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">188 East Blaine Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d1861d24-9553-44a4-9525-be4bad843074" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_15bfb468-fb94-4910-b80c-41bbb49f1077" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Seattle</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_1ab40ed1-4daa-431c-b73f-3cfa38155d13" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c0518b9b-f777-473e-b351-5b168704c49e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98102</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec43f76d-50e4-46b8-9d98-64df478257b9" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">206</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4634815b-ff16-46c7-be9f-919e9581ff9a" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">701-7914</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7786d7ac-5ac9-47b1-8154-d4dcf0235b7b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bc3706f1-5edc-49ca-9c4d-079ed9b24de8" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SANA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7e807241-31a0-459e-9e91-c76283cc2353" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65110dfa-4c37-42bf-9f98-281ce9643de6" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2620dae0-ee24-408c-ba89-22aef5ab3d1f" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.08%;"/>
    <td style="width:1%;"/>
    <td style="width:2.12%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e7845687-e7e5-477f-9cb5-a71ee1ea780b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8ce8518a-89c5-41fd-922d-d11fe5c704af" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a596f406-937d-46ba-80ee-abbcfc6e4165" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1f9a07dc-a942-417a-8799-54aa8728cf7e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7755ccde-eea3-4447-bfe7-52aceb405538" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of May 3, 2024, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85e2e2fb-b472-47c8-8c5e-96e65682e8b9" contextRef="C_91e4e70f-95ff-409e-9dca-3d8f020d91b0" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">221,502,908</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:82.9%;"/>
    <td style="width:8.1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_financial_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Operations</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_compre"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statement_stockho"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_or_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report could be deemed forward-looking statements, including those statements highlighted below. In some cases, you can identify these statements by forward-looking words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; or &#8220;will,&#8221; the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our clinical and regulatory development plans; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations with regard to our preclinical studies, clinical trials, and research and development programs, including the impact, timing, and availability of data from such studies and trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of commencement of future preclinical studies, clinical trials, and research and development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to acquire, discover, and develop product candidates and timely advance them into and through clinical data readouts and successful completion of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intentions with respect to and our ability to establish collaborations or partnerships; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing, and manufacturing expectations, including with respect to the buildout of our manufacturing facility and capabilities and the timing thereof; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact of future regulatory, judicial, and legislative changes or developments in the United States and foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intentions with respect to the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential effects of public health crises on our preclinical and clinical programs and business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the impact of global events and macroeconomic conditions on our business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our business model and strategic plans for our business and product candidates, including additional indications that we may pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth, including our ability to retain and recruit personnel and maintain our culture; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, needs for additional financing, and ability to obtain additional capital; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expected use of proceeds from our initial public offering and our existing cash, cash equivalents, and marketable securities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the performance of our third-party suppliers and manufacturers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our future financial performance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the duration for which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (JOBS Act); and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments and projections relating to our competitors and our industry, including competing products. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events, our business, the industry in which we operate, and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur in a timely manner or at all. You should refer to the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Other sections of this Quarterly Report may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you should not unduly rely upon these statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_i_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I. FINANCI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AL INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolida</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ted Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.193%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:14.223%;"/>
    <td style="width:1%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:14.223%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53c17e3e-475a-469d-b972-6afcfaa93949" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,054</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b5abbaf-1d9d-4315-bb97-5e5a2d1cb6b7" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c8c09c8-c191-4f82-a637-ac8e3775f819" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eb53fe4-924f-4a21-a76b-079b7d7ef0fc" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,678</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b78548a1-9f81-4a63-9181-7ec0a8fee7f8" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc6ea81-a7c1-4686-8d6b-5433925999b3" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad8af7ab-564d-4d52-842b-d837124dac8c" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca36da6-4fce-4ab8-b64c-c919d5db3dd9" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,488</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f7d16da-3e9c-44a1-a3c7-2f0415177cea" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae69d7a8-e86f-43ce-9750-3c02685fb23c" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,515</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b301c4e-1abd-4a9b-a435-b3f46162a12b" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,649</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_584c370c-8184-4e92-9df7-8a4d421a6d5a" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,689</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a89ccc9-f7ed-49cd-9dad-642c4ec65974" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,565</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f34448d-1dc6-4fd3-8a0d-c9f7693b52b2" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_754c02ef-b905-4dec-8f44-75c7c034ccf1" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d80183a-72d1-4d61-885a-d8f8c0dd64a6" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e341bd40-5808-4e58-9151-4939295e8a55" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ecbf232-29b1-4e98-8b73-8ce672bd989e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17e1f16d-e9d9-409d-8178-47a1b859baaa" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6f362f-03a8-4a5a-837a-2bc283c28a6b" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TOTAL ASSETS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0a2bb30-5d36-43e3-a7ab-ef0c1776c57e" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">681,377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b255846-20fe-4bd3-85e8-7fc1c3444c0d" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cab6506-adf6-4ecc-b9aa-4c1c30c59b6b" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5776d78f-b9d1-46b4-ab0e-b0a28821f6f1" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d879e358-6081-472a-a72e-fdfe8d2a194a" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_114ae177-b2cb-45e7-ab8e-4d6346206571" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f086dc00-2346-4e2f-bdae-3cec7b3a6389" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3932d3ad-b554-4f99-909c-98b5f8f7069e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11bebba3-c5aa-424b-9195-585a6c6510b4" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_044825fb-e278-4e05-a975-40b0bba297ac" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5be915f3-8249-4646-b59f-86a2b692a7ae" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27722f3e-6325-47d1-912e-31675d137bdb" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,487</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77441a53-4d61-4639-aab0-4555192605ed" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d3278d0-d2aa-4e06-938f-646df1793c3d" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87c608d-c0a2-43fc-a432-aeda4b47102f" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a621436b-4744-470a-8fd2-3e54dc360d2d" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4baff81-0d84-4912-b151-d7798ba015a1" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:SuccessPaymentLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78978f6d-f6fb-4c6a-97df-3033a27227c5" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="sana:SuccessPaymentLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c4f4bf-dfb2-47c6-97be-69d561401015" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,235</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96284bf2-b58c-4957-9386-6bf1671478ea" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,793</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_89418f0f-6984-4348-b8ec-9c99d5c63b1a;"><span style="-sec-ix-hidden:F_0d6428fa-d4da-42b6-8df5-341dae7d687e;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50c7c6c2-3287-4368-b4b4-81687e83610d" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_893f503b-b705-4d44-b399-2ef95bb168b7" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71344d8-a889-418c-9389-7f9903c56947" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc6d6d16-5e39-4f58-9c57-c110a1ad9cf5" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">50,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1deb4767-931e-4a36-978b-3a82f0c9feb6" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d7027eab-50ef-4af6-b935-0ef636ececa5" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_082f62d3-5782-4cc9-9924-ec025842dc3f" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_decd702e-76fd-4937-97a8-8e61b11a07c7" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2024 and December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_c6d507a7-6a7d-44db-b8c6-e6984e181cbc;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_76611905-94cf-4a23-a199-66b620c77ee6;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_928c76cb-fa0b-4001-859f-c5bd78a3aba2" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_03d2e8cd-fce9-4726-865b-25a7093cf3d9" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_082662f6-c08b-45e8-a599-7fe80b52a771" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4d6a6f44-fc6c-4ff9-8edc-edbaae84b5c1" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">750,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_515cd990-c564-44d2-a7c8-6c207fea5f09" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ebf95dba-b7a5-44ce-864b-a5504979bf2e" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,286</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47a650a2-874b-4aec-810f-7710554cfbe9" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_056948e1-4cad-4616-a5f7-10f4f2094db0" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,857</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d42ee6f-6136-44a5-b3fc-7ba411272f13" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_944217ce-a4f3-4a1f-83c5-d6dd0708475e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb05ad87-ff5e-4193-92e4-340ff894fff9" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,820,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05b420e9-d81b-407a-ba7e-f36ea2fa0a0a" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,625,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbea4d00-18f5-4e0c-8ad0-346c2ba8c2a8" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86152fa0-6ebf-4986-85d6-b5a7f74bb764" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b1cb26-7f44-478a-9859-f9aa4bc13e42" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,445,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bf1a3e7-d7bf-4b09-8535-1c4277748ca3" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,338,091</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_421ab790-3a6e-4530-b85f-487de2e329f0" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3876553a-ce6a-44f3-aa11-5dce4babc29f" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,506</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfef2d73-b435-49ca-9eb2-665b7f6f6447" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">681,377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e17a9de6-e7b8-49e0-9542-2684ece63869" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tatements of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.126%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:11.438%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:11.438%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c57f2af-8fb4-4c40-a3ee-b70f7cd460cc" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_086a84ae-58fc-4c50-ad46-da70d1a71e73" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development related success payments and contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2e53b67-5d52-44e8-bc4f-03865ce2a25c" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e579455d-6e32-47a7-8a0e-f2288e0f5d84" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a70203dd-b82f-44cc-95d6-617e3c31bda7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae8a2fd9-01dd-46fc-85f8-c62826f44a35" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5569b1a-64a3-4b78-8505-f1b5ba40a241" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,724</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be52b09a-f413-4994-8324-430944dc4f8e" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_960d1734-1465-4b37-a3b5-9a3ff0249ddd" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">110,724</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fc08c65-c8c5-45e6-bae9-d78d1126c996" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_717639fb-b43a-4a77-a74a-28de57cbb8d7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd0f8121-6c31-43dc-8894-c65338d319af" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,976</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a5d5bb9-922f-46f2-9044-6616bba7b4a5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad0385ea-58b3-45e5-8ed9-359c9617b25f" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-">47</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e92cf91-1104-469f-baed-3ce20370ecbb" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79e0efef-7080-42fd-8827-c926eb3ec731" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per common share &#8211; basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06a00c5d-1d85-488e-b79c-8295f4a5e5f6" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0c040662-7ef4-4f8b-b137-5ad17d72ea95" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.49</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d627e4b3-1845-47c1-a824-9cc25ba16198" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a6e4c64-a02e-4d09-94c8-46f9e9ec9245" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.43</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares &#8211; basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b1b7768-da41-4817-a57d-6ae380a8ae57" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c9fd1bf8-1120-4488-b819-e2021a4c158e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,290</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd03d08e-7720-4a8c-86da-9bd42af54740" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bef0dab7-4f5b-4459-ab5a-2c6ca754da5d" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,228</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_compre"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ments of Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.96%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:11.200000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:11.200000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79fc240c-9fb3-471b-a488-0495fc2043a8" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a804fa7c-20e6-4e47-b2b2-41dd142b095b" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income, net of tax:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bef461a-f177-43b3-89df-f395ba44fce2" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a71e55c-ba28-485d-85be-025ddb5ba507" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3560b61f-06cc-437c-9fa8-5be45ea0f4cd" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,430</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05313b80-f74c-4170-8f9d-6254638ce8a7" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">79,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statement_stockho"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.5%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.08%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.44%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.44%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.62%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a586d17d-36c3-4347-8c26-832692be3774" contextRef="C_7474455a-fc6d-4cd3-90d2-70280da1b89f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fab2b8fa-a3f5-415a-852f-f68d5ef4513b" contextRef="C_7474455a-fc6d-4cd3-90d2-70280da1b89f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_894ee2ee-396e-427f-9fa1-4e72a981a53b" contextRef="C_2cc9980e-3cae-4e1d-8847-36113c44cfb5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,625,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_799b79e1-bffb-4731-873b-a2655f019e72" contextRef="C_34f78daa-46b2-4c59-83f1-782cdc0c0849" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ae9eaff-c684-4e32-bb88-fad93ffe0b78" contextRef="C_9ef92338-838e-468e-a513-56d2d714ed59" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,338,091</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b013ffd-2225-4c00-a380-6cbe131490ba" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,506</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Issuance of common stock from at the market offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edaf6df8-b7b9-47ee-922c-b98cf511f8e1" contextRef="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9e6fbc3-6742-4e65-854f-1c11346c0586" contextRef="C_6091c139-f87a-4c94-9bf8-6b84025b7ad0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca5fcf7-0f86-47d8-83fa-6c49c4fcb642" contextRef="C_9c74da5e-db6b-4240-81f6-b1cc19323032" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98c5026f-3709-4c09-bf89-397df73cc121" contextRef="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Issuance of common stock from follow-on offering and accompanying pre-funded warrants, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac055fb9-2d28-4054-a137-76e608382c62" contextRef="C_4f29e181-ea6c-400a-8ba7-6bea7dba7a7f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,741</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dd1f496-6527-4a9a-8f90-75b5e9519fc6" contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,773</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a54aff0c-cdd2-4ac3-9125-5e83d1cc3b49" contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df6390b-cfb8-4db1-96a9-882e835aba21" contextRef="C_3855180a-7d90-426b-9874-03499729f15a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2eeab11-9d67-4033-b058-b83469e0382b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,008</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce386e64-982f-4fce-9fd6-2d5542827212" contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca448d7e-d61c-46d5-a3c6-53b5aa263464" contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973e129c-341b-42b6-86e1-2fbbb49d4c73" contextRef="C_3855180a-7d90-426b-9874-03499729f15a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b233d0c1-3b08-4158-ade4-961a761033ee" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37e1f731-3898-4010-81b7-7aca351cb971" contextRef="C_3855180a-7d90-426b-9874-03499729f15a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41c28b30-f544-4f0d-9656-eb473a747263" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable <br/>securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43b9eef7-28cb-419d-8684-a4e2a200e6bb" contextRef="C_50195858-336e-4ba8-93a6-442d74800d39" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c74c197-a61d-4cc8-ab65-348bcb049909" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae59333-aff3-427d-bbd7-9aaab9107ffa" contextRef="C_0b964641-c572-4eb4-ad43-aaa271ec731c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d8f2eb8-3de6-461b-95a9-33177502ff00" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_110faeb5-d8aa-41d9-af21-383aa79ff1a1" contextRef="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2cd3578-40f8-4f14-b5de-90fa980bbff8" contextRef="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f09c9a88-e2ae-43b2-a277-cfeb2310dcba" contextRef="C_9a9d7d6d-eeb7-46e6-b7d4-e0b5c139fee0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,820,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0063670f-1edd-4325-9583-2447802a771a" contextRef="C_d058c627-dfd8-4eb4-89d4-e773af8d23b4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b9a6c3-f285-4a59-8dda-b62f58f40c24" contextRef="C_12ff06ef-947f-4808-a33d-0ff97573bdf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,445,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93aa2dff-fd23-44ba-b58a-d49c190ec8c7" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.5%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.08%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.44%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.44%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.62%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b24f823-fd56-450f-80d2-ecfb04ed3179" contextRef="C_4600a476-bff3-4417-9572-0fce0dfac06c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d7a17e-409d-4f5b-b92b-8b64cf652497" contextRef="C_4600a476-bff3-4417-9572-0fce0dfac06c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c4e875c-ed89-4a56-a703-681557477cf6" contextRef="C_70fd08ab-41b6-404e-b0b7-355ae3c53fbf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,558,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e931f44-5850-4770-a854-61631330a5ca" contextRef="C_e2d83e1b-1262-4dec-b6d4-df0a5108f32b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53f77737-e9ea-4891-984e-75c4acb7c4bf" contextRef="C_50ec5c72-5617-4171-8d33-f4ac6315d6f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,054,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_087b45e6-e680-4cfd-b2e5-9740d4022d9e" contextRef="C_7135efce-efcb-4461-a247-176eda4a968d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fees incurred related to issuance of common stock from at the market offering</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f476bf7b-ff45-41cd-abf8-6ec61eede583" contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2d2f21e-1837-450d-822d-92479f7e6b84" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47fa6da4-7de1-49eb-b12b-81e656acaee3" contextRef="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ca3fe4f-c5fa-4b28-998b-4eafd7033705" contextRef="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fdf0f60-d6a0-423b-81d2-b1bb6a66b129" contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4ad866d-3cfc-4d95-a862-6fe158e68a36" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a620017-59dd-446a-938f-6092777b97bb" contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,751</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc18e823-60df-4ab6-bc47-8fb66aac2a45" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,751</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable <br/>securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1cd6fd9-d684-48e6-9736-0cd16d3a47f4" contextRef="C_eb5073c6-93d6-4f52-8309-895c393ef41f" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c4aa1f5-818d-4a1b-b23c-624d3acc30c0" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29a540d6-2250-4afa-8c54-d4646cc490f1" contextRef="C_0b0fcd89-81c1-4b90-a9c4-cb1922157bbb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a4bf33-c270-4ae7-9fe3-178a91c2172b" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c255f73f-4928-41d2-8deb-3b4b41fcb551" contextRef="C_3b656889-79bb-4672-bcb3-fd154c164adf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,409</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_673b9a12-9f86-418d-b3ae-4e83ec52fa9f" contextRef="C_3b656889-79bb-4672-bcb3-fd154c164adf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51a4fa71-f01f-4407-b3be-41c3c1ef4bad" contextRef="C_a6da32b5-4e8e-4f22-b11e-b496dd2352a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,567,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5dccf6e-91f1-4c6f-9a89-bc17c825fabb" contextRef="C_bc66556d-71cc-4a9b-ab52-0e7d6815bf7c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29d0f388-d236-40ef-bfca-b02b1d1f5871" contextRef="C_68a01da0-f0b5-45cd-b4fe-aae17edbf123" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136,959</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf45b6bd-f3b3-42c6-9846-01a74bedc5b9" contextRef="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tatements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.4%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:11.82%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:11.82%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">OPERATING ACTIVITIES:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca72e03-fccd-497f-93c0-85b1b77dee9b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c487d193-a03e-421b-96e5-973210281719" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and impairment of long-lived assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3338d0d9-58b9-4046-97d0-7858c5810632" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:DepreciationAndImpairmentOfLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_312f29b5-b1f6-4a6c-8a4a-fa250359943e" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="sana:DepreciationAndImpairmentOfLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12c1ab98-788e-4ca8-b76b-123d81deeea5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5353b4f5-afae-482c-a81d-b8b81c17c693" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,751</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the estimated fair value of contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70f11d6b-7b3d-4947-bbab-17a63a270713" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49879107-7928-4c0d-a18f-e0ad21417bb2" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,460</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the estimated fair value of success payment liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07f63c25-0446-4f6d-9ddb-648f1a77c724" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:ChangeInFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cf1268c-0be0-41af-a036-a8d70b938c24" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="sana:ChangeInFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash expense for operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95ce682f-7a36-4efb-9afc-e455fdfe0487" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eb45cab-379a-42ac-9093-037f95f71c66" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-cash items, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_019bfc5f-72d2-4de4-ba30-22a214a69f78" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0efa6e2-2cae-4378-b2eb-6c11d86c3280" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6ebe65d-15e8-466e-9020-c37ee2f0b962" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,380</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f59c29db-c7c6-49d7-8989-5b1fa4e38b3b" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets and liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d75109d-c6c2-4e21-9490-56d89ae98158" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34e28ea3-f446-4a17-b0f2-feb26271d525" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0ad801b-fcc2-411e-b0bc-d8acbf8ac78b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f43f9ce-09e6-4989-a046-8305c41f1d5c" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2c9db16-3c37-40ea-8bb2-c0854dcfc13f" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,821</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7081f2df-1c28-4843-8d78-41c38d441c88" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95007e06-d987-4734-9e83-df6e2fa0c023" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f6143dd-7bb4-49d3-b8fc-c8248e83f3d6" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">79,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INVESTING ACTIVITIES:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b55dad-55d2-4bf6-87d2-b51c4da19967" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,393</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2b0e83-79d3-42cf-aaaa-bb49074f71cd" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f24472c1-70be-4200-b6e8-28a8d23a6af3" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,010</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57e12ef9-7d84-4e63-b5fa-bc3b1bf585f6" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_903585bb-5e72-4750-b6b7-52d14be41089" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,845</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f94ccf5a-0ff7-47c5-90bd-553f6702a22a" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06d32fcd-0b62-4f78-b65b-29b7731e1423" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77,228</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51f8bec1-9264-4707-aa48-bfbf13fdd8b3" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,727</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FINANCING ACTIVITIES:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from employee stock purchase plan and exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60e2b902-e528-4291-aa6f-a4a787465e98" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f1dbce3-2424-41ad-94b6-da56917574f2" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock from equity financings, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48e014cf-d4c7-4b3b-a01c-3d917cb68d8d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c23cf31d-0054-41ad-8b6a-33dd13c72509" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,397</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2541dd2-fc75-4ade-8f13-81b66b0f14b4" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1953d698-7ebc-4a8f-abc8-30e1c3442a33" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,537</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bed8ad88-25c1-428a-be40-bca263f833fb" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,309</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_869eef38-c888-4d0a-b911-d7d6e55dc743" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c028e25c-55af-46ee-93a4-356fdac645b4" contextRef="C_7135efce-efcb-4461-a247-176eda4a968d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,273</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fabf3876-e407-46e0-ad28-592ee44e34e2" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f67effa-584b-4336-aa86-1bbf266826ec" contextRef="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,964</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SUPPLEMENTAL CASH FLOW INFORMATION:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange for lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0090257-9d6d-4d01-bd0d-75362e3c057a" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,984</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f0d4ddb-9080-45b2-8d3e-91ed983100b5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60177e28-8aed-490c-91f5-1b561c7172f7" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash received for tenant improvement allowances</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47e436ac-a208-470d-88ac-df4baa763c71" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:CashReceivedForTenantImprovementAllowances" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Condensed Consoli</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af4b53e3-3a56-46f4-9a8b-6c23113ef649" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc. (the Company or Sana) is a biotechnology company focusing on utilizing engineered cells as medicines. The Company&#8217;s operations to date have included identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, preparing for and executing clinical trials of its product candidates and supporting clinical trials of product candidates developed using its technologies, acquiring technology, organizing and staffing the Company, business planning, establishing and maintaining the Company&#8217;s intellectual property portfolio, raising capital, and providing general and administrative support for these operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks and uncertainties similar to other biotechnology companies in the development stage, including, but not limited to, those related to the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, building out internal and external manufacturing capabilities, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, the need to protect the Company&#8217;s intellectual property and proprietary technologies, and the need to attract and retain key scientific and management personnel. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations with the proceeds from additional equity or debt financings or capital obtained in connection with strategic collaborations or licensing or other arrangements. In the event that additional financing is required, the Company may not be able to raise it on terms acceptable to it or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company completed an underwritten public offering pursuant to which it sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08cf3f95-f30e-4501-9ecf-ebeae320c3f0" contextRef="C_641277e3-749d-4eb9-a24e-d5fc027e6183" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccd05363-ad8e-4a05-9749-2dd63bef6e8e" contextRef="C_18571269-31c5-4f70-a45a-3ef776d6eb61" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23003e58-667c-455f-843e-2c5aa7dfcc8f" contextRef="C_55131829-499c-4826-bd23-4f67ee1ace9e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c76193-6abb-45f4-a1f9-0f19d042e23f" contextRef="C_43cb099f-cefc-4cc9-beab-28440d03eebf" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">180.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), acting as sales agent, pursuant to which it may offer and sell through Cowen up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c0a772-0a61-4035-a43f-4450e906e654" contextRef="C_643555c3-2807-4634-8e1c-203532b68dd5" name="sana:CommonStockMaximumOfferingAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time in a series of one or more at the market equity offerings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(collectively, the ATM facility). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13a9b362-1622-4d30-9a95-8e5859f07c69" contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's common stock under the ATM facility for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f956a0e7-9443-4047-9a15-19ab5fcf731c" contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting commissions and expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses each year since inception and expects such losses to continue for the foreseeable future. As of March 31, 2024, the Company had cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_374bc4d5-6bb5-4380-86b5-df44375ef10a" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:InvestmentsAndCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">311.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd9b3963-439f-4d8b-a34c-30d6710c6070" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="9" decimals="-8" sign="-" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion, which includes cumulative non-cash charges related to the revaluation of the success payment liabilities and contingent consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00761bfe-018b-49b5-84e7-8fa77e2d6722" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:SuccessPaymentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af2b6ee2-5d4a-4c30-a8a4-79a141f23903" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa5c64ef-77eb-41bb-8c3f-2e69c8c88e12" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of significant accounting policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfad2021-4a03-407c-a82f-ce2ff0b61158" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Certain prior period amounts have been reclassified to conform to current period presentation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 29, 2024 (2023 Annual Report).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbf6bf23-277e-4ca8-a4ad-de7ba20a4cf8" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:SignificantAccountingPoliciesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant accounting policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in the preparation of these condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 are consistent with those discussed in Note 2 in the 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20abdb1a-75e6-4909-b748-cefc10ad8d3e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, and operating lease right-of-use assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78db7f19-cecd-4529-8b72-d4c60185b0d5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures that requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU is effective for the Company's fiscal year 2025. Early adoption is permitted. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_855c8e2a-27fc-4fd8-a168-877a38cef2a1" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Acquisitions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cobalt Biomedicine, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a775300-6b77-4728-8fe5-71f501f21618" contextRef="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding equity of Cobalt Biomedicine, Inc. (Cobalt), a privately held early-stage biotechnology company developing a platform technology using its fusogen technology to specifically and consistently deliver various biological payloads to cells (the Cobalt acquisition).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the Cobalt acquisition, the Company recorded an intangible asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7100acfa-0b69-47c7-9440-401f3dc18b6c" contextRef="C_29744a16-e164-4459-bf1b-bc4cbfe6916d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5">59.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which consists of in-process research and development that is classified as indefinite-lived until the successful completion of the associated research and development technology, at which point it becomes a finite-lived asset and will be amortized over its estimated useful life. If the research and development technology is abandoned, an impairment charge will be recorded. The Company is actively developing the fusogen technology and, accordingly, the intangible asset is not complete. Amortization will begin when regulatory approval of a product candidate developed using the fusogen technology is obtained in a major market, typically either the United States or the European Union.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_159810e0-be69-4f5e-9eca-957e61087ea1" contextRef="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5">140.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of goodwill as a result of the Cobalt acquisition, which is primarily attributable to the value the acquisition provides the Company by complementing the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> portfolio with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fusogen cell engineering technology and furthering the Company&#8217;s research in using engineered cells as medicines. The goodwill is not deductible for income tax purposes. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33110ebc-84ef-4156-af47-bee7d34f8ef3" contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments of the intangible asset or goodwill since the acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms and conditions in the Cobalt acquisition agreement, the Company has an obligation to pay to certain former Cobalt stockholders contingent consideration (Cobalt Contingent Consideration) of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a523ca-af06-458b-bff0-1cfb340095c7" contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d" name="sana:MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" unitRef="U_USD" scale="6" decimals="INF">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of certain specified development milestones and a success payment (Cobalt Success Payment) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_702dbac6-39c4-4051-9eef-64871108974a" contextRef="C_3a337850-011f-419d-9b96-9745a28abc2f" name="sana:MaximumPotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, each of which is payable in cash or stock. The Cobalt Success Payment is payable if, at pre-determined valuation measurement dates, the Company&#8217;s market capitalization equals or exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e45a0cc0-22e2-417f-9eba-693b2e48e16e" contextRef="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="INF">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion, and the Company is advancing a program based on the fusogen technology in a clinical trial pursuant to an investigational new drug (IND) application, or has filed, or received approval for, a biologics license application or new drug application for a product developed using the fusogen technology. The Cobalt Success Payment can be achieved over a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_242abe60-c925-4ed9-b181-943ecdce42a2" contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d" name="sana:BusinessAcquisitionMaximumTermForSuccessPayment" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the acquisition, but this period could be shorter upon the occurrence of certain events. A valuation measurement date would also be triggered upon a change of control of the Company if at least one of the Company&#8217;s programs based on the fusogen technology is an active research program at the time of such change of control. If the Company&#8217;s market capitalization is below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aeeca27-1e90-42c4-9592-f677b525ccbe" contextRef="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="INF">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion as of the date of a change of control, the amount of the potential Cobalt Success Payment will decrease, and the amount of potential Cobalt Contingent Consideration will increase. As of March 31, 2024, a Cobalt Success Payment had not been triggered.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2714ebe6-41c4-40ff-a8ae-9872d4b0aca3" contextRef="C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f" name="sana:ScheduleOfMarketCapitalizationsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth various thresholds for the Company&#8217;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sana market capitalization upon a change of control and resulting impact to Cobalt Success<br/>Payment and additional potential Cobalt Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt Success<br/>Payment</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>potential Cobalt<br/>Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6564e5f-7114-4cd6-858c-e5401916196f" contextRef="C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="-8">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cf1e72a-02b9-4b52-bf44-ab3eea4d2a39" contextRef="C_e6ce25b6-c626-470d-b450-ff463c8d2c46" name="sana:PotentialSuccessPayment" unitRef="U_USD" scale="6" decimals="-6">500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a49ff2e7-ca05-47b7-ada2-d01f0c333b2e" contextRef="C_42aa39ff-3900-4c5e-985b-ace73bd8d9af" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="-8">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $8.1 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ede4c08f-8537-4224-bb13-08ac5a6fd8ad" contextRef="C_70a725dd-e57a-4033-8f99-adf5043341f3" name="sana:PotentialSuccessPayment" unitRef="U_USD" scale="6" decimals="-6">150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44885445-83ef-4dc1-a138-aab6b1da3f88" contextRef="C_c6027cc1-7afb-4fa9-88e4-4c01cce1cb2d" name="sana:AdditionalPotentialContingentConsideration" unitRef="U_USD" scale="6" decimals="-6">350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa40623-cc92-4db9-8cf5-cfde6f07f531" contextRef="C_cbe6df99-60ae-4f68-a843-401a8a497361" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="-8">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $7.4 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4d93089-30f0-4943-929d-2f3fd8e6ae55" contextRef="C_9cce18b1-5b05-469a-898d-954d3e894e00" name="sana:PotentialSuccessPayment" unitRef="U_USD" scale="6" decimals="-6">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23e1af54-ba6c-43dc-8e92-622fbd832615" contextRef="C_9fdca39a-64d6-45fd-a2b0-60576cb81cf0" name="sana:AdditionalPotentialContingentConsideration" unitRef="U_USD" scale="6" decimals="-6">400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less than $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d9fee9b-1c1c-426d-9469-8844783c2b36" contextRef="C_12fdc9e8-0ca8-4874-b926-71ede412b36f" name="sana:ThresholdMarketCapitalization" unitRef="U_USD" scale="9" decimals="-8">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de1a582-367c-4496-83a2-891567e53e41" contextRef="C_bd00d5a3-324d-497b-a8e2-82db2e6edc2b" name="sana:AdditionalPotentialContingentConsideration" unitRef="U_USD" scale="6" decimals="-6">500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Cobalt Success Payment and Cobalt Contingent Consideration liabilities are carried at fair value, with changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Success Payment liability was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6063f06-64d5-489a-bdaa-d7f33c96b55e" contextRef="C_5a55ce09-f176-4fab-a2e9-e04a6400a283" name="sana:EstimatedFairValueOfSuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5">39.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3c11b0-c0c6-49b4-ba59-e8032ccb1609" contextRef="C_8a8fc778-052c-4707-bdea-05eb75e7228d" name="sana:EstimatedFairValueOfSuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Success Payment, the Company recognized an expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36035de1-bafa-404d-95f0-5c060a70eb23" contextRef="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef" name="sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d08241e3-752b-4f0f-801b-49d9f514547f" contextRef="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203" name="sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Contingent Consideration was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1950e763-bcfb-4dd5-9399-d8dd5d2a5a2c" contextRef="C_49111c32-8c42-46ee-b4fc-28fe251ba44f" name="sana:EstimatedFairValueOfContingentConsideration" unitRef="U_USD" scale="6" decimals="-5">115.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_532f5651-6d64-47d6-89a5-cf7aa38e45b4" contextRef="C_3e731ce1-98f4-4819-a7ad-0f95050b9b55" name="sana:EstimatedFairValueOfContingentConsideration" unitRef="U_USD" scale="6" decimals="-5">109.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Contingent Consideration, the Company recognized expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b06722b4-8592-485c-bff4-45184667ab51" contextRef="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee61d09-b593-4ceb-9b84-6c4994d001bf" contextRef="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_6a3962f1-0eb4-43fa-a548-a7a09261591a" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. License and collaboration agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Beam Therapeutics Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company entered into an option and license agreement with Beam Therapeutics Inc. (Beam), pursuant to which the Company was granted a non-exclusive license to use Beam&#8217;s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products that (i) are directed to certain antigen targets, with respect to the Company&#8217;s allogeneic T cell programs, or (ii) comprise certain human cell types, with respect to the Company&#8217;s stem cell-derived programs. The Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8d36da5-5ebc-4443-9f37-5a1e4a1149f8" contextRef="C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e" name="sana:UpfrontPaymentToCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Beam, which was recorded in research and development expense for the year ended December 31, 2021. Additionally, under the terms of the agreement, the Company may be obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef56406a-bf04-440d-a6ab-27a3f5e49915" contextRef="C_65e2a512-f26e-46ac-8ba3-43bba960b76f" name="sana:PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" unitRef="U_USD" scale="6" decimals="-5">65.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in specified developmental and commercial milestone payments and royalties on licensed products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each licensed product. At the time of the entry into the option and license agreement, a member of the Company&#8217;s board of directors was a beneficial owner of greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4d93890-d6b9-4c75-b5f2-548403860c83" contextRef="C_17283059-11e9-44c9-8c95-9b47afc70185" name="sana:BeneficialOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of Beam. This director is also affiliated with a member of the board of directors of Beam.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">President and Fellows of Harvard College</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2019, the Company entered into an exclusive license agreement with the President and Fellows of Harvard College (Harvard) to access certain intellectual property for the development of hypoimmune-modified cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company paid to Harvard aggregate consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe18a0c-eb97-4099-b28c-04d74552d9c0" contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983" name="sana:TotalValueOfConsiderationPaidUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, comprising $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46ad2af4-0258-4d03-857c-872bc8abde1a" contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983" name="sana:StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6fa04e4-6e45-4d97-b34b-3896a9bbf32f" contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983" name="sana:PaymentToCollaborators" unitRef="U_USD" scale="6" decimals="-5">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Additionally, the Company may be required to pay to Harvard up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_102a93ff-7241-4934-ae2b-1e0cea1371dd" contextRef="C_b931ac74-0689-4fcf-9fd6-7716f8afe0a5" name="sana:MaximumPotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="INF">175.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in success payments, payable in cash, based on increases in the fair value of the Company&#8217;s common stock (Harvard Success Payments). The potential Harvard Success Payments are based on multiples of increased value ranging from 5x to 40x, based on a comparison of the fair market value of the Company&#8217;s common stock relative to the original issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3697b1fe-5379-4c27-a826-3545390ae076" contextRef="C_cdc2c79f-6027-47c6-b3d8-4dec37b42493" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">4.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share at ongoing pre-determined valuation measurement dates. The Harvard Success Payments can be achieved over a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c53a4903-045f-49f3-80ac-11217a0ebd04" contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983" name="sana:MaximumPeriodExpectedToAchieveForSuccessPayments" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the effective date of the agreement. If a higher success payment tier is first met at the same time a lower tier is first met, both tiers will be owed. Any previous success payments made to Harvard would be credited against the success payment owed as of any valuation measurement date so that Harvard does not receive multiple success payments in connection with the same threshold. As of March 31, 2024, a Harvard Success Payment had not been triggered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d21b129-5405-4646-bdab-6528bea0e6a1" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" escape="true" continuedAt="F_3d21b129-5405-4646-bdab-6528bea0e6a1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the potential success payments and common stock price required for payment:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3d21b129-5405-4646-bdab-6528bea0e6a1_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.2%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:7.58%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:7.58%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:7.58%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:7.58%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:7.58%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Multiple of Equity Value at Issuance</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">30x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">40x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per share common stock price required for payment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80d726c6-43d2-43ab-bf6e-608fc39bf5c6" contextRef="C_d3ae50f3-372a-4d53-b386-1eaa80038130" name="sana:CommonStockPricePerShareRequiredForPayment" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">20.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e92b542c-b8c7-4bcf-8e0d-546ff2adeb39" contextRef="C_f1fcce66-212c-4a70-9718-133d1c668a44" name="sana:CommonStockPricePerShareRequiredForPayment" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">40.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7d2425-f45c-4a38-8349-f1a88a14d0d2" contextRef="C_fb2f913c-2539-43df-900b-bd15d965ab34" name="sana:CommonStockPricePerShareRequiredForPayment" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">80.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_953479b4-d50e-4584-b4ce-2fe9b8f0b233" contextRef="C_546c0313-0f3f-4820-bf29-21b1e0968e55" name="sana:CommonStockPricePerShareRequiredForPayment" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">120.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c15ee6-9894-4c78-841b-36acf22022b5" contextRef="C_06a0dace-22c9-49b4-b126-d21eae97f669" name="sana:CommonStockPricePerShareRequiredForPayment" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">160.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment(s) (in millions)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16f0c711-7e8b-4053-9a05-922455f172e5" contextRef="C_aa78a347-b2c3-4998-92a1-ff2191d35b80" name="sana:PotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">5.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad98775a-be7c-45bb-bfc8-d1a62e87a57e" contextRef="C_3cf9a87b-eed3-43a3-93f1-c8d0035536c6" name="sana:PotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">15.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dee65e79-bae0-4f94-a383-64ee9cafb74f" contextRef="C_cfb14b1e-3ce3-4211-b44b-454387680bb3" name="sana:PotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">30.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8c047bf-5fc4-45de-9a05-effd0dc88622" contextRef="C_2ab6eba0-d3c4-442f-bc85-efd0ea497f3a" name="sana:PotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">50.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1de764e-92ad-4d9c-a0de-fc97066cb848" contextRef="C_04c586a3-4616-447f-9140-209061d79050" name="sana:PotentialSuccessPayments" unitRef="U_USD" scale="6" decimals="-5">75.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Harvard Success Payment liabilities are carried at fair value, with the initial value and changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Harvard Success Payment liability was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36196e0b-d4a2-4214-a519-08c8ced93d44" contextRef="C_ad091749-d991-4041-9e16-79d0ac453e20" name="sana:EstimatedFairValueOfSuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c7fefa8-511a-4e86-9375-cfcf1128c721" contextRef="C_86dab90d-c97a-4375-b478-9bef336bc6ff" name="sana:EstimatedFairValueOfSuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Harvard Success Payment liability, the Company recognized an expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88372381-6bfe-43d7-86d6-c67d3a7d90e7" contextRef="C_1bd66b24-e325-40b8-abb1-65a998714668" name="sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d246bcaa-6d00-43df-a026-9d4baed25483" contextRef="C_e852dc08-0bf7-4b90-9f2e-d291734160a9" name="sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023 respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7246052a-57d9-4425-973b-c1847b9e5f49" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:RestrictedAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a668ec0c-db2d-4470-8ee5-e59d6f89b92f" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">standby letters of credit that are collateralized with a bank account at a financial institution in accordance with certain lease agreements. The aggregate amount of such standby letters of credit was</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f7ad58-8076-46e1-adbf-76619dd3be2d" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6bb4bea3-4218-42f3-9726-0e2d4283cae0" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of each of March 31, 2024 and December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a19df60-eb90-4d0f-91e0-193c7106a282" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Fair value measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3d9af53-f9d3-4bd8-b057-7e3429dfa1cf" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"/>
        <td style="width:1.46%;"/>
        <td style="width:11.278%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.398%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36019788-a2e3-4db0-a64f-b493fd87ce9e" contextRef="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,137</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d79a7b1-c10a-46bb-88fe-3002433842f7" contextRef="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,137</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ac0420f-8eb3-4eb9-9294-6e92b8736fc1" contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8c228b8-9ef5-4921-a7d7-6af096e7678d" contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51043ba3-f09a-4d2d-8e39-7eb17c62b3bf" contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d837ae5d-7425-4869-89ce-f826ef4ace62" contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10166b3f-7bc3-435e-97ff-3212afbac2ea" contextRef="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ab1c460-e882-4848-9e81-052402093e4b" contextRef="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc56632c-e7d0-474c-9a0b-9cb0b455fe05" contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e2c0475-0901-47bf-9b30-9cc98cf688b0" contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e2b1c1a-f34f-49a9-a778-436a728d7f17" contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4fce04-3261-4aef-b4f3-990029785bec" contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db89c9c8-9d96-4296-9852-360aebf2f0ed" contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,671</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d60236f-a756-487c-b819-3237f0fd2518" contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40270e8a-2f3b-429e-89e2-19119e14195c" contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfadbebd-b546-41a2-87a9-9b795de75648" contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8e9118e-8681-44f9-8158-d24dcdb8822f" contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7506b4f2-3801-4d17-954a-e4d4e4950d81" contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_692054b4-59b5-49f2-ac15-dae4c24a2b72" contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1848d1d3-bafb-43f4-ae36-d0a69596e21c" contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,371</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afd5f43b-1630-43f7-8be6-caadf186e533" contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,043</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42bab626-6b9a-42fd-94b5-b422f88f0bb5" contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0406b1a9-8601-4066-82a1-9ac0e0d4b75e" contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab00c7b8-b852-4df1-88d2-601000ff62c0" contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11170fda-ecfd-472e-bfe2-c84e3c27fe49" contextRef="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3">381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dd71a39-c29f-4849-8c98-8cb48d3ef3cb" contextRef="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3">381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9186e794-8fb3-4985-8687-9a7693d8e5fd" contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">299,254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4254d478-fbc0-412d-8cc9-35b88e8465f9" contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73681776-eb86-41f5-863b-dfa20b334ba8" contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39d7feed-7a31-4c89-8642-07282aa96bee" contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">299,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e2f8169-10f8-4562-b285-2f1f5d077706" contextRef="C_8d60103d-6496-453b-beb9-76e3514ed534" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,990</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8c4edd8-1be8-4975-86f7-a68e682d91a7" contextRef="C_8d60103d-6496-453b-beb9-76e3514ed534" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,990</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af124d01-0e33-47ce-b5ff-8df8bc435618" contextRef="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,422</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9e4e0fe-f633-4e0d-923b-5896af1ffe8e" contextRef="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,422</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b6c4b02-fa8c-4490-98c3-2bc24584888f" contextRef="C_4650afc1-9af0-49d7-a045-02b7cc48e08a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c1fd164-90f8-44c3-9632-e4b5ac5c9fcd" contextRef="C_4650afc1-9af0-49d7-a045-02b7cc48e08a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b32a626-0ed0-4025-8ef2-27b847a7665d" contextRef="C_f0806d70-bf3c-4907-8e95-1d6b45653b32" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7089bf3-80b2-479b-9579-ea8a16f71f3b" contextRef="C_f0806d70-bf3c-4907-8e95-1d6b45653b32" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"/>
        <td style="width:1.46%;"/>
        <td style="width:11.278%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.398%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14034f09-bf8f-45d1-9b73-118301f17858" contextRef="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcabe9b9-69fd-43b3-8db9-9e5302f08e94" contextRef="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27ff6939-f5f9-43ab-a2b0-64d43135918a" contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd9e2fe-8775-4ce6-bc26-77cc0eceb725" contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2115fdb6-3645-4705-ae2d-226fb05f9937" contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e30b6f2e-c7b1-4f3b-ab13-f5ef44b3291f" contextRef="C_e53ea5e6-c436-4396-b07d-aa29105b61ad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_875bcdab-a397-46cc-a9a2-3bff258ff6b0" contextRef="C_e53ea5e6-c436-4396-b07d-aa29105b61ad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66587589-4bcb-4c20-946b-984cc93439a7" contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf2eb4a-7033-4886-a1e2-186922932e53" contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1f371bf-4157-48d8-b927-1699ed6bbcc0" contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,471</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b05615c5-6238-43fc-87db-43fb0071cbfd" contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91c09dd9-23e7-4a2d-9d71-3d18db5eadb6" contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf29fb2f-4470-46bb-9cb3-57d4ff564eb2" contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9c72a4-2fe3-4d68-b53f-a2593e4b9201" contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,853</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac0e7e94-1045-4242-a4b5-8a972ffe8adc" contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,817</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5436931e-6c61-4042-9977-91b8e8197e31" contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_226b74c3-6825-46e4-a459-6996d0fc5b5f" contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5308ea36-c4c2-46b8-84ed-45ac9d78e069" contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,825</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb3fcf0b-740d-4136-a82a-35cec7a33691" contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,741</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a7b66c2-c37d-4474-9254-820e8b028afc" contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_317fec0a-1914-4b71-996d-f0397f14f1d9" contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98a599d1-4c8b-45f3-9f14-1e874d742218" contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5796ac3-36ac-4999-9f32-83a95a240d46" contextRef="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8dbda5c-f95c-49b2-b00c-088fb375df16" contextRef="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4bed30e-1ee9-46f8-bde9-d90b3ca6c55e" contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,568</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d91c7f-2de2-429a-b742-8bb77d8c6350" contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a13ce842-4b5b-4970-ba76-a5945ad8eba6" contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae1bdab5-d881-492b-9540-eb3bc41b36ba" contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dff58693-171e-42ac-b932-7158cd9f6e74" contextRef="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88f5af5e-80e8-4954-ac3f-9b266abdb2f8" contextRef="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb763d02-6e92-4c82-a792-b11c2dd4a64d" contextRef="C_0650284f-37cc-47aa-8b3e-b08472cfc282" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef9dcb14-e76c-4b50-a1f7-43461e7a3fa4" contextRef="C_0650284f-37cc-47aa-8b3e-b08472cfc282" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5870ea3f-a1c7-4c8e-8fd5-13e4b4abca0d" contextRef="C_55b234fc-e689-4f6e-ade4-f2280aca3981" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c7b9ce-5c7a-42b3-b156-5d27bdea1a79" contextRef="C_55b234fc-e689-4f6e-ade4-f2280aca3981" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3750b5a-011e-4409-b2d8-170f19d90210" contextRef="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a11177e9-7e5d-4224-bcde-e484c8572486" contextRef="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level 2 marketable securities include U.S. government and agency securities and corporate debt securities and are valued based on either recent trades of securities in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80d67667-6d5e-4f5c-b8dc-e7aa2080845b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.366%;"/>
        <td style="width:1.301%;"/>
        <td style="width:1%;"/>
        <td style="width:8.068%;"/>
        <td style="width:1%;"/>
        <td style="width:1.301%;"/>
        <td style="width:1%;"/>
        <td style="width:8.068%;"/>
        <td style="width:1%;"/>
        <td style="width:1.301%;"/>
        <td style="width:1%;"/>
        <td style="width:8.068%;"/>
        <td style="width:1%;"/>
        <td style="width:1.301%;"/>
        <td style="width:1%;"/>
        <td style="width:8.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.301%;"/>
        <td style="width:1%;"/>
        <td style="width:8.068%;"/>
        <td style="width:1%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1%;"/>
        <td style="width:7.4879999999999995%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 months or greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a9daac1-f211-42cd-9fb0-c6264548aa3b" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,511</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dc00502-27cf-41d8-9e95-e72894aabfbe" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37b7ea51-325f-498d-9dc1-53945dce35c1" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,984</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_474936e9-4581-4e2d-9479-025626ddd1be" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca0bd08d-25f9-4455-82d1-2ebee66577fc" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0c49ee1-cd2f-42fc-80ed-c4d54bdfbd19" contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_308ef987-e8ab-47c8-9cfd-64e774986bb3" contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41633f10-ed7f-46b0-a53b-11151090a6c1" contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_687ad711-0e13-4427-9b03-c360021748a5" contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_043abc2a-e750-49a9-bdc4-cf629e5d8b10" contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f54867e2-58dd-4e02-a0c0-3029e6cbbea7" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,369</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_486fcd91-e49a-487f-882f-4f5cb90c5331" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5acd689d-4a21-4838-bdde-f5867739c694" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,984</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7d0e781-f93c-49b5-849d-75ae9fa1f59a" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e30e9e77-8f58-44e1-8cba-e874078c5787" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,353</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50dc67f9-a566-456d-b0a2-dc6271a5a36b" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89665812-1e4f-43aa-adcb-57e7281945e1" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f8b29e7-08ae-4647-8ea3-e3e6ecacd8ef" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa422555-1e05-48cf-b05a-abbdea653fb9" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,386</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df62a84-301a-4703-9a5e-aa0a9f088f3a" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cbbb529-9cab-4079-8647-6a0288e024bf" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_927c574e-13d0-4d9a-aa2a-7d59a8b6ebc8" contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe9d120a-9a74-4f88-a96c-9996f4de18fd" contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f296384d-0993-44f9-a4a4-2e5c6f670870" contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36bfb3a0-80cf-48e5-a59f-6df5158d538b" contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7461c982-2631-4353-99ee-c6273c8d41f6" contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951ee1cd-d8b9-4975-aaa8-110b08ff119f" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2381a936-c335-4586-8f2c-b189cb1d1371" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0331f0f3-0b3c-4a57-8b69-3cf64f85a1d4" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,386</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f7eff0-bf1b-4963-86c5-7b096346ed3b" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7042ee5-e2f8-4de0-893f-6601e9667903" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6249957-fb99-4aeb-a664-edea6d918b2e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that there was no material change in the credit risk of the above investments during the three months ended March 31, 2024. As such, an allowance for credit losses has not been recognized. As of March 31, 2024, the Company does not intend to sell such securities, and it is not more-likely-than-not that the Company will be required to sell the securities prior to the recovery of the amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, all marketable securities had an effective maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb5cd8c1-b9af-42a9-b2b5-d0bb5027c297" contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f" name="sana:MarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or less. Investments in securities with maturities of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba026c8a-174c-4a49-8eb6-c67e3cf66021" contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f" name="sana:InvestmentsSecuritiesMaturitiesPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or those for which management intends to use to fund current operations, are included in current assets and classified as available-for-sale. As of March 31, 2024, the balance in accumulated other comprehensive loss included net unrealized gains related to the Company&#8217;s available-for-sale debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e11f6bb-55d4-4720-b46d-2e328cb744a7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:11.902000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:11.902000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:11.902000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf7bfba-6102-41e8-bb23-1946328665d3" contextRef="C_1c1f3354-a6f1-4f78-9017-287f0a19140e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e452a598-e86b-4dd9-ae5b-bc67a9ce7c8a" contextRef="C_dafa944e-950c-499e-8b37-2dbf29453f70" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d37d7de-89e3-477f-9f1b-ac3a2e290cc4" contextRef="C_3f674985-b139-480d-b274-2a0503c4dce6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value &#8211; expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acb3350c-5d59-4829-a4f9-0b6f699905d2" contextRef="C_9b2f8dd4-c615-4c6b-b326-f49621a6eb03" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,384</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36230086-736a-4208-b15c-692f305f704a" contextRef="C_06e3eb5f-e863-49fa-8563-0e30982ae5cd" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,920</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_413bde9e-76ec-4847-8b73-cf7c20139da1" contextRef="C_bad0c086-6e01-4d43-9445-ceaacc421516" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_381d5c4b-0c0e-4a89-bbe6-5369f10dfce3" contextRef="C_f8a9dedd-06c5-4477-a6bb-e88883200c61" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,990</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e24fb00a-f6ce-4ea5-8a62-f5055b8630c9" contextRef="C_a51b0686-423c-43e8-94c5-8d8eb699f340" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_227c8d62-07f0-439d-92e7-2e5a8cc0fe3f" contextRef="C_81ea7889-0580-4531-870a-0c65974ac802" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,342</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes significant estimates and assumptions it believes would be made by a market participant in determining the estimated fair value of the Cobalt Contingent Consideration at each balance sheet date. The fair value of the Cobalt Contingent Consideration was determined by calculating the probability-weighted estimated value of the pre-specified development milestone payments based on the assessment of the likelihood and estimated timing that the milestones would be achieved and the applicable discount rates. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. The Company assesses these estimates on an ongoing basis as additional data impacting the assumptions are obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61350f4f-189e-4526-aa52-5d9c099603e6" contextRef="C_9ef25fb2-65c6-460a-a441-dd847f65b914" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Cobalt Contingent Consideration was calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"/>
        <td style="width:1.519%;"/>
        <td style="width:13.954%;"/>
        <td style="width:1.519%;"/>
        <td style="width:15.054%;"/>
        <td style="width:1.519%;"/>
        <td style="width:13.954%;"/>
        <td style="width:1.519%;"/>
        <td style="width:15.054%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rates</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e29e905-d7da-45a9-b6a9-16dbfd1567a1" contextRef="C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8399e3a1-df61-491c-8c08-8ed94f645bdd" contextRef="C_0cd2c1c8-63b2-4e43-b354-bbe68ce2f425" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84b52fa7-ba92-4fd4-86e4-9a16aaa8b4dd" contextRef="C_fec33127-b46e-468d-bbde-9835085b612c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d22a3bcc-229f-4fed-9df6-47d84db7bba8" contextRef="C_16202469-4333-43bd-8ab0-185f07269735" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c01d9739-3bf5-47e2-b32a-49c9f9023700" contextRef="C_25947cd9-a663-4cab-b957-bc7138703866" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e02c3345-ae70-4170-ab4d-374645bc8940" contextRef="C_3e115f01-d2f7-4c57-aad5-86133c460620" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Probability of milestone achievement</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03b4a98-7e76-4a3e-bb93-cf234681a497" contextRef="C_7de50755-31cf-4120-a7ad-64811d98119c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_010094b1-b8d7-4a16-b585-dc5370fdb6b7" contextRef="C_50f28a60-d008-4a0e-9e96-e1ccac671344" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d0307e-ef4e-453b-a2ea-2dbce05d62aa" contextRef="C_beb5b16b-6471-404e-aa6d-b2a7573c831a" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">25.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d0f5442-13f0-4aa9-b505-2a619f85a851" contextRef="C_e77f8e79-8380-4173-9ea0-6fd155040616" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22718c5-48b3-4508-b2e6-2b14884ff6ce" contextRef="C_2f9d4e78-b28f-45b8-a7ec-c2b98459dfc6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4fcb343-b02a-4154-b9de-bd36743fd679" contextRef="C_1ccf1cdd-58e0-4408-a0fa-022aac193bde" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">25.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average unobservable inputs were calculated based on the relative value of the pre-specified development milestones. The estimated fair value of the Cobalt Contingent Consideration may change significantly as development progresses and additional data are obtained, impacting the assumptions regarding probabilities of successful achievement of the milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value assumptions, judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions, inputs and/or different valuation techniques could result in materially different fair value estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Success payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes significant estimates and assumptions in determining the estimated fair value of the success payment liabilities and the associated expense or gain at each balance sheet date. The estimated fair value of the Cobalt Success Payment and Harvard Success Payment liabilities was determined using a Monte Carlo simulation methodology, which models the estimated fair value of the liability based on several key assumptions, including the expected volatility, remaining term, risk-free interest rate, estimated number and timing of valuation measurement dates on the basis of which payment may be triggered, and, for the Cobalt Success Payment, the Company&#8217;s market capitalization, and, for the Harvard Success Payments, the per share fair value of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19b9ddd7-ce1c-4183-95c5-c98ee130c697" contextRef="C_7b455bc1-d635-49ad-bf86-120e8cdbf8b4" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Cobalt Success Payments and Harvard Success Payments were calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"/>
        <td style="width:1.519%;"/>
        <td style="width:13.954%;"/>
        <td style="width:1.519%;"/>
        <td style="width:15.054%;"/>
        <td style="width:1.519%;"/>
        <td style="width:13.954%;"/>
        <td style="width:1.519%;"/>
        <td style="width:15.054%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d790ba18-efc0-4e8f-b0cf-f9aaf39f0951" contextRef="C_5d2713f5-18c1-46f4-a590-7d2440ecea25" name="sana:SuccessPaymentLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b71846ea-0f69-4469-9bec-67f20cf670f1" contextRef="C_d90fc972-dfb8-47f8-aecb-c44ba7bfe28d" name="sana:SuccessPaymentLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3">72.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_659326f4-05a9-4b7e-b6c0-112a31377c31" contextRef="C_c8e330e6-05d0-41c5-9f40-ed43cee976e6" name="sana:SuccessPaymentLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e669bcf-956f-4625-adf4-f4fe0ab8d094" contextRef="C_dfb83220-389a-46ef-9749-8c6f3606deb9" name="sana:SuccessPaymentLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3">72.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_34f34f4f-d74c-46f4-a8e9-eeaf3858ce7d" contextRef="C_18f3293e-df26-43da-a598-50ac321fdc65" name="sana:SuccessPaymentLiabilityExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_06eccc21-ca86-4751-9a15-9e195234872f" contextRef="C_dfd47a7d-8c14-4eb8-8032-56ab21cc27b6" name="sana:SuccessPaymentLiabilityExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3bdad3f2-edf9-421e-8b8e-bb527efa3718" contextRef="C_586b0056-75c6-4ab5-8d42-c2f9ab46e617" name="sana:SuccessPaymentLiabilityExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_87eec537-dd7a-4c99-88ae-1e04b175ebc7" contextRef="C_4a1f55ec-17f1-42c1-b4cf-309cd1fd5eda" name="sana:SuccessPaymentLiabilityExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d91a4fa2-9762-4177-9065-2401d6591984" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Property and equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7af7e458-b589-486e-8f68-bac7d376916f" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed34c559-2e83-420e-b4d8-917cb05d0970" contextRef="C_c5046514-fcb5-4d24-b1c8-fa4729ff4c0a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3babd502-a9f5-4f5f-acf7-8e377e6d2077" contextRef="C_94f4df8f-7b42-4c68-be26-534736b5d5f9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e3b6d4f-4c0d-49f7-8c0d-7a4a4aaa9e7d" contextRef="C_a379388d-c2de-4807-a894-cff2e4a56b6e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73062964-b8b0-4cbc-8e37-34e48cb6828e" contextRef="C_8f3c4803-a059-4ebb-ae2b-4ac87f86d07d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,361</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62bd69e9-71be-46c3-abed-415a7e316abc" contextRef="C_823c66ba-b506-4ca6-9d31-5351ec2592d4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70eb55ea-b39c-45b1-8a58-5fa2fde325d6" contextRef="C_60a4c997-ab06-4f9e-8db8-c507524ec994" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment, software, and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7255910a-58cc-4510-b01d-e9628a1af6f9" contextRef="C_a57b1903-cab8-45b9-8d74-c152b19c7eae" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f302e7ec-21a4-48ba-9d81-97b2e849176e" contextRef="C_25788be5-71c6-4519-9446-0a103addacb4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,124</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7c0e121-76e5-4d2d-8107-52e3f9ff4b41" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,166</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aba53209-6af2-4115-b1fa-5567f416327e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2820c459-79e3-481e-8753-847c6dd0e044" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,517</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ac92247-1cc6-4b59-8b6b-8ec45013656f" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdd2a4f6-cec3-4834-8515-d7f0ea98dbba" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d0164b0-39b8-4f64-a7ff-ba60ab3f6b7d" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e149a09-abcc-47a3-8b8a-e617a707434a" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2dc9cc4-f200-4dfa-9c5d-37fc24d7a2f6" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50c566b3-f72b-44ed-b9b8-6297fc043f08" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Accrued liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b394d44d-f76e-47a8-bf48-749ebb765808" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonuses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33685f69-c922-4180-b480-574cfcdf75e3" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,957</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c818d6cc-db65-4b2c-82e4-f68ad129d2d8" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,379</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued paid time off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7c55258-dae5-406c-8519-d03a3d581e8a" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedVacationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4da0eeb3-f7fb-4d4b-9400-e5d7ec925691" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedVacationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,731</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d50ab3b8-5a80-4b2c-a8f9-992ad88175a1" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,065</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dec071e-d2ad-469f-b470-fcee16cda728" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f7e7b1-a7c6-4d93-92d8-a154e8f0e375" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:AccruedCompensationOther" unitRef="U_USD" scale="3" decimals="-3">545</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93c6d397-f0e2-471f-9391-7ce1516dbb56" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="sana:AccruedCompensationOther" unitRef="U_USD" scale="3" decimals="-3">676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eec4786-9c05-427e-ba45-592585edc1cb" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5692c9b-d140-4387-8986-72c0b78bb0bd" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a23ac715-99ce-47b4-b6c6-ef31965bc5b1" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:AccruedResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,749</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a932373-f310-45fb-a16b-c68626b42787" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="sana:AccruedResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,110</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41ded248-912a-4b2b-9bbf-5f08187fc241" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,509</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dfdb457-ba0c-446d-9782-ed9e2622029e" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,470</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9ffc065-3e41-4395-aa75-c8f097404f65" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:AccruedPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,053</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4acc6f12-3687-4b88-949d-00c64d621f89" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="sana:AccruedPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b29a9bdc-5296-455c-9d07-990ef7d17ed1" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,363</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e2535ab-4318-42e8-b53a-43e599fe6eb4" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea45e8c2-c1dd-4097-83f1-941c4b93571d" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_071347fa-fcd5-49b5-a639-2dd896181807" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb4bc8f4-511d-4cd4-9030-4abb2f839535" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lease portfolio primarily comprises operating leases for office, laboratory, and manufacturing space. These leases contain various rent abatement periods, after which they require monthly lease payments that may be subject to annual increases throughout the lease term. Certain leases include options to extend the term. The renewal option is considered in the remaining lease term for the lease only when the Company is reasonably certain it will renew the lease. Certain leases provide the Company with the right to make tenant improvements, including the addition of laboratory space or build-out of manufacturing capabilities, and include a lease incentive allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company entered into a lease agreement for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f856708-f51a-42d3-bb1a-71e81aa3934c" contextRef="C_00b71411-02d1-4dbc-842b-d19a3cff2367" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">79,565</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office, laboratory, and manufacturing space located in Bothell, Washington (the Bothell facility). The initial term of the lease expires in February 2039, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35beea1b-8e7f-49ee-b9b4-455c7e9aed0c" contextRef="C_3bf2bbd7-4ee7-4371-8586-07b289dc7983" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with the option to extend the lease for up to three additional five-year terms.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The lease agreement also provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f581b282-5c2f-4b2e-893d-7f2499d782ae" contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51" name="sana:ReimbursementOfTenantImprovements" unitRef="U_USD" scale="6" decimals="-5">19.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for reimbursement of tenant improvements, as well as an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69bbe27f-9b8b-4a71-8be4-b01d220766f3" contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51" name="sana:OptionalTenantImprovementAllowance" unitRef="U_USD" scale="6" decimals="-5">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for tenant improvements, available at the Company&#8217;s election, which the Company would be obligated to repay to the landlord monthly over the initial term of the lease with interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1370d6f-af75-46fb-81e6-22fcae5905c5" contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51" name="sana:OptionalTenantImprovementAllowanceInterestRate" unitRef="U_pure" scale="-2" decimals="3">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year.  The Company is obligated to pay base rent of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c27730ed-46fa-4486-9214-10e12314e772" contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5">68.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the initial term of the lease. In accordance with the lease agreement, the Company has obtained a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff72fad0-5b1b-48ec-9d00-16622e184a1b" contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recognized the right-of-use asset and lease liability in the three months ended March 31, 2023, when the lease commenced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fa71e3d-abed-4fef-9662-27fc368c0ad5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:OperatingLeasesAdditionalInformationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains additional information related to the Company&#8217;s operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.12%;"/>
        <td style="width:1.32%;"/>
        <td style="width:20.68%;"/>
        <td style="width:1.32%;"/>
        <td style="width:11.86%;"/>
        <td style="width:1.32%;"/>
        <td style="width:22.92%;"/>
        <td style="width:1.32%;"/>
        <td style="width:22.14%;"/>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Location</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Use</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate <br/>Square Footage</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Commencement Dates</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Dates</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Seattle, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e1795a6-29d6-4d55-9a2d-67573f232883" contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">48,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_05e7777b-6404-4c18-8a54-ca5574fc5fc7" contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616" name="sana:OperatingLeaseCommencementBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_00628e6f-8177-4bdc-a730-a9e88e2ed86d" contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616" name="sana:OperatingLeaseCommencementEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2020</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_872c322a-6c36-4355-a4a4-559806c10890" contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616" name="sana:OperatingLeaseExpirationBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_6f552f07-4d25-42b9-bc6a-381232a70ea3" contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616" name="sana:OperatingLeaseExpirationEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2028</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cambridge, MA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_715a6668-23cc-452e-97ac-29d11f517fd7" contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_42ab5218-eb0b-4680-9dc6-fa6d0cb0d095" contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04" name="sana:OperatingLeaseCommencementBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_1881a911-81ac-412f-810a-434a7ca976dc" contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04" name="sana:OperatingLeaseCommencementEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_5f59419c-752e-4b60-8df0-6d760a59fc7e" contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04" name="sana:OperatingLeaseExpirationBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_35a66299-941e-4d8d-87ba-4967549dc769" contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04" name="sana:OperatingLeaseExpirationEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 2028</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">South San Francisco, CA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82faed73-9733-45b5-a56e-1398cfd4f79b" contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2705ffc2-ed4d-4986-8320-72df97b86687" contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712" name="sana:OperatingLeaseCommencementBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_1170012a-8e63-4015-aaae-1ce9a5acf713" contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712" name="sana:OperatingLeaseCommencementEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2022</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d39aa45b-8f2a-48e9-83f3-8e3773ff88c8" contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712" name="sana:OperatingLeaseExpirationBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><ix:nonNumeric id="F_73477c37-9905-45e4-9ed8-0777ded4d9e9" contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712" name="sana:OperatingLeaseExpirationEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2030</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rochester, NY</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3bd111f-ee19-4f17-94ea-71da21508045" contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2570310d-b476-4946-810d-da62296ef0e6" contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa" name="sana:OperatingLeaseCommencementBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c176c879-4813-490a-9e0d-e95198d7a3fe" contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa" name="sana:OperatingLeaseExpirationEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2025</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bothell, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory/Manufacturing</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a501a3b-025f-4d4b-8ef8-a368c8d01269" contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc" name="sana:AreaOfLeasedSpace" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">80,000</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ec9102d9-08eb-42f3-a356-112a627acae7" contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc" name="sana:OperatingLeaseCommencementBeginningMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2023</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_bff69047-5480-408c-9d37-3390b756f0e5" contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc" name="sana:OperatingLeaseExpirationEndingMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2039</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout the term of the lease agreements, the Company is responsible for paying, in addition to base rent, certain operating costs, such as common area maintenance, taxes, utilities, and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dca8f3fd-9c94-4ff1-823c-8664d4b9864e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s lease costs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.112%;"/>
        <td style="width:2.06%;"/>
        <td style="width:1%;"/>
        <td style="width:14.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.06%;"/>
        <td style="width:1%;"/>
        <td style="width:14.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d365ba3b-6971-42b7-915f-d4fe4c9b5014" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,981</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2f66391-3386-4f6b-aacf-41c7416e03fc" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,061</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8942148-6ffc-44bf-9df6-469eeea10345" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_058a0cc0-26a8-4686-98d8-232fc2336c96" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78f67632-2a47-4054-80e7-2e12a2f730b4" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,995</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c39fef41-0419-4270-ada5-c485ff0d6bcb" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,043</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the weighted-average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72890691-af76-4311-a9c9-ff314e9044b9" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.3 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, and the weighted-average incremental borrowing rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9936e71b-fd88-4fe6-aa9d-95f304367bdc" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4552a84-d535-48d7-a4a7-bb79cc8486ff" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows by fiscal year to the present value of the operating lease liabilities as of March 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.3%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:14.8%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining 9 months)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_544fa7d9-68b2-4d61-9c46-2ba6d920d1f0" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,971</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d91afa56-1dcb-4d71-8731-577901f55ddd" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17432a4a-4cd7-485f-a162-2b0b2bb2148e" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,472</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45172f7c-adf0-4cec-b680-4032dc6a6590" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae0b75a-de4c-4f8f-9f16-de8b2416df47" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f505193-69f0-490a-8ae6-bfd99927d76a" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2a790c9-32c7-4a8a-ba11-06781b06a5f9" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd215489-c1bb-44c1-8c9d-3016c5a64630" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: tenant improvement allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26a9f4b-42b8-442a-8777-5da9afa96bb6" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="sana:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_146355d6-a2e4-48e7-b03d-3e1aa9871874" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f317852-38d2-4a8a-8b86-169a68fc437c" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00e03f72-7e95-488e-bc03-a273a55f3ff9" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,922</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_324af212-363d-4915-be35-4c7da52cdae5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders&#8217; equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company completed an underwritten public offering pursuant to which it sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7a6f46b-1e34-4422-ab1d-f4c7af859761" contextRef="C_641277e3-749d-4eb9-a24e-d5fc027e6183" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc397cf4-9fb3-41af-a0c8-4e0d01825ef2" contextRef="C_18571269-31c5-4f70-a45a-3ef776d6eb61" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74b6cc72-010a-46ac-8b84-267694c45934" contextRef="C_5baaaa87-fae6-4ea1-8c7f-c6624c122de2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_036e289e-c625-4bac-bfab-06e91438e85f" contextRef="C_995d9eee-7d60-4997-aedf-118f7f6b649d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">180.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses. The pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4abcabde-7354-485c-83fb-78ff214c19d2" contextRef="C_223e6244-4447-479e-a802-dff78ea29aef" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of common stock. As the pre-funded warrants are indexed to the Company&#8217;s common stock and otherwise meet the requirements to be classified in equity, the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company&#8217;s consolidated balance sheet.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b41404ae-80b6-454d-9945-9dfe96cf4f42" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:DescriptionOfPreFundedWarrantsExerciable"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pre-funded warrants are exercisable at any time; however, the holders of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1deb8e8-d0da-4c33-b928-1cdbaa571c37" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of pre-funded warrants may increase or decrease such percentages not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37faadb4-6766-4f22-9401-33e877a1bbe8" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pre-funded warrants do not expire. During the three months ended March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afa891f3-db9f-4dd2-b173-bbddfdffeac4" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="sana:PreFundedWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised.</span><span style="color:#0070c0;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company entered into a sales agreement with Cowen, acting as sales agent, pursuant to which it may offer and sell through Cowen up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4888984c-7a23-4264-8762-7302493c5a94" contextRef="C_643555c3-2807-4634-8e1c-203532b68dd5" name="sana:CommonStockMaximumOfferingAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time in a series of one or more at the market equity offerings. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0e69ea6-9d2f-4986-aad9-e59a47ef78a9" contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's common stock under the ATM facility for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4aa861e-8f26-4e23-8b3d-8ec277ff97dd" contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting commissions and expenses.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc600275-638b-4519-a26d-61acac3ba9f4" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_cc600275-638b-4519-a26d-61acac3ba9f4_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity incentive plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the Company adopted the 2021 Incentive Award Plan (2021 Plan) and the 2021 Employee Stock Purchase Plan (2021 ESPP), both of which became effective on the completion of the Company&#8217;s initial public offering. The 2021 Plan provides for a variety of stock-based compensation awards, including stock options, restricted stock awards (RSAs), and restricted stock units (RSUs). The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03d3d11c-b986-4f2c-ba21-81a2b1b70dac" contextRef="C_ae90f9dc-f66e-4ca7-9990-7e8b027d5fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees may purchase shares at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ff4c9b4-70f7-4421-80f9-73915fb4bcfe" contextRef="C_7ec8e97a-eeb9-43b9-a3d4-79634fa4152c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering period or on the purchase date. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e35091c-1557-4376-8dcd-c2330e1e237d" contextRef="C_729027ec-b0b4-4b18-87f2-8db8ae9bdd77" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_805092e9-3d26-453d-9565-bb05ed500f84" contextRef="C_5fe7817f-a59d-4ee9-8d11-4a174e824ba6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares were available for future issuance under the 2021 Plan and the 2021 ESPP, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based compensation expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4635fec7-340a-41c2-9b93-ece0dc456af7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is recognized in the condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.006%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:10.918000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:10.918000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6ec1583-266e-4ddc-b9d9-6242f3be6c6f" contextRef="C_65f65e05-e779-44e5-ae6f-7877d20cf158" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7baf52e6-1640-4d68-bc00-f559393ffb61" contextRef="C_584f9a41-0e9d-44db-a47d-1be5d9acba98" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_879ebc93-2da1-48ce-b29d-ee7d22885e16" contextRef="C_70cd5777-3e29-4131-aad9-ba09ce7c693d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_195ca3e0-e7dd-4505-a6c3-141547f7b1e4" contextRef="C_e95d768c-3dca-4fa7-ad61-ee5856361683" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,779</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1952ee66-1bce-4349-a8bd-6d28883c954c" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,092</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf928ab8-3d46-43d5-a1c9-23124df61d7c" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,751</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47b101f5-8958-47f7-acf7-78cd836bbecb" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of March 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized stock-based compensation expense (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85b27bfe-77d3-4e25-bbdd-2967f67ca2e8" contextRef="C_147c1909-b56c-4e45-bb6a-2f58c5972a51" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,911</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33fe7388-b966-4cc6-ab14-071b0d359126" contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average period costs expected to be recognized (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_12282d14-50c0-4bae-bd2a-233516871cad" contextRef="C_784cd865-32af-4b9e-9a2d-1283b79c0fb7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_82ef70e4-244b-4818-bbc5-1cbf3fc9d96e" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6310310-c9ba-496b-9511-bfe8a894de72" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.6%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:12.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.72%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.700000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Life <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19974386-d3e7-4e48-8f7b-5e9bfb532c46" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,849</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2b13ba7-767e-4b08-999e-e3d92e0c8c3f" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2c3da09d-8af9-4bb6-9901-616541a9c859" contextRef="C_1df77845-a1de-4f4e-81f7-0609b3956c1c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41b66762-e476-42c7-8bca-926450254ba3" contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce4e579a-6dd8-4afb-9280-304262f31c13" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,551</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ad51445-b516-4ed7-8e22-d6bf8e0c12ed" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4784e1c4-88ce-4d1e-8d10-4e427ee77aa4" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0527c461-a237-48da-a999-0d026205d0f8" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_598f0659-9607-4268-96c7-96dbe8245c7b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,048</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8f8d9bf-f812-4a52-9e2c-80d6dbacd47d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71c4c4b5-03cf-47f6-8ac7-91ce2c0ae0b3" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46091c0c-6d87-4aa4-959d-d0b216a5ad0f" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c1ae660d-4a06-4a31-8e67-0f1dc6bc4fde" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c315bb7-a9b3-4d02-b31c-5089443c73f3" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_363aa8de-a4ce-47d4-b656-46bb61fbaa85" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_379352d1-d53b-4358-9d79-7625f1307b91" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.01</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a913226d-22d6-4b00-8610-3dee17a8cd0b" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03f54541-a667-4f02-ae89-5ebbdbd86a1b" contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f8ec7d3-622b-405f-b262-9af716141515" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"/>
        <td style="width:1.9%;"/>
        <td style="width:14.283%;"/>
        <td style="width:1.9%;"/>
        <td style="width:14.283%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Assumptions</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89f3a77d-668f-4351-9080-d0631ed22447" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04b5bb9c-7aef-4829-a5df-dadcd8d96258" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f19a0a8-b258-4375-8e09-dcddd21d7ab0" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7def24c-4704-4921-bf3a-a61a6b993470" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8331a06-4acd-4968-9a96-063767305fa5" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0bfca63-ea74-43a2-9a72-b978910059c4" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cb05e12b-2d6d-4df0-9d7a-c596f9921fe0" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5fb2807a-8e33-49f9-955a-a20be8964c8b" contextRef="C_a1033bd7-dfcc-4e46-b61c-7521a50f2305" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_a75215c2-26d7-4a74-ae7b-d5deb1db2b62" contextRef="C_94d2ec2c-37d2-474c-abc6-bc8a607c98a5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.50</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5038f89-0c83-46c5-8561-3e614568eed7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6eab7f3-a8fb-4b9e-9d9f-ddf0334aa420" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2685d842-5650-4197-a643-d542786cb919" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes additional information related to stock option activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.674%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1%;"/>
        <td style="width:12.322%;"/>
        <td style="width:1%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1%;"/>
        <td style="width:12.322%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average grant date fair value per share for options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68a79f47-bb8c-44e6-b4dd-1eecc582e063" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fe95310-058f-4ef2-b7e9-e1b64039c4c5" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate intrinsic value of stock options exercised (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9633b417-1ced-48c6-bebb-494ec1355193" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf37f2c-038d-43b5-859c-36e7f16605af" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted stock</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_1672d5fc-b374-4603-97fa-b53d1b74fa51" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s RSU activity is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.971%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:18.244%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:20.644%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs<br/>Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_013a9e2f-fe48-416a-8744-5fbfb82ccbb3" contextRef="C_6118355a-f762-4887-9f8b-16f2afbc5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,341</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e936ea6-0a8a-41de-ac78-b0491b832e6b" contextRef="C_6118355a-f762-4887-9f8b-16f2afbc5567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.88</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63ba9815-d884-4d4b-8b8d-e985e985646a" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_995a0090-82eb-4b34-b6be-89c10e6ab3b7" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_987535fa-824a-449c-bc36-6172ad42a216" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">388</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24b77dc3-cea3-45cf-86b3-5c430ea2b131" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6efd6572-eabf-40d5-8863-f91aab021836" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fbf3291-5ce7-4d3a-a040-237e0668954d" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of March 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96819c65-396b-4c0a-86df-28e928e053f0" contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,226</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ece6b7f-6197-44dc-8cc9-45c33d99914f" contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.05</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_cc600275-638b-4519-a26d-61acac3ba9f4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of RSUs that vested during the three months ended March 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f4f8683-07b9-46ae-968c-45714fa1617e" contextRef="C_928be825-e134-4309-ace3-ac7914760235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06fa1dd6-d192-4417-b369-c30a1c9ab077" contextRef="C_5b0a8034-8cf2-4c3d-a6c4-dc826a8a63fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span></ix:continuation></span><span style=""></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83579e20-7b95-4307-9ae3-97804b7db75e" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax provision for interim periods is determined using an estimate of the Company&#8217;s annual effective tax rate, adjusted for discrete items arising in the quarter. The Company&#8217;s effective tax rate differs from the U.S. statutory tax rate primarily due to a valuation allowance on the deferred tax assets. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies judgment in its determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of March 31, 2024 and December 31, 2023, the Company&#8217;s uncertain tax positions were immaterial.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b642d79-a973-4f5a-b894-040d30d500da" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net loss per share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share are calculated by dividing net loss by the weighted-average number of common shares outstanding during the relevant period, including the pre-funded warrants given their nominal exercise price. The Company was in a loss position for all periods presented, and basic net loss per share and diluted net loss per share are therefore the same for all periods, as the inclusion of all potential common securities outstanding would have been anti-dilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63df13a5-167d-483f-8df2-56b7a71351f9" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following securities were excluded from the computation of net loss per diluted share of common stock for periods presented as their effect would have been anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.54%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:15.2%;"/>
        <td style="width:1%;"/>
        <td style="width:1.44%;"/>
        <td style="width:1%;"/>
        <td style="width:15.2%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98cd472e-13f3-4e6e-b021-831a7010392e" contextRef="C_63e6b918-5acf-48a9-b764-d3dbe3d981fe" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa2cfcd8-e594-474a-830d-e049cf01d7cb" contextRef="C_c347a70d-0102-4f86-9df2-224e9dde7027" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5754a3b8-7b8f-4865-93ac-601e384d2afa" contextRef="C_c12ea39b-aeb0-4f12-b248-2e617e0f6530" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_594414be-6da6-4974-a7cc-d76cebddd76a" contextRef="C_95b79823-dbbd-4370-9127-b27adbac303b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec80eea1-53bd-4a85-b7a2-3f1c6173b47b" contextRef="C_bbf6b029-0470-4e87-9590-c00f1975ad8c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b580e94-0064-47b6-a0cc-d8f7bd84b037" contextRef="C_0ca9ade4-b42f-4a4e-999d-db79e5fb7206" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9fac4aa-ee4d-46c8-b6d6-a9bc7931b1bc" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,458</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f7528b-78fc-421c-b805-abc63570ff95" contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_209ac247-f4da-48ad-b38e-54a110a57637" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Employee benefit plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The Company matches each participant&#8217;s 401(k) contributions, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70d87741-addf-4332-b8c8-4b2cc9c5d8c5" contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per year per participant.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and notes thereto and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included as part of our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 29, 2024 (2023 Annual Report). This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements that are based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of numerous factors, including those set forth in the section of this Quarterly Report titled &#8220;Risk Factors.&#8221; See also the section of this Quarterly Report titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice. The key to making this vision a reality will be finding consistent and scalable means of manufacturing cell-based medicines, and we have invested significantly in our hypoimmune platform (HIP) technology with the twin goals of using allogeneic cells that evade immune detection in patients and that we can manufacture at scale. We are developing cell engineering programs to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune diseases, and central nervous system disorders, among others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have four clinical trials that are ongoing, or that we expect to commence in the near-term, evaluating our product candidates, or product candidates developed using our technologies, across seven diseases in multiple therapeutic areas, including B-cell malignancies, B-cell-mediated autoimmune disease, and type 1 diabetes, as described below:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARDENT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our ongoing Phase 1 clinical trial evaluating SC291, our HIP-modified CD19 targeted allogeneic chimeric antigen receptor (CAR) T program, in B-cell malignancies, including non-Hodgkin&#8217;s lymphoma and chronic lymphoblastic leukemia; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GLEAM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our Phase 1 clinical trial evaluating SC291 in patients with lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VIVID</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our Phase 1 clinical trial evaluating SC262, our HIP-modified CD22 CAR T program, in patients with relapsed or refractory B-cell malignancies who have received prior CD19 CAR T therapy; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investigator-sponsored first-in-human study (IST) evaluating UP421 an allogeneic, primary islet cell therapy engineered with our HIP technology, in patients with type 1 diabetes mellitus.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to overcome several existing limitations of gene and cell therapy through our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, both of which may facilitate the development of therapies that can transform the lives of patients by repairing cells in the body when possible and replacing them when needed. For </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> therapies, when diseased cells are damaged or missing entirely and an effective therapy needs to replace the entire cell, a successful therapeutic requires large-scale manufacturing of cells that engraft, function, and persist in the body. Of these, we view cell persistence as the greatest current limitation to dramatically expanding the impact of this class of therapeutics, and in particular, overcoming the barrier of immune rejection of transplanted allogeneic cells. We believe that product candidates developed with our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platform, which uses HIP-modified allogeneic cells that can &#8220;hide&#8221; from the patient&#8217;s immune system, can address this fundamental limitation and unlock a wave of disruptive therapeutics. We refer to this technology as our hypoimmune platform. For </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> therapies that aim to repair and control genes in the body, a successful product candidate requires both gene modification and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> delivery of the therapeutic payload. Of these, we view effective </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> delivery as the greatest current limitation to dramatically expanding the impact of this class of therapeutics. To this end, our initial focus is on cell-specific delivery of genetic payloads. Based upon early clinical as well as extensive preclinical data from our HIP platform, we decided in October 2023 to focus a meaningful portion of our research and development resources for at least the next several years on HIP-modified </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufactured cells as therapeutics.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the time is right to develop engineered cell therapies across a broad range of therapeutic areas. Substantial progress in the understanding of genetics, gene editing, protein engineering, stem cell biology, immunology, process analytics, and computational biology have converged to create an opportunity to markedly increase the breadth and depth of the potential impact of cellular medicines. We continue to make progress developing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cell engineering platforms &#8211; our hypoimmune allogeneic CAR T cell platform and our stem-cell derived platform that also leverages our HIP technology. We are in the early stages of development across a broad pipeline of product candidates, which are summarized below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:1.867%;text-indent:4.62%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img112676973_0.jpg" alt="img112676973_0.jpg" style="width:575px;height:575px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our initial programs provides the potential for meaningful standalone value while also supporting our potential ability to further exploit our platforms in a manner that leads to the development of broadly applicable medicines. Based on our current timelines for our lead programs, we believe our cash runway will enable multiple data readouts across our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023 and 2024, the FDA cleared our Investigational New Drug (IND) applications for each of the ARDENT, GLEAM, and VIVID trials, and we supported the submission of a clinical trial application for an IST, which was authorized by the Swedish Medical Products Agency. These four trials will evaluate our product candidates across seven diseases in multiple therapeutic areas, including B-cell malignancies, B cell-mediated autoimmune diseases, and type 1 diabetes. We expect to share data from each of these trials in 2024.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Additionally, we continue to make progress on advancing our research- and preclinical-stage product candidates into and through preclinical development and toward potential IND submissions in 2024 and beyond. As certain of our product candidates advance toward potential IND submissions, we are conducting good laboratory practices toxicity studies and establishing necessary scale-up for our manufacturing processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the depth and breadth of our portfolio, we expect to assess and prioritize our programs on an ongoing basis based on various factors, including internal and external opportunities and constraints, which may result in our decision to advance certain programs ahead or instead of others. For details regarding our product candidates, see the section titled &#8220;Business&#8212; Overview&#8221; in Part I, Item 1 included in our 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technologies represent an aggregation of years of innovation and technology from multiple academic institutions and companies, including hypoimmune technology licensed from the President and Fellows of Harvard College (Harvard) and The Regents of the University of California, our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering program focused on certain brain disorders acquired from Oscine Corp., fusogen technology acquired from Cobalt Biomedicines Inc. (Cobalt), and gene editing technology licensed from Beam Therapeutics Inc., among others. For details regarding these acquisitions and license and collaboration agreements, see Note 3, Acquisitions and Note 4, License and collaboration agreements to our consolidated financial statements included in our 2023 Annual Report, as well as the section titled &#8220;Business&#8212; Key Intellectual Property Agreements&#8221; in Part I, Item 1 included in our 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations to date have included developing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, conducting clinical trials of our product candidates, supporting clinical trials of product candidates developed using our technologies, acquiring technology, organizing and staffing the company, business planning, establishing and maintaining our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. All of our programs are currently in the development stage, and we do not have any products approved for sale. Since our inception, we have incurred net losses each year. Our net losses for the three months ended March 31, 2024 and 2023 were $107.5 million and $82.1 million, respectively. As of March 31, 2024, we had an accumulated deficit of $1.4 billion, which includes cumulative non-cash charges of $43.0 million and $63.7 million related to the revaluation of the success payment liabilities and contingent consideration, respectively. Our net losses resulted primarily from our research and development programs, and, to a lesser extent, general and administrative costs associated with our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we completed an underwritten public offering pursuant to which we sold 21.8 million shares of our common stock, including 4.5 million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 12.7 million shares of our common stock for net proceeds of approximately $180.0 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we entered into a sales agreement with Cowen and Company, LLC (Cowen), acting as sales agent, pursuant to which we may offer and sell through Cowen up to $150.0 million in shares of our common stock from time to time in a series of one or more at the market equity offerings (collectively, the ATM facility). As of March 31, 2024, we have sold an aggregate of 4.9 million shares of our common stock under the ATM facility for net proceeds of $28.7 million, after deducting commissions and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had cash, cash equivalents, and marketable securities of $311.1 million. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months from the filing of these financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating losses and expenses to decrease in 2024, excluding potential one-time items, as a result of our strategic repositioning in October 2023, and likely increase over the longer term from the 2024 level if our clinical trials are successful, and if we expand our research and development efforts. Cost increases would be driven in large part by advancing our current and future product candidates through clinical trials; identifying additional product candidates; establishing our manufacturing capabilities, including through third-party contract development and manufacturing organizations (CDMOs) and building our internal manufacturing capabilities; advancing preclinical development of our current and future product candidates; advancing and expanding the capabilities of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms; acquiring and licensing technologies aligned with our ambition of translating engineered cells to medicines; seeking regulatory approval of our current and future product candidates; increasing our workforce to support our research, clinical and preclinical development, manufacturing, and commercialization efforts; expanding our operational, financial, and management systems; continuing to develop, prosecute, and defend our intellectual property portfolio; and continuing to incur legal, accounting, or other expenses to operate our business, including the costs associated with being a public company.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to invest in building world class capabilities in key areas of manufacturing sciences and operations, including development of our cell engineering platforms, product characterization, and process analytics. Our investments also include scaled research solutions, scaled infrastructure, and novel technologies to improve efficiency, characterization, and scalability of manufacturing, including establishing our internal manufacturing capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, we announced a strategic repositioning to increase our focus on our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell therapy product candidates. As  a result, we reduced our near-term investment in our fusogen platform for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene delivery, including by delaying the IND submission for our SG299 program. The strategic repositioning resulted in a workforce reduction of approximately 29%. We incurred approximately $5.2 million of cash-based expenses related to employee severance, benefits, and related costs. The strategic repositioning and associated workforce reduction is complete, and is expected to result in 2024 operating cash burn of less than $200.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will need to raise additional financing in the future to fund our operations, including the commercialization of any approved product candidates. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents, and marketable securities, proceeds from any future equity or debt financings, and upfront, milestone, and royalty payments received under any future licenses, collaborations, or other arrangements. Additional capital may not be available on terms that are reasonable or acceptable to us, if at all. If we are unable to raise capital when needed or on attractive terms, our business, results of operations, and financial condition would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Macroeconomic Considerations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business and operations may be negatively affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as the timing of changes to inflation and interest rates, declines in consumer confidence, declines in economic growth, uncertainty in the markets, geo-political and economic stability resulting from the ongoing Russia-Ukraine war, conflict in the Middle East, tensions in U.S.-China relations, and the aftermath of the COVID-19 pandemic. The severity and duration of the impact of these events and conditions on our business cannot be predicted and may not be fully reflected in our results of operations until future periods. If economic uncertainty continues or increases, or if the global economy worsens, our business, financial condition, and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events and conditions on our business, financial condition, and operating results, see the section titled &#8220;Risk Factors&#8221; included in this Quarterly Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisitions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed various acquisitions since inception. For details regarding our acquisitions, see the section titled &#8220;Business&#8212;Key Intellectual Property Agreements&#8221; and Note 3, Acquisitions, to our consolidated financial statements included in our 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License and collaboration agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into license and collaboration agreements with various third parties. For details regarding these agreements, see the section titled &#8220;Business&#8212; Key Intellectual Property Agreements&#8221; and Note 4, License and collaboration agreements, to our consolidated financial statements included in our 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Success payments and contingent consideration</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cobalt success payment and contingent consideration</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms and conditions of the Cobalt acquisition agreement, we are obligated to pay to certain former Cobalt stockholders contingent consideration (Cobalt Contingent Consideration) of up to an aggregate of $500.0 million upon our achievement of certain specified development milestones and a success payment (Cobalt Success Payment) of up to $500.0 million, each of which is payable in cash or stock. The Cobalt Success Payment is payable if, at pre-determined valuation measurement dates, our market capitalization equals or exceeds $8.1 billion, and we are advancing a program based on the fusogen technology in a clinical trial pursuant to an IND, or have filed for, or received approval for, a biologics license application or new drug application for a product based on the fusogen technology. The Cobalt Success Payment can be achieved over a maximum of 20 years from the date of the acquisition, but this period could be shorter upon the occurrence of certain events. A valuation measurement date would also be triggered upon a change of control if at least one of our programs based on the fusogen technology is the subject of an active research program at the time of such change of control. If there is a change of control and our market capitalization is below $8.1 billion as of the date of such change of control, the amount of the potential Cobalt Success Payment will decrease, and the amount of potential Cobalt Contingent Consideration will increase. As of March 31, 2024, a Cobalt Success Payment had not been triggered.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 3, Acquisitions to our condensed consolidated financial statements included elsewhere in this Quarterly Report for details on the amount of the potential Cobalt Success Payment and potential Cobalt Contingent Consideration if there is a change of control based on various thresholds for our market capitalization on such change of control date. See Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8220;&#8212;Critical accounting policies and significant judgments and estimates&#8212;Success payments&#8221; and &#8220;&#8212;Critical accounting policies and significant judgments and estimates&#8212;Contingent consideration&#8221; in our 2023 Annual Report for more information on the accounting treatment of the Cobalt Success Payment and Cobalt Contingent Consideration.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Harvard success payments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Harvard agreement, we may be required to make up to an aggregate of $175.0 million in success payments to Harvard (Harvard Success Payments), payable in cash, based on increases in the per share fair market value of our common stock. The potential Harvard Success Payments are based on multiples of increasing value ranging from 5x to 40x based on a comparison of the per share fair market value of our common stock relative to the original issuance price of $4.00 per share at ongoing pre-determined valuation measurement dates. The Harvard Success Payments can be achieved over a maximum of 12 years from the effective date of the agreement. If a higher success payment tier is met at the same time a lower tier is met, both tiers will be owed. Any previous Harvard Success Payments made are credited against the Harvard Success Payment owed as of any valuation measurement date so that Harvard does not receive multiple success payments in connection with the same threshold. As of March 31, 2024, a Harvard Success Payment had not been triggered.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 4, License and collaboration agreements to our condensed consolidated financial statements included elsewhere in this Quarterly Report for details on the various per share common stock values that trigger a Harvard Success Payment. See Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8220;&#8212;Critical accounting policies and significant judgments and estimates&#8212;Success payments&#8221; in our 2023 Annual Report for more information on the accounting treatment of the Harvard Success Payments.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of operating results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, research and development expenses have related primarily to discovery and development of our platform technologies and product candidates. Research and development expenses are recognized as incurred, and payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid expenses, until the goods or services are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of personnel-related costs, including salaries, benefits, and non-cash stock-based compensation, external research and development expenses incurred under arrangements with third parties, including CDMO manufacturing costs (including pass-through costs) and clinical trial costs, costs for laboratory supplies, costs to acquire and license technologies aligned with our goal of translating engineered cells to medicines, and facility expenses, including rent and depreciation, and allocated overhead costs. The timing and amount of costs to acquire and license technologies in the future cannot be reliably estimated and may fluctuate from quarter to quarter and year to year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We deploy our employee and infrastructure resources across multiple research and development programs for developing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, identifying and developing product candidates, and establishing manufacturing capabilities. Due to our early stage of development, the number of ongoing projects, and our ability to use resources across several projects, most of our research and development costs are not recorded on a program-specific basis. These include costs for personnel, laboratory, and other indirect facility and operating costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. As a result of our strategic repositioning and associated workforce reduction in October 2023, we anticipate that our research and development expenses will decrease in 2024, excluding potential one-time items, and likely increase over the longer term from the 2024 level if our clinical trials are successful and if we expand our research and development efforts. Cost increases would be driven in large part by advancing our current and future product candidates into and through clinical trials; identifying additional product candidates; establishing internal and external manufacturing capabilities; advancing preclinical development of our current and future product candidates; advancing and expanding the capabilities of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms; acquiring and licensing technologies aligned with our ambition of translating engineered cells to medicines; seeking regulatory approval of our current and future product candidates; and increasing our workforce to support our expanded research and development operations. A change in the outcome of any of these factors could result in a significant change in the costs and timing associated with the development of our product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development related success payments and contingent consideration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development related success payments and contingent consideration include the change in the estimated fair value of our Cobalt and Harvard Success Payment liabilities and Cobalt Contingent Consideration liability. The expense or gain associated with our research and development related success payments and contingent consideration is unpredictable, in part, because our success payments are impacted by changes in our common stock price and market capitalization at the end of each reporting period, and continues to vary significantly from quarter to quarter and year to year due to changes in the assumptions used in the calculations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of personnel-related costs, including salaries, benefits, and non-cash stock-based compensation for our employees in finance, legal, executive, human resources, and information technology functions, legal and consulting fees, insurance fees, and facility costs not otherwise included in research and development expenses. Legal fees include those related to corporate and patent matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of our strategic repositioning and associated workforce reduction in October 2023, we anticipate that our general and administrative expenses will decrease in 2024, excluding potential one-time items, and likely increase over the longer term from the 2024 level to support potential expanded research and development activities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the three months ended March 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.492%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:10.102%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:10.102%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:9.282%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,448</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,718</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development related success payments and contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,007</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,887</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,766</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(497</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,724</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,052</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,672</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(110,724</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(84,052</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26,672</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,034</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,976</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,058</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(47</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">262</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(107,475</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(82,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,352</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the components of our research and development expenses for the periods presented:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.42%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:9.8%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:9.8%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:9.020000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,211</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,542</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third-party manufacturing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,780</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,822</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,042</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research, development, and laboratory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,672</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,342</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,670</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility and other allocated costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,468</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,733</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,317</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,048</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(731</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,448</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,718</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expense was $56.4 million and $67.2 million for the three months ended March 31, 2024 and 2023, respectively. The decrease of $10.7 million was primarily due to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $4.5 million in personnel-related expenses due to lower research and development headcount related to the strategic repositioning in October 2023;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $2.0 million in third-party manufacturing costs for CDMOs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a net decrease of $1.7 million in research, development, and laboratory costs due to a decline in laboratory and other research costs associated with lower research and development headcount, partially offset by an increase in clinical development costs; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $1.7 million in facility costs.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development related success payments and contingent consideration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the expenses (gains) associated with research and development related success payments and contingent consideration for the periods presented:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.848%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:9.978%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:9.978%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:9.178%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cobalt success payment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,920</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,760</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,680</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Harvard success payments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,703</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(580</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,283</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,384</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,460</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(76</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development related success payments and contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,007</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,887</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expense related to the change in the estimated fair value of our Cobalt Success Payment was $27.9 million for the three months ended March 31, 2024, compared to a gain of $4.8 million for the same period in 2023. The changes in value were due to changes in our market capitalization. The expense related to the change in the estimated fair value of our Harvard Success Payments was $4.7 million for the three months ended March 31, 2024, compared to a gain of $0.6 million for the same period in 2023. The changes in value were primarily due to changes in our common stock price during the relevant periods. The expenses related to the change in the estimated fair value of our Cobalt Contingent Consideration was $5.4 million and $5.5 million for the three months ended March 31, 2024 and 2023, respectively. The changes in value were due to changes in the timing and probability of the achievement of milestones during the relevant periods.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $16.3 million and $16.8 million for the three months ended March 31, 2024 and 2023, respectively. The decrease of $0.5 million was primarily due to lower personnel-related costs due to a decrease in headcount related to the strategic repositioning in October 2023 and a decrease in costs related our previously planned manufacturing facility in Fremont, California. The decreases were partially offset by an increase in patent and other legal fees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income, net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income, net, was $3.0 million and $2.0 million for the three months ended March 31, 2024 and 2023, respectively, and consisted primarily of interest earned on our cash and marketable securities balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity, capital resources, and capital requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had $311.1 million in cash, cash equivalents, and marketable securities. To date we have raised an aggregate of approximately $1.5 billion in net proceeds from sales of common stock and private placements of our convertible preferred stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we completed an underwritten public offering pursuant to which we sold 21.8 million shares of our common stock, including 4.5 million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 12.7 million shares of our common stock for net proceeds of approximately $180.0 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we entered into a sales agreement with Cowen, acting as sales agent, pursuant to which we may offer and sell through Cowen up to $150.0 million in shares of our common stock under the ATM facility. As of March 31, 2024, we have sold an aggregate of 4.9 million shares of our common stock under the ATM facility for net proceeds of $28.7 million, after deducting commissions and expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any revenue from product sales or any other sources, and we have incurred significant operating losses. We have not yet commercialized any products, and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future funding requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to incur additional losses for the foreseeable future as we conduct and expand our research and development efforts, including conducting preclinical studies and clinical trials, developing new product candidates, establishing internal and external manufacturing capabilities, and funding our operations generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months. However, we anticipate that we will need to raise additional financing in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of clinical trials required for regulatory approval of our current or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our current or future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost, timing, and scope of building our manufacturing capabilities, as well as costs associated with the manufacturing of clinical and commercial supplies of our current and future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements, and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expenses required to attract, hire, and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of global supply chain issues and rising rates of inflation on the costs of laboratory consumables, supplies, and equipment required for our ongoing operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party, including government, payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential interruptions or delays resulting from global geo-political, economic, and other factors beyond our control;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products, and technologies. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate significant revenue from product sales, we expect to finance our operations with our existing cash, cash equivalents, and marketable securities, proceeds from any future equity or debt financings, and upfront, milestone, and royalty payments received under any future licenses, collaborations, or other arrangements. In the event that additional financing is required, we may not be able to raise it on terms that are acceptable to us or at all. Our ability to raise additional financing may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from public health crises, conflicts in Ukraine, the Middle East, or other regions, changes in inflation, interest rate uncertainty, and other factors creating market risk. Recent bank failures have also caused increased concerns about liquidity in the broader financial services industry, and our business, business partners, or industry as a whole may be adversely impacted in ways that we cannot predict at this time. If we raise additional funds through the issuance of equity or convertible debt securities, existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may result in increased fixed payment obligations, and the existence of securities with rights that may be senior to those of our common stock, and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, or acquiring, selling, or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. If we raise funds through strategic collaborations or licensing or other arrangements, we may have to relinquish significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from various factors beyond our control. If we are unable to raise additional capital when desired, our business, results of operations, and financial condition would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.16%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(65,632</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(79,272</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(77,228</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,727</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">186,397</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(16,309</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024, net cash used in operating activities was $65.6 million, consisting primarily of net loss of $107.5 million and the change in net operating assets and liabilities of $7.4 million, offset by non-cash adjustments of $49.3 million. The non-cash adjustments of $49.3 million consisted of $9.1 million of non-cash stock-based compensation, expenses of $32.6 million and $5.4 million for revaluation of our success payment liabilities and contingent consideration, respectively, and depreciation expense of $3.7 million, offset by other non-cash adjustments of $1.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2023, net cash used in operating activities was $79.3 million, consisting primarily of net loss of $82.1 million, the change in net operating assets and liabilities of $10.8 million, and non-cash adjustments of $13.6 million. The non-cash adjustments of $13.6 million consisted of non-cash stock-based compensation expense of $8.8 million, depreciation expense of $4.3 million, and other non-cash adjustments of $0.5 million.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in investing activities was $77.2 million during the three months ended March 31, 2024, and cash provided by investing activities was $62.7 million during the three months ended March 31, 2023. For the three months ended March 31, 2024, this consisted of net purchases and maturities of marketable securities of $61.4 million and purchases of property and equipment of $15.8 million. For the three months ended March 31, 2023, this consisted of net purchases and maturities of marketable securities of $64.9 million, offset by purchases of property and equipment of $2.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024 and 2023, cash provided by financing activities was $186.4 million and $0.2 million, respectively, consisting primarily of net proceeds from issuance of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual obligations and commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our significant contractual obligations and commitments as of March 31, 2024:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.184%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1.4%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payments Due by Period</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than 1 Year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1 to 3 Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3 to 5 Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">More than 5 Years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,333</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,745</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,415</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,964</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,457</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than as disclosed in the table above, the payment obligations under our license, collaboration, and acquisition agreements as of March 31, 2024 are contingent upon future events such as our achievement of specified development, regulatory, and commercial milestones or royalties on net product sales. See the section titled &#8220;Business&#8212;Key Intellectual Property Agreements&#8221; in Part I, Item 1 of our 2023 Annual Report for more information about these payment obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also obligated to make a success payment to Cobalt of up to $500.0 million, payable in cash or stock, pursuant to the terms and conditions in the Cobalt acquisition agreement, and up to an aggregate of $175.0 million in success payments to Harvard, payable in cash. See Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8220;&#8212;Critical accounting policies and significant judgments and estimates&#8212;Success payments&#8221; in our 2023 Annual Report and Note 4, License and collaboration agreements, to our condensed consolidated financial statements located elsewhere in this Quarterly Report for more information on the success payments. As of March 31, 2024, the timing and likelihood of achieving the milestones and success payments and generating future product sales are uncertain, and therefore any related payments are not included in the table above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also enter into agreements in the normal course of business for sponsored research, preclinical studies, clinical trials, contract manufacturing, and other services and products for operating purposes, which are generally cancelable upon written notice. These obligations and commitments are not included in the table above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Off-balance sheet arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not engaged in any off-balance sheet arrangements as defined under the rules and regulations of the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">JOBS Act accounting election</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). We will remain an emerging growth company until the earliest to occur of (1) December 31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (3) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the fair market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our independent registered public accounting firm provide an attestation report on our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use the extended transition period for any new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early if the standard allows early adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical accounting policies and significant judgments and estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Our significant accounting policies are described in more detail in the notes to our condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023, are consistent with those discussed in Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8220;&#8212;Critical accounting policies and significant judgments and estimates&#8221; in our 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and the volatility of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our common stock price.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest rate risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had cash, cash equivalents, and restricted cash of $180.9 million, which consisted of bank deposits and money market funds, and also had marketable securities of $134.0 million. The primary objective of our investment activities is to preserve capital to fund our operations while earning a low-risk return. Because our marketable securities are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a hypothetical 10% change in market interest rates during any of the periods presented would not have had a significant impact on the total value of our portfolio. We had no debt outstanding as of March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market capitalization and common stock price sensitivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We agreed to make a success payment to Cobalt based on our market capitalization payable in cash or stock, and success payments to Harvard based on increases in the per share fair market value of our common stock, payable in cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the estimated aggregate fair value of the success payment liabilities was $45.4 million. For the three months ended March 31, 2024, we recorded an expense of $32.6 million related to the aggregate change in the estimated fair value of our success payment liabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in our market capitalization and the fair value of our common stock as of each balance sheet date may result in a relatively large change in the estimated valuation of the success payment liabilities and resulting expense or gain. For example, for the Cobalt Success Payment, keeping all other variables constant, a hypothetical 20% increase in our market capitalization as of March 31, 2024 from $2.2 billion to $2.7 billion would have increased the expense recorded in the three months ended March 31, 2024 by $9.2 million to $37.1 million. A hypothetical 20% decrease in our market capitalization from $2.2 billion to $1.8 billion would have decreased the expense recorded in the three months ended March 31, 2024 by $9.5 million to $18.4 million. For the Harvard Success Payments, keeping all other variables constant, a hypothetical 20% increase in our common stock price as of March 31, 2024 from $10.0 per share to $12.0 per share would have increased the expense recorded in the three months ended March 31, 2024 by $2.1 million to $6.8 million. A hypothetical 20% decrease in the common stock price from $10.0 per share to $8.0 per share would have decreased the expense recorded in three months ended March 31, 2024 by $1.8 million to $2.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency sensitivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency rates. We do not believe we will experience material impacts from such foreign currency sensitivity. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effects of inflation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and laboratory consumables. We believe that inflation has not had a material effect on our financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, management, including our Chief Executive Officer and Chief Financial Officer, evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2024, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting during the quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_ii_or_information"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II. OTHE</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may in the ordinary course of business face various claims brought by third parties, and we may make claims or take legal action to assert our rights, including intellectual property rights, as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover multiple types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our operations, cash flows, or financial position. Additionally, any such claims, whether successful or not, could damage our reputation and business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc124805_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report, including our financial statements and related notes included elsewhere in this Quarterly Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, reputation, or results of operations. In such a case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The summary risk factors set forth below are the principal risks that we believe are material to our investors and a reader should carefully consider them. The following is a summary of the principal risks and uncertainties; however, there are additional risks and uncertainties described in this &#8220;Risk Factors&#8221; section. This summary does not address every aspect of our risk factors, all of the risks that we face, or other factors not presently known to us or that we currently believe are immaterial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of the principal risks and uncertainties described in more detail in this Quarterly Report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. This uncertainty exposes us to unforeseen risks, makes it difficult for us to predict the time and cost that will be required for the development and potential regulatory approval of our product candidates, and increases the risk that we may ultimately not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional funding to finance our operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce, or eliminate certain product development programs or commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not realize the benefits of technologies that we have acquired or in-licensed or will acquire or in-license in the future. We may also fail to enter into new strategic relationships or may not realize the benefits of any strategic relationships that we have entered into. The occurrence of any of the foregoing could materially adversely affect our business, financial condition, commercialization prospects, and results of operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to develop our cell engineering platforms and product candidates and our future growth depend on retaining our key personnel and recruiting additional qualified personnel.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may encounter difficulties in managing our growth if and</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as we expand our operations, including our development and regulatory capabilities, which could disrupt our operations and otherwise harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of human stem cells exposes us to a number of risks in the development of our human stem cell-derived products, including inability to obtain suitable donor material from eligible and qualified human donors, restrictions on the use of human stem cells, as well as ethical, legal, and social implications of research on the use of stem cells, any of which could prevent us from completing the development of or commercializing and gaining acceptance for our products derived from human stem cells.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must successfully progress our product candidates through extensive preclinical studies and clinical trials in order to obtain regulatory approval to market and sell such product candidates. Even if we obtain positive results in preclinical studies of a product candidate, these results may not be predictive of the results of future preclinical studies or clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical testing of our product candidates may be delayed or otherwise unsuccessful, which would harm our ability to commence and successfully complete clinical trials of, and ultimately commercialize, such product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes. If clinical trials of any of our product candidates are prolonged or delayed, or need to be terminated, we may be unable to obtain required regulatory approvals and commercialize such product candidates on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials may fail to demonstrate that our product candidates, including any future product candidates, or technologies used in or used to develop such product candidates, meet the FDA's or a comparable foreign regulatory authority's requirements with respect to safety, purity, and potency, or efficacy, which would prevent, delay, or limit the scope of regulatory approval and commercialization of such product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause serious adverse, undesirable, or unacceptable side effects or have other properties that may delay or prevent marketing approval. If a product candidate receives regulatory approval, and such side effects are identified following such approval, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following such approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of our product candidates is complex. We or our contract development and manufacturing organizations (CDMOs) may encounter difficulties in production, which could delay or entirely halt our or their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to a number of risks related to the supply chain for the materials required to manufacture our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to perform certain activities, including research and preclinical studies, manufacture of our product candidates and materials used in the manufacturing of our product candidates, and the conduct of various aspects of our clinical trials. Any failure of such third parties to perform their obligations to us, including in accordance with our timelines or applicable regulatory requirements, could materially harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on intellectual property licensed from third parties. If we breach our obligations under the applicable license agreements or if any of these agreements is terminated, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems, or those used by third parties involved in our operations, such as research institution collaborators, clinical research organizations (CROs), CDMOs, and other service providers, contractors, or consultants, may fail or suffer security breaches or incidents.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the United States Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. If we are unable to obtain regulatory approval for our product candidates on a timely basis, or at all, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success payment and contingent consideration obligations in our license and acquisition agreements may result in dilution to our stockholders, drain our cash resources, or require us to incur debt to satisfy the payment obligations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing, or commercializing competing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters, public health epidemics, telecommunications or electrical failures, geo-political actions, including war and terrorism, political and economic instability, and other events beyond our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market and economic conditions may negatively impact our business, financial condition, and share price.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business and Industry</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. This uncertainty exposes us to unforeseen risks, makes it difficult for us to predict the time and cost that will be required for the development and potential regulatory approval of our product candidates, and increases the risk that we may ultimately not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key element of our strategy is to identify and develop a broad pipeline of product candidates using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms and advance those product candidates through clinical development for the treatment of various different diseases. The scientific research that forms the basis of our efforts to develop product candidates with our platforms is still ongoing. We are not aware of any FDA-approved therapeutics that are cell products derived from pluripotent stem cells (PSCs) or that utilize our fusogen technology. Further, the scientific evidence that supports the feasibility of developing therapeutic treatments based on our platforms is preliminary, limited, and remains ongoing. We are therefore exposed to a number of unforeseen risks, and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical and clinical testing of product candidates is inherently unpredictable and may lead to unexpected results, in particular when such product candidates are based on novel technologies. For example, we have not tested our cell engineering platforms on all pluripotent and differentiated cell types or in all microenvironments, and results from one cell type or microenvironment may not translate into other cell types or microenvironments. In addition, our current gene editing approaches rely on novel gene editing reagents that may have unanticipated or undesirable effects or prove to be less effective than we expect. Also, we are in the early stages of testing product candidates developed using our cell engineering platforms in humans, and most of our current data are limited to animal models and preclinical cell lines and assays, which may not accurately predict the safety and efficacy of our product candidates in humans. Additionally, we and third parties may have limited preclinical and clinical data, and a more limited understanding generally, with respect to certain indications, including autoimmune diseases, and we cannot predict the extent to which the safety and efficacy of a product candidate may vary across indications. We may encounter significant challenges creating appropriate models and assays for evaluating the safety and purity of our product candidates and may not be able to provide sufficient data or other evidence, to the satisfaction of regulatory authorities, that certain unexpected results observed in preclinical and clinical testing of our product candidates are not indicative of the potential safety issues of such product candidates. In addition, we may use manufacturing reagents and materials across various programs and initiatives. Certain reagents and materials may be novel and have unknown or unanticipated effects, including with respect to a product candidate&#8217;s safety, efficacy, or manufacturability. Any unanticipated or adverse effects related or attributed to such reagents or materials could affect all the programs and initiatives in which they are used, and result in delays and harm our ability to timely and successfully progress our product candidates through preclinical and clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may develop program plans and timelines for certain product candidates based on our experience with such product candidates in different indications or with other product candidates that incorporate or were developed with the same technologies based on our expectation that such product candidates will perform and act similarly. However, our product candidates may reveal unexpected, important differences, including with respect to safety or efficacy, when developed in different indications or as compared to such other product candidates, including differences that may require changes to the manufacturing process or clinical development plan that require additional time and resources beyond what we initially anticipated. Any such occurrence could require us to adjust or alter our development plans, which could delay, harm, or prevent our ability to develop and commercialize such product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, product candidates developed with our hypoimmune and fusogen technologies have potential safety risks, including those related to genotoxicity associated with the delivery of genome-modifying payloads. For example, DNA sequences that randomly integrate into a cell&#8217;s DNA may increase the risk for or cause certain cancers. Additionally, gene editing approaches may edit the genome at sites other than the intended DNA target or cause DNA rearrangements, each of which may have oncogenic or other adverse effects. PSC-derived cell products may have potential safety risks related to genomic and epigenomic variations that have occurred or may occur during the manufacturing process. We cannot always predict the types and potential impact of these genomic changes, including whether certain changes are or may eventually be harmful. Accordingly, it may be difficult for us to conduct the level of testing and assay development necessary to ensure that our PSC-derived cell product candidates have an acceptable safety profile when used in humans. These risks related to genetic variation are also relevant to our product candidates created from donor-derived cells. Additionally, our stem cell-based product candidates have potential safety risks that may result from cells that are undifferentiated or have not been completely differentiated to the desired phenotype and lead to oncogenic transformations or other adverse effects. As a result, it is possible that safety events or concerns could negatively affect the development of our product candidates, as described elsewhere in these Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the novelty of our technologies, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. However, due to a lack of experience with similar therapeutics or delivery methods, the regulatory pathway with the FDA and comparable foreign regulatory authorities may be more complex, time-consuming, and unpredictable relative to more well-known therapeutics. For example, even if we obtain human data to support continued evaluation and approval of our product candidates, the FDA or comparable foreign regulatory authorities may lack experience in evaluating the safety and efficacy of therapeutics similar to our product candidates or may scrutinize such data more closely than data generated from more established types of biological products. In addition, given that there are no approved PSC- or donor-derived cell therapy products on the market, the FDA and comparable foreign regulatory authorities have not established consistent standards by which to evaluate the safety of such products, and any such standards that they do establish may subsequently change. Moreover, the FDA remains focused on potential safety issues associated with gene and cell therapy products, and as the number of new gene and cell therapy product candidates submitted for FDA review has increased in recent years, the number of clinical holds imposed by the FDA has also increased. For example, the FDA has placed clinical holds on certain product candidates pending further evaluation of genomic abnormalities detected in as few as a single patient following administration of such product candidates. We cannot be certain that the FDA or comparable foreign regulatory authorities will determine that the potential safety risks associated with our product candidates outweigh the potential therapeutic benefits in each indication for which we develop our products, and that they will allow us to commence clinical trials of such product candidates in a timely manner, or at all, or to continue such clinical trials once they have commenced. If we become subject to a clinical hold with respect to any of our product candidates due to a potential safety issue, we cannot guarantee that we will be able to provide the applicable regulatory authority with sufficient data or other evidence regarding the safety profile of such product candidate such that we will be able to commence or resume clinical development of such product candidates in a timely manner or at all. Any such event could delay clinical development of such product candidate, including in other indications, or our other product candidates, increase our expected development costs, increase the length of the regulatory review process, and delay or prevent commercialization of our product candidates. In addition, the evaluation process for our product candidates will take time and resources and may require independent third-party analyses, and our product candidates may ultimately not be accepted or approved by the FDA or comparable foreign regulatory authorities. As such, even if we are successful in building our pipeline of product candidates from our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, we cannot be certain that such efforts will lead to the development of approvable or marketable products, either alone or in combination with other therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to reports of T cell malignancies in patients that previously received chimeric antigen receptor (CAR) T cell immunotherapies, the FDA announced in November 2023 that it is investigating the risk of secondary cancers and the need for regulatory action for such therapies as a class and has advised of new patient monitoring and reporting requirements with respect to such therapies. In January 2024, the FDA imposed a class-wide boxed warning requirement regarding the occurrence of T cell malignancies for all approved CAR T therapies. The FDA has noted that it currently believes that the overall benefits of these therapies continue to outweigh their potential risks for their approved uses. However, all currently approved CAR T cell immunotherapies are approved only in oncology indications, and there can be no assurance that the FDA or comparable foreign regulatory authorities will reach the same risk-benefit determination in other indications, such as autoimmune diseases. We have received and may in the future receive FDA correspondence requesting updates to certain of our CAR T cell clinical trials to address these developments. Additionally, we and our product candidates may be subject to further regulatory actions or requirements of the FDA or comparable foreign regulatory authorities relating to these therapies, such as requiring a black box warning or other labeling disclosures for any approved products. The occurrence of any of the foregoing could increase the cost and complexity of development and commercialization of, and limit the commercial opportunity for, such product candidates, any of which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of our product candidates will depend on or be affected by numerous factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our successful and timely completion of preclinical studies and clinical trials for which the FDA and any comparable foreign regulatory authorities agree with the design, endpoints, and implementation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timely receipt of regulatory approvals or authorizations to conduct clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to timely and successfully initiate, enroll patients in, and complete clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate meets the FDA&#8217;s or such comparable foreign regulatory authority&#8217;s legal standards with respect to safety, purity, and potency, or efficacy, which may include, among other things, demonstrating that the benefits of the product candidate outweigh its known risks for the intended patient population, and that such product candidate can be manufactured in accordance with applicable legal requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timely receipt of marketing approvals for our product candidates from applicable regulatory authorities, including the impact of any changes to the FDA&#8217;s Accelerated Approval Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to address any potential interruptions or delays resulting from external factors, including those related to the current global geo-political, business, and economic environment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent of any clinical or regulatory setbacks experienced by other companies developing similar products or within adjacent fields, including autologous and allogeneic cell-based therapies and the fields of gene editing and gene therapy, or publications or press coverage related to such therapies and fields, which could negatively impact the perceptions of the value and risk of our product candidates and technologies;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent of any post-marketing approval commitments we may be required to make to applicable regulatory authorities, including the conduct of any post-marketing approval clinical studies, and our ability to comply with any such commitments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish, scale up, and scale out, either alone or with CDMOs, manufacturing capabilities for clinical supply of our product candidates for our clinical trials and, if any of our product candidates are approved, commercial supply (including licensure) of such product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience issues or delays with respect to any one or more of these factors, we could experience significant delays or be unable to successfully develop and commercialize our product candidates, which would materially adversely affect our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits of technologies that we have acquired or in-licensed or will acquire or in-license in the future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key component of our strategy is to acquire and in-license technologies to support our mission of using engineered cells as medicines. Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering technologies represent an aggregation of years of innovation and technology from multiple academic institutions and companies, including hypoimmune technology that we licensed from the President and Fellows of Harvard College (Harvard) and The Regents of the University of California (UCSF), our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering program focused on certain brain disorders that we acquired from Oscine Corp., our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licensed from Beam Therapeutics Inc., among others. We continue to actively evaluate various acquisition and licensing opportunities on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The level of success of these acquisition and in-licensing arrangements, including any that we may enter into in the future, will depend on the risks and uncertainties involved, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated liabilities related to acquired companies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty integrating acquired personnel, technologies, and operations into our existing business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty retaining key employees, including of any acquired businesses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management time and focus from operating our business to management of acquisition and integration efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">higher than expected acquisition or integration costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disruption in our relationships with collaborators, key suppliers, manufacturers, or customers as a result of an acquisition; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possible write-offs of assets, goodwill or impairment charges, or increased amortization expenses relating to acquired businesses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in and cost of combining the operations and personnel of any acquired business with our own; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges integrating acquired businesses into our business, including our existing operations and culture. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in October 2023, we underwent a strategic repositioning pursuant to which we updated our portfolio to increase our focus on our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cell therapy product candidates and reduce our near-term investment in our fusogen platform. As part of this reduction, we shifted our focus on fusogen to research activities. We expect to encounter increased costs and difficulties if and when we expand preclinical development and initiate clinical development for product candidates derived from</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our fusogen platform, including those related to scaling up and driving forward clinical development and manufacturing activities. As a result, there is increased risk that the benefits we expected from the fusogen platform at the time of the Cobalt acquisition may be more expensive and difficult to obtain or may not occur at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, foreign acquisitions are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations, and the particular economic, political, and regulatory risks associated with specific countries. The occurrence of any of these risks or uncertainties may preclude us from realizing the anticipated benefit of any acquisition, and our financial condition may be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may not be successful in our efforts to acquire, obtain rights to, or otherwise access certain technologies or products that are necessary for the success of our product candidates or technologies on acceptable terms or at all, including because we may be unable to successfully or timely negotiate the terms of an agreement with the third-party owner of such technology or products or such third party may have determined to deprioritize such technology or products. Such transactions, as well as other strategic relationships we may enter into, may also be impacted by policies of or actions by certain regulatory authorities, such as the Federal Trade Commission (FTC), that have jurisdiction over various aspects of such transactions and relationships. If we are not able to acquire, obtain rights to, or otherwise access certain technologies or products on which certain of our product candidates or technologies may depend, it may be necessary for us to delay, reduce, or curtail the development of such product candidates or technologies, or incur additional costs in order to continue development without such rights.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to enter into new strategic relationships or may not realize the benefits of any strategic relationships that we have entered into, either of which could materially adversely affect our business, financial condition, commercialization prospects, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. In addition, our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms are attractive technologies for potential collaborations due to their breadth of application. Therefore, for certain of our product candidates, including product candidates that we may develop in the future, we may decide to form or seek strategic alliances, collaborations, or similar arrangements with pharmaceutical or biotechnology companies that we believe will complement or augment our development and potential commercialization efforts with respect to such product candidates, including in territories outside the United States or for certain indications. We may also pursue joint ventures or investments in complementary businesses that align with our strategy. To the extent we enter into strategic relationships involving companies located outside the United States, we are subject to similar risks to those described elsewhere in these Risk Factors with respect to foreign acquisitions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may not be successful in our efforts to establish a collaboration or other alternative arrangements for our product candidates on acceptable terms or at all, including because our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate success in clinical trials and ultimately obtain regulatory approval. Additionally, there have been a significant number of recent business combinations among large pharmaceutical companies that have reduced the number of potential future collaborators and changed the strategies of the resulting combined companies. In addition, under the terms of certain license agreements applicable to our product candidates, we may be restricted from entering into collaboration or similar agreements relating to those product candidates on certain terms or at all. If and when we collaborate with a third party for development and commercialization of a product candidate, we expect that we may have to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of our technologies, product candidates, and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and could determine that such other collaboration is more attractive than a collaboration with us for our product candidate. Similar risks exist with respect to any joint ventures we may pursue, as well as risks and uncertainties related to the costs, time, and other resources required to manage and gain the benefit of any such joint venture, and any potential liabilities we may incur in connection with a joint venture.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In instances where we enter into collaborations, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects, and financial condition:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may have significant discretion in determining the efforts and resources that they will apply to a collaboration and may not commit sufficient efforts, funding, and other resources to the development or marketing programs for collaboration product candidates or may misapply those efforts, funding, or resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may experience financial difficulties, including those that could negatively impact their ability to perform their obligations pursuant to the collaboration agreement, such as funding and development obligations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may decide or may be required by regulatory authorities to delay clinical trials, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to relinquish important rights to our product candidates, such as marketing, distribution, and intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to agree to exclusivity, non-competition, or other terms that restrict our ability to research, develop, or commercialize certain existing or potential future product candidates, including our ability to develop our product candidates in certain indications or geographic regions or combine our product candidates with certain third-party products;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may acquire outside of the collaboration or develop, independently or in collaboration with third parties, including our competitors, products that compete directly or indirectly with our product candidates and may decide to advance such product candidates instead of ours; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property rights covering the product candidates that result from our collaboration, and in such cases, we may not have the exclusive right to commercialize such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we and our collaborators may disagree regarding the development plan for a collaboration product candidate, including, for example, with respect to target indications, inclusion or exclusion criteria for a clinical trial, or the decision to seek approval as front-line therapy versus second-, third-, or fourth-line therapy; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise with our collaborators that could result in the delay or termination of the research, development, or commercialization of the applicable product candidates or costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our or the collaborator&#8217;s willingness to complete our or such collaborator&#8217;s obligations under the collaboration; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated, which may require us to obtain additional capital to pursue further development or commercialization of the applicable product candidates; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not achieve the revenue, specific net income, or other anticipated benefits that justify our having entered into, or otherwise led us to enter into, the collaboration. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our strategic collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. Moreover, our initial estimates of the potential revenue we are eligible to receive under our strategic collaborations may include potential payments related to therapeutic programs for which our collaborators may discontinue development. If we are unable to enter into strategic collaborations, or if any of the other events described in this Risk Factor occur after we enter into a collaboration, we may have to curtail the development of a particular product candidate, reduce or delay the development program for such product candidate or one or more of our other product candidates, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to develop our cell engineering platforms and product candidates and our future growth depend on retaining our key personnel and recruiting additional qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends upon the continued contributions of our key management, scientific, and technical personnel, many of whom have been instrumental for us and have substantial experience with our cell engineering platforms and their underlying technologies and related product candidates. Given the specialized nature of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering technologies and the fact that we are operating in novel and emerging fields, there is an inherent scarcity of personnel with the requisite experience to fill the roles across our organization. As we continue developing our product candidates and building our pipeline, we will require personnel with medical, scientific, or technical qualifications and expertise specific to each program. The loss of key management and senior scientists or other personnel could delay our research and development activities. In addition, the loss of key executives could disrupt our operations and our ability to conduct our business. Despite our efforts to retain valuable employees, all of our employees are at-will employees, and members of our management, scientific, and development teams may terminate their employment with us at any time, with or without notice. Moreover, regulations or legislation impacting our workforce, such as the recently-issued FTC rule that generally prohibits employers from imposing non-compete obligations on their employees and renders most existing non-compete obligations unenforceable, and any legal challenges thereto, may lead to increased uncertainty in hiring and competition for talent, and harm our ability to protect our company, including our intellectual property, after termination of employment. If our retention efforts are unsuccessful now or in the future, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, certain of our key employees, including Drs. Terry Fry and Steve Goldman, retain partial employment at academic institutions. We may in the future have other employees that have similar employment arrangements. These arrangements expose us to the risk that these individuals may return to their academic positions full-time, devote less of their time or attention to us than is optimal, or potentially expose us to claims of intellectual property ownership or co-ownership by their respective academic institutions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The competition for qualified personnel in the biotechnology and pharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled employees, including executives, scientists, engineers, clinical operations and manufacturing personnel, and sales professionals. We expect that we may continue to face competition for personnel from other companies, universities, public and private research institutions, and other organizations. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining qualified employees on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel may have greater resources than we do and may be able to provide prospective job candidates or our existing employees with more attractive roles, salaries, or benefits than we can provide. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, including non-solicitation or non-compete obligations, which may result in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline or are otherwise viewed unfavorably compared to those of companies with which we compete for talent, or if we or our prospects are otherwise viewed unfavorably, this could negatively impact our ability to recruit, motivate, and retain highly skilled employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our November 2022 and October 2023 restructurings, we reduced our then-current headcount by approximately 15% and 29%, respectively. Reductions in our workforce may result in reduced employee morale and negative publicity, which may damage our reputation and make it more difficult for us to retain and motivate our current personnel as well as attract new personnel. These workforce reductions have also caused us to lose institutional knowledge, capabilities, and subject matter expertise and could negatively affect our efforts to obtain and maintain our intellectual property rights in the event we are unable to identify inventions made or identify or recreate the necessary scientific records or data. Any of the foregoing could significantly harm our business and future growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Though many of our personnel have significant experience with respect to manufacturing biopharmaceutical products, we, as a company, do not have experience in developing or maintaining a manufacturing facility. We cannot guarantee that we will be able to maintain a compliant facility and manufacture our product candidates as intended, given the complexity of manufacturing novel therapeutics. If we fail to successfully operate our facility and manufacture a sufficient and compliant supply of our product candidates, our clinical trials and the commercial viability of our product candidates could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of gene and cell therapy products often encounter difficulties in production, particularly in scaling up, scaling out, validating initial production, ensuring the absence of contamination, and ensuring process robustness after initial production. These include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, and shortages of qualified personnel, as well as compliance with strictly enforced federal, state, and foreign regulations. As a result of the complexities involved in biopharmaceutical manufacturing, the cost to manufacture biologics is generally higher than traditional small molecule chemical compounds and the manufacturing process is less reliable and more difficult to reproduce, and this is particularly true with respect to our product candidates. The application of new regulatory guidelines or parameters, such as those related to control strategy testing, may also adversely affect our ability to manufacture our product candidates in a compliant and cost-effective manner or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to invest in building world class capabilities in key areas of manufacturing sciences and operations, including development of our cell engineering platforms, product characterization, and process analytics. Our investments also include scaled research solutions, scaled infrastructure, and novel technologies to improve efficiency, characterization, and scalability of manufacturing, including establishing our internal manufacturing capabilities. However, we have limited experience in managing the manufacturing processes necessary for making cell and gene therapies. We cannot be sure that the manufacturing processes that we use, or the technologies that we incorporate into these processes, will result in viable or scalable yields of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates that will have acceptable safety, purity, and potency, or efficacy, profiles and meet market demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key part of our strategy is operating our own manufacturing capabilities, including our own manufacturing facilities. In June 2022, we entered into a long-term lease to establish and develop our own current good manufacturing practices (cGMP) manufacturing facility in Bothell, Washington (the Bothell facility). In addition, in January 2022, we entered into an agreement with the University of Rochester, pursuant to which we have obtained access to manufacturing capabilities within University of Rochester Medical Center&#8217;s (URMC) cell-based manufacturing facility (the URMC site) to support manufacturing of product candidates across our portfolio for early-stage clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designing and building out the Bothell facility and the URMC site are time-consuming and require significant resources, including a reallocation of certain of our existing financial, human, and other resources, including the time and attention of our senior management. In addition, given the volatility in the costs of building materials, as well as the impact of rising rates of inflation in recent years and which may occur in the future, building out our manufacturing capabilities may be more expensive than we expect. We do not have experience as a company in developing internal manufacturing capabilities, and we may experience unexpected costs or delays or be unsuccessful in developing our internal manufacturing capabilities in time to support registration-enabling clinical trials of our product candidates or at all. In order to build out the Bothell facility and the URMC site, we will need to continue to engage third-party service providers and obtain equipment and third-party technology necessary to manufacture our product candidates. However, we may not be able to negotiate agreements with third parties or access necessary technologies on commercially reasonable terms or at all. Moreover, there is no guarantee that the space that we are leasing to develop the Bothell facility will not change ownership over the term of the lease or be subject to additional zoning or other restrictions, and that, in such an event, we will be able to continue to build or operate the facility without restriction or further delay or cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, operating the Bothell facility and the URMC site will require us to continue to hire and retain experienced scientific, quality control, quality assurance, and manufacturing personnel. As described elsewhere in these Risk Factors, this may be difficult given the intense competition for qualified personnel in the biotechnology and pharmaceutical industries. In addition, though we plan to design and build out our manufacturing capacities at the URMC site, we do not control URMC&#8217;s cell-based manufacturing facility, nor do we have control over how URMC manages and operates this facility. If URMC does not maintain its cell-based manufacturing facility in accordance with our requirements, we may not be able to manufacture our product candidates in a timely manner or at all, which may delay our ability to commence clinical trials for, obtain regulatory approval for, and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and expect we will continue to rely, on CDMOs to manufacture our product candidates for preclinical studies and clinical trials. Moreover, it may take us longer to establish and operationalize our Bothell facility than we originally anticipated, which may delay our ability to begin manufacturing certain of our product candidates internally and extend the period of time during which we must solely rely on CDMOs for the manufacture of such product candidates. For example, we may rely on our CDMOs for the potential registration and commercial launch of our first product candidate under our current clinical development timelines, and if there are any delays in our ability to establish and operationalize the Bothell facility, we may be required to rely more heavily on our CDMOs for the potential registrations and commercial launches of additional product candidates as well.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once we have completed the build-out of the Bothell facility and the URMC site, we may be required to transition manufacturing processes and know-how for certain of our product candidates from our CDMOs to the Bothell facility and the URMC site. To date, we and our CDMOs have limited experience in the technology transfer of manufacturing processes. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to the Bothell facility and the URMC site may require utilization of new or different processes to meet our facility requirements. Additional studies may also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We will not know with certainty whether all relevant know-how and data have been adequately incorporated into the manufacturing process being conducted at our facilities until the completion of studies and evaluations intended to demonstrate the comparability of material previously produced by our CDMOs with that generated by our facilities. Similar risks and considerations apply to the initial technology transfer from us to our CDMOs for manufacturing of pre-clinical and clinical supply, as well as between CDMOs in the event we are required to switch to a new CDMO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating the Bothell facility and the URMC site will require us to comply with complex regulations. Moreover, the Bothell facility, and any future commercial manufacturing facilities we may operate, will require FDA or comparable foreign regulatory authority approval, which we may not obtain in time to support registration-enabling clinical trials for our product candidates, if at all. Even if approved, we would be subject to ongoing periodic unannounced inspections by the FDA, the Drug Enforcement Administration, corresponding state agencies, and comparable foreign regulatory authorities to ensure strict compliance with cGMP, current good tissue practices (cGTPs), and other government regulations. We may be unable to manufacture our product candidates if we fail to meet regulatory requirements and may be unable to scale up or scale out our manufacturing to meet market demand. Any failure or delay in the development of our manufacturing capabilities, including at the Bothell facility and the URMC site, could adversely impact the development and potential commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth if and as we expand our operations, including our development and regulatory capabilities, which could disrupt our operations and otherwise harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We experienced rapid growth following our inception in July 2018. However, as described elsewhere in these Risk Factors, we undertook workforce reductions as part of our November 2022 and October 2023 restructurings. These workforce reductions may yield unintended consequences and costs, including difficulty retaining and motivating remaining employees, difficulty attracting and hiring qualified employees, and increased reliance on third parties if needed to support our internal capabilities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite our workforce reductions, if we have success in our initial clinical trials, we expect continued growth in the scope of our operations, particularly if and as we advance our product candidates into and through IND-enabling studies and clinical trials and continue to establish and develop our regulatory, quality, and clinical operations and supply chain logistics and manufacturing. To manage our growth, we have implemented and improved, and plan to continue to implement and improve, our managerial, operational, and financial systems, and continue to recruit and train additional qualified personnel. However, due to our limited financial resources and the complexity of managing a company with such growth, we may not be able to effectively manage the expansion of our operations or recruit and train sufficient additional qualified personnel to achieve our business objectives within our desired timelines. The continued expansion of our operations will be costly and may divert our management and business development resources. For example, members of management will have significant added responsibilities in connection with effecting and managing our growth, including identifying, recruiting, integrating, maintaining, and motivating current and future employees, effectively managing our internal development efforts, including the clinical and regulatory (e.g., FDA) review process, while complying with our contractual obligations to third parties, and maintaining and improving our operational, financial, and management controls, reporting systems, and procedures. In addition, as we grow, we may be required to rely more heavily on third-party service providers, which exposes us to risks to which we would not be subject if we performed all work internally, as described elsewhere in these Risk Factors. Our inability to successfully manage our growth could disrupt our operations and otherwise harm our business, including by delaying execution of our programs and business plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms, and product candidates that we identify for specific indications. Additionally, we have contractual commitments under certain of our agreements to use commercially reasonable efforts to develop certain programs and, thus, do not have unilateral discretion to vary from such efforts. In addition, we have contractual commitments to conduct certain development plans, and thus may not have discretion to modify such development plans, including clinical trial designs, without agreement from our partners. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Additionally, we may be required to invest our resources in a limited number of more advanced programs with higher probabilities of success in the shorter term and, consequently, to reduce our investment in promising earlier stage programs. Such decisions would require us to reduce the breadth and diversity of our product portfolio, which could potentially limit the long-term growth of our pipeline and subject us to greater risk that the failure of any such programs would harm our prospects. Our spending on current and future research and development programs, therapeutic platforms, and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The use of human stem cells exposes us to a number of risks in the development of our human stem cell-derived products, including inability to obtain suitable donor material from eligible and qualified human donors, restrictions on the use of human stem cells, as well as the ethical, legal, and social implications of research on the use of stem cells, any of which could prevent us from completing the development of or commercializing and gaining acceptance for our products derived from human stem cells.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use human stem cells in our research and development, including induced PSCs (iPSCs) and embryonic stem cells (ESCs), and one or more of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates may be derived from human stem cells. The use of such cells in our research, or as starting cell lines in the manufacture of one or more of our product candidates, exposes us to numerous risks. These risks include difficulties in securing viable, appropriate, and sufficient stem cells as starting material, recruiting patients for our clinical trials, as well as managing a multitude of global legal and regulatory restrictions on the sourcing and use of these cells. For example, to the extent regulatory requirements differ across jurisdictions, we may face increased difficulty finding cells that meet all applicable jurisdictional requirements, or may be required to develop our product candidates using multiple different types of cells, which could increase the complexity and cost of development. In addition, certain cells may be subject to restrictions regarding the patient populations in which the resulting products can be used, which could limit the applicability and value of our product candidates. Further, in some states, use of embryonic tissue as a source of stem cells is prohibited and many research institutions have adopted policies regarding the ethical use of human embryonic tissue. If these regulations, policies, or restrictions have the effect of limiting the scope of research or other activities we can conduct using stem cells, our ability to develop our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates may be significantly impaired, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the use of stem cells generally, and ESCs, in particular, has social, legal, and ethical implications. Certain political and religious groups continue to voice opposition to the use of human stem cells in drug research, development, and manufacturing. Adverse publicity due to ethical and social controversies surrounding the use of stem cells could lead to negative public opinion, difficulties enrolling patients in our clinical trials, increased regulation, and stricter policies regarding the use of such cells, which could harm our business and may limit market acceptance of any of our product candidates that may receive regulatory approval. In addition, clinical experience with stem cells, including iPSCs and ESCs, is limited. We are not aware of any products utilizing iPSCs or ESCs as a starting material that have received marketing approval from the FDA or a comparable foreign regulatory authority. Therefore, patients in our clinical trials may experience unexpected side effects, and we may experience unexpected regulatory delays prior to or, if approval were to be granted, after regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, manufacturing and development of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stem cell-derived and allogeneic T cell-derived product candidates will require that we obtain suitable donor material from eligible and qualified human donors. If we are unable to obtain sufficient quantities of suitable donor material, or if we are unable to obtain such material in a timely manner, we may experience delays in manufacturing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates, which would harm our ability to conduct clinical trials for or to commercialize these product candidates. Moreover, if the consent, authorization, or process for the donation and use of those materials is not obtained or conducted in accordance with applicable legal, ethical, and regulatory requirements, we could face delays in the clinical testing and approval of these product candidates, or, potentially, we could face claims by such human donors or regulatory authorities, which could expose us to damages and reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Negative public opinion and increased regulatory scrutiny of research and therapies involving gene editing or other ex vivo or in vivo cell engineering technologies may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain aspects of our cell engineering platforms rely on the ability to modify the genome, including by editing genes. Public perception may be influenced by claims that genome modification is unsafe, and products using or incorporating genome modification may not gain the acceptance of the public or the medical community. Similarly, general perceptions of products relying on ex vivo or in vivo cell engineering techniques may be impacted by developments within the research community as well as across the pharmaceutical and biotechnology industries, including those affecting or related to other companies, including those developing products that are similar or within adjacent fields or that are being developed in the same indications. Negative perceptions of genome modification, including gene editing, or of cell or gene therapy products generally, may result in fewer physicians being willing to enroll patients into clinical trials of our product candidates or prescribing our treatments, reduce the willingness of patients to participate in clinical trials of our product candidates or use our treatments, or otherwise negatively impact the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the novel nature of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering technologies, governments may impose import, export, or other restrictions in order to retain control or limit the use of such technologies. Further, in order to further understand the risks of novel genome modification technologies, regulatory authorities may require us to provide additional data prior to allowing clinical testing or commercialization of product candidates that use such technologies, which may cause us to incur additional costs and delay our development plans for certain of our product candidates. Increased scrutiny, negative public opinion, more restrictive government regulations, or enhanced governmental requirements, either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Development and Clinical Testing of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must successfully progress our product candidates through extensive preclinical studies and clinical trials in order to obtain regulatory approval to market and sell such product candidates. Even if we obtain positive results in preclinical studies of a product candidate, these results may not be predictive of the results of future preclinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before an IND or comparable foreign submission can be submitted to the FDA or a comparable foreign regulatory authority and be cleared or otherwise become effective, which is a prerequisite for conducting clinical trials on human subjects, a product candidate must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation studies conducted in accordance with good laboratory practices. In addition, to obtain the requisite regulatory approvals to ultimately market and sell any of our product candidates, we or any future collaborator for such product candidate must satisfy the FDA&#8217;s or a comparable foreign regulatory authority&#8217;s legal standards with respect to safety, purity, and potency, or efficacy, which may include, among other things, demonstrating through adequate and well-controlled clinical trials that the benefits of the product candidate outweigh its known risks for the intended patient population.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical and clinical testing is inherently unpredictable. We may obtain positive data from early research involving our product candidates but subsequently encounter unexpected or unexplained results in preclinical or clinical studies that may cause such product candidates to be unsuitable for further development. We may also need to perform additional research and preclinical or clinical studies for various reasons, including to determine the cause of any unexpected results, including whether such results were caused by our product candidates or other factors, which could delay our development timelines or prevent us from continuing further development at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain positive results from preclinical or clinical studies of our product candidates, success in preclinical or clinical studies does not ensure that later preclinical studies or clinical trials will be successful. A number of biotechnology and pharmaceutical companies have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical or clinical studies, such as adverse findings observed while clinical trials were underway or safety or efficacy observations during clinical trials, including previously unreported adverse events, and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results have the potential to support approval of a product, and flaws in a clinical trial&#8217;s design may not become apparent until the clinical trial is well advanced. In addition, the results of our preclinical animal studies, including our non-human primate (NHP) studies, may not be predictive of the results of subsequent clinical trials involving human subjects. Product candidates may fail to show the desired pharmacological properties or safety and efficacy traits in clinical trials despite having successfully progressed through preclinical studies or earlier clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to obtain positive results in preclinical studies or clinical trials of any product candidate, the development timeline and regulatory approval and commercialization prospects for that product candidate, and, correspondingly, our business and financial prospects, would be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical testing of our product candidates may be delayed or otherwise unsuccessful, which would harm our ability to commence and successfully complete clinical trials of, and ultimately commercialize, such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable laws and regulations require us to conduct preclinical testing of our product candidates in animals before initiating clinical trials involving humans, and the results and timing of such testing are uncertain. We may experience delays in or difficulty completing studies of our product candidates in animals for various reasons. For example, due to global supply chain issues caused by global geo-political, economic, and other factors beyond our control, as described elsewhere in these Risk Factors, we have experienced and may continue to experience difficulty and increased costs in accessing animal models, specifically certain NHP models, which could delay completion of our preclinical studies involving such models or harm our ability to conduct or complete such studies at all, and could limit the potential patient population for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, animal testing has been the subject of controversy and adverse publicity. Animal rights groups and others have attempted to stop animal testing by pressing for legislation and regulation and by disrupting such testing through protests and other means. To the extent these attempts are successful, our research and development activities may be interrupted or delayed, become more expensive, or both.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to submit an IND or comparable foreign submission to the FDA or comparable foreign regulatory authorities with respect to each product candidate prior to commencing a clinical trial for such product candidate in the applicable jurisdiction. Although we expect our pipeline to yield additional INDs and plan to submit INDs for each of our product candidates, we may not be able to submit future INDs in accordance with our expected timelines for various reasons, including due to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing challenges or delays, including due to challenges associated with scaling up our manufacturing processes and developing and validating assays or otherwise meeting applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in our IND-enabling preclinical studies; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">feedback from the FDA that requires us to conduct additional testing or change the design of a planned clinical trial prior to submitting such IND. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we cannot guarantee that submission of an IND or comparable foreign submission for a product candidate will result in the FDA or comparable foreign regulatory authorities allowing clinical trials of that product candidate to commence in accordance with our timelines or expectations or at all, or that, once begun, issues will not arise that require suspension or termination of such clinical trials. For example, the FDA or a comparable foreign regulatory authority may accept an IND or comparable foreign submission for a product candidate but place clinical trials of such product candidate on hold pending the results of additional testing or the development of additional assays, or may otherwise refuse or terminate the applicable submission. Further, because legal and regulatory requirements for conducting clinical trials vary across jurisdictions, our receipt of authorization to conduct clinical trials in one jurisdiction does not guarantee such authorization will be granted in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, such legal and regulatory requirements may change over time, including in a manner that could cause us to incur delays or additional expense in order to comply. For example, the regulatory landscape related to clinical trials in the European Union (EU) continues to evolve. The EU Clinical Trials Regulation (CTR), which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike the EU Clinical Trials Directive, which required a separate clinical trial application (CTA) to be submitted to both the competent national health authority and an independent ethics committee in each EU member state in which the clinical trial will be conducted, the CTR provides for a centralized process. The CTR allows sponsors for multi-center trials to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA assessment procedure has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. The decision of each EU member state is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical studies may proceed. The CTR foresees a three-year transition period. Compliance with the CTR requirements by us and our service providers, such as CROs, may impact our development plans. For example, because the CTR requires coordination of application review and processing across multiple member states, our ability to commence clinical trials in accordance with our timelines could be delayed. Further, as discussed elsewhere in these Risk Factors, the United Kingdom (UK) withdrew from the EU in 2020, and uncertainty remains as to whether and to what extent certain UK laws and regulations will be aligned with those of the EU, including the CTR, which does not apply in the UK. Local requirements in the UK and the EU have diverged and may further diverge in the future, which could impact any UK clinical and development activities we may conduct. In addition, clinical trial submissions in the UK must be separate from those submitted to EU member states, adding further complexity, cost, and potential risk to any clinical and development activity in the UK.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to satisfy applicable legal or regulatory requirements or standards for an IND or comparable foreign submission, or experience delays in doing so, clinical development of our product candidates may be delayed or we may be unable to execute clinical trials of the applicable product candidate in the relevant jurisdiction. For example, we may decide not to submit an IND or comparable foreign submission in certain jurisdictions due to applicable legal or regulatory requirements in such jurisdiction, including based on future changes to such requirements. Additionally, even if regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or a comparable foreign submission, we cannot guarantee that such regulatory authorities will not change their requirements in the future, which could require us to make costly changes to and delay the conduct of our clinical trials or require suspension or termination of such trials entirely. In addition, because the manufacturing of our product candidates, including our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CAR T cell product candidates, is in its early stages and continues to evolve, we expect that manufacturing-related matters such as chemistry, manufacturing, and controls, including product specifications, will continue to be a focus of regulatory review of our INDs or comparable foreign submissions, which may delay our ability to proceed with the relevant clinical trials. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or comparable foreign submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes. If clinical trials of any of our product candidates are prolonged or delayed, or need to be terminated, we may be unable to obtain required regulatory approvals and commercialize such product candidates on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are expensive, complex, and can take many years to complete, and their outcomes are inherently uncertain and their data subject to varying interpretations and analyses. Product candidates in later-stage clinical trials may fail to produce the same results as observed in earlier trials or fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and earlier clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether our current or future clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials may be delayed, suspended, or terminated, or may not be able to be conducted at all, for a variety of reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or failure to obtain regulatory authorization to commence a trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or failure to obtain institutional review board (IRB) or ethics committee (EC) approval for each clinical trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or failure to reach agreement with prospective CROs and other service providers, clinical trial sites, or companion diagnostic development partners on acceptable terms, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in recruiting clinical trial investigators or clinical trial sites of appropriate competencies and experience, including due to pre-existing commitments or resource and other infrastructure constraints, including resource allocation to other clinical trials, such as those of our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or inability to timely manufacture sufficient quantities of a product candidate for use in clinical trials, including due to lack of sufficient availability of suitable donor material from eligible and qualified donors for the manufacture of our ex vivo cell engineering product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of a product candidate to meet acceptable quality or stability standards, or failure to manufacture product candidates in accordance with cGMP and other applicable laws, regulations, and guidelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in establishing the appropriate dosage levels in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or inability to recruit, enroll, and retain suitable patients in a trial, as discussed elsewhere in these Risk Factors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of patients to complete a trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in identifying the sub-populations that are the target group for a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays caused by the addition of new investigators or clinical trial sites or replacement of existing investigators or sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety, efficacy, or other concerns arising out of investigator-sponsored clinical trials (ISTs) involving our product candidates or technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety or tolerability concerns relating to the product candidate being tested that could cause us or governmental authorities, as applicable, to suspend or terminate a clinical trial or program or impose a clinical hold, including if participants are being exposed to unacceptable health or safety risks or experiencing undesirable side effects, there are other unfavorable characteristics of the product candidate, or regulators deem our product candidate to have the potential for comparable undesirable side effects or risks to those of other product candidates, including those under development by us or third parties, due to compositional, biologic, mechanistic, sourcing, or other similarities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of third-party contractors to comply with regulatory requirements or meet their contractual obligations in a timely manner or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements, policies, and guidelines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the treatment landscape for our target indications that may make it more difficult to initiate or recruit patients for our clinical trials in certain jurisdictions or may make our product candidates no longer relevant; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">claims that the product candidate being tested infringes third-party intellectual property rights, including any resulting injunctions that may prevent further use of such product candidates and interfere with the progress of the trial; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods, and fires, or disease.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials must be conducted in accordance with the FDA&#8217;s and comparable foreign regulatory authorities&#8217; legal requirements, regulations, and guidelines and are subject to oversight by these governmental authorities and IRBs or ECs of the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ECs of the institutions at which such trial is being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial, or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination, including following an inspection of clinical trial operations or a clinical trial site, for various reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from use of the product candidate being tested, or changes in governmental regulations or administrative actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the complexity and novelty of certain product candidates, the clinical trial design, and the indications for which such product candidates are being developed, as well as the combination of these factors, could negatively affect our ability to successfully execute and complete clinical trials of such product candidates in accordance with our timelines. For example, clinical trials involving certain indications, such as autoimmune diseases, may require the involvement and alignment of medical professionals across various specialties. Additionally, we may evaluate certain of our product candidates in multiple indications, including in oncology and B-cell-mediated autoimmune diseases, and across a broad range of diseases in a single clinical trial. Because these diseases can vary significantly, doing so may introduce additional complexities and challenges with executing our clinical trials, any of which could increase the time and expense required to commence and complete the applicable trial. Further, to the extent we develop our product candidates for multiple indications, the occurrence of any potential safety issues or significant side effects with respect to a particular indication or study could negatively affect the development of such product candidate in all indications. We and third parties involved in our clinical trials may not have sufficient resources to adequately address such complexities in accordance with our timelines or at all. If we experience delays in completing, or are required to terminate, any clinical trial of our product candidates, the commercial prospects of the relevant product candidates will be harmed, and our ability to generate product revenues from these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, delay our ability to obtain regulatory approval for the relevant product candidate, and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates, which may impair our ability to commercialize our product candidates and harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, as described elsewhere in these Risk Factors, we rely and will continue to rely on third parties that are responsible for executing or supporting our clinical trials, such as CROs and clinical trial sites, including principal investigators, and to the extent they fail to timely and properly perform their obligations, we may experience program delays, incur additional costs, or both, which may harm our business. In addition, we may experience delays and incur additional costs with respect to clinical trials that we conduct in countries outside the United States, including as a result of increased shipment and distribution costs, compliance with additional regulatory requirements, and the engagement of non-United States-based CROs, and may also be exposed to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening, and medical care.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will depend on timely and successful enrollment and retention of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful and timely initiation and completion of clinical trials will require that we timely enroll and retain a sufficient number of patients. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal, or the occurrence of adverse events. These types of developments could cause us to delay the trial or halt further development of the relevant product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment in clinical trials depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation, including patients&#8217; prior lines of therapy and treatment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility and exclusion criteria for the trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and location of clinical trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to clinical sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical protocol; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition with other sponsors or clinical trials for clinical trial sites or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under evaluation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to recruit and availability of clinical trial investigators and sites with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that enrolled patients will drop out of the trial before administration of the product candidate or trial completion; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of patients resulting from the impact of any pandemic, epidemic, or disease outbreak; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of, and clinicians&#8217; and patients&#8217; satisfaction with, existing and new drugs approved for the indication the clinical trial is investigating; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new therapies that may be approved for the indications the clinical trial is investigating or the approved label expansion of an existing therapy into the indication the clinical trial is investigating. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates. In addition, because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct at least some of our clinical trials at the same sites as those used by our competitors. Competition with other clinical trials may reduce the number and types of patients available to participate in our trials, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for diseases for which there is an approved standard of care is challenging, as patients will first receive the applicable standard of care, and many patients who respond positively to the standard of care do not enroll in clinical trials. In addition, although patients who fail to respond positively to the standard of care treatment may be eligible for clinical trials of our product candidates, treatment with prior regimens may render our product candidates less effective in clinical trials. As a result, the number of eligible patients who have the potential to benefit from our product candidates could be limited, which could extend development timelines or increase costs for our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The circumstances described above and elsewhere in these Risk Factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. If we are unable to timely recruit and enroll patients for our clinical trials, enroll a sufficient number of patients to complete our clinical trials as planned, or retain patients in our clinical trials, we may be required to change our trial design, recruit and enroll a different population of patients than we anticipated, or recruit and enroll patients in geographies that are more challenging. We may not be fully prepared to address such challenges, and even if we are able to address such challenges, the results of our clinical trials may be negatively impacted. Delays in the completion of any clinical trial we may conduct will increase our costs, slow down the development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue for the relevant product candidate. In addition, some of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials may fail to demonstrate that our product candidates, including any future product candidates, or technologies used in or used to develop such product candidates, meet the FDA&#8217;s or a comparable foreign regulatory authority&#8217;s requirements with respect to safety, purity, and potency, or efficacy, which would prevent, delay, or limit the scope of regulatory approval and commercialization of such product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain the requisite regulatory approvals to market and sell any of our current or future product candidates, we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials of the product candidate, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate meets the FDA&#8217;s or such comparable foreign regulatory authorities&#8217; legal standards with respect to safety, purity, and potency, or efficacy, which may include, among other things, demonstrating through adequate and well-controlled clinical trials that the benefits of the product candidate outweigh its known risks for the intended patient population. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials of our product candidates or product candidates developed using our technologies (including those conducted by third parties, such as in the case of ISTs) may not demonstrate that such product candidates or technologies have efficacy and safety profiles necessary to support regulatory approval. Safety or efficacy results for a particular clinical trial, or between different clinical trials of the same product candidate, can vary significantly due to numerous factors, including differences in the size and type of the patient populations, variety of patients and disease types within a trial, changes in and adherence to the clinical trial protocols and trial procedures, and the rate of dropout among clinical trial participants. If the results of clinical trials are inconclusive with respect to the efficacy of our product candidates or those developed using our technologies, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates or technologies, we may experience delays in obtaining marketing approval, or we may not obtain approval at all. Additionally, any safety concerns observed in any clinical trial of one of our product candidates, or those developed using our technologies, in our targeted indications could limit the prospects for regulatory approval of such product candidate in those and other indications or the prospects of other product candidates we may develop that are perceived to have the potential for similar safety concerns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, some of our trials may be open-label trials in which the patient and/or investigator know whether the patient is receiving the investigational product candidate. Data generated from open-label clinical trials may exaggerate any therapeutic effect, as patients and/or investigators are aware when a patient has received the experimental treatment, which may cause investigators to interpret the information of the treated group more favorably. Therefore, positive results observed in open-label trials may not be replicated in later controlled trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we or our collaborators (or other third parties, in the case of ISTs) successfully complete any clinical trials, clinical data are often susceptible to varying interpretations and analyses. We cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Even if positive results are observed in clinical trials, we cannot guarantee that the FDA or comparable foreign regulatory authorities will view our product candidates as having efficacy. Further, the FDA or comparable foreign regulatory authorities may not agree with our manufacturing strategy or may not find comparability between our clinical trial product candidates and proposed commercial product candidates, which may result in regulatory delays or a need to perform additional clinical studies. Moreover, clinical trial results that may be acceptable to support approval of a certain scope in one jurisdiction may be deemed inadequate to support regulatory approval, or may only be deemed sufficient to support a narrower scope of approval, in other jurisdictions. If the FDA or comparable foreign regulatory authorities determine that the results of clinical trials of our product candidates are not adequate to support approval of a marketing application, we may experience delays in obtaining, or fail to obtain, approval of our product candidates, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is obtained for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause serious adverse, undesirable, or unacceptable side effects or have other properties that may delay or prevent marketing approval. If a product candidate receives regulatory approval, and such side effects are identified following such approval, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following such approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause serious adverse, undesirable, or unacceptable side effects, which could cause us or regulatory authorities to interrupt, delay, or halt our future clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign authorities. We do not currently, and in the future may not, have sufficient clinical data or other information to enable us to fully anticipate the side effects of our product candidates. Accordingly, we may observe unexpected side effects or higher levels of expected side effects in clinical trials of our product candidates, including adverse events known to occur in the same classes of therapeutics, such as infusion reaction, cytokine release syndrome, graft-versus-host disease, neurotoxicities, and certain cancers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects associated with our product candidates. In such an event, clinical trials of such product candidates could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of such product candidates for any or all targeted indications. In addition, the FDA or comparable foreign regulatory authorities may more closely scrutinize any side effects or safety concerns associated with our product candidates in the context of the potential benefits observed in diseases that are not immediately life-threatening, such as certain autoimmune diseases, which could harm our ability to develop or obtain regulatory approval for applicable product candidate in such diseases. Moreover, the occurrence of such side effects could negatively affect our ability to recruit and enroll patients in our clinical trials or the ability of enrolled patients to complete the clinical trials, or result in product liability claims. For example, patients with diseases that are not immediately life-threatening, including certain autoimmune diseases, and their physicians may be less likely to enroll or recommend enrollment in clinical trials of our product candidates if there is a risk of certain side effects or safety concerns and may be more likely to cease their participation in such clinical trials if they experience certain side effects. Similar events may occur if it is determined that there are side effects or safety concerns associated with other products or product candidates that are, or are perceived to be, similar to ours. Any of these occurrences could significantly harm our business, financial condition, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, clinical trials by their nature involve only a sample of the potential patient population. Because our clinical trials will involve only a limited number of patients and limited duration of exposure to our product candidates, rare and severe side effects of our product candidates may not be apparent during early clinical trials and may only be uncovered once a significantly larger number of patients have been exposed to the product candidate, including during later-stage clinical trials or following commercialization, or when longer-term data is available. As such, even if applicable regulatory authorities initially determine that our product candidates have an acceptable safety profile for their intended use in humans, they may later prove to cause serious side effects in patients that we were unable to observe or predict during their clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our product candidates receives regulatory approval and we or others later determine that such product may cause undesirable or unacceptable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw or limit approvals of such product and require us to take such product off the market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, specific warnings, or a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients or that we implement a risk evaluation and mitigation strategy (REMS) plan to ensure that the benefits of the product outweigh its risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the therapeutic dose or the way the product is administered, conduct additional clinical trials, or change the labeling of the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to limitations on how we may promote or manufacture the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of the product may decrease significantly; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to litigation or product liability claims; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, topline, or preliminary data from our preclinical studies or clinical trials that we may announce or publish from time to time may change as more data become available or as we make changes to our manufacturing processes. These data are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose interim, topline, or preliminary data from our preclinical studies or clinical trials, which are based on a preliminary analysis of then-available data, and the final results and related findings and conclusions are subject to change following a more comprehensive review of the study or trial data. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data at the time of our initial disclosure of data. Further, modifications or improvements to our manufacturing processes for a product candidate may result in changes to its characteristics or behavior that could cause the product candidate to perform differently and affect the results of our preclinical studies or planned or ongoing clinical trials of such product candidate, and potentially require us to conduct additional preclinical studies or clinical trials. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously disclosed. As a result, topline data should be viewed with caution until the final data are available. Similarly, preliminary or interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Additionally, disclosure of preliminary or interim data by us or our competitors, with respect to clinical trials of their product candidates, could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory authorities, investors, or analysts, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses, or may interpret or weigh the importance of data, including any decisions we may make based on that data, particularly limited or preliminary data, differently than we do, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate, and our company in general. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, investors, or analysts, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, as well as our business, operating results, prospects, and financial condition, could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates or technologies may be involved in investigator-sponsored clinical trials, and we will have limited or no control over the conduct of such trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ISTs involving our product candidates or technologies pose or are subject to similar risks to those set forth elsewhere in these Risk Factors relating to clinical trials that we conduct ourselves. Although ISTs may provide us with clinical data that can inform the development strategy for our product candidates, we will be unable to control the timing, design, and conduct of such ISTs or regulatory matters with respect to such ISTs, including the submission, clearance or approval, or maintenance of any IND or comparable foreign submission required to conduct such ISTs. In addition, we would not control the data collection and reporting, including timing thereof, with respect to any ISTs, and may not control the manufacturing of the product candidate or technology to be tested in any such ISTs. A delay in the timely completion of or reporting of data from any potential IST, including as a result of manufacturing complications or delays, which could occur for various reasons such as the need to obtain additional licenses, delays in recruiting, enrolling, or retaining patients, or other potential issues, including those described in these Risk Factors, could have a material adverse effect on our ability to further develop our product candidates or to advance our product candidates through subsequent clinical trials. Negative results from an IST could have a material adverse effect on our business and prospects and the perception of our product candidates and technologies. Additionally, there is a possibility that ISTs may be conducted under less rigorous clinical standards than those used in company-sponsored clinical trials. Accordingly, the FDA and comparable foreign regulatory authorities may more closely scrutinize the resulting data and may not view these data as providing adequate support for future clinical trials, whether sponsored by us or third parties. In addition, any potential IST could demonstrate marginal efficacy or reveal clinically relevant safety concerns that could delay the further clinical development or regulatory approval of our product candidates. Further, data from a potential IST may fail to demonstrate efficacy for various reasons, including those unrelated to our product candidates or technologies, which may negatively impact the perception of such product candidates and technologies, despite their potential for future success. To the extent that the results of any ISTs raise safety or other concerns regarding our product candidates or technologies, regulatory authorities may question the results of such ISTs or other clinical trials involving the relevant product candidate or technology. Safety concerns arising from any potential ISTs may cause the FDA or comparable foreign regulatory authorities to impose partial or full clinical holds on our product candidates, including product candidates that were developed using the same technology or manufactured using the same reagents and materials as those product candidates that are the subject of such ISTs, which could delay or prevent us from advancing our product candidates into further clinical development and require us to discontinue our development of such product candidates. The occurrence of any of the foregoing would severely harm our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of our product candidates is complex. We or our CDMOs may encounter difficulties in production, which could delay or entirely halt our or their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are considered to be biologics, and the process of manufacturing biologics is complex and requires significant expertise and capital investment, including with respect to the development of advanced manufacturing techniques and process controls. As described elsewhere in these Risk Factors, we have entered into a long-term lease to establish manufacturing capabilities at the Bothell facility and have entered into an agreement to access manufacturing capabilities within URMC&#8217;s cell-based manufacturing facility. We currently rely, and expect to continue to rely, on CDMOs for the manufacture of certain of our product candidates for preclinical and clinical studies. We also anticipate that we will continue to rely on CDMOs for at least some portions of our supply chain following commercialization of any product candidates for which we may receive regulatory approval. As described elsewhere in these Risk Factors, we expect that we will also be required to transition certain manufacturing processes and know-how, including to our CDMOs and to the Bothell facility and the URMC site, over time, which is a complex process with which we have limited experience. If we experience any delays or issues with the foregoing, our ability to begin manufacturing certain of our product candidates internally could be delayed, and we may need to rely to a greater extent on CDMOs for the manufacture of such product candidates for longer than we currently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we and our CDMOs have limited experience in manufacturing of cGMP batches of our product candidates. Our CDMOs and, once we begin to operate the Bothell facility and the URMC site, we, must comply with cGMPs and other complex regulations and guidelines applicable to the manufacturing of biologics for use in clinical trials and, if approved, commercial sale, and any inability or failure to comply with such regulations and guidelines could delay our clinical trials or prevent us from being able to commence clinical testing at all. To date, we have not scaled the manufacturing processes with respect to our product candidates for later-stage clinical trials and commercialization, and we and our CDMOs may not have sufficient capacity, resources, or capabilities to scale such manufacturing processes in accordance with our desired timelines or at all. Further, certain of our product candidates may have characteristics that present increased manufacturing complexity and necessitate longer manufacturing timelines. If we are unable to successfully scale the manufacturing process for these product candidates, including in compliance with cGMP quality requirements, or adapt such manufacturing process to meet late-stage development or commercial quality requirements, we may not be able to manufacture sufficient quantities of compliant product candidates, or manufacture them in a timely manner, which would harm our ability to clinically develop and commercialize such product candidates. In addition, the manufacturing of our product candidates, including large-scale manufacturing, may require the development of novel processes for upstream and downstream activities, including analytical technologies, which could cause delays in the scaling of manufacturing, as well as greater costs that could negatively impact the financial viability of our product candidates. We cannot be sure that the manufacturing processes employed by our CDMOs or the technologies that our CDMOs incorporate into our manufacturing processes will result in viable or scalable yields of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates that will have acceptable safety, purity, potency, or efficacy profiles and, if approved, meet market demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our biologic product candidates are susceptible to product loss or reduced manufacturing success rates at various points during the manufacturing process, including due to contamination, equipment damage or failure, including during shipment or storage, failure of equipment to operate as expected, improper installation or operation of equipment, vendor or operator error, damage to, variability of, or improper use of raw materials or consumables necessary for the manufacturing process, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Any of these issues, and even minor deviations from normal manufacturing processes, could result in reduced production yields, product defects, and other supply disruptions and delays. If microbial, viral, or other contaminations are discovered in our product candidates or in the facilities in which our product candidates are manufactured, including the Bothell facility, the URMC site, or any future manufacturing facilities, or those of our CDMOs, such supply may have to be discarded, our products may be withdrawn from clinical trials and, if approved, the market, and such facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Moreover, if the FDA or comparable foreign regulatory authorities determine that we or our CDMOs, or our or our CDMOs&#8217; facilities, are not in compliance with applicable laws and regulations, including cGMPs, the FDA or comparable foreign regulatory authority may not approve a biologics license application (BLA) or comparable foreign marketing authorization until the deficiencies are corrected or we replace the manufacturer in our applications with a compliant manufacturer, and we may ultimately be unable to manufacture our product candidates. The occurrence of any of these issues could delay our ability to commence or timely complete clinical development, obtain regulatory approval of, and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also may make changes to our manufacturing processes at various points during development, and even after commercialization, for various reasons, such as to control costs, achieve scale, decrease processing time, or increase manufacturing success rate. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could result in changes to a product candidate&#8217;s characteristics or behavior or cause our product candidates to perform differently and affect the results of any of our then-ongoing or future preclinical studies or clinical trials, or the performance of the product, once commercialized. In certain circumstances, if we make changes to our manufacturing process for a product candidate, regulatory authorities may require us to perform comparability studies and collect additional preclinical or clinical data prior to undertaking additional clinical trials or obtaining marketing approval for or commercializing the product candidate produced with such modified process. For instance, if we make changes to our manufacturing process for a product candidate during the course of preclinical or clinical development, regulatory authorities may require us to demonstrate the comparability of the product used in preclinical studies, earlier clinical phases, or earlier portions of a trial to the product used in later clinical trials or clinical phases or later portions of a trial, as applicable. If at any point we switch to a different CDMO or supplier of reagents or materials used in the manufacturing process for a product candidate, including, for example, in order to ensure sufficient supply for later-stage clinical trials and potential commercialization, we may also be required to perform comparability studies in order to demonstrate comparability of the applicable product candidate, reagent, or material from the prior CDMO or supplier to that from the new CDMO or supplier, and otherwise demonstrate that the relevant product candidate, reagents, or materials meet the applicable specifications. We may be unable to successfully generate comparability data, and even if we are able to generate and provide such data, regulatory authorities may disagree with the design of our comparability studies or otherwise determine that the data are insufficient to support a determination of comparability. Similarly, we may be unable to demonstrate that the relevant materials meet the applicable specifications. In such an event, we may be required to make further changes to our process or undertake additional preclinical or clinical testing, which could result in manufacturing delays and affect our ability to timely dose patients in our clinical trials, which could delay further development or commercialization of such product candidate, or we may be unable to continue development of the applicable product candidate at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any adverse developments affecting manufacturing operations for any of our product candidates, including those for which we may obtain regulatory approval, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other supply interruptions that could negatively impact the conduct of our clinical trials or our ability to successfully commercialize any product candidates for which we may obtain regulatory approval. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications as a result of defects or storage over an extended period of time, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Any such issues would harm our ability to timely and successfully complete clinical trials and obtain regulatory approval of our product candidates, which could have a significant negative impact on our business, operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are exposed to a number of risks related to the supply chain for the materials required to manufacture our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing of our product candidates is highly complex and requires sourcing of specialty materials. Many of the risks associated with the complex manufacturing of our final product candidates are applicable to the manufacture and supply of the raw materials required to make such product candidates. In particular, these raw materials are subject to inconsistency in yields, variability in characteristics, contamination, difficulties in scaling the production process, and defects. Similar minor deviations in the manufacturing process for these raw materials could result in supply disruption and reduced production yields for our final product candidates. In addition, we rely on third parties for the supply of these materials, which exposes us to risks associated with dependence on third parties, as described elsewhere in these Risk Factors. Further, we use certain reagents and materials across various programs and initiatives, and any difficulties we experience with such reagents or materials, including with respect to sourcing, quality, or other factors, could have a more significant impact on our portfolio and business than if we used different reagents and materials for each of our programs and initiatives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must obtain suitable donor material from eligible and qualified donors for the manufacture of product candidates from our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platform. If we are unable to obtain sufficient quantities of suitable donor material in a timely manner or at all, including if we are unable to find donors who meet the eligibility criteria or as a result of geo-political, economic, and other factors beyond our control that may prevent individuals from donating blood, we may experience delays in manufacturing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates, which would harm our ability to conduct clinical trials of or to commercialize these product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we require many reagents, which are drug substance intermediates used in our manufacturing processes to bring about chemical or biological reactions, and other specialty raw and intermediate materials, consumables, and equipment, for our manufacturing processes and for quality control testing of our product candidates, some of which are manufactured or supplied by small companies with limited resources and experience with respect to supporting clinical or commercial biologics production. Some of these suppliers may not have the capacity or resources to support manufacturing of products under cGMP on our timelines or at all or may otherwise be ill-equipped to support our needs, including if and as we expand our manufacturing activities to support later-stage clinical trials and, for any product candidates that may receive regulatory approval, commercialization. Reagents and other key materials from these suppliers may have inconsistent attributes and introduce variability into our manufactured product candidates, which may contribute to variable patient outcomes and possible adverse events. We also do not have supply contracts with many of these suppliers and may not be able to enter into supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key reagents, materials, consumables, and equipment to support clinical or commercial manufacturing, which could delay development and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of these reagents, materials, consumables, and equipment, we and our CDMOs currently rely and may in the future rely on sole source vendors or a limited number of vendors. We may be unable to continue to source reagents, materials, consumables, or equipment from any of these vendors for various reasons, including due to regulatory actions or requirements affecting a vendor, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demand from other customers and supply limitations, or quality issues. Additionally, due to global geo-political, economic, and other factors beyond our control, there has been, and there are and may continue to be, a shortage of key materials, consumables, and equipment that are necessary to manufacture our product candidates, including certain consumables such as bags, flasks, and pipette tips, which could affect our or our CDMOs&#8217; ability to obtain the materials, consumables, and equipment necessary to manufacture our product candidates. If any of the foregoing events were to occur, we may experience delays in manufacturing our product candidates, which would harm our ability to conduct future clinical trials and, if approved, commercialize our products and generate product revenues in a timely manner or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, as described elsewhere in these Risk Factors, rising rates of inflation in recent years and other factors have resulted in substantial increases in the costs associated with manufacturing our product candidates, including the costs of materials, consumables, and equipment, that we are unable to offset. Given the unpredictable nature of the current economic climate, including future rates of inflation, it may be increasingly difficult for us to predict and control our future expenses, which may harm our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to develop and scale our manufacturing processes, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of those processes. We may not be able to obtain rights to or sufficient quantities of such materials or equipment on commercially reasonable terms, or at all, and our inability to alter our processes in a commercially viable manner to avoid the use of such materials or equipment or find suitable substitutes would have a material adverse effect on our business. Even if we are able to alter our processes so as to use other materials or equipment, such a change may delay our clinical development or commercialization plans. As described elsewhere in these Risk Factors, if such a change occurs for product candidate that is already being tested in clinical trials, the change may require us to perform comparability studies, demonstrate that the new materials or equipment meet applicable specifications, and collect additional data from patients prior to undertaking more advanced clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in clinical trials or at the commercial stage, and our product liability insurance may not cover all damages arising from such claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. The use of our product candidates in clinical trials, and the sale of any products for which we may obtain approval in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. Physicians and patients may not comply with any warnings that identify known potential adverse effects or patients who should not use our product candidates. If any of our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We would require significant financial and management resources to defend against any product liability claims, even if we are successful in such defense. Regardless of the merits or eventual outcome, liability claims may result in decreased demand for our product candidates, negative publicity and injury to our reputation, withdrawal of clinical trial participants, investigations by regulatory authorities, costs to defend the related litigation, diversion of management&#8217;s time and our resources, substantial monetary awards to clinical trial participants or patients, product recalls, withdrawals, or labeling, marketing, or promotional restrictions, loss of revenue, exhaustion of any available insurance and our capital resources, inability to commercialize our product candidates, and a decline in our share price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to expect to rely, on CDMOs, including third-party testing laboratories, to manufacture our product candidates, as well as materials used in the manufacturing of our product candidates, including testing of such product candidates and materials. Any failure by a CDMO to properly produce acceptable materials or product candidates for us or any failure by us or such CDMO to obtain authorization from the FDA or comparable foreign regulatory authorities or otherwise satisfy regulatory requirements with respect to such manufacturing of our product candidates may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory approvals, or commercialize approved products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently own or operate any cGMP manufacturing facilities, nor do we have any in-house cGMP manufacturing capabilities. Until we are able to begin manufacturing our product candidates at our Bothell facility, we will rely in part on CDMOs, including third-party testing laboratories, to manufacture our product candidates for use in preclinical and clinical testing and expect to continue to rely on such CDMOs to manufacture certain of our product candidates thereafter as part of our manufacturing strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A limited number of CDMOs specialize in or have the expertise required to manufacture our product candidates or materials used in their manufacture. Moreover, our CDMOs have limited capacity at their facilities and require commitments to secure availability well in advance of manufacturing any products or other materials. Additionally, we face competition from other biopharmaceutical companies to secure manufacturing availability at these facilities. If the CDMOs on which we rely to manufacture our product candidates and other materials do not have sufficient availability at their facilities to do so in accordance with our timelines or are not otherwise able to meet our expected deadlines, we will experience delays in manufacturing our product candidates or other materials necessary for their manufacture. For example, because we rely on, and may continue to rely on, single CDMOs for certain manufacturing activities across multiple programs, any issues we may experience with such a CDMO, including inability to secure manufacturing capacity as and when needed, could result in manufacturing delays across all such programs and harm our ability to timely and successfully complete clinical trials and commercialization of our product candidates. In addition, as described elsewhere in these Risk Factors, we assess and prioritize our programs on an ongoing basis based on various factors. We may not be able to secure manufacturing capacity for certain programs as and when needed and may be required to prioritize manufacturing activities for certain programs over others, which could lead to manufacturing delays and harm our ability to further develop the relevant product candidates. We may also experience similar capacity constraints and manufacturing delays in the future with respect to any products we may manufacture at the Bothell facility. Further, for each new program or CDMO we engage, or in the case of certain changes to the manufacturing process for a product candidate, the relevant manufacturing process and related know-how must be transferred to the CDMO. This technology transfer is time-consuming and complex. If we are required to switch from an existing CDMO to a new CDMO, including to meet cGMP quality requirements or support process lock or larger-scale manufacturing for later-stage clinical trials or potential commercialization, we will need to conduct additional technology transfer activities, which could result in delays in further development of the applicable product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CDMOs also face intense competition to attract and retain qualified personnel. If our CDMOs are unable to attract, retain, and motivate qualified personnel, they may be unable to perform their obligations in a timely manner, or their performance may be substandard or may not meet our quality requirements, which could cause us to experience delays in manufacturing our product candidates. Further, as described elsewhere in these Risk Factors, there are few alternatives for the CDMOs that we currently engage, and even if one of our CDMOs fails to perform according to our expectations and we decide to switch to an alternative CDMO, there is no guarantee that such alternative CDMO will be able to perform its obligations in a timely manner or that its performance will meet our expectations or quality requirements. Any delays in manufacturing our product candidates could materially harm our ability to conduct our clinical trials or commercialize our product candidates in a timely manner or at all and could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on multiple CDMOs to produce sufficient quantities of materials required for the manufacture of our product candidates for preclinical testing and clinical trials and intend to continue to rely on such CDMOs for the commercial manufacture of certain of our products, if approved. Global supply chain shortages and rising rates of inflation in recent years have resulted in substantial increases in the costs of materials, including raw materials, reagents, consumables, and equipment that are required to make or used in the manufacture of our product candidates, and such costs may continue to increase. If we are unable to obtain such items from third-party sources, or fail to do so on commercially reasonable terms, we may not be able to produce sufficient supply of product candidate or we may be delayed or be required to incur additional costs in doing so. Such inability or failure, or any substantial delay in obtaining or additional costs for such items, could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to produce certain reagents and biological materials that are used in our discovery and development programs. These materials can be difficult to produce and occasionally have variability from our product specifications. If these materials do not comply with our product specifications, or in the event of any other disruption in the supply of these materials, our business could be materially adversely affected. Although we have control processes and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. Our suppliers may also have low yield from manufacturing batches of these materials, which could increase our costs and slow our development timelines. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of these materials or product candidates generated using such materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reliance on CDMOs entails additional risks to which we would not be subject if we manufactured product candidates ourselves, including those applicable to other third-party service providers, as described elsewhere in these Risk Factors. In particular, such risks include reliance on the CDMO for regulatory compliance and quality control and assurance, including compliance with cGMP requirements and comparable standards relating to methods, facilities, and controls used in the manufacturing, processing, testing, and packing of product candidates, which are intended to ensure that biological products have acceptable safety profiles and that they consistently meet applicable requirements and specifications, and our CDMOs may be unable to satisfy applicable compliance and quality requirements in accordance with our timelines or at all. Additional risks include reliance on the CDMO for volume production, the possibility of breach of or inability to perform its obligations under the manufacturing agreement by the CDMO (including a failure to synthesize and manufacture our product candidates in accordance with our product specifications, failure to properly scale-up manufacturing processes, or failure to deliver sufficient quantities of product candidates in a timely manner), and the possibility of termination or nonrenewal of the agreement by the CDMO at a time that is costly or damaging to us. For example, certain of our CDMOs may be unable to manufacture sufficient supply of our product candidates or materials used in their manufacture, in particular, if and as we implement commercial cGMP practices or scale up manufacturing for later-stage clinical trials and potential commercialization. If we experience any issues with respect to the risks described above, we may be required to seek a replacement CDMO, which could require significant internal resources and additional costs, delay our ongoing manufacturing activities, and ultimately be unsuccessful. If we were unable to timely find an adequate replacement for our CDMOs or another acceptable solution when needed, our clinical trials could be delayed, or our commercial activities could be harmed. In addition, because we depend on our CDMOs, our suppliers, and other third parties for the manufacture, filling, storage, and distribution of our product candidates, we may be unable to prevent or control manufacturing defects in our products, the use or sale of which could seriously harm our business, financial condition, and results of operations. Issues involving any of the foregoing risks could increase our costs, delay our development timelines, and ultimately lead to a delay in, or failure to obtain, regulatory approval of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical manufacturers are required to register their facilities and products manufactured at the time of submission of the marketing application and then annually thereafter with the FDA and certain state and foreign agencies. If the FDA or a comparable foreign regulatory authority does not approve our CDMO&#8217;s facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved, on a timely basis or at all. Any discovery of problems with a product, or a manufacturing or laboratory facility used by us or our strategic partners in connection with manufacturing of that product, may result in restrictions on the product or on the relevant facility, including marketed product recall, suspension of manufacturing, product seizure, or a voluntary withdrawal of the drug from the market. We may have little to no control regarding the occurrence of any such incidents at our CDMOs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical manufacturers are also subject to extensive post-marketing oversight by the FDA and comparable regulatory authorities in the jurisdictions where a product is marketed, including periodic unannounced and announced inspections by the FDA to assess compliance with cGMP requirements. Any failure by one of our CDMOs to comply with cGMP or to provide adequate and timely corrective actions in response to deficiencies identified in a regulatory inspection could result in further enforcement action that could lead to a shortage of products and harm our business, including withdrawal of approvals previously granted, seizure, injunction, or other civil or criminal penalties. The failure of a CDMO to address any concerns raised by the FDA or comparable foreign regulatory authorities could also lead to plant shutdown or the delay or withholding of product approval by the FDA in additional indications or by comparable foreign regulatory authorities in any indication. In addition, because our CDMOs also provide manufacturing services to other companies, including our competitors, there is a risk that our CDMOs may experience the issues described in this Risk Factor with respect to such third parties and their product candidates as well. The occurrence of any such issues could restrict, partially or completely, or otherwise negatively impact such CDMO&#8217;s ability to timely and successfully perform its obligations for us with respect to our own product candidates, which would harm our ability to continue manufacturing and commercialize such product candidates. Certain countries may impose additional requirements on the manufacturing of drug products or drug substances, and on manufacturers, as part of the regulatory approval process for products in such countries. The failure by our CDMOs to satisfy such requirements could impact our ability to obtain or maintain approval of our products in such countries. In addition, as described elsewhere in these Risk Factors, our CDMOs may be subject to various other laws and regulations, compliance with or the effect of which could harm our relationship with such CDMOs and negatively impact our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply interruptions or difficulties, we may be unable to resume supply of such materials or other manufacturing activities within a reasonable time frame and at an acceptable cost or at all, which could materially adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of our product candidates requires the timely delivery of sufficient amounts of raw and intermediate materials. We purchase, and rely on our CDMOs to purchase, certain of these materials from third-party suppliers in order to produce our product candidates for our preclinical studies. There are a limited number of suppliers of these materials, and we may need to assess alternate suppliers to prevent possible disruption of manufacturing of our product candidates for our preclinical studies, our future clinical trials, and if ultimately approved, commercial sale. We rely, and expect to continue to rely, on our CDMOs to purchase materials in order to produce product candidates for our clinical trials; however, we do not have any control over the process or timing of the acquisition of these materials by our CDMOs or the costs of such materials. We work closely with our CDMOs and suppliers, as applicable, to ensure the continuity of supply, but we cannot ensure that these efforts will always be successful. Further, although we strive to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to supply these materials for our intended purpose. Alternative sources of supply may exist when we rely on sole supplier relationships, but we cannot ensure that, if needed, we would be able to quickly establish additional or replacement sources for some materials. The lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in the event a new supplier must be used. In addition, the time and effort to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Although we generally would not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw or intermediate material components thereof, for an ongoing clinical trial due to the need to replace a supplier could considerably delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates. Moreover, we currently do not have any agreements for the commercial supply of these raw or intermediate materials. A reduction or interruption in supply of raw or intermediate materials combined with an inability of us or our CDMOs to timely establish alternative sources for such supply could adversely affect our ability to manufacture our product candidates or approved products in a timely or cost-effective manner, result in a shortage of product supply, delay the development and any commercial launch of our product candidates, and ultimately impair our ability to generate revenues from sales of any approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including service providers such as CROs, clinical trial sites, including principal investigators, and independent clinical investigators, to conduct or support our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including service providers such as CROs, independent clinical investigators, and clinical trial sites, to properly and timely execute or support our preclinical studies and clinical trials and related activities, and to monitor and manage data for our ongoing preclinical and clinical programs and we may rely to a greater extent on such outsourced activities following our October 2023 workforce reduction. However, we are only able to control certain aspects of the activities of these third parties to the extent set forth under our contracts with these third parties, and we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards and rules, and our reliance on these third parties does not relieve us of these obligations. With respect to any of our product candidates that may enter clinical development, we and our CROs and other service providers, as well as our clinical trial sites, including principal investigators, are required, and we rely on them, to comply with good clinical practices (GCP) requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities. Regulatory authorities enforce GCPs through periodic inspections of clinical trial sponsors and clinical trial sites, including principal investigators. If we or any of our CROs or other service providers, or any clinical trial sites or principal investigators involved in our trials, fail to comply with applicable GCPs, the clinical data generated from these clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot be certain that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP. In addition, to the extent third parties executing or otherwise supporting our clinical trials, including CROs and clinical trial sites, including principal investigators, fail to conduct such clinical trials in accordance with GCP, fail to timely and successfully enroll patients in our clinical trials, or experience significant delays in the execution of our trials, including delays in achieving full enrollment or clinical trial data collection and analysis, we may experience program delays, incur additional costs, or both, which may harm our business. Our clinical trials must also be conducted using product produced in compliance with cGMP regulations, and our failure to do so may require us to repeat clinical trials, which would delay the regulatory approval process for the relevant product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, third parties that support our preclinical and clinical programs, such as service providers, including CROs, independent clinical investigators, and clinical trial sites, including principal investigators, are not our employees, and we are unable to control, other than by contract, the amount of resources, including time, that they devote to our product candidates, preclinical studies, and clinical trials. If such third parties, including our CROs or other service providers, are unable to attract, retain, and motivate qualified personnel, they may be unable to perform their obligations in a timely manner, or their performance may be substandard. If such third parties fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard or does not meet our quality requirements, it may delay or compromise the prospects for approval and commercialization of any such product candidates. In addition, in order for these third parties to perform under their contracts with us, we regularly disclose or plan to disclose to these third parties confidential or proprietary information, which increases the risk that this information will be misappropriated. Additionally, disruptions caused by global geo-political, economic, and other factors beyond our control may increase the likelihood that these third parties encounter difficulties or delays in performing their obligations to us, including with respect to initiating, enrolling, conducting, or completing our planned clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a limited number of third parties, including service providers such as CROs and clinical trial sites, that specialize in or have the expertise required to achieve our business objectives. These third parties generally have the right to terminate their agreements with us in the event of our uncured material breach, and may have the right to terminate under other circumstances, including if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so in a timely manner or on commercially reasonable terms. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements, or for other reasons, our preclinical studies or clinical trials may be extended, delayed, or terminated, the results thereof could be negatively impacted, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. Switching from existing to alternative service providers or clinical trial sites, or adding new service providers or clinical trial sites, may involve significant cost and requires management time and focus. In addition, there is a natural transition period when a new service provider commences work, which could lead to delays and materially impact our ability to meet our desired development, including clinical development, timelines. Additionally, even if our service providers perform as required, they may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with these service providers, including our contracted laboratories and CROs, there can be no assurance that we will not encounter these types of challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Intellectual Property and Information Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent rights are national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions are expensive, especially in jurisdictions where we have no local presence, and could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information, and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that, even if a third party is infringing our issued patents, or any patents that may be issued as a result of our pending or future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action, which typically lasts for years before it is concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and/or more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we may receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to initiate or continue our future clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from third parties, and our rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of the applicable license agreements. If we breach our obligations under these agreements or if any of these agreements is terminated, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on patents, know-how, and proprietary technology, both that we own and that we license from others, to research, develop, and commercialize our product candidates. We are a party to a number of intellectual property license agreements and acquisition agreements pursuant to which we have acquired certain of our core intellectual property rights. Moreover, we rely upon licenses to certain intellectual property rights and proprietary technology from third parties that are important or necessary for the development of our technologies and products, including technology related to our manufacturing processes and our product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in such fields of use or territories. These licenses may also require us to grant back certain intellectual property rights to our licensors and to pay certain amounts relating to sublicensing patent and other rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into, and we expect to enter into in the future, license agreements and other agreements pursuant to which we may obtain access to or acquire intellectual property rights and technologies. These license and acquisition agreements impose, and we expect that future license and acquisition agreements will impose, various diligence, milestone and royalty payment, and other obligations on us. If we fail to comply with our obligations under these agreements, we may be required to pay damages, and the licensor may have the right to terminate the agreement. Any termination of these licenses could result in the loss of significant rights and could harm our ability to develop or advance one of our cell engineering platforms, or develop, manufacture, or commercialize one of our product candidates. See the subsection titled &#8220;Business&#8212; Key Intellectual Property Agreements&#8221; in Part I, Item 1 of our 2023 Annual Report for additional information regarding these key agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business, involves complex legal, business, and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including those relating to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other issues related to interpretation of the agreement, certain provisions of which may be susceptible to multiple interpretations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense the patent and other rights granted to us under the license agreement to third parties as part of collaborative development relationships; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed intellectual property rights in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of payments owed under license agreements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The resolution of any contract interpretation disagreement that may arise could change what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Our business may also suffer if any current or future licensors fail to abide by the terms of the applicable agreement, if such licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be unpatentable, invalid, or unenforceable, or if we are unable to enter into or maintain necessary license agreements on acceptable terms or at all. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current or future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, although we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in product candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize any product candidates, we may be unable to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully maintain the intellectual property rights we currently have pursuant to agreements with third parties, or those we may in-license or acquire in the future, we may have to abandon development of the relevant research programs or product candidates, which could harm our ability to commercialize our products, and our business, financial condition, results of operations, and prospects could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend, and enforce certain patents and patent applications that are material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain patents relating to our product candidates are owned or controlled by certain of our licensors. Each of our licensors generally has rights to file, prosecute, maintain, and defend the patents we have licensed from such licensor in their name, generally with our right to comment on such filing, prosecution, maintenance, and defense, with some obligation for the licensor to consider or incorporate our comments, for our exclusively licensed patents. We generally have the first right to enforce our exclusively licensed patent rights against third parties, although our ability to settle such claims often requires the consent of the licensor. If our licensors, third parties from whom they license or have obtained the relevant patents, or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail, or have in the past failed, to properly and timely conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, these licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even if we are permitted to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it could cause us to lose rights to intellectual property that we may need to operate our business or could cause us to lose the ability to exclude our competitors from using the intellectual property rights. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or after our assuming control. In the event we breach any of our contractual obligations to our licensors related to such prosecution, we may incur significant liability to our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product candidates, product candidate components, or processes for our product development pipeline, which may require us to operate our business in a more costly or otherwise adverse manner than we anticipated. We may not be successful in obtaining or maintaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">exclusive rights to owned and in-licensed patents or patent applications or future patents to the extent they are co-owned by us and third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own or license from third parties certain intellectual property rights necessary to develop our product candidates. The growth of our business will likely depend in part on our ability to acquire or in-license additional proprietary rights, including to advance our research or allow commercialization of our product candidates. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development or delay commercialization of one or more product candidates and our business and financial condition could suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain or maintain necessary third-party intellectual property rights, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may rely upon technologies or product candidates that require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may have filed or may plan to file patent applications potentially relevant to our business. In order to work effectively and efficiently, or for other reasons, our product candidates may also require specific formulations, reagents, materials, components, or other technology, which may be covered by intellectual property rights held by others. In order to avoid infringing third-party patents, we may be required to license technology from these third parties to further develop or commercialize our product candidates. We may be unable to acquire or in-license third-party intellectual property rights that we identify as necessary or important to our business operations, including composition, method of use, method of making, or other intellectual property rights required to make, use, or sell our product candidates. Such licenses or other rights may not be available at a reasonable cost or on reasonable terms, or at all, and, as a result, we may be unable to develop or commercialize the affected product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights. In addition, we may need to seek to develop alternative approaches that do not infringe on such intellectual property rights, which, if we were successful in developing such alternatives, may entail additional costs and lead to delays in development. In certain cases, it may not be feasible for us to develop such alternatives, which would harm out ability to continue development of the affected product candidates. Even if we are able to obtain a license to such intellectual property rights, any such license may be non-exclusive, which may allow our competitors to access to the same technologies licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may license the intellectual property rights to other parties, potentially blocking our ability to pursue any of our programs to which such rights relate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is competitive, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete negotiations and ultimately license or acquire the intellectual property rights necessary or useful for the development of our product candidates. Any delays in entering into, or inability to enter into, license or other agreements pursuant to which we obtain rights related to our product candidates could delay or halt the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition, and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our owned and in-licensed patents or patent applications or future patents are or may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owner&#8217;s interest in such patents or patent applications, such co-owner may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, such co-owner may not provide the cooperation necessary to enforce such patents against third parties. Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may depend on intellectual property licensed or sublicensed to us from, or for which development was funded or otherwise assisted by, government agencies, such as the National Institutes of Health, for development of our technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government agencies have provided, and may in the future provide, funding, facilities, personnel, or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. Such government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense, could result in the loss of significant rights and could harm our ability to commercialize or continue commercializing products that are subject to government rights. For example, at least one of our in-licensed patent cases related to each of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms has been funded at least in part by the United States government. As a result, these patent cases are subject to certain federal regulations pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). In particular, the federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights,&#8221; which allow the government, in specified circumstances, to require the contractors or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Intellectual property rights discovered under government-funded programs are also subject to certain reporting requirements, compliance with which may require us or our licensors to expend substantial resources and failure to comply may lead to loss of rights. Such intellectual property is also subject to a preference for United States industry, which may limit our ability to contract with foreign product manufacturers for products covered by such intellectual property rights. Moreover, we cannot be sure that any intellectual property we may co-develop with academic institutions in connection with preclinical research or development activities will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or in-license technology that is critical to our business and is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our platform technologies and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. We have filed numerous patent applications and anticipate that we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if and when any patents will issue from our owned and in-licensed patent applications, and whether the claims of any such issued patent will cover our product candidates and platforms or uses thereof in the United States or in other foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether others will apply for or obtain patents claiming inventions similar to those covered by our patents and patent applications; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file, and we and our licensors may not be able to prosecute, all necessary or desirable patent applications or maintain, defend, or enforce patents that may issue based on our patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection or before another party files a patent application covering the relevant inventions. Although we enter into confidentiality agreements with parties that have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for biological products such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent agencies in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their products for our targeted indications, physicians may prescribe these products &#8220;off-label&#8221; for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement may be difficult to prevent or prosecute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One aspect of the determination of patentability of inventions depends on the scope and content of the &#8220;prior art,&#8221; which is information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our inventions or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result, the impact of such third-party intellectual property rights on the patentability of our own patents and patent applications, as well as upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are typically confidential for a period of 18 months after filing, or may not be published at all, we cannot be certain that we were or will be the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Furthermore, for United States patent applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be instituted by a third party or the USPTO to determine who was the first to invent any of the subject matter covered by the relevant patent claims. For United States patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the Leahy-Smith America Invents Act (the Leahy-Smith Act), which introduced significant changes to the United States patent laws, including new procedures for challenging pending patent applications and issued patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical fields can be uncertain and evaluating the scope and validity of such patents involves complex legal, factual, and scientific analyses, which may vary based on the jurisdiction in which the analyses are performed. Patents have in recent years been the subject of much litigation in the United States and worldwide, resulting in court decisions, including United States Supreme Court decisions, that have increased uncertainties as to the patentability of certain inventions as well as the enforceability of patent rights in the future. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our platform technologies or our product candidates or uses thereof in the United States or in other foreign countries. Even if patents do successfully issue, third parties may challenge the patentability, validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, revoked, or held unenforceable. In the event of litigation or administrative proceedings involving our issued patents, we cannot be certain that the claims of any such patent will be considered patentable by administrative bodies or valid by courts in either the United States or foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately cover our platform technologies or product candidates or prevent others from designing their products to avoid being covered by our patent claims. If the breadth or strength of protection provided by our patent filings is threatened, companies may be dissuaded from collaborating with us to develop, and could threaten our ability to successfully commercialize, our product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, as patent rights are time limited, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope or validity of patent claims, or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application worldwide, including in the United States, that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent&#8217;s claims is determined by an interpretation of the laws of the country in which the patent has been granted, the written disclosure in the patent, and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent worldwide, including in the United States, that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily protect us from all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain rights as trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our pending patent applications may not lead to issued patents for various reasons; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by, or the first to file, certain issued patents or pending patent applications that we own or have exclusively licensed, which may jeopardize our or our licensors&#8217; or future collaborators&#8217; ability to obtain an issued patent or the validity of any issued patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection of any patent that may issue from our own or our in-licensed patent applications is unpredictable and may not cover our product candidates or uses thereof in the United States or in other foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of any patent that may issue based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may develop product candidates or technologies that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors may conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce or defend our patent rights, which will be costly regardless of outcome; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or have exclusively licensed may be revoked or may be held invalid, unpatentable, unenforceable, or not infringed, including as a result of efforts to enforce our patents and legal challenges; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may fail to adequately protect and police our trade secrets and trademarks; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party patent rights may have an adverse effect on our business, including if these rights claim subject matter similar to or improving that covered by our patents and patent applications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent disclosure of trade secrets and other proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, subject matter for which patents are difficult to enforce, and other elements of our product candidates, technology, and product discovery and development processes that involve proprietary know-how, information, or technology that we do not cover through patent protection. Any disclosure, either intentional or unintentional, by our current or former employees, contractors, collaborators, or those of third parties, including those with whom we share our facilities and consultants and vendors that we engage to perform research, clinical trials, or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary or confidential information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we rely and expect to continue to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade secrets and confidential information, however, can be difficult to protect. We seek to protect our trade secrets, know-how, and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, collaborators, and other third parties. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. In addition, we enter into agreements with our consultants, contractors, service providers, and outside scientific collaborators that typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary or confidential information, including our technology and processes. Although we use reasonable efforts to protect our trade secrets and confidential information, our employees, consultants, outside scientific advisors, contractors, collaborators, and other third parties might intentionally or inadvertently disclose such information to competitors or other third parties, including, as to consultants and advisors, to their primary employers, in breach of our agreements with such parties, and adequate remedies for such breaches may be unavailable. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, we may be required to disclose trade secrets and other confidential information to governmental authorities, including in connection with regulatory filings related to our product candidates, and such authorities may make certain documentation or information contained therein available to the public. If we are unable to or otherwise fail to take advantage of any opportunity to protect such trade secrets or other confidential information, our competitors could use such information to compete with us, which would significantly harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement against us or our collaborators may prevent or delay our product discovery, development, or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. We cannot be certain that our platform technologies, product candidates, and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. The legal and administrative landscape related to infringement of the patents and proprietary rights of third parties is fluid as there is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents. These include interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post-grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Litigation and other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and, even if resolved in our favor, are likely to divert significant resources from our core business and distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to enter into or compete in the marketplace. Furthermore, patent reform and changes to patent laws add uncertainty to the possibility of challenge to our patents in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous issued patents and pending patent applications owned by third parties may exist worldwide in the fields in which we are developing our platform technologies and product candidates. We cannot provide any assurances that third-party patent filings that might be enforced against the making, use, or sale of our current product candidates or future products do not exist, which, if they did exist, would result in either an injunction prohibiting our sales, or an obligation to pay royalties on product sales or other forms of compensation to third parties. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates will be subject to claims of infringement of the patent rights of others. Third parties may assert that we infringe their patents or other intellectual property, or that we are otherwise employing their proprietary technology without authorization, and may sue us. There may be third-party patent filings of which we are currently unaware with claims, including claims to compositions, formulations, methods of manufacture, or methods of use or treatment, that cover our product candidates. It is also possible that patent filings owned by third parties of which we are aware, but which we do not believe are relevant to our platform technologies, product candidates, or other proprietary technologies we may develop, could be found to be infringed by our product candidates. Because patent applications can take many years to issue, there may be pending patent applications, including those of which we are unaware, that may later result in issued patents that our product candidates may infringe. In addition, third parties, including our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may obtain patents in the future that may prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates, and may claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. If any such third-party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, or if we are found to otherwise infringe a third party&#8217;s intellectual property rights, the holders of any such patents may be able to block, including by court order, our ability to develop, manufacture, use, sell, or commercialize the applicable product candidate unless we obtain a license under the applicable patents or other intellectual property, or until such patents expire or are finally determined to be held unpatentable, invalid, or unenforceable. Such a license may not be available on commercially reasonable terms or may not be available at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired or delayed, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover the making, use, or sale of various types of products or methods of use. The scope of patent coverage is subject to interpretation by both administrative bodies and the courts, and the interpretation is not always predictable or uniform. If we were sued for patent infringement, we would need to demonstrate that the making, use, or sale of our product candidates, products, or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, which we may not be able to do. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court would invalidate the claims of any such patent. Third parties asserting their patent or other intellectual property rights, such as confidential information or trade secrets, against us may also seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. We may not have sufficient resources to bring any these actions to a successful conclusion. Defense against any of these claims, regardless of their merit and whether we are successful or not, would require us to incur substantial costs and could divert management and other employee resources from our business, cause development delays, and impact our reputation, which could have a material adverse effect on our business and operations. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible to do on a cost-effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our issued patents and patent applications could be found unpatentable, invalid, or unenforceable if challenged in courts or before an administrative body, and we may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors. Our participation in any such action could be expensive, time-consuming, and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our issued patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, our patent applications may be subject to a third-party pre-issuance submission of prior art to the USPTO, or we may become involved in post-grant review proceedings, opposition or derivation proceedings, reexaminations, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. In addition, interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions or the correct inventorship of the inventions claimed in our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. An adverse determination in any such proceeding may result in loss of exclusivity or in our patent claims being narrowed, invalidated, held unpatentable, or held unenforceable, in whole or in part, which could limit our ability to exclude others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products, and otherwise no longer protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, competitors may infringe our issued patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time-consuming and could divert the time and attention of our management and personnel. If we or one of our licensors initiates legal proceedings against a third party to enforce a patent covering one of our platform technologies or product candidates, the defendant could counterclaim that we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In patent litigation in the United States or abroad, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent, including lack of novelty, obviousness, non-enablement, or insufficient written description, or that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation, using post-grant proceedings such as re-examination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post-grant review, opposition, or derivation proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The outcome following legal assertions of unpatentability, invalidity, or unenforceability is unpredictable. In a proceeding before an administrative body, there is a risk that the body will decide that a patent is unpatentable or will be revoked, in whole or in part. In any patent infringement proceeding or declaratory judgment action, there is a risk that a court will decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part. In the event of either decision, we would no longer have the right to stop another party from using the invention covered by the relevant patent. There is also a risk that, even if the validity of such a patent is upheld, the court or administrative body will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. The court could also decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). With respect to the validity and patentability of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent offices were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection for the relevant product candidate, which could limit our ability to assert our patents against those parties or other competitors and prevent us from excluding third parties from making, using, or selling similar or competitive products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement of our or our licensors&#8217; intellectual property, the remedies may be insufficient. For example, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure in the course of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the price of our common stock could be substantially adversely affected. Litigation, interference, derivation, or other proceedings involving our or our licensors&#8217; patents may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. Any failure to obtain or maintain patent protection with respect to our product candidates and other technologies, including as a result of such proceedings, could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The terms of our patents may not be sufficient to effectively protect our products and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have limited terms, and in many jurisdictions worldwide, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent&#8217;s term is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the term of a patent, and the protection it affords, is limited. Given the significant amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic therapies. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Our patents issued as of April 2024 have terms expected to expire on dates ranging from 2028 to 2042, subject to any patent term extensions that may be available. If patents are issued on our patent applications pending as of April 2024, the resulting patents are projected to expire on dates ranging from 2028 to 2045. In addition, although upon issuance in the United States a patent&#8217;s term can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may also be available in the United States and in certain other foreign jurisdictions. However, in the United States, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension in the United States does not extend to the full scope of the patent&#8217;s claims, but instead only as to the scope of the product as approved. The laws governing analogous patent term extensions in foreign jurisdictions vary widely and many differ from the process in the United States. Additionally, we may not receive a patent term extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. If we are unable to obtain a patent term extension for any particular patent, or the term of any such extension is less than we request, the period during which we will have the right to exclude others from using the patent rights will be shortened. Our competitors may be able to obtain approval of competing products following our patent expiration and take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch a biosimilar product earlier than might otherwise be the case, which could reduce our revenue, possibly materially. In general, if we do not have sufficient patent term to protect our platform technologies and product candidates, our business and results of operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may challenge the inventorship or ownership of or otherwise assert rights in our patent and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property, including as a result of being an inventor or co-inventor. In the United States, the failure to name the proper inventors on a granted patent can result in the patent being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions made to an invention by the individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates, or as a result of questions regarding co-ownership of potential joint inventions. For example, inventorship disputes may arise from conflicting obligations of consultants or others who are involved in developing our platform technologies or product candidates or related intellectual property. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against claims challenging or relating to inventorship and ownership of intellectual property rights. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or the right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the United States government, such that we or our licensors are not the sole and exclusive owners of the patents that we own or that we have in-licensed. If third parties have ownership rights or other rights to our patents, including in-licensed patents, they may be able to license such patents to our competitors, and our competitors could make, use, or sell competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, although it is our policy to require our employees, contractors and other third parties who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. As described elsewhere in these Risk Factors, such claims could be expensive and time-consuming to litigate or defend and could divert the time and attention of our management and other personnel, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received confidential and proprietary information from third parties. In addition, we employ and engage individuals who were previously employed by or have otherwise provided services for other organizations, including at other biotechnology or pharmaceutical companies or at academic institutions. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or organizations. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could cause us to incur substantial costs and distract our management and employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of these third parties or organizations. Moreover, any such litigation or the threat thereof may adversely affect our reputation and our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors, or hire employees or consultants, each of which would have an adverse effect on our business, results of operations, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those used by third parties involved in our operations, such as research institution collaborators, CROs, CDMOs, and other service providers, contractors, or consultants, may fail or suffer security breaches or incidents.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and third parties involved in our operations are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we currently and will continue to collect, store, and transmit confidential information (including trade secrets or other intellectual property, proprietary business information, including data from our research, preclinical studies, and clinical trials, and personal information). It is critical that we and these third parties do so in a secure manner to maintain the confidentiality, integrity, and availability of such information. For example, we have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors that have access to our confidential information, including those that provide information technology and data security systems and services, and we do not have operational control over these third-party vendors. In addition, we currently and may in the future share or exchange confidential information with other third parties, such as collaborators, licensors, or strategic partners, none of which we have control over and all of which are subject to similar security risks as we are. As such, we are subject to risks not only from security incidents involving our own systems and networks, but also those of third parties with whom we work.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures (including edge technology designed to identify and protect our network from infiltration by third-party systems), our internal computer systems and those of any third parties involved in our operations, including our third-party research institution collaborators, CROs, CDMOs, and other service providers, contractors, and consultants, including vendors of information technology and data security systems and services, are vulnerable to damage and interruptions from cyberattacks, security breaches and incidents, computer viruses, ransomware, fraud, and other compromises and incidents involving or leading to unauthorized access to or loss, modification, unavailability, use, disclosure, or other processing of confidential information. In addition, certain systems or components thereof require enhanced or otherwise different security measures, which may require us to invest additional resources and may leave such systems more vulnerable to security compromises or incidents. These compromises and incidents may involve acts by current or former employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, &#8220;hacktivists,&#8221; or others. For example, SolarWinds Corporation (SolarWinds), a provider of information technology monitoring and management products and services that we used, experienced a cyberattack in 2020 that was likely the result of a supply chain attack by an outside nation state. We took steps to mitigate the vulnerabilities identified within these products and, following our investigations, concluded that our confidential information was not materially accessed, lost, or stolen as a result of this cyberattack. However, there may be unknown effects from this or other cyberattacks that have occurred or may occur in the future, any of which could have a material negative impact on our business. In addition, in certain cases, we may rely on or incorporate third-party software, code, or other similar materials into our systems, processes, and operations, such as in the case of internal software development, which exposes us to various risks, including that such third-party materials may have harmful components that could enable access and harm to our systems and confidential information. If we are unable to or otherwise do not detect these harmful components, or are unable to manage their effects, our business could be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the current geo-political climate and tensions between the United States and certain countries, including Russia and China, may increase our vulnerability to such cybersecurity attacks. For example, the conflict between Russia and Ukraine may create heightened threats of ransomware attacks and other cybersecurity threats for certain industries, including healthcare and pharmaceuticals. We continue to monitor and take steps to mitigate this risk, but we cannot ensure that such efforts will be sufficient to protect us from any such cyberattacks or other incidents. In addition, in July 2022, the heads of the FBI and MI5 issued joint warnings regarding the threat posed by China to national security due to the Chinese government&#8217;s increasing use of cyber espionage to steal technology from Western corporations and disrupt Western business. Moreover, the biotechnology industry is one of the top industries that China has targeted for domestic growth and development, and it therefore may be a primary target for such cyber espionage efforts. We continue to monitor our systems and upgrade our security capabilities in order to mitigate risk. However, any access to or loss or theft of our confidential information in connection with a future cyberattack could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Threats involving the misuse of access to our network, systems, and information by our current or former employees or third parties involved in our operations, including service providers, contractors, vendors, or partners, whether intentional or unintentional, also pose a risk to the security of our network, systems, and information, including data. For example, we are subject to the risk that employees may inadvertently share confidential information with unintended third parties, or that departing employees may take, or create their own information based on, our confidential information upon leaving the company. In addition, any such insiders may be the victims of social engineering attacks that enable unauthorized third parties to access our network, systems, and information using an authorized person&#8217;s credentials. We and our network, systems, and information are also vulnerable to malicious acts by insiders, including leaking, modifying, or deleting confidential information, or performing other acts that could materially interfere with our operations and business. Although we provide regular training to our employees regarding cybersecurity threats and best practices, we cannot ensure that such training or other efforts will prevent unauthorized access to or sabotage of our network, systems, and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we have not, to our knowledge, experienced any material system failure, accident, or security breach to date, because techniques used to obtain unauthorized access to or to sabotage systems are constantly evolving and generally are not recognized until they are launched against a target, we cannot be sure that our current practices, including our security and data protection efforts and investment in information security and technology will detect or prevent future significant breakdowns, data leakages, breaches in our systems or the systems of third parties involved in our operations, such as service providers, contractors, and collaborators, or other compromises or incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. If such an event were to occur, it could materially disrupt our operations and programs, the development of our product candidates could be delayed or otherwise negatively impacted, and our business could be significantly harmed. Any such event that leads to unauthorized access to or loss, modification, unavailability, use, disclosure, or other processing of personal information, including personal information regarding our clinical trial subjects or employees, or any reporting or belief that any such event or impact has occurred, could delay further development and commercialization of our product candidates, harm our reputation directly, require us to comply with federal or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. As a result, we could incur significant legal and financial exposure and reputational harm that could have a material adverse effect on our business. In any case, if we experience a cyberattack or security breach or incident, we could incur significant costs to remedy the resulting damage, including costs to deploy additional personnel and security and protection technologies, train employees, and engage third-party experts and consultants. We and the third parties involved in our operations may face difficulties and delays in identifying, responding to, and remediating security breaches and incidents, and we may find it necessary or appropriate to put in place additional measures designed to identify, protect against, and otherwise address cyberattacks and security breaches and incidents. Although we maintain cyber liability insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred or that insurance will continue to be available to us on commercially reasonable terms or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, our personnel, and those of any third parties involved in our operations, including vendors, service providers, collaborators, contractors, and consultants, may develop and use artificial intelligence technologies in the course of performing work for us, including generative artificial intelligence technologies (GenAI) that have the ability to output new content and information based on user inputs. GenAI has the potential to benefit our business and operations, possibly significantly, including by potentially creating efficiencies and enabling powerful research and development that may otherwise not be possible, and we may be at a competitive disadvantage if we do not or are unable to use GenAI, or only use it for limited purposes. However, use of GenAI in connection with our confidential, proprietary, or otherwise sensitive information, including personal data, may result in leaks, disclosure, or otherwise unauthorized or unintended access to or use or other processing of such information, including incorporation of such information into the applicable GenAI system or use of such information to further refine and train the GenAI models. Any such access or use, or any improper or inappropriate use, of GenAI could, for example, reveal trade secrets or other confidential information that may enable third parties to replicate or improve upon our technologies and programs, advance their technologies or programs more rapidly than we do, or otherwise negatively impact the value of, or our ability to obtain or maintain, intellectual property rights. Access to and use and other processing of personal data may subject us to risks and potential liability and obligations under applicable data privacy laws, as described elsewhere in these Risk Factors. Further, we may use the output of GenAI in our technologies, programs, and other aspects of our business, and such output could incorporate third party intellectual property, or we may otherwise be unable to own, protect, further develop, or ultimately use such output, which could significantly harm our business to the extent such technologies, programs, or other aspects of our business rely upon such output. Such output may also be false, non-sensical, biased, or otherwise harmful to our operations and business if incorporated therein. Further, our ability to use GenAI or further develop or use its output may depend on access to specific third-party software and infrastructure, such as processing hardware or third-party artificial intelligence models, and we cannot control the availability or pricing of such software and infrastructure, especially in a highly competitive environment. We may also face novel and urgent cybersecurity risks and emerging ethical risks relating to the use of GenAI, which could adversely affect our operations, assets, including intellectual property and data, and reputation, as well as those of any third parties involved in our operations. Use of artificial intelligence technologies in general, and GenAI in particular, in our business could subject us to additional costs and expenses, litigation, regulatory actions and investigations, and other negative consequences. There is significant uncertainty with respect to the nature of the laws and regulations that have been and may in the future be adopted, including how such laws and regulations will be interpreted and applied, both within and outside of the U.S., with respect to the use of artificial intelligence technologies in general, and GenAI in particular, including the ownership of or right to use the output of GenAI. We may need to expend significant resources to modify and maintain our business practices to comply with such laws and regulations and to otherwise ensure appropriate and lawful use of artificial intelligence technologies, including GenAI and its output, in our technologies, programs, and other aspects of our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have entered into and expect to continue to enter into collaboration, license, contract research, and manufacturing relationships with organizations that operate in certain countries that are at heightened risk of technology, data, and intellectual property theft through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or intellectual property to our company may be diminished and our competitive position could be harmed. In such a case, our efforts to protect and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from such intellectual property, and we may be at heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft or intrusion destroys the proprietary nature of our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently and in the future will need to maintain and protect our trademarks and trade names to ensure, among other things, name recognition by potential partners and, if our products receive regulatory approval, customers in our markets of interest. We may not be able to protect our rights in our current or future trademarks and trade names or may be forced to stop using these trademarks or trade names, including as a result of such trademarks and trade names being challenged, infringed, circumvented, or declared generic or descriptive, or being determined to infringe on other marks. In any such case, we may no longer be able to enforce or use our rights in these trademarks and trade names. During trademark registration proceedings, our applications may be rejected by the USPTO or comparable foreign agencies. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in many comparable foreign agencies, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected. We may license our trademarks and trade names to collaborators or to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these guidelines or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any name we may propose to use as a trade name for any of our product candidates in the United States must be approved by the FDA, regardless of whether we have applied to register it as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or a comparable foreign regulatory authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would be registerable under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA or comparable foreign regulatory authority. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trademarks or trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought against us by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims against third parties, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in United States and foreign patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, and patent rights in particular. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs associated with protection of, and may diminish our ability to protect, our inventions and our ability to obtain, maintain, and enforce our intellectual property rights and, more generally, could adversely affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith Act signed into law on September 16, 2011, could increase uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act introduced a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, and provide more efficient and cost-effective avenues for competitors to challenge patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack patents by USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings. In addition, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system for filings made after March 2013, under which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. As a result, we must be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our platform technologies, product candidates, and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensors&#8217; patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention if the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in 2012, the EU Patent Package regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (UPC) for litigation involving European patents. The EU Patent Package was implemented on June 1, 2023. As a result, all European patents, including those issued prior to ratification of the European Patent Package, now by default automatically fall under the jurisdiction of the UPC. The UPC provides third parties, including our competitors, with a new forum to seek to centrally revoke our European patents and to seek to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the current EU Patent Package, we have the right to opt our patents out of the UPC for the first seven years of the UPC&#8217;s existence, but doing so may preclude us from realizing the benefits of this new unified court.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the patent position of companies in the biopharmaceutical industry is particularly uncertain. Various courts, including the United States Supreme Court, have rendered decisions that could negatively affect the actual or perceived value of patents, such as recent federal district and appellate court rulings that have narrowed the scope of patent protection available in certain circumstances, weakened the rights of patent owners in certain situations, and in certain cases invalidated patents entirely. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the United States Supreme Court held that certain claims to naturally occurring substances are not patentable. Although we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by Congress, the federal courts, the USPTO, or the relevant law-making bodies in other countries may impact the value of our patents. Accordingly, evolving laws in the United States and other countries may adversely affect our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and may facilitate third-party challenges to any of our owned or licensed patents.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar requirements during the patent application process. Additionally, periodic maintenance fees on any issued patent must be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in a failure to perfect a priority claim, abandonment, or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, failure to pay fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Regulatory Environment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. If we are unable to obtain regulatory approval for our product candidates on a timely basis, or at all, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other activities we may engage in relating to our product candidates are subject to extensive regulation. In the United States, marketing approval of biologics requires the submission of a BLA to, and approval of such BLA by, the FDA, before a party can market any product candidate in the United States. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes. Any issues encountered by such regulatory authorities, including as a result of any prolonged government shutdown, could delay or otherwise negatively impact the development and commercialization of our product candidates. For example, closures of government agencies or staffing shortages or furloughs could increase the time required for interactions with regulatory authorities, including with respect to the review, acceptance, or approval of regulatory applications or other correspondence or submissions related to our product candidates, as well as our patent or other intellectual property applications, and could also result in delays in the interpretation and implementation of important laws and regulations relevant to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not submitted a BLA to the FDA or similar applications to comparable foreign regulatory authorities for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval once a BLA or similar application has been submitted. The process of obtaining regulatory approval is expensive, uncertain, often takes many years following the commencement of clinical trials, and can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications, patient population, and regulatory authority involved. As a company, we have no experience with the preparation and submission of a BLA or any other application for marketing approval. Further, the FDA has not yet granted approval for a therapeutic derived from stem cells, which we believe may increase the complexity, uncertainty, and length of the regulatory approval process for certain of our product candidates developed using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platform. In addition, the FDA has the authority to require a REMS plan as part of a BLA approval or after BLA approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate satisfies the FDA&#8217;s or such comparable foreign regulatory authorities&#8217; legal standards with respect to safety, purity, and potency, or efficacy, for its intended patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials may not be sufficient to support the submission of a BLA or other comparable foreign submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those of CDMOs with which we contract for clinical and commercial product supply; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may change in a manner that renders our clinical data insufficient for approval, including, for example, as a result of positive or negative data from third parties regarding other products or product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lengthy approval process, as well as the unpredictability of clinical trial results, may prevent us from obtaining regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining whether and when regulatory approval will be granted for any product candidates, including those that we may submit for approval in the future. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of, and opinions on preclinical and clinical data, and certain regulatory authorities may more closely scrutinize our data, including our processes for maintaining the integrity of and disseminating such data, in particular, as our product candidates advance into later stages of development. We may be required to conduct additional preclinical studies, alter our proposed clinical trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and, if approved, market our products. In addition, from time to time, the FDA and other governmental or regulatory authorities across jurisdictions may adopt or promulgate laws, regulations, guidance, standards, or policies, or issue communications in areas applicable to various aspects of our research and development programs. Our efforts to comply with or address such laws, regulations, guidance, standards, policies, or communications could increase the time and expense required, or make it more difficult, to complete development activities and ultimately obtain regulatory approval for our product candidates. Further, certain of such laws, regulations, guidance, standards, policies, or communications may be subject to varying interpretations, which may increase our risk of potential non-compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if we obtain approval for any of our product candidates, regulatory authorities may grant such approval for fewer or more limited indications than we request, may not approve the price we intend to charge for such product, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve such product with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product. Notably, to date, the FDA has required that any patient receiving a gene therapy be followed for 15 years post-treatment. This post-treatment follow-up, and any other requirements that the FDA or other regulatory authorities may impose for gene or cell therapy products, increases the cost and complexity of developing and ultimately commercializing such products. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain of our product candidates, including SC262, may require or otherwise benefit from use of a companion diagnostic to such product candidate for efficacy, safety, or other reasons. If we or our collaborators are unable to successfully develop and obtain regulatory approval for any necessary companion diagnostics for these product candidates, or experience significant delays in doing so, we may be unable to obtain regulatory approval for, commercialize, and generate revenue from such product candidates or be unable to realize their full commercial potential.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our product candidates, including SC262, may require or otherwise benefit from use of a companion diagnostic to such product candidate for efficacy, safety, or other reasons. In such cases, the FDA and comparable foreign regulatory authorities may require the development and regulatory approval or clearance of at least one companion diagnostic as a condition to approving such product candidate for use in the relevant patient population. We do not have experience in or capabilities for developing or commercializing companion diagnostics and expect that, if companion diagnostics are needed for our product candidates and satisfactory companion diagnostics are not commercially available, we will need to collaborate with third-party diagnostic development collaborators to perform these functions. The process of identifying suitable collaborators and developing and obtaining approval or clearance for companion diagnostics is lengthy, costly, uncertain, and time-consuming.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and may require separate regulatory approval prior to commercialization. The approval or clearance of a companion diagnostic as part of a therapeutic product&#8217;s further labeling limits the use of the therapeutic product to only those patients who express the specific characteristic that the companion diagnostic was developed to detect. For any companion diagnostic developed for use with one of our product candidates, we or our collaboration partners may experience delays in obtaining or may be unable to obtain regulatory approval or clearance for or be able to continue marketing of such companion diagnostic for various reasons, such as difficulties in manufacturing, technology transfer activities, or obtaining adequate third-party reimbursement, which could harm our business. If we or our collaboration partners are unable to obtain necessary regulatory approvals or clearance for companion diagnostics necessary for our product candidates or experience delays in doing so, we may suffer significant negative consequences, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to successfully complete clinical trials of the applicable product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the applicable product candidate may not receive marketing approval on a timely basis or at all, if its safe and effective use depends on use of a companion diagnostic; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not realize the full commercial potential of the applicable product candidate.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any of these events could harm our business, possibly materially.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical or clinical studies, or additional data analysis from prior studies, beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive approval through the FDA&#8217;s accelerated approval pathway, if our confirmatory trials or additional analysis do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek accelerated approval for one or more of our product candidates. Under the FDA&#8217;s Accelerated Approval Program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that is reasonably likely to provide a meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is typically contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional confirmatory studies or additional data analysis from prior studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval confirmatory studies or additional analyses fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner or at all, the FDA may withdraw its approval of the drug on an expedited basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to certain concerns regarding the current accelerated approval pathway, Congress has considered and may in the future consider legislation that could change aspects of the accelerated approval pathway, including in ways that may have uncertain outcomes. For example, in December 2022, President Biden signed an omnibus appropriations bill to fund the United States government through fiscal year 2023, included in which is the Food and Drug Omnibus Reform Act of 2022, which, among other things, introduced reforms intended to expand the FDA&#8217;s ability to regulate products receiving accelerated approval, including by increasing the FDA&#8217;s oversight over the conduct of confirmatory studies, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements. To the extent the FDA requires us to amend the design of our clinical trials or requires additional trials to meet changes in the data requirements for approval, our clinical timelines and approval will be delayed, which could have an adverse effect on our business and operations. However, the ultimate impact of these reforms remains unclear. In addition, there is uncertainty regarding the extent to which reimbursement will be available for products that receive approval through this pathway. As a result, even if we obtain approval for a product candidate through this pathway, we may not receive reimbursement at the levels we expect, which could harm our ability to generate revenue and achieve or sustain profitability. The future of the Accelerated Approval Program is uncertain, and we cannot predict which, if any, additional changes Congress, the FDA, or other governmental authorities will make, when such changes will be adopted, or how existing or future changes will affect our business. These changes may alter the accelerated approval requirements in ways that make it more difficult or otherwise negatively impact our ability to obtain accelerated approval for our product candidates, and could increase the burden of compliance with post-marketing requirements, each of which could increase our costs and harm our ability to commercialize our products and achieve and sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that, after our evaluation of the feedback and other factors, we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review, or approval, or that, if we decide to pursue any such pathway, our applications will be granted on a timely basis or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. In addition, even if we are able to obtain accelerated approval or any other form of expedited approval for any of our product candidates, we may not obtain such approval in a timely manner or otherwise in accordance with our timelines, and the costs of obtaining such approval and performing any additional studies or analysis may be higher than we currently anticipate. Further, if the results of any such additional studies or analysis do not ultimately support full regulatory approval of the applicable product, it may be withdrawn from the market, which could harm our ability to generate revenue and otherwise negatively impact our business and financial prospects. A failure to obtain, or delay in obtaining, accelerated approval or any other form of expedited development, review, or approval for any of our product candidates would extend the period of time until commercialization, if any, of such product candidate, could increase the cost of development of such product candidate beyond what we anticipate, and could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our product candidates receive regulatory approval, we and such products will be subject to ongoing obligations and continued regulatory review, which may require us to incur significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing legal and regulatory requirements. These requirements include submission of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP regulations for any clinical trials that we may conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the approved product. Compliance with the requirements and limitations described in this paragraph, or any issues that arise in connection with such compliance, may require us to incur significant expense and limit our ability to timely and successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations, as well as, for the manufacture of certain of our product candidates, the FDA&#8217;s cGTP regulations for the use of human cellular and tissue products to prevent the introduction, transmission, or spread of communicable diseases. As such, we and our CDMOs will be subject to continual review and inspections to assess compliance with cGMP and cGTP regulations and adherence to commitments made in any approved marketing application. Accordingly, we and third parties that we engage or with which we conduct business must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, quality control, and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we obtain approval for any of our product candidates, our product labeling, advertising, and promotion will be subject to stringent legal and regulatory requirements and continuing regulatory review. In the United States, the FDA and the FTC strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular way, and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false, misleading, unsubstantiated, or for unapproved (or off-label) uses may result in enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or the FTC. In particular, a product may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may be subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions and false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid, and other federal and state healthcare programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If there are changes in the application of legislation or regulatory policies, or a regulatory authority subsequently discovers problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the manufacturing of such product, including the facility where it is manufactured, or disagrees with the promotion, marketing, or labeling of a product, such regulatory authority may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we or one of our distributors, licensees, or co-marketers fail to comply with applicable legal or regulatory requirements, a regulatory authority may, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose civil or criminal fines or penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend, limit, or withdraw regulatory approval, which could require us to conduct additional clinical trials, change our product labeling, or submit additional applications for regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any of our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve our pending applications or supplements to approved applications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct inquiries investigations, which could require us to expend significant time and resources in response and generate negative publicity; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our operations, the product, or its manufacture, including requiring us to close our and our CDMOs&#8217; facilities; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose regulatory sanctions, seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall or remove the product from the market. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these events were to occur or if we otherwise fail to comply with ongoing legal and regulatory requirements, our ability to commercialize and generate revenue from our product candidates could be significantly impaired and we may incur substantial additional expense, which could materially adversely affect our business, financial condition, results of operations, and the overall value of our company. Moreover, the policies of the FDA and comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products may be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel, including personnel with the expertise necessary to evaluate product candidates such as ours, and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years. Moreover, these and other factors have increased the uncertainties associated with interpreting the FDA&#8217;s guidance and predicting its areas of focus and responses to various issues. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also extend the time necessary for new biologics or modifications to licensed biologics to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the United States government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns, staffing shortages, budget restrictions, or other changes in government policies prevent the FDA or comparable foreign regulatory authorities from conducting their normal operations, such as regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with healthcare professionals, healthcare facilities and institutions, clinical investigators, consultants, vendors, customers, and third-party payors in the United States and elsewhere are subject to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us to substantial penalties, contractual damages, reputational harm, administrative burdens, and diminished profits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, healthcare facilities and institutions, physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare professionals, healthcare facilities and institutions, clinical investigators, consultants, customers, and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and regulation by the federal and state governments and by foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws that affect our ability to operate include, but are not limited to, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under any United States federal healthcare program, such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including stock options. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Any arrangements with prescribers must be for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> services and compensated at fair market value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the United States federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by private citizens on behalf of the United States federal government through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> actions, and the federal civil monetary penalties law which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the United States federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the United States federal government. Pharmaceutical manufacturers can cause false claims to be presented to the United States federal government by, among other things, engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. Further, pharmaceutical manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the United States Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the United States Physician Payments Sunshine Act and its implementing regulations, which require, among other things, certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and Medicaid Services (CMS) information related to certain payments and other transfers of value to physicians, as defined by statute, certain non-physician practitioners (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous United States state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">similar healthcare laws and regulations in foreign jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. We have entered into, and expect to enter into in the future, consulting and scientific and clinical advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements may include the provision of stock or stock options in addition to or in lieu of cash consideration. Because of the complex and far-reaching nature of these laws, it is possible that governmental authorities could conclude that our payments to physicians may not be fair market value for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> services or that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. For example, these relationships and any related compensation could result in perceived or actual conflicts of interest, or the FDA&#8217;s determination that the financial relationship affected the conduct or interpretation of one of our preclinical studies or clinical trials. In such a case, the integrity of the data generated from such preclinical study or clinical trial may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any regulatory submissions related to our product candidates. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of noncompliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. Further, defending against any governmental actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions, our business may be impaired. In addition, if any of the physicians or other providers or entities with whom we expect to do business are found to violate applicable laws or regulations, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, vendors, commercial partners, and other third parties that we engage or with which we collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud and other misconduct committed by our personnel and third parties that we engage or with which we collaborate in the course of our operations, including our employees, independent contractors, principal investigators, consultants, vendors, and commercial partners. It is not always possible to identify and deter misconduct or business noncompliance by such parties. We cannot ensure that precautions we take to detect and prevent inappropriate conduct, including our compliance controls, policies, and procedures, will in every instance protect us or be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from unlawful acts committed by such parties in the jurisdictions in which we operate, including trade restrictions and sanctions and employment, foreign corrupt practices, environmental, competition, and patient privacy and other data privacy and protection laws and regulations. Misconduct by any such third parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, report financial information or data accurately, comply with federal and state healthcare fraud and abuse laws and regulations, including prohibitions on pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs, and other business arrangements, or disclose unauthorized activities to us. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any actions are instituted against us as a result of such misconduct or noncompliance, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition, results of operations, and prospects. For example, we may be subject to or experience significant civil, criminal, and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may charge for such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Patient Protection and Affordable Care Act (the ACA) was enacted in 2010, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the pharmaceutical and biotechnology industries, which includes biologics, are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase in the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of the manufacturer Medicaid rebate obligation to drugs paid by Medicaid managed care organizations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement for manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a licensure framework for follow-on biologic products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in force in its current form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United Stated since the ACA was enacted, including aggregate reductions of Medicare payments to providers through 2032. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of products, which could have a material impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires, beginning in 2026, manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates, first due in 2023, under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and, beginning in 2025, replaces the Part D coverage gap discount program with a new discounting program. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has issued and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of the IRA and these judicial challenges on the pharmaceutical industry and our business cannot yet be fully determined, but it is likely to be significant. If we obtain regulatory approval for any of our product candidates, the IRA could substantially and negatively impact the prices we may charge for such products, which could harm our ability to generate revenue and achieve and sustain profitability. In addition, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation, which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, individual states in the United States have passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing and costs. Similar developments have occurred outside of the United States, including in the EU where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. To obtain reimbursement or pricing approval in some EU member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there have been a number of, and there may in the future be, other policy, legislative, and regulatory proposals aimed at changing the pharmaceutical industry. The United States government, state legislatures, and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage, drug importation programs and proposals, and requirements for substitution of generic products for branded prescription drugs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could exclude or limit our product candidates from coverage and limit payments for pharmaceuticals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the policies of the FDA and of comparable foreign regulatory authorities may change and additional laws, regulations and government actions may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, if the Supreme Court reverses or curtails the Chevron doctrine, which gives deference to regulatory agencies in litigation against these agencies, including the FDA, more companies may bring lawsuits against the FDA to challenge its longstanding decisions and policies, which could undermine its authority, lead to uncertainties in the industry, and disrupt its normal operations, which could delay its review of any marketing applications we may submit for our product candidates. Moreover, currently enacted legislation may not be renewed once it expires, which may make it more difficult for us to obtain regulatory approval for and commercialize our product candidates. For example, the Prescription Drug User Fee Act (PDUFA) was enacted by Congress in 1992 to allow the FDA to collect fees from parties that produce certain human drug and biological products. Among other things, the fees collected under PDUFA provide for the timely review of regulatory submissions, such as BLAs. PDUFA has been renewed multiple times since its enactment, including at the end of September 2022, which will allow the FDA to continue collecting prescription drug user fees in future fiscal quarters. However, there is no guarantee that future renewals will occur in a timely manner, if at all. In addition, there may be amendments to PDUFA that could significantly affect how regulatory submissions are reviewed, and we cannot predict the extent of such amendments and how they will affect our business. If PDUFA is not renewed or its renewal is delayed, or if PDUFA is amended in certain ways, the FDA&#8217;s ability to review any regulatory submissions and related correspondence for our product candidates may be materially adversely impacted, which could negatively impact our development timelines and ability to obtain regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 13, 2021, Regulation 2021/2282 on Health Technology Assessment (HTA) amending Directive 2011/24/EU (the Regulation), was adopted in the EU. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once the Regulation becomes applicable, it will have a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The Regulation will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, and ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the UK, the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) currently returns a portion of funds to the National Health Service (NHS) based on the sales of branded prescription medicines (innovative brands, branded generics, and biosimilars) when a maximum sales growth rate is exceeded. The 2019 VPAS caps the growth of NHS branded medicine spending at a nominal rate of 2% per year, with the industry returning any spending beyond the cap. However, the 2019 VPAS is due to come to an end in December 2023. It is possible that a future VPAS will include higher payback rates which could have a negative impact on our future potential NHS-based revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action in the United States or any other jurisdiction. If we or any third parties we may engage or with which we collaborate are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may be unable to obtain regulatory approval or lose any regulatory approval that may have been obtained, and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern regulatory approvals, pricing, and reimbursement for drug products vary widely from country to country. Some countries require approval of the sale price of a drug product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription drug product pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers, and other organizations, which consider various factors in determining the level of coverage and reimbursement, including the nature of the disease to be treated, the availability and cost of other therapies for the same disease, and the size of the patient population that could benefit from such treatment. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. For example, the cost of treatment with our product candidates may be expensive or more costly than other available treatment options, in particular, because such product candidates may require only a single or minimal number of administrations. Even if treatment costs are partially offset by coverage from third-party payors, required co-payments or deductibles may cause treatment with such product candidates to be too expensive for certain patients. Because our product candidates are in the early stages of development, we are currently unable to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third-party payors that reimburse patients or healthcare providers are requiring that drug companies provide these payors with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly-approved drug products, and coverage may be more limited than the purposes for which the drug product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any product for which we receive regulatory approval will be reimbursed in all cases or at a rate that covers our costs, including for research, development, manufacture, sale, and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim reimbursement levels for new drug products, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drug products that are already reimbursed, may be incorporated into existing payments for other services, and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drug products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of drug products from countries where they may be sold at lower prices than in the United States. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because our product candidates are physician-administered injectables, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often time-consuming and costly and will likely require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed elsewhere in these Risk Factors, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict what initiatives may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare or impose price controls may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for any of our product candidates that may receive regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our approved products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for an approved product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, companion diagnostic tests that we or our collaborators may develop require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biologics products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biologics products, will apply to companion diagnostic tests. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for the product candidates that we may develop and for which we obtain regulatory approval or any companion diagnostics that we or our collaborators may develop could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential liability related to the privacy of personal information, including health information we utilize in the development of products developed from our ex vivo cell engineering platform, as well as information we may obtain from research institutions participating in our clinical trials and directly from individuals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our partners and vendors are subject to various federal, state, and foreign data protection and privacy laws and regulations. If we fail, or are alleged to fail, to comply with these laws and regulations, we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, and criminal or civil penalties, as well as negative publicity, reputational harm, and potential loss of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, our and our partners&#8217; and vendors&#8217; operations are subject to numerous federal and state laws and regulations, including state data breach notification laws and federal and state data privacy laws and regulations that govern the collection, use, disclosure, and protection of health information and other personal information. For example, most healthcare providers, including research institutions from which we obtain patient health information, are subject to data privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. For example, under HIPAA, we could potentially face substantial criminal or civil penalties if we knowingly receive protected health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of such health information, or otherwise violate applicable HIPAA requirements related to the protection of such information. Even when HIPAA does not apply, failure to take reasonable steps to keep consumers&#8217; personal information secure may constitute a violation of the Federal Trade Commission Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of the materials we use in our therapeutic research and development efforts, as well as stem cell lines used as starting material in our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering product candidates, are derived from human sources, which may contain sensitive identifiable personal information regarding the donor. In addition, we or our partners or vendors may maintain or otherwise have access to sensitive identifiable personal information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who may enroll in our patient assistance programs, if any. We may become subject to further obligations under HIPAA as a result of our access to such information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our collection of personal information generally, including information of our employees, human donors, or patients, may subject us to state data privacy laws governing the processing of personal information and requiring notification to affected individuals and state regulators in the event of a data breach involving such personal information. For example, we may be subject to state laws such as the California Consumer Privacy Act (CCPA) and its related regulations, and the California Privacy Rights Act (CPRA), which establish data privacy rights for California residents, with corresponding obligations on businesses related to transparency, deletion, and opt-out of the selling of personal information, and grant a private right of action for individuals in the event of certain security breaches that has increased the likelihood of, and risks associated with, data breach litigation. The CPRA, which became effective on January 1, 2023, significantly modified the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information and imposing new audit requirements for higher risk data. The CPRA also created a new state agency that is vested with authority to implement and enforce the CCPA and the CPRA, which could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Numerous similar laws, and other laws governing privacy and information security, such as Washington&#8217;s My Health, My Data Act, have been passed and continue to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive, and personal information than federal, international, or other state laws, and such laws may differ from each other and have potentially conflicting requirements that would make compliance challenging, require us to expend significant resources to achieve compliance, and restrict our ability to process certain personal information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any clinical trial programs, including related regulatory filings, and research collaborations that we engage in outside the United States may implicate international laws and regulations concerning data protection and privacy, including those governing various aspects of clinical research and, in the EU, the General Data Protection Regulation (GDPR). The GDPR imposes obligations in relation to the collection, use, sharing, disclosure, transfer, and other processing of data relating to an identifiable living individual within the European Economic Area (EEA), or &#8220;personal data,&#8221; including a principle of accountability and the obligation to demonstrate compliance through policies, procedures, training, and audit. The GDPR imposes stringent operational requirements for data controllers and data processors of personal data. Among other things, the GDPR requires that detailed notices be provided to clinical trial subjects and investigators, as well as maintenance of certain security levels for personal data and notification of data breaches or security incidents to appropriate data protection authorities or data subjects. Further, as a result of the UK&#8217;s withdrawal from the EU effective as of December 31, 2020, we are required to comply with both the GDPR and the GDPR as incorporated into UK national law (UK GDPR) with respect to any clinical trial data generated from the EU and the UK, respectively, which may have differing requirements. We may be subject to diverging requirements under EU member state laws and UK law, such as whether consent can be used as the legal basis for processing of clinical trial data and the roles, responsibilities, and liabilities and respective data protection obligations as between CROs, clinical trial sites, and sponsors. As these laws develop and the rules diverge, we may need to make operational changes to adapt, which could increase our costs and adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR and UK GDPR regulate cross-border transfers of personal data out of the EEA and the United Kingdom, respectively. Recent legal developments in Europe have created complexity and uncertainty regarding the legality of and requirements with respect to transfers of personal data from the EEA and United Kingdom to the United States and other countries in which we or our partners or service providers may operate. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses, which are a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. We currently rely and expect to rely in the future on the EU standard contractual clauses, the UK Addendum to the EU standard contractual clauses, and the UK International Data Transfer Agreement, as applicable, to transfer personal data outside of the EEA and the UK, including to the United States. Following a period of legal complexity and uncertainty regarding international personal data transfers, particularly to the United States, we expect that the regulatory guidance and enforcement landscape will continue to develop in relation to transfers to the United States and elsewhere. As a result, we may have to make certain operational changes and implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. If we are unable to transfer personal data between and among countries and regions in which we or our partners, collaborators, vendors, or clinical trial sites operate, it could adversely affect the manner in which we operate our business, affect the geographical location or segregation of our relevant systems and operations, and adversely affect our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These laws and regulations may also apply to service providers and vendors that store or otherwise process personal data on our behalf, such as CROs and other service providers that may support the conduct of our clinical trials and information technology or other vendors. If our data privacy or security measures fail to comply with applicable data privacy laws, or if a service provider or vendor misuses data we have provided to it or fails to safeguard such data, or otherwise fails to comply with such laws, we may be subject to litigation, regulatory investigations, enforcement notices, or enforcement actions imposing fines or requiring us to change the way we use personal data, as well as negative publicity, reputational harm, and potential loss of business. Failure to comply with the GDPR could result in penalties. Since we may be subject to the supervision of relevant data protection authorities under both the GDPR and the UK GDPR, we could be fined under each of those regimes independently in respect of the same breach. Penalties for certain breaches are up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of our global annual turnover. In addition to fines, GDPR noncompliance may result in regulatory investigations, reputational damage, orders to cease or change our data processing activities, enforcement notices, assessment notices for a compulsory audit, or civil claims, including class actions. As we continue to expand certain of our operations into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that we will need to expend significant capital and other resources to ensure ongoing compliance with applicable data privacy and security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations related to data privacy and security, even if we are not found liable, could be expensive and time-consuming to defend and could result in negative publicity that could harm our business. Moreover, even if we take all necessary action to comply with legal and regulatory requirements, we could be subject to a data breach or other unauthorized access of personal information, which could subject us to fines and penalties, as well as litigation and reputational damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to keep apprised of and comply with applicable international, federal, state, or local legal and regulatory requirements and changes thereto, we could be subject to a range of legal or regulatory actions that could affect our or any collaborators&#8217; ability to develop and seek to commercialize our product candidates. Any threatened or actual government enforcement action, or litigation when private rights of action are available, could also generate negative publicity, damage our reputation, result in liabilities, fines, and loss of business, and require that we devote substantial resources that could otherwise be used in support of other aspects of our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and third parties involved in our operations are subject to United States and certain foreign laws and regulations relating to export and import controls, sanctions, embargoes, anti-corruption, and anti-money laundering. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to export control and import laws and regulations, including the United States Export Administration Regulations, United States Customs regulations, various economic and trade sanctions regulations administered by the United States Treasury Department&#8217;s Office of Foreign Assets Controls, the United States Foreign Corrupt Practices Act of 1977, as amended (FCPA), the United States domestic bribery statute contained in 18 U.S.C. &#167; 201, the United States Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. International trade, tariff, and import/export laws and regulations may require us to obtain licenses or permits in order to complete certain activities necessary for the research, manufacture, and development of our product candidates. Moreover, we expect such laws and regulations, along with associated guidance and interpretations, to evolve over time in ways that may impact various aspects of our business. The process for obtaining any necessary licenses or permits may be lengthy and time-consuming, and if we are not able to obtain any such licenses or permits in a timely manner, we may experience delays in our ability to manufacture, develop, and commercialize our product candidates. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, collaborators, and other third parties from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell products, if any, for which we receive regulatory approval outside the United States, to conduct clinical trials, or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. In the ordinary course of our business, we may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We may be held liable for the corrupt or other illegal activities of our employees, agents, contractors, collaborators, and other third parties, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, including sanctions, treaties, tariffs, taxes, regulatory requirements, and other limitations on cross-border operations. The United States government has and continues to make significant additional changes in United States trade policy and may continue to take future actions that could negatively impact United States trade. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what interactions, including products or services, may be subject to such actions, or what actions may be taken by the other countries in retaliation. If our interactions with parties affected by any such actions are limited or no longer possible, our business, liquidity, financial condition, or results of operations could be materially and adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties involved in our operations, including CDMOs and other service providers, partners, and collaborators, may also be impacted by various laws and regulations, including those described above, compliance with or the effect of which could negatively impact the ability of these third parties to perform their obligations under our agreements with or otherwise harm our relationships with such third parties. For example, recently proposed legislation and acts by United States lawmakers, including the proposed BIOSECURE Act, have called for limitations on certain interactions with certain Chinese biotechnology firms and review of certain of these firms for sanctions due to potential threats to United States national security. To the extent that any such legislation or other similar legislation becomes law or reviews or other actions are initiated, and any third parties involved in our operations are the subject of these laws or actions, then our relationships with these third parties, and our programs and business generally, could be materially negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition, and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since inception, have not generated any revenue from product sales, and have financed our operations historically through private placements of our convertible preferred stock and, more recently, through our initial public offering (IPO). We expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. We had net losses of $107.5 million and $82.1 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $1.4 billion, which includes cumulative non-cash charges related to the revaluation of our success payment liabilities and contingent consideration of $43.0 million and $63.7 million, respectively. Our losses have resulted principally from expenses incurred for the research and development of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, management and administrative costs, and other expenses incurred while building our business infrastructure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating losses and expenses will decline in 2024, excluding one-time items, as a result of our strategic repositioning in October 2023, and likely increase over the longer term from the 2024 level if our clinical trials are successful, and if we expand our research and development efforts. Our operating losses and expenses are, and will in the future likely be, driven by our ongoing operations and our potential future expanded operations, including if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our research and development efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance and expand the capabilities of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance preclinical development of our current product candidates and initiate additional preclinical studies, including with respect to future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commence and advance through clinical studies of our current and future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish our manufacturing capabilities, including through CDMOs and building our internal manufacturing facilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire and license technologies aligned with our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approval of our current and future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborate with third parties to support the development and regulatory approval of companion diagnostics to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engage in commercialization activities, including product manufacturing, marketing, sales, and distribution for any of our product candidates for which we obtain marketing approval; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our operational, financial, and management systems and increase personnel, including those required to support our preclinical and clinical development, manufacturing, and potential future commercialization efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to develop, prosecute, and defend our intellectual property portfolio; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to incur legal, accounting, and other expenses necessary to operate our business, including the costs associated with operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have devoted a significant portion of our financial resources and efforts to building our organization, developing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, preparing for and commencing clinical trials of our product candidates, acquiring technology, organizing and staffing the company, business planning, establishing and maintaining our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. We are in the early stages of development of our product candidates and have not completed development or commercialization of any product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in identifying, developing, obtaining regulatory approval for, and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, continuing to discover and develop additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, accessing manufacturing capacity, establishing marketing capabilities, and commercializing and ultimately selling any products for which we may obtain regulatory approval. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If any of the foregoing events were to occur, the value of our shares of common stock could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or increases in the amount of expenses we will incur or when, or if, we will be able to achieve profitability. If we are required by the FDA or comparable foreign regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in commencing or completing our clinical trials or the development of any of our product candidates, our expenses could increase and our ability to obtain commercial revenue could be further delayed and become more uncertain, which will have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require additional funding to finance our operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce, or eliminate certain product development programs or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and uncertain process that takes years to complete. As described above, our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase if and as our ongoing activities grow in scope and breadth. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or eliminate certain research and development programs or any future commercialization efforts with respect to such programs, and our business, results of operations, and financial condition would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had $311.1 million in cash, cash equivalents, and marketable securities. Based on our current business plans, we believe that our existing cash, cash equivalents, and marketable securities as of March 31, 2024 will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources more quickly than we currently expect, which could require us to seek additional funds sooner than planned, including through public or private equity or debt financings or other sources, such as strategic collaborations. Furthermore, we hold significant balances of cash and cash equivalents, including as necessary to conduct our day-to-day operations, some of which are held in deposit accounts at commercial banks in excess of the government-provided deposit insurance. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. For example, in August 2022, we entered into a sales agreement with Cowen and Company, LLC (Cowen), acting as sales agent, pursuant to which we may offer and sell through Cowen shares of our common stock having an aggregate offering price of up to $150.0 million from time to time in a series of one or more at the market equity offerings (collectively, the ATM facility). As of March 31, 2024, we had raised $28.7 million in net proceeds under the ATM facility. Further, on February 12, 2024, we completed an underwritten public offering pursuant to which we sold 21.8 million shares of our common stock, including 4.5 million shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, and pre-funded warrants to purchase 12.7 million shares of our common stock (the Follow-On Offering). Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current or future product candidates, including the development of companion diagnostics to such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of clinical trials required for regulatory approval of our current or future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our current or future product candidates and any companion diagnostics to such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost associated with building our manufacturing capabilities, as well as costs associated with the manufacturing of clinical and commercial supplies of our current or future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expenses required to attract, hire, and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party, including government, payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential interruptions or delays resulting from global geo-political, economic, and other factors beyond our control; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products, and technologies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic, geo-political, and market conditions and other factors over which we may have no or limited control. Market volatility, including as a result of bank failures, including Silicon Valley Bank (SVB) and Signature Bank (Signature) in 2023, and measures taken in response thereto, and the resulting impact on the broader banking sector, geo-political and economic instability resulting from the escalation in conflict between Russia and Ukraine, the conflict in the Middle East, tensions in US-China relations, and the aftermath of the COVID-19 pandemic, or other factors, could also adversely impact our ability to access capital as and when needed. Additional funds may not be available when we need them, on terms and at a cost that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, or on terms and at a cost that are acceptable to us, we could be required to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, limit, reduce, or terminate preclinical studies, clinical trials, or other research and development activities, or eliminate one or more of our development programs altogether, or otherwise restructure our operations or reduce our workforce; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, limit, reduce, or terminate our efforts to access manufacturing capacity or establish and operationalize our manufacturing facility, establish sales and marketing capabilities, or other activities that may be necessary to commercialize any product candidates for which we obtain regulatory approval, or reduce our flexibility in developing or maintaining our sales and marketing strategy with respect to any product candidates for which we obtain regulatory approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, as described elsewhere in these Risk Factors, we implemented the October 2023 strategic repositioning and associated workforce reduction in order to focus our resources on our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cell therapy product candidates, and correspondingly, reduce our near-term investment in our fusogen platform, which involves shifting our focus on fusogen to research activities. We will require additional funding and other resources in order to expand preclinical development and initiate clinical development for product candidates derived from our fusogen platform.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents, and marketable securities, proceeds from any future equity or debt financings, and upfront, milestone, and royalty payments received under any future licenses, collaborations, or other arrangements. Additional capital may not be available on terms that are reasonable or acceptable to us, if at all. If we raise additional capital through the sale of equity or debt securities, existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. In addition, any such issuance, or the possibility of such issuance, may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock, and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, or acquiring, selling, or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success payment and contingent consideration obligations in our license and acquisition agreements may result in dilution to our stockholders, drain our cash resources, or require us to incur debt to satisfy the payment obligations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We agreed to make success payments, payable in cash, pursuant to our license agreement with Harvard and contingent consideration and success payments, payable in cash or stock, pursuant to our acquisition agreement with Cobalt. Pursuant to the terms of our license agreement with Harvard, we may be required to make up to an aggregate of $175.0 million in success payments to Harvard (Harvard Success Payments), payable in cash, based on increases in the per share fair market value of our common stock. The potential Harvard Success Payments are based on multiples of increasing value ranging from 5x to 40x based on a comparison of the per share fair market value of our common stock relative to the original issuance price of $4.00 per share at ongoing pre-determined valuation measurement dates. The Harvard Success Payments can be achieved over a maximum of 12 years from the effective date of the agreement. If a higher success payment tier is met at the same time a lower tier is met, both tiers will be owed. Any previous Harvard Success Payments made are credited against the Harvard Success Payment owed as of any valuation measurement date so that Harvard does not receive multiple success payments in connection with the same threshold. As of March 31, 2024, a Harvard Success Payment had not been triggered. See Note 4, License and collaboration agreements to our consolidated financial statements included elsewhere in this Quarterly Report for more details on the various per share common stock values that trigger a Harvard Success Payment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Cobalt acquisition, we are obligated to pay to certain former Cobalt stockholders contingent consideration (Cobalt Contingent Consideration) of up to an aggregate of $500.0 million upon our achievement of certain pre-defined development milestones and a success payment (Cobalt Success Payment) of $500.0 million, each of which is payable in cash or stock. The Cobalt Success Payment is payable if, at pre-determined valuation measurement dates, our market capitalization equals or exceeds $8.1 billion, and we are advancing a program based on the fusogen technology in a clinical trial pursuant to an IND, or have filed for, or received approval for, a BLA or new drug application for a product based on the fusogen technology. The Cobalt Success Payment can be achieved over a maximum of 20 years from the date of the acquisition, but this period could be shorter upon the occurrence of certain events. A valuation measurement date would be triggered upon a change of control if at least one of our programs based on the fusogen technology is the subject of an active research program at the time of such change of control. If there is a change of control and our market capitalization is below $8.1 billion as of the date of the change of control, the amount of the potential Cobalt Success Payment will decrease, and the amount of potential Cobalt Contingent Consideration will increase. As of March 31, 2024, a Cobalt Success Payment had not been triggered. See Note 3, Acquisitions, to our consolidated financial statements included elsewhere in this Quarterly Report for details on the amount of the potential Cobalt Success Payment and potential Cobalt Contingent Consideration if there is a change of control based on various thresholds for our market capitalization on such change of control date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to satisfy our obligations to make these success payments, if and when they are triggered, we may issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash or incur debt to satisfy the success payment obligations in cash, which may adversely affect our financial position. In addition, these success payments may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The contingent consideration and success payment obligations in our license and acquisition agreements may cause our operating results, net losses, and financial condition as reported by United States generally accepted accounting principles to fluctuate significantly from quarter to quarter and year to year, which may reduce the usefulness of our financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success payment and contingent consideration obligations under our license and acquisition agreements are recorded as liabilities on our balance sheets. Under United States generally accepted accounting principles (GAAP), we are required to estimate the fair value of these liabilities as of each quarter end, with changes in the estimated fair value recorded in research and development-related success payments and contingent consideration. Factors that may lead to increases or decreases in the estimated fair value of the success payment liabilities include, among others, changes in the value of our common stock and market capitalization, changes in volatility, the estimated number and timing of valuation measurement dates, the term of the success payments, and changes in the risk-free interest rate. Factors that may lead to increases or decreases in the estimated fair value of our contingent consideration obligations include, among others, the estimated likelihood and timing within which milestones may be achieved and the estimated discount rates. A small change in the inputs and related assumptions with respect to our success payment liabilities and contingent consideration may result in a relatively large change in the estimated valuation and associated liabilities and resulting expense or gain. As a result, our operating results, net losses, and financial condition as reported by GAAP may fluctuate significantly from quarter to quarter and year to year for reasons unrelated to our operations, which may reduce the usefulness of our GAAP financial statements. For example, as of March 31, 2024 and December 31, 2023, the estimated aggregate fair value of the Cobalt Success Payment and Harvard Success Payment liabilities was $45.4 million and $12.8 million, respectively, and the estimated fair value of the Cobalt Contingent Consideration was $115.0 million and $109.6 million, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024, we recorded expenses of $27.9 million and $4.7 million, respectively, related to the aggregate change in the estimated fair value of the Cobalt Success Payment and Harvard Success Payment liabilities. For the three months ended March 31, 2024, we recorded an expense of $5.4 million related to the change in the estimated fair value of the Cobalt Contingent Consideration. We have incurred net losses since our inception and expect to continue to incur net losses for the foreseeable future. It is possible that future fluctuations in the price of our common stock and market capitalization and the resulting change in the estimated fair value of our success payment liabilities could lead us to record net income in a future period despite us incurring operating losses and negative cash flows during such period. Alternatively, significant stock appreciation during a future period could lead to a significant increase in our recorded GAAP net loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history upon which to evaluate our business and prospects. Since our inception in July 2018, we have devoted substantially all of our resources and efforts to building our organization, developing our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering platforms, identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, preparing for and conducting clinical trials of our product candidates, acquiring technology, organizing and staffing the company, business planning, establishing and maintaining our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. We have not yet demonstrated our ability to successfully complete any clinical trials, including Phase 3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, predictions about our future success or viability are difficult to make and may not be as accurate as they could be if we had a longer operating history.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing, or commercializing competing products before or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop, and obtain marketing approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large pharmaceutical companies, biotechnology companies, academic institutions, government agencies, and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and marketing of products that compete with our product candidates. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources, including intellectual property that may be necessary or useful for the development and commercialization of our product candidates, being concentrated in our competitors and becoming unavailable to us on commercially reasonable terms or at all. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the proliferation of new drugs and therapies for our target indications, and as new technologies become available, we expect to face increasingly intense competition. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and are able to commercialize, including those for the treatment of various cancers, B-cell-mediated autoimmune diseases, and type 1 diabetes, will compete with existing therapies and new therapies that may become available in the future, which may include CAR T, cellular, antibody, small molecule, and other types of therapies. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technologies obsolete, less competitive, or uneconomical. Our competitors may, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have significantly greater financial, manufacturing, marketing, drug development, technical, and human resources than we have; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects than any products for which we may obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain quicker regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish proprietary positions covering our products and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">implement more effective approaches to sales and marketing; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">form more advantageous strategic alliances. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business, financial condition, and results of operations could be materially adversely affected by any of the foregoing events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our potential future collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license to them, which could have a material adverse effect on our future business, financial condition, and results of operations. As described elsewhere in these Risk Factors and in the subsection titled &#8220;Business&#8212;Competition&#8221; in our 2023 Annual Report, we currently and in the future will compete with third parties in the development and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market opportunity and market growth for our product candidates may prove to be smaller than we initially estimated, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates or at all, or we may otherwise be unable to capitalize on this opportunity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to initially focus our product candidate development on treatments for various diseases caused by missing or damaged cells. Our projections of addressable patient populations within any particular disease state that may benefit from treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates, including if the cost of treatment with our product candidates, including any required co-payments, is expensive or higher than other available therapies. Our market opportunity may also be limited by future competitor therapies that enter the market. If any of our estimates proves to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished, which would have an adverse material impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, certain of our product candidates are intended to treat cancer, and, in particular, B cell malignancies. Cancer therapies are sometimes characterized as first-line, second-line, or third-line and beyond, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first-line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first-line therapy, which usually consists of chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more chemotherapy, antibody drugs, tumor-targeted small molecules, radiation therapy, or a combination of these. Third-line therapies can include chemotherapy, antibody drugs, and small molecule tumor-targeted therapies, more invasive forms of surgery, and new technologies. The use of certain classes of therapies, including CAR T therapies, has been limited to a subset of patients with relapsed or refractory disease. Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who are in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. Consequently, even if our product candidates are approved for a later line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if the market opportunity for our product candidates achieves or exceeds the level and growth we anticipate, we may be unable to grow our business at the rate or in the manner necessary to successfully capitalize on this opportunity, including due to limited financial, personnel, and other resources. Our ability to successfully commercialize our product candidates will also be affected by numerous factors beyond our control, including limitations on third-party resources and infrastructure and other factors discussed in these Risk Factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Each of these commercialization strategies carries substantial risks to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no marketing, sales, or distribution capabilities because all of our product candidates are in the early stages of development. If one or more of our product candidates complete clinical development and receive regulatory approval, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party, both of which involve significant risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we elect to establish our own sales and marketing capabilities, we will incur significant additional costs, including to hire and retain qualified personnel to build out the organization, and we may be unable to build out this organization in a way that will enable us to successfully market our products and generate revenues. If we elect to enter into arrangements with third parties to perform sales and marketing with respect to our product candidates, we may be unable to identify suitable partners, and even if we do identify such partners, we may be unable to negotiate the terms of such arrangement in a timely manner or at all, which could delay our marketing efforts and our ability to generate revenues. To the extent that we are able to enter into collaboration agreements with respect to marketing, sales, or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would subject us to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our ability to complete our obligations under these arrangements, may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. If we are unable to enter into these arrangements on acceptable terms, or at all, we may not be able to successfully commercialize any products for which we receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our ability to generate product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate substantial evidence that such product provides benefits that outweigh its known and potential risks for the intended patient population, as well as data that demonstrate that such product can be manufactured to a pre-defined standard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any of our product candidates that may be approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Jurisdictions outside the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2004. However, biosimilars can only be authorized once the period of data exclusivity on the reference biological medicine has expired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. As a result of this and uncertainties regarding patent protection, we are not currently able to predict with certainty the length of market exclusivity for any particular product candidate that may receive marketing approval based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. There may also be future changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for any product for which we receive regulatory approval could materially and negatively affect or prevent our ability to generate revenues, which could prevent us from achieving or sustaining profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, our executive officers, directors, holders of 5% or more of our capital stock, and their respective affiliates, beneficially owned, in the aggregate, approximately 53.2% of our common stock. Therefore, these stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments to our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that other stockholders may feel are in their best interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales of our securities by us in the public market could cause our common stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At any time in the future we may sell a large number of shares of our common stock or rights to acquire a large number of shares of our common stock. Such sales, or the perception that such sales could occur, could cause our common stock price to decline as a result of, among other things, dilution from these sales, including pursuant to the exercise or conversion of rights to acquire our common stock, or discounts to the trading price of our common stock associated with such sales. In addition, transactions involving a large number of shares of our common stock, or the possibility that these transactions may occur, may also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that we will need significant additional capital in the future to support our planned operations, including conducting clinical trials, manufacturing, and other research and development activities, commercializing any product candidates for which we may obtain regulatory approval, and continuing to operate as a public company. To raise capital, we may sell shares of our common stock, warrants, convertible securities, or other securities in one or more transactions at prices and in a manner we determine from time to time. For example, as described elsewhere in these Risk Factors, we have sold shares of common stock in the ATM facility and shares of common stock and pre-funded warrants in the Follow-On Offering. If we sell additional securities in the future, whether in the ATM facility, in future public offerings, or otherwise, you could experience material dilution. In addition, such sales could result in new investors gaining rights, preferences, and privileges senior to the holders of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market, or the perception that such sales could occur, could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our existing stockholders sell, indicate an intention to sell, or there is a perception in the market that they intend to sell, a large number of shares of our common stock, the trading price of our common stock could decline. As of March 31, 2024, 221.3 million shares of our common stock were outstanding, which excludes shares of common stock sold in the ATM facility and shares of common stock issued upon exercise of outstanding equity awards, in each case, after March 31, 2024, and 43.1% of such shares were beneficially owned by holders of 5% or more of our common stock. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, applicable lock-up agreements, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended (Securities Act). If these additional shares of common stock are sold, or there is a perception that they will be sold, in the public market, the trading price of our common stock could decline. Further, certain holders of shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value of our common stock, which is not certain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a staggered Board divided into three classes serving staggered three-year terms, such that not all members of the Board are elected at one time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our Board to issue new series of preferred stock without stockholder approval and create, subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate the ability of our stockholders to fill vacancies on our Board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permit our Board to establish the number of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that our Board is expressly authorized to make, alter, or repeal our bylaws; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that stockholders can remove directors only for cause and only upon the approval of not less than 66 2/3% of all outstanding shares of our voting stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of not less than 66 2/3% of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the jurisdictions in which certain stockholder litigation may be brought. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a Delaware corporation, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a breach of a fiduciary duty owed by any director, officer, or other employee to us or our stockholders, (iii) any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law, (iv) any action to interpret, apply, enforce, or determine the validity of our second amended and restated certificate of incorporation or amended and restated bylaws, or (v) any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended (Exchange Act).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock will be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Tax Cuts and Jobs Act of 2017 (Tax Act), as modified by the Coronavirus Aid, Relief, and Economic Stability Act (CARES Act), our federal net operating losses (NOLs) generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOL and other pre-change tax attributes, such as research and development tax credits, to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past and may experience ownership changes as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use and gain the benefit of a material portion of our NOLs and tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. and foreign tax laws could have a material adverse effect on our business, cash flow, results of operations, or financial conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to tax laws, regulations, and policies of the United States federal, state, and local governments and of comparable taxing authorities in foreign jurisdictions. Changes in tax laws, and in the administration of such laws, could adversely affect our effective tax rate, our cashflow, our operating results, or our reported financial condition. For example, the Tax Act eliminated the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize those expenditures over five or fifteen years pursuant to Code Section 174. If and when we come profitable, these changes may cause us to pay federal income taxes earlier under the revised tax law than under the prior law and may increase our total federal tax liability attributable to orphan drug programs and other research and development activities. There can be no assurance that our effective tax rate, tax obligations, tax credits, including the orphan drug designation credit, or incentives will not be adversely affected by these or other developments or changes in law.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and variations in the level of expense related to the current or future development of our programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and status of enrollment for our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes or fluctuations in our stock price and market capitalization, which could impact the value of our contingent obligations and cause fluctuations in our operating expenses as a result of these non-cash adjustments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact of geo-political, economic, and other factors beyond our control on us or third parties with which we collaborate or that we engage; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials, or the addition or termination of such clinical trials or funding support by us or potential future partners or other third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our execution of any collaboration, licensing, or similar arrangements, and the timing of payments we may make or receive under such arrangements or the termination or modification of any such arrangements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any intellectual property infringement, misappropriation, or violation lawsuit or opposition, interference, post-grant proceeding, or cancellation proceeding in which we may become involved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions and departures of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments, or changes in business strategy; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of global supply chain issues and inflation on the costs of laboratory consumables, supplies, and equipment required for our ongoing operations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if any product candidate we may develop receives regulatory approval, the timing and terms of such approval and market acceptance and demand for such product candidate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of establishing a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with current or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments affecting current or future product candidates or those of our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount of expense or gain associated with the change in value of the success payments and contingent consideration; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in general market and economic conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stock price may be volatile or may decline regardless of our operating performance, which may result in substantial losses for investors and may potentially subject us to securities class action litigation, which is expensive and could divert management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock, as well as investor perceptions of our business and its value, may be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways, and many of which are beyond our control, including the factors listed below and other factors describe in these Risk Factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the commencement of, enrollment in, or results of current and future preclinical studies and clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including the issuance by the FDA of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceptions regarding the significance of data from our clinical trials, particularly preliminary data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical trial, or to terminate an existing preclinical study or clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse actions taken by regulatory agencies with respect to our preclinical studies or clinical trials, manufacturing supply chain, or sales and marketing activities, including failure to receive regulatory approval of our product candidates or companion diagnostics to such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations, including preclinical study or clinical trial requirements for regulatory approvals worldwide; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse changes to our relationship with manufacturers or suppliers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing, supply, or distribution shortages; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to successfully commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patent rights, trade secrets, litigation matters, and our ability to obtain patent protection for our technologies or product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our results of operations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our cash position; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publication of research reports about us or our industry, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell engineering products in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements made by us or our competitors about new product candidates and programs, success, setbacks, or other updates related to product candidates and programs that exist or are under development, strategic transactions and relationships, such as acquisitions collaborations, and joint ventures, or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to establish or successfully maintain any collaborations or other strategic relationships, if needed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth of our initial target markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">academic or other publications regarding our or adjacent industries, including regarding cell and gene therapy products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">press reports, whether or not true, about our business and the fields in which we operate; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales or perceived potential sales of our common stock by us or our stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overall fluctuations in the equity markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in accounting practices or principles; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes or developments in the global legal and regulatory environment, including any new laws or regulations, or amendments to existing laws or regulations, that may impact the commercial environment for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation involving us, our industry, or both, or investigations by regulators into our operations or those of our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general political and economic conditions both within and outside the United States, including changes in interest rates, inflation, geo-political and economic instability resulting from the escalation in conflict between Russia and Ukraine, the conflict in the Middle East, tensions in US-China relations, and economic and tax policies announced by foreign countries; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our common stock does not exceed your purchase price, you may not realize any return on, and may lose some or all of, your investment. In addition, because the biotechnology industry is complex and subject to heightened risks as compared to many other industries, investors may be reluctant to place value in and invest in our company and choose instead to prioritize investment in other companies and industries, including those that may be perceived as more stable or that prioritize initiatives that may not be relevant to our industry or practical for us to prioritize at this stage in our development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. The market price of our common stock has fluctuated since our IPO and may continue in the future to be volatile. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market and economic conditions may negatively impact our business, financial condition, and share price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concerns about inflation, interest rates, energy costs, geo-political issues, the United States mortgage market and a declining real estate market, unstable global credit markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity and credit availability, declines in investment in industries perceived as complex or higher risk, such as biotechnology, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in recent years. Our general business strategy may be adversely affected by any such economic downturns, volatile business environments, and continued unstable or unpredictable economic and market conditions, including as a result of a prolonged government shutdown, or the perception or possibility that such a shutdown may occur. The closures of SVB and Signature in 2023 and their placement into receivership with the Federal Deposit Insurance Corporation created bank-specific and broader financial institution liquidity risk and concerns. Although government intervention ultimately provided depositors at SVB and Signature with access to their funds, adverse developments with respect to specific financial institutions or the broader financial services industry that have occurred or may occur in the future may lead to market-wide liquidity shortages, impair our ability to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur, and we cannot predict the impact or follow-on effects of these insolvencies more broadly or on our business in particular. Further, there is no guarantee that the government will intervene to provide depositors with access to funds if similar events occur in the future. If other banks and financial institutions with which we have commercial relationships enter receivership or become insolvent in the future, our ability to access our existing cash, cash equivalents, and investments may be threatened, which could adversely affect our business and financial condition.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the depth and breadth of our portfolio, we assess and prioritize our programs on an ongoing basis based on various factors, including internal and external opportunities and constraints, which may result in our decision to advance certain programs ahead or instead of others. Given the volatility in our stock price and the increased difficulty in accessing global credit markets and raising capital due to the market and economic conditions described above, we have adjusted our pipeline prioritization strategy and resource allocation in order to enable the success of our most advanced product candidates. In particular, we have gated investment in our programs, with future investment dependent on our achievement of certain milestones. Even if our programs achieve the required milestones, development and potential commercialization of our product candidates may be delayed, which could harm our competitive position. In order to manage resource constraints, we may be required to make decisions regarding how to prioritize our programs based on limited data. As a result, we may be required to delay or halt the development of potentially promising earlier stage programs to focus our resources on a limited number of more advanced programs with higher probabilities of success in the shorter term. Such decisions have, and in the future would, reduce the breadth and diversity of our portfolio and investments therein, potentially limit the long-term growth of our pipeline, and increase the risk and extent of the negative impact on our business if such programs are not successful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if any of the events described occur, or if the market and economic conditions described above continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and stock price. As a result, we may be required to further adjust our pipeline prioritization strategy and resource allocation in order to extend our cash runway and enable the success of certain of our product candidates, which may require that we make adjustments based on limited information and slow or stop the development of certain product candidates. Additionally, rising rates of inflation in recent years have increased the costs associated with conducting our business, including by causing substantial increases in the costs of materials, including raw materials and consumables, equipment, services, and labor. Given that we do not currently generate revenue from sales of any of our product candidates, we do not have an ability to offset these increases in our costs. Moreover, given the unpredictable nature of the current economic climate, including future changes in rates of inflation, it may be increasingly difficult for us to predict and control our future expenses, which may harm our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters, including earthquakes, fires, typhoons, and floods, public health epidemics, telecommunications or electrical failures, geo-political actions, including war and terrorism, political and economic instability, and other events beyond our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our partners, CROs, CDMOs, or other service providers, may experience interruptions to our operations, including the conduct of our research and development programs, clinical trials, and manufacturing operations, due to natural disasters, including earthquakes, fires, typhoons, and floods, public health epidemics, such as the COVID-19 pandemic, hardware, software, telecommunication or electrical failures, geo-political actions, including war and terrorism, or political and economic instability, which could significantly disrupt or harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters and other facilities, including the site of our planned manufacturing facility, are located in areas that have experienced significant natural disasters, including the San Francisco Bay Area and Seattle, Washington, each of which have experienced severe effects from wildfires and, in the case of the San Francisco Bay Area, severe earthquakes. We do not carry earthquake insurance. Earthquakes, wildfires, or other natural disasters could severely disrupt our operations, and could materially and adversely affect our business, financial condition, results of operations, and prospects. If a natural disaster, electrical failure, or other event occurs that prevents us from using all or a significant portion of our headquarters, damages critical infrastructure, or otherwise disrupts operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. For example, a prolonged electrical failure could result in damage to or destruction of materials that are critical for our research and manufacturing operations, including our master cell banks, which would delay the advancement of our programs and materially harm our business, operating results, prospects, or financial condition. In addition, a failure of our computing systems could result in the loss of research or preclinical data important to our research or development programs, interrupt the conduct of ongoing research, or otherwise impair our ability to operate, which could delay the advancement of our programs or cause us to incur costs to recover or reproduce lost data. In addition, if in the future a natural disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our manufacturing capabilities, we may not be able to manufacture sufficient supply of our product candidates required to conduct our clinical trials or commercialize our products in accordance with our timelines or at all. The disaster recovery and business continuity plans we currently have in place are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, together with our lack of earthquake insurance in particular, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen, and severe adverse events. In addition, our supply chain is vulnerable to changes in the geo-political and economic climate, including changes in relationships between the United States and countries from which we may need to source materials and other resources necessary for the preclinical evaluation of our product candidates, including animal models, and specifically non-human primate models, or to manufacture our product candidates, including raw and intermediate materials and consumables. If any such event or change were to affect our supply chain, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the COVID-19 pandemic and related public health guidance measures, we experienced and may in the future experience disruptions that could materially and adversely impact our preclinical and clinical studies and development and our business, financial condition, and results of operations. Potential disruptions resulting from the COVID-19 pandemic or another pandemic, epidemic, or infectious disease outbreak may include delays or disruptions in our research, preclinical, clinical, manufacturing, and regulatory activities, including due to limitations on employee or other resources both internally and at third parties, including government agencies, or delays in procuring, or inability to procure, necessary supplies, materials, and equipment. The extent to which the impact of the COVID-19 pandemic and any other pandemic, epidemic, or other outbreak may affect our preclinical studies, clinical trials, business, financial condition, and results of operations will depend on future developments, which continue to be highly uncertain and unpredictable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, geo-political actions, such as the conflicts in Ukraine and the Middle East, trade restrictions, and the resulting political and economic instability, could negatively impact our operations. Although it is difficult to anticipate the impact of any of the foregoing on our company in particular, such geo-political actions, and any actions taken in response thereto, could increase our costs, disrupt our supply chain, impair our ability to raise or access additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business, our market, or our competitors, or if they adversely change their recommendations regarding our common stock, the trading price or trading volume of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock is influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. We do not have any control over the analysts or the content and opinions included in their research and reports. If one or more of these analysts issue an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors, or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease such coverage or fail to regularly publish reports on us, we could lose visibility in the financial markets and demand for our common stock could decrease, which could cause the trading price or trading volume of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an emerging growth company, and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act); </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports and annual reports on Form 10-K; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding non-binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our status as an emerging growth company will end as soon as any of the following takes place:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the last day of the fiscal year ending after the fifth anniversary of the completion of our IPO, which is December 31, 2026. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive as a result of our decision to rely on any of the exemptions afforded to emerging growth companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for any new or revised accounting standards during the period in which we remain an emerging growth company (or we affirmatively and irrevocably opted out of the extended transition period); however, we may adopt certain new or revised accounting standards early. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The requirements of being a public company may strain our resources, result in an increased risk of litigation, and divert management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time-consuming, or costly, and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet the requirements of the Sarbanes-Oxley Act, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure create uncertainty for public companies, increase legal and financial compliance costs, and make some activities more time-consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to continue to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from potential revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards fail to meet the requirements of the applicable regulatory or governing bodies, including due to ambiguities related to their application in practice, regulatory authorities may initiate legal proceedings against us, and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New laws, rules, and standards and our efforts necessary to comply may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation and talent committee, and qualified executive officers. Additionally, the dramatic increase in the cost of such insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover defense costs, settlements, and damages awarded to plaintiffs in connection with any securities litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By disclosing information in the periodic filings required of a public company, our business and financial condition are more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have implemented and may need to continue to implement additional financial and management controls, reporting systems, and procedures, and may need to hire additional accounting and finance staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement with a related party, which could cause us to fail to make a required related party transaction disclosure. Additionally, controls can, depending on the circumstances, be circumvented by the acts of a single individual, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The withdrawal of the United Kingdom from the European Union, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the United Kingdom or European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the United Kingdom or European Union, and may require us to incur additional expenses in order to develop, manufacture, and commercialize our product candidates in the United Kingdom or European Union.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK left the EU on January 31, 2020, commonly referred to as &#8220;Brexit.&#8221; Pursuant to the formal withdrawal arrangements agreed between the UK and EU, the UK and EU negotiated a framework for partnership for the future in their Trade and Cooperation Agreement (TCA), which became effective on January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, including the mutual recognition of cGMP inspections of manufacturing facilities for medicinal products and cGMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because a significant proportion of the regulatory framework in the UK applicable to our business and our product candidates is derived from EU directives and regulations, Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval, and commercialization of our product candidates in the UK. In general, the EU laws that have been transposed into UK law through secondary legislation remain applicable in Great Britain. However, these rules may have diverged or may in the future diverge from the EU rules, and general uncertainty regarding the future of the relationship between the UK and EU, as well as the laws and rules in each such jurisdiction, remains.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) is the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules apply in Northern Ireland than in Great Britain; broadly, Northern Ireland continues to follow the EU regulatory regime, but its national competent authority remains the MHRA. However, on February 27, 2023, the UK Government and the European Commission reached political consensus on the &#8220;Windsor Framework,&#8221; which will revise the Northern Ireland protocol in order to address some of the perceived shortcomings. Under the proposed changes, Northern Ireland would be reintegrated under the regulatory authority of the MHRA with respect to medicinal products. The implementation of the Windsor Framework will occur in various stages, with new arrangements relating to the supply of medicines into Northern Ireland due to take effect in 2025. There could be additional uncertainty and risk around what these changes will mean for any of our business operations in the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Transition Period, the UK is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and companies established in the UK must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain marketing authorization to commercialize a product in the UK. The MHRA may rely on a decision taken by the European Commission with respect to the approval of a new (centralized procedure) marketing authorization when making a determination with respect to an application for a Great Britain marketing authorization, or use the MHRA&#8217;s decentralized or mutual recognition procedures, which enable marketing authorizations approved in EU member states (or Iceland, Liechtenstein, or Norway) to be granted in Great Britain. Any delay in obtaining, or an inability to obtain, any marketing approvals in the UK or EU, as a result of Brexit or otherwise, could prevent us from commercializing our product candidates in the UK or EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other requirements, some of which could be significant, in connection with the importation of our product candidates into the UK or EU, or we may incur expenses in establishing a manufacturing facility in the UK or EU in order to circumvent such requirements. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval for our product candidates in the UK or EU or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability. Any further changes in international trade, tariff, and import/export regulations, as a result of Brexit or otherwise, may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Securities and Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not sell any unregistered securities in the three months ended March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds from our Initial Public Offering of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 3, 2021, our Registration Statement on Form S-1 (File No. 333-252061) relating to our IPO was declared effective. On February 8, 2021, we closed our IPO and issued 27.0 million shares of common stock, including 3.5 million shares of common stock sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, at a public offering price of $25.00 per share, for aggregate net proceeds of $626.4 million. Morgan Stanley &amp; Co. LLC, Goldman Sachs &amp; Co. LLS, J.P. Morgan Securities LLC, and BofA Securities, Inc. acted as joint bookrunning managers of the IPO and as representatives of the underwriters. No offering expense were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold the remaining balance of the net proceeds from the IPO in cash and cash equivalents and money market funds in accordance with our investment policy. There has been no material change in the planned use of the net proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n Senior Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c)</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_083ca282-bf9a-4088-a941-827319b84476" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, the following officer, as defined in Rule 16a-1(f), adopted a &#8220;Rule 10b5-1 trading arrangement&#8221; as defined in Regulation S-K Item 408, as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2401d043-3f35-4948-8ac9-ab5e79176758" contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b31e089e-8d14-4c76-bbe7-c168c079645f" contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nathan Hardy</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bd5bf51-b897-4e00-bd50-8f3517d68ac2" contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, adopted a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_905f05bb-4a08-4af7-bfdd-abcd94c9fb0f" contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e159c8e-110c-4ff4-a9a7-5d0c043aa225" contextRef="C_a16970d7-1af4-4067-88b3-324a3854a541" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">76,125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49d244dc-3c73-4276-bd7e-2ab995077f9a" contextRef="C_cca9dd29-2dba-4680-84e1-d43e2ddb90e4" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,813</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock issuable upon the exercise of options. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 15, 2026, or earlier if all transactions under the trading arrangement are completed. On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7ded5a1-850d-4887-a3cb-599c2e843352" contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 13, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27a21dc0-e46a-4241-b993-8d3bb8e70fec" contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Hardy</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> terminated a separate </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76df8f33-9e07-41b8-b08c-4d6e475d50b1" contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63506a92-35e0-4738-9dbe-ef7a0efb7ba6" contextRef="C_a197803e-4cdd-43c1-9127-6f070156a3c2" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">140,236</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6889dbac-0135-40a6-bd8b-140f64c3c3ff" contextRef="C_e48bacc4-19a5-4b6d-bd4a-f5ea9f59378a" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">76,692</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock issuable upon the exercise of options. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until April 20, 2024, or earlier if all transactions under the trading arrangement were completed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other officers or directors, as defined in Rule 16a-1(f), </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc720b9c-2813-4524-8f2b-b68213d1eb88" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_d7fb71d1-e00f-4e2b-920e-57ea32147f7d" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and/or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f3ea77d-2d6a-4ade-bbcb-e13b9f227713" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_3e4f0726-cc83-44c3-9186-8346c32b80e7" contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the last fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:1%;"/>
    <td style="width:89%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001770121/000119312521032935/d112159dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39941), filed with the SEC on February 9, 2021)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:6.5pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001770121/000119312521032935/d112159dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39941), filed with the SEC on February 9, 2021)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reference is made to Exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/0001770121/000119312521032935/d112159dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.1</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/0001770121/000119312521032935/d112159dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.2</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001770121/000119312521019984/d60414dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-252061), filed with the SEC on January 28, 2021)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/d745670dex41.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39941), filed with the SEC on February 8, 2024).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sana-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 4 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of April 4, 2024.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sana-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sana-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.1*+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sana-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.2*+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sana-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SANA BIOTECHNOLOGY, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8.65pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Steven D. Harr, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steven D. Harr, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nathan Hardy</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nathan Hardy</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President and Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sana-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT NO. 4 TO OPTION AND LICENSE AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment No. 4 to Option and License Agreement</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fourth Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is made as of April 4, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fourth Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Beam Therapeutics Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware corporation having an office at 238 Main Street, Cambridge, MA 02142 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Beam</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware corporation having an office at 188 E Blaine Street, #400, Seattle, WA 98102 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sana</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Sana and Beam are referred to in this Fourth Amendment individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recitals</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties have entered into that certain Option and License Agreement, dated October 15, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Original Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as amended by that certain Amendment No. 1 thereto dated June 6, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that certain Amendment No. 2 thereto dated July 19, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and that certain Amendment No. 3 thereto dated March 17, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)  (the Original Agreement as amended by the First Amendment, the Second Amendment and the Third Amendment, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) pursuant to which Sana obtained a non-exclusive license from Beam to use Beam&#x2019;s proprietary nuclease editing technology in connection with research and development of engineered cellular therapy products and, if successful, for Sana to further develop and commercialize such products;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> pursuant to Sana&#x2019;s request under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement, the Parties desire to document the replacement of a certain PSC Product type (&#x201c;[***] differentiated from PSCs&#x201d;) with a certain Antigen Target ([***]) and to make certain conforming changes to certain definitions of the Agreement to reflect such replacement; provided that the Parties acknowledge and agree that pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement, Sana has no further rights to designate any Replacement CAR Antigen Targets or Replacement PSC Product Types;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to extend the Additional Selection Term by a period of [***];</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to  increase the amount of an Additional Option Payment to [***] Dollars ($[***]) each; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to amend the Agreement in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 14.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Now, Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties now desire, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, to amend the Agreement as set forth in this Fourth Amendment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE 1</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>amendments</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms used herein (including in the Recitals section above) but not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment of Definitions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The definition &#x201c;Additional Selection Term&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-8.993%;padding-left:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Selection Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period starting on the Effective Date and ending on [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The definition &#x201c;CAR Antigen Target&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-8.993%;padding-left:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CAR Antigen Target</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means: (a) a [***] Antigen Target; (b) a [***] Antigen Target; (c) a [***] Antigen Target; (d) a [***] Antigen Target and (e) up to [***] ([***]) Additional CAR Antigen Targets selected pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; provided, however, that if any Replacement CAR Antigen Target is selected pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to replace any of the foregoing Antigen Targets, such Replacement CAR Antigen Target will become a CAR Antigen Target and the replaced Antigen Target will no longer be a CAR Antigen Target.</font></p>
  <p style="margin-left:9.173%;text-indent:-10.102%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following new definition &#x201c;[***] Antigen Target&#x201d; is hereby added as a new Section 1.64A of the Agreement:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-8.993%;padding-left:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.64A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	 &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Antigen Target&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means the [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The definition &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Genetic Target Maximum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.62</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-10.102%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.62</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Genetic Target Maximum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any PSC Product Type, [***] ([***]) genes.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The definition &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PSC Product Type</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.95</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-10.102%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">1.95 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">PSC Product Type</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the following human cell types: (a) [***] differentiated from PSCs; and (b) if applicable, any Additional PSC Product Type selected pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">; provided, however, that if a Replacement PSC Product Type is selected pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> to replace the foregoing PSC Product Type in subsection (a) above, such Replacement PSC Product Type will become a PSC Product Type, and the replaced PSC Product Type will no longer be a PSC Product Type.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.6%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The PSC-derived cells &#x201c;[***]&#x201d; including all of the Genetic Targets for &#x201c;[***]&#x201d; are hereby deleted from Exhibit C of the Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment to Section 8.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Agreement is hereby deleted and replaced in its entirety by the following:</font></div></div>
  <p style="margin-left:9.173%;text-indent:-10.102%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8.3 	Additional Option Payments.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> For each Antigen Target that is designated as an Additional CAR Antigen Target pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and for any Product Type that is designated as an Additional PSC Product Type pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Beam will issue Sana an invoice for a one-time payment equal to [***] Dollars ($[***]) (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Option Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Sana shall pay such Additional Option Payment within [***] ([***]) Business Days after its receipt of such invoice from Beam.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">ARTICLE 2</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>MISCELLANEOUS</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Fourth Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party may rely on the delivery of executed electronic copies of counterpart execution pages of this Fourth Amendment and such electronic copies shall be legally effective to create a valid and binding agreement among the Parties.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Agreement and this Fourth Amendment constitute the entire and exclusive agreement between the Parties with respect to the subject matter hereof. All previous discussions and agreements with respect to this subject matter are superseded by the Agreement and this Fourth Amendment. </font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as amended herein, all other provisions of the Agreement shall remain unchanged and in full force and effect.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Remainder of Page Intentionally Left Blank]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties intending to be bound have caused this Amendment No. 4 to Option and License Agreement to be executed by their duly authorized representatives as of the Fourth Amendment Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.22%;"></td>
    <td style="width:49.78%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Beam Therapeutics Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By: /s/ John Evans</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: John Evans</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:	CEO</font></p><p style="margin-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sana Biotechnology, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By: /s/ Steve Harr</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: Steve Harr</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-30.6pt;padding-left:30.6pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:	CEO</font></p><p style="margin-left:35.1pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sana-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Steven D. Harr, M.D., certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Sana Biotechnology, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Steven D. Harr, M.D.</font></p></td>
   </tr>
   <tr style="height:2.15pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steven D. Harr, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sana-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Nathan Hardy, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Sana Biotechnology, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nathan Hardy</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nathan Hardy</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sana-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Sana Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.54%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Steven D. Harr, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steven D. Harr, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>sana-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Sana Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nathan Hardy</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nathan Hardy</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img112676973_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img112676973_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" <%!P8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !16)XL\:^'_ NG)?^(]:L-"L6D$2W&HW"01EST7<Q SQ
MTKDO^&D/A3_T4CPK_P"#>#_XJMH4:M17A%M>AE*M3@[2DD_4](HK,\/^)-)\
M5Z?'J&BZG::M8R?=N;*998S_ ,"4D5RVL?'GX;^']4N=-U3QYX=T_4+5_+GM
M;K4X8Y(F'564MD'ZTHTJDI.,8MM>0Y5(12E*229WE%>?67[0?PQU*ZBM;3X@
M^&;BXE;:D4>K0,S'T W5V\VH6UO8O>O<1)9I&96N"X\L(!DL6Z8QSFB=*I3T
MG%KY!&I">L9)EJBO-_\ AI+X4?\ 12/"O_@W@_\ BJ='^T=\*Y9%1/B-X79V
M(5575X,DGH!\U:?5J_\ S[?W,S^L4?YU]Z/1J*8CK(JLC!E89##H17)^)OB]
MX&\%WBVFO^,-#T:Z(R(;[4(HG_)F!K&,)5'RP5V:RG&"O)V1U]%9^C:]IOB.
MQ2]TG4+;4K.0?+<6DRRH?HRDBL;7/BAX/\,Z_;:%J_BC2-,UJYV^3I]W>QQS
MR;CA=J$Y.3P.*:ISD^5)W!SBES-Z'4T4@K#\6^./#O@.QBO?$FN:?H-G+)Y4
M<^HW*0(SX)V@L0"< \>U3&+D^6*NQRDHJ\G9&[16$WCGPZOA0>)SKNGCPX8O
M/&K?:4^S>7G&_P S.W&>^:/"?CCP[X\L9+WPWKFGZ]9QOY3SZ;<I.BOC.TE2
M0#@CBG[.=G*SLA<\6TKZLW:*YKQ=\2O"?P_:U7Q-XETKP^;K=Y U*\C@\W&,
M[=Q&<9'YTGBKXE>$_ MK9W'B/Q+I6A6]YDVTNH7D<"S8 )V%B,\$'CUJE2J2
MM:+UVTW$ZD%>\EIN=-15:PO[;5+*WO+.XCNK2X1989X6#)(A&0RD<$$=ZYKQ
M1\7/!'@F[6U\0>+M$T6Y;I#?W\4+_DS U,:<YOEBKL<IQBN:3LCKJ*SM"\0:
M7XFT]+[2-1M=4LI.5N+.994/XJ2*T*EIQ=F4FFKH6BN%A^.7P[N-<&C1>.O#
MTFK&?[*+%=3A,QFW;?+V;L[L\8ZYKMV8*I9CM Y)JY4YT_C31,:D)_"[CZ*Y
M?PO\3O"'CB_NK'P]XGTG7+RU&ZXM]/O8YGB&<995)(YXYKIQ4RC*#Y9*S'&4
M9*\7<6BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **HZQK>G>'[%[W5+ZVTZSCY>>Z
ME6-!]22!7,^'?C1X!\7:@+'1/&F@ZM>L,BWL]1BE<_10V:TC3G).48MI&;J0
MB^5M7.THI*R/%/B_0_!&EG4_$.KV.B:<'6,W>H7"PQAFZ+N8@9-1&+D[15V6
MVHJ[V-BBN<\(?$3PO\0(KF7PSXBTOQ!';$+,VFW:3B,GD!MI.,X/7TIGB_XE
M>$_A^UL/$WB72O#YN<F$:E>1P>9CKMW$9Q[5?LZG-R<KOVZD>TAR\_,K=^AT
MU%0V=W!J%I!=6TT=Q;3(LD4T3!D=2,A@1P00<YKG;3XF^$;_ ,62>%[;Q/I-
MQXDB+*^DQWD;72E1E@8P=PP.3Q24)2O9;%.48VN]SJ***X6/XY?#N77!HR>.
M?#S:L9_LHL5U.$S>=NV^7LW9W9XQUS3C3G4OR)NPI3C"W,[7.ZHJKJ&H6VDV
M-Q>WMQ':6ENAEEGF<(D:@9+,3P !6/X/^(/ACX@6]Q/X8\0Z;X@AMV"32:;=
M).L;$9 8J3@D5*C)Q<DM$/FBGRMZG145SWBKQ_X9\"P+-XC\0:9H43<*^HW:
M0 Y]-Q%)X4^(?A;QW'(_ASQ%I>NHAPYTZ\CGV_7:35>SGR\_*[=^A/M(<W)=
M7['144@I:S- HHHH **** "BBB@ HHHH *\]_:&_Y(9X[_[ ]S_Z+->A5Y[^
MT-_R0SQW_P!@>Y_]%FNG#?QX>J_,Y\1_!GZ/\CX"_8=_93\"_M >!]?U3Q6F
MI&ZL+Y;:'[#=^2NPQAN1M.3GO7/_ !Z^''_#%/[0WA:^\#ZO>?9IHX[^&.:3
M,JIYI22"0C&]& [CO[57_9*T[]H.^\):PWP>O[6TTA;M1>K<-:@F;8,$><I/
MW<=.*]L^'O[$/Q,^(WQ4L?&OQMUR"[6UF662S2<3RW&PY2/Y0$2//) [<8YS
M7Z3B,1]6QE6>)Q"=.S]R]WMM;H? T:'UC"TH4*#52_Q[+?>YRG_!1ZSAUKX\
M?#VVG5O(N[&*)P/E;:]P 1['!KW27_@FE\'Y[-Q$=?MY73Y)/[1W;&(X."F#
M@]J\+_X*56L]Y\=O =M:S?9[F:P2.*;)'EN;C"MD<C!(/'I7)_M$?#O]H/X%
M^'K>]\0?$C6O$'AJ^/V:>ZT_5KEHHRW CD5R" PZ'H>E<E&%:KA,)3HXCV;:
M>FNNIU59TJ>)Q-2K1]HDUKVT.H_X)[ZWJ?@G]H[Q7X"M;]M0T!X;H2;&)C+P
M2A4F Z D$J?7(]!5;XL>(O%'[;'[3\OPWTO57TSPCI5Q-$%0DQB.$[9KAE!P
M[EN%!X&1[U] ?L"_"OX<Z)X"N/%WA#5;CQ!K.I)]EOKJ^C$4MH1AC!Y8)V\X
M.<G=P<XKY_\ V([J/P?^V5XMT75=EM?W']H6D0DX/FK/NVJ?< D>H%*5:$\5
MBL52C[].*2NNO65@C2G'#X;#5)>Y4D[V?3HKGM'B/_@F%\.[KPO);Z+JVL66
MNK%^[OKF=98GD _BCVC )QT/ KC_ -@CXU>)O#_Q&UCX+^,+J6\^Q><NGO.Y
M=K>2$XDA#'DH5!90>FWWK[ZR ,G@5^9?P-N$\<?\%'M6UG1W\[3H]3U*[,T?
M(\H0O'GZ%F _&O*P>)JYAA<33Q;YE&/,F^C7GYGI8JA2P.)P\\,N5RERM+JC
M'T7X2Z!\;/V\/&OA;Q(MRVES7=].WV.;RI-R!2OS8/'->I?M#?\ !/'PIX/^
M&NJ>)? 5[JEIJVCQ->-;7ESYRSQIRP5L JP'(/M6!\"?^4DOBW_KMJ7_ *"M
M?<OQJU2UT;X0>-+V\=4MHM(NB[/TYB8#]2*ZL=C\5A<5AX49NW+#3HS#!X/#
MXC#5I58J_-+7JCYN_93^-NI?%[]E3QC::[<O>ZUX?LKFR>ZE.7GA,!:)V/<X
MRI/?;FN3_P""4P_XIGX@<?\ +[:_^BVKE/\ @GGI-TWP:^,UR$8P2V8MTXZR
M+;RDCZX=:ZG_ ()3R)_PCOQ CWKYGVRU;;GG'EL,U>.I0HT,="GMS0_'4C!U
M)U:N#G/?EE^&AN?\%4/^23>#_P#L.'_TGEKH_&GQLN?@3^PWX0UG2V1=<O=*
ML]/TYG (CE>+)DQWVJK$>X%<W_P508?\*H\'+D9.ML<=\?9Y?\17#_M>:)>2
M?L1_!^Z6-C%9BT6?_8WVS!2?;(Q^(K+!TH5\)@Z=39S9IBZLZ.)Q4Z>Z@@_9
ME_8ATWXY>"T^(GQ,UC5M2NM=9YK:&&YVR%-V/-DD()))!PO  Q6G9_LA?$O]
MGKX^Z1J_PBGFU3PQ-MDNUO[I8D\K>!);S?W_ )3N5@O&/45]-_L?ZU9ZY^S7
MX"FLV0I'IZV[JA!V2(Q5E/H<C]:V_B-^T-X!^$_B;3-!\5Z_'I&H:C$9H%DC
M9EV[PF68 [<D\9ZX/I7'5S/'RQ56C%<RU7):ZLO)=CJIY?@XX:G5D^5Z/FO9
MW?GYG!_$S]AWX:?%[QMJ'BOQ!%K']KW^PS_9;\QQ_*H487;QP!7PS^S'^SUX
M1^+7[0GC+P9KR7QT;2OMGV;[-<^7*/*N?+3<V#GY>OO7ZSPR+-$DB'<C ,K#
MN#WK\X_V%?\ D\;XD_34O_2T5KEF-Q/U/$WJ/W(JVNWH9YAA*'UG#^XO>D[^
M9]F? W]G#P?^SS;ZQ#X26_5-5>.2X^W7/G'*!@NW@8^\:]3HHKY*K5J5YNI5
M=V^K/IJ=.%&*A35D@HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y"_X*<_\D#T[_L,P_\
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MVZ^X]2_X*J &\^'7?B[_ )QT?\%-O^2<_"O_ '9O_1,5?//QR^.G_"Z?A/\
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M55HX?$JC2E=3BK_XEO\ J<3_ ,$U1_Q>SXE\?\NY_P#2EJ_1BOSG_P"":O\
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MPKZ.K#$8:KA:GLJT;2-:&(IXF'M*3NA:***YCH"BBB@ HHHH **** "BBB@
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MT3W5_P#P.B_PKLI9/CZT%4IT[I[:K_,Y:F:8.C-PG4LUZ_Y'W31FOD[X>_\
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MRNS;870V^G^FQU^C=?'<0N^.;\H_D?4Y&K8-+S?YA1117S)] %%%% !1110
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M@=S7H5HR^LXJ;?Q4KKNEV?F<%&4?J^'BE\-2S]>Z\C](J^&O^"JG_(@^!_\
ML(S_ /HH5]J?\)%I7_03L_\ P(3_ !KXI_X*G3)<?#OP+)$ZR1MJ,Y5E(((\
MH=#7RN1IK,:-^[_)GTN<-/ 5+>7YHY_]JK_DPSX5?[NG_P#H@UY/^QA\6-1_
M9W^+VFZ5XC62R\->,+6W9_,/R 2#-M<CMC)*D]@S=Q7K'[57_)A?PJ_W=/\
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MZ?+*@W2LPPRC!X(KR#]K3XY>%/CQ\=/ 6L>$;FYNK*SBM[29KFV> B3[46P
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MWP"_;4DT*TB\8KX!\26\WEK<7VFB.2Y5P0(2S%5(!P0=W'XUV'[=7AR7P?\
ML=Z+H<^I/K$NG7-A:MJ$B!&N-BE=Y )P3C/6O,OV[O@C\%_A_P" 8M6\+I8Z
M)XKFND2#3].N-R7$1)WDQ9(4 <[ACTYJ/XIZMK.M?\$U_!EUKCS27OVV&-)+
MC.]H5FD6$DGKF,)S4T:<9?5*U"4O9J=E&5KI^3ZHJK4E'ZS2K17/R7<HWL_5
M=SI?V9?VR_A)\,?@CX8\->(KN[CUFQA9+A8]+DE4$NQ&' (/!%?17P?_ &J/
MAE\:_%$NA^$;BYFU2*W:Y83:<\ " @$[F '<<5Y)^R5\$_A'XJ_9]\):IXC\
M*^&K_6;B!S<7-[%&TSD2, 6).<XQ7T!X%^%7PO\  6M&^\)>'_#^CZK+&8?.
MTY(TE9#R5XY(X_2O&S)X'VM91C/GN^JM>_Y'K8%8SV=)RE'ELNCO:WYGHHKY
M^_:F^#/Q!^.%QH.@>&_%/_",>$G63^VV5R&F!(VJ%7E^,\$A?6OH&BOG\/7G
MAJBJPM==U<]JM1CB*;ISV?;0_,#]F/P/9_#7]O:;PMI\TUS9Z2;NUCFN,;W
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M*H\U.=FY)V<7;=7>WE^!NG+#O#NKRU(72BUI)?UU-O\ ;HUFT\._MC>%-5U
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MGP=^*&I^(?"OCHZE<WZ31Q:-!>0M$D+-N"%02S[,<'(Z9-?,/CKXA:+\*_\
M@HIJ?BCQ#-+;Z18W),TD,1E<;K7:,*.3R16'^QWH_A[1/VWK>Q\+7SZMH%M]
MNBL;^4#?/$(B YP!U]@*ZW6_"^D>-/\ @I5>:-KVFV^KZ5<W+":SNT#QOBTR
M,CO@@'\*]2%%T<56^L3<TZ+;=K.W;U//E55;#4O804&JJ2ZJ_<]J^)/[?WP>
M\3?#OQ1H]CJNIO>ZAI=U:0*VES*#))$RJ"2.!DCFN4_X)71K)X'\?(ZJZ_VC
M;95AD?ZIJ]J^*_[,7PFT?X6^,+^R^'OA^UO+71[R>">.R0-'(L+E6![$$ _A
M7B__  2I_P"1)\>_]A&V_P#135Y7-A7E5?ZJI)7C?FMW\CTK8A9E1^L-/25K
M7[>9L_\ !4.UAM_@CX;:*&.,_P#"01\H@!_X]IZ]U_9=L;:3]G?X?,UO$S'2
M(26*#)X^E>'_ /!4K_DA_AO_ +&&/_TFGKW?]EG_ )-U^'O_ &"(?Y5Q5_\
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M-"U36_$NI6%II,?EQZ;:QQF*3+AG+%AG+  ?2O=K2UBL;6&WA01PPHL:*HP
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MHRJ^V<?>M:_D?#G_  ZI\(GKXZUP_P#;M!_A7=_"C_@G9\-_AMKMKK%]/?\
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M)/V.,QSHI/\ =+C('M7JWP&_8X\ _ '4/[6TJ&YU7Q!Y?E#4]1<,\:D8;RU
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M)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\
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M![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\
MXFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\
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M?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\
MH"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=.
M_*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?\,5?";_H
M"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_
M $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^
M2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\
MPQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\
M%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?
M\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_
M (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'
ML<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_
M ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^
M)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@
M+>_^![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\
MI/\ XFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+
M>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\
M0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*
M'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##
M%7PF_P"@+>_^![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6
M_P"A]T[\I/\ XFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_P
MQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\
MAM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>Q
MRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\
MQ->&_P##%7PF_P"@+>_^![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XG
MN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M
M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD
M_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[
M_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#
M[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?\,5?";_H"WO_ ('O1['*/YJG_DH>
MVS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5
M?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_
M *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%
M7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&
MTO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?\,5?";_H"WO_ ('O1['*
M/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_ $/NG?E)_P#$
MUX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y
M?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO
M_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=._*3_
M .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?\,5?";_H"WO_
M ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_ $/N
MG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;
M-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\
M)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\
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M![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\
MXFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\
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M?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\
MH"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=.
M_*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##%7PF_P"@+>_^![T?\,5?";_H
M"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\ XFC_ (;2^"W_
M $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\ @>]'L<H_FJ?^
M2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\ 0^Z=^4G_ ,37AO\
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M>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\ AM+X+?\
M0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*
M'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\ Q->&_P##
M%7PF_P"@+>_^![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6
M_P"A]T[\I/\ XFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_P
MQ5\)O^@+>_\ @>]'L<H_FJ?^2A[;-/Y8?B>Y?\-I?!;_ *'W3ORD_P#B:/\
MAM+X+?\ 0^Z=^4G_ ,37AO\ PQ5\)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>Q
MRC^:I_Y*'MLT_EA^)[E_PVE\%O\ H?=._*3_ .)H_P"&TO@M_P!#[IWY2?\
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M)O\ H"WO_@>]'_#%7PF_Z M[_P"![T>QRC^:I_Y*'MLT_EA^)[E_PVE\%O\
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M![T?\,5?";_H"WO_ ('O1['*/YJG_DH>VS3^6'XGN7_#:7P6_P"A]T[\I/\
MXFC_ (;2^"W_ $/NG?E)_P#$UX;_ ,,5?";_ * M[_X'O1_PQ5\)O^@+>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8P-P]C3T)UM8\U^!?@.\\+?L:_$?5[V%H#KUN]Q K@@M#&H17^C$G'TKM/\
M@G;&J_"?7) /G;6&!;U BCQ_,U]$>,?!UGXQ\%:GX8D=K"QOK4VA>U108DX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 .C_UB?[P_G7L\?\ JU^E>,1_ZQ/]X?SK
MV>/_ %:_2L*AM3ZCJ***Q-PK'\6_\B]>?[O]16Q534[%=4L9;5V*+(,%EZBF
MMQ/8\?HKO?\ A7-K_P _<WY"C_A7-K_S]S?D*Z?:1.?V<C@J*[W_ (5S:_\
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M."HKO?\ A7-K_P _<WY"C_A7-K_S]S?D*/:1#V<C@J*[W_A7-K_S]S?D*/\
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M\_<WY"CVD0]G(X*BN]_X5S:_\_<WY"C_ (5S:_\ /W-^0H]I$/9R."HKO?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4J_>'UI*5?O#ZT >)?LR?\
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M4445P'8%%%% !1110 4444 %%%% !1110 4444 %>*_M ?\ )0/@G_V-:_\
MHEZ]JKQ7]H#_ )*!\$_^QK7_ -$O7H8'^.O27_I+./&?P7ZQ_P#2D>U4445P
M'8%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "E7[P^M)2K]X?6@#Q+]F3_ (^?BQ_V.=W_ .@)
M7ME>)_LR?\?/Q8_['.[_ /0$KVRN_'?[Q+Y?DCBP?\"/S_-A1117 =H4444
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MC[=&J%I%SDKM8Y7CJ<?2O!_V*=<L/$_Q/^..KZ5<K>Z;>ZK'/;W" A9$.[#
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M>/0"3)/TKZ+_ ."@?Q\^(/PI^)^@:=X1\4W>A6-QI(GE@MTC8-)YKC<=RD]
M!^%?,EC^VQ\;;&ZBN/\ A/;RX\L[O*N((&C;V8;!Q^->3A<1FV+H1KP]G:7^
M(]3$4,LPU:5&?/=?X?\ (\M\9>!_$'P]UI](\2Z/>:)J2*'-O>1%&*GHPSU'
MN*[+X6_LU?$;XT:+<ZMX.\/C5M/MYS;2S&\@AVR!0V,2.IZ$<^]?77[5VH1_
M&[]B?P;\3-;TZ'3O$T<D+J54KP[M'(JYYVOM#@5G_L:Z]J'A?]C'XL:OI-T]
MCJ5E/<SV]S& 6C<6Z$,,@C(]Q3EFE=X+VT(I5%+D:>JO>Q,<MHQQ?LIR;@X\
MRMH[6N>$?\,#_'/_ *$M?_!I:?\ QVO+_B)\&_&WPGN$B\6^&K_1!(Q6.:>/
M,,A'99!E3^!KME_;.^-O!_X6)J1[_P"J@_\ C=?57[+?[2B_M36>K_"?XL6=
MIJT][:O+:7JQ",SJH^92!PLBYW*XQT/I6E7$YE@X^VQ$82@M^6]TN^I%/#Y?
MBI>RH2E&;VYK6OVT/S\T#0[[Q/KEAI&FP_:-0OIEM[>'<%WR,< 9) '/K7N?
M_# _QT_Z$M?_  :6G_QVL'POX$N/AC^UCHWA2Z?S9=)\316PD_YZ()1L?\5P
M?QKZ!_;B_:0^)7PS^/E]H?ACQA>:-I*6-M*MK"D14,R98_,A/)]ZVQ.+Q4L1
M3HX/E]Z/->5_+MZF6'PN'C1G5Q?-[LN72WGW]#QS_A@?XY_]"6O_ (-+3_X[
M7EGQ0^$OBKX,Z_%HOC#3!I.I2VZW20B>.;,9+*&S&S#JIXSGBNX_X;0^-?\
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MP)*.DA4LS,P[;F(!YQ6ZE%:I_(Y^64M&M>Y\_?MSVUS\+/VP?!OQ N(7.DW
MLKH2!<Y,$F)D'OL(('O7Z-:3XRT/7/#,/B&QU6TGT26$7"WRS+Y00@');.!P
M><]*Y_XQ?!?PM\=/"$OAWQ78_:K4MYD,\9V36TG9XW[']#T-?(%U_P $LY8[
MJ2UT_P"*NI6WAYWR=/DLRQ*GKG;*J$GUV5%XR2N[%VE%MI7N>P_ W]M:P^.?
MQBUKP1I'ABZ:RL3<21:Y%.KP/!&P59&4@%=Y. !GJ*\__; _:GU>\\6#X+_#
M*ZAA\37S"WU/69+A88[,,N3$LC$!6V\LV?E' YKW_P" G[-?A3]G7PQ<Z9X9
M266_O,&[U:\PT\[ ';G  "C/"C KY2US_@E?J?B+5M0U+4/BC'<7=]<27,[M
MHA.YW8LQ_P!?ZFFN3F%+GY;'MO[)?P*^'O[/>DE8/%&C^(/&VJ@)>:BMY&S,
M2<^3"N[(7/XL>3V \\_:N\!_ _XU?&33/"VI^*;KPI\4I6CLQ<6EH9$<%=T8
MG!PO(.$;</3GBLOX8?\ !,%_AS\1O#7BG_A/K>]&C7\=[]F71O+,NPYV[O..
M,^N#7L'[3W[%'A_]HK5;7Q!!JT_ACQ5;QK#_ &A!$)4F13E0Z94EE[,&!%%U
MS7N%I<MK'P3^U1^SKH'P5\8>#_ OAW6;KQ-XJU%=U_=W+ -ODD5((_+!.S.2
M<$DGK7Z\:'8_V7HNGV1))M[>.'G_ &5 _I7S%\ /V _#OPA\80^+O$.OW7C?
MQ+;'=:S7<>R&%\8$FTLS,X' +,<=A7U52G*]D.G'EN['YL_LK?\ *0[QW_UT
MU3_T-:_2>OF;X3_L<3?#/]HO7OBBWBM-135&NF&EBP,9C\X@_P"L\PYQC^Z,
MU],TIM-Z%4XN*U"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH *2EKR/X
M_P#[2GAO]G^STJ/4K6\UK7M8E,6FZ)IB![FY(^\V.RCU]3@ TTF]$)M)79ZW
M7#_$7XS>&/A7K'A73/$%S<07?B:^_L_35AMWE#S9488J/E'SKR>*^=KK]OK7
M?!\D%WX^^!OBWP;X>DD$;:M.3(J9/4JT2 \<_>IG[9NJVNN>.OV:=1L9EN+*
M[\3QSPS+T=&,!4_D:M1=]2'-6NCZ+\7?&CPOX)^(/A7P7JMS<1:]XF,@TZ*.
MV=T?8,MN<#"_C7=5\@_M*_\ )ZW[.O\ UTN__037H?Q[_:ZT'X*^(K/PI8:)
MJ/C7QM>()(M"TD9=%/W3(V#MSV !/?&,4N7:P^:U[GO=%?,'P[_;BLM8\=V/
M@_X@^!=;^%NN:B0M@-9RT,[$X52Y1"I)X'&/<5]/U+36XU)2V&331V\+RRNL
M44:EG=R J@#))/85\\^,OV_O@AX)U9].NO%WV^>-BKMIEK)<QJP.""Z#'Y5Q
M'[??BS6=:NOA[\(-!O)+"?QQJ'E7L\+8;[,K*"G'8ELD=]F*]Z^''[/G@#X6
M^&;;1=$\,:<D$4:I)//;))+.P'+NS DDDG\ZJR2NR;MNR-+X7_&3P;\9M%?5
M/!VO6NM6T9"S+"V)(6(SAT/*GZBNR9@BDL0H R2>@KYRC_9/?P5^T;I'Q%^'
M=Y8^%M'E@:#7M%5&$=Z#W1%^53T/U&>YK>_;,^*C?"?X ^(KVT8_VSJ2#2M.
MC3EVGF^48'<@%C2LF[(?,TFY'1?"/]I#P)\<-8U[2_"6J27MYHCA+M);=XNK
M,NY"P&]<J1D>H]:],FF6"&25^$12Q^@&:_/32_ TG[%_Q'^!?B>0"VTO7=,7
MP_XD<\*+A\-YCGV+*?\ MD:_035/^09=_P#7%_\ T$TY12V",F]]SYEF_P""
ME'P+@D9)-=U-&4D$'29^QQ_=K9\'_P#!0+X(>--9ATRU\5M93S,$C?4K.6WC
M9B<!=[# .?6O/?\ @G38^&[C]G^Y?5K?2I;K^WKT;KQ(B^WY,?>YQUK8_;LL
M_A-!\ =>_M2/0H=<$6='^R");G[3D8V;/FV\'=VQFKY8WY3/FER\USZS219$
M5T8,K#(93D$>M>:_&[]HKP3^SSI^E7OC6^N+&WU.9X+9K>U><LZKN((4'''K
M5/\ 93.LG]G'X>G7_-_M7^R8O-\_[^WG9G_@&VO2]2T73]85%O[&VOE0Y1;F
M%9 I]1D<5EHGJ:ZM71\SK_P4J^!;JQ77=3(7J1I,^!_X[71_#G]NSX1?%7QM
MI?A3P]K%]<ZSJ3M';12Z=+&K%49SEB,#A37EO[6OAW2K']IW]FZWM]+LK>WN
M-:D6:**V15E&^'A@!\P^M?7]IX4T33[A+BUT?3[:X3E)8;5%9>W! R*M\J1"
MYFVKFK124M9FH4444 %%%% !1110 4444 %%%% !1110 4444 %8/B/_ %T/
M^Z?YUO5@^(_]=#_NG^=5'<F6QCU\L?MF?\E&^!7_ &,?^%?4]>5?&CX&O\7/
M$G@/55UI=*'A?4O[0,36QE^T]/D!W#;TZ\UK'<PEJC!_:V^$.H>./#=IXM\*
MLUMX]\(RG4-+FBX>55.YX3ZY R!Z_6O#?!OQ>L/C?^UI\'O$]HH@N7T&Y@O[
M/O;7*B0.A'IGD>QK[G9R9"XX.<U\]:'^R#IGA7]I#_A:6BZNMC9.TDTN@BUR
M/.D0J[+)N^523NQM]:I-6U)DM;HXKQ%X7T;QA_P4,73M>TFRUK3SX1\S[+?P
M+-%N4/AMK C(]:]^C^ ?PQWK_P 6\\+]?^@3!_\ $UB_\*/?_AI)?BM_;*[!
MHW]D_P!D_9CGH?WGF[O?IM_&O55.U@?0YI-]AI'RA^QKIUIH_P 6OCO8V%M#
M965OJZ1PV\"!(XU&["JHX 'H*M_L&_\ ('^)_P#V-4_\VKT[X0? ]_A7XV^(
M/B!M:74QXKO1>"W6V,7V7&?E+;COZ]<"O'],_8O^('A;4=:F\*_''4/#%GJE
M])?2V=AI[(N]V)YQ+R0#C-/1W)LU8^M:*^>_A_\ L^_%/PKXSTG5];^.^L>)
MM*M)A)<:1<6K+'=+_<),AP/PKZ$J&6@HHHI#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /@G_ (*:?\C!X#_Z];K_ -#CKXHK[7_X*:?\
MC!X#_P"O6Z_]#CKXHK]CR/\ Y%U+Y_FS\LSG_?ZGR_)$UE9S:C>06EM&TUS<
M2+%%&O5W8@*!]217Z7_&3]F?QXW[+_@GX4^ -/M+I(BEQK<\UVD&^0?O"!NZ
M[I6+>VP"OE_]@'X4_P#"Q_CQ9ZG=0A]*\-1_VC,6'RF7I"O_ 'U\W_ :3]H#
M]L#X@ZY\8O%$WA3QMJVC^'(;MK:QMK&X*1>7'\F\#U8@L?K7)CO;XO&PH89K
M]W[SO>UWHMOO.K!>QPN$G6Q"?[SW5;>RW_R/JO\ 99_9Q\=^%_A%X[^&GQ(T
MRU@\/ZPC/92V]ZEP4>1=KC:O3#*C@^N:_/;2?"]_X)^-.F>']4B,6H:;KT%K
M,N/XDN%&1['J/8BO0_AE^V)\3/#/Q \/ZGKGC;6M:T:WO(S>V-U=%XYH2<."
M/H21[@5[?^W!\+X-)^/OP\^(>DJLFD^)[VR6::+&PSI(A5_^!QX.?]FL*'UC
M!8N<,2U^^3:M>W,EKOW1T5O88S#0GAT_W32=][-_HSW#]K'6/V>-/\;:2GQ>
MTNZOM=:P!M9($NR!!O;C]RP'WMW7FL?X6_"7]EOXBZ#>^)?!'A&/Q%+I:F27
M3%ENI+H'!PIMY9.<]LC%>%_\%1/^2Q>%_P#L"#_T=)7S?\$_C!K/P-^(FF^*
MM&=F,#;+JTW$)=0$_/&W\QZ$ UQ83+*E;+H5*%::DUMS/E]+=+G5BLQIT<?*
MG6I1<;[\NOJ>N?M>?M77'QJ-IX0TC0YO"WA/19L#3[A0DTDJ#:N]!Q&$&0%'
MKSZ5ZE^RG_R8O\9?]ZZ_])TI?VVOA#HWQ3\!Z7\>?A_&MQ9WD"/J\<*\LAX$
MS ='0_(_T!YQ6G^Q;X:U'QE^QS\5-#TB 76J:A<W%O;0EU0/(UN@ W,0!]2:
MNI4P_P#9</8KE49QNGT=];D4Z=?^T9^U?,W%V:ZJVECX 7[H^E>[_L.17$G[
M4G@<P X2:=I<?W/L\F?U(J\O[ 7QT^4'P=".W_(5M./_ ")7TM^S]^S[8?L7
MZ+K?Q2^*.K6*:K%:O;V=C:R;_+!Y*J3C?*Y 7 & ._7'KYAF6%EAITZ4U.4D
MTDG=MO3H>7@<OQ,<1"I5@XQB[MM65EKU/&_CE)!)_P %%$, X&N:8KD=-XAA
M!KZ*_:9_:(^#OPW^*ESHOC3X61^+-<2VAD?4FT^TF+(RY5=TIW<"OAKP/XTO
M?B-^U+H7B?4/^/O5?$L5VZYR$W2@A1[ 8 ^E?3_[:/[*'Q0^+GQSO?$7A7P[
M'J6D265O"MPU_;PDLJ88;7<'@^U>7B,/0AB,/1Q<^51IVO>VJMU/2H5ZTZ%>
MKA8\S<[VM?1WZ&?_ ,-B_LY?]$'A_P#!1I__ ,57R5\</%_AWQY\2M=U[PGH
M0\->'[ORS:Z6L4<0@VPHK?+'\HRRLW']ZO4/^& _CI_T)T7_ (-K3_X[7F?Q
M<^!_C/X(W=E9>,])72;F_A>:W1;F*?>JG!.8V8#D]Z]? PR^E5_V:KS2:VY^
M;SVN>7C)XZI3_?TN6*>_+;\;'U=^WYJ5UHW@3]G^_L9Y+6]M;*6:":,X9'6*
MT(8'V(K=\9:?:?MY?LV0>*-,AC7XH^$T,=U;Q@!IP!EXP/[K@;T]&!%<S_P4
M/_Y)G\"?^P;/_P"B;6OG?]FCX[7_ .S_ /%"QU^$O+I,Q%MJEFI_UUN3R0/[
MR_>'TQW->5A<+.KEU.O0_BP<FO/WG=>C/1Q.)A2QU2C6_AS44_+W59_(^B?@
MNC1_\$WOBRCJ4=;ZX#*PP0?]'R#7Q!7ZQ_'KPSX8T7]D7XJ:OX1DCDT?Q-"=
M<#0D&(O,8MS)Z!MH..Q)K\G*[LCKK$*O52M>>WR1R9S2=#V-)N]H_JS[J_8]
M_P"3+OCE_P!<[S_TB%?"B_='TK[K_8]_Y,O^.7_7.\_](A7PHOW1]*Z,O_WK
M%?XE_P"DHY\=_NV&_P +_-BT445[QX@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113HXGGE2*-&DE
M=@J(@)9B>  !U)H 6%)))HTA5WF9@$6,$L6)X QSG/I7Z[?LSV?CRP^$6D0_
M$.99=:"_N5;)GCM\#8LY[R ?IC/->,?L??L?1^ X[3QMXVM%E\2.HDL=-E *
MV"D<.X[RX_[Y^M?7?O7YEQ!FE+%-8>BDU%_%Y^7EW[GZ'DF75,,G7JNSET_S
M"BBBOC#ZH**** "BBB@ HHHH **** "BBB@ KQ7]H#_DH'P3_P"QK7_T2]>U
M5XK^T!_R4#X)_P#8UK_Z)>O0P/\ '7I+_P!)9QXS^"_6/_I2/:J***X#L"BB
MBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2K]X?6DI5^\/K0!XE^S)_Q\_%C_L<[O_T!*]LKQ/\
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M%=&0S:?&$>)]XVOPRG&X=<4[P!\>OB#\*]+GTWPEXJO="L)YC<26]LL95I"
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M33PM"E+FITTGY)(J>*KU(\LYMKS;.L\;?%CQA\2+#2++Q-K]UK-II"-'817
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M2NP5$099B>  .Y)K]#_V/_V/X_ <5IXV\;6BR^))%$EAILH!6P4]'<=Y2/\
MOGZT?L??L?Q^ X;3QMXVM%E\22*)+'390"M@I'#N.\I'_?/UKZ\/)S7YUG>=
M^TOA<*_=ZOOY+R_/TW^]RC*/9VQ&(6O1=O-^8G4YHHHKX4^P"BBBD 4444 %
M%%% !1110 4444 %%%% !7BO[0'_ "4#X)_]C6O_ *)>O:J\5_: _P"2@?!/
M_L:U_P#1+UZ&!_CKTE_Z2SCQG\%^L?\ TI'M5%%%<!V!1112 **** "BBB@
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M?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\
M/'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:
M,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1
M:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9
M?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6
M;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<
MQ/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H
M_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_
M -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:
M?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F
M:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\
MP_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_
M .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-
M_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_
M]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?
M\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\ ?V7_ .*H_P!:,)_)
M+\/\P_U<Q/\ /'\?\C\F:*_6;_AC?X-_]"1:?]_9?_BJ/^&-_@W_ -"1:?\
M?V7_ .*H_P!:,)_)+\/\P_U<Q/\ /'\?\C\F:*_627]CGX.+#(1X(M 0I(_>
MR^G^]7F/[-/[,OPR\<?!_3M8USPI;W^I2WEY&]Q))("52X=5'#=E %;+B3"R
MIRJ\DK)I=.M_/R,GD&(514^=7:;Z]+>7F?G317ZS?\,;_!O_ *$BT_[^R_\
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MI?\ H(W_ /W^_P#K4?\ "-+_ -!&_P#^_P!_]:GIW%J;5%8O_"-+_P!!&_\
M^_W_ -:C_A&E_P"@C?\ _?[_ .M1IW#4VJ*Q?^$:7_H(W_\ W^_^M1_PC2_]
M!&__ ._W_P!:C3N&IM45B_\ "-+_ -!&_P#^_P!_]:C_ (1I?^@C?_\ ?[_Z
MU&G<-3:HK%_X1I?^@C?_ /?[_P"M1_PC2_\ 01O_ /O]_P#6HT[AJ;5%8O\
MPC2_]!&__P"_W_UJ/^$:7_H(W_\ W^_^M1IW#4VJ*Q?^$:7_ *"-_P#]_O\
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M$:7_ *"-_P#]_O\ ZU'_  C2_P#01O\ _O\ ?_6HT[AJ;5%8O_"-+_T$;_\
M[_?_ %J/^$:7_H(W_P#W^_\ K4:=PU-JBL7_ (1I?^@C?_\ ?[_ZU'_"-+_T
M$;__ +_?_6HT[AJ;5%8O_"-+_P!!&_\ ^_W_ -:C_A&E_P"@C?\ _?[_ .M1
MIW#4VJ*Q?^$:7_H(W_\ W^_^M1_PC2_]!&__ ._W_P!:C3N&IM45B_\ "-+_
M -!&_P#^_P!_]:C_ (1I?^@C?_\ ?[_ZU&G<-3:HK%_X1I?^@C?_ /?[_P"M
M1_PC2_\ 01O_ /O]_P#6HT[AJ;5%8O\ PC2_]!&__P"_W_UJ/^$:7_H(W_\
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MT: 7**I_V8/^?FX_[[H_LP?\_-Q_WW1H!<KQ3]H#_DH'P3_[&M?_ $2]>O\
M]F#_ )^9_P#ONO+?C%J1T'QC\++46UO?#4_$*VIEO$WO;?NG/F1'^%^,9]#7
M;@[JLK:Z2_\ 26<F*UI._=?FCUZBJ?\ 9@_Y^;C_ +[H_LP?\_-Q_P!]UQ:'
M67**I_V8/^?FX_[[H_LP?\_-Q_WW1H!<HJG_ &8/^?FX_P"^Z/[,'_/S<?\
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MH?\ =/\ .JCN3+8QZ***LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_D?;U%?$/\ P\TM/^A#F_\  X?X4?\ #S2T_P"A#F_\#A_A1_8.8_\ /O\
M%?YA_;&!_P"?GX/_ "/MN;_42_[C?R->-_L>_P#)!=)_Z_\ 4/\ TJDKP=_^
M"F5HT;K_ ,('-\RD?\?P[CZ5Q7P:_;NMOA3\/[3PV_A"346@N+B?[0MV$!\V
M5I,8QVW8_"NN.2X]8:=-T]6XO==%+S\SFEFV"=>$U4T2ET?5Q\O(_12BOB'_
M (>:6G_0AS?^!P_PH_X>:6G_ $(<W_@</\*Y/[!S'_GW^*_S.G^V,#_S\_!_
MY'V]17Q#_P /-+3_ *$.;_P.'^%'_#S2T_Z$.;_P.'^%']@YC_S[_%?YA_;&
M!_Y^?@_\C[>HKXA_X>:6G_0AS?\ @</\*/\ AYI:?]"'-_X'#_"C^P<Q_P"?
M?XK_ ##^V,#_ ,_/P?\ D?;U%?$/_#S2T_Z$.;_P.'^%'_#S2T_Z$.;_ ,#A
M_A1_8.8_\^_Q7^8?VQ@?^?GX/_(^WJ*^(?\ AYI:?]"'-_X'#_"C_AYI:?\
M0AS?^!P_PH_L',?^??XK_,/[8P/_ #\_!_Y'V]17Q#_P\TM/^A#F_P# X?X4
M?\/-+3_H0YO_  .'^%']@YC_ ,^_Q7^8?VQ@?^?GX/\ R/MZBOB'_AYI:?\
M0AS?^!P_PH_X>:6G_0AS?^!P_P */[!S'_GW^*_S#^V,#_S\_!_Y'V]17QKX
M8_X*3:#J?B"RM-9\*7&D:;-($FOTN1+Y /\ $4QR!WQSBOL/3]0M=6L+>^LK
MB*[L[B,2PW$+!DD0C(92.H->=BL#B,$TJ\+7_KH=V'QE#%INC*]B>BBBN [
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M0%HHHJ#0**** "BBB@ HI*6@ HHI,T +1110 44E% "T4E+0 44E+0 4444
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M:^6_%W_*0?P3_P!BY-_)Z^I*&"ZA1114E!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\$_\ !33_ )&#P'_UZW7_ *''7Q17VO\
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M#=1+)]X*_P!G8 ^XS5J.NIFYZ:'NOQ(_: A^'GQF^'OP_?0Y;^7Q>TJIJ"7
M1;78,\H5);/L17K5?(7[2O\ R>M^SK_UTN__ $$UN?&K]ISQFWQ4E^%?P;\-
MVWB/Q=;0";4M0OW(M-/#8P&Y&2 5SD_Q <FERWM8?-:]SZAI:^-K#]I[XN_
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MHN1^-*R;T'=Q3<BQ^S=^V1HO[17BSQ!H%KH=QH-SI\?VFT:YN%D^WV^\H94
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M*D<\'TKQSQ-^TE?^)?V@/"GP]^&<UCK=NC--XCOA&)H881@[5D!X8 'D'&7
M[4GB#]@'X.Z]J3WB:5J>D;R2;?2]0:*').?NE6Q^=>K?"[X+^#?@SI<MCX2T
M6'3%FQY]QDO//CIO<\GZ<#VI^ZA:GA^B21Q?\%#_ !&7=8U_X1A/F=@HZ>]?
M4/VRV_Y^K?\ [^K_ (UXK\5OV.?AY\9?&4_B?Q%_;7]J31)"_P!BO_)CVH,#
M"[#Z^M<A_P .Y_A!D'/B7@Y_Y"__ -KHT8M45_&,B1_\%!?!+.ZHO_".3?,S
M #H_>OJ'[9;?\_5O_P!_E_QKQKXJ?LA_#_XQ:OINI>(?[8^TZ?8QZ=!]BO\
MR5\I!A<C8<M[UQ1_X)R_" ]_$O\ X-__ +71H&J/I\,&&00P[$'(HK.\->'[
M3PGX=TS1+#S/L.G6T=K!YS;GV(,#<>YP.M:-26%%%%( HHHH **** "BBB@
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M#KQ6;5L-CYPE9P3[*_W]SUS]KCXT_$7XF>/IM%\=V*^'SHDK)#H5OGRHB?\
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M;VNSRIV)0XDW*3CY!]TCJ:]2IMZ(E*S;"BBBI+"BBB@ HHHH **** "BBB@
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M@4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *5?O#ZTE*OWA]: /$OV9/\ CY^+'_8YW?\ Z E>
MV5XG^S)_Q\_%C_L<[O\ ] 2O;*[\=_O$OE^2.+!_P(_/\V%%%%<!VA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 *OWA]:[1?NBN+7[P^M=HOW14
MR-("T445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %)2T4 )12T4 )12T4 )2T44 %)2T4
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M_5I?\_?P_P""?B!_9=[_ ,^=Q_WZ;_"C^R[W_GSN/^_3?X5^W_V.V_Y]H/\
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M\F_X ?ZM+_G[^'_!/Q _LN]_Y\[C_OTW^%']EWO_ #YW'_?IO\*_;_[';?\
M/M!_WZ7_  H^QVW_ #[0?]^E_P */]:_^G/_ )-_P _U:7_/W\/^"?B!_9=[
M_P ^=Q_WZ;_"C^R[W_GSN/\ OTW^%?M_]CMO^?:#_OTO^%'V.V_Y]H/^_2_X
M4?ZU_P#3G_R;_@!_JTO^?OX?\$_$#^R[W_GSN/\ OTW^%']EWO\ SYW'_?IO
M\*_;_P"QVW_/M!_WZ7_"C[';?\^T'_?I?\*/]:_^G/\ Y-_P _U:7_/W\/\
M@GX@?V7>_P#/G<?]^F_PH_LN]_Y\[C_OTW^%?M_]CMO^?:#_ +]+_A1]CMO^
M?:#_ +]+_A1_K7_TY_\ )O\ @!_JTO\ G[^'_!/Q _LN]_Y\[C_OTW^%']EW
MO_/G<?\ ?IO\*_;_ .QVW_/M!_WZ7_"C[';?\^T'_?I?\*/]:_\ IS_Y-_P
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M_GSN/^_3?X5^W_V.V_Y]H/\ OTO^%'V.V_Y]H/\ OTO^%'^M?_3G_P F_P"
M'^K2_P"?OX?\$_$#^R[W_GSN/^_3?X4?V7>_\^=Q_P!^F_PK]O\ [';?\^T'
M_?I?\*/L=M_S[0?]^E_PH_UK_P"G/_DW_ #_ %:7_/W\/^"?B!_9=[_SYW'_
M 'Z;_"C^R[W_ )\[C_OTW^%?M_\ 8[;_ )]H/^_2_P"%'V.V_P"?:#_OTO\
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M_P!]BC[9!_SWC_[[%4?^$9TO_GQA_*C_ (1G2_\ GQA_*C0-2]]L@_Y[Q_\
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M_P"?&'\J- U+WVR#_GO'_P!]BC[9!_SWC_[[%4?^$9TO_GQA_*C_ (1G2_\
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MD_OK^='G)_?7\Z@_LNT_YX)1_9=I_P \$HT G\Y/[Z_G1YR?WU_.H/[+M/\
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M_4JBORU_X;T^,_\ T,-A_P""FW_^)H_X;T^,_P#T,-A_X*;?_P")H_U8QO\
M-'[W_D'^L.#[2^Y?YGZE45^6O_#>GQG_ .AAL/\ P4V__P 31_PWI\9_^AAL
M/_!3;_\ Q-'^K&-_FC][_P @_P!8<'VE]R_S/U*HK\M?^&]/C/\ ]##8?^"F
MW_\ B:/^&]/C/_T,-A_X*;?_ .)H_P!6,;_-'[W_ )!_K#@^TON7^9^I5%?E
MK_PWI\9_^AAL/_!3;_\ Q-'_  WI\9_^AAL/_!3;_P#Q-'^K&-_FC][_ ,@_
MUAP?:7W+_,_4JBORU_X;T^,__0PV'_@IM_\ XFC_ (;T^,__ $,-A_X*;?\
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M,-A_X*;?_P")H_U8QO\ -'[W_D'^L.#[2^Y?YGZE45^6O_#>GQG_ .AAL/\
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M_M ?\E ^"?\ V-:_^B7KT,#_ !UZ2_\ 26<>,_@OUC_Z4CVJBBBN [ HHHI
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X)_X*:?\ (P>
M_P#KUNO_ $..OBBOM?\ X*:?\C!X#_Z];K_T..OBBOV/(_\ D74OG^;/RS.?
M]_J?+\D%%%%>Z>*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Z=\!?CWKWP%\6KJFELUUIEP0NH:6[8CN4]1Z..S?T
MKS&BLJM*%>#IU%=,UI59T9JI3=FC]I?AK\2M!^+'A&S\1>';L75C<##*?]9
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M!*-SCTKU[]L#]L?5?A!K6A^"_ 6G0:MXPUB))Q),AD6".1BL05 ?F=B#C/
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MK_Z)>O0P/\=>DO\ TEG'C/X+]8_^E(]JHHHK@.P****0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M*OWA]:2E7[P^M 'B7[,G_'S\6/\ L<[O_P! 2O;?2O$OV9/^/GXL?]CG=_\
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M#R$+O T,F^&8J.J9)#>G&>*['0_^"H7PVG\%QWNJ:?J]OXC6']YI<-MOC>4
M9VS?="DYY/(':OLMXUD1D=0ZL,,K#((]#7G5_P#LX_"S5-8;5KOX?>'9]19@
MYN7TZ+?N'0]*GF35I%.,DVXO<^7_ -AOQI\7/C-\2/$WCO7];U"V^'LCS20:
M=.=UO),[?+'"6&0D:CDJ0,X'<U\\_M3?M/6GQL^-*Z9K4FI2?"S0[UH1INDR
M(DUX4)5ILM\N6884G[J\CDU^LMOI]K9V26=O;16]HB[%@B0(BKZ!1P!7F'_#
M*'P;_P"B9>&/_!;'_A34U>[1+A+ELF?._P #?V^/AL=6\*?#GPG\/-8\/V5Y
M=1V%JH:W$43.<;WPY)YY)Y)KSG]M/PWJ'P,_:Q\+?&(:9)J'AR>XM;J7RUPB
MSPX5XBW1690&!/\ 2OMK1_V:/A3X>U:SU33/A[X=L-1LY1-;W4&GQK)$XZ,I
M X(KO=9T/3O$6G36&JV-OJ-C,,26]U$)(V^JD8HYDG=(?))JS9^8G[97[1&@
M_M<7G@+PG\.=-U/4M1BNI)#Y]L8G:210@B5>N!]XM]T8KL?VWOCWJ_PO\$^&
M?@GH-^UO>P:/;)KM_ V'*>6%6!2.F[:6;O@J.YK[E\$_!GP)\-[J6Y\+>$='
MT"XEX>:PLTB<\8Z@9Z50\4_L]_#3QOKMSK6O^!="UC5KK;YU[>6222R;5"KE
MB,G"@#\*?/'331"<).^NK/@GX _MI?![]G7PBNF:#\//$4NH2QJ=0U6:2U,]
MTX'.3OX0'.%' 'ODU^CO@GQ3#XX\'Z+XAMH)+:WU2SBO(X9B"Z*ZA@#CC(SV
MK@V_9/\ @VRD'X9>&"/^P;'_ (5Z9I6E6>AZ;:Z?I]M'9V-K&L,%O"H5(T48
M55 Z  5,FGL7",H[ENBBBLS0**** "BBB@ HHHH **** "BBB@ HHHH *2EK
MQ+]HV/XQ:U-H&@_"YK/0[&[=FU?Q1=RQ$V48Z*D3'<2>Y /8<<TTKB;LCVRO
M!OVE?C?XB^$OC3X2:5H<=B]KXIUT:;?F\A9V$6Z,9C(8;6^<\G/;BOFWXOZ;
M\4_V:_#<WC&S_:5'BR^LBLC:#JNW%RI8 JB&1]QZ\8' /-=E^U%XG?QIJG[*
MNOR0BWDU+7X+IXE.0C/]G8@>V36BCJC)ST?1GKOQB^./B/P)^T9\)? VFQV#
M:+XI>=;]KB%FF&P$KY;!@%_$&O?*^0OVE?\ D];]G7_KI=_^@FH?B9\2?B=\
M>_CMKOPJ^%VO1^#-$\-Q+_;?B+9NG,IQE(SU!!. !@DAB3BERW2'S6;/L.EK
MX9\4ZW\9OV*];T'7/$_CJ;XI_#G4;V.QU!K^$K=6COT9<EB. <88@XP0.*^X
M;:YCO+>*>%Q)#*@D1UZ,I&0?RJ6K%QE<XSXR?&#P[\#? =]XJ\2SM%8V^$CA
MB&9;B4_=C0=V/Y#DFOFS3/C;^U'\6+./7O _PW\/>'O#LXWVJ>)+AOM$\9^Z
M^-RXR/;N*J_ML0_\)M^T=\ O M_N;0KW47NKF%ON2L&4#([X"L/^!5]I1QK'
M&J(H1%&%51@ >@JM(I.Q&LFU?8^;_@1^U7J_BKX@7'PT^)OA<^"?B!%%YUO&
MKEK:_0#),9/0XR<9((!YXKZ!\2>(+3PKX?U+6=0D\JQT^WDN9G/9$4L?Y5@^
M)/A'X2\6^--#\6:MHT-YXAT0$:??,S!X,G/&#@\^OK7@_P#P4#\;7-K\-='^
M'NDSK#K?CG4(],5BP&RWW RN<D<<J/QI:2>@[N,7<R_V2OVOO%'QB^(E_P"'
M?&FFV.E)J5A_:_AQK6%XS/;!V!#%G.YMN#QC[K5]:WLS6]G<2KC='&S#/3(&
M:^'/VIO#>F? G2_@Y\0O"-W:3R^ 98-*O([>="TUDP .0#G&=X/_ %TK[3@U
MBU\0^$TU6QE$UE?67VF"0?Q(Z;E/Y$4Y6W00;V9\2?"GX^?M5_&WPS+XB\):
M'X%NM(2[EL_,NA)"^]",C:9?0CFMGQ5^T%^TU\#=/'B7XB^ _#6K>%(G5;MM
M!F;S8%+ ;R=[8ZX&1C)&2*\J_8__ &Q_#7P)^%%SX:U;PQXIU>Z.K75W]HT>
MP6:#:^T!=Q<?,-IR,=Q79_%7]LJY_:>\#ZO\.OA3\/O$&J:IK4?V*ZN;^%$2
MTC8X9F",P' ZL1CD]JTY7?;0Q4E;XM3[>\#^,M-^(7@_1_$NCR^=INJ6R74#
M'@[6&<'W'(/N*X3X_P!]\8++3='/PBT_0=0O6G<:@NO.558MORE,,O.ZMGX"
M_#J;X2_!OPCX0N)A<7.DV*032+T,G+-CV#,1^%=_6&S.C=:GP-XX_:&_:I^'
M7C#PEX8UO1/ L.K^*KAK72XX0\B/("H(=A+\@^<<FO8_A=K'[4MQX^TB/QWH
M?@NU\)-(WV^;3)6-PJ[&V[ 9#SNV]NF:Y']K_P#Y.F_9G_[#<G_H<-?8E:2:
MLM#.*=WKL)2T45D;!1110 4444 %%%% !1110 4444 %%%% !1110 5@^(_]
M=#_NG^=;U8/B/_70_P"Z?YU4=R9;&/6+XV\8:9\/O".K^)=9F\C2]+MVN9V[
MD*/NCW)P!]:VJ^9/VTM0E\0:A\+?AQ&[+;^)]?C>]13_ *R"$@[?IFM4KLP;
MLCUGX0^,O$&O?"^#Q;XW2RT=[Q)-12WBC,8LK(_-&LI).7"<L>.N,5XE'^U#
M\3OC5JE]#\$? UK=Z%9RF$^(O$3F."9AUVKE0 >W.>1G%=;^W?KD_A;]F+Q)
M'IVZ$7#6]CE/X82X#+]"HV_C7I'P)\*V?@OX->#-(L8UC@CTN"8[!C<\B"1F
M/J26Z^U5I:XNMCQ"Q_:<^(_PE\5:5I'QR\(6.E:5JDOD0>)-#<O;1R'& XR1
MCGDYR.N*[']K+XT^*_@]H'A.;P9'I=UJ&MZHM@O]I1&2)@R$J00RXR<<^E>K
M^//A]X>^)WAU]"\3Z9'JVDO*DQMY20-ZG*G(YKYQ_;AL8-+T7X0V5K'Y5M;>
M)K>**,'.U57 'X"A6;$[I%J;6OVP;='=O#G@&7RP28XY@6;'8#S>M=5\ _VG
M9_B1XLU3P)XS\/MX.^(&FJSOI[,3%<H.K1D]P"#CN#D&O?I_]=)_O'^=?('[
M5T*^%?VGO@=XIL/W.I7%W]AG:/@RIO"C=ZX#L*/BTL#]W4^H?&7C;0OA[X>N
MM<\1ZG;Z3I=LI:2>=P,_[*CJS'L!S7CW[,/[1][^T-KGCN;[%#8:#I=Q$FEQ
M["+@Q,#\TIR02<9P ,9KN?B-^S_X0^*WC30]<\4VTVJC1PR6^FR2D6CL6!WR
M(/O$8[\5XS^QW#';_%SX\PPQK%%'K:(D<:A551N   Z"EI8;O<]%_:(_:"?X
M-KH>BZ'HK^)_&WB"7RM,TE&(! ."[D<XSQC^E>:W7QW^.WP=MX?$'Q7\#Z)<
M>#6E1+N[\/39GT]6.-[KN;.,CKCH:A_:4U2+X4?M1_"[XE:]!(?"*6\NFW%Z
MB%Q:2G.&(^AS],UH_M0?M)?#[7/@GXE\.^&_$%GXMUO7K%[2WL=(?SWC! +2
MR ?<50"><526VA+>^I]-Z;J-MK&GVM_93+<V=U$L\,R='1@"I'X&O-_VD?C,
MWP&^%5[XJBL%U.\%Q%9VMM(Q5&ED)P6QS@8/3VK-_8]OI=0_9G\ O,Y=H['R
M58\_*KL!^E>)_P#!1CP;K<OA.Q\3)XKNX] 2[M;)O#00^0TY+8N<[L;AZ;?Q
MJ4O>L4W[MSW+X"ZM\9-:COKGXI:9H&FVDT,4NFIH[?O<MRPE&]L8&.*]<YKP
MG0_!?Q5^%'P<UJ'2/$MQ\5O&EXT;Z6VKE8%M590"#YDA!5>N,C/I7F>L?!_X
MN6&D'6_$/[2PT'61&))--#K':1R8R(R1(..QPF/K3LF%[=#ZD\>2>)(?!NKO
MX/AL[CQ.L&=/BU XMVER.'.1QC/>O*OCC\5O'/P=_9E;QA=6^DIXYM5M4O(?
M+,MFLKN%D"@,,CT^:O-/!WQX\6^.OV+_ ![XBO=4\GQ5H7G6::UIK"-I=KIM
ME4CH<$\CKUJI\?=9O_$/_!.G3=3U2\FU#4;NTTV6XNKA]\DKEQEF/<FA1UU$
MWIH?6_AG4IM8\,Z1J$X43W=G#<2!!A=SH&.!V&36E7RC\>/&_B'PBW[.5KHF
MMWVDVVJ75O!?0VDQ1;J/9;_)(!]X?,>/<U[A^T!K%]X?^"OC74M+O)M/U"UT
MV66"ZMVVR1.,893V-38JYWU%?(WBOXE>*=/_ & =(\71>(=2C\2M#:O)JRW!
M%R^9R&R_7D#%;_PI\*_$[47TCXK^-?B==6FA/:-J5QX0M8B+9+<1$HI;=@MP
M"?EYYYI\HN8^FJ*^,?"U]\5OVIX;CQ=;_%.#X4^$Y)Y(])TVP=?M+QJ<;Y?G
M0\^Y^@KM/@O\5/&?@OXK7OPI^(6M6?B^X.FOJ>C:]8LI>ZC0$M%)C^/ /7G/
MJ,4<H<Q]-4M?"?P]\2>/_P!J+4M:U4?'2/X;2V]_+;6GAG3\+(L:YP7!=">G
M7G.#]*^D/V?[?XKZ/;ZWHGQ/-KJB64J_V3XBMY(\W\)Z[T4[@1URP!.>]#C8
M%*Y-\*OBGJNM>.O&'@/Q;':P>*="F%S;R6D9CBOM/D/[J95)."/NMSU%>JU\
MP_M,WQ^&_P ?O@OX[M?W+7E[)X?OB#@3PR8(5OIGCZU]02+Y<C+_ '3BD^XU
MV&T445(SX)_X*:?\C!X#_P"O6Z_]#CKXHK[7_P""FG_(P> _^O6Z_P#0XZ^*
M*_8\C_Y%U+Y_FS\LSG_?ZGR_)!UR#7W_ *AG]I;_ ()ZP7('VGQ)X+.&Q\SD
MVXP?Q:!@?K]*^ *^M/\ @G]\:="^'_B+Q7X7\7ZM;:3X:UZQW?:+Z41PK,F5
MP6;@;D=A[D"GF].;HQKTE>5-J2_5?<+*JD55E1J/W:B:?Z/[SI/V?Y%_9Y_8
MW\;_ !-F'DZ]XI;^S-(8\-M^9$8?B99/<(*^++;+74.3D[U)/XU]2_MP?%+P
MOJT7@KX=_#_4K74/!OAJRWK+8S"2)YFX"[AP=JC\"QKY9MV"W$1)P ZDD_6K
MRV$I0GBJBM*H[Z]$M(K[OS)S"<8SAAZ;O&FK?/=O[S[A_P""H'_']\+O^P==
M?SAKR3]@OXF_\*Y_:&T:">7R].\0*=)GW' W/@Q'_OX%'T8UW'_!0_XC^%?B
M'=_#IO#'B+3=?6RL;F.Y.GW"R^2Q,. V#QG!_(U\AV=[/IMY!=VTC17%O(LL
M3J<%64Y!!^HKDR[#>VRF.'J*UU)?BSJQV(]CF;KTW>S3_!'U?\7/V9Y;W]N*
M+P=;6S+HWB&]35P57Y5MF)>X'X%7'MN%8G_!0#XG1>-OC<_A_3F']C>$[<:7
M"B_=\X8,Q ]B%3_MG7UK>?M/_"JZ\$6'Q4D\0:3+\1+'PU);P:7]H3[2L\@4
MO%Y6<_ZQ1_P'FORXU'4+C5M0N;^\E::[NI6GFD8Y+.Q)8D_4USY6JV)J1J8B
M+7LH\JOUEU?W)?>;9DZ.'IRIT))^T?-IVZ+[VS[C_P"":/\ R+/Q?_Z\[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=_A!^S]XP\-3:7\2;BX\-^/]+GDM]1MM0U<V4;[6P&3< OL1G/%>R_!'P+\
M/#?QP^S?"^VU[7_%>CVDUT+VWO6GTU/E(V-*<#<QPH(!&3UKWOX@?L[_  V^
M*6I#4/%/@_3]5O\ H;H[XI'[#<T;*6_'-=!X%^&WA;X8Z6=.\*Z%9Z':,072
MU3#.0, LQRS'ZDU3D)1L?&\7A;]G7]I*35]5UG'PE\9PWDL=]8S:E' PD#8\
MS:X5&)//&#G-=1^QCJNI:3\6O'?@S2/&-WX\^'VF0));:K<[G5)RV-BN?;.<
M'!QD5[SXZ_9I^%_Q,UAM5\2>#=/U'4FY>Z!DA>0\#+&-EW'CJ<UV'@WP-X?^
M'NBII/AK1[31=.4[O(M(PH+8QN8]6/N<FES: HN]SYV_;:#:YXF^"7AJUP]_
M=^*H[M$QEMD>W)'Y5]4SL&FD8="Q/ZU\X>"[%?C=^TUJGC\CSO"O@F%M$T67
M^"XO2<W$J>H7[N1W%?1=2^B&NK"BBBI*/@G_ (*:?\C!X#_Z];K_ -#CKXHK
M[7_X*:?\C!X#_P"O6Z_]#CKXHK]CR/\ Y%U+Y_FS\LSG_?ZGR_)!1117NGBA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%>E? ?X#Z_\ 'KQ<FE:4AMM.A(>_U1US';1_U<]E[_2LJM6%"#J5'9(U
MI4IUIJG35VP^ _P'U_X]>+DTK2D-MIT)#W^IR+F.VC_JY[+_ $K]6?AE\,M
M^$?A&T\.^';06UE ,O(W,EQ)_%)(>['].E'PS^&>@?"/PC:>'?#MH+:SA&7D
M;F2>3^*20]V/Z=!755^39MFT\PGRQTIK9=_-_P!:'Z;EF60P,.9ZS>[_ $04
M445\Z>V%%%% !1110 4444 %%%% !1110 4444 %>*_M ?\ )0/@G_V-:_\
MHEZ]JKQ7]H#_ )*!\$_^QK7_ -$O7H8'^.O27_I+./&?P7ZQ_P#2D>U4445P
M'8%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "E7[P^M)2K]X?6@#Q+]F3_ (^?BQ_V.=W_ .@)
M7ME>)_LR?\?/Q8_['.[_ /0$KVRN_'?[Q+Y?DCBP?\"/S_-A1117 =H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "K]X?6NT7[HKBU^\/K7:+]T
M5,C2 M%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6#XC_P!=#_NG^=;U8/B/_70_[I_G51W)EL8]%%%68C(K>*WW^5#'
M#O;<WEH%W-ZG'4^]/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!D,$5M&(X8HX8P<[(D"KSU.!3Z** "BBB@#XO_;N^
M&_B#XK?$CX?>'O#-FE]JTMC>RI#),D0*H4+'<Y Z5X#_ ,,)?&C_ *%FU_\
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MLVO_ (-;;_XNOU/HH_UGQO\ +'[G_F'^KV#[R^]?Y'Y8?\,)?&C_ *%FU_\
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M_/T/^^3_ (5J>4G]U?RH\I/[J_E1H&IE_P#"6:5_S]#_ +Y/^%'_  EFE?\
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M*C:O]T?E1H!5_M:T_P">P_(T?VM:?\]A^1JUM7^Z/RHVK_='Y4: 5?[6M/\
MGL/R-']K6G_/8?D:M;5_NC\J-J_W1^5&@%7^UK3_ )[#\C1_:UI_SV'Y&K6U
M?[H_*C:O]T?E1H!5_M:T_P">P_(T?VM:?\]A^1JUM7^Z/RHVK_='Y4: 5?[6
MM/\ GL/R-']K6G_/8?D:M;5_NC\J-J_W1^5&@%7^UK3_ )[#\C1_:UI_SV'Y
M&K6U?[H_*C:O]T?E1H!5_M:T_P">P_(T?VM:?\]A^1JUM7^Z/RHVK_='Y4:
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M5_M:T_Y[#\C1_:UI_P ]A^1JUM7^Z/RHVK_='Y4: 5?[6M/^>P_(T?VM:?\
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M  %TF[\*W'Q%;58?L@U+Q1<WUID@^9"RH%?CIG!X/->J_P!K6G_/8?D:\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^_[?XT?ZJ/\ Y_?^2_\ !#_65?\ /K\?^ ?M]YT7_/:+_OX/\:/.B_Y[1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KQ7]H#_DH'P3_[&M?_ $2]>U5XK^T!_P E ^"?_8UK_P"B7KT,#_'7
MI+_TEG'C/X+]8_\ I2/:J***X#L"BBBD 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K]X?6DI5^\/
MK0!XE^S)_P ?/Q8_['.[_P#0$KVRO$_V9/\ CY^+'_8YW?\ Z E>V5WX[_>)
M?+\D<6#_ ($?G^;"BBBN [0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** %7[P^M=HOW17%K]X?6NT7[HJ9&D!:***@T"BBB@ HHI* %HI** %HI*
M.: %HI** %HI** %HHI* %HHI* %HHHH **** "BBB@ HHHH **** "BBB@
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M_<*/H?D^:?[[5]0HHHKV#R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5XK^T!_P E ^"?_8UK_P"B7KVJO%?V@/\ DH'P
M3_[&M?\ T2]>A@?XZ])?^DLX\9_!?K'_ -*1[51117 =@4444@"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+1]-M-/@55AM(4MT"CC"J%'\JG9%)W=RQ1114%!1110 4444 %%%% !1110
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MO8#YFQVRV3^-=314RE=61<8V=V[A1114%A1110 4444 %%%% !1110 4444
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M-DLL;Q/_ &G>';(I4_>7L:^D*"2>M+F"PE%%%24%%%% !1110 4444 %%%%
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MFG^^U?4****]@\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBON?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?XH_E(XY_P"\P_PR_.)[11117GG8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>*_M ?\E ^"
M?_8UK_Z)>O:J\5_: _Y*!\$_^QK7_P!$O7H8'^.O27_I+./&?P7ZQ_\ 2D>U
M4445P'8%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "E7[P^M)2K]X?6@#Q+]F3_CY^+'_8YW?_
M * E>V5XG^S)_P ?/Q8_['.[_P#0$KVRN_'?[Q+Y?DCBP?\  C\_S84445P'
M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 J_>'UKM%^Z*XM?O#
MZUVB_=%3(T@+1114&@5PGQN^(-[\+?A?KWBC3M,_MB]TZ(216/S?O26 Q\HS
MW_2N[K'\697P_>'/.W^M:4W&,XN2NK[=S.HFX-1=G;<^$O\ AY)X_P#^B4#_
M +ZG_P#B:/\ AY)X_P#^B4#_ +ZG_P#B:^G/,;^\?SH\QO[Q_.OI/K>!_P"@
M1?\ @3/ ^K8W_H)?_@*/F/\ X>2>/_\ HE _[ZG_ /B:/^'DGC__ *)0/^^I
M_P#XFOISS&_O'\Z/,;^\?SH^MX'_ *!%_P"!,/JV-_Z"7_X"CYC_ .'DGC__
M *)0/^^I_P#XFC_AY)X__P"B4#_OJ?\ ^)KZ<\QO[Q_.CS&_O'\Z/K>!_P"@
M1?\ @3#ZMC?^@E_^ H^8_P#AY)X__P"B4#_OJ?\ ^)H_X>2>/_\ HE _[ZG_
M /B:^G/,;^\?SH\QO[Q_.CZW@?\ H$7_ ($P^K8W_H)?_@*/F/\ X>2>/_\
MHE _[ZG_ /B:/^'DGC__ *)0/^^I_P#XFOISS&_O'\Z/,;^\?SH^MX'_ *!%
M_P"!,/JV-_Z"7_X"CYC_ .'DGC__ *)0/^^I_P#XFC_AY)X__P"B4#_OJ?\
M^)KZ<\QO[Q_.CS&_O'\Z/K>!_P"@1?\ @3#ZMC?^@E_^ H^8_P#AY)X__P"B
M4#_OJ?\ ^)H_X>2>/_\ HE _[ZG_ /B:^G/,;^\?SH\QO[Q_.CZW@?\ H$7_
M ($P^K8W_H)?_@*/F/\ X>2>/_\ HE _[ZG_ /B:/^'DGC__ *)0/^^I_P#X
MFOISS&_O'\Z/,;^\?SH^MX'_ *!%_P"!,/JV-_Z"7_X"CYC_ .'DGC__ *)0
M/^^I_P#XFC_AY)X__P"B4#_OJ?\ ^)KZ<\QO[Q_.CS&_O'\Z/K>!_P"@1?\
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M[Q_.CS&_O'\Z/K>!_P"@1?\ @3#ZMC?^@E_^ H^8_P#AY)X__P"B4#_OJ?\
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MP7_0(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\ _$T?\/ O'G_1+O\
MT?\ _$U]9^8W]X_G1YC?WC^='US!?] B_P# F'U3&?\ 02__  %'R9_P\"\>
M?]$N_P#1_P#\31_P\"\>?]$N_P#1_P#\37UGYC?WC^='F-_>/YT?7,%_T"+_
M ,"8?5,9_P!!+_\  4?)G_#P+QY_T2[_ -'_ /Q-'_#P+QY_T2[_ -'_ /Q-
M?6?F-_>/YT>8W]X_G1]<P7_0(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\
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MP7_0(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\ _$T?\/ O'G_1+O\
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ML_,;^\?SH\QO[Q_.CZY@O^@1?^!,/JF,_P"@E_\ @*/DS_AX%X\_Z)=_Z/\
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M(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\ _$T?\/ O'G_1+O\ T?\
M_$U]9^8W]X_G1YC?WC^='US!?] B_P# F'U3&?\ 02__  %'R9_P\"\>?]$N
M_P#1_P#\31_P\"\>?]$N_P#1_P#\37UGYC?WC^='F-_>/YT?7,%_T"+_ ,"8
M?5,9_P!!+_\  4?)G_#P+QY_T2[_ -'_ /Q-'_#P+QY_T2[_ -'_ /Q-?6?F
M-_>/YT>8W]X_G1]<P7_0(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\
M_$T?\/ O'G_1+O\ T?\ _$U]9^8W]X_G1YC?WC^='US!?] B_P# F'U3&?\
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M(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\ _$T?\/ O'G_1+O\ T?\
M_$U]9^8W]X_G1YC?WC^='US!?] B_P# F'U3&?\ 02__  %'R9_P\"\>?]$N
M_P#1_P#\31_P\"\>?]$N_P#1_P#\37UGYC?WC^='F-_>/YT?7,%_T"+_ ,"8
M?5,9_P!!+_\  4?)G_#P+QY_T2[_ -'_ /Q-'_#P+QY_T2[_ -'_ /Q-?6?F
M-_>/YT>8W]X_G1]<P7_0(O\ P)A]4QG_ $$O_P !1\F?\/ O'G_1+O\ T?\
M_$T?\/ O'G_1+O\ T?\ _$U]9^8W]X_G1YC?WC^='US!?] B_P# F'U3&?\
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MK/S&_O'\Z/,;^\?SH^N8+_H$7_@3#ZIC/^@E_P#@*/DS_AX%X\_Z)=_Z/_\
MB:/^'@7CS_HEW_H__P")KZS\QO[Q_.CS&_O'\Z/KF"_Z!%_X$P^J8S_H)?\
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M1_P\"\>?]$N_]'__ !-?6?F-_>/YT>8W]X_G1]<P7_0(O_ F'U3&?]!+_P#
M4?)G_#P+QY_T2[_T?_\ $T?\/ O'G_1+O_1__P 37UGYC?WC^='F-_>/YT?7
M,%_T"+_P)A]4QG_02_\ P%'R9_P\"\>?]$N_]'__ !-'_#P+QY_T2[_T?_\
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M)]/N](_::U^POYS=7UK;W<$\[$DR2+)AF)/)R036E^Q^JC]JKQZ0 #]GO/\
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M3ZCUXS18+GU/1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 .C_UB?[P_G7L\?^K7Z5XQ'_K$_P!X?SKV>/\ U:_2L*AM3ZCJ
M***Q-PK'\6_\B]>?[O\ 45L5C^+?^1>O/]W^HIQW0I;,\LHHHKL.,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** '1_P"L3_>'\Z]GC_U:_2O&(_\
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MW,#_ #/[F?H=17YX_P##R[QO_P!"?X<_[[N/_BZ/^'EWC?\ Z$_PY_WW<?\
MQ='^KN8?RK[T']N8'^9_<S]#J*_/'_AY=XW_ .A/\.?]]W'_ ,71_P /+O&_
M_0G^'/\ ONX_^+H_U=S#^5?>@_MS _S/[F?H=17YX_\ #R[QO_T)_AS_ +[N
M/_BZ/^'EWC?_ *$_PY_WW<?_ !='^KN8?RK[T']N8'^9_<S]#J*^!?#'_!2O
M79->LE\1>$M)BT5I MU)ISS>>B'^) S$$CK@]:^Y_#/B;2_&6@V6M:)>QZCI
M=[&)8+F$Y5@>WL1W':O,QF6XG 6]O&R?S._"X[#XR_L97L:=%%%>8=X4444
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M&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOVR-%^$&DZCX>\+2+XB^(3PR!+*S'FKIX"Y:><C(&T<[>N1S@5PO[-\::/\
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MEOJ2:38IJ-O!]FAO%MD$T47_ #S5\9"_[(.*.9:NP<KT5]$:5+1169J%%%%
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MK6T3M^)TYMA\/AYT_JZLFK_BT%%%%?0'@A1110 4444 %%%% !1110 4444
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MX5^''A#P%KF@6=Y<QV-JNVW$4;.?ON1(6))Y)Y)H_:L_:@O?AC\:=*\&>.O
MNBZW\,[HQW+W5[9FZEGA(PQC5CL#QOG(P21]:^A]$_9<^$GAO6+/5M+^'N@V
M.I6<JS6]U#:*KQ..C*>Q%=EXT^'_ (:^(^E?V9XHT*QUZP#;Q!?P+*H/J,]#
M]*GFC>]A\LK6N?F-\7-9T#]KSXX>!? WPDT#[%X3TQ?+D^SV0M(T1Y%:>8H
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M'A_3[SQ%IP"VFJ30@SP $D!6]LG\Z(RL$HWV.BHHHJ2@HHHI %%%% !1110
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MW^2.#,OX>'_P?JPHHHKW3PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH *\5_: _P"2@?!/_L:U_P#1+U[57BO[0'_)0/@G_P!C6O\
MZ)>O0P/\=>DO_26<>,_@OUC_ .E(]JHHHK@.P****0!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*O
MWA]:2E7[P^M 'B7[,G_'S\6/^QSN_P#T!*]LKQ/]F3_CY^+'_8YW?_H"5[97
M?CO]XE\OR1Q8/^!'Y_FSY^_;.TQ['P+X;\<VZ_Z7X-UZUU,NH^?[.7"3 ?\
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MR#\26_.K'B;X?^&?&E[I=YKV@V.L7>E2^?837D0=K:0X^9#V/RC\A6_[T-Z
ME9W/SP_9]TF]U[XS>"OA=>HS6?P[UG5M2N%D!VL%8"#\R7_,5^B!Y))ZUS^E
M_#_PSHGBG4O$NGZ#8V7B'4E"7NIPQ;9[A1C =N_0?E6_1)W!*P4445!04444
M %%%% !1110 4444 *OWA]:[1?NBN+7[P^M=HOW14R-("T445!H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?$O[8WB:7Q%^T%X%^&WB7QA>> _AWJ%E)>7-_:3&#[7< D+&
MTG91P.>!G)K[:KCOB9\(/!OQBT=-,\8^'[37;2,[HQ."'B)ZE'4AESWP1FJB
M[.Y,ES*R/SN_:<^&7[-?P=^%NIVG@^^C\3>.-1 %A)'JOVYK?)&^1F0[5  /
M!Y)/2O2?C)*DV@?L=.C!E.J6F"/]VWKZ4T']COX-^&=&U/2]/\ Z;%:ZC"T%
MRTADDE:-A@JLK,77_@)%;LW[/'P_N=+\%Z=+H DL_!LPGT*-KJ<_8W!!!!WY
M?&T<.2.*TYT9>S>IX3^TK_R>M^SK_P!=+O\ ]!-<Y\-O'&D_LZ_MF?%G2/'%
MRNAV?C&=-3TK5+H[;>0%F8*7Z#[[#)X!0BOK+Q)\)?"GB[QIX=\6ZOI*W?B#
MP^7.F7AFD4V^X8;Y58*V?]H&F?$KX/\ @SXP:6FG^,?#MEKMO'GRS<*1)%GK
ML=2&7/L14\RM8KE=[H^5?V[OC'X:^)7@_1/A=X*U*V\6^*M<U:V98-)E%PL,
M:L3N+H2N2<<9Z DXK[,\/Z:VCZ#INGNWF/:VT<!<=RJ!<_I7!_##]FWX:?!N
M\>[\(>$+'2+U@5^U_--, >H621F90?0&O3*EM6LBHIWNSY*_;X\#ZW;V?@CX
MK^&K.2_U7P+J(NI[>($LUJQ4NP ]"HSZ D]J]3^&_P"UI\+/B5X:@U:T\8Z3
MIDC1JT]CJEW':S0,1RA#D9Q@\KD5[ ZK(K*RAE88*L,@CTKQ/Q3^Q5\$_&.J
M/J&I?#_3C=.2S-:R2VRL2<DE8G5<_A3NFK,5FG>)YEJG[2VM_&S]HSPGX-^#
MVJ-/X:TF0W7B;6HX ]M)#Q^Z!8>VT$8R6XSBN&\0^ M,_;8_; \6Z9K<MW)X
M%\#6(TU?L4WE%[HM\^' ./GW9]1&*^SO OPU\+_#'1?[)\*Z%9:%8$Y:.SB"
M%SC&YFZL?<DFJ'PU^#?A#X00:I%X2T==*&J7'VN\;SY)GGEY^9FD9CW/?N:?
M,EL+E;W/G37/^"8OPD;1;\:4NN0:F;>06LDNILZ++M.PLI7D9QD5;_8%^)-S
MXB^".L>"M89AX@\%S3:9/'(?F\H;MGN<$,O_  &OK2N$\-_ [P3X/\:^(/%N
MC:(MAKVO@KJ5S'<2[;C)R<QEM@YYX ZGUI<S:LQ\EFG$\*_X)G_\FYW7_8P7
MO\HZY?\ :F\#ZS^S3XZL?CI\-H3;:=YR0^*M#M@5M[J,L!YI0<#/0G'#;3W-
M?5OPU^%GA?X/^'&T'PCI:Z1I37#W1MUFDES(^-S9=F/.!QG%;NN:'8^)='OM
M)U2UCOM-O86M[BWF&4DC8893]0:.;WKAR^ZD9GP]\=Z1\3/!FD>)]"N!<Z7J
M4"SQ,.JY'*L.S Y!'J*Z*N.^%_PD\+?!GP^^A^#]-;2=):9I_LIN99E#GJ5\
MQV*YQR!Q78U+\BU>VI\=_M?_ /)TW[,__8;D_P#0X:^Q*X[Q?\(_"?CSQ3X9
M\1Z[I"WVL^&YS<:5=&:1#;2$J2VU6 ;E1]X'I78TV[I"2LVPHHHJ2@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *P?$?^NA_W3_.MZL'Q'_KH?\ =/\
M.JCN3+8QZ***LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^"?^"FG_(P> _\ KUNO_0XZ^**^U_\
M@II_R,'@/_KUNO\ T..OBBOV/(_^1=2^?YL_+,Y_W^I\OR04445[IXHFT>E+
M110 A4'J*-H]*6B@! H'04;1Z4M% ";1Z4;0.U+10 @4#H*6BB@ (SUI-H]*
M6B@ I  .@I:* $P,YQS2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%=;\+_ (7Z_P#%
M_P 76GAWP[:F>[F.Z25@1%;QY^:21NRC]>@J)SC3BYS=DBX0E4DH05VP^%WP
MNU_XO^+[3P[X=M#<7<QW22MQ%;QY^:20]E'Z]!7ZL_ OX%Z!\!_"*:1I""XO
MI@'O]3=0);J3U]E'9>U'P+^!>@? ?P@FD:0@N+Z8![_4Y% DNI/7V4=E[5Z/
M7Y5G&<2Q\O94M*:_'S?Z(_2LKRN."C[2IK-_AY(****^7/H HHHH **** "B
MBB@ HHHH **** "BBB@ KQ7]H#_DH'P3_P"QK7_T2]>U5XK^T!_R4#X)_P#8
MUK_Z)>O0P/\ '7I+_P!)9QXS^"_6/_I2/:J***X#L"BBBD 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !2K]X?6DI5^\/K0!XE^S)_Q\_%C_L<[O_T!*]LKQ/\ 9D_X^?BQ_P!CG=_^
M@)7ME=^._P!XE\OR1Q8/^!'Y_FPHHHK@.T**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!5^\/K7:+]T5Q:_>'UKM%^Z*F1I 6BBBH- HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\%DO^%?L9N/K1N/K1_K57_Y]K\0_U;H?\_&?CG_PSO\ %+_HG?B;_P %DO\
MA1_PSO\ %+_HG?B;_P %DO\ A7[&;CZT;CZT?ZU5_P#GVOQ#_5NA_P _&?CG
M_P ,[_%+_HG?B;_P62_X4?\ #._Q2_Z)WXF_\%DO^%?L9N/K1N/K1_K57_Y]
MK\0_U;H?\_&?CG_PSO\ %+_HG?B;_P %DO\ A1_PSO\ %+_HG?B;_P %DO\
MA7[&;CZT;CZT?ZU5_P#GVOQ#_5NA_P _&?CG_P ,[_%+_HG?B;_P62_X4?\
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M\%DO^%?L9N/K1N/K1_K57_Y]K\0_U;H?\_&?CG_PSO\ %+_HG?B;_P %DO\
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M25Y&89SB,PBH2]V/9=?4]3 Y50P,G..LN[Z!1117SY[(4444 %%%% !1110
M4444 %%%% !1110 4444 %>*_M ?\E ^"?\ V-:_^B7KVJO%?V@/^2@?!/\
M[&M?_1+UZ&!_CKTE_P"DLX\9_!?K'_TI'M5%%%<!V!1112 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I5^\/K24J_>'UH \2_9D_X^?BQ_P!CG=_^@)7ME>)_LR?\?/Q8_P"QSN__
M $!*]LKOQW^\2^7Y(XL'_ C\_P V%%%%<!VA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 *OWA]:[1?NBN+7[P^M=HOW14R-("T445!H%17-U%9P
M/-,^R-1DL>U2TC*&&",CT- &3_PE>E?\_B?D?\*/^$KTK_G\3\C_ (5I^1'_
M ,\U_P"^11Y$?_/-?^^15:"U,S_A*]*_Y_$_(_X4?\)7I7_/XGY'_"M/R(_^
M>:_]\BCR(_\ GFO_ 'R*- U,S_A*]*_Y_$_(_P"%'_"5Z5_S^)^1_P *T_(C
M_P">:_\ ?(H\B/\ YYK_ -\BC0-3,_X2O2O^?Q/R/^%'_"5Z5_S^)^1_PK3\
MB/\ YYK_ -\BCR(_^>:_]\BC0-3,_P"$KTK_ )_$_(_X4?\ "5Z5_P _B?D?
M\*T_(C_YYK_WR*/(C_YYK_WR*- U,S_A*]*_Y_$_(_X4?\)7I7_/XGY'_"M/
MR(_^>:_]\BCR(_\ GFO_ 'R*- U,S_A*]*_Y_$_(_P"%'_"5Z5_S^)^1_P *
MT_(C_P">:_\ ?(H\B/\ YYK_ -\BC0-3,_X2O2O^?Q/R/^%'_"5Z5_S^)^1_
MPK3\B/\ YYK_ -\BCR(_^>:_]\BC0-3,_P"$KTK_ )_$_(_X4?\ "5Z5_P _
MB?D?\*T_(C_YYK_WR*/(C_YYK_WR*- U,S_A*]*_Y_$_(_X4?\)7I7_/XGY'
M_"M/R(_^>:_]\BCR(_\ GFO_ 'R*- U,S_A*]*_Y_$_(_P"%'_"5Z5_S^)^1
M_P *T_(C_P">:_\ ?(H\B/\ YYK_ -\BC0-3,_X2O2O^?Q/R/^%'_"5Z5_S^
M)^1_PK3\B/\ YYK_ -\BCR(_^>:_]\BC0-3,_P"$KTK_ )_$_(_X4?\ "5Z5
M_P _B?D?\*T_(C_YYK_WR*/(C_YYK_WR*- U,S_A*]*_Y_$_(_X4?\)7I7_/
MXGY'_"M/R(_^>:_]\BCR(_\ GFO_ 'R*- U,S_A*]*_Y_$_(_P"%'_"5Z5_S
M^)^1_P *T_(C_P">:_\ ?(H\B/\ YYK_ -\BC0-3,_X2O2O^?Q/R/^%'_"5Z
M5_S^)^1_PK3\B/\ YYK_ -\BCR(_^>:_]\BC0-3,_P"$KTK_ )_$_(_X4?\
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M_*C8O]U?RHT J_VK:_\ /8?D:/[5M?\ GL/R-6MB_P!U?RHV+_=7\J- *O\
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MB_W5_*C8O]U?RHT J_VK:_\ /8?D:/[5M?\ GL/R-6MB_P!U?RHV+_=7\J-
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M%_NK^5<6AUE7^U;7_GL/R-']JVO_ #V'Y&K6Q?[J_E1L7^ZOY4: 5?[5M?\
MGL/R-']JVO\ SV'Y&K6Q?[J_E1L7^ZOY4: 5?[5M?^>P_(T?VK:_\]A^1JUL
M7^ZOY4;%_NK^5&@%7^U;7_GL/R-']JVO_/8?D:M;%_NK^5&Q?[J_E1H!5_M6
MU_Y[#\C1_:MK_P ]A^1JUL7^ZOY4;%_NK^5&@%7^U;7_ )[#\C1_:MK_ ,]A
M^1JUL7^ZOY4;%_NK^5&@%7^U;7_GL/R-']JVO_/8?D:M;%_NK^5&Q?[J_E1H
M!5_M6U_Y[#\C1_:MK_SV'Y&K6Q?[J_E1L7^ZOY4: 5?[5M?^>P_(T?VK:_\
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MH 6BDS10 M%%% !1244 +124M !1124 +124M !1110 4444 %%%% !1110
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M_P#!E-_\51_PM3QK_P!#?KW_ (,IO_BJ/]5:G_/U?=_P0_UDI_\ /M_?_P
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M\$/]9*?_ #[?W_\  /VEVGTHVGTK\6O^%J>-?^AOU[_P93?_ !5'_"U/&O\
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M7M5>*_M ?\E ^"?_ &-:_P#HEZ]# _QUZ2_])9QXS^"_6/\ Z4CVJBBBN [
MHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4J_>'UI*5?O#ZT >)?LR?\?/Q8_['.[_ /0$KVRO
M$_V9/^/GXL?]CG=_^@)7ME=^._WB7R_)'%@_X$?G^;"BBBN [0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** %7[P^M=HOW17%K]X?6NT7[HJ9&D!
M:***@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY9VZGITZ4:*07DXES]E3Q-J/B3]G'P5K>NZE/J>H7%@9KF^NWWR2$.WS,>_
M_2OGKP[K'QA_;0\1>)-5\,>/9_A;\/-)OWL+!M.A+W5VZ<%V(921R"?FP,C
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MCM49QCH.M=9\*_VN?!?Q"^,&DVWQA^%6CZ'XV\^&"W\1FS^>&X5OW0=91OC
M.,-N.#Z#FNAI=%H<J;35WJ?1/[77[5]C^S5X:LX[6TCU;Q9J@86%C(Q$:*O#
M328YV@D  <D\5\YV>J?ML>,=&3QA8S0:?82H+B+2!%;122)C(VPNA;D'H7!-
M<M^ULH\5?M_>$](U4[M.CETJ!8I/N;#(7(QZ,>#ZU^FP 7"@8 & !4:12T--
M9MZ['R=^QK^V1?\ QMU;4O!7C:RATOQOIT;2@PH8END1ML@,9/R.A(R,X(.1
MT->7>/OVJ/C%\=/C9K'@#X'_ &;3K/27DC>_=8R\OE-M>5Y) RHA;Y5 4D\>
MM?<^D^!?#N@ZI>:GINA:?8ZC>2-+<W<%LB2RNQRS,P&23WKE/$T7PV^ >G:W
MX_O-,TGPV?("7FHVULD<]PH)*Q94 N2W1?4U*DKW2*Y96LV?*?P)_:M^*?@?
MX]6GPC^,\4-[>WLJVT-^B(LL<KC=&VY $DC8<9 !%:G[2W[5WQ"U'XV1?!WX
M.011Z\K"*YU&1%=S,5WLB;P5147EF8'H?3G@?@+H>O?MA?M:2_&2[TV32?!N
MA7*/:&4?ZQHEVPPJ?XF_C<C@9QZ"L?XW2:S^R3^VU+\4;[1KC4_"^JW$EXL\
M8^5UEB\N6,.>%=2<@'&>.QK6ROMJ97ER[Z7_  .Q\"_M5_&+X!_&+2_ OQT2
M'4;#5'0)J2)&'B$C!5E1XPJO&&X8%01SS7V!\9/C]X*^!/A\ZGXJU>.V>1"U
MM8Q?/<W1':-!R?J<#WK\M_VROVAHOVD/%V@>(M*T*_T;0-/M7L[.XOE >X<L
M'<_*2O! '!-?I/KG[.O@GXRZAX+\7>,=-;6K_2],B2"UG?\ T8E@KEG0??.>
MQ./:IE%*S94)-W2/F?\ 9)_:T\>_';]J'4++4]4:#PC<VEU<VFAK%%LMU7;Y
M8\P+O8@=3GJ:^_J_-7]D^&.V_P""A'C>&&-(88VU-$CC4*JJ&4  #H *_2JH
MJ6OH73;:U"BBBLS4**** "BBB@ HHHH **** "BBB@ HHHH *^;?VU/@AXA^
M)'AWP]XL\#KN\=>#[P7]A$,!KA 06C&>IRH('?D=Z^DJ*:=G<4ES*S/COPY_
MP4J\$:?I<=M\0="U_P '^)HE"W%@VGO(K..&*'@XR/X@*S/ FJ>-/VP/C]X:
M\<MH^J>#OA?X0+2V*W9:&;4IS@]!C*DJA/5<*!R37V5=:+I]]+YES86UQ)TW
MRPJQ_,BK:(L:A54*JC 51@ 57,NB(Y6]V? _Q(^-WA7X"_\ !0+Q!XA\6W-Q
M!ITGAJWM5-K;F9S(V"/E'., \UWNM?\ !2[X;W6G31>#=-\0>*_$#*1;:=#I
MKIN;'!8GMG&<#-?5]UH>G7TQEN=/M;B4C!DEA5F_,BBUT/3K&42V^GVL$O\
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M+5[ZGJE%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+D?*#SGI6%_P4,^%,7@OXP0^*]-56T7Q9#]L62/[GVA0!)@CCYAM;\37<?\
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M/LN:E.C%13CT]6%%%%?2GSH4444 %%%% !1110 4444 %%%% !1110 4444
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M&A)78KMI'V#\3O%T?@/X<^)O$;.$73=/FN48]-P7Y/\ QXK7&?LKZYXI\5?
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M+B6,\JS95B#CU"]>E5_VT81XN_:<_9]\'Z@"VB7.H/<S0MRDCAUQD=\!<?\
M J^TU4*H"C  P .U5\*1&LFU?8^8_@?^T_XIN/B:WPK^+_AZ#PSXW:+SM/N[
M1LVNHH!D[>3\V 3P<<$8!%?0_BSQ+9>#?#&JZ]J+B.QTVVDNIF)Q\J*6(^IQ
MBJ&N_#;POXF\3Z3XCU71+2_US2018WTR9DM\G)VGMS7SG_P4+\=/!\/] ^'-
MC>Q66H^-]1CLI9II5C6&T5E,KLS$ +DJ.:6DGH/6*=S&_9#_ &KO&OQ,^)5Q
MX>^("6MO#K^FG6?#7DVXA)MP[ H2#\QV\Y_Z9M7V'?2M!8W$J?>2-F'U )KX
M1_:LD\*?"[1?A'XZ\!^(-%O]0^']Q!826ME?PR2SV1 !&U6)(R&R!_ST-?;=
MAKUGXJ\&PZSI\@FL=0L1=0..Z/'N'Z&G)+=!!O9GP]\&?B5^UA\>?",WB;PQ
MXA\%Q:6MY-9!=0L_+EWQD9X5&&,,.<UN^,_BA^U7^S_I#>+?&EIX3\8>&+5E
M^W0Z0A22",L 7)VJ>^,X(&>>*\N_9!_:OG^"_P *;GP]'\,O%WBU3JUU='4-
M$M?,M_FV_)G'WAMY^HKK/'_[6_BW]K/PGK'PW^&/PTU2*\U)19ZG>ZG*FVSB
M9L-N .%Z$$L<CG S6EG?;0Q37+N[GW#\//'&G?$KP/HGBG268Z=JUJEU#NZJ
M&'*GW!R/PKBOC_8_&"^TW1Q\(M1T'3KU9W.H-KJ%E:/;\H3"MSNK?^!_PY_X
M5'\(_"W@\S_:GTBQ2WDF'1WY9R/;<3CVKN:PV>AT;K4_/SXA?%3]J_X9^.?!
M7A/5_$/@Q]4\77+6FG-:V6^)7!4'S"4!4?..@/>O;?A?H_[4MOX^TB3QWKW@
MR[\)*[?;X=,A87#+L;;L)C'.[;WZ9KD?VO\ _DZ;]F?_ +#<G_H<-?8E:2>B
MT,XQU>NPE+1161L%%%% !1110 4444 %%%% !1110 4444 %%%% !6#XC_UT
M/^Z?YUO5@^(_]=#_ +I_G51W)EL8]?(O_!0#5+30[SX/ZA?3"WL[7Q&MQ-*V
M2$1=K,<#DX /2OKJLGQ!X1T'Q=%#%KNB:=K4<+%HDU&TCN!&Q&"5#@X./2M8
MNS,&KJQY--^W'\#FFD8>/K<@L2/]"N?7_KG73_#7]I#X;_%SQ"^B^$?$\.LZ
MI'"UR]O';S1D1J0"V70#JP[]ZU_^%,?#W_H0_#/_ (*+?_XBM+0?A[X6\*WK
M7FB>&='T:\9#&;C3["*"0J>JED4'' X]J- UZGSQ^Q P;Q'\<\$''BZ3./\
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MV,4#.N<X)11D9[&MRH]"M>H4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M$!Y!!8'\*[;X/_M#?"WX2GXX:=97.I_V/XIW?V$JV#956AE&QQGY0K2!03U
MS7#5P=?#T:^"IQ<H7C*+WZKF7RW.VEBJ->K2Q<Y)2M*,EMT=G^@G[!>I6_Q
M\$_$OX.:E)^YU_3&O;%6_AF5=CD>_P#JF_X :7P+9S? ']BGQWKMVOV3Q+XP
MU%M!MUZ.L49:.3'J,";\Q7SY^S[\3&^#?Q<\+^*V,GV6PN +M8>6>W8;90!W
M.TGBO7/VV/VD?#GQSU#PSIW@Q;B'PWI,4LS1SVWV?=<R-\Q">F._JQKT<1A:
MTL=[.,?W<W&4GTO'I\[1."CB:2PG/)_O()Q7I+K\M3TGX,<?\$T/BAC_ )_K
MK_VVKX;KZ<^'/[07A'PS^QEXW^&=]+>#Q1J]S/+:I';%H2K^3MW29P/]6U?,
M==V7TYTZF(<U:\VUYJR.+,*D*E.@HN]HV?WL****]D\<**** "BBB@ HHHH
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MF[U>UTBQM=6O%"W-_#;(D\ZC& [@;F' ZGM6E1)W"*L%%%%24%%%% !1110
M4444 %%%% "K]X?6NT7[HKBU^\/K7:+]T5,C2 M%%%0:!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7PQ^VMK&GZM^T/\/O"7Q&US4/#GPHN;.2XEFM)&CCGN@2 )' X ^7GL
M#GWK[GKGO&WP^\-?$C1SI7BC0['7=/)W>1?0B10?49Y!^E5%\KN1)<RL?F[^
MTJO[,'@7X5ZIHOPOT[3=>\7ZBG[F]L9Y;S[$F1OE:5F8+P, #N<\5Z3\8KB.
MZ\._L=2Q.'C;5+3##O\ +;U]::+^SG\,?#NAZCH^F^!=#M--U&-H;N".T7]\
MC##*2><'TS5V3X'^ Y-/\+V#^%M/>S\+RB;186CRM@X((:+G@Y _*M.=&?LV
M?/7[2O\ R>M^SK_UTN__ $$URWACX@:9^RG^V%\3+?QZ[:1X?\<RIJ6FZU(A
M,!8L6*LPZ %G4^A49X.:^PM<^&WACQ-XIT3Q)JNB6E]KVBECIVH3)F6UW?>V
M'MFI/&GP_P##?Q&TDZ9XGT.QUVP.?W-]") N>I&>1^%3S*UF5RN]SXS_ &R?
MCSX:^/FAZ#\)OAG?1^,_$&M:G;S2R:8?,AMX4)))<<9R03Z '..*^WM"TW^Q
MM$T_3]_F?9+>.#=Z[5"Y_2N:\ _!?P-\+?-/A+PII>@O+]^2SMU5S[;NN/;-
M=G4MJUD5%.]V?*W[>'PSU_5M#\)?$CPC9O?^(_ U^+[[+$I9Y;8E3(% Y."B
MDX[9Q72_#O\ ;M^#_CCPY!?WOBVR\,W^Q?M.G:Q)Y$D,F/F49X< YY&>U?0E
M>9>*/V8_A3XTU)M0UKP!H5_>MRTSVBJQR<DG;C)SWIIJUF+E:=XG@<?[07B#
M]IG]HCPOHOPFU+4+/P%X=E-UX@UR)"D%X./W.&'(.,#//S,1P*YN'P/HO[9_
M[8'CB3Q);2:KX"\%6@TB"!)WC26XW'<=R$'[PD/!Y"KFOM?PUX1T7P;I*:9H
M6E6>D:>@XM[.%8D],X Y/O6;X#^%_A3X86M[;^%-!L]"AO9OM%RMFFWSI/[S
M'N:?,EL+E;W/"=<_X)T_!*XT74(M+\*-I^I26\B6UTNHW+&*0J=K8:0@X.#@
MC%<_^P#\0;N_^$?B3X=ZTS+K_@FYGL7C<\^02VW ] P=?RKZ^KD=%^$?@[P[
MXNUCQ1IGAVQL?$&L*5U#4($VR7(.,ASWZ"ES75F/ELTXGS[_ ,$S_P#DW.Y_
M[&"]_P#:=8/[87PYUKX-^*M/^/GPW1K2_P!.D5/$>G6^1%?6Y('F.HX/'RL?
M<-V)KZL\"_#OPU\,=%;1_"NC6NA:8TSW!M;--J&1L;FQZG _*MK4M-M=8T^Y
ML;VWCN[.YC:&:"9=R2(PPRD'J"#BCF]ZX<ON\ISGPL^)6C_%SP#H_BS0Y?-T
M_4H1(%)^:)^C1MZ,K9!^E=97+?#_ .%_A7X4Z1+I?A'0[30-.EE,[VMFI6,R
M$ %L9ZG KJ:E^1:O;4^._P!K_P#Y.F_9G_[#<G_H<-?8E<SXD^&GA;QAX@T+
M7-:T.SU+5]"E,^F7EPF9+1R02R'L<J/RKIJ;=TA)6;84445)04444 %%%% !
M1110 4444 %%%% !1110 4444 %8/B/_ %T/^Z?YUO5@^(_]=#_NG^=5'<F6
MQCT4459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\$_\ !33_ )&#P'_UZW7_ *''7Q17VO\ \%-/
M^1@\!_\ 7K=?^AQU\45^QY'_ ,BZE\_S9^69S_OU3Y?D@HHHKW3Q0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOH
M7]E7]E6_^.>K)K&L)+8>";23$UP/E>]8=8HCZ?WF[=!STYL1B*6%I.M6=DCH
MP^'J8JHJ5)7;#]E7]E2_^.>K+K&L++8>";23$UP/E>]<=8HCZ?WF[=!S7Z=Z
M+HMAX;TFTTO2[2*PTZTC$4%M NU(U'0 4:+HMAX<TBTTO2[2*PTZTC6&"V@7
M:D: < "KM?D.99G5S&KS2TBME_74_4<OR^G@*?+'63W?]= HHHKQCU HHHH
M**** "BBB@ HHHH **** "BBB@ KQ7]H#_DH'P3_ .QK7_T2]>U5XK^T!_R4
M#X)_]C6O_HEZ]# _QUZ2_P#26<>,_@OUC_Z4CVJBBBN [ HHHI %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4J_>'UI*5?O#ZT >)?LR?\?/Q8_P"QSN__ $!*]LKQ/]F3_CY^+'_8
MYW?_ * E>V5WX[_>)?+\D<6#_@1^?YL****X#M"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 5?O#ZUVB_=%<6OWA]:[1?NBID:0%HHHJ#0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?$?^NA_
MW3_.MZL'Q'_KH?\ =/\ .JCN3+8QZ***LQ"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2OVOOA#/\
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M6K_]#[I__@#)_C7WM11_K!F/_/S\%_D']B8'^3\7_F?!/_#LK5_^A]T__P
M9/\ &C_AV5J__0^Z?_X R?XU][44?ZP9C_S\_!?Y!_8F!_D_%_YGP3_P[*U?
M_H?=/_\  &3_ !H_X=E:O_T/NG_^ ,G^-?>U%'^L&8_\_/P7^0?V)@?Y/Q?^
M9\$_\.RM7_Z'W3__  !D_P :/^'96K_]#[I__@#)_C7WM11_K!F/_/S\%_D'
M]B8'^3\7_F?!/_#LK5_^A]T__P  9/\ &C_AV5J__0^Z?_X R?XU][44?ZP9
MC_S\_!?Y!_8F!_D_%_YGP3_P[*U?_H?=/_\  &3_ !H_X=E:O_T/NG_^ ,G^
M-?>U%'^L&8_\_/P7^0?V)@?Y/Q?^9\$_\.RM7_Z'W3__  !D_P :/^'96K_]
M#[I__@#)_C7WM11_K!F/_/S\%_D']B8'^3\7_F?!#?\ !,S5T1F/CW3SM!/_
M !XR=A]:X_X2_L'ZE\5O UKXE@\7V6G1W$\\ MY+1W8>5*T9.0>^W/XU^DDW
M^HE_W&_D:\;_ &/?^2"Z3_U_ZA_Z525UQSS'O#SJ.>J<5LNJE?IY(YI9/@E7
MA!0T:;W?1Q\_,^</^'96K_\ 0^Z?_P" ,G^-'_#LK5_^A]T__P  9/\ &OO:
MBN3_ %@S'_GY^"_R.G^Q,#_)^+_S/@G_ (=E:O\ ]#[I_P#X R?XT?\ #LK5
M_P#H?=/_ / &3_&OO:BC_6#,?^?GX+_(/[$P/\GXO_,^"?\ AV5J_P#T/NG_
M /@#)_C1_P .RM7_ .A]T_\ \ 9/\:^]J*/]8,Q_Y^?@O\@_L3 _R?B_\SX)
M_P"'96K_ /0^Z?\ ^ ,G^-'_  [*U?\ Z'W3_P#P!D_QK[VHH_U@S'_GY^"_
MR#^Q,#_)^+_S/@G_ (=E:O\ ]#[I_P#X R?XT?\ #LK5_P#H?=/_ / &3_&O
MO:BC_6#,?^?GX+_(/[$P/\GXO_,^"?\ AV5J_P#T/NG_ /@#)_C1_P .RM7_
M .A]T_\ \ 9/\:^]J*/]8,Q_Y^?@O\@_L3 _R?B_\SX)_P"'96K_ /0^Z?\
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8->YC?\ "12_] J^_P"_8_QH_P"$BE_Z!5]_W['^-;-%&G8->YC?\)%+_P!
MJ^_[]C_&C_A(I?\ H%7W_?L?XULT4:=@U[F-_P )%+_T"K[_ +]C_&C_ (2*
M7_H%7W_?L?XULT4:=@U[F-_PD4O_ $"K[_OV/\:/^$BE_P"@5??]^Q_C6S11
MIV#7N8W_  D4O_0*OO\ OV/\:/\ A(I?^@5??]^Q_C6S11IV#7N8W_"12_\
M0*OO^_8_QH_X2*7_ *!5]_W['^-;-%&G8->YC?\ "12_] J^_P"_8_QH_P"$
MBE_Z!5]_W['^-;-%&G8->YC?\)%+_P! J^_[]C_&C_A(I?\ H%7W_?L?XULT
M4:=@U[F-_P )%+_T"K[_ +]C_&C_ (2*7_H%7W_?L?XULT4:=@U[F-_PD4O_
M $"K[_OV/\:/^$BE_P"@5??]^Q_C6S11IV#7N8W_  D4O_0*OO\ OV/\:/\
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M_&LC6M8>XDC)L+J+ Z.F,_K785@^(_\ 70_[I_G51M<F5['-_P!H-_SZ3_\
M?-']H-_SZ3_]\U<HK30R*?\ :#?\^D__ 'S1_:#?\^D__?-7**- *?\ :#?\
M^D__ 'S1_:#?\^D__?-7**- *?\ :#?\^D__ 'S1_:#?\^D__?-7**- *?\
M:#?\^D__ 'S1_:#?\^D__?-7**- *?\ :#?\^D__ 'S1_:#?\^D__?-7**-
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MT&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\
MOFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y]
M)_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T
M&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4
M_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N4
M4: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^
M^:N44: 4_P"T&_Y])_\ OFC^T&_Y])_^^:N44: 4_P"T&_Y])_\ OFC^T&_Y
M])_^^:N44: 4_P"T&_Y])_\ OFO+?C%IRZUXR^%ES)=P:<VG>(5N4AO&VO=G
MRG'EQ#N_.<>@KUZO%?V@/^2@?!/_ +&M?_1+UVX/6LK::2_])9R8JRI.^NJ_
M-'KW]H-_SZ3_ /?-']H-_P ^D_\ WS5RBN+0ZRG_ &@W_/I/_P!\T?V@W_/I
M/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@
MW_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\
MT?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/
M_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W
M_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_
M &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC
M0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS
M5RBC0"G_ &@W_/I/_P!\T?V@W_/I/_WS5RBC0"G_ &@W_/I/_P!\TJZ@VX?Z
M)/\ ]\U;I5^\/K1H!X_\"=.7P_/\0S'=P:K]N\3W-VPL6W_9BRH/*D]'&.1[
MUZG_ &@W_/I/_P!\UX_^S)_Q]?%C_L<[O_T!*]LKMQFE>2>NWY(X\)K1C;3?
M\V4_[0;_ )])_P#OFC^T&_Y])_\ OFKE%<6AV%/^T&_Y])_^^:/[0;_GTG_[
MYJY11H!3_M!O^?2?_OFC^T&_Y])_^^:N44: 4_[0;_GTG_[YH_M!O^?2?_OF
MKE%&@%/^T&_Y])_^^:/[0;_GTG_[YJY11H!3_M!O^?2?_OFC^T&_Y])_^^:N
M44: 4_[0;_GTG_[YH_M!O^?2?_OFKE%&@%/^T&_Y])_^^:/[0;_GTG_[YJY1
M1H!3_M!O^?2?_OFC^T&_Y])_^^:N44: 5%U!MP_T2?K_ ':] 7[H^E<6OWA]
M:[1?NBHD:0%HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BN*\2?&KX?\ @_4/
ML&N>-M TF]_Y][S48HI!_P !+9KJ=*U:QURQBO=.O(+^SE&8[BVD$B,/9@<&
MF*Y<HKBO%'QJ\ >"=6?2O$'C70=$U-$61K._U"*&55;[I*LP.#5;1_C]\-/$
M&H1V.F>/_#=_>2?<@M]4A=V^@#46871WU%-4@@8.1ZTRYN8K.WEN+B5(8(D,
MDDDC!510,DDGH *0R6BL_0M>TWQ/I-MJFD7]MJ>FW*[X+NTE$D4@SC*L.",@
MUE>,/B5X4^'T<3^)_$ND^'UF.(SJ5Y'!O//3<1GH: .EHK/T/7M-\3:;#J.D
M:A:ZG83#='<V<RRQN/9E)%:% !115+6-:L/#NEW6I:I>0:?I]JADGNKF01QQ
M*.K,QX ]S0!=HKF+_P")_A'2]#TS6KSQ/I-KI&J.D=C?37D:PW3/]U8W)PQ/
M;'6NF'3UH 6BBB@ HHHH **2D5U<94AAG'!S0 ZBBB@ HHK%D\9Z#'XH3PTV
MLV*^(9(#<II9N%^TM$.KB/.[;[XH VJ*** "BBB@ HHHH **** "BBB@ K!\
M1_ZZ'_=/\ZWJP?$?^NA_W3_.JCN3+8QZ***LQ"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=?CAX^T
M'X:_M(?#37/$E^NFZ5'I.IQO<,I8!F"!1@<\FN@_X;,^#G_0Y0_]^)/\*^<_
M^"FG_(P> _\ KUNO_0XZ^**_0\#DM#,,)2K5)-.S6EOYGY'P^,S:M@<55I4X
MIJZ>M^R\S]8_^&S/@Y_T.4/_ 'XD_P */^&S/@Y_T.4/_?B3_"OR<HKM_P!5
M\)_/+\/\CE_UCQ/\D?Q_S/UC_P"&S/@Y_P!#E#_WXD_PH_X;,^#G_0Y0_P#?
MB3_"OR<HH_U7PG\\OP_R#_6/$_R1_'_,_6/_ (;,^#G_ $.4/_?B3_"C_ALS
MX.?]#E#_ -^)/\*_)RBC_5?"?SR_#_(/]8\3_)'\?\S]8_\ ALSX.?\ 0Y0_
M]^)/\*/^&S/@Y_T.4/\ WXD_PK\G**/]5\)_/+\/\@_UCQ/\D?Q_S/UC_P"&
MS/@Y_P!#E#_WXD_PH_X;,^#G_0Y0_P#?B3_"OR<HH_U7PG\\OP_R#_6/$_R1
M_'_,_6/_ (;,^#G_ $.4/_?B3_"C_ALSX.?]#E#_ -^)/\*_)RBC_5?"?SR_
M#_(/]8\3_)'\?\S]8_\ ALSX.?\ 0Y0_]^)/\*/^&S/@Y_T.4/\ WXD_PK\G
M**/]5\)_/+\/\@_UCQ/\D?Q_S/UC_P"&S/@Y_P!#E#_WXD_PH_X;,^#G_0Y0
M_P#?B3_"OR<HH_U7PG\\OP_R#_6/$_R1_'_,_6/_ (;,^#G_ $.4/_?B3_"C
M_ALSX.?]#E#_ -^)/\*_)RBC_5?"?SR_#_(/]8\3_)'\?\S]8_\ ALSX.?\
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M)1;V[>A]E44IXX/!I*^*/JPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HOW17%K]X?6NT7[HJ9&D!:***@T"BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !2K]X?6DI5^\/K0!XE^S)_Q\_%C_L<[O_T!*]LKQ/\
M9D_X^?BQ_P!CG=_^@)7ME=^._P!XE\OR1Q8/^!'Y_FPHIS(T>-RE<\C(Q0D;
M2'"*6/HHS7 =HVBE(*D@C!IRPR, 51B#T(% #**4Y4X/!IPC<H7",4_O8XH
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M9'^ZEU24CY%$H<'@?PA6ZDTUJQ-V5SW;3?&OA[6+H6MAKVF7UR>D-M>1R/\
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MF"@@?Q#(_&O868LQ+'<3U)I*+ZW"VECR+]E+Q[J'Q ^!OAZZUBUN[+6K&/\
ML^\CO('A=FC&%?#@'#+CFOGC]IW1?%?PN^+WBJ?P;I-[>VGQ.T5=/D:S@>1+
M>\#JA=MH(4%<<GL2:^YGD>1LNQ8^K'-"R/&"%=E!ZX.,T^:SN*VECE?A?X%M
M?AE\._#WA:S4"'2[.. L/XW ^=C[ELFNHHHJ2@HHHI %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?!/\ P4T_Y&#P'_UZW7_H<=?%%?:_
M_!33_D8/ ?\ UZW7_H<=?%%?L>1_\BZE\_S9^69S_O\ 4^7Y([KX'?$B3X1_
M%CPUXM56DATZZ5KB->KPL"L@^NTDCW KZ\_;&_9>U'XPZE;?%SX6I'XGL-9M
M8Y+RSLG!D8A0%FC'\60 &7J"#[X^":],^$/[1_Q ^![NOA779+>QD;?)IUPH
MFMG/<[&^Z?=<&M<9A*TJT<5A6E.*M9[-=F9X3%4HTI8;$IN#=]-T^XOA'3OC
M)X+O)]*\,6GC709[B3]];Z;'=6XD<#^+: "0.YK[B^ WAWXH>#_V>/BSJ/Q<
MU+4D^W:7.+"/7]1,TL2_9Y%((9CLW,5 &<DXKQ&3_@I_\3WL# NA>&8Y]FW[
M4()RX/\ >P9-N?PQ7@GQ8_:$\?\ QLF!\6>()[VT5MT>GP@0VR'VC7 )Z<G)
MXKS:V%QN/]RM3A!73;WEIVV_$]"EB<)@O>I3E-V=ELM>Y]/?\$V8WD\"?&5$
M1G=K"!551DD^3<< >M?&\/P\\6"&,'PKKOW1_P PR?T_W*])_9W_ &I/$G[-
MJZX/#^E:5J7]KF$S?VFLIV>7NQMV.O7><YST%>R_\/2/B3_T*WA7_OW<_P#Q
MZMI4\=A\76JT*2E&?+O*VRL0JF"Q&%I4ZU1Q<;[*^[/DG5/">NZ+:_:-1T/4
M].M]P7SKNREB3<>@W,H&:^TOC-HVH:Y_P3[^$L&FZ?=ZC.MS$YCLX'F8+MFY
M(4$X]Z\>^._[;/C#]H'P*/"VN:)H>GV(NX[SSM/682;D#8'SR,,?,>U;WPR_
MX*$>._A7X#T;PGIOA[P[=6.E0>1#-=).977).6VR 9Y["GB88ZO"E5]FE.$K
MVYM+6?4G#SP5"=2G[1\DHVO;K==#Y[_X5[XK_P"A5US_ ,%D_P#\14%]X.\0
M:3:O=7V@:K96L?WY[FPECC7MRS* *^LO^'I'Q)_Z%;PK_P!^[G_X]7&_%[]O
MCQO\9OA]JOA#5]!T"RT_40BRS6*3B4!75QC=(1U4=1713KYC*:4Z"2Z^]T^X
MYYT,O4&X5FWT]T]C_9_O#^RE^QKKGQ/>VA/B;Q',G]G1W2DJR[MD 8 @[3\[
MG!&1BO.?^'FOQ<_Y\/"__@!-_P#'J\L^,_[3_B/XU^$?#7AB_P!,TO1=$T$
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M#_NG^=;U8/B/_70_[I_G51W)EL8]%%%68A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?!/_  4T_P"1
M@\!_]>MU_P"AQU\45]K_ /!33_D8/ ?_ %ZW7_H<=?%%?L>1?\BZE\_S9^69
MS_OU3Y?D@HHHKWCQ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "G1QM(ZHBL[L0JJHR23T %$<;2.J(K.[$*JJ,DD]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]_'_ ,:]BHH^O8O_ )^R^]A]3PW_ #[C]R/'?^&/_@__ -"39_\ ?Q_\:/\
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M^#__ $)-G_W\?_&C_AC_ .#_ /T)-G_W\?\ QKV*BCZ]B_\ G[+[V'U/#?\
M/N/W(\=_X8_^#_\ T)-G_P!_'_QH_P"&/_@__P!"39_]_'_QKV*BCZ]B_P#G
M[+[V'U/#?\^X_<CQW_AC_P"#_P#T)-G_ -_'_P :/^&/_@__ -"39_\ ?Q_\
M:]BHH^O8O_G[+[V'U/#?\^X_<CQW_AC_ .#_ /T)-G_W\?\ QH_X8_\ @_\
M]"39_P#?Q_\ &O8J*/KV+_Y^R^]A]3PW_/N/W(\=_P"&/_@__P!"39_]_'_Q
MH_X8_P#@_P#]"39_]_'_ ,:]BHH^O8O_ )^R^]A]3PW_ #[C]R/'?^&/_@__
M -"39_\ ?Q_\:/\ AC_X/_\ 0DV?_?Q_\:]BHH^O8O\ Y^R^]A]3PW_/N/W(
M\=_X8_\ @_\ ]"39_P#?Q_\ &C_AC_X/_P#0DV?_ '\?_&O8J*/KV+_Y^R^]
MA]3PW_/N/W(\;D_9!^#ZQ2$>";/(4D?O']/K7E_[,_[-?PT\;?![3M6UOPK;
M7^HR7EY&]Q([@E4N'51P>P %?6,W^HE_W&_D:\;_ &/?^2"Z3_U_ZA_Z525W
M0QF)^JU)>UE?FCU?:1R2PN'^L07LU:TNB[Q)?^&/_@__ -"39_\ ?Q_\:/\
MAC_X/_\ 0DV?_?Q_\:]BHKA^O8O_ )^R^]G7]3PW_/N/W(\=_P"&/_@__P!"
M39_]_'_QH_X8_P#@_P#]"39_]_'_ ,:]BHH^O8O_ )^R^]A]3PW_ #[C]R/'
M?^&/_@__ -"39_\ ?Q_\:/\ AC_X/_\ 0DV?_?Q_\:]BHH^O8O\ Y^R^]A]3
MPW_/N/W(\=_X8_\ @_\ ]"39_P#?Q_\ &C_AC_X/_P#0DV?_ '\?_&O8J*/K
MV+_Y^R^]A]3PW_/N/W(\=_X8_P#@_P#]"39_]_'_ ,:/^&/_ (/_ /0DV?\
MW\?_ !KV*BCZ]B_^?LOO8?4\-_S[C]R/'?\ AC_X/_\ 0DV?_?Q_\:/^&/\
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M_P"/GXL?]CG=_P#H"5[97B?[,G_'S\6/^QSN_P#T!*]LKOQW^\2^7Y(XL'_
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M*+@4_,O_ /GC#_WW1YE__P \8?\ ONKE%%P*?F7_ /SQA_[[H\R__P">,/\
MWW5RBBX%/S+_ /YXP_\ ?='F7_\ SQA_[[JY11<"GYE__P \8?\ ONCS+_\
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M**+@4_,O_P#GC#_WW1YE_P#\\8?^^ZN447 I^9?_ //&'_ONCS+_ /YXP_\
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M_P \8?\ ONKE%%P*?F7_ /SQA_[[H\R__P">,/\ WW5RBBX%/S+_ /YXP_\
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M_P \8?\ ONCS+_\ YXP_]]U<HHN!3\R__P">,/\ WW1YE_\ \\8?^^ZN447
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M/GXL?]CG=_\ H"5[97;C?=KR6^WY(Y,([T8OU_-E/S+_ /YXP_\ ?='F7_\
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MB'_H1M)_\"I:^,**/[#R[_GU^+_S#^V,=_S\_!?Y'V?_ ,/,O$/_ $(VD_\
M@5+1_P /,O$/_0C:3_X%2U\844?V'EW_ #Z_%_YA_;&._P"?GX+_ "/L_P#X
M>9>(?^A&TG_P*EH_X>9>(?\ H1M)_P# J6OC"BC^P\N_Y]?B_P#,/[8QW_/S
M\%_D?9__  \R\0_]"-I/_@5+1_P\R\0_]"-I/_@5+7QA11_8>7?\^OQ?^8?V
MQCO^?GX+_(_0[X*_\%!+#QUXQAT/Q?H]KX8AO,1VNH03,\0E)X63=]T'LW3/
M6OK_ -".0>01WK\,J^VOV.OVQ3IILO ?CR]S9DB'2]9N&_U7989F/\/96/3H
M:^:SC(8PC[?!K1;Q_5?Y'T.5YTYR]CBGJ]G^C/O.BCT(.1U!%%? 'V@4444
M%%%% !1110 4444 %%%% !1110 R;_42_P"XW\C7C?['O_)!=)_Z_P#4/_2J
M2O9)O]1+_N-_(UXW^Q[_ ,D%TG_K_P!0_P#2J2O0I_[G4_Q1_*1QS_WF'^&7
MYQ/9Z***\\[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME;7_  4&U2Z\/_LLZ_#IN;>*YFMK*7R1M"P,XRO'0?*!]#7F'P]\:?M*^$?
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M^.WPPB_9#\2:)\6/AH)M+T9KU+/7-!60M;RQN>H!/ (!&.QP17VR<=B&!Y#
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M$JQKD]!EB!FI@0P!!R#T(H ****0!1110 4444 %%%% !1110 4444 %%%%
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MM??$<*6\:11#$4:B-!Z*!@?H*3T5BUJ[BT445F4%%%% !1110 4444 %%%%
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ME"*6/11W)]AS705\M?ME7GP>T?7/!FK_ !-75M?U*S>0Z3X6T]C(ETQ^]))
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MSAL?0#Z9J;715]3VWP?^UA\)?'FN1Z/HOC6RGU&5MD<,Z26_F-T"JTBJ"3Z
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M%%% !1110 J_>'UKM%^Z*XM?O#ZUVB_=%3(T@+1114&@4444 %%%% !1110
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M5]A4F*7,4XGPWXF\+_&S]L_6]!TCQAX-_P"%6_#K3KQ+V^@N9_,NKJ1,X R
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M'.X9P2>*^N**.8.4^'/CO-^T/^TA\/+^P/PX;P?H%J%N9M+EN?-O]0D5AM1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P B]>?[O]16E*;IU(S6Z9G4BIP<7U1^=W_#-OQY_P"BL/\ ^#&X_P#B:/\
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M37U]11_;.)[1_P# 4']E8?O+_P "9\@_\,V_'G_HK#_^#&X_^)H_X9M^//\
MT5A__!C<?_$U]?44?VSB>T?_  %!_96'[R_\"9\@_P##-OQY_P"BL/\ ^#&X
M_P#B:/\ AFWX\_\ 16'_ /!C<?\ Q-?7U%']LXGM'_P%!_96'[R_\"9\@_\
M#-OQY_Z*P_\ X,;C_P")H_X9M^//_16'_P#!C<?_ !-?7U%']LXGM'_P%!_9
M6'[R_P# F?(/_#-OQY_Z*P__ (,;C_XFC_AFWX\_]%8?_P &-Q_\37U]11_;
M.)[1_P# 4']E8?O+_P "9\@_\,V_'G_HK#_^#&X_^)H_X9M^//\ T5A__!C<
M?_$U]?44?VSB>T?_  %!_96'[R_\"9\@_P##-OQY_P"BL/\ ^#&X_P#B:/\
MAFWX\_\ 16'_ /!C<?\ Q-?7U%']LXGM'_P%!_96'[R_\"9\@_\ #-OQY_Z*
MP_\ X,;C_P")H_X9M^//_16'_P#!C<?_ !-?7U%']LXGM'_P%!_96'[R_P#
MF?(/_#-OQY_Z*P__ (,;C_XFC_AFWX\_]%8?_P &-Q_\37U]11_;.)[1_P#
M4']E8?O+_P "9\@_\,V_'G_HK#_^#&X_^)H_X9M^//\ T5A__!C<?_$U]?44
M?VSB>T?_  %!_96'[R_\"9\@_P##-OQY_P"BL/\ ^#&X_P#B:/\ AFWX\_\
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M][/CS_AF#XY?]%2_\J%Q_P#$T?\ #,'QR_Z*E_Y4+C_XFOL.BC^V<3VC_P"
MH/[)P_>7WL^//^&8/CE_T5+_ ,J%Q_\ $T?\,P?'+_HJ7_E0N/\ XFOL.BC^
MV<3VC_X"@_LG#]Y?>SX\_P"&8/CE_P!%2_\ *A<?_$T?\,P?'+_HJ7_E0N/_
M (FOL.BC^V<3VC_X"@_LG#]Y?>SX\_X9@^.7_14O_*A<?_$T?\,P?'+_ **E
M_P"5"X_^)K[#HH_MG$]H_P#@*#^R</WE][/CS_AF#XY?]%2_\J%Q_P#$T?\
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M\>?\,P?'+_HJ7_E0N/\ XFC_ (9@^.7_ $5+_P J%Q_\37V'11_;.)[1_P#
M4']DX?O+[V?'G_#,'QR_Z*E_Y4+C_P")H_X9@^.7_14O_*A<?_$U]AT4?VSB
M>T?_  %!_9.'[R^]GQY_PS!\<O\ HJ7_ )4+C_XFC_AF#XY?]%2_\J%Q_P#$
MU]AT4?VSB>T?_ 4']DX?O+[V?'G_  S!\<O^BI?^5"X_^)H_X9@^.7_14O\
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M^\OO9\7:7^R7\9])-X;3XAV]C]IG:>;[/?W \YSU=OE'S'^E7O\ AF#XY?\
M14O_ "H7'_Q-?8=%-YUBF[M1_P# 4)93AEHG+[V?'G_#,'QR_P"BI?\ E0N/
M_B:/^&8/CE_T5+_RH7'_ ,37V'12_MG$]H_^ H?]DX?O+[V?'G_#,'QR_P"B
MI?\ E0N/_B:/^&8/CE_T5+_RH7'_ ,37V'11_;.)[1_\!0?V3A^\OO9\>?\
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M_P#*A<?_ !-?8=%']LXGM'_P%!_9.'[R^]GQY_PS!\<O^BI?^5"X_P#B:/\
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M&/V?/C+JMBQ2\M51HG7JK& @,/<9S^% ET/HKX@?M@?#/X<ZW-I%]J=UJ-]
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M[97-Q)Y4$NH6OE0RN3@*'W'K[XKUOQ3XJTGP3H=WK.NW\.F:9:C=+<3G 'H
M.I)[ <FOAC]NCX>Z!X'\8>#;SP_I5IHOVR-EEBL8A$A:-UVMM7@'#=>^*V_^
M"@'B6^FL?AYH9ED-I<69U"90?];+\J GU/7'UI#N>RZ/^W#\*-8UI=._M._L
M0S[!>7MF8[?K@'<&) ]R*]YAFCN88YH9%EAD4.DB$%64C(((ZBOSS^(WB3P)
MXF^%:^&_#_P5\3Z-K5O'']DUA]-^?>,;C*RC<X;GKGKQ7U!^QKJ.KWGP)TNT
MUJWNK>ZTV>:TC6\B>.3R@V4&& . #@?2@$];'M]%%%(L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ='_K$_WA_.O9X_\ 5K]*\8C_ -8G^\/Y
MU[/'_JU^E85#:GU'4445B;A6/XM_Y%Z\_P!W^HK8K'\6_P#(O7G^[_44X[H4
MMF>65R7Q<T^ZU;X6^++*RMY+N\N--FCAMX5W/(Q7A5'<FNMHKM.,^9?V$? _
MB+P+X%\0VWB+0[_0KF:_22**_@,3.HC R >HS7(_M=?LZZX?&&G_ !#^'FFW
M5SJTDZM>VNFQEI4G7E+A%'KC#>^#WK[(HH)MI8^6OBY\+_$O[4'P1\/ZK/HM
MQX=\>Z26\W3=2B-OYYQAU4MT#<,IZ9R.U<GIGQ<_:DL]*LO#4'@F?[9:A81J
M\]BQ+JO&&=F\H@@8W8_&OM&C- 6/!OBW\)?%/QJ^ MMI/BV[TNW\<PR"[A:W
M8I;^: <0[F/)*D@D<9 /05XMX!NOVC]/\)CX:0^&6TNP2-K8>(-0@*FUMR#N
MV2[MK@ G! )]*^I?C=\)[?XS> Y_#\E])I=RLJ75G?1@DP3J"%8@$$@AF!]C
M7S3!^SC^T;I.DR^';#XAVY\.MF,HVIN"8VQNX:,L/IN[=J!/<R_^">-J/^$N
M\=0RKYT7V-(7)Z/^\(/Y\U*OPS^+_P"RQ\1M:U3X>:.WBGP]JC$"&&)I0R;B
MRI)&I#*R$GYAQ[U] ?LU_L\P? /P[?Q37ZZIK>IR+)=W4:%44*#MC0'G R22
M>I->Q4 HZ'SY\#?&?Q]\9>+&N_&FDV7A_P *'+/;75N8IQQ@)$N[=UYW/FO/
MO GPX\5V/[<&J^)+CPWJ<'AZ2:\*:I);,+=@T6%(?IR>!7V)10.Q\D?MV?#W
MQ1XYU#P2_ASP]J6N+:^?Y[6%NTHBRR8W8Z9P?RKL/VG/V?=1^,GPY\/2:-LC
M\2Z)"IBMYCL\]"BAXMQ^ZP(R,\9S7T/10%CXPTWXO?M2QZ=9>'8/!,RWEMMB
M_M>XL6S*J\89V;R\$?Q >^:[7]ISPG\0O&W[..E6.I:8-=\8_;X9KJVT&%I%
M50K]!DYQD D<9Z5]-YI* L>>_L\Z/?>'_@?X+TS4[.;3K^VT\1SVMPFR2)M[
M<,O8\BODC1? ?QG_ &:_BYKNI>%/"<GB>#4C)$ETMNT\,L+2;E+,A#1L#C.2
M.AZBOOFB@+'P2OPS^+.G_M&>$/'7BWP]>:O<WEW!>W\FD6YFBL4#%/*8KP"B
M@'&3QCFN[_;.^$_C/6OB!X4\:>$M$GU[^SHE22&T3S)$E27>A*#DJ?45]=T4
M7#E/CSXZVOQ,^,G[.>D2ZMX+O(/%/]MEY-)T^U<M' $PKE"2P!)/4]:^@?@;
MX?GL?@7X1T36[&6TG72$M;NSN4VNF5(964]#S7H6310.Q^=?A/\ 99\8)\<K
M;PS?Z'J(\$V6LM<G4)(3]D>%>00_0EE54K[E^+GP[MOBK\.=:\+3RBV%]#B&
M?&1#(IRC8] 1^1KKZ*!)6/ACP/JW[1G[/.CW'@W2_!DFO::DKM:W$=N]S'"6
M)RT;QL!@GYMK=/2OI?X"ZC\5M4\/W%S\4$L;>X<K]DMX$"S@=VEVG:,]@!FO
M4** L%?(O@7X<^*+']N;5_$]QX>U*WT O>-%JDENPMWW0E5P_3D]*^NJ*0['
MY^>-OV:?$NI?M37$=MX;U&7PC>:U'=-J2VS&W2%F#OE^G'(^M>@_M1?#7Q3X
MD_:1\#:SHWAO4M3TNV:Q^T7UI;L\402X!;<PX&%Y^E?85&:=Q<I\M_M5? 3Q
M;K7Q TOXF?#S]]K^GE#+;1L%EW1DE)4SPQQP5ZX Q63H_P 7_P!J/QEK%C:6
MW@R'P^B';//?V3PPR _Q.TC'&.N$Q7UU2YH"Q\S?M;?L^>(OBOH^@>(]#:*Y
M\8:/$([B&!O*%RI(8F(L>&5AD GI[UY=XEU+]HSXR?#VZ\+:KX2ETO3K6#?>
M73V;07-^$&5C"D_.6('" 9[U]TT4!8^8/V9_ _B/PW^S)XOT?5M"U#3-7N3>
M&&QNH&2:3=%A=JGDY/%9/[%_PGUK3?AW\0=!\8^']1T2'6)4A$=] 8FDC,)5
MF7/7!/YU]:T4!8^#_"GA+XX_LI:]K-AX6\,_\)AH=\^Y&BMWN(GVY"281@R/
MC@@\?7BO2_V8?AO\59/B)J/CKQ_J-_I-I=-)*NBR3D">63&2T0.$11T4\Y K
MZE_2B@+'QW\#_ASXKT/]L/Q-K^H>&]3LM"G^W^5J4]LRP/O9=N'Z'.#CZ4?#
MOX<^*]/_ &W-8\277AO4[?P_)+>E-4DMF%NP:/"D/TY/2OL3GUHH#E/D;]NK
MX>^*?'&L>"9/#OA[4M<2U$WGM86[2B++)C=CIT/Y5V7[4'[/NI?&3X?>'I]$
MV)XET2%?+MYFV>>A1=T>X_=8$9&>.M?0]% 6/C'3?B_^U(+"R\/0>"IH[RVV
MQ'5KBQ;,H7C#NS>7@C^( >N:^L? [>)6\*Z<?&$EG)XB,>;K^SP1"I[*,DY(
M'4C@GI6[S10.P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #H_P#6)_O#^=>SQ_ZM?I7C$?\ K$_WA_.O9X_]6OTK"H;4^HZBBBL3<*Q_
M%O\ R+UY_N_U%;%8_BW_ )%Z\_W?ZBG'="ELSRRBBBNPXPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ='_K$_P!X?SKV>/\ U:_2O&(_]8G^\/YU
M[/'_ *M?I6%0VI]1U%%%8FX5E>)X9+C0[J.)&ED9<!5&2>:U:*8CR/\ L#4O
M^?&?_O@T?V!J7_/C/_WP:]<HK7VC,_9H\C_L#4O^?&?_ +X-']@:E_SXS_\
M?!KURBCVC#V:/(_[ U+_ )\9_P#O@T?V!J7_ #XS_P#?!KURBCVC#V:/(_[
MU+_GQG_[X-']@:E_SXS_ /?!KURBCVC#V:/(_P"P-2_Y\9_^^#1_8&I?\^,_
M_?!KURBCVC#V:/(_[ U+_GQG_P"^#1_8&I?\^,__ 'P:]<HH]HP]FCR/^P-2
M_P"?&?\ [X-']@:E_P ^,_\ WP:]<HH]HP]FCR/^P-2_Y\9_^^#1_8&I?\^,
M_P#WP:]<HH]HP]FCR/\ L#4O^?&?_O@T?V!J7_/C/_WP:]<HH]HP]FCR/^P-
M2_Y\9_\ O@T?V!J7_/C/_P!\&O7**/:,/9H\C_L#4O\ GQG_ .^#1_8&I?\
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M#E.2_L^Y_P">$G_?-']GW/\ SPD_[YKK:*.8.4Y+^S[G_GA)_P!\T?V?<_\
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MAS+R_%I'>_V?<_\ /"3_ +YH_L^Y_P">$G_?-=;17-S&_*<E_9]S_P \)/\
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M[U\S&=N1G\J;)=0PMMDFC1NN&8 T 2T5 M];NP"SQ,3T <5/0 4444 %%%%
M!13/.3S/+WKYF,[<\_E3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *P?$?\ KH?]T_SK>K!\1_ZZ'_=/\ZJ.Y,MC'HHH
MJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#Q7QM_R=A\,/^P-JO\ Z"E>U5\K_M3?%VT^!_QP^''B
MJ]TZ;5((=,U" V]O($8E]B@Y(/2N=_X>8>&O^A(U7_P-C_\ B:^B>6XO%T:-
M2A"ZY;=/YI>9X:Q^&PU6K3K3L^;S_EB?95%?&O\ P\Q\-?\ 0CZK_P"!L?\
M\31_P\Q\-?\ 0CZK_P"!L?\ \367]AYA_P ^G]Z_S-/[7P/_ #\_!_Y'V517
MQK_P\Q\-?]"/JO\ X&Q__$T?\/,?#7_0CZK_ .!L?_Q-']AYA_SZ?WK_ ##^
MU\#_ ,_/P?\ D?95%?&O_#S'PU_T(^J_^!L?_P 31_P\Q\-?]"/JO_@;'_\
M$T?V'F'_ #Z?WK_,/[7P/_/S\'_D?95%?&O_  \Q\-?]"/JO_@;'_P#$T?\
M#S'PU_T(^J_^!L?_ ,31_8>8?\^G]Z_S#^U\#_S\_!_Y'V517QK_ ,/,?#7_
M $(^J_\ @;'_ /$T?\/,?#7_ $(^J_\ @;'_ /$T?V'F'_/I_>O\P_M? _\
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M;'_\31_8>8?\^G]Z_P P_M? _P#/S\'_ )'V517QK_P\Q\-?]"/JO_@;'_\
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MS2 8*]@V*[(9/CUAIP=+5N+W712\_-'-+-,$Z\)JIHE+H^KCY>1^@M%?&O\
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M_HEZ]JKQ7]H#_DH'P3_[&M?_ $2]>A@?XZ])?^DLX\9_!?K'_P!*1[51117
M=@4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *5?O#ZTE*OWA]: /$OV9/^/GXL?]CG=_\ H"5[
M97B?[,G_ !\_%C_L<[O_ - 2O;*[\=_O$OE^2.+!_P "/S_-A1117 =H4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "K]X?6NT7[HKBU^\/K7:+]
MT5,C2 M%%%0:!1110 4444 %%%% !124M !1110 44E% "T4E% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7R'^WIG_A,OV?\$C_ (K&/H?]
MROKROC#_ (*-:7<ZY??!33K/4)=)N[SQ/Y$.H0#,EL[*JK(O(Y4D$<CI5P^(
MSJ?"?9]?(OB;/_#R7PGR<?\ "+3<9XZ/2_\ #&?Q7_Z.?\9?]^7_ /DBO//A
MM\-M?^%O[?'AG2?$?CG4OB!?2>'[B==4U12LJ(58",9=N!@GKWJHI:V9,F]+
MHZ_Q-G_AYQX:Y./^$8/&>.DE<Q\<O@[H/QT_;ZM?"OB5[Y-+D\+I<'[!<>3)
MN0N1\V#Q^%=-XG_Y2<>&O^Q8/\I*Y?XZ:C\0-+_;XM;CX9Z3IFM>*!X70+:Z
MM+Y<!B)?><[UY Z<U2_0A]?4[C4/^"9/PSBLIGT+6?%&CZPJDVM]_:7F>3)V
M;;M&?S%;'[ ?Q1\2>-/!/BKPOXKOI-6U;P=JS:5_:,K;GGC&0,MU."I&3R1B
ML&_UO]LSQ-:2Z9_PC'@GPP+E3&=5M[H.\&0?F ,K\_\  37K_P"RS^SU'^SO
M\/IM*N-0&L:_J5RU]JNI $":9AC SR5 Z$\G))J6]-7<N*]Z\58]?O+R'3[.
M>ZN9!%;P1M+)(W1549)/T KS"Z_:G^$UCX1L?$]QX[TF+0KZ1X;:[:1@)F1B
MKA5QN."""<8KN/'?_(C^(?\ L'7'_HIJ^*/^"?O[-/@GQG\&;?QCXNT:U\47
MEW<W%O9P:HGG06<*2%2$C;Y06<,Q.,\BI25KLN3=TD?;'@_QQX?^(.B1:OX;
MUBSUO39/NW%G*'7/7!QT/L<&N&U+]J;X3Z/H4&L7OCK2;;3;BZELXII'8;YH
MR!(H7&?E)&3C'/6OGWX;>$+3]G/]NB7P7X4WVG@_Q;H;W[:5YA9+>>,D[E!Z
M#@X[X;&>*YG]A/X#^#?B5IOC[7_%^A67B:2/6Y]/M(-3B$T5M&#N?8C< L6&
M3C/%5RK<CFELMSZ,\/Z?\*]6_:6F\4:7XCDO/B)>Z#&?[/2X8PFP8(4E";<<
MC;SN[]*[:;XZ> +35_$NEW'BO3K:^\-HDFKPS2&/[&K_ '=Y( Y[8)KYZ\-V
ML-A_P4CU>VMXEAMX?!T4<<2#"HH$0  ] *X;P/\ !_0OB]^WI\8(_$UJ-4T;
M2?L]TVES,?L]S*418S*G1POS$*>,FCE77L',^G<^OOA_\=?A_P#%.UOKCPKX
MMTS68K%2]T89MIA4=68-@A?]KI[U0\*_M)?"_P ;^*7\-Z%XWTC4];5VC%G#
M/\S,.H4D88_[I-?(7QO_ &?_  IIO[9'P]\+>';(>%] \5:?(FM6.D$V\5S#
M&Q+1X7  <!0<>GK6M^W1\$?!'PE\&^ _%'@KPY8^%M:LO$EG:I<:7$(2T9#'
MYL?>.4'S'GKZT<L=/,.:6K['VSXJ\8:'X'TE]4\0:M9Z-IZ$*;B\F6-,GH 3
MU/L*\^\+_M8?"#QIK$6E:/\ $#1KN_E.V.$S&,L2<  N "2>V:\N_;(B^#MI
MKG@[6_BQJNJW_P!BWG3_  C8GS8KUS]Z1X57<<<#.X#@#GD5\H_M#^./AWX^
M^%>HR^"OV?M4\)O:,LG_  DTFG)8+:$,,[O+SN&,#D]31&"82FXGZ;^,_B!X
M>^'EG97?B/58-)M[RZCL;>2?.))WSL08!Y.#7$:G^U9\(]'U/5].NO'FE)>Z
M2&-]$CLY@"L%;.U2#@D XSBOG;]MFZNM4_8_^'$SW,GVVYOM+S<[OGWM"PW9
M]<G.:]Z\,_LJ_#?0_ 4ND6/A73;6]OM&DTRZU18%-U,LJ 2,TA^9B6PV2>H%
M*R2NRN9MV1ZOX?U_3O%6B6.L:3=QW^F7T*W%M<PG*2QL,JP^HK%\-_%'PKXP
M\4:[X<T;6[;4=;T-Q'J5G#N+6K$D .<8SD'OVKYB_9+^+3?#']G7QYH?B655
MU3X87-Y:3)(3\T8+-#[X9L@>Q%=-_P $^_!-WI?P?O?&NKJQUWQOJ$NL3R2#
MYC$6(B'TQN;_ ('2<;7!2O8^H:***@T"BBB@ HHHH **** "BBB@ HHHH **
M** "L'Q'_KH?]T_SK>K!\1_ZZ'_=/\ZJ.Y,MC'HHJ189)%RL;,/4*35F)'14
MOV6;_GC)_P!\FFO#)'@NC(#TW B@!E%*JEVPH+'T HH 2BI?LLQ_Y92?]\FF
MO$\>-Z,O^\"* &4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'P3_ ,%-/^1@\!_]>MU_Z''7Q17VO_P4T_Y&#P'_ ->MU_Z'
M'7Q17['D?_(NI?/\V?EF<_[_ %/E^2"BBBO=/%"BBB@ HHHH **** "BBB@
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M^TKX)\<^"?VAO"_QB\.>"V^(^DV>F'3KO1XEWSVY)/SQI@G)!X8 X.<BO/\
M]HCQM\>/VFOA=JFE:3\(-5\'^&84%Q?1:@2]_>E&!$44>U6(S@X"\XZU^@U%
M"E:V@G"]]=SXM_:4\*>)O&W[(GPNL],\,:Q<ZO#>:5)<Z9'8R-<VX2,A_,CQ
MN4*>N:^S+-2MG K J1&H(/;BIJQO&2ZX_A/6!X9DMHO$/V63^SVO5+0^?M.S
M> ?NEL TKWT*4;:GY^?MG_#S6=._:(3PWX9E\FU^+L-I;7\,1^;?!,HD?'H5
MVD_[IK]"_#6@VGA7P]IFC6*".RT^VCM84 QA$4*/T%?-?P1_9_\ B-JGQB;X
MK?&G4-*N_$=E:?8-)TS1\FVM5/WI.>YR?4\DD]*^I:J3V1,%JV+11169H%%%
M% !1110 4444 %%%% !1110 4444 %8/B/\ UT/^Z?YUO5@^(_\ 70_[I_G5
M1W)EL8]>&?%_]E&Q^,'C-_$5QX\\6>'I&@C@^Q:/=". ;,_-@]SGGZ5[G16E
M[&&^Y^>/A7]F\^(/VGO%_P ,9OB-XSBTG1=*CU"&^CU _:)';RLJP)VX_>'H
M,\"OJOX,_L^Z=^S[/KNKCQIXC\1PW5JJS+KLXE2!(RSET [X)S]*\W^&_P#R
MD,^*'_8MP?SMJ^J9(TFC>.1%DC<%61AD,#U!'<5<FR(I;GP)^TO^U%X@^*&A
M6R>!K'4M*^'D.J6]O=>(W#6[ZA,7&V.(\$)QDXY/&<=*^]K7_D'0$\G[.I)_
MX *^8OV^[*WTWX)>'+6SMXK2UA\06:QP0($1!NZ!1P!]*^G;7_D&P?\ 7NO_
M * *3V5BHWOJ? G[._[.O_#0&F^+]<U;XA^,-'FLM?N;*.#3K\^64#%@?F)Q
MUQQQ78^/_P!G_P"(7[-6A7'CCX;?$;7?$$.EXN=0T;7I/.$\(^^?0@#M@'&2
M#Q77?\$_O^1%\?\ _8UW5?1'CHPCP/XD-SC[,-+NC+NZ;?)?.?PJFW>Q*BK&
M1\'?B99?&'X:Z'XML$\F/4(-TL&[/DRJ=LB9]F!_"NRKYB_X)V^;_P ,\@M_
MJ#JUS]G]-GR]/QS7T[42T9:=U<****D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\$_\%-/^1@\!_P#7K=?^AQU\45]K_P#!33_D8/ ?
M_7K=?^AQU\45^QY'_P BZE\_S9^69S_O]3Y?D@HHHKW3Q0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% 'P3_P4T_Y&#P'_P!>MU_Z''7Q17VO_P %-/\ D8/ ?_7K=?\
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M_NG^=;U8/B/_ %T/^Z?YU4=R9;&/1115F(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P3_ ,%-/^1@
M\!_]>MU_Z''7Q17VO_P4T_Y&#P'_ ->MU_Z''7Q17['D?_(NI?/\V?EF<_[_
M %/E^2"BBBO=/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***T_#/AG5/&6O66BZ+92ZCJ=Y((H+>%<LS'^0'<]J4
MI**;;T&DY.RW%\,^&=4\9:]9:+HME+J&J7D@B@MX5RS,?Y#U/:OU%_9A_9@T
MOX!Z"+N[$6H>,;R,"\O@,K I_P"6,7HH[M_%]*7]E_\ 9ATOX!Z"+N[$6H>,
M;R/%Y?@96!3UAB]%'=OXOI7N=?E^=9T\6WAZ#_=]7W_X!^BY3E*PJ5:LO?\
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M4 %%%% !1110 5@^(_\ 70_[I_G6]6#XC_UT/^Z?YU4=R9;&/1115F(4444
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M^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\
MA6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?
M^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[
M_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U1
M1?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U
M_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^
M%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"
MWF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_
MQ_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W
M^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8O
MVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH
M^U:[_P ^%K_W^/\ A6U11?R"WF8OVK7?^?"U_P"_Q_PH^U:[_P ^%K_W^/\
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M_@L7_P".U^9E%=_^K6!_O??_ , X_P#6#&>7W'Z9_P##Q#X2>GB+_P %B_\
MQVC_ (>(?"3T\1?^"Q?_ ([7YF44?ZM8'^]]_P#P _U@QGE]Q^F?_#Q#X2>G
MB+_P6+_\=H_X>(?"3T\1?^"Q?_CM?F911_JU@?[WW_\  #_6#&>7W'Z9_P##
MQ#X2>GB+_P %B_\ QVC_ (>(?"3T\1?^"Q?_ ([7YF44?ZM8'^]]_P#P _U@
MQGE]Q^F?_#Q#X2>GB+_P6+_\=H_X>(?"3T\1?^"Q?_CM?F911_JU@?[WW_\
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M1]MAKN*W75>?I^1[N69TL5+V.(TET[/R]3ZDHHHKXP^J"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"E7[P^M)2K]X?6@#Q+]F3_CY^+'_ &.=W_Z E>V5XG^S)_Q\_%C_ +'.[_\
M0$KVRN_'?[Q+Y?DCBP?\"/S_ #84445P':%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 J_>'UKM%^Z*XM?O#ZUVB_=%3(T@+1114&@4444 %%%%
M !17.>(OB3X2\'W"V^O>*=%T2=N5BU'4(8&/T#L#W'YUJ:+KVF>([%+W2=1M
M-4LW^[<64ZS1M]&4D4 7Z*2N4OOBUX'TO4CIU[XS\/VFH!@IM)]4@27)Z#86
MSG\* .LHJ.&:.XA26)UEC<95T.01Z@CK3Z %HK TCX@>%_$&LW6D:7XCTG4M
M6M=WGV-G?12SQ;3AMZ*Q9<'@Y'6I?$WC;P]X+A@F\0Z]IFA0SL4BDU*\CMUD
M8#)"ER,GZ4"-JBN'7XZ?#:1E5?B#X69F. HUJV))/;[]=NK!E# Y!Y!H"XM%
M8=KXX\.7OB*;P_;Z_I<^O0@M+I<=Y&UU&!C):(-N&,CJ.];E PHHHH ****
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M+>*H=$MH;*"]\,I?36\"A429V4-A1TSM#?\  J^QJF72PX=;A1114&@4444
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M% !1110 4444 %%%% #)O]1+_N-_(UXW^Q[_ ,D%TG_K_P!0_P#2J2O9)O\
M42_[C?R->-_L>_\ )!=)_P"O_4/_ $JDKT*?^YU/\4?RD<<_]YA_AE^<3V>B
MBBO/.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *\5_: _P"2@?!/_L:U_P#1+U[57BO[0'_)
M0/@G_P!C6O\ Z)>O0P/\=>DO_26<>,_@OUC_ .E(]JHHHK@.P****0!1110
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M\$!AU'N#@CZ5OT5)1\2>'?A'^U-\$='/@CP/KGAGQ%X2C+1V&HZKE+FQB).
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M8^ /P=\7>#=)UZ]^)'C*Z\:>(=>;-U TKFPM(\$>5!$?E4')R0!V':O%-/\
M@'\>_P!G/5-2TOX,ZOH6N>!]0N7N(--\0$A]-+'G;R,_@><<C-?:6**.9AR(
M^3?@7^S?\1/ /[25_P"/O%VK6_B/^U=$\N_U1)0O^F%Q^ZCBQD1*BJH/M7UG
M244F[CC%1T0M%5_[0M?MGV3[3#]KV[_(\P>9M]=O7%%OJ%M>231P7$,TD)VR
MI&X8H?1@#P?K2*+%%%% !6#XC_UT/^Z?YUO5@^(_]=#_ +I_G51W)EL8]>9?
M$#]F?X9?%3Q$VO>*O"D&KZNT2PFZDN)D)1<[1A' XR>U>FT5H8GP5X(_9O\
MAMJW[9WCWP3=^%H)O"VFZ)%=VFG&>8+%*?(RP8/N/WVZDCFOJ[P+\$? 'P+C
MUG5O!WAA=*N)[;_21;32R/.D>65 '9N<YQCUKQOX;_\ *0SXH?\ 8MP?SMJ^
MK*N39$4C\Z_VH/%7Q1^*7A32/%GB+1V\%> 5U>V@TW0+AC]JNW9^)YA[ < ]
M,\>M?H9:_P#(-M_^O=?_ $ 5\T_\%"&+?!W0B3D_\)%9_P#H5?2UK_R#8/\
MKW7_ - %*3T0X[L^'?V1?V=?AS\7/#OC?5?%WAB#6=0M_$MU;Q323RQE8\D[
M<(X'4FNP^.'[%_AGPKX1O?%_PK2Z\&^*M!B-_"+.ZD:.98P6<?,20V 3G.#C
M!'-:W_!/[_D1?'__ &-=U7T'\0]2M]'^'_B>^NW6.VM]+NI)&8X&/*;C\3@?
MC5-OF)458Y+]FWXL/\:?@WH'B>Y54U&6,P7JJ,#SXSM9@.P;&['O7IM?,_\
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MIK"?LJ:KXETGXM_ S_A,?MFIS77_  E;6B7GG1L200\JE0HZ\%3R<CBOIO\
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MYQ/9Z***\\[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KQ7]H#_DH'P3_P"QK7_T2]>U5XK^
MT!_R4#X)_P#8UK_Z)>O0P/\ '7I+_P!)9QXS^"_6/_I2/:J***X#L"BBBD 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2K]X?6DI5^\/K0!XE^S)_Q\_%C_L<[O_T!*]LKQ/\ 9D_X
M^?BQ_P!CG=_^@)7ME=^._P!XE\OR1Q8/^!'Y_FSRC]J#X=ZE\2O@[J=AH5O]
MI\1V4\&I:5'N"L;B&0.H!) &<=SBJ/[)?PSU?X7?"""T\26YM?$VI7UQJ>I1
M,RL5ED<D E202%QT)KV6BN*^ECLMK<^2OVPOV>_%WQ,^(7AK5_"%@]U;:A9_
MV+KTD<J(8K8S(^\[F&0 O09/R]*^KK"QATNQMK*V18[>VB6&-%'"JH  'Y5/
M11>ZL%K.Y\D_M@?L]^,/B9\0/#^H^#[ W%EJEJFD^()%D1!';I<)*KL&8%AQ
M_#D_)7UA8V4&FV=M96XVVUM$D$:^B*H4#\@*FHHOI8+6=SY#^!_[-OBCP7^T
MWK.L:MIIC\$Z3+?W>@W#2(4>2Z9,A5#;@5 '4#[M?7E%%#=P2L%%%%2,****
M "BBB@ HHHH **** %7[P^M=HOW17%K]X?6NT7[HJ9&D!:***@T"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "OAK]NBQ\0ZE^TA\#K?PE<PVGB8_:GTZ6X_U?G(5<*WLVTK_P
M*ON6O OC+\#O$?CW]HCX1^-],EL4T;PK+.^H)<3,LS!Q@>6H4AOQ(JXNS(FK
MJQX[X\\=?M%?M!>'+KX<0?"AO 0U!?LFK>(KZZ+6_DY D,/ X//0L2#@>M7?
MCC^S?XJ^'5M\'O$/PVT:+QB/AY;FVET.YQFX7J947/+%BW3D':><5]HTM'-V
M%R=V?"WQ2\=_M%?M&?#W6/#&C_".;X?Z9-;N-0N-4NMUQ<1JN[R8%*J<MC;P
M"><9%2^,OA_XR\0?\$W=.\)P^$-87Q7;QP6[:&;4BZ_=W779Z;0&SZ&ON2BG
MS=D')W9RWPZL+G3OAGX:L[J"2WNX-)MXI8)!AT<1*"I'8@C%?)OP!_9PUKQ?
M^SY\6O WBW2K[PS-KFN7,UE)?0E#]X-'*!W7('X9K[;HJ5)HIQ3W/ASP;\4O
MVD/@KX0M?A[<_!V;Q=?:; +'3?$5E<$VWE*-L32X!#8 '=3@#/-%_P#LW^.O
M"W['/Q-M=6%WXG^(WBZ5;^YT^R9IS&WFH1#&,XX&XG;QSQP*^XZ*KG[(GD[L
MX3X0Z#-:_!7PGHVKV<EO,NB6]K=V<Z[70^2%=&'8]0:^5?"-E\;OV,;S5?#&
MA>!)OBM\/9[R2ZTM]/F*75MO.2C8#%1Z@KC/(/)K[EHJ5(;C<^=/@MXD^.WQ
M,^( \1>+])@^'/@.& K%X:D2.:]NY".&DD9=R 9SQMS@#'4UY%'I?Q9_95^-
MGQ UG0OAC+\3O#_BZ]-_!>:?)BZ@/)V.P5BH&XC!&#@$&ONBBGS>0N7S/SQ^
M)6E_M ?%+XI?#;X@>)?A]/IOA[2=:A^R^']-/VFYM8V(,D\X'/08).,8Z>OI
M'[2&B_$/X=_M0>%_BWX/\!WGQ TZ'19-,GL-/?$JR$R9S@$J-K*0<$9R*^QJ
M*?/Y!R>9\H_%OPKXJ\9?M.? #Q7;>&-273;."2;4Y%B+)IS/&3Y<K=B"<5D?
M%#X9?$SX%?M :Q\7/AAH*>--*\0P+'K?A\2;9PRX^:/N<E000#@DY!%?8M%+
MF'R'Q;IWAWXN_M7?%CPCKGC3PI=?"_P'X7G^V?V7/=-]IOY\CY6P%)4E1U
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M* "BBB@ HHHH **** "BBB@ HHHH ^"?^"FG_(P> _\ KUNO_0XZ^**^UO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?ZB7_<;^1KQO]CW_ )(+I/\ U_ZA_P"E4E>R3?ZB7_<;^1KQK]CW_D@ND_\
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MVJ*.8+&+_9NL?]!9?_ <?XT?V;K'_067_P !Q_C6U11S!8Q?[-UC_H++_P"
MX_QH_LW6/^@LO_@./\:VJ*.8+&+_ &;K'_067_P''^-']FZQ_P!!9?\ P''^
M-;5%',%C%_LW6/\ H++_ . X_P :/[-UC_H++_X#C_&MJBCF"QB_V;K'_067
M_P !Q_C1_9NL?]!9?_ <?XUM44<P6,7^S=8_Z"R_^ X_QH_LW6/^@LO_ (#C
M_&MJBCF"QB_V;K'_ $%E_P# <?XT?V;K'_067_P''^-;5%',%C%_LW6/^@LO
M_@./\:/[-UC_ *"R_P#@./\ &MJBCF"QB_V;K'_067_P''^-']FZQ_T%E_\
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M_8H^S7G_ #^+_P!^Q5RBBX%/[->?\_B_]^Q1]FO/^?Q?^_8JY11<"G]FO/\
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M*YUE/[->?\_B_P#?L4?9KS_G\7_OV*N447 I_9KS_G\7_OV*/LUY_P _B_\
M?L5<HHN!3^S7G_/XO_?L4?9KS_G\7_OV*N447 I_9KS_ )_%_P"_8H^S7G_/
MXO\ W[%7**+@4_LUY_S^+_W[%'V:\_Y_%_[]BKE%%P*?V:\_Y_%_[]BC[->?
M\_B_]^Q5RBBX%/[->?\ /XO_ '[%'V:\_P"?Q?\ OV*N447 I_9KS_G\7_OV
M*/LUY_S^+_W[%7**+@4_LUY_S^+_ -^Q1]FO/^?Q?^_8JY11<"G]FO/^?Q?^
M_8H^S7G_ #^+_P!^Q5RBBX%/[->?\_B_]^Q1]FO/^?Q?^_8JY11<"G]FO/\
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M+B*?V:\_Y_%_[]BC[->?\_B_]^Q5RBBX%/[->?\ /XO_ '[%'V:\_P"?Q?\
MOV*N447 I_9KS_G\7_OV*/LUY_S^+_W[%7**+@4_LUY_S^+_ -^Q1]FO/^?Q
M?^_8JY11<"G]FO/^?Q?^_8H^S7G_ #^+_P!^Q5RBBX%/[->?\_B_]^Q1]FO/
M^?Q?^_8JY11<"G]FO/\ G\7_ +]BC[->?\_B_P#?L5<HHN!3^S7G_/XO_?L4
M?9KS_G\7_OV*N447 I_9KS_G\7_OV*/LUY_S^+_W[%7**+@4_LUY_P _B_\
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M (.&_P#C-'_#SFY_Z)S;_P#@X;_XS7P]11_8.7?\^OQE_F']M8__ )^?@O\
M(^X?^'G-S_T3FW_\'#?_ !FC_AYS<_\ 1.;?_P '#?\ QFOAZBC^P<N_Y]?C
M+_,/[:Q__/S\%_D?</\ P\YN?^B<V_\ X.&_^,T?\/.;G_HG-O\ ^#AO_C-?
M#U%']@Y=_P ^OQE_F']M8_\ Y^?@O\C[A_X><W/_ $3FW_\ !PW_ ,9H_P"'
MG-S_ -$YM_\ P<-_\9KX>HH_L'+O^?7XR_S#^VL?_P _/P7^1^C'P?\ ^"@V
MB?$#QE;Z%XET&/PC%=X2VU#[:9XO-)X23*+L![-R,]<5]:U^&7MVK[=_8Y_;
M%^P_8? 7CV^S;?+#I6M7#?ZOLL,S'^'LK'IT/'3YS-\@C3A[?!K1;QW^:_R/
M?RO.G4E['%O5[/;Y,^\****^!/LPHHHH **** "BBB@ HHHH **** "BBB@!
MDW^HE_W&_D:\;_8]_P"2"Z3_ -?^H?\ I5)7LDW^HE_W&_D:\;_8]_Y(+I/_
M %_ZA_Z525Z%/_<ZG^*/Y2..?^\P_P ,OSB>ST445YYV!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7BO[0'_ "4#X)_]C6O_ *)>O:J\5_: _P"2@?!/_L:U_P#1+UZ&!_CK
MTE_Z2SCQG\%^L?\ TI'M5%%%<!V!1112 **** "BBB@ HHHH **** "BBB@
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M?%'PMH/CO1_!FH:S#;>)]8B>>PTUE<O/&N[<P(&T8VMU(Z5U.*?-(GDB>/\
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M_KUNO_0XZ^**^U_^"FG_ ",'@/\ Z];K_P!#CKXHK]CR/_D74OG^;/RS.?\
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M/\4?RD<<_P#>8?X9?G$]GHHHKSSL"BBB@ HHHH **** "BBB@ HHHH ****
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M[A8\A_9?^#NH?!?X5KI&N20W'B2]N9KW4KB"0RJ\K\+AR 6PH7GUS7-_L_\
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M$_\ T+.M?^"Z;_XFC_A _$__ $+.M?\ @NF_^)H]I#^9![*I_*_N,.BMS_A
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M_P!#%I/_ (&Q?_%4?\)YX:_Z&+2?_ V+_P"*K3V<^S(]I#N;M%87_">>&O\
MH8M)_P# V+_XJC_A//#7_0Q:3_X&Q?\ Q5'LY]F'M(=S=HK"_P"$\\-?]#%I
M/_@;%_\ %4?\)YX:_P"ABTG_ ,#8O_BJ/9S[,/:0[F[16%_PGGAK_H8M)_\
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MO_BJ/9S[,/:0[F[16%_PGGAK_H8M)_\  V+_ .*H_P"$\\-?]#%I/_@;%_\
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M%_\ %4>SGV8>TAW-VBL+_A//#7_0Q:3_ .!L7_Q5'_">>&O^ABTG_P #8O\
MXJCV<^S#VD.YNT5A?\)YX:_Z&+2?_ V+_P"*H_X3SPU_T,6D_P#@;%_\51[.
M?9A[2'<W:*PO^$\\-?\ 0Q:3_P"!L7_Q5'_">>&O^ABTG_P-B_\ BJ/9S[,/
M:0[F[16%_P )YX:_Z&+2?_ V+_XJC_A//#7_ $,6D_\ @;%_\51[.?9A[2'<
MW:P?$?\ KH?]T_SI?^$\\-?]#%I/_@;%_P#%5B>(/''AR2:';X@TH_*>E[%Z
M_P"]3C3G?9DRG&VXZBL?_A-/#W_0?TO_ ,#8_P#XJC_A-/#W_0?TO_P-C_\
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M_P# V/\ ^*H_X33P]_T']+_\#8__ (JCV<^S#GCW-BBL?_A-/#W_ $']+_\
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MI?\ X&Q__%4?\)IX>_Z#^E_^!L?_ ,51[.?9ASQ[FQ16/_PFGA[_ *#^E_\
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M_P#%4?\ ":>'O^@_I?\ X&Q__%4>SGV8<\>YL45C_P#":>'O^@_I?_@;'_\
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M ,)IX>_Z#^E_^!L?_P 51_PFGA[_ *#^E_\ @;'_ /%4>SGV8<\>YL45C_\
M":>'O^@_I?\ X&Q__%4?\)IX>_Z#^E_^!L?_ ,51[.?9ASQ[FQ16/_PFGA[_
M *#^E_\ @;'_ /%4?\)IX>_Z#^E_^!L?_P 51[.?9ASQ[FQ16/\ \)IX>_Z#
M^E_^!L?_ ,51_P )IX>_Z#^E_P#@;'_\51[.?9ASQ[FQ16/_ ,)IX>_Z#^E_
M^!L?_P 51_PFGA[_ *#^E_\ @;'_ /%4>SGV8<\>YL45C_\ ":>'O^@_I?\
MX&Q__%4?\)IX>_Z#^E_^!L?_ ,51[.?9ASQ[FQ16/_PFGA[_ *#^E_\ @;'_
M /%4?\)IX>_Z#^E_^!L?_P 51[.?9ASQ[FQ16/\ \)IX>_Z#^E_^!L?_ ,51
M_P )IX>_Z#^E_P#@;'_\51[.?9ASQ[FQ16/_ ,)IX>_Z#^E_^!L?_P 51_PF
MGA[_ *#^E_\ @;'_ /%4>SGV8<\>YL45C_\ ":>'O^@_I?\ X&Q__%4?\)IX
M>_Z#^E_^!L?_ ,51[.?9ASQ[FQ16/_PFGA[_ *#^E_\ @;'_ /%4?\)IX>_Z
M#^E_^!L?_P 51[.?9ASQ[FQ16/\ \)IX>_Z#^E_^!L?_ ,51_P )IX>_Z#^E
M_P#@;'_\51[.?9ASQ[FQ16/_ ,)IX>_Z#^E_^!L?_P 51_PFGA[_ *#^E_\
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M6/\ P%C_ ,:^XJ6C^W,Q_P"?K^Y?Y!_8^ _Y]?B_\SX<_P"'6'AG_H?-8_\
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M9_Z'S6/_  %C_P :/^'6'AG_ *'S6/\ P%C_ ,:^XZX?XM_$S_A5OA^TU/\
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M:Q_X"Q_XU]R44?VYF/\ S]?W+_(/['P'_/K\7_F?#?\ PZO\,_\ 0^:Q_P"
ML?\ C1_PZO\ #/\ T/FL?^ L?^-?<E%']N9C_P _7]R_R#^Q\!_SZ_%_YGPW
M_P .K_#/_0^:Q_X"Q_XT?\.K_#/_ $/FL?\ @+'_ (U]R44?VYF/_/U_<O\
M(/['P'_/K\7_ )GPW_PZO\,_]#YK'_@+'_C1_P .K_#/_0^:Q_X"Q_XU]R44
M?VYF/_/U_<O\@_L? ?\ /K\7_F?#?_#J_P ,_P#0^:Q_X"Q_XT?\.K_#/_0^
M:Q_X"Q_XU]R44?VYF/\ S]?W+_(/['P'_/K\7_F?#?\ PZO\,_\ 0^:Q_P"
ML?\ C1_PZO\ #/\ T/FL?^ L?^-?<E%']N9C_P _7]R_R#^Q\!_SZ_%_YGPW
M_P .K_#/_0^:Q_X"Q_XT?\.K_#/_ $/FL?\ @+'_ (U]R44?VYF/_/U_<O\
M(/['P'_/K\7_ )GPW_PZO\,_]#YK'_@+'_C1_P .K_#/_0^:Q_X"Q_XU]R44
M?VYF/_/U_<O\@_L? ?\ /K\7_F?#?_#J_P ,_P#0^:Q_X"Q_XT?\.K_#/_0^
M:Q_X"Q_XU]R44?VYF/\ S]?W+_(/['P'_/K\7_F?#?\ PZO\,_\ 0^:Q_P"
ML?\ C1_PZO\ #/\ T/FL?^ L?^-?<E%']N9C_P _7]R_R#^Q\!_SZ_%_YGPW
M_P .K_#/_0^:Q_X"Q_XT?\.K_#/_ $/FL?\ @+'_ (U]R44?VYF/_/U_<O\
M(/['P'_/K\7_ )GPW_PZO\,_]#YK'_@+'_C1_P .K_#/_0^:Q_X"Q_XU]R44
M?VYF/_/U_<O\@_L? ?\ /K\7_F?#?_#J_P ,_P#0^:Q_X"Q_XT?\.K_#/_0^
M:Q_X"Q_XU]R44?VYF/\ S]?W+_(/['P'_/K\7_F?#?\ PZO\,_\ 0^:Q_P"
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M"O\ L.1_RKVW4_"^EZQJVE:G>6BSWVEN\EG,68&%G7:Q !P<CCG->)?M@?\
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M1C:F%&%QZYZ5A>"_V>_#OP_\:2>(M'O-3@+B0?V<TX:U&\<_+MSQVR:]0I:
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MT)KU/6O"&C>(M0TR_P!2TZ&\O-,E\ZSFE&6@?CYE]^!^5;% &)XE\&Z-XO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO&-L;:<@87[2GW23ZG _.F_%F,?$KX\>#/!@7S]/TD'5]03&5R/N _@/_'J
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MX[DR]E8O_8^FL>FU?OL/R_\ 'J][H *:[K&C.[!549+,< #UIU>5_M*>.?\
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M#!?NG.>*\-^,NCVGC#]FC2O$VK1M=ZW8V$,D%T78%6<HK,0#@DCUIGBA=/\
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M#NR>O?(Q5CXN:I+X@TKX(:C=?O+BXU""5V(Y+$1Y/YT ?2[N(U+,0JJ,DDX
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MMEN+*YAO+=N%FMY Z'Z$'%?+VF^+HOVC_$FE^"8[]]*\):?9QS7,62D^JE
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M7BO![_Q+XG^ ;:K\---C:_.J.#X9NV<?N$E8JRMG^[SCWY[UTWC?X#Z!X/\
MV>-2@N[<7NKV$,FI27VY@SW97!<X/S = #F@#U3X2^-4\5_#W2=1O=3M;K43
M:+->E)$!C8Y)W 'Y?Q]*Z63Q1HT4=L[ZO8HER,P,UR@$O./E.?FY]*\;^$W@
M'0_#7P'O=8TZS\C4-8T.22]E,C-YK"-\'!.!U/3%<I^SS\#?#WCSP#I?B+Q-
M#-JEVDI2R5IW2.VBC?Y555('+;B<^M 'TOJ&K6.DPB:^O;>RA/22XE6-3^)-
M)INLZ?K$;/I]];7R*<,UM,L@'UVDU\Z?%+P[\-]-\=:GJ7Q,\7/JSS!1::'$
M)$%G%V&V-B3V.>.YKA_"&L>#]+^.7A!OANFJ:?IUU*UO>1W.\0S*0?NASD^O
M/M0!]A3:YIMO)<I+J%K&]JH>=7G4&)3T+C/R@^]2V.I6FJ6PN+.ZAN[<])8)
M Z?F#BOF34/ =K\2/VGO%>C:G)-_8@M8+F\M89#']H*HH16(YP"<TWXZ/H?P
MOM?"_P /-/O)_"_A*\>2[U.>V+R2F,M]P'ECDY_(>E 'TI9>)-(U*Z:VM-5L
MKJY7.88;A'<8Z\ YJQJ&I6FDVQN+ZZALK<$ RW$BQH">@R3BOB_Q!<? :VT.
M67PKK>I:/XDMT,EI?1K<EGF494-D8P3W&,9KM/BCXTF^(7[(ECK-[MDNY9H(
M[@XX9TD*EOQQG\: /I.\\2Z1I\T<5UJMC;2R %(YKE$9@>A )YK15MR@@Y!Z
M8KY_TG]EGPMK7@>"\UN2]U'Q%=6BSOJDER^Y)"@(VKG;M' P0>E5_@7<:KXH
M_9_UC29/$;:/-9W$]DNKR+O,$*D$D98=!D YXS[4 >Z77BS1+&Y-O<ZSI]O<
M X,,MTBO^1.:FUB;_B0WTT,G_+M(Z2(?]DD$$5\C3:?^SSH]F+&ZO+_Q/K")
M^\O;0SO)*W=EP=@YR<<_C7>?LN:M-??#+QA9^?<RZ?97,RV:W9S)'&T9.T^G
MT]2: .M_93UB_P!<^$-K=:E?7.H71O+A3/=2M*Y ?@;F).!7L%>)_L?_ /)%
M;3_K]N?_ $97LUYYWV6?[/C[1L;R]W3=CC/XT 4]0\2:3I$RPWVJ65E*PRL=
MQ<)&Q^@)JU)?6\5FUV]Q$EHJ>89V<! N,[MW3'O7Q'X5G^'+:AJEO\7;+5SX
MLDO9#)=732[ ,\;0AR/Q!'2OH7X*^"M#M/"^O:?I'BM?%GA34'98;5\.;164
MAHRVXYR".PZ>] 'K%G>V^I6L=S:7$5U;R#*30N'1AZ@C@U&NK63:@U@MY;M?
M*N]K42KYH7U*YSBO$_V9M1;POI_BOP1J4OER^&;Z0HTA_P"79LLK?3C/XUB_
M!FUU+QE-\2OB/:1_\334FFL])+#E41?E S_P ?@: /?KSQ/H^FW0MKO5K&UN
M3TAFN41_R)S4NK:M;Z3I<][/<PP0QH6$LT@1,XX^8G'-?$_@%OA)=V!L_B-;
M:M;^,&D<75[>O,,.6ZC:> /]H=0:]_\  _PUT+4?A%J6@S>)!XX\,32/-:,&
M*F%!\PC+JY)P1[?2@"_^SW\4+GXC>$YKK6-0LWUE[V8+:0LJLD2XVX3.<>YK
MTC4M?TS160:AJ-I8E^5%S.L>[Z;B,U\S?LX^'M"\*_"S5_B']@W:_8_;(EN#
M(V#&H&%VYV]>^,UPWA+7OA)XDM)-9^)NM7VL>*+UVDGA9+@16W/RJFP<X&.^
M/:@#[>AFCN84EAD66)QE7C8,I'J#WJHNO:9(MVRZC:,+,[;DB=?W!]'Y^4\=
MZ^:?V>_'>C:;\6;WPGX4UFZU?PA?6K75K'>!@]K,N-RC< <$?TJG\./AA:?$
MKXL?$VWU>:X;0+?5WDFT^WE,2W,Q=PA<K@D*-W&>IH ^IM/U6RU:W^T6-W;W
ML&<>;;RK(N1U&0<5%I^OZ9JTTD5CJ-I>2Q_?2WG61E[<@'BOEH_"J+0?CQ-X
M T#4KW2/"NKV*W5[:PS'=Y:Y)16/(R1C/7#'K5[XC?#'1O@E\0?AYJ_A!9],
M>^U1;.YA\]W6125!SN)/(8@]J /<=0\.K-\4M-U<^+)[9X;1HAX=6<".?.?W
MI3=DD9ZX[5UFH:E::5;F>]NH+.'.#)<2!%_,FO#_ !(H_P"&OO"YP,_V++SC
M_?KF_#OA.#]HSXI>+[[Q/<7%QX>T.X^Q66FQS%(VY/)Q_NY..23UXH ^E-/U
M*TU:W$]E=P7D!./,MY!(N?J#5JO&?"'P)N_AE\3(=4\(ZA':>$KB$QW^D74T
MCMNYVF/@C@X/)SU%>RT >'_LP^)+O4/"OBR[UG5)KE+;6IU$]]<%A%&%7C<Q
M^51^5>U6=];ZA:QW-K/%<V\@RDT+AT8>Q'!KY9^%H#?L_?%L$9'VR^_]%K7L
M/[-BA?@AX3 &!]E[?[[4 >@VNK65[<SV]O>6]Q<6YQ-%%*K/&?1@#D?C5<>)
MM(:SEO!JMB;2)_+DG^TIY:-_=+9P#[5XK\#5"_'#XL$  F[3/'UK@/@!\&=.
M^)EKXAN/$,MQ<:%:ZM.D&F12F*-YC@O(Y4@DXV 4 ?6EC?VVI6Z7%G<17=N_
MW98'#H?H1Q3+/5K+499X[2\M[J2W;9,D,JN8V]& /!]C7SQH_AO_ (4'\=M!
MT;1+JX;PMXFC=&L)I"X@E7."N?0XYZX)ZUI_LTJ%\=?%C  SK;9P/]IZ /=)
M]6LK6]ALYKRWBNYAF*WDE59'_P!U2<G\*74-4L])A\Z^NX+*'./,N)5C7/ID
MFO#/BDH/[37PS) )$$V#CW-<+\:;G2+;XY7;?$VSU2\\)FT1=,6U9A #QDG:
M02<YZ'.<=J /JW3]4LM6A\ZQO+>]ASCS+>59%SZ9!JU7SM\'?#/@+_A/+;6/
MAQXO:TM/(9;SP[)O8S+V;#L&7!P>A_"OHF@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAKVL0>']%OM3N6VV]I"
M\SGV4$U?I/PH ^?_ -F7PG'XETG7_&OB#3X;J^\07[RQK=PARD2D@8##CDG\
MA7>_%;X4Z1XN^'VMZ;9Z59V][);L]O)!;HCB1?F4 @=R,?C7H=+0!\5>)O&%
MYXQ_9P\*V[*YUK2-<AL'5U.=RJ_EL?;&!GV->I:I^U!<Z;I[Z')X/U@^.E7R
M/L/D;H6EQC>KCEE/7@=.]?0.T>E+[XYH ^<1\/=0\ _LK^*;?55_XG-_%)?7
M2+R4=V7Y..I _4FJ/P^_:&/PU^'>A:1XH\.ZJ;I;*,Z=-9PAXKN$K^[^8D;2
M!A2.>E?3F*-H]* /G/P)X8UZ\\._$SQ[XBL6TR^\06,RVU@X.^*!8VQD'D9X
MZ\\>]=O^R^K+\#_#8965MDG##!_UC5ZK1]!0!\L^;_PSWXX\0Q^(_";:[X1U
M6Z-Y::E;VBSO;ECRAR/?&"1TR.M=3X5^)D/Q&\7:9;^"_A] FC))OOM8U:Q6
M$1*#TC"_Q\''->^XH_"@#R?]I;PE-XB^'$FHV"DZMH4R:G:LHRP*'+ ?AS^%
M<Y^S%;W?BW4/%?Q%U2 PWFM7(MX$8'*0H!P,]L[1_P !KWNB@#P;X21R?\-!
M?%C 9"WD[6*G&>:\X\"^+-"^#&L>(-/^('A"]N]>GOI9DU(6:W/VB-FXQN(X
M]QG.:^P/PHQ[9H ^2[/QIJ?BC]H;P3K5_P"&[GPWHL@DM--CN(MAD&#ESQP2
M2/TZUN:UXR@^$/[2^OZKKEAJ#:;K5E!!:W%K!O!;Y,]QP""#Z5],8]J,9ZC-
M 'A%VC?\-A6+;6V?V"XW8X_.N7\/^)-0_9?\3>(-+UO1+[4/"6H7;7EEJ5A%
MOV;OX2.F>@(R.F>AKZ?Q[48H ^9KC5]5_:5^(7AF73M%O-+\&:'<_;);Z_CV
M-</D':!TSP!@$XR2:W&1O^&RD;:VW^P?O8./SKWW\*.^<4 >&?M?(S_#W2@J
MLY_M>WX4$]S4GQ.\=^(OAYXCL+O4M&_X2+X=W-FJSPP6BR26TP'+-GJ,#//'
M)':O;\9HH ^.]3A\.?&#QAX>_P"%;>#;[1[VWODN+W6'@^S11(I!((!(SZ=#
MVKZ5\6_$_2?!?B30-#OH;V6\UIS';O;PAXU(('SG(V]?>NOQCIQ1CVH *\&_
M:FU2ZUJW\-^ =.W&\\07J>?M!(6%6'7V+<_\!KWFC'M0!@:?X#\/:;86UI'H
MNGM';Q+$K/:QEB%  R<<GBO"_C!91_![XS>$/'&GVJVVD7>;#48[6+"@="=J
MCKM.?^ 5])T$9ZT ?._P)TF+XF>/_''CW5K*.ZM9[C[!I\=U$&41(0<@,/0+
MS]:]>\3?#70/$7A_4=,.D6$!NH'B$L=LBLA(P&! SP<&NJHH \)_9/\ $EU_
MPC&J^#M4#QZEX=NGA"R @F(L<?DP8?B*YSX[7E_\(OB5-XITJWD>+Q+I,VG2
M")20MTH'EO@?\!_6OIG'MS1^% '$_!GP2/A_\-]%TAEVW2Q":Y]3,_S-GW!.
M/PJ;QE\4M'\"^(?#^CZC%>/=:Y*8K9K>(-&K J/G)(Q]X>M=C7+>,/!LGB[4
MM :6Z6'3=-O!?2P*F7GD0?NQGLH))/K@4 =37SOXX3_A:G[26@>'#'Y^B^&H
MC?789,QM*<$*<\'^ 8^M?1%)CF@#(_X0_0?^@'IO_@)'_A7@_@)3\(_VDM=\
M,^68=#\2(+NS"J1&DG)"CL/XU_*OH^C'MS0!X1\"49?B]\6"RL ;],$@@'@U
MK_M"?#^^U73[+QAX<!C\4^'B9X3&/FGAZO&?7C) ^OK7L&** /G[]DVR37/A
M+K=O>P?N;[4;A98V4@%71<C!^IKG_"OB;Q'^R_<7GAS7M#O=:\'^>TUCJMBF
M\Q(QY![?\!)'.<<&OJ'I10!\V^+/CUJGQ=TJ?PS\.O#FJ27&H+Y$^HWT/E1V
MZ-PW<@<=R?7BL[XJ>&)=$\+?#WX.Z=/)<W%_.DE_/AB"@;))]%+%C_P 5]1X
MQT%&._>@##M? WAZSM8;=-$T\I$BHNZUC)P!@9.*\(^)EFGP=^/7A7Q;86JV
MVBZNO]GWT=O'MC4\#.%'H5/_  $U]*4A&>HS0!PVI?!'P#KFH7.HWOA;3KN\
MNY#--.\>6D9N2Q.>]>4?M!^#8_"LW@6^M/#C:GX'T.5_M6CV:G9&#R&*^GZ<
M8[U](44 ?*_B_P"-&G^,/!FIZ+\.O U]YT]NT=S=MIZPI;1!>3\N<G;G&2/Q
MK5\,^)O%>B?L^^"-7\)6JZG;6):+5M,,&^6:$.0P7/((QV'1L]J^D\8Z"C&.
M@H ^/?B!XV\ _%72+C3O#_P[U&7QA<+Y<+1V0A\AR<%BRGD ]<CGVKU'Q')X
M]^%OP[\%O86RZ];Z=$D&N:<L0FEDCP/N-UXZ<"O<<8[44 ?&_P 0O%7@7XO:
M7+IOA+X?:@_B^ZVI'.EF(! Q/+,RDY4'.<@5Z%\3_A[XG\.Z=\/_ !;I,#:U
MK?A:%(;RU3+/-'@;MO<X^8'OSGM7T-C':B@#YSU_]J1?%6@W.C>%O"NMW'B>
M[C:W^SRV^$@9@5+9!R<?0>]37WP U7_AFR+PI&ZMXCAD_M+:K#:9]VXQ@_[O
M&?45]#8[XYI: /G#3?VJ3H_AV+1]2\)ZTGC*WA$"V2VQ\N20+@-GJ <9Q@UR
MOCK2_%UK\/\ P%/XRN[B\UJ\\2QW)BFPQMHR1MCX'&.OMFOKC'?'-&/:@#YT
M_:0L9=+^(7A+Q1JVAS^(O"%A%)'=6L*EQ%(3]]E^F,9X.W%<Q\2?C!:^// .
MKZ1X \$7T=K+ QO]0>P6!((EY; 7.20/7IGBOK*C'M0!\_:W97'BS]C^&'2X
M)+JX_LR';!&A+ML<;@!UR,$_A6-+=0_M"? H:1X<MKJ'7O#2VC>3>Q!%DE1/
MNH2>00K=<=J^FOPHQCM0!\RZ7^T+X4T^QCL/$7P[N[3Q-&HCDLX=*C*R28QP
M2 1D]L''O7077A#7_C!\&=>@O/#6G^$KV\D%QIEG GER,$.4,W3!/('3&<U[
MU@=<<T4 ?._A[]IRXT?2;7P_K7A#6SXSMXUMA90V^4G<#:&W$Y .,]"*O?LK
MKJ0F\?MJ\7E:F^LEKA5^Z'*Y(![XZ5[UCOCFC\* %KY8_:2CU3X;^.+CQ%H=
MN[KXJTN32;@1@\3<!6X[[?Y5]3TA'MF@#SSPIX!N?"?P3A\,Z:XAU)=,>,2#
MC]^ZDD_]]$UX)\*?B5X4^%?AY/#_ (B\!Z@/%L#L)2+!9GN'R2IW-R.O;/K7
MU_28[XYH ^5_A3KVMZY^T3JM]K&DR>&KS5M'8V%K-$?W4:XV$C R>"2..]6;
MKXQ6NCI=Z#\9/!TVHZG#*ZQ7UMIR/'<1YX*\C'!Z@U]/X]J-N>HH ^;OV??!
M)U#Q5XPUW3]#NO#'@[5;46EK8W1(:3/5PIZ#!./KBLOX>_$6\_9JM[_PAXRT
M34I=/CNI)K#4[&'S$E5NW) [9ZY&2"*^I:,9ZB@#P[X9:MXR^*?B[7?$=Z+[
M0_!TEJUKIVEW.%\UB,>:1C/J<],D8SBO/_A'\5F^ >GZAX*\4>'=7^V17DDE
MFUG;^9YX8\8Y'!(X(SUKZQHQ[4 ?-'PIOM8UC]IK7-2UK3I-*N+O2EE2SDY:
M&(E0BL<?>P,D>]:O[+L;)\-_&@9&4G5KO 8$?\LUKZ"QW[T8H ^9_@[I%WK'
M[*GB:PM8));R<WZQ0JIW.V3@ >IK5^!_Q'T_Q#\(;_PK':WMMJ^AZ-*MTMQ#
MM0Y#CY3GGGM@5]!]*,>U 'S1\,+KQ?I7[,6FWO@Y%?5;6[EEDM9H YGA$K;U
M4'^+'(^E8/B[XJ?#SQ]I5Q97'PVU&?Q=)&T:VT5B$=)L?\]%^;CKRM?6OX8H
MQWQS0!Y'\.'N/@C\ [6Z\5)<.VFPF:>WMQYDL:L_RH!D9(W#C/'->C^%?$EI
MXP\.Z?K5BLJV=]$)HEF4*X4^H!.#^-+XHT^]U;P]J%EI]U'97EQ"T4=Q(F\1
MYX)QW.,_C2>$_#EOX1\-:;HMJS206,"P+(_WGP.6/N3D_C0!'XT\+6OC;PKJ
MFAWG%O?0-"6 Y4D<,/<'!_"OGSP7\5O$'[/^GKX3\=^'M0NM.L6*6>L:?'YB
M/%D[1S@'\P1T(KZ=I/UH ^9?&7Q*UW]HJS'A/P1H6H6.C7CJM_K.H1>6J1@@
ME1U Y'J2<5:_:6T^W\$>#/AW;1K-/::3J,0)4%W943D_4XKZ0Z=J,9ZC- 'A
M/_#9'@C_ *!WB'_P 7_XNN=^/GQ"T[XE? ZRUW2K>]2T7684,=U#LERAR3M!
M/%?2^T>@_*EVCTH \$M?VQ/!,-M%&VG>("40*<6"]A_OUWW@_P",VA^-O!^L
M>)+"VU&*PTM9&GCN;<)*VQ-YVKN.>.G/6N]VCT%0WB3M9SK:M''<%&$32#*A
ML<$@=1F@##\ >.M.^)'AFVUW2H[B.RG9E5;I D@*G!R 3W]ZU=<TM-;T:^T^
M0XCNH'A8^@92,_K67X!\'IX'\+VNDBX:[E1GEFN&&TRRNQ=VQV&2<#TQ714
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M1V]^]% '):&#_P *EL 1S_8D?'_; 5PW[)"LGP;M RLI^US\,,'[U>S48]J
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MNHX'TF^?RG$;Y_>JQ7Y@.XP.M 'N5WJUE8W%M;W%U##/<OL@B=P&D;&<*._
MJW7R;\7/B'JMG^T-X=NX_"&I7,NC+-#:VR9W:BK#EXOEZ#/OTKW;Q9\7]*\!
M^"=/U_Q!;W%A/>1H8]+"[K@R$9,>..1W)Q0!WE%>!P_M6?8)+:?Q%X$USP_H
MMPP6/4YE+H0>AQM'&.>"?QKLOB?\;M-^&^AZ!K MO[6TW5KA8EN(9@JQQE=W
MF]#N ';K0!Z56/XN\6:;X'\.WFN:O,UOIUHH::14+D L%' &3R17C.I?M7BQ
M U!? >O/X8+X7673RT9<_>"E<?3YJ].U:Z'Q*^&LLWAV6UGCU>U MY;U"T:J
M_!8K_>49./4"@#H]%UBU\0:19ZG9.9+2[B6:)F4J2K#(.#R.*N5YUXI\<:+\
M!? NBVMY]HOY(XX[&SM;=<S7+JH&0.WJ?K7(6G[41T_4+6/Q;X'UOPC87,@B
MCO[Q2T>XG SE5P.1TS0![K138Y%D171@R,,AE.01ZUD^+/%>F>"?#]YK.KW
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M;.UL;%O.EO2-VYP OR*-O.<]:30?VJ-$N(-4B\0:-J/AO6; *?[)G7S)IRQ
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M6&ZU3P7K6C>';AML.M3H3"<_=+?*  ?4$XH ]>\8>+M,\"^'KO6]8F:#3K4
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M[V:;$C4CY5QCKCG\:VM,^!?Q)\!M/IO@SQ[:V?AR25I$@OK??+%N/(7Y6 _
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M)F(9L,,_,3VKZ8KS7Q'\,=0UCXT>&_&,5W:I8:9:R02V[[O-<MG!7 QCGN:
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MV$6GM:MX@L%8X&2#N51_O''_  "N>\5^&YO#W[(;37BXU+5;N+4[HGKOEF#
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M(!/YT >+?LV^'[+Q5^SO%I&HQ">RO&N(94/H6ZCW'4>XKSO5-?OO _PU\?\
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MBV:^:"6]NVN(O,"0*0H.,C'S']* /=J2O/=2^*T'A'X/V'C#6U\Z62RAE,,
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M??\ 7U;_ /H=<UX0;_A7WQ[TM.(=-\8:)"X'1?M,<8SCW('ZTSXW> 8/AO\
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M;CR P"L>^0*O?!6QU+Q)X;^)?A;3=9NM?\,)$UOI>H7(8;Y"I^52>W3/;\Z
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MDI&\:C=^GZB@!?$/PQ^)/@GPGJFLKX\N?$TOV20W^D7J$PO&5.\1$DX(!)'
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M)':6,#F4$DCEPIROT.#FL+Q#)>3?M._#234(XXK]M$E:>.+.Q9"LNX#/. :
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M96_BSX;:SXF6+7K&!);7Q'I1!:6 D'=\I'S#@'D'DYZ5@?LC^#=0\N\\0?\
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MS-X!M;J*?>#S.9#'&P_X!N'TQ6%>:+=R>/KKX01QNNEW'B1=8.!P+/9YA7Z
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M1U:TB@LS"<-]HEPGRGL02Q'TK(_91A74O@[/'<Q?+<7]V)(F']YN5_4BO//
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M]JWAFPN[MOO3%"C,?4[2,GW-=/HNAZ?X=L$L=,LH+"T3[L-O&$4>^!WJ_10
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MQ''XU<HH X3X+^"Y_ ?@.WTVXMX[.5IYKG[)"VY+=7<LL8/?:N!GUS7=4M%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sana-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-07T13:52:22.9048+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://sana.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:sana="http://sana.com/20240331" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" id="StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions" id="Role_DisclosureAcquisitions">
        <link:definition>995475 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" id="Role_DisclosureLicenseAndCollaborationAgreements">
        <link:definition>995485 - Disclosure - License and collaboration agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash" id="Role_DisclosureRestrictedCash">
        <link:definition>995495 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995505 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995515 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>995525 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995535 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995545 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995555 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995575 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>995585 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEvent1" id="DisclosureSubsequentEvent1">
        <link:definition>995595 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables" id="Role_DisclosureAcquisitionsTables">
        <link:definition>995615 - Disclosure - Acquisitions - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" id="Role_DisclosureLicenseAndCollaborationAgreementsTables">
        <link:definition>995625 - Disclosure - License and collaboration agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995635 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995645 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>995655 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995665 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995675 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995685 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>995695 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" id="Role_DisclosureAcquisitionsAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails" id="Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails">
        <link:definition>995715 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails" id="Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails">
        <link:definition>995725 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails" id="Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails">
        <link:definition>995745 - Disclosure - License and Collaboration Agreements - Summary of Potential Success Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails" id="Role_DisclosureRestrictedCashAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Restricted Cash - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995765 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails">
        <link:definition>995775 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails" id="Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails">
        <link:definition>995795 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails">
        <link:definition>995805 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails">
        <link:definition>995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995825 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995845 - Disclosure - Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails">
        <link:definition>995865 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>995875 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
        <link:definition>995885 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails">
        <link:definition>995895 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails">
        <link:definition>995925 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails" id="Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails">
        <link:definition>995935 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails">
        <link:definition>995955 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails">
        <link:definition>995965 - Disclosure - Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRsuActivityDetails">
        <link:definition>995975 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" id="DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails">
        <link:definition>995985 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>995995 - Disclosure - Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="sana-20240331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:href="sana-20240331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="sana-20240331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables" xlink:href="sana-20240331.xsd#Role_DisclosureAcquisitionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails" xlink:href="sana-20240331.xsd#Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails" xlink:href="sana-20240331.xsd#Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureRestrictedCashAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="sana-20240331.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:href="sana-20240331.xsd#DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="sana-20240331.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="sana-20240331.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sana-20240331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="sana-20240331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sana-20240331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="sana-20240331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="sana-20240331.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization" xlink:href="sana-20240331.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="sana-20240331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions" xlink:href="sana-20240331.xsd#Role_DisclosureAcquisitions" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:href="sana-20240331.xsd#Role_DisclosureLicenseAndCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash" xlink:href="sana-20240331.xsd#Role_DisclosureRestrictedCash" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="sana-20240331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="sana-20240331.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="sana-20240331.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="sana-20240331.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="sana-20240331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare" xlink:href="sana-20240331.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:href="sana-20240331.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEvent1" xlink:href="sana-20240331.xsd#DisclosureSubsequentEvent1" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sana-20240331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" xlink:href="sana-20240331.xsd#Role_DisclosureLicenseAndCollaborationAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="sana-20240331.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="sana-20240331.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="sana-20240331.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="sana-20240331.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="sana-20240331.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails" xlink:href="sana-20240331.xsd#Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:href="sana-20240331.xsd#DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2" xlink:href="sana-20240331.xsd#Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_IndustrialPropertyMember" xlink:label="srt_IndustrialPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementEndingMonthAndYear" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedCompensationOther" xlink:label="sana_AccruedCompensationOther"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityExpectedTerm" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeamTherapeuticsIncorporatedMember" xlink:label="sana_BeamTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AcquisitionAgreementMember" xlink:label="sana_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeAndLaboratoryMember" xlink:label="sana_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeneficialOwnershipPercentage" xlink:label="sana_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ScheduleOfMarketCapitalizationsTableTextBlock" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanOneMember" xlink:label="sana_Rule10B51TradingPlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UpfrontPaymentToCollaborators" xlink:label="sana_UpfrontPaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForTenantImprovementAllowances" xlink:label="sana_CashReceivedForTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationMember" xlink:label="sana_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilities" xlink:label="sana_SuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PercentageOfWorkforceReduction" xlink:label="sana_PercentageOfWorkforceReduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationTable" xlink:label="sana_DescriptionOfOrganizationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationThreeMember" xlink:label="sana_MarketCapitalizationThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwrittenPublicOfferingMember" xlink:label="sana_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CowenAndCompanyLLCMember" xlink:label="sana_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPeriodExpectedToAchieveForSuccessPayments" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneTwoMember" xlink:label="sana_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketableSecuritiesMaturityPeriod" xlink:label="sana_MarketableSecuritiesMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationEndingMonthAndYear" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationFourMember" xlink:label="sana_MarketCapitalizationFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPotentialSuccessPayments" xlink:label="sana_MaximumPotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="sana_SignificantAccountingPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LicenseAndCollaborationAgreementsAbstract" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BusinessAcquisitionMaximumTermForSuccessPayment" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfContingentConsideration" xlink:label="sana_EstimatedFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityMeasurementInput" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationLiabilityMember" xlink:label="sana_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndIndustrialMember" xlink:label="sana_OfficeLaboratoryAndIndustrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneOneMember" xlink:label="sana_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LeaseTerminationFeesIncurred" xlink:label="sana_LeaseTerminationFeesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermFinancialLiabilitiesMember" xlink:label="sana_LongTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltSuccessPaymentLiabilityMember" xlink:label="sana_CobaltSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardCollegeMember" xlink:label="sana_HarvardCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ChangeInFairValueOfSuccessPaymentLiabilities" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermMarketableSecuritiesMember" xlink:label="sana_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AreaOfLeasedSpace" xlink:label="sana_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationLineItems" xlink:label="sana_DescriptionOfOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FutureLetterOfCreditAmount" xlink:label="sana_FutureLetterOfCreditAmount"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RochesterNewYorkMember" xlink:label="sana_RochesterNewYorkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndManufacturingMember" xlink:label="sana_OfficeLaboratoryAndManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsExercised" xlink:label="sana_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MrHardyMember" xlink:label="sana_MrHardyMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanTwoMember" xlink:label="sana_Rule10B51TradingPlanTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFourMember" xlink:label="sana_MilestoneFourMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesMember" xlink:label="sana_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneThreeMember" xlink:label="sana_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InProcessResearchAndDevelopmentIntangibleAssetMember" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NathanHardyMember" xlink:label="sana_NathanHardyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltContingentConsiderationLiabilityMember" xlink:label="sana_CobaltContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedPropertyAndEquipmentCurrent" xlink:label="sana_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LaboratoryEquipmentMember" xlink:label="sana_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeasesAdditionalInformationTableTextBlock" xlink:label="sana_OperatingLeasesAdditionalInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BothellWashingtonMember" xlink:label="sana_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AdditionalPotentialContingentConsideration" xlink:label="sana_AdditionalPotentialContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFiveMember" xlink:label="sana_MilestoneFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermMarketableSecuritiesMember" xlink:label="sana_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ThresholdMarketCapitalization" xlink:label="sana_ThresholdMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowanceInterestRate" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowance" xlink:label="sana_OptionalTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardSuccessPaymentLiabilityMember" xlink:label="sana_HarvardSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DepreciationAndImpairmentOfLongLivedAssets" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InvestmentsSecuritiesMaturitiesPeriod" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermFinancialLiabilitiesMember" xlink:label="sana_ShortTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockMaximumOfferingAmount" xlink:label="sana_CommonStockMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" xlink:label="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockPricePerShareRequiredForPayment" xlink:label="sana_CommonStockPricePerShareRequiredForPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfPreFundedWarrantsExerciable" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesNoncurrent" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationBeginningMonthAndYear" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PaymentToCollaborators" xlink:label="sana_PaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NumberOfStandbyLettersOfCredit" xlink:label="sana_NumberOfStandbyLettersOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockGross" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationTwoMember" xlink:label="sana_MarketCapitalizationTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ReimbursementOfTenantImprovements" xlink:label="sana_ReimbursementOfTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayment" xlink:label="sana_PotentialSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ConstructionInProgressCostsWriteOff" xlink:label="sana_ConstructionInProgressCostsWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayments" xlink:label="sana_PotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementBeginningMonthAndYear" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_IndustrialPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Industrial Property [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_IndustrialPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industrial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life (years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Estimated Fair Value of Level 3 Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Vacation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued paid time off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement ending month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Ending Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commencement Dates, Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedCompensationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued compensation other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedCompensationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Compensation Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedCompensationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of pre-funded warrants increase or decrease by providing atleast 61 days prior notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Pre-funded Warrants Increase Decrease By Providing Atleast Sixty One Days Prior Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Percentage Of Pre-funded Warrants Increase Decrease By Providing Atleast Sixty One Days Prior Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability expected Term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement input expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeamTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beam Therapeutics Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeamTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beam Therapeutics Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeamTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beam Therapeutics Inc. (Beam)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense (in thousands)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on lease termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Laboratory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office/Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share for options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership percentage held by a member of board of directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the various thresholds for the Company&#8217;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Market Capitalizations Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10B51Trading Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10 B51 Trading Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10 B51 Trading Plan One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UpfrontPaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment to collaborators.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UpfrontPaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment To Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UpfrontPaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment to collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value 12 months or greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received For Tenant Improvement Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Received For Tenant Improvement Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Liabilities using Unobservable Inputs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend the lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock from equity financings, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock from Equity Financings, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock from equity financings, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction In Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PercentageOfWorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of workforce reduction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PercentageOfWorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Workforce Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PercentageOfWorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of organization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Organization [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Organization [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market Capitalization Three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Capitalization Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Capitalization Equal to or exceeds $6.8 billion, but less than $7.4 billion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of Success payment liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of success payment liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of success payment liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and Company, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen And Company L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum period expected to achieve for success payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Period Expected To Achieve For Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum period expected to achieve for success payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested shares as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested shares as of March 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of Equity Value at Issuance, 10x</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agencies Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum contingent consideration upon achievement of certain pre specified development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Contingent Consideration Upon Achievement Of Certain Pre Specified Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contingent consideration upon achievement of certain pre-specified development milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration ending month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Ending Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease arrangement, contractual expiration period, ending year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market capitalization four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Capitalization Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Capitalization Less than $6.8 billion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum potential success payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Potential Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cobalt success payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MaximumPotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cobalt success payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate, Type of Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 750,000 shares authorized; 221,286 and 197,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash items, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant accounting policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Income (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of dilutive securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum&#8203; term for success payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Maximum Term For Success Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term for success payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income, net of tax:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sana</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of contingent consideration, long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes infair value - expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_EstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total value of consideration paid under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Value Of Consideration Paid Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregated consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restricted Cash And Cash Equivalents [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Holding Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' Option To Purchase Additional Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Option To Purchase Additional Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters option to purchase additional shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability measurement input.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndIndustrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office, laboratory and industrial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndIndustrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Laboratory And Industrial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndIndustrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office/Laboratory/Industrial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of Equity Value at Issuance, 5x</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LeaseTerminationFeesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination fees incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LeaseTerminationFeesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Fees Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LeaseTerminationFeesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination fees incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic earnings (loss) per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Financial Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cobalt success payment liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cobalt Success Payment Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cobalt Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cobalt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard College.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard College [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard College</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of success payment liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the estimated fair value of success payment liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the estimated fair value of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants not exercise if holder together owns maximum percentage of number of common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants Not Exercise If Holder Together Owns Maximum Percentage of Number Of Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded Warrants Not Exercise If Holder Together Owns Maximum Percentage of Number Of Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of organization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Organization [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfOrganizationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Organization [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FutureLetterOfCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future letter of credit amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FutureLetterOfCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Letter Of Credit Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FutureLetterOfCreditAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future letter of credit amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RochesterNewYorkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rochester New York.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RochesterNewYorkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rochester New York [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RochesterNewYorkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rochester, NY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted earnings (loss) per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability tenant improvement allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Tenant Improvement Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office/Laboratory/Manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Laboratory and Manufacturing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OfficeLaboratoryAndManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office laboratory and manufacturing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input probability of milestone achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Of Milestone Achievement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Milestone Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of operating lease right-of-use asset for lease termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Operating Lease Right-of-use Asset For Lease Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of operating lease right-of-use asset for lease termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MrHardyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mr. Hardy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MrHardyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mr. Hardy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10B51Trading Plan Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10 B51 Trading Plan Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_Rule10B51TradingPlanTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10 B51 Trading Plan Two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of Equity Value at Issuance, 30x</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of Equity Value at Issuance, 20x</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In process research and development intangible asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Intangible Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_NathanHardyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nathan Hardy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_NathanHardyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nathan Hardy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic earnings per common share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cobalt contingent consideration liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cobalt Contingent Consideration Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cobalt Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FremontCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fremont California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FremontCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fremont California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FremontCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fremont, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_FremontCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fremont, CA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property And Equipment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period costs expected to be recognized (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted earnings per common share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeasesAdditionalInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases additional information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeasesAdditionalInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Additional Information Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeasesAdditionalInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Additional Information Related to Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bothell, Washington.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bothell Washington [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bothell, Washington</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bothell, WA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco, CA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FINANCING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AdditionalPotentialContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional potential contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AdditionalPotentialContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Potential Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AdditionalPotentialContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional potential Cobalt Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to pay base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MilestoneFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of Equity Value at Issuance, 40x</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of dilutive net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right of use liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in operating lease right-of-use liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential amount of milestone payments and royalties payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Amount Of Milestone Payments And Royalties Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developmental and commercial milestone payments and royalties on licensed products payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Additional Information Related to Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ThresholdMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold market capitalization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ThresholdMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Market Capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ThresholdMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold market capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Optional tenant improvement allowance interest rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Optional Tenant Improvement Allowance Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional additional tenant improvement allowance, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Optional additional tenant improvement allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Optional Tenant Improvement Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OptionalTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional additional tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan and exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard Success Payment Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard Success Payment Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_HarvardSuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Harvard</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation and Impairment of Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation and Impairment of Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent accounting pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments securities maturities period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Securities Maturities Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in securities with maturities period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase decrease in operating lease right-of-use assets and operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Financial Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ShortTermFinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock maximum offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Maximum Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock maximum aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised (in thousands)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, percentage of voting interests acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash And Cash Equivalents Items [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments and Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments and Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Holding Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received for amounts related to tenant improvement allowances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for amounts related to tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market capitalization one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Capitalization One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Capitalization Equal to or Exceeds $8.1 billion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of potential success payments and common stock price required for payment to Harvard.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Potential Success Payments Harvard Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potential Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockPricePerShareRequiredForPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock price per share required for payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockPricePerShareRequiredForPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Price Per Share Required For Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CommonStockPricePerShareRequiredForPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Per share common stock price required for payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 (remaining 9 months)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested shares as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested shares as of March 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of pre-funded warrants exerciable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Pre-funded Warrants Exerciable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of Pre-funded Warrants Exerciable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of common stock per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment, Software and Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, common stock in connection with license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock In Connection With License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Incentive Award Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Incentive Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Stock Price Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Standby letters of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent, Nature of Restriction, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, noncurrent, nature of restriction, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fees incurred related to issuance of common stock from at the market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltBiomedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cobalt Biomedicine, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltBiomedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cobalt Biomedicine Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_CobaltBiomedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cobalt Biomedicine, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain expense in connection with change in estimated fair value of success payment liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Expense In Connection With Change In Estimated Fair Value Of Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value of success payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expense in connection with change in estimated fair value of success payment liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of contingent consideration, short term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage allowed for eligible employees to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INVESTING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liabilities noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liabilities Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contribution by employer under retirement and savings plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Cash-Based Arrangements, Liability, Current and Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash-based expenses related to employee severance, benefits and related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Asset Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, impairment of intangible assets or goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill and Intangible Asset Impairment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life (years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due year five and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five And Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration beginning month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Beginning Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease arrangement, contractual expiration period, beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to collaborators.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PaymentToCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage related to employees able to purchase shares at lower of fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_NumberOfStandbyLettersOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of standby letter of credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_NumberOfStandbyLettersOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Standby Letters Of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_NumberOfStandbyLettersOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of standby letters of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market capitalization two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Capitalization Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_MarketCapitalizationTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Capitalization Equal to or exceeds $7.4 billion, but less than $8.1 billion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ReimbursementOfTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement of tenant improvements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ReimbursementOfTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Of Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ReimbursementOfTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential success payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Success Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cobalt Success Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, MA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in estimated fair value of success payment liabilities and contingent consideration recorded in research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Related Success Payments And Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development related success payments and contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ConstructionInProgressCostsWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Construction in progress costs write-off.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ConstructionInProgressCostsWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress Costs Write Off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_ConstructionInProgressCostsWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress costs write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At The Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WASHINGTON</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle, WA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average number of common shares - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential success payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_PotentialSuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Success payment(s)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash expense for operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issue price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price per Share Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price per Share Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses 12 months or greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement beginning month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Beginning Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commencement Dates, Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of offering costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate common stock sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remeasurement of operating lease right-of-use asset for lease modifications.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remeasurement Of Operating Lease Right Of Use Asset For Lease Modifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of operating lease right-of-use asset for lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_IndustrialPropertyMember" xlink:to="srt_IndustrialPropertyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OperatingLeaseCommencementEndingMonthAndYear" xlink:to="sana_OperatingLeaseCommencementEndingMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AccruedCompensationOther" xlink:to="sana_AccruedCompensationOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" xlink:to="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SuccessPaymentLiabilityExpectedTerm" xlink:to="sana_SuccessPaymentLiabilityExpectedTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_BeamTherapeuticsIncorporatedMember" xlink:to="sana_BeamTherapeuticsIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AcquisitionAgreementMember" xlink:to="sana_AcquisitionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="sana_AccruedResearchAndDevelopmentServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PreFundedWarrantsMember" xlink:to="sana_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OfficeAndLaboratoryMember" xlink:to="sana_OfficeAndLaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_BeneficialOwnershipPercentage" xlink:to="sana_BeneficialOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ScheduleOfMarketCapitalizationsTableTextBlock" xlink:to="sana_ScheduleOfMarketCapitalizationsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_Rule10B51TradingPlanOneMember" xlink:to="sana_Rule10B51TradingPlanOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_UpfrontPaymentToCollaborators" xlink:to="sana_UpfrontPaymentToCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CashReceivedForTenantImprovementAllowances" xlink:to="sana_CashReceivedForTenantImprovementAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ContingentConsiderationMember" xlink:to="sana_ContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SuccessPaymentLiabilities" xlink:to="sana_SuccessPaymentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" xlink:to="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PercentageOfWorkforceReduction" xlink:to="sana_PercentageOfWorkforceReduction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="sana_DescriptionOfOrganizationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MarketCapitalizationThreeMember" xlink:to="sana_MarketCapitalizationThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:to="sana_EstimatedFairValueOfSuccessPaymentLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_UnderwrittenPublicOfferingMember" xlink:to="sana_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CowenAndCompanyLLCMember" xlink:to="sana_CowenAndCompanyLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MaximumPeriodExpectedToAchieveForSuccessPayments" xlink:to="sana_MaximumPeriodExpectedToAchieveForSuccessPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MilestoneTwoMember" xlink:to="sana_MilestoneTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" xlink:to="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MarketableSecuritiesMaturityPeriod" xlink:to="sana_MarketableSecuritiesMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsMember" xlink:to="us-gaap_AssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OperatingLeaseExpirationEndingMonthAndYear" xlink:to="sana_OperatingLeaseExpirationEndingMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MarketCapitalizationFourMember" xlink:to="sana_MarketCapitalizationFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MaximumPotentialSuccessPayments" xlink:to="sana_MaximumPotentialSuccessPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="sana_SignificantAccountingPoliciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LicenseAndCollaborationAgreementsAbstract" xlink:to="sana_LicenseAndCollaborationAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_BusinessAcquisitionMaximumTermForSuccessPayment" xlink:to="sana_BusinessAcquisitionMaximumTermForSuccessPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_EstimatedFairValueOfContingentConsideration" xlink:to="sana_EstimatedFairValueOfContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" xlink:to="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:to="sana_UnderwritersOptionToPurchaseAdditionalSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SuccessPaymentLiabilityMeasurementInput" xlink:to="sana_SuccessPaymentLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ContingentConsiderationLiabilityMember" xlink:to="sana_ContingentConsiderationLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OfficeLaboratoryAndIndustrialMember" xlink:to="sana_OfficeLaboratoryAndIndustrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MilestoneOneMember" xlink:to="sana_MilestoneOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LeaseTerminationFeesIncurred" xlink:to="sana_LeaseTerminationFeesIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LongTermFinancialLiabilitiesMember" xlink:to="sana_LongTermFinancialLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CobaltSuccessPaymentLiabilityMember" xlink:to="sana_CobaltSuccessPaymentLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_HarvardCollegeMember" xlink:to="sana_HarvardCollegeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ChangeInFairValueOfSuccessPaymentLiabilities" xlink:to="sana_ChangeInFairValueOfSuccessPaymentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ShortTermMarketableSecuritiesMember" xlink:to="sana_ShortTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AreaOfLeasedSpace" xlink:to="sana_AreaOfLeasedSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" xlink:to="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_DescriptionOfOrganizationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_FutureLetterOfCreditAmount" xlink:to="sana_FutureLetterOfCreditAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_RochesterNewYorkMember" xlink:to="sana_RochesterNewYorkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OfficeLaboratoryAndManufacturingMember" xlink:to="sana_OfficeLaboratoryAndManufacturingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="sana_MeasurementInputProbabilityOfMilestoneAchievementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" xlink:to="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PreFundedWarrantsExercised" xlink:to="sana_PreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MrHardyMember" xlink:to="sana_MrHardyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_Rule10B51TradingPlanTwoMember" xlink:to="sana_Rule10B51TradingPlanTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MilestoneFourMember" xlink:to="sana_MilestoneFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SuccessPaymentLiabilitiesMember" xlink:to="sana_SuccessPaymentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MilestoneThreeMember" xlink:to="sana_MilestoneThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_InProcessResearchAndDevelopmentIntangibleAssetMember" xlink:to="sana_InProcessResearchAndDevelopmentIntangibleAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_NathanHardyMember" xlink:to="sana_NathanHardyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CobaltContingentConsiderationLiabilityMember" xlink:to="sana_CobaltContingentConsiderationLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_FremontCaliforniaMember" xlink:to="sana_FremontCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AccruedPropertyAndEquipmentCurrent" xlink:to="sana_AccruedPropertyAndEquipmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LaboratoryEquipmentMember" xlink:to="sana_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OperatingLeasesAdditionalInformationTableTextBlock" xlink:to="sana_OperatingLeasesAdditionalInformationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_BothellWashingtonMember" xlink:to="sana_BothellWashingtonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AdditionalPotentialContingentConsideration" xlink:to="sana_AdditionalPotentialContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MilestoneFiveMember" xlink:to="sana_MilestoneFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" xlink:to="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LongTermMarketableSecuritiesMember" xlink:to="sana_LongTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityMember" xlink:to="us-gaap_LiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ThresholdMarketCapitalization" xlink:to="sana_ThresholdMarketCapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OptionalTenantImprovementAllowanceInterestRate" xlink:to="sana_OptionalTenantImprovementAllowanceInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OptionalTenantImprovementAllowance" xlink:to="sana_OptionalTenantImprovementAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_HarvardSuccessPaymentLiabilityMember" xlink:to="sana_HarvardSuccessPaymentLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_DepreciationAndImpairmentOfLongLivedAssets" xlink:to="sana_DepreciationAndImpairmentOfLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_InvestmentsSecuritiesMaturitiesPeriod" xlink:to="sana_InvestmentsSecuritiesMaturitiesPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ShortTermFinancialLiabilitiesMember" xlink:to="sana_ShortTermFinancialLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CommonStockMaximumOfferingAmount" xlink:to="sana_CommonStockMaximumOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:to="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MarketCapitalizationOneMember" xlink:to="sana_MarketCapitalizationOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" xlink:to="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CommonStockPricePerShareRequiredForPayment" xlink:to="sana_CommonStockPricePerShareRequiredForPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_DescriptionOfPreFundedWarrantsExerciable" xlink:to="sana_DescriptionOfPreFundedWarrantsExerciable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" xlink:to="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:to="sana_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_CobaltBiomedicineIncMember" xlink:to="sana_CobaltBiomedicineIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:to="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_SuccessPaymentLiabilitiesNoncurrent" xlink:to="sana_SuccessPaymentLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:to="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OperatingLeaseExpirationBeginningMonthAndYear" xlink:to="sana_OperatingLeaseExpirationBeginningMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PaymentToCollaborators" xlink:to="sana_PaymentToCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_NumberOfStandbyLettersOfCredit" xlink:to="sana_NumberOfStandbyLettersOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ProceedsFromIssuanceOfCommonStockGross" xlink:to="sana_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_MarketCapitalizationTwoMember" xlink:to="sana_MarketCapitalizationTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ReimbursementOfTenantImprovements" xlink:to="sana_ReimbursementOfTenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PotentialSuccessPayment" xlink:to="sana_PotentialSuccessPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" xlink:to="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_ConstructionInProgressCostsWriteOff" xlink:to="sana_ConstructionInProgressCostsWriteOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_AtTheMarketFacilityMember" xlink:to="sana_AtTheMarketFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WA" xlink:to="stpr_WA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_PotentialSuccessPayments" xlink:to="sana_PotentialSuccessPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_OperatingLeaseCommencementBeginningMonthAndYear" xlink:to="sana_OperatingLeaseCommencementBeginningMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" xlink:to="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesNoncurrent" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="sana_SuccessPaymentLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_15"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DepreciationAndImpairmentOfLongLivedAssets" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForTenantImprovementAllowances" xlink:label="sana_CashReceivedForTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ChangeInFairValueOfSuccessPaymentLiabilities" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sana_DepreciationAndImpairmentOfLongLivedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_CashReceivedForTenantImprovementAllowances" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sana_ChangeInFairValueOfSuccessPaymentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanOneMember" xlink:label="sana_Rule10B51TradingPlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanTwoMember" xlink:label="sana_Rule10B51TradingPlanTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NathanHardyMember" xlink:label="sana_NathanHardyMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MrHardyMember" xlink:label="sana_MrHardyMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sana_Rule10B51TradingPlanOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sana_Rule10B51TradingPlanTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sana_NathanHardyMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sana_MrHardyMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LicenseAndCollaborationAgreementsAbstract" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_LicenseAndCollaborationAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEvent1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="sana_SignificantAccountingPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sana_SignificantAccountingPoliciesPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ScheduleOfMarketCapitalizationsTableTextBlock" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ScheduleOfMarketCapitalizationsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LicenseAndCollaborationAgreementsAbstract" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" xlink:label="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_LicenseAndCollaborationAgreementsAbstract" xlink:to="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesMember" xlink:label="sana_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltContingentConsiderationLiabilityMember" xlink:label="sana_CobaltContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sana_SuccessPaymentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeasesAdditionalInformationTableTextBlock" xlink:label="sana_OperatingLeasesAdditionalInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sana_OperatingLeasesAdditionalInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationTable" xlink:label="sana_DescriptionOfOrganizationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationLineItems" xlink:label="sana_DescriptionOfOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockMaximumOfferingAmount" xlink:label="sana_CommonStockMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CowenAndCompanyLLCMember" xlink:label="sana_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwrittenPublicOfferingMember" xlink:label="sana_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilities" xlink:label="sana_SuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockGross" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_CommonStockMaximumOfferingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sana_DescriptionOfOrganizationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sana_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_CowenAndCompanyLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_SuccessPaymentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="sana_DescriptionOfOrganizationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_ProceedsFromIssuanceOfCommonStockGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AcquisitionAgreementMember" xlink:label="sana_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InProcessResearchAndDevelopmentIntangibleAssetMember" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPotentialSuccessPayments" xlink:label="sana_MaximumPotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ThresholdMarketCapitalization" xlink:label="sana_ThresholdMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BusinessAcquisitionMaximumTermForSuccessPayment" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfContingentConsideration" xlink:label="sana_EstimatedFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_AcquisitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sana_InProcessResearchAndDevelopmentIntangibleAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_MaximumPotentialSuccessPayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ThresholdMarketCapitalization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_BusinessAcquisitionMaximumTermForSuccessPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_EstimatedFairValueOfSuccessPaymentLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_EstimatedFairValueOfContingentConsideration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayment" xlink:label="sana_PotentialSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationTwoMember" xlink:label="sana_MarketCapitalizationTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AdditionalPotentialContingentConsideration" xlink:label="sana_AdditionalPotentialContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationThreeMember" xlink:label="sana_MarketCapitalizationThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationFourMember" xlink:label="sana_MarketCapitalizationFourMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_PotentialSuccessPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_AdditionalPotentialContingentConsideration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ThresholdMarketCapitalization" xlink:label="sana_ThresholdMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationTwoMember" xlink:label="sana_MarketCapitalizationTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationThreeMember" xlink:label="sana_MarketCapitalizationThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationFourMember" xlink:label="sana_MarketCapitalizationFourMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ThresholdMarketCapitalization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LicenseAndCollaborationAgreementsAbstract" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UpfrontPaymentToCollaborators" xlink:label="sana_UpfrontPaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeamTherapeuticsIncorporatedMember" xlink:label="sana_BeamTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardCollegeMember" xlink:label="sana_HarvardCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeneficialOwnershipPercentage" xlink:label="sana_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPotentialSuccessPayments" xlink:label="sana_MaximumPotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PaymentToCollaborators" xlink:label="sana_PaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPeriodExpectedToAchieveForSuccessPayments" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_LicenseAndCollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_UpfrontPaymentToCollaborators" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_BeamTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_HarvardCollegeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_BeneficialOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_MaximumPotentialSuccessPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PaymentToCollaborators" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_MaximumPeriodExpectedToAchieveForSuccessPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_EstimatedFairValueOfSuccessPaymentLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneOneMember" xlink:label="sana_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LicenseAndCollaborationAgreementsAbstract" xlink:label="sana_LicenseAndCollaborationAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockPricePerShareRequiredForPayment" xlink:label="sana_CommonStockPricePerShareRequiredForPayment"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardCollegeMember" xlink:label="sana_HarvardCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneTwoMember" xlink:label="sana_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayments" xlink:label="sana_PotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneThreeMember" xlink:label="sana_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFourMember" xlink:label="sana_MilestoneFourMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFiveMember" xlink:label="sana_MilestoneFiveMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sana_LicenseAndCollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_CommonStockPricePerShareRequiredForPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_HarvardCollegeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PotentialSuccessPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NumberOfStandbyLettersOfCredit" xlink:label="sana_NumberOfStandbyLettersOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FutureLetterOfCreditAmount" xlink:label="sana_FutureLetterOfCreditAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="sana_NumberOfStandbyLettersOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="sana_FutureLetterOfCreditAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationMember" xlink:label="sana_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermFinancialLiabilitiesMember" xlink:label="sana_ShortTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermMarketableSecuritiesMember" xlink:label="sana_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermFinancialLiabilitiesMember" xlink:label="sana_LongTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermMarketableSecuritiesMember" xlink:label="sana_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesMember" xlink:label="sana_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="sana_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_ShortTermFinancialLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sana_ShortTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_LongTermFinancialLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sana_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_LiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sana_SuccessPaymentLiabilitiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_OtherAssetsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketableSecuritiesMaturityPeriod" xlink:label="sana_MarketableSecuritiesMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InvestmentsSecuritiesMaturitiesPeriod" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_MarketableSecuritiesMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_InvestmentsSecuritiesMaturitiesPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationLiabilityMember" xlink:label="sana_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltSuccessPaymentLiabilityMember" xlink:label="sana_CobaltSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardSuccessPaymentLiabilityMember" xlink:label="sana_HarvardSuccessPaymentLiabilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltSuccessPaymentLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_HarvardSuccessPaymentLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltContingentConsiderationLiabilityMember" xlink:label="sana_CobaltContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="sana_CobaltContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sana_MeasurementInputProbabilityOfMilestoneAchievementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityMeasurementInput" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltSuccessPaymentLiabilityMember" xlink:label="sana_CobaltSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityExpectedTerm" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardSuccessPaymentLiabilityMember" xlink:label="sana_HarvardSuccessPaymentLiabilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_SuccessPaymentLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltSuccessPaymentLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_SuccessPaymentLiabilityExpectedTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_HarvardSuccessPaymentLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LaboratoryEquipmentMember" xlink:label="sana_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sana_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedPropertyAndEquipmentCurrent" xlink:label="sana_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedCompensationOther" xlink:label="sana_AccruedCompensationOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="sana_AccruedResearchAndDevelopmentServicesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedVacationCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="sana_AccruedPropertyAndEquipmentCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="sana_AccruedCompensationOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BothellWashingtonMember" xlink:label="sana_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AreaOfLeasedSpace" xlink:label="sana_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ReimbursementOfTenantImprovements" xlink:label="sana_ReimbursementOfTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowance" xlink:label="sana_OptionalTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowanceInterestRate" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ConstructionInProgressCostsWriteOff" xlink:label="sana_ConstructionInProgressCostsWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LeaseTerminationFeesIncurred" xlink:label="sana_LeaseTerminationFeesIncurred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_BothellWashingtonMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_AreaOfLeasedSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_ReimbursementOfTenantImprovements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OptionalTenantImprovementAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OptionalTenantImprovementAllowanceInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_ConstructionInProgressCostsWriteOff" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_LeaseTerminationFeesIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AreaOfLeasedSpace" xlink:label="sana_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeAndLaboratoryMember" xlink:label="sana_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementBeginningMonthAndYear" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_IndustrialPropertyMember" xlink:label="srt_IndustrialPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementEndingMonthAndYear" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndIndustrialMember" xlink:label="sana_OfficeLaboratoryAndIndustrialMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationBeginningMonthAndYear" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndManufacturingMember" xlink:label="sana_OfficeLaboratoryAndManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RochesterNewYorkMember" xlink:label="sana_RochesterNewYorkMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationEndingMonthAndYear" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BothellWashingtonMember" xlink:label="sana_BothellWashingtonMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_AreaOfLeasedSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeAndLaboratoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseCommencementBeginningMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_IndustrialPropertyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseCommencementEndingMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeLaboratoryAndIndustrialMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseExpirationBeginningMonthAndYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeLaboratoryAndManufacturingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_RochesterNewYorkMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseExpirationEndingMonthAndYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_BothellWashingtonMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockMaximumOfferingAmount" xlink:label="sana_CommonStockMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CowenAndCompanyLLCMember" xlink:label="sana_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwrittenPublicOfferingMember" xlink:label="sana_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsExercised" xlink:label="sana_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfPreFundedWarrantsExerciable" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockGross" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_CommonStockMaximumOfferingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sana_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_CowenAndCompanyLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwrittenPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_PreFundedWarrantsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_DescriptionOfPreFundedWarrantsExerciable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_ProceedsFromIssuanceOfCommonStockGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sana_TwoThousandTwentyOneIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PercentageOfWorkforceReduction" xlink:label="sana_PercentageOfWorkforceReduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sana_PercentageOfWorkforceReduction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_PreFundedWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DepreciationAndImpairmentOfLongLivedAssets" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:label="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CashReceivedForTenantImprovementAllowances" xlink:label="sana_CashReceivedForTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ChangeInFairValueOfSuccessPaymentLiabilities" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" xlink:label="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" xlink:label="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sana_DepreciationAndImpairmentOfLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_CashReceivedForTenantImprovementAllowances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sana_ChangeInFairValueOfSuccessPaymentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanOneMember" xlink:label="sana_Rule10B51TradingPlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_Rule10B51TradingPlanTwoMember" xlink:label="sana_Rule10B51TradingPlanTwoMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sana_Rule10B51TradingPlanOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sana_Rule10B51TradingPlanTwoMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NathanHardyMember" xlink:label="sana_NathanHardyMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MrHardyMember" xlink:label="sana_MrHardyMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sana_NathanHardyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sana_MrHardyMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ScheduleOfMarketCapitalizationsTableTextBlock" xlink:label="sana_ScheduleOfMarketCapitalizationsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ScheduleOfMarketCapitalizationsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesMember" xlink:label="sana_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltContingentConsiderationLiabilityMember" xlink:label="sana_CobaltContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sana_SuccessPaymentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltContingentConsiderationLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationLineItems" xlink:label="sana_DescriptionOfOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfOrganizationTable" xlink:label="sana_DescriptionOfOrganizationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockMaximumOfferingAmount" xlink:label="sana_CommonStockMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CowenAndCompanyLLCMember" xlink:label="sana_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwrittenPublicOfferingMember" xlink:label="sana_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilities" xlink:label="sana_SuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockGross" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_DescriptionOfOrganizationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_CommonStockMaximumOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sana_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_CowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_InvestmentsAndCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sana_DescriptionOfOrganizationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_SuccessPaymentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sana_DescriptionOfOrganizationLineItems" xlink:to="sana_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AcquisitionAgreementMember" xlink:label="sana_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InProcessResearchAndDevelopmentIntangibleAssetMember" xlink:label="sana_InProcessResearchAndDevelopmentIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" xlink:label="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPotentialSuccessPayments" xlink:label="sana_MaximumPotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ThresholdMarketCapitalization" xlink:label="sana_ThresholdMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BusinessAcquisitionMaximumTermForSuccessPayment" xlink:label="sana_BusinessAcquisitionMaximumTermForSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfContingentConsideration" xlink:label="sana_EstimatedFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_AcquisitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sana_InProcessResearchAndDevelopmentIntangibleAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_MaximumPotentialSuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ThresholdMarketCapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_BusinessAcquisitionMaximumTermForSuccessPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_EstimatedFairValueOfSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_EstimatedFairValueOfContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayment" xlink:label="sana_PotentialSuccessPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltBiomedicineIncMember" xlink:label="sana_CobaltBiomedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationTwoMember" xlink:label="sana_MarketCapitalizationTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AdditionalPotentialContingentConsideration" xlink:label="sana_AdditionalPotentialContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationThreeMember" xlink:label="sana_MarketCapitalizationThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationFourMember" xlink:label="sana_MarketCapitalizationFourMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_PotentialSuccessPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sana_CobaltBiomedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_AdditionalPotentialContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationFourMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationOneMember" xlink:label="sana_MarketCapitalizationOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ThresholdMarketCapitalization" xlink:label="sana_ThresholdMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationTwoMember" xlink:label="sana_MarketCapitalizationTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationThreeMember" xlink:label="sana_MarketCapitalizationThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketCapitalizationFourMember" xlink:label="sana_MarketCapitalizationFourMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sana_ThresholdMarketCapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sana_MarketCapitalizationFourMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UpfrontPaymentToCollaborators" xlink:label="sana_UpfrontPaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeamTherapeuticsIncorporatedMember" xlink:label="sana_BeamTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" xlink:label="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardCollegeMember" xlink:label="sana_HarvardCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BeneficialOwnershipPercentage" xlink:label="sana_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPotentialSuccessPayments" xlink:label="sana_MaximumPotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" xlink:label="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" xlink:label="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PaymentToCollaborators" xlink:label="sana_PaymentToCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPeriodExpectedToAchieveForSuccessPayments" xlink:label="sana_MaximumPeriodExpectedToAchieveForSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_EstimatedFairValueOfSuccessPaymentLiability" xlink:label="sana_EstimatedFairValueOfSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" xlink:label="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_UpfrontPaymentToCollaborators" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_BeamTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_HarvardCollegeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_BeneficialOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_MaximumPotentialSuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PaymentToCollaborators" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_MaximumPeriodExpectedToAchieveForSuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_EstimatedFairValueOfSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneOneMember" xlink:label="sana_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockPricePerShareRequiredForPayment" xlink:label="sana_CommonStockPricePerShareRequiredForPayment"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardCollegeMember" xlink:label="sana_HarvardCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneTwoMember" xlink:label="sana_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PotentialSuccessPayments" xlink:label="sana_PotentialSuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneThreeMember" xlink:label="sana_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFourMember" xlink:label="sana_MilestoneFourMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MilestoneFiveMember" xlink:label="sana_MilestoneFiveMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_CommonStockPricePerShareRequiredForPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_HarvardCollegeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sana_PotentialSuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sana_MilestoneFiveMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_NumberOfStandbyLettersOfCredit" xlink:label="sana_NumberOfStandbyLettersOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FutureLetterOfCreditAmount" xlink:label="sana_FutureLetterOfCreditAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="sana_NumberOfStandbyLettersOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="sana_FutureLetterOfCreditAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationMember" xlink:label="sana_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermFinancialLiabilitiesMember" xlink:label="sana_ShortTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ShortTermMarketableSecuritiesMember" xlink:label="sana_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermFinancialLiabilitiesMember" xlink:label="sana_LongTermFinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LongTermMarketableSecuritiesMember" xlink:label="sana_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesMember" xlink:label="sana_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsMember" xlink:label="us-gaap_AssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="sana_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_ShortTermFinancialLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sana_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_LongTermFinancialLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="sana_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_LiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sana_SuccessPaymentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MarketableSecuritiesMaturityPeriod" xlink:label="sana_MarketableSecuritiesMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_InvestmentsSecuritiesMaturitiesPeriod" xlink:label="sana_InvestmentsSecuritiesMaturitiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_MarketableSecuritiesMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_InvestmentsSecuritiesMaturitiesPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ContingentConsiderationLiabilityMember" xlink:label="sana_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltSuccessPaymentLiabilityMember" xlink:label="sana_CobaltSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardSuccessPaymentLiabilityMember" xlink:label="sana_HarvardSuccessPaymentLiabilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltSuccessPaymentLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_HarvardSuccessPaymentLiabilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltContingentConsiderationLiabilityMember" xlink:label="sana_CobaltContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:label="sana_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="sana_CobaltContingentConsiderationLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sana_MeasurementInputProbabilityOfMilestoneAchievementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityMeasurementInput" xlink:label="sana_SuccessPaymentLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CobaltSuccessPaymentLiabilityMember" xlink:label="sana_CobaltSuccessPaymentLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilityExpectedTerm" xlink:label="sana_SuccessPaymentLiabilityExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_HarvardSuccessPaymentLiabilityMember" xlink:label="sana_HarvardSuccessPaymentLiabilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_SuccessPaymentLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_CobaltSuccessPaymentLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sana_SuccessPaymentLiabilityExpectedTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="sana_HarvardSuccessPaymentLiabilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LaboratoryEquipmentMember" xlink:label="sana_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sana_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BothellWashingtonMember" xlink:label="sana_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AreaOfLeasedSpace" xlink:label="sana_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ReimbursementOfTenantImprovements" xlink:label="sana_ReimbursementOfTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowance" xlink:label="sana_OptionalTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OptionalTenantImprovementAllowanceInterestRate" xlink:label="sana_OptionalTenantImprovementAllowanceInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ConstructionInProgressCostsWriteOff" xlink:label="sana_ConstructionInProgressCostsWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LeaseTerminationFeesIncurred" xlink:label="sana_LeaseTerminationFeesIncurred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_BothellWashingtonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_AreaOfLeasedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_ReimbursementOfTenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OptionalTenantImprovementAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OptionalTenantImprovementAllowanceInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_ConstructionInProgressCostsWriteOff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_LeaseTerminationFeesIncurred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AreaOfLeasedSpace" xlink:label="sana_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeAndLaboratoryMember" xlink:label="sana_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementBeginningMonthAndYear" xlink:label="sana_OperatingLeaseCommencementBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_IndustrialPropertyMember" xlink:label="srt_IndustrialPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseCommencementEndingMonthAndYear" xlink:label="sana_OperatingLeaseCommencementEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndIndustrialMember" xlink:label="sana_OfficeLaboratoryAndIndustrialMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_FremontCaliforniaMember" xlink:label="sana_FremontCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationBeginningMonthAndYear" xlink:label="sana_OperatingLeaseExpirationBeginningMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OfficeLaboratoryAndManufacturingMember" xlink:label="sana_OfficeLaboratoryAndManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_RochesterNewYorkMember" xlink:label="sana_RochesterNewYorkMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_OperatingLeaseExpirationEndingMonthAndYear" xlink:label="sana_OperatingLeaseExpirationEndingMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_BothellWashingtonMember" xlink:label="sana_BothellWashingtonMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_AreaOfLeasedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeAndLaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseCommencementBeginningMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_IndustrialPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseCommencementEndingMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeLaboratoryAndIndustrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_FremontCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseExpirationBeginningMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="sana_OfficeLaboratoryAndManufacturingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_RochesterNewYorkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sana_OperatingLeaseExpirationEndingMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sana_BothellWashingtonMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CommonStockMaximumOfferingAmount" xlink:label="sana_CommonStockMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AtTheMarketFacilityMember" xlink:label="sana_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsMember" xlink:label="sana_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_CowenAndCompanyLLCMember" xlink:label="sana_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwrittenPublicOfferingMember" xlink:label="sana_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_UnderwritersOptionToPurchaseAdditionalSharesMember" xlink:label="sana_UnderwritersOptionToPurchaseAdditionalSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsExercised" xlink:label="sana_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DescriptionOfPreFundedWarrantsExerciable" xlink:label="sana_DescriptionOfPreFundedWarrantsExerciable"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" xlink:label="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" xlink:label="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockGross" xlink:label="sana_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_CommonStockMaximumOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sana_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sana_CowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_PreFundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_DescriptionOfPreFundedWarrantsExerciable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sana_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="sana_TwoThousandTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sana_TwoThousandTwentyOneIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_PercentageOfWorkforceReduction" xlink:label="sana_PercentageOfWorkforceReduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sana_PercentageOfWorkforceReduction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="sana_SuccessPaymentLiabilitiesNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_SuccessPaymentLiabilitiesNoncurrent" xlink:label="sana_SuccessPaymentLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" xlink:label="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sana_DepreciationAndImpairmentOfLongLivedAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sana_ChangeInFairValueOfSuccessPaymentLiabilities" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="9" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_DepreciationAndImpairmentOfLongLivedAssets" xlink:label="sana_DepreciationAndImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" xlink:label="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_ChangeInFairValueOfSuccessPaymentLiabilities" xlink:label="sana_ChangeInFairValueOfSuccessPaymentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="sana_AccruedResearchAndDevelopmentServicesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="sana_AccruedPropertyAndEquipmentCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="sana_AccruedCompensationOther" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="sana_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedPropertyAndEquipmentCurrent" xlink:label="sana_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_AccruedCompensationOther" xlink:label="sana_AccruedCompensationOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="sana-20240331.xsd#sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sana_FremontCaliforniaMember" name="FremontCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_InvestmentsSecuritiesMaturitiesPeriod" name="InvestmentsSecuritiesMaturitiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_SuccessPaymentLiabilityExpectedTerm" name="SuccessPaymentLiabilityExpectedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" name="IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" name="RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OperatingLeasesAdditionalInformationTableTextBlock" name="OperatingLeasesAdditionalInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" name="DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_SuccessPaymentLiabilitiesNoncurrent" name="SuccessPaymentLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" name="SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" name="StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_CobaltContingentConsiderationLiabilityMember" name="CobaltContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_FutureLetterOfCreditAmount" name="FutureLetterOfCreditAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_BothellWashingtonMember" name="BothellWashingtonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_PreFundedWarrantsExercised" name="PreFundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" name="ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MilestoneTwoMember" name="MilestoneTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CashReceivedForTenantImprovementAllowances" name="CashReceivedForTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_MeasurementInputProbabilityOfMilestoneAchievementMember" name="MeasurementInputProbabilityOfMilestoneAchievementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_AreaOfLeasedSpace" name="AreaOfLeasedSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_BusinessAcquisitionMaximumTermForSuccessPayment" name="BusinessAcquisitionMaximumTermForSuccessPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_AdditionalPotentialContingentConsideration" name="AdditionalPotentialContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_NumberOfStandbyLettersOfCredit" name="NumberOfStandbyLettersOfCredit" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_EstimatedFairValueOfSuccessPaymentLiability" name="EstimatedFairValueOfSuccessPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_ScheduleOfMarketCapitalizationsTableTextBlock" name="ScheduleOfMarketCapitalizationsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_SuccessPaymentLiabilities" name="SuccessPaymentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_MaximumPotentialSuccessPayments" name="MaximumPotentialSuccessPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" name="PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_Rule10B51TradingPlanTwoMember" name="Rule10B51TradingPlanTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" name="MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_MarketableSecuritiesMaturityPeriod" name="MarketableSecuritiesMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_InProcessResearchAndDevelopmentIntangibleAssetMember" name="InProcessResearchAndDevelopmentIntangibleAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_HarvardSuccessPaymentLiabilityMember" name="HarvardSuccessPaymentLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MilestoneThreeMember" name="MilestoneThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OperatingLeaseExpirationBeginningMonthAndYear" name="OperatingLeaseExpirationBeginningMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_ChangeInFairValueOfSuccessPaymentLiabilities" name="ChangeInFairValueOfSuccessPaymentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_OptionalTenantImprovementAllowanceInterestRate" name="OptionalTenantImprovementAllowanceInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sana_MarketCapitalizationFourMember" name="MarketCapitalizationFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_LeaseTerminationFeesIncurred" name="LeaseTerminationFeesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_AtTheMarketFacilityMember" name="AtTheMarketFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_LicenseAndCollaborationAgreementsAbstract" name="LicenseAndCollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CobaltBiomedicineIncMember" name="CobaltBiomedicineIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OptionalTenantImprovementAllowance" name="OptionalTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_MilestoneFiveMember" name="MilestoneFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_DescriptionOfPreFundedWarrantsExerciable" name="DescriptionOfPreFundedWarrantsExerciable" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_LongTermFinancialLiabilitiesMember" name="LongTermFinancialLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_AccruedPropertyAndEquipmentCurrent" name="AccruedPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_ShortTermFinancialLiabilitiesMember" name="ShortTermFinancialLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_UpfrontPaymentToCollaborators" name="UpfrontPaymentToCollaborators" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_PercentageOfWorkforceReduction" name="PercentageOfWorkforceReduction" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_SuccessPaymentLiabilityMeasurementInput" name="SuccessPaymentLiabilityMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sana_MarketCapitalizationOneMember" name="MarketCapitalizationOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_PaymentToCollaborators" name="PaymentToCollaborators" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_BeamTherapeuticsIncorporatedMember" name="BeamTherapeuticsIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_PotentialSuccessPayment" name="PotentialSuccessPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_SuccessPaymentLiabilitiesMember" name="SuccessPaymentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances" name="CashReceivedForAmountsRelatedToTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_DescriptionOfOrganizationTable" name="DescriptionOfOrganizationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_AccruedCompensationOther" name="AccruedCompensationOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_TotalValueOfConsiderationPaidUnderLicenseAgreement" name="TotalValueOfConsiderationPaidUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_AccruedResearchAndDevelopmentServicesCurrent" name="AccruedResearchAndDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_DescriptionOfOrganizationLineItems" name="DescriptionOfOrganizationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" name="PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_NathanHardyMember" name="NathanHardyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OperatingLeaseCommencementBeginningMonthAndYear" name="OperatingLeaseCommencementBeginningMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" name="ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_MarketCapitalizationTwoMember" name="MarketCapitalizationTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MrHardyMember" name="MrHardyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CommonStockPricePerShareRequiredForPayment" name="CommonStockPricePerShareRequiredForPayment" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sana_ConstructionInProgressCostsWriteOff" name="ConstructionInProgressCostsWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" name="GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_PotentialSuccessPayments" name="PotentialSuccessPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_TwoThousandTwentyOneIncentiveAwardPlanMember" name="TwoThousandTwentyOneIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_UnderwritersOptionToPurchaseAdditionalSharesMember" name="UnderwritersOptionToPurchaseAdditionalSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_EstimatedFairValueOfContingentConsideration" name="EstimatedFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_ReimbursementOfTenantImprovements" name="ReimbursementOfTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_AcquisitionAgreementMember" name="AcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CobaltSuccessPaymentLiabilityMember" name="CobaltSuccessPaymentLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OperatingLeaseCommencementEndingMonthAndYear" name="OperatingLeaseCommencementEndingMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_OperatingLeaseExpirationEndingMonthAndYear" name="OperatingLeaseExpirationEndingMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_ThresholdMarketCapitalization" name="ThresholdMarketCapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_MilestoneFourMember" name="MilestoneFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_SignificantAccountingPoliciesPolicyTextBlock" name="SignificantAccountingPoliciesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_Rule10B51TradingPlanOneMember" name="Rule10B51TradingPlanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_OfficeLaboratoryAndManufacturingMember" name="OfficeLaboratoryAndManufacturingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_RochesterNewYorkMember" name="RochesterNewYorkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MaximumPeriodExpectedToAchieveForSuccessPayments" name="MaximumPeriodExpectedToAchieveForSuccessPayments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MarketCapitalizationThreeMember" name="MarketCapitalizationThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_DepreciationAndImpairmentOfLongLivedAssets" name="DepreciationAndImpairmentOfLongLivedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sana_HarvardCollegeMember" name="HarvardCollegeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_CommonStockMaximumOfferingAmount" name="CommonStockMaximumOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" name="MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sana_OfficeLaboratoryAndIndustrialMember" name="OfficeLaboratoryAndIndustrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sana_MilestoneOneMember" name="MilestoneOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469529940352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sana Biotechnology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001770121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,502,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1381173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">188 East Blaine Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">98102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">701-7914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SANA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525415776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177,054<span></span>
</td>
<td class="nump">$ 133,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">134,028<span></span>
</td>
<td class="nump">71,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,832<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,349<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">321,263<span></span>
</td>
<td class="nump">213,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">81,649<span></span>
</td>
<td class="nump">70,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">71,565<span></span>
</td>
<td class="nump">74,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">59,195<span></span>
</td>
<td class="nump">59,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">140,627<span></span>
</td>
<td class="nump">140,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">681,377<span></span>
</td>
<td class="nump">565,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">4,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">13,965<span></span>
</td>
<td class="nump">23,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">19,674<span></span>
</td>
<td class="nump">23,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">13,167<span></span>
</td>
<td class="nump">13,195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">52,901<span></span>
</td>
<td class="nump">64,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">92,922<span></span>
</td>
<td class="nump">90,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">114,990<span></span>
</td>
<td class="nump">109,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilitiesNoncurrent', window );">Success payment liabilities</a></td>
<td class="nump">45,422<span></span>
</td>
<td class="nump">12,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">306,235<span></span>
</td>
<td class="nump">277,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 750,000 shares authorized; 221,286 and 197,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,820,701<span></span>
</td>
<td class="nump">1,625,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,445,566)<span></span>
</td>
<td class="num">(1,338,091)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">375,142<span></span>
</td>
<td class="nump">287,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 681,377<span></span>
</td>
<td class="nump">$ 565,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SuccessPaymentLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liabilities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SuccessPaymentLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431206688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">221,286,000<span></span>
</td>
<td class="nump">197,857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">221,286,000<span></span>
</td>
<td class="nump">197,857,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525297472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 56,448<span></span>
</td>
<td class="nump">$ 67,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration', window );">Research and development related success payments and contingent consideration</a></td>
<td class="nump">38,007<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,269<span></span>
</td>
<td class="nump">16,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">110,724<span></span>
</td>
<td class="nump">84,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(110,724)<span></span>
</td>
<td class="num">(84,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">215<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,475)<span></span>
</td>
<td class="num">$ (82,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares - basic</a></td>
<td class="nump">217,290<span></span>
</td>
<td class="nump">191,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares - diluted</a></td>
<td class="nump">217,290<span></span>
</td>
<td class="nump">191,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of success payment liabilities and contingent consideration recorded in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525538464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (107,475)<span></span>
</td>
<td class="num">$ (82,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities, net</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (107,430)<span></span>
</td>
<td class="num">$ (79,935)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432548288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At The Market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 499,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,558,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,327)<span></span>
</td>
<td class="num">$ (1,054,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Fees incurred related to issuance of common stock from at the market offering</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities, net</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(82,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">428,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,139)<span></span>
</td>
<td class="num">(1,136,959)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 287,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(1,338,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">197,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,773<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 180,008<span></span>
</td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,006<span></span>
</td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Fees incurred related to issuance of common stock from at the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities, net</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(107,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,475)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 375,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,820,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (1,445,566)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">221,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524769440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sana_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 9,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469546965184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (107,475)<span></span>
</td>
<td class="num">$ (82,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DepreciationAndImpairmentOfLongLivedAssets', window );">Depreciation and impairment of long-lived assets</a></td>
<td class="nump">3,746<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,092<span></span>
</td>
<td class="nump">8,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="nump">5,384<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ChangeInFairValueOfSuccessPaymentLiabilities', window );">Change in the estimated fair value of success payment liabilities</a></td>
<td class="nump">32,623<span></span>
</td>
<td class="num">(5,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash expense for operating lease right-of-use assets</a></td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="num">(4,879)<span></span>
</td>
<td class="num">(2,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="nump">5,804<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(9,821)<span></span>
</td>
<td class="num">(10,339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(65,632)<span></span>
</td>
<td class="num">(79,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(114,393)<span></span>
</td>
<td class="num">(20,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">53,010<span></span>
</td>
<td class="nump">85,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,845)<span></span>
</td>
<td class="num">(2,176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(77,228)<span></span>
</td>
<td class="nump">62,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from employee stock purchase plan and exercise of stock options</a></td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet', window );">Proceeds from issuance of common stock from equity financings, net</a></td>
<td class="nump">181,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">186,397<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">43,537<span></span>
</td>
<td class="num">(16,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">137,349<span></span>
</td>
<td class="nump">187,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">180,886<span></span>
</td>
<td class="nump">170,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">8,375<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CashReceivedForTenantImprovementAllowances', window );">Cash received for tenant improvement allowances</a></td>
<td class="nump">$ 6,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_CashReceivedForTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Received For Tenant Improvement Allowances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_CashReceivedForTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ChangeInFairValueOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of success payment liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ChangeInFairValueOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_DepreciationAndImpairmentOfLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Impairment of Long-lived Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_DepreciationAndImpairmentOfLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase decrease in operating lease right-of-use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock from equity financings, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525558384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (107,475)<span></span>
</td>
<td class="num">$ (82,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469545263584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, the following officer, as defined in Rule 16a-1(f), adopted a &#8220;Rule 10b5-1 trading arrangement&#8221; as defined in Regulation S-K Item 408, as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 5, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nathan Hardy</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, adopted a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76,125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock issuable upon the exercise of options. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 15, 2026, or earlier if all transactions under the trading arrangement are completed. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 13, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Hardy</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> terminated a separate </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> providing for the sale from time to time of an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140,236</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76,692</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock issuable upon the exercise of options. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until April 20, 2024, or earlier if all transactions under the trading arrangement were completed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other officers or directors, as defined in Rule 16a-1(f), </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and/or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the last fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sana_NathanHardyMember', window );">Nathan Hardy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Nathan Hardy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March 5, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">76,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sana_MrHardyMember', window );">Mr. Hardy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mr. Hardy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">March 13, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">140,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=sana_Rule10B51TradingPlanOneMember', window );">Rule 10B51Trading Plan One [Member] | Nathan Hardy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">23,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=sana_Rule10B51TradingPlanTwoMember', window );">Rule 10B51Trading Plan Two [Member] | Mr. Hardy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">76,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sana_NathanHardyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sana_NathanHardyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sana_MrHardyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sana_MrHardyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=sana_Rule10B51TradingPlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=sana_Rule10B51TradingPlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=sana_Rule10B51TradingPlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=sana_Rule10B51TradingPlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429641616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sana Biotechnology, Inc. (the Company or Sana) is a biotechnology company focusing on utilizing engineered cells as medicines. The Company&#8217;s operations to date have included identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, preparing for and executing clinical trials of its product candidates and supporting clinical trials of product candidates developed using its technologies, acquiring technology, organizing and staffing the Company, business planning, establishing and maintaining the Company&#8217;s intellectual property portfolio, raising capital, and providing general and administrative support for these operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks and uncertainties similar to other biotechnology companies in the development stage, including, but not limited to, those related to the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, building out internal and external manufacturing capabilities, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, the need to protect the Company&#8217;s intellectual property and proprietary technologies, and the need to attract and retain key scientific and management personnel. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations with the proceeds from additional equity or debt financings or capital obtained in connection with strategic collaborations or licensing or other arrangements. In the event that additional financing is required, the Company may not be able to raise it on terms acceptable to it or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company completed an underwritten public offering pursuant to which it sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">180.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), acting as sales agent, pursuant to which it may offer and sell through Cowen up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time in a series of one or more at the market equity offerings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(collectively, the ATM facility). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's common stock under the ATM facility for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting commissions and expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses each year since inception and expects such losses to continue for the foreseeable future. As of March 31, 2024, the Company had cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">311.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion, which includes cumulative non-cash charges related to the revaluation of the success payment liabilities and contingent consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524901280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of significant accounting policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Certain prior period amounts have been reclassified to conform to current period presentation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 29, 2024 (2023 Annual Report).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant accounting policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in the preparation of these condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 are consistent with those discussed in Note 2 in the 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, and operating lease right-of-use assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures that requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU is effective for the Company's fiscal year 2025. Early adoption is permitted. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469430707920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Acquisitions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cobalt Biomedicine, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding equity of Cobalt Biomedicine, Inc. (Cobalt), a privately held early-stage biotechnology company developing a platform technology using its fusogen technology to specifically and consistently deliver various biological payloads to cells (the Cobalt acquisition).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the Cobalt acquisition, the Company recorded an intangible asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">59.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which consists of in-process research and development that is classified as indefinite-lived until the successful completion of the associated research and development technology, at which point it becomes a finite-lived asset and will be amortized over its estimated useful life. If the research and development technology is abandoned, an impairment charge will be recorded. The Company is actively developing the fusogen technology and, accordingly, the intangible asset is not complete. Amortization will begin when regulatory approval of a product candidate developed using the fusogen technology is obtained in a major market, typically either the United States or the European Union.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of goodwill as a result of the Cobalt acquisition, which is primarily attributable to the value the acquisition provides the Company by complementing the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> portfolio with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fusogen cell engineering technology and furthering the Company&#8217;s research in using engineered cells as medicines. The goodwill is not deductible for income tax purposes. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments of the intangible asset or goodwill since the acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms and conditions in the Cobalt acquisition agreement, the Company has an obligation to pay to certain former Cobalt stockholders contingent consideration (Cobalt Contingent Consideration) of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of certain specified development milestones and a success payment (Cobalt Success Payment) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, each of which is payable in cash or stock. The Cobalt Success Payment is payable if, at pre-determined valuation measurement dates, the Company&#8217;s market capitalization equals or exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion, and the Company is advancing a program based on the fusogen technology in a clinical trial pursuant to an investigational new drug (IND) application, or has filed, or received approval for, a biologics license application or new drug application for a product developed using the fusogen technology. The Cobalt Success Payment can be achieved over a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the acquisition, but this period could be shorter upon the occurrence of certain events. A valuation measurement date would also be triggered upon a change of control of the Company if at least one of the Company&#8217;s programs based on the fusogen technology is an active research program at the time of such change of control. If the Company&#8217;s market capitalization is below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion as of the date of a change of control, the amount of the potential Cobalt Success Payment will decrease, and the amount of potential Cobalt Contingent Consideration will increase. As of March 31, 2024, a Cobalt Success Payment had not been triggered.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth various thresholds for the Company&#8217;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sana market capitalization upon a change of control and resulting impact to Cobalt Success<br/>Payment and additional potential Cobalt Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt Success<br/>Payment</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>potential Cobalt<br/>Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $8.1 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $7.4 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less than $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Cobalt Success Payment and Cobalt Contingent Consideration liabilities are carried at fair value, with changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Success Payment liability was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Success Payment, the Company recognized an expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Contingent Consideration was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">115.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">109.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Contingent Consideration, the Company recognized expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429660672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and collaboration agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. License and collaboration agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Beam Therapeutics Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company entered into an option and license agreement with Beam Therapeutics Inc. (Beam), pursuant to which the Company was granted a non-exclusive license to use Beam&#8217;s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products that (i) are directed to certain antigen targets, with respect to the Company&#8217;s allogeneic T cell programs, or (ii) comprise certain human cell types, with respect to the Company&#8217;s stem cell-derived programs. The Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Beam, which was recorded in research and development expense for the year ended December 31, 2021. Additionally, under the terms of the agreement, the Company may be obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in specified developmental and commercial milestone payments and royalties on licensed products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each licensed product. At the time of the entry into the option and license agreement, a member of the Company&#8217;s board of directors was a beneficial owner of greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of Beam. This director is also affiliated with a member of the board of directors of Beam.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">President and Fellows of Harvard College</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2019, the Company entered into an exclusive license agreement with the President and Fellows of Harvard College (Harvard) to access certain intellectual property for the development of hypoimmune-modified cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company paid to Harvard aggregate consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, comprising $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Additionally, the Company may be required to pay to Harvard up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in success payments, payable in cash, based on increases in the fair value of the Company&#8217;s common stock (Harvard Success Payments). The potential Harvard Success Payments are based on multiples of increased value ranging from 5x to 40x, based on a comparison of the fair market value of the Company&#8217;s common stock relative to the original issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share at ongoing pre-determined valuation measurement dates. The Harvard Success Payments can be achieved over a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the effective date of the agreement. If a higher success payment tier is first met at the same time a lower tier is first met, both tiers will be owed. Any previous success payments made to Harvard would be credited against the success payment owed as of any valuation measurement date so that Harvard does not receive multiple success payments in connection with the same threshold. As of March 31, 2024, a Harvard Success Payment had not been triggered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the potential success payments and common stock price required for payment:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.2%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Multiple of Equity Value at Issuance</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">30x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">40x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per share common stock price required for payment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment(s) (in millions)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Harvard Success Payment liabilities are carried at fair value, with the initial value and changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Harvard Success Payment liability was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Harvard Success Payment liability, the Company recognized an expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023 respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524901808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">standby letters of credit that are collateralized with a bank account at a financial institution in accordance with certain lease agreements. The aggregate amount of such standby letters of credit was</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of each of March 31, 2024 and December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429485776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Fair value measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:11.278%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,137</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,137</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,671</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:11.278%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,853</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,825</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level 2 marketable securities include U.S. government and agency securities and corporate debt securities and are valued based on either recent trades of securities in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.366%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.4879999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 months or greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that there was no material change in the credit risk of the above investments during the three months ended March 31, 2024. As such, an allowance for credit losses has not been recognized. As of March 31, 2024, the Company does not intend to sell such securities, and it is not more-likely-than-not that the Company will be required to sell the securities prior to the recovery of the amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, all marketable securities had an effective maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or less. Investments in securities with maturities of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or those for which management intends to use to fund current operations, are included in current assets and classified as available-for-sale. As of March 31, 2024, the balance in accumulated other comprehensive loss included net unrealized gains related to the Company&#8217;s available-for-sale debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value &#8211; expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes significant estimates and assumptions it believes would be made by a market participant in determining the estimated fair value of the Cobalt Contingent Consideration at each balance sheet date. The fair value of the Cobalt Contingent Consideration was determined by calculating the probability-weighted estimated value of the pre-specified development milestone payments based on the assessment of the likelihood and estimated timing that the milestones would be achieved and the applicable discount rates. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. The Company assesses these estimates on an ongoing basis as additional data impacting the assumptions are obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Cobalt Contingent Consideration was calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rates</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Probability of milestone achievement</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average unobservable inputs were calculated based on the relative value of the pre-specified development milestones. The estimated fair value of the Cobalt Contingent Consideration may change significantly as development progresses and additional data are obtained, impacting the assumptions regarding probabilities of successful achievement of the milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value assumptions, judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions, inputs and/or different valuation techniques could result in materially different fair value estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Success payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes significant estimates and assumptions in determining the estimated fair value of the success payment liabilities and the associated expense or gain at each balance sheet date. The estimated fair value of the Cobalt Success Payment and Harvard Success Payment liabilities was determined using a Monte Carlo simulation methodology, which models the estimated fair value of the liability based on several key assumptions, including the expected volatility, remaining term, risk-free interest rate, estimated number and timing of valuation measurement dates on the basis of which payment may be triggered, and, for the Cobalt Success Payment, the Company&#8217;s market capitalization, and, for the Harvard Success Payments, the per share fair value of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Cobalt Success Payments and Harvard Success Payments were calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span></span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429570096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Property and equipment, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment, software, and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525374096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Accrued liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonuses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,379</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued paid time off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,731</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429660672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lease portfolio primarily comprises operating leases for office, laboratory, and manufacturing space. These leases contain various rent abatement periods, after which they require monthly lease payments that may be subject to annual increases throughout the lease term. Certain leases include options to extend the term. The renewal option is considered in the remaining lease term for the lease only when the Company is reasonably certain it will renew the lease. Certain leases provide the Company with the right to make tenant improvements, including the addition of laboratory space or build-out of manufacturing capabilities, and include a lease incentive allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company entered into a lease agreement for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79,565</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office, laboratory, and manufacturing space located in Bothell, Washington (the Bothell facility). The initial term of the lease expires in February 2039, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with the option to extend the lease for up to three additional five-year terms.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The lease agreement also provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for reimbursement of tenant improvements, as well as an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for tenant improvements, available at the Company&#8217;s election, which the Company would be obligated to repay to the landlord monthly over the initial term of the lease with interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year.  The Company is obligated to pay base rent of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the initial term of the lease. In accordance with the lease agreement, the Company has obtained a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recognized the right-of-use asset and lease liability in the three months ended March 31, 2023, when the lease commenced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains additional information related to the Company&#8217;s operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.12%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:20.68%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:11.86%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:22.92%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:22.14%;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Location</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Use</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate <br/>Square Footage</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Commencement Dates</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Dates</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Seattle, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">48,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2020</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2028</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cambridge, MA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 2028</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">South San Francisco, CA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2030</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rochester, NY</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2025</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bothell, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory/Manufacturing</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">80,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2023</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2039</span></span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout the term of the lease agreements, the Company is responsible for paying, in addition to base rent, certain operating costs, such as common area maintenance, taxes, utilities, and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s lease costs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.112%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,995</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the weighted-average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.3 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, and the weighted-average incremental borrowing rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows by fiscal year to the present value of the operating lease liabilities as of March 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.3%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.8%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining 9 months)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,472</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: tenant improvement allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469436343936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders&#8217; equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company completed an underwritten public offering pursuant to which it sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of its common stock, for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">180.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses. The pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of common stock. As the pre-funded warrants are indexed to the Company&#8217;s common stock and otherwise meet the requirements to be classified in equity, the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company&#8217;s consolidated balance sheet.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pre-funded warrants are exercisable at any time; however, the holders of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of pre-funded warrants may increase or decrease such percentages not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pre-funded warrants do not expire. During the three months ended March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants were exercised.</span><span style="color:#0070c0;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company entered into a sales agreement with Cowen, acting as sales agent, pursuant to which it may offer and sell through Cowen up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time in a series of one or more at the market equity offerings. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company's common stock under the ATM facility for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting commissions and expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469430535664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity incentive plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the Company adopted the 2021 Incentive Award Plan (2021 Plan) and the 2021 Employee Stock Purchase Plan (2021 ESPP), both of which became effective on the completion of the Company&#8217;s initial public offering. The 2021 Plan provides for a variety of stock-based compensation awards, including stock options, restricted stock awards (RSAs), and restricted stock units (RSUs). The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees may purchase shares at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering period or on the purchase date. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares were available for future issuance under the 2021 Plan and the 2021 ESPP, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based compensation expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is recognized in the condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.006%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.918000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.918000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,751</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of March 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized stock-based compensation expense (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average period costs expected to be recognized (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Life <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,849</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:14.283%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:14.283%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Assumptions</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.34</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.50</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes additional information related to stock option activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.674%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.322%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.322%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average grant date fair value per share for options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate intrinsic value of stock options exercised (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted stock</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s RSU activity is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.971%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.244%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs<br/>Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,341</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.88</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of March 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,226</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.05</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of RSUs that vested during the three months ended March 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525204496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax provision for interim periods is determined using an estimate of the Company&#8217;s annual effective tax rate, adjusted for discrete items arising in the quarter. The Company&#8217;s effective tax rate differs from the U.S. statutory tax rate primarily due to a valuation allowance on the deferred tax assets. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies judgment in its determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of March 31, 2024 and December 31, 2023, the Company&#8217;s uncertain tax positions were immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525671056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net loss per share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share are calculated by dividing net loss by the weighted-average number of common shares outstanding during the relevant period, including the pre-funded warrants given their nominal exercise price. The Company was in a loss position for all periods presented, and basic net loss per share and diluted net loss per share are therefore the same for all periods, as the inclusion of all potential common securities outstanding would have been anti-dilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following securities were excluded from the computation of net loss per diluted share of common stock for periods presented as their effect would have been anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.54%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525384048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Employee benefit plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The Company matches each participant&#8217;s 401(k) contributions, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per year per participant.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432605184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Certain prior period amounts have been reclassified to conform to current period presentation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 29, 2024 (2023 Annual Report).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant accounting policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in the preparation of these condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 are consistent with those discussed in Note 2 in the 2023 Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, and operating lease right-of-use assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures that requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU is effective for the Company's fiscal year 2025. Early adoption is permitted. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429601120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ScheduleOfMarketCapitalizationsTableTextBlock', window );">Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth various thresholds for the Company&#8217;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sana market capitalization upon a change of control and resulting impact to Cobalt Success<br/>Payment and additional potential Cobalt Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt Success<br/>Payment</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>potential Cobalt<br/>Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $8.1 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equal to or exceeds $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion, but less than $7.4 billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less than $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;billion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ScheduleOfMarketCapitalizationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various thresholds for the Company&#8217;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ScheduleOfMarketCapitalizationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429718016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and collaboration agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock', window );">Summary of Potential Success Payments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the potential success payments and common stock price required for payment:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.2%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.58%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Multiple of Equity Value at Issuance</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">30x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">40x</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per share common stock price required for payment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment(s) (in millions)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of potential success payments and common stock price required for payment to Harvard.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469430893184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:11.278%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,137</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,137</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,671</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">299,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.193%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:11.278%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,853</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,825</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Success payment liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.366%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.068%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.4879999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 months or greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,858</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,984</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Estimated Fair Value of Level 3 Financial Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.902000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent<br/>Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard <br/>Success Payment<br/>Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value &#8211; expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,990</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sana_SuccessPaymentLiabilitiesMember', window );">Success Payment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Liabilities using Unobservable Inputs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of the Cobalt Success Payments and Harvard Success Payments were calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cobalt</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Harvard</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Cobalt Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Liabilities using Unobservable Inputs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Cobalt Contingent Consideration was calculated using the following unobservable inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.906%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:13.954%;"></td>
        <td style="width:1.519%;"></td>
        <td style="width:15.054%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rates</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Probability of milestone achievement</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sana_SuccessPaymentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sana_SuccessPaymentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_CobaltContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_CobaltContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469528641888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,361</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment, software, and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525536256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation and accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonuses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,379</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued paid time off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,731</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,363</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524926272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeasesAdditionalInformationTableTextBlock', window );">Schedule of Additional Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains additional information related to the Company&#8217;s operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.12%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:20.68%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:11.86%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:22.92%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:22.14%;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Location</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Use</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate <br/>Square Footage</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Commencement Dates</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Dates</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Seattle, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">48,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2020</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2028</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cambridge, MA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 2028</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">South San Francisco, CA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;to </span><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2030</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rochester, NY</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2022</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2025</span></span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bothell, WA</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office/Laboratory/Manufacturing</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">80,000</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2023</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2039</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s lease costs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.112%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,995</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows by fiscal year to the present value of the operating lease liabilities as of March 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.3%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.8%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 (remaining 9 months)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,971</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,472</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: tenant improvement allowances</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cef0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OperatingLeasesAdditionalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OperatingLeasesAdditionalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429429984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock Based Compensation Expense Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is recognized in the condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.006%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.918000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.918000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,751</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of March 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized stock-based compensation expense (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average period costs expected to be recognized (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s stock option activity is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise Price per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Life <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,849</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:14.283%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:14.283%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Assumptions</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.34</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.50</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Additional Information Related to Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes additional information related to stock option activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.674%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.322%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.322%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average grant date fair value per share for options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate intrinsic value of stock options exercised (in thousands)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the Company&#8217;s RSU activity is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.971%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.244%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs <br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RSUs<br/>Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,341</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.88</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested shares as of March 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,226</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.05</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469529870480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following securities were excluded from the computation of net loss per diluted share of common stock for periods presented as their effect would have been anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.54%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,458</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431169344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,445,566,000<span></span>
</td>
<td class="nump">$ 1,338,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilities', window );">Success payment liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common stock</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="nump">21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters' Option To Purchase Additional Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common stock</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember', window );">Cowen | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfOrganizationLineItems', window );"><strong>Description Of Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockMaximumOfferingAmount', window );">Common stock maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_CommonStockMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock maximum offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_CommonStockMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_DescriptionOfOrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_DescriptionOfOrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwritersOptionToPurchaseAdditionalSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwritersOptionToPurchaseAdditionalSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432576096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Estimated fair value of contingent consideration, long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,606,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,384,000<span></span>
</td>
<td class="nump">$ 5,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Business acquisition, impairment of intangible assets or goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">140,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones', window );">Maximum contingent consideration upon achievement of certain pre-specified development milestones</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_BusinessAcquisitionMaximumTermForSuccessPayment', window );">Maximum term for success payment</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_EstimatedFairValueOfContingentConsideration', window );">Estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities', window );">Change in estimated fair value of success payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement | Long-term Liabilities | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_EstimatedFairValueOfSuccessPaymentLiability', window );">Estimated fair value of success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ThresholdMarketCapitalization', window );">Threshold market capitalization</a></td>
<td class="nump">$ 8,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MaximumPotentialSuccessPayments', window );">Cobalt success payment</a></td>
<td class="nump">500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember', window );">Cobalt Biomedicine, Inc | Acquisition Agreement | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Business combination, intangible assets</a></td>
<td class="nump">$ 59,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_BusinessAcquisitionMaximumTermForSuccessPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum&#8203; term for success payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_BusinessAcquisitionMaximumTermForSuccessPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_EstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_EstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_EstimatedFairValueOfSuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_EstimatedFairValueOfSuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain expense in connection with change in estimated fair value of success payment liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contingent consideration upon achievement of certain pre specified development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MaximumPotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MaximumPotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ThresholdMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ThresholdMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_AcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_AcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sana_InProcessResearchAndDevelopmentIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sana_InProcessResearchAndDevelopmentIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524672896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details) - Cobalt Biomedicine, Inc<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember', window );">Market Capitalization Equal to or Exceeds $8.1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayment', window );">Cobalt Success Payment</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationTwoMember', window );">Market Capitalization Equal to or exceeds $7.4 billion, but less than $8.1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayment', window );">Cobalt Success Payment</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AdditionalPotentialContingentConsideration', window );">Additional potential Cobalt Contingent Consideration</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationThreeMember', window );">Market Capitalization Equal to or exceeds $6.8 billion, but less than $7.4 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayment', window );">Cobalt Success Payment</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AdditionalPotentialContingentConsideration', window );">Additional potential Cobalt Contingent Consideration</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationFourMember', window );">Market Capitalization Less than $6.8 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AdditionalPotentialContingentConsideration', window );">Additional potential Cobalt Contingent Consideration</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AdditionalPotentialContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional potential contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AdditionalPotentialContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PotentialSuccessPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential success payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PotentialSuccessPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sana_CobaltBiomedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525475184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details) - Sana<br> $ in Billions</strong></div></th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Market Capitalization Equal to or Exceeds $8.1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ThresholdMarketCapitalization', window );">Threshold market capitalization</a></td>
<td class="nump">$ 8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Market Capitalization Equal to or exceeds $7.4 billion, but less than $8.1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ThresholdMarketCapitalization', window );">Threshold market capitalization</a></td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Market Capitalization Equal to or exceeds $6.8 billion, but less than $7.4 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ThresholdMarketCapitalization', window );">Threshold market capitalization</a></td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Market Capitalization Less than $6.8 billion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ThresholdMarketCapitalization', window );">Threshold market capitalization</a></td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ThresholdMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ThresholdMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sana_MarketCapitalizationFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431150528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_BeamTherapeuticsIncorporatedMember', window );">Beam Therapeutics Inc. (Beam) | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_UpfrontPaymentToCollaborators', window );">Upfront payment to collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_BeamTherapeuticsIncorporatedMember', window );">Beam Therapeutics Inc. (Beam) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable', window );">Developmental and commercial milestone payments and royalties on licensed products payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_BeamTherapeuticsIncorporatedMember', window );">Beam Therapeutics Inc. (Beam) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_BeneficialOwnershipPercentage', window );">Beneficial ownership percentage held by a member of board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Harvard College</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_TotalValueOfConsiderationPaidUnderLicenseAgreement', window );">Aggregated consideration paid</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement', window );">Common stock shares issued</a></td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PaymentToCollaborators', window );">Payment to collaborators</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MaximumPeriodExpectedToAchieveForSuccessPayments', window );">Maximum period expected to achieve for success payments</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Harvard College | Long-term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_EstimatedFairValueOfSuccessPaymentLiability', window );">Estimated fair value of success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Harvard College | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities', window );">Expense in connection with change in estimated fair value of success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Harvard College | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MaximumPotentialSuccessPayments', window );">Cobalt success payment</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_EstimatedFairValueOfSuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_EstimatedFairValueOfSuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain expense in connection with change in estimated fair value of success payment liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MaximumPeriodExpectedToAchieveForSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum period expected to achieve for success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MaximumPeriodExpectedToAchieveForSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MaximumPotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MaximumPotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PaymentToCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to collaborators.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PaymentToCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential amount of milestone payments and royalties payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, common stock in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_TotalValueOfConsiderationPaidUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total value of consideration paid under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_TotalValueOfConsiderationPaidUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_UpfrontPaymentToCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment to collaborators.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_UpfrontPaymentToCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sana_BeamTherapeuticsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sana_BeamTherapeuticsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sana_HarvardCollegeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525466784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Summary of Potential Success Payments (Details) - Harvard College<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Multiple of Equity Value at Issuance, 5x</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockPricePerShareRequiredForPayment', window );">Per share common stock price required for payment | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayments', window );">Success payment(s) | $</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Multiple of Equity Value at Issuance, 10x</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockPricePerShareRequiredForPayment', window );">Per share common stock price required for payment | $ / shares</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayments', window );">Success payment(s) | $</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Multiple of Equity Value at Issuance, 20x</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockPricePerShareRequiredForPayment', window );">Per share common stock price required for payment | $ / shares</a></td>
<td class="nump">$ 80.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayments', window );">Success payment(s) | $</a></td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Multiple of Equity Value at Issuance, 30x</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockPricePerShareRequiredForPayment', window );">Per share common stock price required for payment | $ / shares</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayments', window );">Success payment(s) | $</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember', window );">Multiple of Equity Value at Issuance, 40x</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockPricePerShareRequiredForPayment', window );">Per share common stock price required for payment | $ / shares</a></td>
<td class="nump">$ 160.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PotentialSuccessPayments', window );">Success payment(s) | $</a></td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_CommonStockPricePerShareRequiredForPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock price per share required for payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_CommonStockPricePerShareRequiredForPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sana_HarvardCollegeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sana_HarvardCollegeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_MilestoneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_MilestoneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sana_MilestoneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sana_MilestoneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524972976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash And Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Standby letters of credit</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription', window );">Restricted cash and cash equivalents, noncurrent, nature of restriction, description</a></td>
<td class="text">standby letters of credit that are collateralized with a bank account at a financial institution in accordance with certain lease agreements. The aggregate amount of such standby letters of credit was<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature and provision of restriction as to withdrawal or usage on cash and cash equivalents, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432018960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 164,830<span></span>
</td>
<td class="nump">$ 104,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">164,830<span></span>
</td>
<td class="nump">104,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">85,137<span></span>
</td>
<td class="nump">70,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">85,137<span></span>
</td>
<td class="nump">70,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | US Government Agencies Debt Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">79,179<span></span>
</td>
<td class="nump">33,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">79,179<span></span>
</td>
<td class="nump">33,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Corporate Debt Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">134,043<span></span>
</td>
<td class="nump">71,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">134,028<span></span>
</td>
<td class="nump">71,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-term Marketable Securities | US Government Agencies Debt Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122,671<span></span>
</td>
<td class="nump">57,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">122,657<span></span>
</td>
<td class="nump">57,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-term Marketable Securities | Corporate Debt Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,372<span></span>
</td>
<td class="nump">13,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,371<span></span>
</td>
<td class="nump">13,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Financial Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">299,254<span></span>
</td>
<td class="nump">176,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">299,239<span></span>
</td>
<td class="nump">176,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Assets | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">160,412<span></span>
</td>
<td class="nump">122,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">160,412<span></span>
</td>
<td class="nump">122,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Financial Liabilities | Contingent consideration | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">114,990<span></span>
</td>
<td class="nump">109,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">114,990<span></span>
</td>
<td class="nump">109,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Financial Liabilities | Success Payment Liabilities | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">45,422<span></span>
</td>
<td class="nump">12,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">45,422<span></span>
</td>
<td class="nump">12,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">160,412<span></span>
</td>
<td class="nump">122,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 160,412<span></span>
</td>
<td class="nump">$ 122,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=sana_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=sana_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_LongTermFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_LongTermFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=sana_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=sana_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sana_SuccessPaymentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sana_SuccessPaymentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469434552464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value less than 12 months</a></td>
<td class="nump">$ 119,369<span></span>
</td>
<td class="nump">$ 10,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value 12 months or greater</a></td>
<td class="nump">5,984<span></span>
</td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total fair value</a></td>
<td class="nump">125,353<span></span>
</td>
<td class="nump">20,968<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total unrealized losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value less than 12 months</a></td>
<td class="nump">111,511<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value 12 months or greater</a></td>
<td class="nump">5,984<span></span>
</td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total fair value</a></td>
<td class="nump">117,495<span></span>
</td>
<td class="nump">19,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total unrealized losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value less than 12 months</a></td>
<td class="nump">7,858<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total fair value</a></td>
<td class="nump">7,858<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total unrealized losses</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431212240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - Maximum<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MarketableSecuritiesMaturityPeriod', window );">Marketable securities maturity period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_InvestmentsSecuritiesMaturitiesPeriod', window );">Investments in securities with maturities period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_InvestmentsSecuritiesMaturitiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments securities maturities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_InvestmentsSecuritiesMaturitiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524936992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details) - Fair Value, Inputs, Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 109,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes infair value - expense</a></td>
<td class="nump">5,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">114,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Cobalt Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">11,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes infair value - expense</a></td>
<td class="nump">27,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">39,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Harvard Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes infair value - expense</a></td>
<td class="nump">4,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 6,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_CobaltSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_CobaltSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_HarvardSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_HarvardSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431717232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details) - Cobalt Contingent Consideration<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Discount Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.109<span></span>
</td>
<td class="nump">0.117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Discount Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.113<span></span>
</td>
<td class="nump">0.124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Discount Rates | Weighted-Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Probability of Milestone Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Probability of Milestone Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.55<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember', window );">Probability of Milestone Achievement | Weighted-Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.257<span></span>
</td>
<td class="nump">0.257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=sana_CobaltContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sana_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sana_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525210384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Stock Price Volatility | Cobalt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilityMeasurementInput', window );">Fair value measurement input</a></td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Stock Price Volatility | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilityMeasurementInput', window );">Fair value measurement input</a></td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (Years) | Cobalt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilityExpectedTerm', window );">Fair value measurement input expected term (years)</a></td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">15 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (Years) | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_SuccessPaymentLiabilityExpectedTerm', window );">Fair value measurement input expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SuccessPaymentLiabilityExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liability expected Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SuccessPaymentLiabilityExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_SuccessPaymentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liability measurement input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_SuccessPaymentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_CobaltSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_CobaltSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=sana_HarvardSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=sana_HarvardSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524938352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 127,166<span></span>
</td>
<td class="nump">$ 112,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(45,517)<span></span>
</td>
<td class="num">(41,771)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">81,649<span></span>
</td>
<td class="nump">70,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sana_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">53,447<span></span>
</td>
<td class="nump">51,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">33,848<span></span>
</td>
<td class="nump">31,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">35,028<span></span>
</td>
<td class="nump">26,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment, Software and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 4,843<span></span>
</td>
<td class="nump">$ 3,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sana_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sana_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469614218432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469529905680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract', window );"><strong>Accrued compensation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">$ 3,957<span></span>
</td>
<td class="nump">$ 14,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued paid time off</a></td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">4,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">4,065<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AccruedCompensationOther', window );">Other accrued compensation</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total accrued compensation</a></td>
<td class="nump">13,965<span></span>
</td>
<td class="nump">23,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued expenses and other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services</a></td>
<td class="nump">9,749<span></span>
</td>
<td class="nump">10,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,509<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AccruedPropertyAndEquipmentCurrent', window );">Accrued property and equipment</a></td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued current liabilities</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 19,674<span></span>
</td>
<td class="nump">$ 23,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AccruedCompensationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AccruedCompensationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469529883696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Obligation to pay base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sana_BothellWashingtonMember', window );">Bothell, Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet | ft&#178;</a></td>
<td class="nump">79,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend the lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">with the option to extend the lease for up to three additional five-year terms.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_ReimbursementOfTenantImprovements', window );">Reimbursement of tenant improvements</a></td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OptionalTenantImprovementAllowance', window );">Optional additional tenant improvement allowance</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OptionalTenantImprovementAllowanceInterestRate', window );">Optional additional tenant improvement allowance, interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Obligation to pay base rent</a></td>
<td class="nump">$ 68,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OptionalTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Optional additional tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OptionalTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OptionalTenantImprovementAllowanceInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Optional tenant improvement allowance interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OptionalTenantImprovementAllowanceInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_ReimbursementOfTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_ReimbursementOfTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sana_BothellWashingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sana_BothellWashingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432183696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Seattle, WA | Office/Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementBeginningMonthAndYear', window );">Commencement Dates, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementEndingMonthAndYear', window );">Commencement Dates, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationBeginningMonthAndYear', window );">Lease arrangement, contractual expiration period, beginning year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationEndingMonthAndYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028-04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Cambridge, MA | Office/Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementBeginningMonthAndYear', window );">Commencement Dates, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementEndingMonthAndYear', window );">Commencement Dates, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationBeginningMonthAndYear', window );">Lease arrangement, contractual expiration period, beginning year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationEndingMonthAndYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028-02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">South San Francisco, CA | Office/Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementBeginningMonthAndYear', window );">Commencement Dates, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementEndingMonthAndYear', window );">Commencement Dates, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationBeginningMonthAndYear', window );">Lease arrangement, contractual expiration period, beginning year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationEndingMonthAndYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2030-04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sana_RochesterNewYorkMember', window );">Rochester, NY | Office/Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementBeginningMonthAndYear', window );">Commencement Dates, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationEndingMonthAndYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sana_BothellWashingtonMember', window );">Bothell, WA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="nump">79,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sana_BothellWashingtonMember', window );">Bothell, WA | Office/Laboratory/Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_AreaOfLeasedSpace', window );">Square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseCommencementBeginningMonthAndYear', window );">Commencement Dates, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_OperatingLeaseExpirationEndingMonthAndYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2039-01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OperatingLeaseCommencementBeginningMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement beginning month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OperatingLeaseCommencementBeginningMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OperatingLeaseCommencementEndingMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement ending month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OperatingLeaseCommencementEndingMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OperatingLeaseExpirationBeginningMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration beginning month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OperatingLeaseExpirationBeginningMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_OperatingLeaseExpirationEndingMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration ending month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_OperatingLeaseExpirationEndingMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=sana_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=sana_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sana_RochesterNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sana_RochesterNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sana_BothellWashingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sana_BothellWashingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=sana_OfficeLaboratoryAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=sana_OfficeLaboratoryAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432544944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,981<span></span>
</td>
<td class="nump">$ 7,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 7,995<span></span>
</td>
<td class="nump">$ 9,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469525209312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remaining 9 months)</a></td>
<td class="nump">$ 16,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">25,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">22,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">19,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">15,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter', window );">2029 and thereafter</a></td>
<td class="nump">93,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">193,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(85,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Less: tenant improvement allowances</a></td>
<td class="num">(1,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">106,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liabilities</a></td>
<td class="num">(13,167)<span></span>
</td>
<td class="num">$ (13,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 92,922<span></span>
</td>
<td class="nump">$ 90,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469425208704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PreFundedWarrantsExercised', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_DescriptionOfPreFundedWarrantsExerciable', window );">Description of pre-funded warrants exerciable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> The pre-funded warrants are exercisable at any time; however, the holders of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of pre-funded warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice', window );">Maximum percentage of pre-funded warrants increase or decrease by providing atleast 61 days prior notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding', window );">Pre-funded warrants not exercise if holder together owns maximum percentage of number of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember', window );">At The Market Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common stock</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="nump">21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwritersOptionToPurchaseAdditionalSharesMember', window );">Underwriters' Option To Purchase Additional Shares | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember', window );">Pre Funded Warrants | Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common stock</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember', window );">Cowen | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sana_CommonStockMaximumOfferingAmount', window );">Common stock maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_CommonStockMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock maximum offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_CommonStockMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_DescriptionOfPreFundedWarrantsExerciable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Pre-funded Warrants Exerciable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_DescriptionOfPreFundedWarrantsExerciable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage Of Pre-funded Warrants Increase Decrease By Providing Atleast Sixty One Days Prior Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded Warrants Not Exercise If Holder Together Owns Maximum Percentage of Number Of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sana_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwritersOptionToPurchaseAdditionalSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sana_UnderwritersOptionToPurchaseAdditionalSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sana_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sana_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431928624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage related to employees able to purchase shares at lower of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage allowed for eligible employees to purchase shares of common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneIncentiveAwardPlanMember', window );">2021 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sana_TwoThousandTwentyOneIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432360512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,092<span></span>
</td>
<td class="nump">$ 8,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,244<span></span>
</td>
<td class="nump">$ 2,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469430920480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense (in thousands)</a></td>
<td class="nump">$ 75,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period costs expected to be recognized (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense (in thousands)</a></td>
<td class="nump">$ 27,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period costs expected to be recognized (in years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431404928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding, Beginning Balance</a></td>
<td class="nump">26,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">5,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(1,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/Cancelled</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding, Ending Balance</a></td>
<td class="nump">30,232<span></span>
</td>
<td class="nump">26,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options Exercisable</a></td>
<td class="nump">13,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share Outstanding, Beginning Balance</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Granted</a></td>
<td class="nump">9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Exercised</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Forfeited/Cancelled</a></td>
<td class="nump">9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share Outstanding, Ending Balance</a></td>
<td class="nump">7.12<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (years), Outstanding</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (years), Exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 113,377<span></span>
</td>
<td class="nump">$ 11,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 57,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469431406896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.50%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469432644192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share for options granted</a></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised (in thousands)</a></td>
<td class="nump">$ 3,586<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469524661696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares as of December 31, 2023 | shares</a></td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">2,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares as of March 31, 2024 | shares</a></td>
<td class="nump">4,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares as of December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">9.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">4.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">5.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares as of March 31, 2024 | $ / shares</a></td>
<td class="nump">$ 7.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469430992048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares - basic</a></td>
<td class="nump">217,290<span></span>
</td>
<td class="nump">191,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings (loss) per common share</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares - basic</a></td>
<td class="nump">217,290<span></span>
</td>
<td class="nump">191,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares - diluted</a></td>
<td class="nump">217,290<span></span>
</td>
<td class="nump">191,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings (loss) per common share</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469530068928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of dilutive net loss per share</a></td>
<td class="nump">34,458<span></span>
</td>
<td class="nump">31,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of dilutive net loss per share</a></td>
<td class="nump">30,232<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of dilutive net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of dilutive net loss per share</a></td>
<td class="nump">4,226<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140469429679056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching contribution by employer under retirement and savings plan</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7RXH4577!NKW.5<Z8'VCOV(T7ZW&_P%02P,$%     @ JH*H6.*3DQ'G @
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MC.B$H5;?;58?OKAH_-N2O3IYI\XV>-0%]350U]C R''$&3S);L@2"H4/VK(
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M\.]7E+*7C>K)^?W_D[C\%U!+ P04    " "J@JA8[CPGNH8"   K!@  &
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M%+@.4.=[QN31T GZP1S_!E!+ P04    " "J@JA8RH%=OAP&  #:(   &0
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M4E+Q3'NSUZ\<UW[7QK@CL ;_8<E_:$*'>"HJ& G1$Q611#QH*Z"V"!AACXW
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M W _X%QM+O0$Y;\SS/X%4$L#!!0    ( *J"J%B B/X*NP<  'D2   9
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M.3F?J)(JW=GTF]_\DWI_7K.^PMLH_ZM-WGN*$XLN)M_TPGANC,M_]4,?AY'
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M)=_(SYHPRP;>@/7*8Z[J'_B X6O3U?\!4$L#!!0    ( *J"J%COZ4,VW 8
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MG-&4Y\/8D5L>H5Z96\I<[MD>(>,+^J;,O;-8%]F'#\(=SJ#L!E^'RN*<>5B
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MI#&TO8FNE>_PA8OXJI=EA5,Z>=Z ]TN' TJ^80/]#S,7_P502P,$%     @
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M&&5-%43D*=<?5?F) -!BD5,$.&:XMEN,<F#O2F C&/?58+*LM988*P;%  V
M,VAU1[((USIFBN0PS!D1*XJ @8&WY(Z-B@U<4;W6Z&W'2(FRXJS58(M"K.G1
M=I^6*8'<]S,H8% < +8HW>6?]!'O<'-E2:CC\JF*_;CRO-J Q"5?GW=+@N$_
MV=(%:(\W8@UBCFKKOI<VAF=>SOP#21*0/:<,UWQ'V]+;<GG"X1!R1E;H$8%5
M&(]!_C6XK+OG<74<4*24>>AC2^(8=*&/"8[6"Y^$,@CPA,[DN%[0BKL9WI>(
M#Z-_V'B^Q]WS?-L[)HXJK,IW71O@/8\=D*'GN8[\\.).UO) @APL!9:V58Y[
M>Q90[I%RC_Y>]_J]>(4J31W%O7[QF4&:Z0_!=.Q"^#P]</;M^&P+Z0P?F@7B
M?@+2(9_9^50LSJ<'N+P9OSO(92 AW%7/IM,7?]EN#VG%:=#V"%JR_[Z7X5I)
M\(/#N'ECB,JDM>&&Y<4*HU0</T_BC!@C%":?[=YP*E;UX2N,)1WN/8]F@WZL
MVCO;["^Y0/()K:I: J73ZB)BQ?:"-5!Q=PI_[*;.!1MQ+SD^B_<(93<1L2@,
M^[/A-18V-I2N4!%?F+"_#,,+VM3%*0\90_^&1PJ85Z<WO>!3UBME?AHH_[@%
M3R_E*1Y(&7IH0KL.P][\[?C]CF52%-S)PN894JO;Z_"&(8A$%9_)B)_)]H4B
M>G_HE?])W ZC= C;;'8^F&13W*;OMY>T_X/ '3+A8 13^%P:UH$.NP:>C\__
MBT';]P8X&3S/XFI2A$=HOHV@F<:7VGZU?^>^CL^[V^/QD1Q:X Z($9)6()V.
MWYZ/A(T/S_&/-TUX[%T:[TT5?I8DX20^@/V50<-)?UA __I_]1]02P,$%
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MQCWA,-BF'+'H#:GFZ,S[IFZ'MW@ZUN',81Y^QR$^.L2.]Q#(L7PG2*R76AU
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M*_Y)H;8&?+]3BDX;&V#\[:W_ 5!+ P04    " "J@JA8#0T;71H#  !(!P
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MZTI%["NW:YQP",-K M0\8) E_W9O0E$@V4ZB*'RB8;;-LWC<H(RIO-A[L3
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M>0M!]NRG] -9.!1-I6Y8[G#,6.MT'O/VG.#.?+Z@%F[$V&1V/ZPI7?B8WD/
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M[&0#UDMKPVX@!XS_3JS^!U!+ P04    " "J@JA8Y.ZRN"$'  !_$0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R-6$USV[86W>M78-2T8\^PE$CJ
MRXGM&3EU^[+HU&,[[>)-%Q )B:A!@@5 *WJ__IT+DA+M2$X6-D'PWHMSOPX
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MGWY8Q-'\@X5[TDFN6%6OE$PAM19&EIN0/7:8_-J5T<\R$Y:!#1EGS]Q(@>#
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MY0!:+PQ]3OV$"^Q_!2S_ U!+ P04    " "J@JA8?TH'J[X"   *!@  &0
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M.,5 ;^.'G'CA31T^GDR-]Z8*RP)O7V1Y Y[/#*:F=,$&VJ]IE_\"4$L#!!0
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M]+-0XJRY*2NA7SZ\NTK[EU\<7]8@/GLC7CAOF$_(!07S!&2%8$6^G;$ZR\7
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MO1E\V//C='#-U)+PWYH"#"/YP*"H^0/07'Z%LC1O0(Y\XFM>$DI>D33V:)C
MX,3][,+@?G0[(@NQYK)&#IOX0%VI\P>BT'T;):LG($GFT20#A:_A]\9-!]="
MKH0$V)#94WU(+J81&#W!Z^!.:' CWX-/Z"3RTM!O=;OYX'8)T3K17%;.-=SV
MCHW3/^D"#0)ODE"2@IT@0$.X$"='>$&I%R:!06@$<4J=/^H%F(2&D>='(<E0
M.D)Q7 C2P<_ )KFEIS45DC"E)F!P=0:>,/D5";+,"^((1M2'/] ;@UZW'F8=
MTG08?SKX).J%13H__, UE")@/<8R%W"2S(#3AKE;=)1&7I;Y!J$;#VZ;/.=
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M*RJ72IIKC;Q#L'!G$\9'RF#8EL'P>!G4WQ-3!9;9Q!2E.^E]%*>[6+LX7W_
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MT?H WI\:0RO'%VCOX_0W4$L#!!0    ( *J"J%@I!D!6V <  % Z   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;,6;66_;.!" _PKA+18MT-3B)=G=
MQ$".IBV08(-ZTWU8[ -C,[%067(E.FD7_?%+R8JI8\38,0._)#Z&HYG1</AI
M2!\^).FW;":E0C_F49P=]69*+=[W^]ED)N<B>Y<L9*R_N4W2N5#Z;7K7SQ:I
M%--BT#SJ$\_S^W,1QKW18?'953HZ3)8J"F-YE:)L.9^+].>)C)*'HQ[N/7[P
M);R;J?R#_NAP(>[D6*KKQ56JW_776J;A7,99F,0HE;='O6/\_M3G^8!"XFLH
M'[+*:Y2[<I,DW_(WGZ='/2^W2$9RHG(50O^[EZ<RBG)-VH[OI=+>^IKYP.KK
M1^WGA?/:F1N1R=,D^CN<JME1;]!#4WDKEI'ZDCQ\DJ5#A8&3),J*O^BAE/5Z
M:++,5#(O!VL+YF&\^B]^E(&H#,"L8P I!Y!-!]!R "T<75E6N'4FE!@=ILD#
M2G-IK2U_4<2F&*V]">/\-HY5JK\-]3@U.A=ABKZ*:"G1I139,I7Z'JD,':#Q
MZL:BY!:=A[&()Z&(T'&62?VMB*?H(A0W812J4&:/0Z=(*%31J&_3%SE9IFD8
MWZ$3D849>GTFE0BC[(V^@I%\6Y$[0-?C,_3ZU1OT"H4Q^FN6+#-]O>RPK[2_
MN=7]2>G;R<HWTN';I4C?(8K?(N(1!@P_M0\_DY/U<%H?WM=17H>:K$--"GVL
M0]^IR&;HP_=E>"^B/,:00U8-^91^GRW$1![U])S-9'HO>Z/??\.^]P?DGB-E
M-6?IVEE::*=/Y]6)B'3V2#0NRM+'-%DN\OMLDFJLA"K2#IV*13ZY,_3/A=:'
M/NN/LW^A.%&7<7*DK!8GMHX3LR;%\3Q)5?B?GCJG2:8@5U?C_6)\7I3O1]AG
M ^H=]N^K3@!B'F/^8"U6,X^OS>-6\_3=RC)T'>L5(BJL_)1$T_SN?=0K!)C!
M*WV\:D?#TK8$A8WTUT;ZSS/R0G\N02O]E@T'33.MUWQF5@1KCP*K1Q\R%>HE
M2KMBYA'D1M .-I0;@)C.C0##81^LC1QL5<_0+W29Q/(GTG7WFY[IYTM=M?6'
M%_)>1@A#]ELOL.TT=J2L%HOA.A;#?9:[H<LX.5)6BQ/V#&]X.Q:\4D$U70<<
MTZ"1U(!8X%',X:3&%2#"3N9>J>9),]MB-C,-3.#M:$)/M.LQ^IC<RS0NDNOX
M3NI\TW!V)F\4&N=\M8*U7S7P^APOEBI[6\Y2 GKJE$I<::O'S7 )WBN88*=D
MXDI;/5:&3?"N<%(JJ&7W$ ?#YB1HBU'J#3L6(&SH!+O&$_PTGP B'8""#:%@
MYXB"-V 4^U6?FQ^&4K ;3,%M  &SI"V69PGK"+[A%+PUJ)PFZ2))M>D.JJ-3
MB'&EK1XJ@S%XKQR#G8*,*VWUIWE#,F17DB%M1.&8-;(>$,*>3^"D)P9CB!N,
M(6T^ 6QL"UELK#1$[ PSGND('BB9SLMG!G$3R<ID!.UUVR)Y"1@A!D;(7F&$
M.(415]KJL3(P0G:%$=*F#$R9QV@SFP%HP0'KH!%B:(2XIA'21HWFH@B(8+_#
M4H,CQ#F.$ !'2*M. $*59;YNK<$,X@8S"-#GT/>?#)I6 CB"_:"C548,9Q [
M9SQ5SE[P$<UNV=8S_24@A!@((7N%$.(40EQIJW?9#83072&$ GQ!B!\TGR4
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M,IP*D%F:$K$;8\*W0\=W]A-W=+E29L(=#=9DB3-4W]93H4=NR1+3%)FDG('
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M2Z>/>B+OF/.!XFO;=,ZYTBVLO5TAB5$8 _U\P;G:#\P+RO\M1O\"4$L#!!0
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M=Z (9?*#UO_Z<(?>O_N WB%:HR\E;Z7VE6M7Z8@,EYL-])]Z>O\"_5]$W*
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M!OI^P;EZ&9CCYOAYL?T/4$L#!!0    ( *J"J%C"Y[G8'P0  &@0   9
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M;:(_B=U?K&K0..=%(E'%7[*K[O5Z)-HJ+=(J&&J0\JS\3V\K(5H!P+$'!%5
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M:I4SF>A6;G "(T^G&@EB"][XYY_"0?!K$RJ78K$CL1K&7H6Q9]6[IY;*&@M
M#4OE3@B<K4!G0X4F;^BXWPR_V>:['18I^NLW+8D>%##Y=Q/WGDON+L5B1V(U
M[OV*>[]U^MYC(M 6TQP07Z*MGLR-.6+2JG(NO4(L#*R:^?/<CGL=G0JVQU0:
M.@6=0=6I%NV@BG;0&JW)..@;VU#^!E"NUUDNDK6>3VA&<=84>JODN:&[%(L=
MB=507E4HKSYYP5ZYY.Y2+'8D5N-^77&_;IW",Q")9JC+1ET94FS^=Q1'4,YI
MB?""@FG9[*>U- .@VQ7292@(L\R79M'K2O1%E[YV[3?A+]RXJ2V_ZWY]D4Y;
M?3T7JR.Q&M:;"NM-*];?<[8HX.QY;74=9F'JZ@PM<Y7K:4RDS'&6-/)JU3]W
MNA9B_2/X@WY@/N^2I*.7UI"%P:&\#7XLG:)_T2-^)2QGC75KJ_JYR)RJQ:[4
MZF2/-@[A)V?7T@%7\%VJQ:[4ZO"C _SHHRD64Y,T4YL#@)(5,0GAD&P;\JS.
M( EG3 ^5-.NA$7W4D%K#]ZFUW<FSD3I2JR,];)+"]EV2S10/F<%*ME!.T5,%
M5[O6V5/3Z1[)E5J=XV&7%'[V-BETND]RJA:[4JO#/VR5PO:]TH_7".TO.!MN
M_W]50A3<-)4)KMY;@/./3L08B)4]690Z[>69*HZ!JM;J]/+.GMF]:Y^:4TU[
MTG:0*8Y$'[%8D4PB"DLM&72N= "B.&4L;A3?V'.W!5>*,WNY!IR",!WT\R7G
M:G]C7E"=]8[_ U!+ P04    " "J@JA8O,-K<C@#   ##   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6S-5FMOTS 4_2M60 @DMJ1)GZ.-M';C(3%1
MM0P^(#ZXR6UCS8F#[;8;OYYK)PUIR2HF%8DOC1_WGIQ[?..>X5;(.Y4 :'*?
M\DR-G$3K_,)U591 2M6YR"'#G:60*=4XE2M7Y1)H;)-2[OJ>UW53RC(G'-JU
MJ0R'8JTYRV JB5JG*94/8^!B.W):SFYAQE:)-@MN.,SI"N:@;_.IQ)E;H<0L
MA4PQD1$)RY%SV;J8M#R38".^,-BJVIB84A9"W)G)AWCD>(81<(BT@:#XV, $
M.#=(R.-'">I4[S2)]?$._:TM'HM94 43P;^R6"<CI^^0&)9TS?5,;-]#65#'
MX$6"*_M+MF6LYY!HK;1(RV1DD+*L>-+[4HA: N(T)_AE@G^8T'XD(2@3 EMH
MP<R6=44U#8=2;(DTT8AF!E8;FXW5L,P<XUQ+W&68I\.Y%M'=V1B%B,E$I-@=
MBEI]S\@<6R9><R!B26P8:0B[OC=C(#.(Q"IC/W'_Y15HRKAZA1BW\ROR\ODK
M\IRPC'Q.Q%K1+%9#5R-U0\"-2IKC@J;_",V W(A,)XI<9S'$^_DNEES5[>_J
M'OM' 6^H/"=!ZS7Q/;_=P&?R]^G!$3I!=0R!Q0L>P;M.<RX> ,@<Y(9%^$RH
MA";!+SD743'\M*S+/@7)A E66I%O'_$%Y(.&5'UO4KM@TVYF8ZZ."Y73"$8.
MW@T**8$3OGC6ZGIOFJ0Z$=B><.U*N/8Q]/"ST)039;MX8=6*ZFI!T9Y-$A2X
M78MK+KM-./ &_M#=U$O[,ZC?Z[2JH#W*G8IRYRCE&8I 9900_!3(%6SP*LWQ
M8M2[;ZF)[%'$IY[7B<#VBN]6Q7?_JT;OGE*X$X'M"=>KA.O]HT8O<#NU'N[T
MV_V#1F\(&O3\YD;O5Y3[1RF_@PPDDC9]3F/\\V)*2VK^MIMH'L5ZZDF="&RO
M[$%5]N"_:O'!*84[$=B><"WOMQGQ_E&3E\#UFSKPV^V#+F^(\GN]P4&;NS4[
ME8)<69>ID,HZTX7#J%8K)WMI_=O!^M@X7&O3?L,4]AC]PXIEBG!8(J1WWL,O
M3Q:.LYAHD5O3MA :+: =)NC209H W%\*H7<3\X+*]X>_ %!+ P04    " "J
M@JA8_V)<UT #   4"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6S%
M5MMNXS80_96!NB@2H(DNOJ>V 3M)T06Z6,.NFX>B#[0TMHA(I$K2=MRO[Y"2
MM0XJJT"![;[8O,WA.7,19WR4ZE6GB ;>\DSHB9<:4SSXOHY3S)F^EP4*VME*
ME3-#4[7S=:&0)<XHS_PH"/I^SKCPIF.WME#3L=R;C M<*-#[/&?J-,=,'B=>
MZ)T7EGR7&KO@3\<%V^$*S;I8*)KY-4K"<Q2:2P$*MQ-O%C[,P\ :N!._<3SJ
MBS%8*1LI7^WD8S+Q LL(,XR-A6#T=\!'S#*+1#S^K$"]^DYK>#D^H__DQ).8
M#=/X*+,7GIATX@T]2'#+]IE9RN//6 GJ6;Q89MK]PK$Z&W@0[[61>65,#'(N
MRG_V5CGBPB#J73&(*H/(\2XO<BR?F&'3L9)'4/8TH=F!D^JLB1P7-BHKHVB7
MDYV9KHR,7^_FI"N!1YE3L#5S[KJ#%65 LL\0Y!;60F$L=X+_1>>NVCQ*;30L
M,6.&MHPDLP-J.YX=F4HT,)' BW,4)G>S RH*/"Q0<9G 9YK"2\KCM,)A"N'Y
MK:#PE6 ;).B:Q,T3&L8S?0L?@ OX-95[3?!Z[!MRBQ7GQY4+YJ4+HBLNZ, G
M*4RJX5DDF+RW]\F=M4^CLT_G42O@)Z;NH1/^ %$0=6&]>H*;#[<MN)TZ5AV'
MV[V"^YP7F3PAE@& SX5U>I/>5AA;YP^Z8#%./"IDC>J WO3[[\)^\&,+R6Y-
MLNO0.]<2*K5Q:TB.F5),[) JVL#\!)?G%NSDEEV6P.^_$"1\-)CK/YK4=;^"
MNEZMKM<:@G=UH%T=;)R$^%(JOMDQP@TEICDGYFV3EO*VOKO-?D /TT%O%(9C
M_]! LE^3[+>2K"N,5156E!46N[+"]R5UH<?2/2%3S53;[XQ*2QA!7A93.(2$
MG72+SP>UG$$K])(^(8H[RF7BKP4G'3?+U;J9:2O<?TR084UV^(W3?_@5U(UJ
M=:/_-?U'_TC_:# <])O3/PR^O&G!-RB ?[FT4U5 OZJ )G?[%P]UCFKGVA%-
MO/;"E&]VO5JW/+/RH?]RO.R7Z)'9<:$APRV9!O<#^I2HL@4I)T86[MG?2$--
MA!NFU+:AL@=H?RNE.4_L!74C./T;4$L#!!0    ( *J"J%@ZH/!\FP0  ,$6
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;+58:T_C.!3]*U86K1@)
MFMCIDVTKT<+NCK1H$%UF/IODMK5(XJ[M4OCW:Z<A2=/@TJCP@<:.[^,</^Z)
MAQLNGN420*'7.$KDR%DJM;IR71DL(::RQ5>0Z#=S+F*J=%,L7+D20,/4*(Y<
MXGE=-Z8L<<;#M.]>C(=\K2*6P+U <AW'5+Q-(.*;D8.=]XX'ME@JT^&.ARNZ
M@!FHQ]6]T"TW]Q*R&!+)>(($S$?.-;Z:$F(,TA$_&6QDZ1D9*$^</YO&]W#D
M>"8CB"!0Q@75/R\PA2@RGG0>_V5.G3RF,2P_OWO_,P6OP3Q1"5,>_6*A6HZ<
MOH-"F--UI![XYF_( '6,OX!',OV/-ME8ST'!6BH>9\8Z@Y@EVU_ZFA%1,B#^
M!P8D,R 5 ]S]P,#/#/P4Z#:S%-8-570\%'R#A!FMO9F'E)O46J-AB9G&F1+Z
M+=-V:CQ3/'B^G&@B0C3EL5X=DJ;\7J+9=F81GZ-T%/JQ2M]<&^:9>D/G-Z H
MB^0W/?AQ=H/.S[ZA,^0BN:0")&()>DR8DA>ECG^7?"UI$NK.LYWVT%4:C<G)
M#;+,)]O,R0>9^^B.)VHIT6T20EAC/[7;8V)QX&H:<R[).Y<38O5X1T4+^?@"
M$8^TZQ*RF]] D)O[EG3\?&K]U)]OF]ILTFKYW9JWZ\W-^7$E5S2 D:,/" GB
M!9SQ[[_AKO='';83.=M!VLZ1MFW>=Y&B'VLEE5Y3+%E<H DL6)+H1S2A$4T"
MJ"-BZ[V3>C?GWLN8=/OMP=!]*2.TYM 082='V/D\P@OTEZ")JEWTD\X>EDZG
M@RM0K,$:0NGF4+K'0+E]!1$P60^FNP?F$F/B5=!8XS5$T\O1](Y!HTO+')B>
M&G=J%EL4U>/JU>#RVOT*+FODAKCZ.:Y^TRUUF_[:]E-_#YZOCS12@;<_:G?7
M[>0]R/,>')%WMKCH4U2;YV O ^SC?J^2IS5@PVG 7E&?/>LI_BL5(A!>7K^
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M9B+3H]"0-!M@F#8RIEY&](:,&&ZE,(6&3R+#["4^I)2T>8FV>9E&1PEOF>I
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MV!852F9[ND9%.TMM)',T-:O8U@99&4!2Q&F2C&+)N(KR+*S-3)[IQ@FN<&;
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M]BEZ=BNN+ A<$C3I?20!IJW]=N)T'>IMH1U5;QA6U"[1^ #:7VKM]A.?H&O
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MNE(F=/7H5-D &K_16S\21E9J-MJ?(J0IQ"<3H)+$E>F*@G.;)X5;7Q7=4P?
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M+F#?5W-M9;'_RG+_A>CY3U!+ P04    " "J@JA8TDF\;1$"   7)@  &@
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MC[\LOTY.WMX+SNFVHC[_!5!+ P04    " "J@JA8P(AM=.D!  !^)0  $P
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M/SSSUM3=(9\-?[N:O0%02P$"% ,4    " "J@JA8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *J"
MJ%B-(B1F[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( *J"J%B97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ JH*H6/"UY*X%
M!@  K"   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( *J"J%A^"W /@P8  ,$:   8              "
M@4D.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "J@JA8
MXI.3$><"  #S"0  &               @($"%0  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ JH*H6-YP%.3Z P  @PT  !@
M     ("!'Q@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M *J"J%CDE8V_[0(  $@(   8              " @4\<  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "J@JA80-\'@,@'  !;0@  &
M            @(%R'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ JH*H6.X\)[J& @  *P8  !@              ("!<"<  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *J"J%BGS@P>-@<  +\=
M   8              " @2PJ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "J@JA8OL/A-DH"  "D!0  &               @(&8,0
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ JH*H6,J!7;X<
M!@  VB   !D              ("!&#0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "J@JA8@(C^"KL'  !Y$@  &0
M@(%K.@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *J"
MJ%COZ4,VW 8  *01   9              " @5U"  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ JH*H6#&P2^:6"   "1@  !D
M         ("!<$D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "J@JA8R)&)1HT'  "%$P  &0              @($]4@  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *J"J%@;S+COF (  ,X%
M   9              " @0%:  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ JH*H6&,K* N6"P  K2(  !D              ("!T%P
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "J@JA8A8V3
MK2T#   "!P  &0              @(&=:   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( *J"J%@-#1M=&@,  $@'   9
M  " @0%L  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MJH*H6#Z7V7'$!P  +!,  !D              ("!4F\  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "J@JA82X/;_"T%  !:#   &0
M            @(%-=P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( *J"J%CD[K*X(0<  '\1   9              " @;%\  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ JH*H6*^V[YKR P
M1 D  !D              ("!"80  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "J@JA8^)WT\9,#   1"   &0              @($R
MB   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *J"J%A_
M2@>KO@(   H&   9              " @?R+  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ JH*H6,Y8T;@=!P  61,  !D
M     ("!\8X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J"J%AR_:(X, ,  'H'   9              "
M@8"G  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ JH*H
M6)LW/>#I!   &@P  !D              ("!YZH  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "J@JA8I?DS/!4&    $0  &0
M        @($'L   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( *J"J%AS@\;1Y@(  %(&   9              " @5.V  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ JH*H6#4^)PQ/!@  [3$
M !D              ("!<+D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "J@JA8Y=GK+Z<&   ,,0  &0              @('VOP
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *J"J%BF3I%3
M@@,  (D-   9              " @=3&  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ JH*H6&^D_O$N P  Q0L  !D
M ("!C<H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "J
M@JA8>)[.N>\&   >/@  &0              @('RS0  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *J"J%A@(A@UT0,  ,41   9
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M970T,RYX;6Q02P$"% ,4    " "J@JA8\.FUMHP#   ]#0  &0
M    @(&>ZP  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M *J"J%B?7!15VP,  .P5   9              " @6'O  !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ JH*H6/V9G*.C P  PQ   !D
M             ("!<_,  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " "J@JA8)%_@[;<#  !O$0  &0              @(%-]P  >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( *J"J%C[81QV:P(
M ,T%   9              " @3O[  !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ JH*H6+L-@S>  P  :@P  !D              ("!
MW?T  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "J@JA8
MPN>YV!\$  !H$   &0              @(&4 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( *J"J%A31)HF?P4  +TD   9
M      " @>H% 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ JH*H6/N'/BRG @  ^P8  !D              ("!H L! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "J@JA8EN@"L]T#  !U#@
M&0              @(%^#@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( *J"J%@)TGR"[@8  ,<N   9              " @9(2 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ JH*H6%WFVOM(
M!   ]Q4  !D              ("!MQD! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " "J@JA8O,-K<C@#   ##   &0
M@($V'@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( *J"
MJ%C_8ES70 ,  !0*   9              " @:4A 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ JH*H6#J@\'R;!   P18  !D
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M=#8R+GAM;%!+ 0(4 Q0    ( *J"J%@?I#NA=P,  (P/   9
M  " @0HX 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
MJH*H6%7FF)9J @  C 4  !D              ("!N#L! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " "J@JA8/K++CU(#  "N%0  #0
M            @ %9/@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *J"J%B7
MBKL<P    !,"   +              "  =9! 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( *J"J%@P\EFF^00  *4J   /              "  ;]" 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "J@JA8TDF\;1$"   7)@  &@
M        @ 'E1P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "J@JA8P(AM=.D!  !^)0  $P              @ $N2@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     2 !( *\3  !(3 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - License and collaboration agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and collaboration agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Acquisitions - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables</Role>
      <ShortName>Acquisitions - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - License and collaboration agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables</Role>
      <ShortName>License and collaboration agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails</Role>
      <ShortName>Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails</Role>
      <ShortName>Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995735 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995745 - Disclosure - License and Collaboration Agreements - Summary of Potential Success Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails</Role>
      <ShortName>License and Collaboration Agreements - Summary of Potential Success Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Restricted Cash - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Restricted Cash - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sana-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sana-20240331.htm">sana-20240331.htm</File>
    <File>sana-20240331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img112676973_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="497">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sana-20240331.htm": {
   "nsprefix": "sana",
   "nsuri": "http://sana.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "sana-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "sana-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 232,
   "keyCustom": 52,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 39,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 193,
   "entityCount": 1,
   "segmentCount": 78,
   "elementCount": 601,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 497,
    "http://xbrl.sec.gov/dei/2023": 31,
    "http://xbrl.sec.gov/ecd/2023": 16
   },
   "report": {
    "R1": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_7135efce-efcb-4461-a247-176eda4a968d",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7135efce-efcb-4461-a247-176eda4a968d",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4f29e181-ea6c-400a-8ba7-6bea7dba7a7f",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions",
     "longName": "995475 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements",
     "longName": "995485 - Disclosure - License and collaboration agreements",
     "shortName": "License and collaboration agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash",
     "longName": "995495 - Disclosure - Restricted Cash",
     "shortName": "Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995505 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995515 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "longName": "995525 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995535 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995545 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995555 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995565 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995575 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan",
     "longName": "995585 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables",
     "longName": "995615 - Disclosure - Acquisitions - (Tables)",
     "shortName": "Acquisitions - (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f",
      "name": "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f",
      "name": "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables",
     "longName": "995625 - Disclosure - License and collaboration agreements (Tables)",
     "shortName": "License and collaboration agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995635 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995645 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "longName": "995655 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995665 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:OperatingLeasesAdditionalInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:OperatingLeasesAdditionalInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995675 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995685 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "longName": "995695 - Disclosure - Organization - Additional Information (Details)",
     "shortName": "Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:InvestmentsAndCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Acquisitions - Additional Information (Details)",
     "shortName": "Acquisitions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
     "longName": "995715 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details)",
     "shortName": "Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_e6ce25b6-c626-470d-b450-ff463c8d2c46",
      "name": "sana:PotentialSuccessPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6ce25b6-c626-470d-b450-ff463c8d2c46",
      "name": "sana:PotentialSuccessPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails",
     "longName": "995725 - Disclosure - Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details)",
     "shortName": "Acquisitions - Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11",
      "name": "sana:ThresholdMarketCapitalization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11",
      "name": "sana:ThresholdMarketCapitalization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:ScheduleOfMarketCapitalizationsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
     "longName": "995735 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e",
      "name": "sana:UpfrontPaymentToCollaborators",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e",
      "name": "sana:UpfrontPaymentToCollaborators",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails",
     "longName": "995745 - Disclosure - License and Collaboration Agreements - Summary of Potential Success Payments (Details)",
     "shortName": "License and Collaboration Agreements - Summary of Potential Success Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_d3ae50f3-372a-4d53-b386-1eaa80038130",
      "name": "sana:CommonStockPricePerShareRequiredForPayment",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3ae50f3-372a-4d53-b386-1eaa80038130",
      "name": "sana:CommonStockPricePerShareRequiredForPayment",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Restricted Cash - Additional Information (Details)",
     "shortName": "Restricted Cash - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995765 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_b81110b3-94ea-476b-8d47-6401255ca2bf",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b81110b3-94ea-476b-8d47-6401255ca2bf",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails",
     "longName": "995775 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details)",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_e5f766dc-31ca-402b-9dbd-c586a549b71f",
      "name": "sana:MarketableSecuritiesMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5f766dc-31ca-402b-9dbd-c586a549b71f",
      "name": "sana:MarketableSecuritiesMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
     "longName": "995795 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details)",
     "shortName": "Fair Value Measurements - Changes in Estimated Fair Value of Level 3 Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_1c1f3354-a6f1-4f78-9017-287f0a19140e",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c1f3354-a6f1-4f78-9017-287f0a19140e",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
     "longName": "995805 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value of Contingent Consideration Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails",
     "longName": "995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liabilities Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_5d2713f5-18c1-46f4-a590-7d2440ecea25",
      "name": "sana:SuccessPaymentLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d2713f5-18c1-46f4-a590-7d2440ecea25",
      "name": "sana:SuccessPaymentLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995825 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995845 - Disclosure - Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails",
     "longName": "995865 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616",
      "name": "sana:AreaOfLeasedSpace",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:OperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616",
      "name": "sana:AreaOfLeasedSpace",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sana:OperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails",
     "longName": "995885 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Summary of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails",
     "longName": "995895 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1998177-1c58-4e27-be53-21c13d9ca1d7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:PreFundedWarrantsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "sana:PreFundedWarrantsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_928be825-e134-4309-ace3-ac7914760235",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_928be825-e134-4309-ace3-ac7914760235",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails",
     "longName": "995925 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Based Compensation Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails",
     "longName": "995935 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_147c1909-b56c-4e45-bb6a-2f58c5972a51",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_147c1909-b56c-4e45-bb6a-2f58c5972a51",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_1ff8bdde-18f8-4091-bad9-c22cba67895c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails",
     "longName": "995955 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails",
     "longName": "995965 - Disclosure - Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Additional Information Related to Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
     "longName": "995975 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_6118355a-f762-4887-9f8b-16f2afbc5567",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6118355a-f762-4887-9f8b-16f2afbc5567",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
     "longName": "995985 - Disclosure - Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)",
     "shortName": "Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "995995 - Disclosure - Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be1d75be-894d-4c8e-a248-7743778c933d",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
     "longName": "996005 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_e5f766dc-31ca-402b-9dbd-c586a549b71f",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5f766dc-31ca-402b-9dbd-c586a549b71f",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sana-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r600"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "sana_AccruedCompensationOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AccruedCompensationOther",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation other.",
        "label": "Accrued Compensation Other",
        "terseLabel": "Other accrued compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued expenses and other current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "sana_AccruedPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued property and equipment current.",
        "label": "Accrued Property And Equipment Current",
        "terseLabel": "Accrued property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sana_AccruedResearchAndDevelopmentServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current.",
        "label": "Accrued Research And Development Services Current",
        "terseLabel": "Accrued research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r575"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued paid time off",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r49"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r131",
      "r468"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r78",
      "r138",
      "r465",
      "r480",
      "r481"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r27",
      "r377",
      "r380",
      "r416",
      "r476",
      "r477",
      "r702",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712"
     ]
    },
    "sana_AcquisitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AcquisitionAgreementMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition agreement.",
        "label": "Acquisition Agreement [Member]",
        "terseLabel": "Acquisition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r600",
      "r781"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r490",
      "r710",
      "r711",
      "r712",
      "r760",
      "r782"
     ]
    },
    "sana_AdditionalPotentialContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AdditionalPotentialContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional potential contingent consideration.",
        "label": "Additional Potential Contingent Consideration",
        "terseLabel": "Additional potential Cobalt Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r314"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Fees incurred related to issuance of common stock from at the market offering",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r97"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r645",
      "r670"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r636",
      "r646",
      "r663",
      "r671",
      "r675",
      "r683"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r352"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of dilutive net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "sana_AreaOfLeasedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AreaOfLeasedSpace",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area Of Leased Space",
        "terseLabel": "Square feet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r134",
      "r157",
      "r198",
      "r200",
      "r202",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r370",
      "r374",
      "r396",
      "r461",
      "r517",
      "r600",
      "r612",
      "r727",
      "r728",
      "r765"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r139",
      "r157",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r370",
      "r374",
      "r396",
      "r600",
      "r727",
      "r728",
      "r765"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Member]",
        "terseLabel": "Financial Assets",
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": []
    },
    "sana_AtTheMarketFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "AtTheMarketFacilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market facility.",
        "label": "At The Market Facility [Member]",
        "terseLabel": "At The Market Offering",
        "verboseLabel": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Holding Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r245",
      "r460"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r245",
      "r455",
      "r714"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "sana_BeamTherapeuticsIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "BeamTherapeuticsIncorporatedMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam Therapeutics Inc.",
        "label": "Beam Therapeutics Incorporated [Member]",
        "terseLabel": "Beam Therapeutics Inc. (Beam)"
       }
      }
     },
     "auth_ref": []
    },
    "sana_BeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "BeneficialOwnershipPercentage",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership percentage.",
        "label": "Beneficial Ownership Percentage",
        "terseLabel": "Beneficial ownership percentage held by a member of board of directors"
       }
      }
     },
     "auth_ref": []
    },
    "sana_BothellWashingtonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "BothellWashingtonMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bothell, Washington.",
        "label": "Bothell Washington [Member]",
        "terseLabel": "Bothell, Washington",
        "verboseLabel": "Bothell, WA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r593",
      "r594"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r364",
      "r593",
      "r594"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "sana_BusinessAcquisitionMaximumTermForSuccessPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "BusinessAcquisitionMaximumTermForSuccessPayment",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum\u200b term for success payment.",
        "label": "Business Acquisition Maximum Term For Success Payment",
        "terseLabel": "Maximum term for success payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, percentage of voting interests acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in the estimated fair value of contingent consideration",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r705"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r60",
      "r366"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Estimated fair value of contingent consideration, short term liabilities",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion",
        "verboseLabel": "Estimated fair value of contingent consideration, long-term liabilities",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r365"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Business combination, intangible assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "South San Francisco, CA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r129",
      "r574"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r84",
      "r155"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r84"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "sana_CashReceivedForAmountsRelatedToTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CashReceivedForAmountsRelatedToTenantImprovementAllowances",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for amounts related to tenant improvement allowances.",
        "label": "Cash Received For Amounts Related To Tenant Improvement Allowances",
        "terseLabel": "Cash received for amounts related to tenant improvement allowances"
       }
      }
     },
     "auth_ref": []
    },
    "sana_CashReceivedForTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CashReceivedForTenantImprovementAllowances",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for tenant improvement allowances",
        "label": "Cash Received For Tenant Improvement Allowances",
        "documentation": "Cash Received For Tenant Improvement Allowances"
       }
      }
     },
     "auth_ref": []
    },
    "sana_ChangeInFairValueOfSuccessPaymentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ChangeInFairValueOfSuccessPaymentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of success payment liabilities.",
        "label": "Change In Fair Value Of Success Payment Liabilities",
        "terseLabel": "Change in the estimated fair value of success payment liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r197",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r483",
      "r484",
      "r485",
      "r486",
      "r588",
      "r690",
      "r708"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of common stock per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock",
        "terseLabel": "Number of warrants to purchase common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "sana_CobaltBiomedicineIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CobaltBiomedicineIncMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cobalt Biomedicine, Inc.",
        "label": "Cobalt Biomedicine Inc [Member]",
        "terseLabel": "Cobalt Biomedicine, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sana_CobaltContingentConsiderationLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CobaltContingentConsiderationLiabilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cobalt contingent consideration liability.",
        "label": "Cobalt Contingent Consideration Liability [Member]",
        "terseLabel": "Cobalt Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "sana_CobaltSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CobaltSuccessPaymentLiabilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cobalt success payment liability.",
        "label": "Cobalt Success Payment Liability [Member]",
        "terseLabel": "Cobalt Success Payment Liability",
        "verboseLabel": "Cobalt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r124"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r68",
      "r462",
      "r504"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r257",
      "r258",
      "r560",
      "r725"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares available for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "sana_CommonStockMaximumOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CommonStockMaximumOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock maximum offering amount.",
        "label": "Common Stock Maximum Offering Amount",
        "terseLabel": "Common stock maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r710",
      "r711",
      "r760",
      "r780",
      "r782"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "sana_CommonStockPricePerShareRequiredForPayment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CommonStockPricePerShareRequiredForPayment",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock price per share required for payment.",
        "label": "Common Stock Price Per Share Required For Payment",
        "terseLabel": "Per share common stock price required for payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r505"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r505",
      "r523",
      "r782",
      "r783"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 750,000 shares authorized; 221,286 and 197,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r464",
      "r600"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r144",
      "r146",
      "r150",
      "r456",
      "r473"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment, Software and Other",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r370",
      "r371",
      "r374",
      "r375",
      "r418",
      "r570",
      "r726",
      "r729",
      "r730"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r370",
      "r371",
      "r374",
      "r375",
      "r418",
      "r570",
      "r726",
      "r729",
      "r730"
     ]
    },
    "sana_ConstructionInProgressCostsWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ConstructionInProgressCostsWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction in progress costs write-off.",
        "label": "Construction In Progress Costs Write Off",
        "terseLabel": "Construction in progress costs write-off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction In Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "sana_ContingentConsiderationLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ContingentConsiderationLiabilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liability.",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "sana_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r592",
      "r779"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r272",
      "r278",
      "r417",
      "r576",
      "r578"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sana_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company, LLC.",
        "label": "Cowen And Company L L C [Member]",
        "terseLabel": "Cowen"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value 12 months or greater",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r249",
      "r584"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized losses 12 months or greater",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r249"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair value less than 12 months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r249",
      "r584"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized losses less than 12 months",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r249"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r247",
      "r584"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total unrealized losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r248"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value Available For Sale Debt Securities Continuous Unrealized Loss Position",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r584",
      "r721"
     ]
    },
    "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Cash-Based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Cash-based expenses related to employee severance, benefits and related costs",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements. Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Matching contribution by employer under retirement and savings plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "sana_DepreciationAndImpairmentOfLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "DepreciationAndImpairmentOfLongLivedAssets",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and impairment of long-lived assets",
        "label": "Depreciation and Impairment of Long-lived Assets",
        "documentation": "Depreciation and Impairment of Long-lived Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sana_DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "DerecognitionOfOperatingLeaseRightOfUseAssetForLeaseTermination",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of operating lease right-of-use asset for lease termination.",
        "label": "Derecognition Of Operating Lease Right-of-use Asset For Lease Termination",
        "terseLabel": "Derecognition of operating lease right-of-use asset for lease termination"
       }
      }
     },
     "auth_ref": []
    },
    "sana_DescriptionOfOrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "DescriptionOfOrganizationLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of organization.",
        "label": "Description Of Organization [Line Items]",
        "terseLabel": "Description Of Organization [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sana_DescriptionOfOrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "DescriptionOfOrganizationTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of organization.",
        "label": "Description Of Organization [Table]",
        "terseLabel": "Description Of Organization [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sana_DescriptionOfPreFundedWarrantsExerciable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "DescriptionOfPreFundedWarrantsExerciable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of pre-funded warrants exerciable",
        "label": "Description of Pre-funded Warrants Exerciable",
        "documentation": "Description of Pre-funded Warrants Exerciable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r317",
      "r345",
      "r346",
      "r348",
      "r596"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Additional Information Related to Stock Option Activity",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per common share - basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Basic earnings (loss) per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r176",
      "r179",
      "r189",
      "r190",
      "r191",
      "r195",
      "r385",
      "r386",
      "r457",
      "r474",
      "r580"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per common share - diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Diluted earnings (loss) per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r179",
      "r189",
      "r190",
      "r191",
      "r195",
      "r385",
      "r386",
      "r457",
      "r474",
      "r580"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r192",
      "r193",
      "r194"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Total accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current [Abstract]",
        "terseLabel": "Accrued compensation:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense (in thousands)",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period costs expected to be recognized (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address Address Line1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r125",
      "r147",
      "r148",
      "r149",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r196",
      "r238",
      "r239",
      "r292",
      "r349",
      "r350",
      "r351",
      "r358",
      "r359",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r476",
      "r477",
      "r478",
      "r490",
      "r543"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r664"
     ]
    },
    "sana_EstimatedFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "EstimatedFairValueOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of contingent consideration.",
        "label": "Estimated Fair Value Of Contingent Consideration",
        "terseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "sana_EstimatedFairValueOfSuccessPaymentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "EstimatedFairValueOfSuccessPaymentLiability",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of Success payment liability.",
        "label": "Estimated Fair Value Of Success Payment Liability",
        "terseLabel": "Estimated fair value of success payment liability",
        "verboseLabel": "Estimated fair value of success payment liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r394"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r394"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Liabilities using Unobservable Inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r67"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r389",
      "r425",
      "r426",
      "r427",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r103"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r392",
      "r395"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r296",
      "r301",
      "r389",
      "r425",
      "r590",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r296",
      "r301",
      "r389",
      "r426",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r389",
      "r427",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in Estimated Fair Value of Level 3 Financial Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes infair value - expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r425",
      "r426",
      "r427",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r395"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r250",
      "r251",
      "r274",
      "r288",
      "r382",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r472",
      "r584",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "sana_FremontCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "FremontCaliforniaMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fremont California.",
        "label": "Fremont California [Member]",
        "terseLabel": "Fremont, California",
        "verboseLabel": "Fremont, CA"
       }
      }
     },
     "auth_ref": []
    },
    "sana_FutureLetterOfCreditAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "FutureLetterOfCreditAmount",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future letter of credit amount.",
        "label": "Future Letter Of Credit Amount",
        "terseLabel": "Future letter of credit amount"
       }
      }
     },
     "auth_ref": []
    },
    "sana_GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain expense in connection with change in estimated fair value of success payment liabilities.",
        "label": "Gain Expense In Connection With Change In Estimated Fair Value Of Success Payment Liabilities",
        "terseLabel": "Change in estimated fair value of success payment",
        "verboseLabel": "Expense in connection with change in estimated fair value of success payment liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Termination of Lease",
        "terseLabel": "Loss on lease termination",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r527"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r252",
      "r454",
      "r585",
      "r600",
      "r722",
      "r723"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Business acquisition, impairment of intangible assets or goodwill",
        "totalLabel": "Goodwill and Intangible Asset Impairment, Total",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "sana_HarvardCollegeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "HarvardCollegeMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard College.",
        "label": "Harvard College [Member]",
        "terseLabel": "Harvard College"
       }
      }
     },
     "auth_ref": []
    },
    "sana_HarvardSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "HarvardSuccessPaymentLiabilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsChangesInEstimatedFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard Success Payment Liability.",
        "label": "Harvard Success Payment Liability [Member]",
        "terseLabel": "Harvard Success Payment Liability",
        "verboseLabel": "Harvard"
       }
      }
     },
     "auth_ref": []
    },
    "sana_InProcessResearchAndDevelopmentIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "InProcessResearchAndDevelopmentIntangibleAssetMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process research and development intangible asset.",
        "label": "In Process Research And Development Intangible Asset [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r528"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r528"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r488"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sana_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "terseLabel": "Increase decrease in operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "sana_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase decrease in operating lease right-of-use assets and operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities",
        "negatedLabel": "Operating lease right-of-use assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use liabilities.",
        "label": "Increase Decrease In Operating Lease Right Of Use Liabilities",
        "terseLabel": "Increase decrease in operating lease right-of-use liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock options and restricted stock units",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r191",
      "r316"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r90"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r636",
      "r646",
      "r663",
      "r671",
      "r675",
      "r683"
     ]
    },
    "srt_IndustrialPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "IndustrialPropertyMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Industrial Property [Member]",
        "terseLabel": "Industrial"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r687"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible asset",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "totalLabel": "Investments and Cash, Total",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r777"
     ]
    },
    "sana_InvestmentsSecuritiesMaturitiesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "InvestmentsSecuritiesMaturitiesPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments securities maturities period.",
        "label": "Investments Securities Maturities Period",
        "terseLabel": "Investments in securities with maturities period"
       }
      }
     },
     "auth_ref": []
    },
    "sana_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r599"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "sana_LeaseTerminationFeesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LeaseTerminationFeesIncurred",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination fees incurred.",
        "label": "Lease Termination Fees Incurred",
        "terseLabel": "Lease termination fees incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Reconciliation of Undiscounted Operating Lease Cash Flows by Fiscal Year to Present Value of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Obligation to pay base rent",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "sana_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "documentation": "Lessee operating lease liability payments due year five and thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining 9 months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "sana_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement allowance.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "negatedLabel": "Less: tenant improvement allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend the lease term",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r157",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r371",
      "r374",
      "r375",
      "r396",
      "r503",
      "r581",
      "r612",
      "r727",
      "r765",
      "r766"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r106",
      "r467",
      "r600",
      "r709",
      "r720",
      "r762"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r128",
      "r157",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r371",
      "r374",
      "r375",
      "r396",
      "r600",
      "r727",
      "r765",
      "r766"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability [Member]",
        "terseLabel": "Financial Liabilities",
        "documentation": "Probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": []
    },
    "sana_LicenseAndCollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sana_LongTermFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LongTermFinancialLiabilitiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term financial liabilities.",
        "label": "Long Term Financial Liabilities [Member]",
        "terseLabel": "Long-term Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_LongTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "LongTermMarketableSecuritiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Cambridge, MA"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MarketCapitalizationFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MarketCapitalizationFourMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market capitalization four.",
        "label": "Market Capitalization Four [Member]",
        "terseLabel": "Market Capitalization Less than $6.8 billion"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MarketCapitalizationOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MarketCapitalizationOneMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market capitalization one.",
        "label": "Market Capitalization One [Member]",
        "terseLabel": "Market Capitalization Equal to or Exceeds $8.1 billion"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MarketCapitalizationThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MarketCapitalizationThreeMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Capitalization Three.",
        "label": "Market Capitalization Three [Member]",
        "terseLabel": "Market Capitalization Equal to or exceeds $6.8 billion, but less than $7.4 billion"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MarketCapitalizationTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MarketCapitalizationTwoMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market capitalization two.",
        "label": "Market Capitalization Two [Member]",
        "terseLabel": "Market Capitalization Equal to or exceeds $7.4 billion, but less than $8.1 billion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "sana_MarketableSecuritiesMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MarketableSecuritiesMaturityPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities maturity period.",
        "label": "Marketable Securities Maturity Period",
        "terseLabel": "Marketable securities maturity period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term marketable securities",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "sana_MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum contingent consideration upon achievement of certain pre specified development milestones.",
        "label": "Maximum Contingent Consideration Upon Achievement Of Certain Pre Specified Development Milestones",
        "terseLabel": "Maximum contingent consideration upon achievement of certain pre-specified development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r311",
      "r452",
      "r475",
      "r495",
      "r496",
      "r548",
      "r550",
      "r552",
      "r553",
      "r555",
      "r571",
      "r572",
      "r583",
      "r588",
      "r595",
      "r601",
      "r731",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "sana_MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of pre-funded warrants increase or decrease by providing atleast 61 days prior notice",
        "label": "Maximum Percentage Of Pre-funded Warrants Increase Decrease By Providing Atleast Sixty One Days Prior Notice",
        "documentation": "Maximum Percentage Of Pre-funded Warrants Increase Decrease By Providing Atleast Sixty One Days Prior Notice"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MaximumPeriodExpectedToAchieveForSuccessPayments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MaximumPeriodExpectedToAchieveForSuccessPayments",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period expected to achieve for success payments.",
        "label": "Maximum Period Expected To Achieve For Success Payments",
        "terseLabel": "Maximum period expected to achieve for success payments"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MaximumPotentialSuccessPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MaximumPotentialSuccessPayments",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential success payments.",
        "label": "Maximum Potential Success Payments",
        "terseLabel": "Cobalt success payment",
        "verboseLabel": "Cobalt success payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rates",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term (Years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Stock Price Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "sana_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input probability of milestone achievement.",
        "label": "Measurement Input Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of Milestone Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "sana_MilestoneFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MilestoneFiveMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone five.",
        "label": "Milestone Five [Member]",
        "terseLabel": "Multiple of Equity Value at Issuance, 40x"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MilestoneFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MilestoneFourMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone four.",
        "label": "Milestone Four [Member]",
        "terseLabel": "Multiple of Equity Value at Issuance, 30x"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MilestoneOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MilestoneOneMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone one.",
        "label": "Milestone One [Member]",
        "terseLabel": "Multiple of Equity Value at Issuance, 5x"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MilestoneThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MilestoneThreeMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone three.",
        "label": "Milestone Three [Member]",
        "terseLabel": "Multiple of Equity Value at Issuance, 20x"
       }
      }
     },
     "auth_ref": []
    },
    "sana_MilestoneTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MilestoneTwoMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone two.",
        "label": "Milestone Two [Member]",
        "terseLabel": "Multiple of Equity Value at Issuance, 10x"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r311",
      "r452",
      "r475",
      "r495",
      "r496",
      "r548",
      "r550",
      "r552",
      "r553",
      "r555",
      "r571",
      "r572",
      "r583",
      "r588",
      "r595",
      "r601",
      "r731",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property"
       }
      }
     },
     "auth_ref": [
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate"
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "sana_MrHardyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "MrHardyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Hardy [Member]",
        "documentation": "Mr. Hardy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "sana_NathanHardyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "NathanHardyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nathan Hardy [Member]",
        "documentation": "Nathan Hardy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r123"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r86",
      "r107",
      "r126",
      "r143",
      "r145",
      "r149",
      "r157",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r187",
      "r198",
      "r199",
      "r201",
      "r203",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r386",
      "r396",
      "r471",
      "r525",
      "r541",
      "r542",
      "r582",
      "r610",
      "r727"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r176",
      "r177",
      "r188",
      "r191",
      "r198",
      "r199",
      "r201",
      "r203",
      "r582"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r191"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r663",
      "r671"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of RSU Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "sana_NumberOfStandbyLettersOfCredit": {
     "xbrltype": "integerItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "NumberOfStandbyLettersOfCredit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of standby letter of credit.",
        "label": "Number Of Standby Letters Of Credit",
        "terseLabel": "Number of standby letters of credit"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office/Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OfficeLaboratoryAndIndustrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OfficeLaboratoryAndIndustrialMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office, laboratory and industrial.",
        "label": "Office Laboratory And Industrial [Member]",
        "terseLabel": "Office/Laboratory/Industrial"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OfficeLaboratoryAndManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OfficeLaboratoryAndManufacturingMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office/Laboratory/Manufacturing",
        "label": "Office Laboratory and Manufacturing [Member]",
        "documentation": "Office laboratory and manufacturing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Operating Income (Loss), Total",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r201",
      "r203",
      "r582"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OperatingLeaseCommencementBeginningMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OperatingLeaseCommencementBeginningMonthAndYear",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement beginning month and year.",
        "label": "Operating Lease Commencement Beginning Month And Year",
        "terseLabel": "Commencement Dates, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OperatingLeaseCommencementEndingMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OperatingLeaseCommencementEndingMonthAndYear",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement ending month and year.",
        "label": "Operating Lease Commencement Ending Month And Year",
        "terseLabel": "Commencement Dates, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r599"
     ]
    },
    "sana_OperatingLeaseExpirationBeginningMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OperatingLeaseExpirationBeginningMonthAndYear",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration beginning month and year.",
        "label": "Operating Lease Expiration Beginning Month And Year",
        "verboseLabel": "Lease arrangement, contractual expiration period, beginning year"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OperatingLeaseExpirationEndingMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OperatingLeaseExpirationEndingMonthAndYear",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration ending month and year.",
        "label": "Operating Lease Expiration Ending Month And Year",
        "verboseLabel": "Lease arrangement, contractual expiration period, ending year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Less: current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsByFiscalYearToPresentValueOfOperatingLeaseLiabilitiesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Non-cash expense for operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r599"
     ]
    },
    "sana_OperatingLeasesAdditionalInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OperatingLeasesAdditionalInformationTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases additional information.",
        "label": "Operating Leases Additional Information Table [Text Block]",
        "terseLabel": "Schedule of Additional Information Related to Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OptionalTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OptionalTenantImprovementAllowance",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optional additional tenant improvement allowance.",
        "label": "Optional Tenant Improvement Allowance",
        "terseLabel": "Optional additional tenant improvement allowance"
       }
      }
     },
     "auth_ref": []
    },
    "sana_OptionalTenantImprovementAllowanceInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "OptionalTenantImprovementAllowanceInterestRate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optional tenant improvement allowance interest rate.",
        "label": "Optional Tenant Improvement Allowance Interest Rate",
        "terseLabel": "Optional additional tenant improvement allowance, interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r87",
      "r88",
      "r102"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedCompensationAndAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, net",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities, net",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r236"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Long-term Liabilities",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r644",
      "r669"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r672"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r672"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Sana"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sana_PaymentToCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PaymentToCollaborators",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to collaborators.",
        "label": "Payment To Collaborators",
        "terseLabel": "Payment to collaborators"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r592"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "sana_PercentageOfWorkforceReduction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PercentageOfWorkforceReduction",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of workforce reduction.",
        "label": "Percentage Of Workforce Reduction",
        "terseLabel": "Percentage of workforce reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "sana_PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential amount of milestone payments and royalties payable.",
        "label": "Potential Amount Of Milestone Payments And Royalties Payable",
        "terseLabel": "Developmental and commercial milestone payments and royalties on licensed products payable"
       }
      }
     },
     "auth_ref": []
    },
    "sana_PotentialSuccessPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PotentialSuccessPayment",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential success payment.",
        "label": "Potential Success Payment",
        "verboseLabel": "Cobalt Success Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sana_PotentialSuccessPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PotentialSuccessPayments",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential success payments.",
        "label": "Potential Success Payments",
        "verboseLabel": "Success payment(s)"
       }
      }
     },
     "auth_ref": []
    },
    "sana_PreFundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PreFundedWarrantsExercised",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants exercised",
        "label": "Pre-funded Warrants Exercised",
        "documentation": "Pre-funded Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sana_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sana_PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants not exercise if holder together owns maximum percentage of number of common stock outstanding",
        "label": "Pre-funded Warrants Not Exercise If Holder Together Owns Maximum Percentage of Number Of Common Stock Outstanding",
        "documentation": "Pre-funded Warrants Not Exercise If Holder Together Owns Maximum Percentage of Number Of Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r505"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r505",
      "r523",
      "r782",
      "r783"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r463",
      "r600"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net",
        "verboseLabel": "Net proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sana_ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from equity financings, net",
        "label": "Proceeds from Issuance of Common Stock from Equity Financings, Net",
        "documentation": "Proceeds from issuance of common stock from equity financings, net."
       }
      }
     },
     "auth_ref": []
    },
    "sana_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance of common stock",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "documentation": "Proceeds from issuance of common stock gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchase plan and exercise of stock options",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r143",
      "r145",
      "r153",
      "r157",
      "r165",
      "r173",
      "r174",
      "r198",
      "r199",
      "r201",
      "r203",
      "r237",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r369",
      "r372",
      "r373",
      "r386",
      "r396",
      "r458",
      "r470",
      "r489",
      "r525",
      "r541",
      "r542",
      "r582",
      "r597",
      "r598",
      "r611",
      "r704",
      "r727"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r118",
      "r121",
      "r122"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r130",
      "r469"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r459",
      "r469",
      "r600"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r294",
      "r311",
      "r340",
      "r341",
      "r342",
      "r428",
      "r452",
      "r475",
      "r495",
      "r496",
      "r548",
      "r550",
      "r552",
      "r553",
      "r555",
      "r571",
      "r572",
      "r583",
      "r588",
      "r595",
      "r601",
      "r604",
      "r724",
      "r731",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r294",
      "r311",
      "r340",
      "r341",
      "r342",
      "r428",
      "r452",
      "r475",
      "r495",
      "r496",
      "r548",
      "r550",
      "r552",
      "r553",
      "r555",
      "r571",
      "r572",
      "r583",
      "r588",
      "r595",
      "r601",
      "r604",
      "r724",
      "r731",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r664"
     ]
    },
    "sana_ReimbursementOfTenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ReimbursementOfTenantImprovements",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of tenant improvements.",
        "label": "Reimbursement Of Tenant Improvements",
        "terseLabel": "Reimbursement of tenant improvements"
       }
      }
     },
     "auth_ref": []
    },
    "sana_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of operating lease right-of-use asset for lease modifications.",
        "label": "Remeasurement Of Operating Lease Right Of Use Asset For Lease Modifications",
        "terseLabel": "Remeasurement of operating lease right-of-use asset for lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r272",
      "r278",
      "r417",
      "r577",
      "r578"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r353",
      "r773"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "sana_ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated fair value of success payment liabilities and contingent consideration recorded in research and development expenses.",
        "label": "Research And Development Related Success Payments And Contingent Consideration",
        "terseLabel": "Research and development related success payments and contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r630",
      "r640",
      "r665"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r631",
      "r641",
      "r666"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r673"
     ]
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "verboseLabel": "Standby letters of credit",
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r707",
      "r774",
      "r777"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash And Cash Equivalents Items [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent, Nature of Restriction, Description",
        "terseLabel": "Restricted cash and cash equivalents, noncurrent, nature of restriction, description",
        "documentation": "Description of nature and provision of restriction as to withdrawal or usage on cash and cash equivalents, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r707"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r699",
      "r707"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Unvested Restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Unvested RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r97",
      "r466",
      "r479",
      "r481",
      "r487",
      "r506",
      "r600"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r238",
      "r239",
      "r349",
      "r350",
      "r351",
      "r358",
      "r359",
      "r376",
      "r378",
      "r379",
      "r381",
      "r384",
      "r476",
      "r478",
      "r490",
      "r782"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r599"
     ]
    },
    "sana_RochesterNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "RochesterNewYorkMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rochester New York.",
        "label": "Rochester New York [Member]",
        "terseLabel": "Rochester, NY"
       }
      }
     },
     "auth_ref": []
    },
    "sana_Rule10B51TradingPlanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "Rule10B51TradingPlanOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10B51Trading Plan One [Member]",
        "label": "Rule10 B51 Trading Plan One [Member]",
        "documentation": "Rule10 B51 Trading Plan One."
       }
      }
     },
     "auth_ref": []
    },
    "sana_Rule10B51TradingPlanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "Rule10B51TradingPlanTwoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10B51Trading Plan Two [Member]",
        "label": "Rule10 B51 Trading Plan Two [Member]",
        "documentation": "Rule10 B51 Trading Plan Two."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Compensation and Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r364"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Calculation of Basic and Diluted Net Loss Per Share of Common Stock",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation Expense Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389"
     ]
    },
    "sana_ScheduleOfMarketCapitalizationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ScheduleOfMarketCapitalizationsTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various thresholds for the Company\u2019s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration.",
        "label": "Schedule Of Market Capitalizations Table [Text Block]",
        "terseLabel": "Schedule of Various Thresholds for Market Capitalizations Resulting Potential Success Payment and Additional Potential Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule Of Restricted Cash And Cash Equivalents [Table]",
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r104",
      "r777"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r95",
      "r96",
      "r97",
      "r135",
      "r136",
      "r137",
      "r197",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r483",
      "r484",
      "r485",
      "r486",
      "r588",
      "r690",
      "r708"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Stock-Based Compensation Costs Related to Unvested Awards and Weighted-Average Period Over Which Costs are Expected to be Recognized",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r492",
      "r493",
      "r494",
      "r549",
      "r551",
      "r554",
      "r556",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r589",
      "r604",
      "r732",
      "r778"
     ]
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage related to employees able to purchase shares at lower of fair market value",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested shares as of December 31, 2023",
        "periodEndLabel": "Unvested shares as of March 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested shares as of December 31, 2023",
        "periodEndLabel": "Unvested shares as of March 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage allowed for eligible employees to purchase shares of common stock",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised (in thousands)",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Stock Options, Forfeited/Cancelled",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Forfeited/Cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share for options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options Outstanding, Ending Balance",
        "periodStartLabel": "Stock Options Outstanding, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price per Share Outstanding, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price per Share Outstanding, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Vesting of restricted stock (in shares)",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationCostsRelatedToUnvestedAwardsAndWeightedAveragePeriodOverWhichCostsAreExpectedToBeRecognizedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share issue price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "sana_ShortTermFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ShortTermFinancialLiabilitiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term financial liabilities.",
        "label": "Short Term Financial Liabilities [Member]",
        "terseLabel": "Short-term Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_ShortTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ShortTermMarketableSecuritiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SignificantAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies Policy [Text Block]",
        "terseLabel": "Significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r25",
      "r125",
      "r147",
      "r148",
      "r149",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r196",
      "r238",
      "r239",
      "r292",
      "r349",
      "r350",
      "r351",
      "r358",
      "r359",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r476",
      "r477",
      "r478",
      "r490",
      "r543"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r492",
      "r493",
      "r494",
      "r549",
      "r551",
      "r554",
      "r556",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r589",
      "r604",
      "r732",
      "r778"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r196",
      "r453",
      "r482",
      "r491",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r605"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r196",
      "r453",
      "r482",
      "r491",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r605"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r643",
      "r668"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "terseLabel": "Aggregate common stock sold",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97",
      "r483",
      "r543",
      "r557"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Stock Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97",
      "r326"
     ]
    },
    "sana_StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, common stock in connection with license agreement.",
        "label": "Stock Issued During Period Value Common Stock In Connection With License Agreement",
        "verboseLabel": "Common stock shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97",
      "r490",
      "r543",
      "r557",
      "r611"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r72",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r25",
      "r97"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r89",
      "r507",
      "r523",
      "r544",
      "r545",
      "r600",
      "r612",
      "r709",
      "r720",
      "r762",
      "r782"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r156",
      "r275",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r292",
      "r383",
      "r546",
      "r547",
      "r558"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r420"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent",
        "label": "Subsequent Event [Member]",
        "verboseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r420"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r420"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r420"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureRestrictedCashAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r420"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureSubsequentEvent1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r421"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://sana.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "sana_SuccessPaymentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SuccessPaymentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liabilities.",
        "label": "Success Payment Liabilities",
        "terseLabel": "Success payment liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SuccessPaymentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SuccessPaymentLiabilitiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liabilities.",
        "label": "Success Payment Liabilities [Member]",
        "terseLabel": "Success Payment Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SuccessPaymentLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SuccessPaymentLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liabilities noncurrent.",
        "label": "Success Payment Liabilities Noncurrent",
        "terseLabel": "Success payment liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SuccessPaymentLiabilityExpectedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SuccessPaymentLiabilityExpectedTerm",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability expected Term.",
        "label": "Success Payment Liability Expected Term",
        "terseLabel": "Fair value measurement input expected term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SuccessPaymentLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SuccessPaymentLiabilityMeasurementInput",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfSuccessPaymentLiabilitiesUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability measurement input.",
        "label": "Success Payment Liability Measurement Input",
        "terseLabel": "Fair value measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "sana_SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of potential success payments and common stock price required for payment to Harvard.",
        "label": "Summary Of Potential Success Payments Harvard Table [Text Block]",
        "terseLabel": "Summary of Potential Success Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "sana_ThresholdMarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "ThresholdMarketCapitalization",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsScheduleOfVariousThresholdsForMarketCapitalizationsResultingPotentialSuccessPaymentAndAdditionalPotentialContingentConsiderationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold market capitalization.",
        "label": "Threshold Market Capitalization",
        "terseLabel": "Threshold market capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "sana_TotalValueOfConsiderationPaidUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "TotalValueOfConsiderationPaidUnderLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of consideration paid under license agreement.",
        "label": "Total Value Of Consideration Paid Under License Agreement",
        "terseLabel": "Aggregated consideration paid"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r274",
      "r288",
      "r382",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r472",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "sana_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sana_TwoThousandTwentyOneIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "TwoThousandTwentyOneIncentiveAwardPlanMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Incentive Award Plan.",
        "label": "Two Thousand Twenty One Incentive Award Plan [Member]",
        "terseLabel": "2021 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfPotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAvailableForSaleDebtSecuritiesContinuousUnrealizedLossPositionDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r590",
      "r775"
     ]
    },
    "sana_UnderwritersOptionToPurchaseAdditionalSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "UnderwritersOptionToPurchaseAdditionalSharesMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriters' Option To Purchase Additional Shares",
        "label": "Underwriters Option To Purchase Additional Shares [Member]",
        "documentation": "Underwriters option to purchase additional shares."
       }
      }
     },
     "auth_ref": []
    },
    "sana_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten public offering."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "sana_UpfrontPaymentToCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sana.com/20240331",
     "localname": "UpfrontPaymentToCollaborators",
     "crdr": "credit",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment to collaborators.",
        "label": "Upfront Payment To Collaborators",
        "terseLabel": "Upfront payment to collaborators"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r115",
      "r117",
      "r119",
      "r120"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r599"
     ]
    },
    "stpr_WA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "WA",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Seattle, WA"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueOfContingentConsiderationUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted-Average"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r767",
      "r769",
      "r772"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of common shares - diluted",
        "totalLabel": "Weighted-average number of common shares - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r191"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://sana.com/20240331/taxonomy/role/DisclosureNetLossPerShareSummaryOfCalculationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",
      "http://sana.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares - basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average number of common shares - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r191"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-7"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000950170-24-055727-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-055727-xbrl.zip
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MV_;"PW17OK0JAJ1;5_ENV13)_73)EOQPE 4^I7:[']RKGUZ"4*8 HE+PIA2
MMD@G\C]BMEB7H N32M=^B$] ^_M?LP2!PD5S7L.FBJ?**8#1AA,%8(4IV>\D
M?ZRD2*0BKB*>[\GSVYO:WF$W\&TKGC1+TD7(-286G6:1ZP*[]V_F'KRX5!TO
M9GK089<YZ/6V-3MY9LSZ3*FM")_8(^N;?7_>K.8]K($[]59)6'Q!7.^,YLU
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MW;&66;\\374"/_&PMT <TY*4UP1G(!ICHA-E]RI@&JNAXK:M=0)5TD>$V?7
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MQ4S$P&#$\$8W_%)8TH'F!5(TW EX@?Q+B';FV(2KJ,"C0C8=)?QM\53J6Z]
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M.9^J=OP845X)^N._$S3,$BI:=SX[WV"OMZ&]J8.X4]R2MD>LU\/:\>!\2$7
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MU1WB A_>!^,4DPF&86/ID!K/R*,V#\+#IAF1]A;"]2ZH?._C7>G&=$&5"KA
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MDRM.[+(LEOR6Z95(UBT>@S# _[/DGX#^5?([6Y;?+#>L)V&1JU:?5P@FE[;
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M?/W)]2ZY;>O/]N]#./$66W>@=(O<4B( ?$^OXM8R=A*OO"*252T.W&E:IS*
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M$E](]9M?;!C(G&5+>U$T ,9\FB@Q8%*/G(3#EQK34:CG6)9['SIRA&1['C#
M-5(B#"'47]!=4MFIY<L%X0'2U>/4F=G)W3YV?%<O JI! WSP)0)?(%,J9<RH
MJ$G7;RO-FFM]#:3/N:U 3!\YSWB9VFZ><ZJP/02]'R!\@-DC7X5WJ!C\9$2T
MJ434C?]#O' -F5',><MKGA=RGP;XZCH'FV:BSZI6JZF'89GV#!8[_ZE@$+LZ
MC*PRYZ,!SK?712XO9K>]CE3FA7C(_F:D 4R%O, X$\.(()FH-R$RRX/\O5(R
MYNF',S:#;A_NW9YI$WL%^J2KI.YU6-E%98PMM9PF<TZEKNTOS,]:>7-;FAJH
M%9]T*/R&=3QKN^W2=G.,?'O1AH/*:FVNM];<&#GT4"SYW8E7G@/Q6[/75&)0
M.G2*!'V95C=/LIK7+=FA :H<AEM36CU"(;B^I8]6:3M'/P/V+#,N-?&C%Y[U
MI=[K?19_)*ISFDX46V3K5(6C_/6(J\M95D#%4RICFD%2)#;-H-?S,PU075JR
MPVM>21U'K?:UYTSG= H#_$D:=676UIL'6AK[O3_T[I,O3Y#U ]<[P/301+*2
MSS@X+-KP=W9U'8>3'HEF3O,)_BGU5_HV&S:+"/_=*]YA1+@?-+$Q=-<G*W=E
MI]%^KZBR(Z8,6S::9\:1_-'S9LJ1&RH[@SZA7<2OISEA9.U%O:E9_]PY2N6"
MHEJTXTV59<KW,S1 6T^H*GZT=P;*1'[HY7G)DZA]=*YY@&]X)G\->;_MXI:P
M).4[#?"&]190:$8[SW;;X]6X_:?E>[R[":8=<2E,-U'30HI)X/P<(=!*-/DA
M?;J"G], HZZ2X4JY)6MW*_07%.X<S@Z3J<Y.YI;C[7^^3K4R5_COTP R2?M1
M9([>28'$J#8%V1[!?+?GBTWA-,"=>%4J4Q93'VZO@Y%?0H;P==J4%[A50G</
MNL@3L6Q%&N#75]"I^"BLPQ2TDA,@)@2KI;N]$5,T#:# U4(#$,82J:_!,I2&
M":(YR9?,@X-W@5E<4"FK6UO<*K[<4V=\/_$R<@'>7+D;* 29;V.DCL#8J"JV
M;F^)TJYK&09/@A-5>K"X\J>\=RX&F9_!^2\".]S!&,./GGX@!J+9LE'#*':E
M(3W 7GJ?M\.^.W,ENVX;R:8A2%8CAOK[AO#E;J1+#:+"0 2K&_*E+7'8K8N0
MKCZ]LY3<(KX#=)D9VF2ZH]SF)U94V-K7@"0TSVD$U@BVT^1\?@:< \29.GRB
M G,('DB"+H4!/@PC2O2=[D51F_^[<2I--R5)*:"<E6%F51K@;<D^><29P-<$
MN@1S\8P&LE;J1(X21E5)IDF- IPJ1S1 H7&R85W(!/YG/K&LA&Q*3+NM\4Q#
MI'X,JS/$\D9,0'O$_C%QJAJ*XK%*[  EVG+@AZ+5&H\,62N:55D\':,[Q$20
MJ2/4E"&; #$J.PU %+NCDO^9W:<\(%=U[=W6<X9/ B!-"F3G%U;K;5_%UK[V
M.BQX7_N/N<'S;$:L7CI8IN8DNVK)\$2SDLZ>MB,TP*;#I.=.+.DE^0[Q,<[0
M (>.J:S,G;S>F&UN4=OW_5WS*O35)36SM$^@5>XF&4JP-@U0D&@-J@)VH".R
M98GG"K:R)7'#47[J3GK-7X/C'XFC['_^?J[GTPZ7SOOQRX_Z*R.Q/JT+N13T
MUC1;.O&7*^@U8IHP' &LZ^M$Q@G+(G#HB$H/ITG1^+5XIS%A+E3X'7_VL)Z0
MGR0O-W,D-PS"QD!6"OXD,H)=&$4/F+6SO5T<N 5JN0H NI&<.V"7H)P!0-NH
M%[B^*#7E_&TF?O'=-R+QHETL7.<%#\ <U+DFQ^-.3U1S)Y!#OS;958G5U:N5
MX:*>_UF+@YF85XD5;U=!Y@''1Z^GFDX"*Z">1 >X'&'@?&NSX8+Y*JH/;07J
M1%[:T+B2V$F "HWE_3.3N3E=5RU[OY?QE?9?0^] A57P61K  7F9?($844XL
M>CREH,3_88!CT]EM5IOYON,C9:D:7H8;K3)ZQ)'%4.>.3TO-,$[7G&DM&>5*
MU"JGUKUDWJN?N^Y+! YS8= U_MC8,NH_$'<=#7 9%6#%B9N(3@^H*UYU=/RH
M,1W2?>W#WL:E7:^>@/&?B;YE]^>UL6@J&[C[2$+O?.FH,4)I!D&^G!-VP!8%
ME2 &+PYCL<NPJP&Y2Q#W6Y(9&_QZ ?Q."YA'\65#]Q6P8"#((_$C^DH;"[&K
M*TBCJ'B@U"W(-Y70?RM#0E)9\&SW*S8?6U,<NB.(K9N-*&X>[POC<.5.7T@]
M0/^>3*OZ)'+GY[MZ-B^P-G0TIP;6N<<<<@$_5)$?P/9H[$A57=K2?;=B9^+U
MIW;,UX2/YN/V!1\L,F4K^)3W.R?=%K2',:E2F+(F S5$]B;Z[SIH,8T&V']T
MA":QZ='MO1U<D4CQH@%8^4B^ 8;M1D[;CW&'GX26X)+[U-/EMZ<7GI&FS.G9
MDXSW*WI/ SAZ"A(33KK?-=D6^/FNT-.<._LY_'U@?,@Z274#)AQBNI1SA?R,
MZ%!H/>^FE';UH7^QK4+5F7P[D5S&WS2 <])F3(-1O2I/C+?1ZHCB3F/ZWNKI
M=]T*7,!+D&3*D:MD\ZT@PR[+J)T^$LPM6Q"TT0:<JN2?%!5SN^1,60%^0 X0
M3=%$"<V6M&P-8K#GE?D[DSY:L9F.Z:8 J%/+%T(F+JTO0P KLL30HZZ(FMQ"
M/=W!^@D\ANPW527?[3P;)+B84_ .5I^6^).81P,P2?8\%ZPL*"ROEH;NM'DS
M<I(BSYO[22CUVE6YZ1JF]-3N5G[97O-^4=Q6%MW9T%#Y>M1M:#"OF6X$ LBV
MK3A0;!TR7$."S=$;P:%7U/7VK7T#^.@?])JG<,/];4L:H*:(G _I QU-O: !
M_O7XHA'H#GK"8ME6,>RE 1@DK;:"7O^K+_['PO7:;O4EE8%I8?H8?H_R2>T5
M#7 %YBYEV#W:+N4T42%3N1)A\$@.>^?,X: 7*EN,-?KO;9>BB_G-.I['N[X+
M 4&'=Q7\5M)=CV-G=^5;N&B VRKCL!V98/K:\E?".AZVR)01]9:/(Z@WMOB5
MI\C72MPJ6$JMT+ZR'@$WU3GO'RVN')5"F>F&),L-1.!II6L(J^TP'D9HFX3R
M4D?^D37P.5&']W"GV"6IXN'SB;<126\%5V.$X,=MMN^/<[TK6!SY1A(52B3+
M9NHF%QP^NAHRFRDX#@15#DW5'.PKYW!3QT%T6G0UC!PCJH(#0QA]O'BYI_S3
MZ8X_)#9.126D]>*]I,^0,34A7&K?XOI.V+*^B [>GWPK2&$B GN4==I=')/(
M)MYL&280+KA>QO^;\D/C''58*8=5 7E5[V+L3SV"CK24GY3PJKWLLQ=?4='O
M?EO^NI?@8RM&XMQJZIG::<:W=:ZNN7.,CJ3_!LWIV#(^^].6>:E?F'K4U6]0
M>15E]S+OTI!27/F1NY3PNJ?:YE+@/2;9+[&U>:AYHP/0^W*/%B#&YNJ27S(B
MYR>QD-G_S>?[\4Z:Y'=(#-B-.I]]RS"&GVY><P";E8YU>-$=E;BPP%L\XL6&
MY OS2";<\(<V1C ?M#.']VZ\:&].65=Q3U@F;VY<%=UQ\.LVDGC1;C !D"O\
M(GJ;R3FV4^5*S*W^ZV9<][J(U(-#.(QGP+@<[QDDB(XS <>JO538'$O@<K=.
M._ G7XZE,N;9RR-15_M2=1]+U2?)7X]ZB_!BVP07F)[T_]=.X[_:U#J>[ND_
M.[-VOHJGL,(^<)X??N[17H+G'U#2D3)_/:N,TDD$77IE0P'_SYJ6_UW;LHX@
M<T$H_EU[QS(@0A;TX]3_^T8HD WV^T_.\+YS!-WH-[PX@;I\H3)Q=\"<T1]O
M'IX!':9 /E$BH))NH+-0F0'<<8_;*?3[DF;$DF5B/]? #Y?7#(4S[!_6I]S?
MY>#H9NE$*><C;+>(FBSUACJ!K&G)5J%DD]GQS%W_?N%EHGP%E!JOQ*D18IGN
MB0A9R1VPN2]\:$MD,XYM-^F<(KHUEA'\1RCKX599IO'9MQ)[]#5GF^J+5UN,
MZ/'P9)0&V-YGH]R0'T:%/89U/%*[R'O11/K;);O/4!];,$YLR>:X9WCV<;NP
MZ 0GJ^[2TY^-;WW6U-Y5\,&(W',4';@AI3C? KGX8^&\O^,32]].RV@ ZWJR
MH>X&P3@OIDC7NC<6[/6W5*M>V$^DIOS[,3R^38#HL\03N5<KY:]=BQS;77:9
MN?G)NU%0-M/1PN^\]R7X!]!BEM7$>AA5(V"O_:)_<D<R;+YJ>0B1X40.2KEI
MOI M3<S">)XC!AU832IL,ZLROY#>5^_T>?_4E*_?8?JR?@@/?86W_^VI>>&W
M^T!7XILUBR2&U'HWUU_J(9V"/^<I' 3"E CO9%!D;C-D\"&9[4>?-R68=8<J
MV7S*"7H%.E'U% P*3271 +IF90$QW= Q(.YYH+Q0:/9V%\IQ);5SXAN6I%[-
M+<[P:E>Y[SC>DA(&6L&VT'7"%H$^-:XSZ>'I(CC2,^$'G26A0-O9+E3*2AK8
M%?6.DKXD6]!7V:<,VIT:'4=.E06#$F>"6_<\LIW##-#&!<.X8'W8X@GP!_46
MT1 #Y";*PIC0&_S!+LF/7NF]KM>TT+K+$@"\+?20JX,Z"*LFI)$49MQPKMG7
MQNL2L7("?].LC;E>_V8I5N&XS#C\0+(2G]C'=B% IAVA<:<9SYTEG2)XT<66
M.=_'^ZUN?H"8ET-[7T6@TDX1R6P;+'P(Y(308S72O59([-&#X1+KO[W*UBQ_
MPZR;BOM5$V35(9C-+D%<'3^RIJF51*8!'F^OW^'O'C-8&!V:Q.Y3#-DIS0IE
M.7' 6J4N]$>KEW';+"/JHT6:J>_XI':JI/?>I*^VN#HP[&20_%W2(SX^ZNOB
M_QG%#O\3ZRD;_1J<VQ19>0[31'Y%',1/]< XH;R;G\&0*[:_E[9V.E9G\W\F
M<3U9N:UAT2<81YH81GUI1]9J-&.VP5QDBU'WRUEYU#756;,:UBM)4><?S4;/
M,1B%@0.U/KK\264RO9'W>UD<O;"6VAPZJ:%8X6IJ>L^K2$SZ]5A]:D(&U7EK
M #4[=]<_YK:.H-PU93+D( <CVJ)/ UR0Q3]QDK]'01H),,4CM]C<2%<))D0Z
MY# [+"I%*#3>//!<1G";M^R+Q:[8PQ8 2B,1(:&X1*JQYU(BZ9(;Z/3:U,!J
M[?KC[:]%+7:BQ\#'B27\:-,2H<S<X0HDI,S"G09PRHG6$G>(R[J[DAM&AH#5
MZ8E2@_QT@8V22KT.B6G.,6QI;-3L]1YX\Q'ZPWP$7,] S@!URY NYE!8(>N>
M1+'AR.$XD",Z6H77O:+8=FY6TIG7N?X!R%B\DTY.KU^LSZ*T:(#W]IZ4DLLV
M)\"MMT"<(3@"Y=\+!A*12PQQ%6.VS56I2A&>/'^UFK[6M,2QG2\^Q[?9/&T^
MBQ: 7B0Z+_.\5U"_:CPJ9;LR"YKV2!:U="]D_OKZE>S%G=>^(C%$" % A!>2
M68F?EM  XH+?/[&VE!L)UL/S?4+CFE][5RCS[7%7^X27VF:)JZ2' 7J+]-$H
MJ%L=6]4$$^H_6U@^EFU!R'%U7GBNT_NT?^.">^8=,"&=8+[9[U[AB!CVN5.!
M0=:@ZQ"VD-,CRG]-6-+;U.D>_ J9U4M.S\'3"972\L;@QIMO*[.;S1*&HVUJ
M_V"8ZSA"5>"R^P7'6"K[O/%M_GV9$_^4%1_NT$_QD4'O]L#V_Q6IMP&WF(O(
MC_#S?UFYXB<R7.M'[U[3G9%]:CY^FTENSS('9VAX81/&SK-L&%E7?&'H>\E#
M3T]YYW_]&KS_E?/M/(#GI=[*YFB3K3;72]Z>TJ;XJ_%BMNQ=,+>5G$ZP^Q/"
MGTCF(99C;0K4+C/;.V,Q<-1>Q87!!K4.E50.+6A\9O"KD2+BU9?$>'J2&AFI
MA;'=_+(%=H"DU,6J5G*H-O+E">>_#]B+.;FZY([\!'/>A@F1^28F*N4'FF>#
M2:X9[]]=K7Y-\+VF]-.*=*X3QM-BBE,B,.#88M6D\J?=L.Y-JK_W)K4L,)!/
MD?BJK[C9('SX2RX<G#DJ3U!.7Z7T>=N@@A]5VUWP4;=Y*9ZQL 1ELYN-7 L$
M[R22;$,TB)*+3CCG.#4I+[N@+W^F5 I:T_^,[3I$?&<;;GPX&\<>AFKU(003
M57$#W3G"E5!QLBPQGC/I3K(A*$)J)U7FEK*#A(/RJP[_*VA_P'M).-&\+.0:
M!:XA9+'=)O5/[9Y,#!>3V[M9L]L5:\.B.JJ$S+.,8N&3;<]L@%WTR*(!/.#,
MF\A+=7QP^:H2JPZ)V2'G%QR"+[N!()7S<P8^<7Y+N2,]ANS\;B]*:T_@SCSH
MT):<.== NY\/!WL+5"NM746/H:!/IQ6:G.;K1;,1__>!,I ;UF&,7$DFFE.[
M@"2=LE@BE@807R3Z4;%1U$&;(C*7)%5')@*V<X\&J$UO0":@]Q/8HL"[T["=
MB>,&MN-G0$H(K 1O@3[.!%/HSE&DAQY>H)BFG!TTWN>Q>^C-&APBMN+&P??A
MW;\&3R,784TS#/^X#^%FE*IO(&P/;O!KI#'*DBYL)*/*1"M*%L]RVHX8CAZC
MN@C6I4$&'9)FDM'!2^W&N,_.<RQPTN.YJ0%;(6)&2<@S8C\N4M]&!SE2*8\5
M+7)(_2[2*,"'1 &P=/V ZYOTVHO%%>7G%C'*Z.<,PJR$'0U"1"_9.9>_7A9'
M#@+I6JZ+7*D+D1T6^0VFW+8B;9O@$F*7W"_K*YF.OH'O2-OOKR$:PBR%GG;P
M]H30)_^"I B51[M+U@#P_G7.Z8D5:9+42Q7^Y^N,'/<;5!GZLW#MP%!A]/P#
M!F,?L&C"^FD"VY=@/4^3S5\AR)<]/M@ JO9ZVDYG/$Z;L(MG"ZO=O&G#OP6I
M /UV&C(R'XK2*-#F.X:/_IU:*]KY \<C"5@\3T+M]/=:/<G8B@=S[.UF)BR@
MV,M>&ZQ!?0F5R#=U^,(6-07W0D04=%Z)X&I7Y*$X.YR6-=BLZG7<>%0Y-\M\
M5/Z,LU1+[GFBDEP]<LU[M2&Q#+,R+BK>^&>N]%20@<QU[T- %V89,6\=V'_*
MR-T:JTU!MEV<V51\KA<:(AIS/AZYI"_S_ <0<P3/A'F*+)7()X:#<5DW(4N3
M8X[\N7VK.P<M/7,,:?O+FSVA*3__^U/FN5LCOB>W<.8?G\$]!53E[W%8% \'
M339UC@W@1KI+=.<F5R'(G$5GS26QA&[=<#T,4C8TH68QAZ["9._1(R'MCN1!
MA;JO ^>Q"AG6G[M?L]SE6T+>I$IL!-67X3.6-'>_L%0K)A;/;5WM9UOXH) I
M\YTH)S-6 >TDJ^% ']0N>/H[+K;*Z(Q>;["3QVVZQ0B];W=B/C'OA%6_RX"4
M4V=!7.4R/_3*),OT#1@7/SN^UFJ(DTW:>%C<C^?$57=/Y?$,\!8YMZTZ?16+
M3A".-VO,"*I(-!C74.G"+Q,8\ DE\J5^)"%Y2[<JYQQE&U#@H5?DZ9=-:S1.
MG^U$\02TH^Q' _S0! -#G'&5"-*-@.T^*"M"1SKD^C*K<EZMLT-D;(#++(7X
MC4OC9PU8#]K==A]!="5Q$G.ZCPVXU:5/J1AOE88$J7"\/<.R#>_<S>MI UNH
MSOREY0/KD.PHC:M7;R_G80^_7AMO,X0U++7=DJ6.@1"$1$PH\@UN/>)WY))&
M5<I'/K%YZD'6]U,SYYT37SI')F)'EF3.S8&^Y$.^##AS[Z4\]5FW5MIZ'@H9
MI$LLC 7ZC^<X'=T-BD YMAQLF>A!_(L7%$KN]'0G%(N]\DIN%!D3*DW$"F&0
M"5 >O%D4'KCT+LO3L30?_]BUV$JAGB5):(/OE5A2 N-VG'GY+[QW !M$V,#
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M8='4:*Y$$M"-G6A(F)PDJR[:/((,GY]37]%\$I&7O'"O2>E0U9I)H)*MU2V
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M1@.0[CKRDD];[-O.X$5;%JSFP*ZYRM*F'6<Y_IH^93@O- =5F(;.VPJF==
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MW.#!A'T-:;HN!&^EGJYC39=;M4:^8V7N>'I<=[+)SYOO_?-TYZTVUR9=ZDW
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M[3G$J^6;246@5+^@1UMW8SXY5,F9<A;AR;;OI.^KJ;T4M,.YK_IT4"]1^ZU
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MVFF$#&] KJS_\_B4YZ\!>ORM5&+19U/U?N]!MO-0+&^050\R/X5J1B'O.K(
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M4584KP2$ X*_/E:\@I@-OXN.P[ABQ@0"-RO)\HFKEQ>\]FF[5^C<=.*+.UA
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MS39V23PR-3955M#9>V1!/, ($C6L(7I8U]<^XV8E^!L$]I,OJB67D;BY+.O
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M@>6Y\_W?_&2B[SW6=SVBG?74?Q7JC!C"/T5*8&XC]].O#F_,!ZP*&LFIY-U
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M -H$JL&K3@AWH2>!#LNB*[&OQ2\ZG,IY]^.?./YWY%W5&'QZ&R92'!>OWBP
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M#5IH 1C4D!)-%SH;L!QF4CE<O4X"JBW5D97Z?*]1?4H/?-I$(Y*(P ZI119
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M7V^A!D50PAA2OZ[@7I3 423 32A*8'8._8 O<NH!$^#LIG*HL&8%&<$$5)E
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MZ<A.F8>]TE=&P2$/;Y>ES;!)9IF&]+V"?3=G)P(N"XX@4GX#J(RWR?LI0VE
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M19C@CA43V,=&P>!Y7X)%:&KYL"/7*P96U?,/GRXWE1 (?/:!T(Q"7V/KOD]
M=U&FJ2HXQH!=V%-O/W,A!S<&;\47$^]'*1=;5[.#"]Z!7ONT$0Z2<U];HYPS
MY?(FV\P;<./AB'.,'K&D)YNI>T7JM 1LCMA!E1Y,^C5A0T1:;#C%Y= ^$;L5
M&!6,"XCW)L6(O$PR#/]HV+,P]BCH>4'=_=:(C)(G<8$G,%<][L4%"9I5*[%<
MH\]=?],_0E^@U]4I?89!;U(>D]+U2^(MJH@WR-XK!/;*4<DG]Z:_''WZ>']7
M,-*BZU  GXYE1L>17)OH <';04^U(SZA;1[>J4Y *1,Y5O2)S02ML&-#ZCA1
M=TW2>043;Z1_XL;%ECOY"J\>GEN(=;R *VLK)V62DXC=SQ#\BWN7FL3.0M./
M>'1XR52^/0BJM79ZA7!X'W6G>G%?@)0L_3F" U9TW?/B=H-_["V5#JY3LQ51
M<0^O?IVP*2H/*@I!B,'L\5X1ZNF<;OY!@B\"U/UC]YW&3=Y;Q/Y(1BR.I)BL
MPLM!+]4QW"PQ,H8;!>0O^@?=R"5F'9!#5QE?*Y9F\SW,6H7ZE&9R%,5]*GC_
MG/5 '30C!78]_?30[KF?KT*,;_PF$^<3T41)I1ZER5-:";EU1@0<MV;N9U/^
MBQOT&L+1&WLX-3.?3^LEA+]G-"+WTL[E&@5#I[3=/UZ-#/35;4%&:"> $[1;
MQPAE"<N!E<N@# _T>5)."R8ZJ" J48BA6+>^697%?L3KLXG3(N:!ZZ!=_1KY
M'1.(?TP)90*WH2@Z,)PY>G-\H>++V)B^9'G92>D8D6ORQY^$ !)[KL-OX%.U
MV](D!AXI.;+Y92\>UJCO/#:JU=;,[F5Y@,9MKC'QAXS4X-]GI.YT)@4TF(]!
MVZ1D^M$R,*,K/3KV^-JVTD00GX-LV<9QB8-"O_E-UE?$&4]'V?2C.8A74<2Y
MIB#O%YM<5G<S%WIW-(=F#5]ES+SS<KZY;FYU2ZX5/&J#]VX+MM4P%Z)<'K\V
M,+!/*]9$MJZ0 ] V_&8OM?,QN=;9Q]]X!ZM?2NQN18Z#&G9=FZ'V&D3>YL>B
M7EZN?=-[NU<L]^[=SW9H5*'[W%C0,'*:=Z2RA2%/\J\LT"?-8<5TQ**7AWT6
MR/%5+P8=.@Z\"@S]>6O*I\<&0].AN."]GXL=Z*V3_3#F9N>_LB*8=_OK2-N<
M2P?HH4EA1DH\.N1]02YQN&U"R'NTB-#=P"M"B;PQH&.*7^&9].2U(.TCJEZ1
MW'9VOVK2SG]D@-[LF$*]B>AUW%-.3X>;>^=0XJ\,^W'[7HT;:L*:5]G^?%VS
MWGH][L/U1-GBZ/)-N? ZI2Q8_Z6:WJT)S7'KOM6D.T-)/F'1V"J-F4E1>B2"
MFP*FWEIPY*IX:F8Y:6H:;A>8Y2,0$G9S]-V;]8.B5\3.)28)*]B8YJX/MWVH
M)&O04PU]F< 13[7=X7S&^$VP -@5'H6BF#"!SS=6[7#+2U,@/IA<LR,_IM?.
MDZ,YWD#OK<?I62LV[#;/%#4%M'+$7NH\Y1(>$BY6^6)+^?!"07 @?KRH8J'D
MX RJ/065PMF@-2&A:22PD_ATQA\I_0WIC>+PT%.COZTSX4EB3[+15.9YW_.;
M:I^1.'R*AV)ISV"#G(6?HJ<@[V+"$6S]6TR 8N:GI(F?LJXOJ2<=>F#JK?FC
M1O N>XCOT[/2@KORWT2-;XL:-W)\*.(D:2UK$4U;QS:6Q,*>>.Y;1LV"1UV3
M)S7OS\1+> G'#\>X&UI;2WP(\)T#\<*E*;9%<&X*WHEHZ,T/#8 XV=M'UNN_
M75EU/*'*7ODP,_#859]%7>@8\@YR3*WA?-CR#KZ6Y?;R+P2=SOXP4O#QP]W@
MAU],N-H.?+4^^N6H:]06UFZ7MTF/NX?&\7Y\'BW95_#(4_Z'L[;]V::C6V<E
M3;9TAA,H_61EBMHT$^#3J_T,D_IN=MEH0S9NS-9SR$9.-M7EKK7,EHROD>KC
M,(683U-P7>HE#U"9:U-W=*7U^;UVL$N72^I*^\J=%)(&?+@2/9]?N 9P/$40
M/^-&'9;UCC*:R R^/C][TVA_,Q[RQ#(^]0I)3>=)P(F'U3(/C7P@%O._:%/!
MOX'K9KMK)HI)6(CP-XF$1#J)R-N@'_JF5<]6(5^ 2Y6;4:%IB@-U)E-,@*<P
M,M_C3'E]2^RM;U]=3DM\BGZ3%_U-)40EXEQ"V+>U7*+Y<@>1=TJX96T?/:6-
M<6Q01V5Z0M-$:<M!<\G65/900<C7PJJV,RIQ^OOK0UGM-::'V-FT>5KI4SP+
M8&&.I.B/L0'B#O2<%3O/F@[1J+#71QUP9]IX[7:E":[+*&(*@?QEK#*<)ND>
MF'>N,\E_W<13)D>DX\UH *@06DAQ)2(;<1R/_/MU)-_;N?D7ZL<O+YI^N]!P
M>DX1N^CQ[NOUE9Z=%#(OI1Z/8J>IU5.@A%3+[F8I!>+W[ #!UK1\U?&W?-F*
M$L)'I4Q$OL,$39M! F7*$>G$:U0N#,^MCQ^R%R;%JXJ%B:B)6\;BOJ^]"9Q7
M?\2H*LR#(I EV*:U:+&LH/1(N"STTZ))U*3A&GLAQX45\5.W=3?L$.+T=!H;
M:\!'YG<9X?AY]7I3X_[Q*R50FT<Q"OZ>G>B;VB9R<2U'UDS?>F [E(1=>A;<
M3T&E;_\OW%.H9@)2E(V+%%>\_1H?)8:NOG*BRU>FH$-%E\\F7T4'4'A?](H)
MW'<;)PACS9_BN.7\&6T#1<FKZ_P/2EXU ,&&/<VD N?"3O$2Y3'$<#I_7:"X
M!YB'L7\Q:#NL>GUMBRO]6+9CY_L'^HT+R9OF3]++R FD4%LTBW>9DS!PVQ 7
M.IC7$I]JJ-J;IKK?B..=Q'"IOC=W:IWU4*]2_6=YZ0B1-D&!0P"'4P0>;D(T
M;=8[2?GP 7ZA)F86Q#]/>O,^;0BB=,<J30: T_C/Z9[-R11,]^6]2ID("*9>
M]D!RQ<1Z)?H'62Y>NGZD..$-JLI*A VGL:2Q/ON$"9SB)8'HD0=I^8OGK_#-
MC VW+=4KD%_UH$5.H[R5TK(_ZKT?2[G:=/-;Z/JSM@/3A= AZ$^,,/*;/HWE
M+SG/X-J7%B^+G/Y@('#]]?\S[TJJ[7X*YO!#QN .?X;+9IH)9K<VF2@FV7"V
MG70Q:+^'U0MY''M+,KB<*C-RB7B)[$&))<5;0.3)NQS]ZD]_"#6._;IUJV+!
MFLPNOUF1<*=/YZPH$Z^#'2-IWV_MESH;L:A&L2[J!6G!@RG"!8SN-&TF\,S5
MKNK%3MKHZ??U%88W/QI.K7!WLQ\.;GV0S/-ZEUS]<2'VZY?VQ[Z">5^G$BQ7
M!8[$-&N0A[%0?WK6K_Q(!^"FH72%%K0@Z.[@VPN37U4D6K;/WD9MWM,@89HQ
M.R>EA)G EX(<1LSE;K:(5+B:G]Y9!]-!9-IL5:?Z20)_#O%R5Q!X$3L,(2XR
M 5%DS\8'Y)3BP"AX*E%/X^9$?-O8H9C]-Q!=9]HWNRZQ^*HW6'@?H0*[=U8Y
MIX+C-_8LJQ+>K3[?$.B,I')KT$K%!_8:__)<V75-9R@T]] 3S&CC=^BWQL_=
MPF$OCCGSS]I4'J>M!KTI6J8I!5J0N<>+U)B =#EEG*I'Z9CB*?=T(N3+&!<V
M0DV7;#:4YK"3>XJ;#T7ESB6O,@%7R$BW(SVS3@Y9Y*XGW?\(=G^-.^52X*&8
MGT_SO?;!L%V[-KV8LIE==#5U+\7(DA(2A5;=*(#X->U[]]6V05%;*'(?QFX6
M<_>@%&C$>UJ\;44\?^+PUU9CL.M5?4'^SF*U!JIQV<><=K^\R6$;B8<T71UO
M:;-&;')W<-$]5V1S/NTN$[CT_3D3""FUB:9YT:,0QVG<_7<'MQ1,@UWTHXM/
M9&<7^[UT!;X^\[H&F\O1(.07>82<$LLF2J=3=N-IT!7DB#0Y:JC.@-#.$*+T
MD2%\\T&MGS.ZJ09UL^%-<23^'V7W4]!6/:B@A<(-Q4-2QV\(&F.MJP,=:D8S
M.2&CE/8\OH\+[<MKP?#N:+@@/K#.D[ B?*$R3=MVR[1JA3]0_Y2X]FT5MCB.
M\F 6-.0I(B71><\+,_9V.;)$C),,?HZL"$8]=YH@.X!;B 7H5;3I^;I UFA4
MAUEF<M_^4I($KBSF_>Y]L99$S"CYO4;R%9?OWQ'S;1[%(E$&]PWD81X1?*\#
M"_N",9WO]*2BQ03EG4]55W4DMH]C=B25:><Q;<A-G7D(A4L#OD#]#;YO .,*
M%AVC^-X8]/2+C(P41!^Q;9M_8COA_VJ"<6EG6):>.JV\LT42IN^RE"-GRR!C
MLM14*IO\P4\,'[>!?%-W9Z]X[# XVA_O[CQMN96?6_CM%$+KG(K&F9+GN=<>
M!(][;^IN$[#+-H2UYTC.91WX6&I,=5;GJPX?R==72^RP\D\+QVL*C2V-KD3L
M+.W8+)'K2;X7B=8IQ,C&M%,53\UY8>-&CP_F5%%9B^L"G[V.I[=*DFZX%20%
M5\[18(H;W28$ST9TR"1+#GD]2JF8ZPI)KS'??D7+(>HN??^F)E^5N.",D L0
MGI!SW3 +QGJY)_4W9]OPEI3$+8]A?F!A1F3/0;@#D:,%(WA[Z'/!9A>/[;$D
M\S@YM:]6'3]OPC/U;B_-0WOT#B :'64I/XGC5TB)J814A2MEZ,!8S\*"G^["
M'0F9YQ2PLFK8@@#6_"!_BB,%F< 2F85&/)<(51K0I9LM#R .^B+SL5<7,^?W
M%"P,M!+JRTX-_/1)C2\)LG6GK-ZU%+DEGWG^]<[KS(""<O3<&/AW2[P=,Y6(
M4'TA[#L=?>"Y)98NA!@LI1[#3?Q M*6+_TQ<)=A::G>5Z'SNQ,Q?()I\I2G@
MLX?]=#,9)P*PJ)T=ED2C>.G9C@5VR)NFL>-3=@N(.8> I-Z<JSE?O%,AA""H
M5XOP-7'[W"EGT8S83)F 1FEPMH'^7'Q[!OK+SE_8SG^T%'T$W\&,C2U-3?S;
MYM[D?]K<"ZU!!B+YUC9T!3LBFOK:+!]!%7+H#I)G[YM=43*PCB\U6M7\P[:?
MYO:0EHJC[2U#V1<$H4-QQT0/9?D)ZB+N(MJ1Y07#C;64NE\;DK7$&YWI"@^[
M<\Z!@W6OL9 D0QJW6?N'(U7QQ^/B;XH45UULG:J>A\J\-+QT2E*_Z*N:8D6A
M@TU<4.LRE06>P!8-+@O3N1M8PTH'S-217@/!&:DW?^TBQE^<H([EMR+=>'=.
M@MB9P#(40N??FK^-C*G_E6NG%"5*$UX"T4])#?ZZW3G",G='_^GPH%]!8":_
MTD"[L;5@_NP M;[UKR2%KB7AUOAW$,:$1B:P%PSN2C,G6DW?G6MA(2<8M7FW
M N6=X3$I.(!N<:Y,S3[2$N"9-,LF.CX^8.V]HD^]](/1S0#US/6KGX4;?5X<
M-C]T'MZO?J'MI>T/0?89_DQ2X>6S2+P]8^+^A?5':R WF3F*W>*A.WN6GIM3
MYP?T9+Y$$K97RN]F_#C>E4E1:UXW>5"P<:JJVB%3;^HLF,@Y4U+_/;]6ZB<Q
M!]L#MZ3XXM<$Q]M>?<QW*RU30>./K(NJX0X=F*U#MH'*I>IS8+6$C[%XW,&1
M)<TT]GZ7^L3%Q]72T+<\$[V P),R%2: -G-%M 0-TXY/<I&&G_B=@E<2#2M]
M1=QYP7?OUQ23 42Y\+(+_F7=72(3( A':AAW:,5LI72M'&W7Q*DJ+Z[U4S,B
M91_4^NLNX9$Q1RE)Q+5FM'QEM!/*NC1FJ=WPA_0]B8_!*$&"GBJ].*4)4W8+
MS!/?3-X6XW>T=]^N6;I54U_?DK^M.>W-_FEF\T0Z]<A2-![S7$^.^#%OT@'[
MI#RRP\3EU?J7IW=NI5_A!W,2W6@<OB0VLCD+CES(/UV="TNH,[E[%'2^V?M$
M*[#KZ8R<4N^S&3B]_#F81"@(XCU(<;49\GJYKKYDXI4N!RQ;CM",V4B%:F0X
MY4,N_![%]B.LV:IWJB?=(O"*D/^&>N8W&_G/IGO:VZ#?D.[F$1#B*T3;%X^:
MQZ@*2M/8MZ8#TSIOY13JC7J><C\>;D8=;)P"AS$DB"LE]\/,^O$5;#^.?@_>
M2$Y]M9;;:V$@N.]_;6O9Y@VC+P@715,CNK;8=8<X:I!.I!ZH";]3>20LFN?.
MM;#<\7B*38ZEZ@O+ U]U#KL7M&P9M8%*P2N_\N>E\^+,*(UY,']E ;NNH[Z?
M]06$A@\7?U/UWM$'5J3/3>LN_60"8P]!  [1RQ"HI @+<']2[SEH_YO<\DKP
MW-X7BCZO5.+J;'Y #H.GTIG ?L8QJ.5BO%N G=+ ]SLI5*'Y\:RHH+@W\F!
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MM\CM+THY?/"Y>+,7_^5-](=SZ>\R%T?+*GJG[ <]>\>@;PXDF2Q*7)V:O-J
M5\.5&WQO+"C@F^)6$[:'\:AP%H&F9BCWQ'>"IRF([J^*.KP3%HSU'. I;UP:
ME-1,$ ^JM=E85CM66MUK_?FAY[VQ%QXO=Y8NQ00M;J)[E-Z=#LKI*#C]8=<F
M;NE]#0>UZ-7XN1D^#NNG?/AD!Q/.J(FN-Y06.A#ZZN2J( ;+)O[$>V%KZQIR
MF7?I'(HDG48MHN93,^RI^7,[L"=D);\LNVW$]R=C^%3C;_I1CQ$EY)-*E:WH
M44""(<K>=1\=\*D=(EE2<_R%*/RPL&2[",H5MYIE-,<]0RXX7'+LE1S+'%=
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M+$*I9!AE_:9Z<V*ECW)L"]G2-9)N,346+L-D82&[,'FB3O\>-RS!Z752%23
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M9T9'N(,Z"/>N' VZO.")?M!'$TJ'!3> B3%SR8;YZ>F/$]GL/--N;3<.$=T
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M+X]82NGZJPKQKB<@<&@L@XWJ/ZWSY\9R6F7]3>M"X.L8*I1@>F$V D<?8$E
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MSEDQ_:X/I/0.V8<\_5!ZM]83;#G&.$ES(&8ML,S4"$8 ]G BNF5E,>\F8/1
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MD^>E_-F%K_Z.^V3"1PU#OF&#O:VG1EZLVNY%\M/<25F+PCG.R8P"YYL90TS
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M50[1E<P8+5<-,JASB4 Q0(RG7MX7:4)R+_#*;9.\"G)VRU9;?(AJK@G-R/.
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MI@$VK96LT?_\T-C(MK(A]<?FLFM TC6W7EL @I7AB%J@$IH5:"-TP!DZ .-
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M*Q"OMC"IR*BL:L0=,XQ:.+>?U_%434\<=_Y7,*0/@5F:4Z$#LD'MR/W9;CJ
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ME<8LQ.-.+:(Y8/9 9IJBS60WUN@=>U=LJ55L@LLEAH-;JPTL,V^\3HJIHKY
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MX40AH+Q6]HN\INL\N[=_71J0%!K_G=9E%.5&!SAX3,ZT*R9LCOJTW'%_D#C
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MSZ!]@^W2-]*!*7+0:#/X1H#;CJ6C]L4P=:@-SX6J-"7:G>#@$'P^[=2BYQ&
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MKD%S5@5.T&0+$\32K.FM]I8?51)3$4V/2YM..)J%::U)F0^CA>B##&#->;P
M1@N88@!=>$R^9#@)50O;#ZXW0/E)PN4I4N0"?&E'8[3ST\B#A7Z94M@'K-/J
M8VRIKC(C93<T.[XF!4MH_LVXXAH29&<.-0K[7IS-5H]:_,( G!F ?,;*[:*+
M<TG!!8?_P5QIY@DT>#:=&BK,S  P)AC:(7DPJ6JW-:_C4,TU$["=S;+=]A P
MP9)DQ0BZ:E\5*AYV[CMJ? &!$SVBJ^J5'GRZ>UYK5RO[*R^<&58Z^^SS7G8V
M9;5?WP&[OZAU*=SKOK[OR*'7,;OD1)2LKT1H&I\!4H!?7P"W#\P*]G3_XX>"
M?WC,'&H9@/\. VA@ 'S&NXMO49I7:?B\V,.;!J39F2BUI>3-.0EQN=Z03Z-1
MYP]':YQ1-OL*FA'+X2!NDJ)S"'3M^FG6[J8AZ<A;X;&=\I:LN[/!NU- E)XP
M]R%":L^F6.\[+YW&M+IY]:Y8V;O!(77+9?5JG(\G6S5JW^G(E!,E51_8<'U3
M=T7_^*-Y!#S:BK\^?XU\OS -![FZ([*1@Y$,9X?VI!6@ J-V^[+*=.>O]@B&
ME_89-O7Y5\9 ?BYJ0VL0^V>![%W5NTZ=IQ8#T+ 2O@Q*#\!V[BEE!9_)8_ZZ
M:ZQ=_X?E^&M9C?J5X]?%%H1L1Y/621;T)@4<C4ER1+*> ?S^4' \G &XQ[:M
MJ1_E!+FVZ<]W:4\H_'M9"BSP"BAV6'J4M^%/\>L?!:X;GTGZW/7_-2C^;R>R
M_V9>C?UKUO]"<NFE'TV[\[/]'TW"X Q$320)'QU 6!+@@'7<H6B/G 5I2_=%
M6PL.K9/ZSUI.JLOMJ3)@  %N8.JNN[-:/PZ>BZ5*;@3^"2& XP\( 8,E.X-#
M7=\7IG_8R#S:VX_)90 ?T9(F9]+#Z_6SK\GFXO8BK^T:C K4>PP@R6W2@7I4
MBWX$]7]_YJ7PE^QTE^P,H!?U4=MD'#>LOPRR3D*'HXC?&< 1W%P"&,\ 6*)V
MIQ3DS[Y!-MI#"W?_4+GZ#&!VF*I",]F5%XP?G-WUX%9)6O2@\2 <T4@:U/W=
M9\.EIX1%-<*B^DX_G.Z-J?\GT7\2_2?17T3V,H#:<M)Y-G&ZV*_7[W;1V:G7
M25?BX@(B)W+=]+ZZ/C&)-]DO&O91PX#IU<*^$Y1@VH>/$9'2L.KQYL$P9%/*
M;GF_'@\&$$M380":*7D?2%+6=Z/A3PNM7191:]>FW^KJ)^LD+,13<NE6,^/4
MR[@&Z1UQY&D&4/,$AU?_W6=X?GQ$[O&(7*<_L7LG8M,^D$JU(J#_SI*0/ZB5
MPPS 8 [5V?CW*Z1N.M:0 :!M29S_>RA.P?P9@"4Z&'EF,*<0!][ ADG9/]DW
M6!8=7^? OF7E*@C >'IPMZ$L5(XN*#.H*A-VDJ5AHUJ)GK:P-_8>2E4H%NNI
M1M P5WOT:?+RO@RMT0C+P;[-"]?T#QSX1,@IK_)1/6+8F=C\M_92_K?FR?'R
M=O09O%#LA3;W/<E?OM=S*>"8B$A7%ZL.5<S3D$H7GT+51H":&YAMJD[S[KRT
MWMXU!SIE&4"5JO!-U'H':C52_S/V,@POV8.;)<%$=KN\UC 5U3F)5*=*ZC1'
MT#TPM+4S:R*_=GT9 ")8YN#MSG]3'808/0]?!]&1#("]]U_?4GRS.^GB&,#X
MJ3!FO<MT[DI).HIG#;8[$/^%J4+JO[P3<0JV/8/;:DZ^WM?. /PPFKM#JYX:
M\4M][3>/WE4R0=L08B[L3V_]B:DNV7^R_4^V_\GV/]G^_RO;!FJEF!]F&ES!
MTZ: TRO;K'^MOXYTY%F!BI_N6F+=0!RV)7K):7QX +W^ ZD6L6P"WUZ"B1@4
M26\9KB4_9@ N*(E>E5,8<BZ&2H9$)E,,!NE>G,W]N2&T?FK&#]PHO#4,R*9E
M[]:K%#CUC-Z/W252MR9K^X>B5WZKYKH$ [ 9WETY'FT+P+!VJ-FOU##C/Y3]
MK9HN=MQP$>ZOTI?9\T_R?Q?Y@;](7C&PP5-_E $L\T]P'E;>_TZ]=Z-2C2/[
ML]J/1%6S8'7S%[;],&SN;VQY<(8EQ))S0,MC3[F*PK)BKK](\;_-+2] _HW3
M[&(NI*8A'4XK4S\M_+/?CCJ>HODW69_L6OS?(OK_A>33SV?:=#7OK1.[)0C1
M7&, 0[%:941XS:B"QL"7*P*A;K%1BH>43YKCAW2$/_N"@SGMV5-M:YB?]F.-
M%6[D&T_1$]#W:P6:,W0&,/-V!49:%W<R^XKKMQJ)@[T/US!9/+QJC714<O@C
MZ>X_M=5FH(&^0+__'+Z"F38U%K*$_Y%U]3_RFFW"1\G>ULU'E>&B!9@,_U9Q
MM5?Z?Q*<#.I/@L+^5O+X;Y5\YD7]46R0/PHJ]P\%?ZOC&<L_:?_7T/ZC,C)L
MM#N]6F]^&=1S2[]AGUN(YI(:70J^?KAN6F[,:434&0/_;216P F+A>90\%Q&
M>S!=0O]A.E-@%!6B:U:B0+%L&X;O:%V[:$"^0QN<B3"G#Q3^==*&1P.-_F?+
M[9^T_SIMS3+LYT<4_&!7?\(O)9:IS_=BVQ"3*L!$8 !,,O$X]DX2/_:!<;N-
M^=G2JL*?RNN/+*_G7?PQ,9CUKTITC7/HR[ M.KC*0B8>8>F:73'[[,>G QO"
M_<L*OPT@^ROT,=.1^6V1=_L=+(Y[T)__.QHZ3^K0M__6*OZ_G/RWA8'XP-5
MN(K9SEKRO.F]I!6(Q.9&7C]R+F?*FNE94K#O]?\<!.1W,G?W=/_:[-%0!:2.
MO"\$=%7%_O3/[[>#?OWP%V(C_GJN]X:NJM&;?S",AVFRZ@H#>/<5?,0 'MH9
M,@!E37)E>D_5$0;P.GS1.,!G<A48LXX=E'<9'AK-*"F,3GJ[I_OUU;-L<=M\
M]*/I8:@YAT$<T?(J ^"%VP4VSW[ 9PR$]O2,H#S0XG"Y #8N@_=?O!UP43!K
M5[3F%;0FU7C7[\@DP'>.;ZY2^;490,.N>\.AUXC;N+HX#EZ*9P#!N:A^8_3Z
MIO<X\39N0!.UODQC $3.8;/TGK#T'MQ1'-[&?9 >0/-B *QZ*-)]5&T?"4,[
MN+-%/Y#& "8S&("^#:JS?PM5P[D9A:924"@J,SG6>B/9>@/3@ &-$V49P!><
M.0.H>3].U8<0L8J[8TP%6<D ?,_BP"S8GXBKT)ZD,P#H^#@# &BIP]YGAKTE
M2;:_:[,Z54I'@ %TC6-0$ZT.=(F(38-T*@WN1CW, (S.[H[,XBT&4/T?:'PR
M33]SU]4S_!6-"OMGZ__9^O_AK7\VHS?5UD2\NB9+@.4OH,&[<3J0M3^B,F_[
M_XL$<'^00-:P6[WTD3ERB.VC23/SUGX-RX"QG0==W"_O,%N(?AJ\Z6Z3\JPU
M%FM<2%Y&P2[O=V2Y:B"K%-\MB_-"15+,"G=T"W<,)P=_S]GO6^[$ +*PL-D%
M"FYBEVC.>P8P.T)A !.0PG*=U.,ZJ4BI/Y?L[[J.GM7' -#9*[M:$K(H!MLF
M[[H1(-OR^=YYM=YY> C\SV3[^Z[[$P.!.RTZ=&\<CLY$T?I[^8<LY.IL[U2M
M@B?IW_1VV7!890"OD#W+T/=VT&@0^V?#ZO<]MY.M1T=BRNG[4/^=VG[/D(#R
MIRN #* 6>B*_?XEJE*WE:'TBTJ*L(NH9NM^,_\U#=5;<'9P59ICO!DC#ZWH\
M,6@RP]Z5%1*+E^) ><,J^94X[0,JGK>)86)K[N-D/+&]?9LO^+&"SI^XIV.M
M^C9MSB15.6_]S3B!_Z'AM%]_9:0O_WNG/;Q(XL[@,YRSX5&<N[=M(;Q,XLE_
M@I&#.4K;U5K/,G!6:.81<^,'81;U.]CJ_!Z9]D_:%^FGF\34U)FC;C'G>FDC
M#"EWU62E1]Z1D?E]%YQQ8ZUOFJ8OL8KRK);>RY)8O7=ZV)A/9GQHG1P.1EH(
METYBPK;,]_?E';E5=M[?[L-GMH0(;->3%W*CXW%]X&72NTE8G4[87800B'-D
M+84F,Y5T56C;'NU^R8K4N,!FEG-)S>V X)3 3D]6AX6UU)3A)9/:K8NAZI=/
MQ>K.<>KJQ%&^O#2YWQD,E32FJH*9E&>V,$[J-9*.*5$XUN&+<L:I'Y<UCJZ$
M[GTT^.[3K%*VA0'M ^X9C&U((]O=BNS3KZB1-2*IZ&F/L3?@)UXNGG$S3?05
M$=S,+N.DIA37H\AG5:@#5159+QVQ0:'W,4XUN"?H88E90I.?K*0WLL$YXKB[
M)V%)OB$X+!OW5E1?,>/Y!9%\O1'>!F0?NL@,XY.#'6>C*H;#N=W)'![(0;%/
MEOCNKO/F1@\<*]5/>CNB53J0WVUB8,68)@5;08ZS#XVL.'J_CP6NM\EZZ31U
M,H.H6MP>NL3XO(!2(MH[RSK6D*_XPLV]Q=Q'IA/*$A/D=9/>FM\1ZQS2JQ^.
M"()905AL/5=2H>D9I@_X\QSRQA%1AY?7+ZY6TR1G,8<6(<=0=IQ<[N_TB4T1
M5J )<5T#Y\7!VOM%VL5UOL;UY/O(9O&9ZN;JB<$2>B.YQ8-RQIUUOYQ&89%:
MTQ<WUBIG4(>4B/IAOEJ/XT2*@%;&L3>]#6R7(:8]=HBY%8OWLPZB>]P[37W?
MJG*X_0)Q)BOIX2'U: A"%,1;$]TF RHY0W@,O]EV'@)#5:>U8;$))$V%(J9K
M4T0/V4U5I(M[]J0:CN1&;@3/3LXCKGKA(SB5?L9XBGI&;;O%WGW5:#0&F]![
M"VP(+:X<5"&XU56*WRW-KR3-!N2LVDT]2RM&&Q9KG'*1L[24?JN\]["UQG,Y
M+6?7G!IET0FF=W%KN&&1AAYK'!/"*Q-$/3ALXRK_Y)NJRR.Y]1,OY$YD;FN[
MXY8?$;1U)G&AR&/4TT1X$+0AU;TCI1(W4/BQ;CO&<?;-Z)U]"J:?A%TQSP<A
MI$ZR4!?R$(*?I/.FZKBM\4!TEHEUCY#FV RQ@S7=_OJZP4U%YM"O(E^.J$EJ
M^:6,+D48$JM")C$A\ *KVO@?]-,+PIS]K<;CY@OEQ6T9KP[-F<::KE*1T1O.
MQ6^-*RYJ.PJ^U'1MS,-KH:]SZFU@.F%A;[XA&W$%&1+'4+;6?D^L!BIYZ.P<
MAS*=)E&OKPP++5J7-7POD,W%+EG,^J0\>%M&>77G[-KH#TT#PPUH([;_W.K3
M*$FO$O&8RX&W4@TL=UZYIYDN&GLG5!>75!6]=@I5%6W-<>I][00_154&]?"P
M'SH3#" 4X32ACWO74$S^.I_IE3F*;7SJQ@!,L"5L,1:+A88^[DYUD&]5E7A0
M%O8&?DS6S*TI5G?_RJ:*U&0AS]>6^WM.7<BY<WE^."K8,ZPCE[,/:I,ZEO\H
MO3W?#&YBHCGN<OJC;D07#WP?8B\M,X\J0K0BB(6:BSH(*D\\H*YRVL:>+!X=
M:2D]Q>W 5&7 ,?A)T#4;S<( 'BUS$-!U9K"F\2,NHVYF)-2;I*N++Z0_LL2L
M:?H+^H8?DC_T2K?-KBZ1 ;!#F\%H M.$#F!+/Z%BW_O@08?37K=+>S7,1,YE
M?PJ="O\YR$,YAS# @75$P[HJL8&5G*E!EWW3<9-C@S9O N,6LK\*O@*8$VUK
M'7!/.WF,Z>W(:\2(!F]518U4=Y?9/NIE;UOODR5#@O86/-/JP,1RBV!D(LM5
MLBCHC8?YH0M"J(^*L*4,P"^ <K/DG:Y;R=-PU6!U2_8$OA5I343V^VOHBV1]
M<JYEVMZKL3%D'_HJ6B(-^5'V\;6H9P.W1I^$!>B_G^):.(A\ (H_ (5(WP8(
MC9!"S@:.$=Q1F\N*(5_JMW1KTM3+]P5--ZJ/-JE$-%:JD,W ;OQX($30!06
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M/<-9<_(]$S[54RA).WZ]=]G\^_?)[>M>@>>$.ELUB=<%>> I.[-+BQ/HT++
MUU0S@I L-ILF?3OH!#9AU[<+>IAGU.6]GEA/&/X%(AV]_ZISQ$<&L&NH]S;A
MA' V0C?:]/H%./?]'#8S'7YF>\1$JM]UVZ*=H_*-T!W/.,H.3A;U!+0HVG6#
M_=S'CEG<>A2&E;E%N)N5Q7\=./2*G2:1D6D[9W9EN&]7<;7W_56--C,^HC<1
M^ 8IZNY6-W:.*+]"&O1=9:'YJ3#E'3YL?#$Q76*?T+;0XKS$V70K1PTGR<L$
MW"%4C68%5_J\XPA"N6O7364#X\0X'!\.>S7G$ +.N,LUTT](7JZ.2P^#/>>,
M&!,@M3W;2?>MX@.O%Q9)NAKS8\]^YU0.S93PVS0](_@.;FGVK,Q[H\JRPQ];
MGW"UC3V?VIS]+$3 7Y\]ZP*O&O ;3'1TY1 15A\1-L8+<NRN<GM(;&\0)DZ.
MK GB ;G+]X='/GYJ_B$R+4@ ULU6=AEB.0\ZN*1K\_DZCQ]VQ]0?2#&Q[IK/
MBX\7/"I>Y/CIP&#_EK%P@O?%F%D=;,G[4'XQ?R/<I3/8KHU%_IM%.]XYW P
M>49?9X8%:MG/=BYZJ3,>]ACF"SU-](X(II\ UXX6D=!A>?0AI13?V2(_[M;<
MN?I\N:4]LW&;TL,NK^F=J,-!<I ?@Y =)HQ.FO8!-Z["ETDMQP]<DFL6Z0I.
MM"U_GVQIT0![7'20<HXJ?V(*9>4"V>Q>;!DD#^) :0+JB#N<4!0A^ZJXPJK;
MQ1MRV[6HO CVPL+),O^[\N;> X8_#,@DX]I\96X5[M!SCAGZD.L2DAU7>G7U
M^5R_CK),[4_FC$A35<@N__*R_%=O^4ME(?OAA>0$DF.A%HVG&LJ3[Z7$BSW3
M?F_LIYQ"BCZLEED8&;TX=H(67+4?S#;O<\DUK#9PBTM+=A0;[:\S,V4^E]>0
M\(8;N*2A>,"PJ$E 12!)(NE,M?XQP%,O\QKT55+9 L*)HH60Q(%G<ZB28 21
M4/<2_HS.;'3N?*'DJ=53/ZI>ZHGF-\XS+:A->-O&@4.4%W-P?B2G>WH=[)"S
MMNV] ?O"(5RA97GAA9K4D:P9J\C.O<L'/A]*":;D9=8E_S#):>,-*[2]4)\5
M>8:3OB5(E]74RN()F>OL= B[=^(/8,XE_P;,N5$?3*7(3[W2"0([!R1VOFN?
M;S5Q_^PE)WSLS<7&[K/W1;XP"^JMG+/+2Q1/'#L;)U)V)9+Y"#19Z: @A>.=
MEK JQ10AA@-[B9!ZJ%"//OP!T_DE"PL?T?RBB=WY^<R>^6?PMD,U RC<JHXX
M"#YM4P-CB5&#=6-7\H/L\I9&:K^VD(/NVYU/?XI\K+"EI&-,VY?E)J_DOU1K
M&W+<>N98?=2-G)_.4\&:QD;ANN5ET-O$"/\96C*=A:J)[:'S6L,YG)?M?XX\
MB\K]9C(*7VX3:0\16#:KN3ZU"8UN1O#1BC?@/JB#NZ8+@+C7Y;+,V4 7#EG:
MO^=!X>N-DR?9$Y4"/(4_#XY^9@&8?/3M"^,EY^^9Q"MX!?&M5.1+<FV(ZLV8
MR ABG#O?TX_8P'GI%Q 0L'@2=4QJ.C$>,S2*"4!<4RH[]U9Y&BI_YJ6)1++C
MM1IH= >] <:%D"+ID;W1$T%>Y?"CUCM2/XW#L!VEJF'F!K<#E&Y=.F^8,5,U
M+/A"CM=X7*L 6Q(U>?S6R<3;JS%RT4;?7KZ\WI+:D5;3NH*%R=&YJ5J@&^7J
M7!1""5PEEO6,F/:(12EX>U3 >(<7N.Q;KZREY-=0AA0MOF!>@#R3XP>I+TB-
M^0Q@'[PF]W*=\-[P6A-'PG[GN:6\68_#><U<%FS6!E,K\YN8;&F9-B6M9^6%
MK^>D1]>3#9MZ3Z4''%N>?) 4]CA,C?<P )#WQ$?7?QXTXWR-9*=W.2(;!)#I
MQ.+)QHBL!\;66[UMR;8&5W)E^%XT3[\.=?NN0WC-*C%8.QY4%M$P/E*G0I(=
M"'+[;,V'/%8J(%OTN?R\&-:@YN.[K #O>L[;AC\'XUS2DK**=V>AQ*>,N L3
M$-W(.Y2#Q</<A"62QUSY43/?EYC/2H[+ZI>6!"-4O??/_27%_#<3D#!Q.#O(
MFS%9H@1"*9^H\\:D+K9L!4-#2U7[B]X[!I3[2K[8WRDXV(-=XZ,>$=XA:+W#
MBTVGQB]<-:"?6/]2$(I/=P%R+'S;#K,13-2=$DV..Q!-R&@U2YBPS*?,)NKK
M0 ; CU$#12;@(>8\ R[\52*(F]](N7Y=6<8FPT/;I_<S<[??:6@6V5.QX#"<
M36#6G*)W($7O/8B"]E%14P*;<!\<3X4)Z?SX_=@&^"$L9^ WXULA>XW]4CN:
M1<1BSY0TW=D871*S1<NYL]T#::2ZAO'#30%5YTQ -VTBO?P*6@B[Z?<2$3_^
M\%Z^\)Z\:S-EG$?==<BIH.UG<S!&.JA,/930FVP]TX,JZ#\0F='&]6%0]%"U
MK[D346%R*PPI (Y,;A;[0X\NH \_+"?=7--Q3&]M+FH7OLOU-2Q*69R8%V).
MRX6>19A7]$,%0!/\6^)@R/DO[N=94[T_2A$>!3S,>\-4H[B^D550RF>@Y(.$
MC2&NT]YN1@3)<Z >+^K.][Z;QM,[7;B&1]SV[.L4$:ET&R]8#<+"^!$\1-?2
M7#,L/=O[88'ISV]9'P7?M; #0@KL:W9Z>$[JF?$?;O5T'B^_\@I?S=*2\D3%
M)>N4DQ_.>PS+<Z9Z7EW*90"G9XD,@%X3M.NWR6IA"Z7,=Q(S58\86/X9Z/9?
M>7[Y)+^'^"'C_AP)*'\*M78^=9TZM/W4B<X ]*:W3^H;J^G?-?J UU?3@$:3
M9^MP/R)JS $B+R8,J0"^G;O[,R-*2OBLG^JE2UPC+ G-"QERFQA.6@B5SY:
M&=:J/6J8'Y1K9^FU%1:@XB%AIDP>+:3S=M/'45Q83D%DU_# 1\5.VD<\K>BH
MZ]#V77]6]:;LBXH[@,*]QONY;QK46=00P3][;+W,6TY]?3]_MTZ+WUCQ.S5?
MQW;5U7/-%I=_/O,J^6YWWL;:KAM-[WU2H6^*$EZ;<EHLKO2(6%:FB%CC#BA*
M6I"8\?0BA-;$\1G]2WQ&YB-N/^T6Z[XH6@&^-9BXG(UXFH91SM)YS)Y/%XM]
MI@#*,AOO0J(06$/BJX6QNHP'=,WSP/PW-02L.V82)!797SPX*6+S^OX5QQK^
MCALU!K5]H<3-5"D7/;>R1?MV7&Y/PPU=C*J4C*/!X*9Z)K(>Q8K@)YG4PH\X
M*!I^4<TQ?4:.;+,0C6H.8+W8KL%TS"K:O'0>?OIF0](-#]$]O^%(L_W"D4;]
M#D<ZEQ@M?LY>XI*;5LR8^:K*@?LB@L+"&C;;F-F,'1H3T:$./K1:C2J0]E%T
M(8G4'G1QS+Z9K^5F/WA)\1WWK-B]ZT MF7>;:KOQ$<FTB"Y47U(AEE_ODMZ@
M05=&VLJM98\Z\NO.Y+$V6'SZNFPZU*^ZKULO \\G96QG_=3Y"=$IVO#860WU
MF_V;97+2H [LL<X.CP,#( I0&$#X+Q3IQ#.T."PJ\*4)]1QQ<^#C) Y[LTVQ
MZV?6]@GTA:<:[&L7A\LPH$M3/6:'GRK) %#V*+##0WJ9@W+:/9ULW[-ARP .
M+Y2II1[-5(PAYGU8RU?3/Z#EH$H0CF[SW_'+;KC7<.?>W*=XG6F+;-[-']WO
M,@-"#9'Z7R;%IUN6X5_&65&/5_?8C@,RY3H\UJ3T>C3W?*QQ.-KE7(]H$8'=
M8MCG=8+/I/@)&@$N2/^.XYC:]8ABZZ#']G58*S7'$7VV[ C;4^(+K#"!'3AA
M</G:[FI2O)R)+T^X<K=*B&AR.N*<+B0ZDFZ2J'3=#D=D,KN6LCB0*7C^J+:&
M^%4':7_$4$=,;9C R_K'(NY%29C9\FV1R5P3K;*N3:V.*SLB+,N?.AT4M?O-
MCF5SM@OLK)+W@E+$K<FT0,(B Q!^=F&1RYKS>;>6S%KCB1M1?#"1\^JMG-?F
M'\")=SO]+[I+$_9")7OU351)3V#/C40HZ&=W]WX0B?A@YU _Z,@ ]E+-QEGI
MBLQ=\]40*FM)1M/C,1&)G8:S<J4OEY/-UW2H(36/#""7R+R\/3/C>6')#;#G
M&-\RAQI<Z-91>9:,0N+W5.NC7]+4<MJS=XW0@,<:3/UEB7Z&(<_*M+_C<A[,
MN^I^=)!.#Q_>*V0T^CJ#VN&-(A$@@K#'F  &P&4!1>;C8P3N9(H;##OR2^VZ
M40^:.ZD;LM7(FD3FD :T<,YF_-+I2+R7M6Q(ILG*6=TWZPQ@CQAN@K<WH%$S
M9H^^1'EK0N^Z8R^I=_4:Z9BJGI" <W^R@NP< VB#E^Q8$9J6XHGQU; "> A6
M6Z0NIG,R@>U.^%E9V=)/)65[I+[?K_KYEI(?BAB57+?!J4I1/:[6K_X()'0&
M6YU#%6Z.;"<?['_<\34,M9<=QDY=S+D$>_[%@'=F6DS29K7[N!6T+>[]7(.J
MW,;F(]4CACUH^?\G^.EN*@STR4-<()G%OJE0\!R0C\Y^<F'ZB?D< 7P?OD_V
MNZ[>F49'QZ@R2[5[?N^3EKIW5BE*N_J/KXD!L'.,*!7)+V?Y9,S?'I>1HFW0
M-YYL*)4);-I0[_]IJRQ;FLO==3/'Y=]LE<TI8P;@KV#\4G1YQ+5"TCEYQ,X3
M2D=E'_?)'V+P"@N+K=[Q7]M:5D8*U5HC]^C'J1"'-9A&JY-J6$1!)@G3U+[Q
MZ]#QP<Z)_S%IYNJZB=%_88MKX^+_?8]L(AL%BE E7<DDF4SB?! FV1K9YL^N
MSD,31/.3+@VU)"2S)\L=A(@KV8J3F\%, FR?N)_B1>*Z[CMMTAVLXOK'I##1
M1PX'GGRMRS[ [=0+GJVZ'$CG75TNG4AX@8B!RO:<[IYM8LH[-:-(^82AK=\F
M+HC7CX^\JX_M13( +2(T(.ZYQ;>?.I'BA(#W2/VF@5E#+6$T18ZJ%CO95./
M#D;-.$#I"R-M%6]?[4\XM&ND,,FQ11@3E^&3;O4H8?<1PC"H4[\E\#1R@L)T
M*/9@Q>&RW,F'S1I/1(E1I,3:7'HK\D0(7GNP$;=G@7/:!%31*^E?QHL?EQ+2
M^H2\40;_X5;W',>R*DO3%!QUQ^F5]:U<@E+O-!SQOG", 51G+K_H'Q*.H"A1
MK\=.IM>@]H%QDW#HSDX+<@!DOIQG<(<-XBZP'3\)698EA$'(4>6Q.OU3(?B
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M>'JIQ<0J9^ORZ=))#2M=QSV<99$GA2B?PNO"K7-OCD8X81(9@ TD-/$,:$)
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M05*"EQ'O2E,*X^/OXI(+HEM5M+I6DEVGK24H3N:/F^[-L2@<YQ$MMK$<6=N
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M4B&O9[&)AK3A%&X1\>#V!()^'@V,F.^3B:!Y&WF3_'NHVC@J@(D=N7NBD0I
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MFN*A1EFMXB89=>X)\+,(__J YFGH8VQ !Q!858HFW]>XR3@FA'UIZNHOJ/9
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M)VT-=3/')BNK<A9ES87<Y(17\L2U[/3<1WR^(2OWV\%/P&<J$/0DCS+BPXS
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M $<I0QH*8&D\)Q)5>4?!^(6 >K3_B ([0W>T@>"]CZQR5YR$LLB1')G$"X%
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M&C4LYKLAS_3G137?:UB[_6HZ,_6[W?+0+-;H]8SQ4:CC-=T 5T:.7W6OC#H
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M@7<\.E2@/L^9"H2E^(91GKH*4X&#6>BH"V@3(K,D#?I#(ZF 7!=EJ W9W=V
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MQFEM [LQO1%15*/JZ%3DVVWRT9-OF?#HBZV66Q/!JA/0!O-5MCRV: "-G&K
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M+Q\3CW8- H 'Y;N#UC0?J!&#-1;C\HIT=@698&L&?9Z/YIIME50\HK]2?S#
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M>,OLV.AX6[Y5BD1RXM7K[9>/O32"YO>7?M?R#^_3%T+XP86QD+5@)QRDL8^
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MB[3HAJ"#.1639VO=ZJS)^9"Y68@3ALC016J!\7WA;RM=F>0''YY&L=^C\ V
M]6#9]_;-TB?MF[S0W"V,KB.C[2,Z8Y@+0EN])6 ZX@VX% %5=!S49"]5BND?
M/2/Q6B@D4S#70,;" \^%?K.S$3K"T;Q!N/"HPG%&[&*_UPH?/^-&<2>ER,+2
MX1BG#U#NL68.<34(X^?&GAML,F GN&M^_";_$JY^N#+Y>J!K<WCB34X!.H&8
M3]WG"Q+O&\B-[?>U("1[X(SONM_[!IN4]UYL5R-W]0>RG?K&;!Q +[]EL<9
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M_C7B=UK:9\J</*TY=)9(/+C%1B*FA"_ M?$@4B4K%3R>QO8M^F/=5KYJ$ 2
ML6-CGJ@I8[H-E&_BU9%0E'&MPOY!<VEX1ZKN*3I9+4NG%I_9-\,9@77(@J5
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ML(2I]1$="O"N)JBJ?KGSGJ<J*ZK*QSQ>K>34A]V[.$W5KML$=0K0O@TM)L]
M#E@M+V;AN:[AHP@/5PZ4BN_+[O2L2Z<F%WQ_^?G%\ /3Z*9^\<5^C>.DS[7<
MT+&FETYE*0GK"5U-:6:L*YRU9@I?+AP%>:YNAN^BV/%YNICKH8_S5\LQRRD.
M.1,R38N 'Z 2YT_3C@P!WX\)K61X2KP]/=;#LFR1(C<FXI HS?U<QT;Y9D$I
ME(%YN%;:@WR49L9V.3]0T.F>-7-F<_* N!%\J'/KG<3 ;NO0RPU_V1C" Z+D
MD&+F[Y3H5:H2];]G7[[ZY/%A49:'TI.W4U1?VZ?P<%K=-5H6/F'^*O+9D17I
M[9X9Y3 UQAF/8%<TBH7(@=6(*K!M!8THAO8'!LSR1>9G>(4L%OIA(4:!+971
M2%^,A'[)4,%&P4;)R$))E(<P=&XKR.$P-^V3XPQ]3PQM!:<TV4W._*N7!G^6
M?UP>_:5ECGU! 88D"(W[P\6MY(+ A."K+@':5+,\K.(?6.668E@OP\K!6D[\
MYXZ.2?VJSB@E)W1Y\&.U2,M@X_&45:?"_LC])-Q)#/A%-=,TY,08-.(JZEOA
M/92N<#B9EDWE15T;0T[70W#I\-IJ(8C;F0*<( LZEUNJE,3GV8TN%R4F2-B9
MH-G]9IDW@R9KV]*?N6?&)-;*PN2P<NN7,=J-!_D',JVA,/\/B=N/)O1$/!;?
MW![4?\3<>'KY3?1@^S*""^RBKR[5V6@$%8>7V00_=]G^7B2;U\(S4IU^A'LB
MIJ6V-^,\?<QA?#DFJ1G,6WMHS%E#IJIOG>AU[-D&9_F=1+(3PXD-^W8I'5'/
MERR7[62F^9"C8$/,:[PS2XBM_B>=T>_0(*,GN:7E0ALCLNN%@ 3=H0#I%4C4
M%.,Z^1ST.)RE/4 \Z>'GS,&W.[?BZ5:.6 B=T#GU&F0/.5]/N$#NK;P>+Q?J
MIG%J#'&\S%YR-/69O=M]=,89C=0JGW>&7G)DQED7,%H6.Z" ?,OUO8]+(H.,
M"=K?-D$V@B,HP.?6)G=7,[QO1GDX3/VC_"'N.\Y7Q6<ZXK0^*'QF#;S=6A-
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M/CKMUG.&^LRGV7\Y(.?/\O];$0 =-%$ *%P%!Z4 @\B^ZCO@W3 RANR]AJ4
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M7"D BSQFF'3D $D^W/K[\_Z_J2"%OH;W9.\AMUG682Q$(A&T#_IG63T/O[T
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MM#B6580QQ<A>;=?25!.<LQQ&E0RWNK*,;*/M,F8N=NA_U-'HRAPI6O!/9/
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M11\ENL_WCXLT-QX:+ >QP?K&#R])._+K_5PQ8JR^&KSHN@!M#Y/0JD#B5IM
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M^NTJ$'=W$YDN6HIG"\8AFY/=S<"K+ (SO4YG]9^>QB2S'@J3XOU1*E2B9M+
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M&J 4EC W$V0M@X,C=L5'//OYU*T@*?4VK/82;KS;?:=J%C_T%P5(ZX+E1>*
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M$K6)$E1F1QI A(E.AU:'Z8Q,)Z91$DVG1+.YJ*U+/NS4!F?,CLHJ%D%!BM
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MQ<3W9)&RX35%F2<!NLXN%;P#C79G -Q&'9=\%U.6-*SFP./RA-<E8%9BEMX
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MN2T\TJ=ZD<UG$?&S$#2;"61Q+IY';/2TC=^Z^,(97=YTSK!X1&*+<]],H^O
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M_".@]3<"%."M?<[PI7<3=!(XAR'V0C5U@:.JWN0#LBWU,:4"26\#%40#B&P
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MXQ5)+J/1C2@9=5ECMV$@(<J-DVU!MUFO763*/ZY30V;4]6QZQM=K%;6K_GS
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MKNZC^;.G@GLWM/] #*L?PV\3@M&4 R>I+M:WQ">L\Z$L]$R3X(F;0_=$3PJ
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M<*TJ7&1!IOL/YP3C2K$)M5>RV(M/:M8!4R9MJ++/"1C$2C&&DV]2IR/=D(*
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M2E-J]SV3(<Y[W5?B5L)VY:@LU;@!Z0.PGJ].?=J16LV#G)#U(QL^5Z[HH-*
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M"<(G<:TQ2 M-[+NT,$N=;I41!4F1<QF!]5UT,96BERFXD8XIW9<*'6!V!Y#
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MF>-6K:(@*66GU_Y"L8A.,;KT&@V@04^%ZB+I1ON;L;KDTRG"-, ':L*>@=$
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MXPU[!LZ?.$IL7-4C=Z1;+AI=:!*/6;/J^1F(]W0J.,_@^F2L,NY)].>H6AI
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M[UT\1AV8P5>PG_#,Z%I10QK@69 3.[/QYX/BJM?>VH :Y4H.JYSP/4;LBY3
MK#V'VU=;2IL,2$&U,!+513&.\0,SLGK=>O>CJQ@9>ZXTU1#%L3VAON='UH)
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MZ4^I0L7/X[KX;8)L&0OZ]!9AI3%.^&,WB6XD">*5);WU?J,:"5ONYJ:S!Q:
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M1F\3&>'32#;9T7&Q*T92A_5GVF;/J7Y>BT#T55#$T6 !V FB8X\%;C4I;6%
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M8Q$M_ATF,1.>//_H7_ ' =,^+"SZYUDV12>7?%OE:*3I5MXT1NZOV5UPH2'
M&#E%%_SA3*4%*][9@3-HGQ&4ZNAZ^+ I[;Y=XIP,R<DSR9X6#1'2 P0LP5.T
M+<X!O]-,.FW<9TAV[](=@N37E(K\L.$U22Y'"DG26 NQ^62_*]$#2F+O;7@Q
MH*U_#9"$V]6%.H5?UTSN>JW!J"29VC+78+G<<P#C"B:VQ1[(@[6QEB_$JLWZ
M?IG721MM6\V*J?$?4%Q+OPP(LO/!2]SK*ND:*+!W=P<X_5=[!?U:[>KR?H9+
MBN%XL7>TI]K92O-7NFUVRZ?E!> ?M]&!(TB',]I.))/MA.J36ZO9>)VJKCK=
MU3I;$N(_9J>/K$.%  &4>2^9GY".61(+V?9!"EA90[_,</_^70V-U%[\!)P_
MUI[M3/BS=7%W-:@/RP&C6M/P(%-,\1=I>]LM+?,EJ@#9QUM\EZT'?3^C<P':
M_."[0ZKV_0#J^B.[JD!/:^?3!Q9_<!D\""U"C.F#P9QUGG\2W Y_'OF%'8?;
M]/X\2]O^E;Z)GS5)$L^;_5/\M'R.D_GFFY+(;DW/R3(7P)&:1B<6_$7A6U#1
MJ^FGFHC&Z*^Q+3==#IL[33URAIXFM"^)B[KR6OQ[@@@#HP@B'>GV95%R,V5\
MY/"TOY.?J[:L]GL,8ZM !6KBA6<)/E O_"[?>L##I#Y<CLR@O5L^LA@E&K-4
MH[7V_A%(<V:3FR<I8;HM$*8VUW*R"5\UB8<<?15 =9=,RF91% CG@$B$<1$Y
MP:!\3R[6@@J15)V$R>81$MZ/_BY-#@%;MQ!6FXD*I%!B>C@PUJ<%:#:E(=CI
M;.=QZG_E:O@L "0/+\V@\B99GP-^5N,S3D\6*%:>7BY"\J/G &<#P9;W!XTL
MIH90^ ?B!KOK$Q3;'NO*FF+I&#F#%+;]OQ\2KU'1+:<^ +\$)X5T6K)*D?-N
MR?S&9&* VRB+_DI/6HJ=M-NT*-M,^C@^@Y'*2H[&0SK.1#I?( R(<C&U^7\G
MB+,JA=N^UHR(C,:,[N;1S@07/Q!#]2>Y_!O5XQ::J7,:[EY\.BORCU/3(7P$
MJ3"P,!F31Y$:3N@0XAN68[FJN"R_/V?P*17V9MI&VJM1)!?@!#]M#U8AT^1@
M\/VRF&34QX-3YVR>&O,"25X=#*]8W.SK/?&"LRR*;:!8AQ0CE$]O>^*[#].I
M#F/-CVRWN,8:]IRW7B--)]VG&$C5?!$D0N[T3*$C(#A-N2;KU^.8)*D+@O3\
M));Q(H[Z;3YXG/N:\P5<2=B[IELUUQ1!F77_%4HS+-^AO1"K]@][OJ@5@_R+
M*KT G68?O_P*,#*:Y"!F=YL*T9 =2Z$FWT]=I;=KQ3*_?#2&7,C^'=J<%N+M
MA-Q9B>:= GM'E7?EEI8W908SQ>1<-JC8[N&=4O>;M=7J];^^M?\,FRW'H\4)
M_9.MC26"D@C[D@WSA4^EIOV-C=_<U>->]-%A9=K4]D>:>4@PHF82WDVCBWHI
MVC"A$\T>=T,B;.'NPC*DERAMFWH)?G:'=IW?(A]6LE17DZSR490__M7W![\/
MZ3R@4>1OQ'M][6AZ(GWNKXT 5VQN#.N;\!VVE@"&JR\%UL(PUN)MNQ1=/#+$
MK9#R<-0.NE^H".9M= 35Z;PJ$G<\;5I:2#\<A2\L@M]?U&!ZR2AT9]9Z@W3M
M3X%.4'V8VK0ECR)$6A"@E E\2=9=>DFTZ9@3>]X\MNU>S>%4:?WU"TULG,XL
MS3$2]'3]+5$SEM-WX*0YZE;/7^;).W1-2RM*Q_4'9?QDO45!8(<-S:Y/K/)@
MSYA<+*N.E/T#6?]B$80 Q_NQ@ZYW&96#_WLCO]^J;/.Q28\9FXM]:O3'W$][
M^V<LU=C8B$&B+O5DB&'D)*+$+J?]-KJYMN+#03S>.-;@ CE2BM=/.O^_8,<J
M9W(@@[-)A;"@1YS(*T \(WIM#$H_=\[J%%5WY+&MD1<E*2W5EX+:^3!A!RUQ
MUM=@$>N%SB<^8R4P?\$!(G.O^FG6@$$9>(R&Q(E=38'=NC!A\VY2H9"/_]CU
MKP>2LGMANT93&R;)N;_K*ALB=F8/$AEI\U99Q5?U-%I]6]@ASKM<_["I"<@W
M3*\D81*VGS&DT/PLKH]K@-318&5P) $]V7X. #X\_4.1PHECXG=?I$\UQ7_O
M"VKUMTO(Z DP9!A)M!8=D1/_55,U[EI::JH4P?_![_IFJU(17T2N<\X,?_1F
MOFM)&Z#/\V9W2'J8*!XM1;R,:86ZL9HAQ"^&&>23Q- ?YR"^V43_K_8:;^WH
MCJYW0ZO(V4LZZ!O!/8G*_3O3DBO)5W98%1UUKB92/#.Z+_)0$U'R2UZ_@*EY
M26Q5!<!(J?0Y[_M_C\22ATUF,\,^![Q!(T>0]AE,4&N&T'V+^*/G1*[QGP,G
M.4E2]:)WKF#K9ZH\I-77C:F79UW0=\XR#F-O&[#5H.32.DFZ13V-?Z\5T'U)
M%*1_I+1T4=:=).O[P_?=]9H'*O-F9FG#F&NURXXYDE->I5!%%48UQ"B-VNLW
M020=.C8;$;T\ZJ"RVO?RAJ86(OCWI].^&0V5/^)^]FU32G\PD%B_C(K5$KFC
M#JGK9L='#]9)IK(2R7.I?P3<>%4,\D;'D@&;2'NU-^< 2[(&U*? QG*#1W,/
M]^S(J*KT43#]JNBBZ6_33U3,.6#OB1MDD[1V#M TK;3V7[#/V"*?:G;O'7G/
MQ<F2ARY?F$FR_I<''4&%9F9/.\0%_\]J9Y&1C467PR3,D]W\GG^$K\<U2=E&
MOV>!DYW!7!FX/A>^W):N&0E+<H7N-'.2J9YDJVSW4*0(D<Z[+"OX*EE<HXJ
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M3A=C;=I-B@IF7B5&FXPR\Z\D7UN6MMR[@K$=KL2B$[J5K\K$A8: U<COEV
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M8I1E>FA%F?T6B:EL5@JAATA>\G&3&[[_E8VS$%>*?K*@E%9=Z]QIY8\KW0'
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M$0X<'$983 (! [)(@[@XL#0SI;$V-!Y<=T>%X15@Z57;PO[^ZIT)TZ1]>CY
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MWY>);-UME[QY[!WZ<E3?UDEV[:ZR")H4?]>,";Y&FWS,+)1(_S9[N- 0$MV
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M=AT>S'I62<N$;*W]W<WX$BC_,RFJ)X#&HR6:[!.N3IG'@V*/!]NR40X_W8/
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M+QEA-4P3WZ,AN#T2^,ACL=<X2KW]#=C)=1ET'K9%GQ'W7,\5EP^&NK=2%'V
M3DF.40I: H5H3'^S?G2Q#%-RM=Y3OP%&0=KS;()W=_NE>>I_V;T.0(3^,]8W
M&://6L?*WAE>%KT@LB2F'MDO,@GB"A\*ER>_5G<I1L&;.1QZ5'#I_=9/W(A%
M,8^LKCUUP& %)3C?32$,*=(56P4RB;TT3MP9 "],5N^ZDJ-O-/*[? ,#" GC
M]+G!F#!&DX6CM,FQD6544]+3G'H<1#>KD?UAW]T+ M*'M7-J] 4(D[2_^I'*
M17:-!QM^W@)Q86S$6L6RY?/=RZ9[_^BL<J8LWOH'*4SV!UU27N3>@/(B.#S+
M/$9T/WF8@?FM'=Y6*WW6N9LI^>HR@*%39(2UW"*"AFL@+[A!.!H_,*4-UO0*
M?US_\302]"Z4&-S8MQBK'M<S!^7L+IN?G57)K<"&76V>C]5ENM2BO5:P!QBF
MN!3&.NS=F#D#+ X@*5]V#5$,ZR#@&<!]D=D*'OI?HF%#3E_PBY3KSP6_=D,5
M-"LW$G8=N*@*$\JIR6+"Y"2+P(IGI=8#3 T[+8.O9CIMV9T*5B/NL@T?@0U!
M)X#"TX)6 L:08-$%$H8Y7/Y$CGNM?*JJ5Z#!6\>RK9)^W+"MHKBT6K<-X:.Z
MDYEDG2JI#VJCC=\^-Q\G!AJFO#['!<>V DPI%HJ4EH,"\L)WE_O-86_97*X[
M-!/_53"2S:F5Z\TK$'ZJ_%CX98JG?[Z,4M7@JJV=8:IB,!2S.!)8!8IKQKVI
M@4A1UAY.*5L&:"H.+&<,R!*>\OV\ZF+Y(2K*]H;@@!+#QN0N_^MP48H?@9_(
M3+X'XG(WV4R?'63K^E;'\;J<*;DDY.)Q( ;74<@> +Q(?4QN?+/M172IPUG?
M85+PVA6?O;N8GOHC0GH^?!#)OHS^@.LR?_;N @B3/7ZZN0N*5H@_ [AXB^E%
M7ZPNOU7^]YSCQ>-7A#O*F-KHJ!]/>+:E!R&7J))-)&C$OC?G5A ?[B?2SU<\
MUZX3\5T-^XMAZ,8YZ,R;2 H(GR1"V\#2[GO\@;#]R@P? ?%:JW"V><@]64OS
MT5^]A8JC,2#NDPP-B^%^!/9 L<M9]^;L%P-^>83\[;\"\NG6A%51H*1':WCO
M)+!A>5BS=*N&J>44P"H'D6)5(N&8\0I.A^JLT_2_>+;EN5JAT\_HBFN*3OG%
M$NS'+W(*>])+H.B=V/S+XC]+!E9OBS0P.BE/4[DH=N54A4:R2$C,?/7,Q+Y4
M:_SL]M'E \\.O[TR&(A=651_.39Q^4D+VDZ];X!8,-\87(4%IRBDA+DQIE.,
MZ=OZ5;+AZ30R8VRC_1_<NOTT(O-(TG:JC8/2;D2I"R;LG(=G#!LW3(KQE,_:
MW[-LKC#YT7Y3) 9,TE8>G:'>F9"EJ2_"YVN(CW)]RV1SYC@6?)XU9O8I8*L!
M/@[?!O.@I+<(HY9_.")T3A[X(270RRFUU,B2O (#$NV6#+CN#4B^_O*758;E
MKTL+*!K)A@;%"<4E;LOOR'IE6TWD''!YM]PH ZMHK15,M$E1',JW"@4Q=Y;/
M>Q&=OHX15V)M@E6#:VS4I".3_'Z/L(J2WHFWGA:W2=DNWFKXS)K-6^MEY3BD
M" 44YIN??JWZ:V- 2A[_Q*$;\"1%JF/!"=QT[.HIGPJ&/EL&)?$;+Z5>;J2#
MJ?O!9J/I,-MYK^*./@.!YPSV@+L"RPF[J4D%#&39E,]XFU0!^'>P+L%P_J%T
MJ(WP$S814R_A/#E6B:6P4<H(:P7BX1D@,X_B>@:PSP9-55*?),CJ'.11_&#E
M,6&:LB59ES.W/S2JJ.W_*-NPT^^#O@Y92P9KT\.4B^)@$ZV+J_<A]QV:9B55
M!H 9^_?$696=L XLJY3LI7E.#M@3O@6Y<2X[Y<K+'3Q+WE=\_V4P8 7HB5]'
M>)J?? ;XWRL6="IN*:=_?3^PZB]P3_LXBD&,T*8[\3HGM0,4\]6>488#)?#4
MX6-\K<#Q*]@4"L)"-2*_^^9&DZ7$L=-$V<']?QU[QF]HBA!MUQ@K(!B<,5EZ
M"49)["[@&$7<E2W]X%SDH._[;:5V7F@?$/&J9V67ONKNY.M#+!17@K 3MP!+
M[JUX\K^EJQV]KY#?YOCI#?,[#R_!2#M17H=(CTGB,/)?W-.:]97GZ]/$!_*+
MOJ5=P'K!"BFJ2[#A6+I8[[4#%W]K!P2X"8 ;YAI$_@]X1-Q%I3H Y["R^,,Q
MJC;L(Z72N.G.QB>"KI@O]LK-E?3(?M8%S*(M)89,-V1$- $47;]XF>*E\EBS
MQRWE"\,)MEQJ_!9S*+!WY_57JDGM^(+PD5*8WW^YPU\G/@JZY39!^C"TY:7"
MGATAFYKT96@\WZ&8V/.VL+9\[P:K"5#S8"U<;=L($)H:%P"S\],>WV?CG7/U
M.V=XD3B'?L#$'M@+QQ+=[A>(DCZC._NR51K/+;AN_QU&3K4V&H[+[MFI3'6-
M06]-34G&2FS%F$9:+EX"LY8B'I"J%V*^5 J[=TA+(,"/[EHX^+@Q&IO5?LO5
M_EZ7HW8&J)N=*7;K%P:W-O5I*CA J%R6RZ<?,-9I>5W5%3+([0C?X^=HF7!6
MZH.,RR1:&9E_F!22*H-EE[ ;N"3P[^?R%2[L MC"B'2X1/NXM/@Z9/&U<TM]
MQBII_KQD(C(K\<I5QA>ND4DCK/EP[XXIY"6H"^B\^[<M\V.^3]^.IGA^]_-:
M/Q-_YF-\=]@KQ/0+I7+9.,+_Y"W9.$YI47"=Z^.)SI=*%X6D.B?42'60"GVP
MFQX.3/6%3%NJM37%92 5#KU^[FOO[_ Z_V:@!XWT1>_H17[E7)519>0;/JQ6
MFD )+-1[+SMUI&'DE;Y#[FX1I],R-N$YN:P;&MO8)M;06#LNCV96F+4M-X27
MF+[69TPNVC[H#9 %$2^2!*P7NUBX6]A?B'[V37(:YUV$.3 A-*JH"@TD;8.K
MX]6FNO6;?C)F<K[70_,R"VUSEF1I7-3G=6@A,)2;V!?/^O8Z[)57#_QO[RL@
M%4@N8B9=SPPFB2^AW@ACLP(MLGQ_MW:YDV[G2 $;N2*Z 7Q_0YZHRWTFM_2&
M>.;-JF3C%\^[9=[GP"C*K24H*I;<6&)W=.*=GZ.>'WU&>1RT%/3]>X[P5WO8
MT:,-Z^?:NW?WKOBN0X7P5>$<5-O&<9PVE-L33SJ6S_BFXV4TDOJ5_<DE7]H\
MP*^02>G)9'6XO+N]Y.22=[UM,'_SIV]8L7\"_$Q+ .&C)[-R[\@HO'FV.ZQ(
MY<.R,8=6^_I/+K-!OE?G\J)3PHP"H>Q05PL2E'I=7:\XC*4:7_V*]\WE;7[1
M\\^IGL-WF<2ZONV= :(6>1$@+R4D.T('G=@]\*];E-BV\>F>\8\RF!-CZ?FU
ML8@[RL WE^#8@T#RG/LL4[C I$P=RV<GF$"RC@+#;T?V/Z\X@PF55(W$Y3!4
ME-(+THH]CY#43'JU7W[O^<UIFKP# E>#T*3<*87+=ZD7) ?[7F^$?!TZSI\?
MIA.# -@U,I6,@M31X1[4822;&@D.Y:B)^F6M86<&5/@X<%+Y[RM5[\Z&EA"(
M)5R,<JA-^8"B9/?ZNIM<KWY9J>B>(5I]*SUV)H6350J,^X[+1]RD/*0Q-$T$
MV%E8-9&!\?O7(.-A=Z_>2XE/+&"E7*Q>XO#K:83R@7U+/)KKA0K>N?XQ=!7%
M//PT^4+&7,JQ*/LBRRLC.BO"55+IVU]8-=UGN:$;]KOV_,NHZ#8PAE(1N@P\
M#T\T'"T@3&DX[)7GZ,^RBC,+AA B-(<PXO;T@,>0#D\C/],=JX(UDJ:YXDK@
MBTLZ PPGG '(.9NEE&>5ME274;"K['[QG-5&[!#<I\LB+3K+7B$I![#2IKAA
M@;R(\'4B&^J^61A-F(4=I'-*OLZ[X+NIMC;]!,2Z;VCG?9!$B2RW^J^1+\B<
M;USW5H'@@Z1H^]TO[@VS4[E^ST(O_K:V[1LUY$F*-;NM"U^CBV:$1?MY\#/4
MHDJQ=^AG>]V56;V/F!63DUAJDO]RM);8C*']LR4BK&<,X4P.3ZW8_+HI)-N*
ML5#QT>9._1;WG%<T*LKFHK$$V;Y02^S_=UN-]LGUPJ,;AHLG@3HIIUL-(S3!
M32$'+/ 29<JPQ75\7_H\T:G1;L'CV]\!+X74MWN:6TF3;><H[=WA2I,!PW$%
MLM'WX\S3?@:XAG+NFTM!;\QV_'NDR"!8Q )O?H&<7>ZZ42,X;ICY*J4R;7I0
M'Y\H+(V:8^S]]ON+<F_;![;9[;]_Q-GUV\9@^MW(NH/J(JK9*-C&%U53*W/[
M@;)P8NL"XM_7*R\!GD],(UA@;Z:H7*'+WK-^?=(E6SQNZD.%S[P#G(,%^KE?
M)C]LVB[A!NX7<0X?M,7B:+QMA:_P%J9Q3Z+_ON(449"Z:FQ?V&_^ B@=CLMY
M;.M[!^[O/=\YWYA^M(JNAT9"I,C\;_:(,()Q0C'YTOB+74^EK0>8EK#3#[&7
M T6_8ZVG**TD8Q-R67S],"_<R9;60884%)@97<L422R@K#A)^%^)3@#TG'XM
MU:7XE>H-,0Y4VOQ]//G50(UZ:ZU//JX1HM!"*OB(W[DTZ[:@,"Z^*U/4E*Z=
M?YX);PQVW(U27_V^PTL;*E BKR:RT\3),6W5A/->XFXZXKJNW@)WP[Y\4?P+
M$+QB@20_7EJDRK"%\1UT/PD#]LRJJH2\%5=;<C9&^%+\MK3$'E=1_Z.D+]G
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MF5KT1PYQ+0LI^&.0@S3Z\/2X/>%LMZUDNS8;K2F=RW>^H21@87H\^TE.V]X
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M\F%:M2]L"VV8H9^?;WSDJ1G2*BWZ]P0.R5,QQM"I+3$HWE'?C#)TQQDNZY7
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ML*A;BOE3Q"MF:ON>/9NN"V^,4OSOUFL<C\3>.MX'/1%>TMXEV8/0KKB32$W
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M0 XYX=$I;R=RF>B]UY=?U,:>6)K:_G@P^;" +ME8??C.$PGSXE*N#GCJE?\
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M3.:MGB_CZGJ!D.ZHER[E,R?K6,=],#;Y<('D,Q2Z9BI#UR/+AHE*#7,>X#F
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M$PT>&V580\\V!UHP"C(1]'2L>%*ZZ;Z1SW?DLX^/?%ZF&9[VFT]  $Y&"&X
M83IN!P-7;A;'H@][[IV(,2&\?7)32Y_<>K.'J-W[JM).\ACM!\HBF6UZ"Z<L
M',1:TPZ%D(J]I*%)R<1)$CA99NKM^Q00)*[24N?4XS &S]DDU^_73M .D0:C
MS3W^@LYHRU5DCP?C@A )Q]QA2IW9\]ZC.'47EQ -LS+;[%E^:;$$+Q*@JD_
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M-Y JA,#O,[V\Y]>1L*8J.QGF01J::8"[=]"MQ_1=#X;8&F>7EY 9E#V6<28
M^E3V?56$/F-H?9O(<TK=DP;#UN.;NT+_!'ZW-Q!F7K\Y,G6UF'X&B"F<5_B.
M2E &J@5>A=P"Z((O'39YF3@'*VVR/LZ8Q1E)Z@GU1O")GXR^CR:CV-8<.487
MQ^KA,K0CR!43>$_^>^/^=7,OAL[_XQG-/@K.C[DSN1VT6@UV4#OG$=2]]4+;
M?TC.-QF$IQK&!4&%]+RX6M[AR_6]9 KX7@N+IRVQ5(4EX9L1R;3(5#F;>M--
MC06?O[;BQQ7>N<M7J@^Z/T[;\)&&-=;6)SRL;TS])UER]1D+B%Z1,@DY"3 [
MXKQ:MMD\?LVJ2F;=R%G1YHW]>^WYA4"H*:4G>=I#A?\@^/W.=WCOV?/K_H3#
MW,6?=!;\4O ?4/(X+*UWUF/ 1W*2WOJS#S&80BE+%F@PCU#@!5D+)./.%0*+
M@S[@3:F9>['1ZT,Y<C1MPP6OD&30#RU)RG 7Z:2'F,[(3UJ_Q.'8[9S 38:6
M$RN!BHXV,6K/^YD-HGYU.<_1O/:- 9IO,07<RA 341[ @XPX<3.?6:]N7.28
M]E+*_M!776UOT&LCERMOT1QB*F+=RWEK\)BF>B[)J4:;N]7=4D<X^^DQ;YA>
MQQ0BN,B=/R)XX 3':)%2_-3)#$,R''*%TINY.*A=&9RJ,7\7B_CMZB_XD+N,
M!EG$RA1RF7:ULVE=7HA,_#1"A[IB9L48\N_:-YIF1)<S..R,D"I?A'.?G?,8
M-:_\5I1,I-:U2:I_%EYJHF\$)(/ZJ:H)M)H+'C?6(B;^C4A$7^6@F.:7Q+\<
MF>@>VSQO;JX%[YV4._L4WKQE_N3A5=:R'CN&UK9*+TS%*8O<6CS XZWY&P,K
MY+Z\?$-./"U,;QKVMFY#+R!932E?PD+F31K,.>^]_?81@3JY(NB]7T6484X:
MB3X#G,>KSGN/1REA9F;WTGOM4?Z?WHB5>JQ!N;3 1:O$K$SG$CVO=^MFVZ'>
M"0TF0]>Z=WH-2X,81A::1(=B !O#AK'ZO'L?QS>S'ZE05SPY5IBA=K^'EUA1
MQ<!&&3Q*E3*9'S4E5QY;/CL[\Q/^Z/FS?[A@[= EISOC_!(&\F7O!PFQ_85L
M!W?R6%)+B0_@E])(C"P#9@;)/F']51%DJ2.F2C]/24M=@IV-@H_O#JIPWOFZ
M\1U7\72(RRD](IY6$TBIB:5Q,T]C&^)+B&M^M0.GSY]JJR(<2S5,*J?4WK\O
M'^!W/3<8] ^#O2^\1?&)\:1"E#;'N:<'MS7I[5N[O5 V0C,V[GC2-/*URZ?&
MER&XNV6N#R//1A (#)EVH:AV:/A6'!7[D,TU- =G&E_O@R)6/-2.9#%]VO">
M"-9X_L.N+)6#//RU0Y^4R6/_K-DX0=F5 A+N(LU3AGE9'\BCE%LO+N%CN*K1
MO9D& WRO/TH/Y"1J&_TV_MG:8E-'/P>X22>U<762MWGL2C*<PNL<IQMU)*!^
M2VW7T1&[IQJ?PP-Z8]MQO(]+"CF.V'4_4'I?>I6NA?2[88CO/C]$:5HB6;R4
M>MJYHFXN]:0&'_&,6UT_ZLN!^&FK<@A'/FXVD6$NH*"?:*DO/'!48#; CDT
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M*CR,P"@3DD;G184'.AT],K#507C)'+&+H<Z%[M;+R<%!.<W;7F^/0^9!X!C
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M7YK>'"!);3$)%J.$'=@8P@?D>,JG2)&H&%PBE/65A:X9(?8Q3BT8?N&5K<9
M(>O>FLZ0?+(I)N4C$I*!:->,(^-@?S!Q*ECX%[/8UZVY:T_IC4]R!S?#9^^M
M"8$:1(/+83$:HQP_CP)GD8;@#(Z\;W1V83CB.SO=M^/KA"1>ZQU[E<V93$#(
M*^_X.!M%@G\79'[UP\B.WX_OX!SV.*KQ5G$M-&@6B0,E(BGB(7KD9. H)&P%
MP=G+[?JVWS\H\K>]GQW,1MF7\'ZZ'ZM\7Q7W\].^QO8L=ZV[1;M3T,(Z:YS
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MA<-68\:1]BDG>[& P+[F*'A-I05;&^!Q7\GJ@B;5]V/<W,_1O)7!,II[S$9
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MXB()<6(",LY(9!07-K>K]+2W,NV^C@/75Z_IVD,83B3;9 WA*,O%"Z/4)L>
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M"%L;+4':JX2\E)1[0FF(O56J71?"O#Y-]:36S$GS:;7X\.W,)Z,T!IS%?0"
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MT&BRB .H0V"5\5RUT^OH/.>F=V? UY4RV].]_3@O_&3]=<CE8<H9;Q+%F%K
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M$=Q/B:7U)(^0D)327"!+<DN5Q,%H(4DA++%QS CIU^_;>!CB*@H6K8@2><Y
M#3(CD<-@\%A+#<'"26)[&[\\E-![8O$\O0&/5!BN?##(-K&]WCKDC%#(>468
M5IAIV3N_P% -_;I@^8^R]CEMZB-(CH="D5IS3*/B2!&!\\F_158QAJA-B5D
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MHE[4Q32.XN'^!$#VN/&X;!3 DZ-9]M(7%L@)""/$K>*G]9S/1L]94C(@@2/
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M :%'*XQ,'$MDF JY%@7@2!P!#CKGDY>1$]E1,;T%,?VYH:67+2G=+8I<?^O
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M5BK9M]7!V4/-<^VZS49*YMH2RP?E]S0H/<YG!Y30;#+\OQ4 Y;2  6:"/IS
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M'#L"F) 84&L54 I3X"W$3%+L+.DD,^N^"9Y.)_5$5ZZLSC>]C=ZFG?1 \.
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MF:,CUZ+W8^?*1"UZ6%SITH&R*JR^2@EU&>#WFE\RP-]VSD"FG10@!.8!18H
MA3T%A,((XXJ&$#KQ/=VPV\?(;2?5VY;7NJHG-9 8#L3!]P+(,'7H6[FG, 69
MH1AZ!9Q$Z6Q2Z*A3"@\"X5[CH&'\?Q=ZZ*9ABF,VX"0WX^M!7, .JJS63B^G
MPW1@7(PF%WX<"?XRWG7AJ[K\[(OAJ,[%[?:;<PY5*GR_E4,O:[RF#L(D,5CJ
MCV6!U Y&99A;;+2T6,M.E.$;1CY-?/QVF8U/JLC5_GWDY0]^<AH^Z:]/ESYU
M7/OXZ5MBZ/DE[?K,1;?)X*$=_R$CXP[M:4;&?B&CY(@E-1MP;P*@2G(@F>/
M,"V"H,8(3CO1OU\7&?E^.9-?@(S9J_QB%=WY4-IRDN7.NARS)^45U]SL ZA'
MNAW9A:5!UF .1&@Z@TD-E&0*!*4U-5%+][23N/;?_427E7?O]+@JJ_-Z"0M^
M::&@<T5^0"D;,+[!3F"]Y,'M:_R'4VMZMRDCH_.NH3,Q 6GB!7 B618&JFA9
M$!:!EV(A!)56KX2^K6-9O 8Z$R('<7 9G3=G=>2#@1_G+6[J>VI;9N/CV:R5
MMK^7?+5YV?:TJ>^\8'L@XP4C;82"@&CN 64$ B-9%$E2.(\]P2JLI(2L8R8L
MEZ!]US!I5^UJ!!L@NHE0[ -FB:S_9VK( -EJZE)PQH@&UG,-: H(UQHAP)Q-
MO72-C0C9A::^,8#$4@S81MJF[Q%+9,?_>BKXZ:?C]\7[D^.?3]Z??#IY=U8<
M?_BE./MT^O;__-?I^U_>_7[VE^+=__WCY-/_RRIY-]8N/L*)Q=QH:H:^__;N
MGS:FC=R_$'LJA&SP 3M!@*&$ 1I5;*"\P8!S9D3@@=-NRO N-2L[KMS&1!*7
M:$#$!N-!>\HSKZ2XWYG_P:GN_2:*#*3;3/Q!0BOG.?#"1%!4'@+%* :82^JC
MAD\D[Z3 QY: E'$VP)ML*=]3GEE?P8\_=1Q\\[$7X'?S;A)?_>C;GCKI3<_M
M!A">R:MWQO+8Z]M+TY._U>[QS/M"VY03H*OK5'NE&DU\??3JZ_'2%7C6=KOR
M\V*"0_\5N'+L&RAX$[=E>EG]Z,KZ:JBOWZ1O?[S2+E6I6;+:R_9],Y.W_<,_
MI_6D#-?S5S>W E^Y" I?TQSB$]XL\.'K$V$ X6]-^W7I[J%59[= )2YWL^P7
M"V?!E3[WK1\ Z!!'^48/O^CK^L?O_GIW?^:+/^O#>]_*OV2!MXE8W='PS9+V
M%[B^M%MDHASO8@W.=*6+G\L(5O:BBD,XOQX4)Y5]#>!JE*,X,N>KVKM_Q$^-
M"R]%"?RC3D4XFV:Z_QA=^;&>]&/UWLY'6[Q=&FUQMF;TQB:&N%BX5 KLM%F[
M",CUJPNF5UJ.[Z>5GKI4U_6'@UV"LBHF%Z-IK2M7#PK_U?JH3D?**)IJ<H6^
M'$TCO6QS?5X5]=/D&G5\H=>W TV#>J.GD]'<_DAC2=(P#CU=#J(F,YI&C:3\
MZMV/[:L0A$?PS_,;;*H5?%7[-[6_TI'Q_'P-&C.S??9W=QW^G\NZ;*RVZS?S
M^^_SY#>O$_ (8?[GF7R_YP)TQ![[]K'OT!$E<MV;M_':1TY+9$==>%=)]"6=
M/>7V-?WMM2W=G<DM^I;R;_0M7?=4<;-+L8[4>/#D[&(<[=;?XN\7=?$NZC+N
MIEKH>L31SS7KB'PRXFP9<2Y+YX9^YR?W[4[)LXGVDWNZ1)Q4@G@](NCGVFR-
M!]:/@MN=!<A\LLPGWVSVMTMKLWD)O$Z$U+VC>IG([6N0U,SU4YU'@_\J^:SJ
M-\^DKU<*#-LNP.S!)//$=FUBF2QW=&(;SYEKIE&F0X;9$]>,4%UV:3;/67XP
MO.M6[:'X^MW7OO%,I/8ESG_VP]%5.M;H*K-@=VGP^='RKZZX;#2\+,UP3^/&
MJ&4B8!V #(8":BD$FG@/C(!!6$<YM/9NW)CQR EF/)"*NGB/]$!C*H$0E @A
MK2+$K>9KM\QV7+E?;ECM7:LW=A8T-J!4;B@?9">"P3),]6X3,TQUT_N3:TFU
M!TP&&R&'19B*X 2<%M A+9 7*V4E&-(4PG2Y27D"6B.@*%. 6!60LA(S=T]9
MB<W#%!<#M)$:/SL#4QM/2LLZ[C=TW&+LVZIV]=1:7]?%E;YN0WK2A>G^LCI/
MUZ60J=+-0GQRKMNZX>8[P9:'6G/U?I$3L&?$< &88QA0ZB4PE@8 B>3,>JPQ
M>Y%F7.M*/R!O?F^9\ZSES8\SUHS7O%TPYMMEONRJXH0<0'CHS0PRGAWZ5NXI
MGGDFHOK+'.">1#P36@"IH0<!8RD]#,S)E9K/SU&A^X=G*#<3S,[D+2G:?_-5
M)-YAHSYK%Z\JZTDBYL\^^VD.MOA*KD?T#/FD!<20N @[$H>H;UL+5.I)P)'P
MQ!)DG%XI!;&.)WK&J5'Z'-_BTVZ=/(@/,-]$_G)FCURY+9/"82.EEQH'IP!$
M$2XIC_JY9$$"R['$/%"J">O"&;XUI!0;<X?O"7MLU6&..]+C\2[J\6WMY=%*
M9&/6X@^6^;)L>HYL8HPK@S3@40I%82-DE$V0@8 ,,U$$1?4<=:'%+V*/9\*H
M[DH:(3@0*9\DBZ.LN&=PS.#8)3@:S["!2H- 401'I2B0!%- "524.DN#]%TH
M[IL"1TD'D.6*]*_K<N_WH>0+>"9U BW">'0Y5[]OUY3):O<^A8 =9&SC=EIP
M*0X=$H0"1#F+8H,(H(EA0&D2M2Q,E7.N4Q7\II%OYSVW-JJ-OSH\;K3588:]
M#'N'!'LR6"AM1#PK;80]YCDPVBO@A'0(86Z5XITJUYN#O8WJV;N%>KWH7[*3
MZO1)@@I?3XJRH=-!4?F<VK@;_)+ER@OD@$""$Q5,:BFB(Z:+J/X*J@&6SC-A
MC9&NDSB2.7^U8F#F:?DPJA9G1Q_\,WK0/AZ8/8!DCY3@G->8,>JP,<HY&"3"
M"'!+$*#$62 C]("HOA(B'4%*K_3>6T=7W2)&H8$2.:DQ.W[7X)'3R84?S]34
MXOM9Q,4/66$][(.4?++X#(&"-7/,& 443L'3/&"@(*6 <\2-T<)0O1(2N);/
M-['JL@"Y)5F>+$I^PHCE8\0<8I&!, -AO[W*VD$BF=> 24.25YD!Z5W4NIFR
MBB-A,.M$4^\(6!<.YI_H)A*Y>\M5V</\"GI[-!Z+X:C.01HOYJ+>])_<<K6J
M@VC8NAU!);S"-B@$$((T6@ JI.-/%X6.QY (Z*TQ75@ D>DW&.\!Q8"*[9@&
M.\9SG<6$Y!;:>T47&8M[B,7*0Q]\  )*""@.#DB)!; *<V^(MX*L),&L8S1L
M%(LE'J#4,")#\8;,B.S^OVU&-/TB(S5?1CYJVT;^[_\E,4(_%D;7I6U+&);#
MZ<2[;'$<&,ME*=<_*0>YAM R!Y"3#% I4]5P98'$B@6JF6=A)>!R'8OCG1Y7
M975>?_3CLP0+O[08<%O>Q8_>G:7.Q/5I.+[TX[COOZ1>I^.ZN6DA#>&R-,1/
M%88/K("%%'*.@? AVEQ!&F 0$8!IAX03V&O5R:G+W17X.>'A5N</C^A]Q6RR
M;I#-M"S L@#;30'F.!:>&@*0I%& "8N EI@"92UF1B..E.S"3.NO $.:>VHY
M!1IB#ZB#*L[&RA1 H+SRT5ZEG502ZH4 N\^6S0(LGY%MU+C][V:5O ,ZSD:?
M^R)2IHEV[BC<,G7K;.L>@*KP&K$?>ZHAW"_/B$%&""Z!TQ1%DQ0)H)EP@&M/
M)-12>]9)[L><JX];IO[0\/1I: 15?3J=U)/(P%'@K<JYEMO7C+&^?])1[CID
M@@0(80AH-,2!D4@!CR&.LMHBMEI5I,-)S[29E;EW-VV,Q "K^VIY'Y+X[@%X
M9+,SD\/!R!+K('$P J,0"5:UM$!RIX$RCF(=&!44=F$;]4J6&!^@TT8 &IB)
MLB2.71NF ;;<:L&HTVRE=DB'D]Z\+$$*#3"^KTEDEB5/R6Z*/W4<?/.Q%R+@
MSKL??=U39[WIR=W Y#,1[!F3;2]-3WY33N)K[8/3/_.^T#9:HW$LUZGF;36:
M^/IH31?<1H98W-D<5WY>;,_0?P6N'/N&;=_$$4XOJQ]=65\-]?6;].V/5]HE
M$%D*62Y;8IBY,-H__'-:3\IP/7]K<ROPE8L\_#5-*#[AS8*=OSZ1:Q'^%DV^
M+I4\M.#\%@;$Y6Z6_6+A_+F*H-WZ=8 .<91O]/"+OJY__.ZO=_=GOO@-P]R_
M\B]9X-T$F)LE[2_,?&FWR(R&KHLU.-.5+GXN([38BRH.X?QZ4)Q4]N@58+?1
M=>+(7$JM</](+2Y3_D)J4?6/.GF@F_94_TB(./;]6+VW\]$6;Y=&6S3^\I<
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MF6'O@#<R*RD'L,F96_=D(S.W'L F9V[=DXT\")."(HNE(1 $1BF@ 3J@../
M&RJ(%E1@OA(#ML[Y3C8I=H5;<EK3&LSU1Q6G/(P#=,6Y+JLB\E=\^;_\1)NA
M+_[#C/_Z4^WM=!P)UK?-K;+$V6,>ROIAWN3^3"US:^;6S*V96P]Z(S.W'L F
M9V[=DXT\#-\+,<K[( "6U@"*E .22PHT]5AC"#TW*X7L&42*228!(=P#:K0$
MBF@.*,5.4 FA(^JN[^5T<N''R:4R]A>^JLO/_J2RHTO_?E37QY]U.4Q&ZJ^C
M\9D>^K.%E7KCL?G@)Z?AD_[:5<@M.VP'2\:VP][(K(D<P"9G;MV3C3P(381;
M02U2 FB.THF.E4 ;S@"ATE@#J5)PI4GP.J= 61/I%4ODS)\U."C28#&,])J%
MQ9J<82*Q^/%BJ$?L:E+4HV'IBOE^[ +OK+G5WYY\5@\SH3P^^1:%(<FXD<DA
MXT8FE(P;F1PR;F1"R;B1<2/C1L:-OA!*QHU,#NOCQF8=ZD\ CCL[\\ *?C]?
MO"VZZ[7V3!%"@ Z! (J% \8X 936VB@$10CZKKL>&L4IIPA8)C"@WE"@'8V/
MT!H+Y*T@R-YUUW_PDQO__--][G5<]?CI6ST!H!A0L4$/?!_Y\#8I/+3K/V1\
MSOB<\7EG\5DZ&; W$A#G.: <&:"85H 0) 2#.#(=[.(X->-SC_ YY\VMP3\_
MZZ&NK"]TG1J"_:;']J(@:%!@B&D^8-TCQLH";KL1/0C!H+UAP$FM 45.16,!
MI\I11&NA0D!ZI524\]! S 7PF$03P3H)M* 6$*,Q#Y(8[U9$T-O1Y>6H:JJA
MMIW$3J>3>J(K5U;GW?4/PQ@-L.2')8OZP#+91,CD<* (:K%UA(E49R_$?P*B
MP##G@8K JB0T)@39!8(VV'DQ&L8UK]_]>UI.KI^LR4=<S)"8(3%#8H;$K4!B
M@,HJ+66$-^T!)08#C84 -GB#"8+.FA6_L]+*"<<=\-X(0+GGP A'041*9A%1
MP7O8(21^JP^MQ' @(,JPF6$SPV:&S3UP-D/("1<P !25RPC*F '%) &84B$A
MUD*@%5!VD$G+L0 N1!6U.0R4*H&R$$0'Z3 QM$M0?J+'.3N;\V%@QN>,SWN%
MSP8;I;DE(&#) -5, >F<!H;CP&2@T&)Z%Y]1.B+D/@!%10!40@DT(0[ $)1@
M@A@75JH\; &?!Y2R >,'YH?-,)UA.L/TZWL?%-$:NQ! B/HIH-1$#&52 T>5
M10IZ*ZVX"Z0>*261$ !9EA3=J/(:SZ)RC"PB3EF-G-B:]X$(-D TNVR?F)4>
M?Z9R ,W'3=+R#<=\$^V6WH[CVQ]]X5/GG:;7E@F>KU@[U+28;_1T,IIO:QI+
M69VGP:?+P5!?CZ:3^/BOWOW8O@I!> 3_/+\A<N!07]7^3>VO]%A/_'P5&NYM
MG_W=W9"5SV5=FG(8J?[-_/[[@E&:UV%YI.B??_SNKP]\C];\3ARQ#3SU\3="
MN>57JB.ZB;5[_)7J(&;)\9-N?21B2SR__,6]@+'*.<\)4!*[I<WMX]3BSJ=O
M_O,[_MWCTWR6DC8?]087YGZI]E1+^DO+!B9J00^N7!OZ4S3JTGJDL1MKMC5.
M6=_LVSENPM_@IC[L>Y>\<M/QI.D%D=J>@)-J/3+IP]IDZ9'I_5%ZMW9Z.1U&
MF\,U!-\4?FL^W:K^EAD@,T!_]G13#)")/!-Y;_:T2R+_-)KH8;'L+_W+P1-[
M'YP*KY,&]LIHL2M3>S):[(9UW"6>M!E$V9>0?0F9CUZD?%Y& ?/-#I.[O%J9
MCS(?;<'#W?8ESHR4&2DSTDL8Z?T3ZN7O\EIE+LI<M'DN^L6'TI99K\N,E!GI
M18S41G5F/NJ^05"N:76WIM4OWOI+X\?SLE8XE[5Z>+X[WU$K-YE[)%'58!HD
M)B XQ@%E,  )'0;>!@.I=P2)E29SE$.HJ># -)5N*1) I?JU$60\=$%;R%>J
MUFZG)!52:  W67]EC\D]XU8?,M;^E 'LF9F<U F-A <4*@=H8 88A0V0AE,;
M.,-4K20@K0-@FRM_HC)<9;CJW49FN-I04U_JI6 6>"=52CSG0 M( )>(,4&%
MB)AU%ZX$# Y*;0!%)NIH42T#!AH!"&/:$\M(,&&+U9H8DP/*,FIEU.K?1AXJ
M:NUT,0[B%4&!4L D@R!B( 1:,@HXX@01 C6S*\62/':2>&0 PAP#&N$)&.XH
M<"%>CJ ,!)OM%^.@ X+%/@'C]LML9(3LPXYFA.P50D853PA!!/#*:T"E0D#)
MJ 9&19)J:X2E20.\C9 ,>LMLM&H9C_9MM'$1D(X0$.(=$5>9XX&]1KDBR.A
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M,%1QYS!A6-_?0FX];/R&9CE@7 P(W6#AGSXR3,;/C)\9/_?>#<V<M8%[H%!
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M=9Y+@=A].QPEE4@R@Z94@ A1@9$F0)*"4$L5M6JC*7=(,C(M).08/(BD YC
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M*>#+Q]44X11;?AF&&??QT3B,_J2<C@0<V;@?VJE*7%GM:4X@N2ZA$J;!&::
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M]^ZX='7C6I^N+W>1KB]/,.X\3]?/_:$;AC[^5"/0G8I 'W\:NKGVKT!C=EF
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M(N82=2XHQ&.$/Y@B2 LM$5:.:A.\,IK=MM+_%NLZQG<+E=<PU+L&US^,?VS
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M,1BIJ!THLB!2Q!MF^5(]KBK0USF@^;$)&WQ_O:%!&X&8>[L+QG\_<\L3ZM]
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M$EO(DZXN:(Y-[2<[&#998ME230TE;K($;R)B-Z;MN@$.=F1CF5ZUAO3PNO]
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M6XF5-]H^M^T3^('H54(LW9A%8?!I$.+H7K.SBDGT?-P\+S#321N$O0:U(KU
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M(.;?YTYNFYO8.&7@OKV)/EXZD%I&>M5]TVG/E'@'DME[4>-Y1#6[9H)G>C*
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M(\"*&CR#QK<H]AG89ZP/5TTKL%CKFUGVQ4H[.BZ!XPL"TE@0@^$LH\-H=9O
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MPC.3&5AK<D\!#4\H7F9X4C@ F?'RXN2> BL[22<^C?3HS3)Y%:6W(EU[A^_
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MCB9?$ JF';S$]II+F%Z">2+4:M+!&G3Q@V(U)M2F.$EK&GN")381S2+$>2Y
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MR9D\(K@RP/KW3>(XG8QA!IJ#=;8@:#QRKH<,<2J3T&J357@J*?4LAF(^2X(
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MZH@@[\12JT'1MI-S(O&X03R4*G1(C\]:@CXNOCU/MV\LT$E K7_NO%9 ,9R
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M]=)]60N:5T8R C%MI)D0-+%\'*#\HFAX0_EN,N(QO8MP71C.98Y[(5\2.R%
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MZ[%\4F_AD:L[0]N^RP\DES]C3'QQTAGV%B*-@7I$(G4(D;T/#V!X['1'./A
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M$VBM/V5,9UI51S!Q7;=P,'K__39;<[=.+QKO% C#!RJ]2^<LEI?3BVL]Z!]
MA&SZLME?-2J5,]=#0AF^Q2D%4Y'Q+('L)!G2?IZ6]@O<T]P=Y*J&#%&,C^.(
MR8K!';G1W4ZYKI2I2D40)L440U$D CQ-3]$2G4<B2$'8 VSK"X^,MZ( )]-:
M'DC(*+LIT2T.@7D;VRQ"<9#A"C,5-XXHM4\TJ2XFC&(4O6"A+UA?A*YE]1K:
MRG*::0$R*[C6)2JX\>_LZK(ZX> R[A&[0ZF&DQLUCJ,M*A!S?9@U=OE11:"S
MK-$(GN-)^@)[N7_-!_*323E]]?VN\P$FQ<=15VD0212FB '31*T4MZ?2GA;Q
MQ$LA%)/^<U*"BAA2C=@KWR:*(Y^7IY\Q3+VBYR2N)QY,Z!;H\Y88!3Z, /$_
M9?]1\N&2]:"OBAHIVQG6S8W"%D'TX&^]];0GEV# Q9K M+S'_VYB#URI!'KI
MD09P_;?8M0G/"]39\8<$0EP!>A(43"*0D'0UT%"5XHA^?'() 0M!CYT>*DHI
ML>O >XRIXEAR 0XW +Q=E&4&7#-7+,R3]48[@9:/,5(W[R?2-I0%0K(!6AX3
M0.LP#G=!:(/K/49ZR-2BPB>+"4<1A1^QD@8*TGA:!$Z+4B=@\)11O;:)0'WZ
M14.)K>N"K[A$[G5B[ $$-SU1N?][B33C!Y9$ZL*GB:^(+TB'.;8BRI.+(;G!
M8<8O)F,2]H:M)R1L%37$X#^-HI1)XTW)*A;,/KA'J(8<+[T/B\M&N)8@0&>N
M"ZJ[V&P;7-U3.+Z]:\"!$ ER!\#X<7!B\(?\F^0U#^$' <B/E36D<42PV%-^
M':.OY%?E],!!D:F _ RH:"4T?2;GPXRX (G*^<";<0C/,)E:)<KTAIZA1)F-
M$PM#3T3'G'<.<$[ _W0#P5?@?[-4]%B3%#T#1J<J\71GFORVX&Q_/N[EZZ6$
M<!ZG,_I!!GH))@.L@[@%<A%%_&PS3$\1GR%Y7IH<M&.YR.FG%=!2*$@FJ60"
M&U1ZH;DB."S%9!TL::\=$/"'(03?X:Z"/'#@]IU,9=Q&O0GE=DE6)$,IYKL4
MB'/2EP_#$%E>*]*M:XXT+1 ^,T',N(KG+HCAJ4$ QO=#&#C#84LSR& ;Y7J7
M^08YCG;HC!(D+)66*0PO<L?=^"Q[U!,XHVA$Y81X>\#%SQ 8_\NGT',NZ WN
MVS<A2D5NMV2]7\O&>BL;ZX"3#=_Q0K[6A?P$>-H/6!;Y1*GJ+S*LBE3?=K09
MQTN<J-3E/"*-5""^#S6&;J16CXZ+!>)^Y-2C;B7T1>$HG.47%S[#4*2GMO.#
M0-M8@'YZ@]!.S$V;",2+OFR8)?Q%]NQ&.<^5#_D_\LQ.]H<F_;\57?Y,H_<_
M8?_6FQU0R<P0>_;C]E3U2,S!2$G\F\&XR:?VCJF. (5I5W94;@\YX-;M(&)2
MQ@H).W!$VS\\GM!(F'H(9?JLV%4CV N"CD)_.3,QM> 0;MKY>G^,C+8?X1&L
MMC.:]&53G>RW^40^<7"BVVBQ 8'$GN;J2NZ9\FJKXZ']*TN7+8#"''$]5"<:
M;DM=TB)VHB"MAYAKMM8;7 @Y>/W]L_<'959539FG6)5^B6#>&)*7W9ZG0(&R
MA?'#MRL:AX"7WZ[_\*F%<Y\'>8$_KS"TU53#(JL1AFU&-=3U':<=H,2>&JO.
M5VY=XPX5.5FLP$U)$L8!?2)*W0#%=\-)AW2\E*=OBH9>*>U^:6CD;U9HY J-
M_-#+\)TY8^+ D_.2"L+ HV.AH;'A6 Y\J)(ZI_$C%A,(VH'4=&:^0/I^,Q'R
M=H03=*O#\H:-UV"W6OY333WVF7#51H]R%"HPC\H.,\$Q@[U 7Y,!)(=(%]",
MF_ *1!H.3*9D"QE1'_3:3<*//90=HD2)?2/N;,"D @S@5PV/Q91<<((S,X*X
MX;K8[XJX SZXK!OBV_ B*FR0S_KIK#HHF:PE*,[69Y2BC3L&R7PJ(E^1-'ZZ
MM,*[_H(KXC=D:+B0U^QI(=8RS!77KJ(">4P;']&&W)*[*?=>")%?;;XT\]]7
M50JUT2<,FSA!MH]H]7HW;,L=S9%/,,1@@ S=S"6[0KEQ92D*5B'M=7"%9^J
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M)AC@CZ./RX-\"8&5?S"1PB*%VM"L@8Y>V^ 2,(>+W;'EYN]M!;<<KK&]H&J
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MAVCFBHP@TQN.42XV(_H*U@JY7.0LFP:8/4Q(P.H,1P*OR=IEJW?6P!;JL/A
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MDEFI_#5\DMV?"N#Q&SN8:J_ZLD?"!\.ZYE?I^(_1NVI(6"_G8XO7.]1MN^>
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M[3^GQJ<X?#3/'2 YJA[!K30;\:&WAWA9L$0(> !%@Q-+X;(T\5Q)[-_<A0T
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M>-*-:H%R5Z8/-TF#M 1&3'@XB\7!5F:839C?0S,0Z&SK^@[?V9G2'?DMN 8
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MB$QU?*.GL"Z@,&T6GM8S4WP%$5EL79T&2I3^GEI.$OU]^=\1X!7Q)QZD<U.
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M2HP[5*S/TU  AM<G&M5-3SZ%9V4GZ]*YBZ4U!8LB:Q4PF,UEJ'8D5UN\#MS
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M*N#0Q8R72?DI5 MIO4(I9[HBX0O^=//' ,+71R#0Q7M1P?&DQ@2;AN6T96[
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M*%JH]%/&22$M&[?VG$%BR0^0!E'JR;5"&@IVB>15:J"5#&BU]E_0VE/H2-G
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M7&T3R *2[U(FEBIG^1$<KE;DX5/>[2A+Z3D.N!*/<+68SLW[J^D,1D@&DS2
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M'!H(85UL*@32T */<<9W0%ME@"K&/@V>?,\"DXD\5-M3'3Y1[7I4^$;#DKO
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M;]U)_Y>GA!W8XBKJ;%8GUGLJ;7<HCBZ7C^$XC\:%4<(<$KP4FPB")GD0?03
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M5HEBB'>JL?'89'YIL7E)#RL\U3&(Z7;)3,VAQ?*"S O3*ZWE.KYY'0_)1%Q
M6VG;MG<I(5I^#"1A,>M3.V-V=EF_SO8[X3ABH3FK>( --2CA= E=DH-*"NM0
MQIE@L*)X5F8.(/1 C<?-NQAA'N(N?OLI5Y_P'"(Q(^KDRZ1UMZ$?BEG.C1))
MQ2_^$3[T]I-/WU8))-$*F[AAW;96K@*_MS%RGM.^2+!3 F\)-C-_D,H%]0GW
M(9'M_/#D)_M]EEK4XK.PW:Q0RS*ZL^A"&?8@3#8-8/WI856(@+8EYFU-@J1#
MFHO1J-SX6KR!"!G88AOTT==-5]=UA76_6BGJ7?FUVB\YETA$LMI 3L;A%[&P
MK=VL\@Z5& ;_4^2*RO-HF$/7&RCO&!)%X283,-F3-T!U#^6IVR!/^5W-Q3IG
MQOEW\0=Z3*/(J<A/T=Y\O?DZWG>/=S@E0Y/F_7B9,Q]K+R1;XN*2*6*/;DSJ
MGT#@;[^Y6)0FFANI/M":&6] \G5V.9##X!*!L_Y>..])RH/0.G5,?. D7]C^
M2YR1$ % ,;T1136,?6 ($6S <(ZHB5-<BVB<O$<A-*G\T.,0*..NEY863T41
MY0@_@K,%%.,9QB!CF(AP6/>Z. B <6!B+)H' GRGE6E0Q^U%K$V0'!L11A.7
M'N2,9Q^EPK(X*HW*LFZ'*U$DRB+ SS7N+_Z7.+"Q4L4RZ4-YF?9,\DBC$6<X
M;R0(XU!)HS.!>[HU!F35B/Z_(^D\D)B9DA@CCRVPMS)OBRPC,.=(9R4"@]@I
MGMX-G897B!]E$=@3&&>,G^AR[4MW0+DWA5'I3-V%RA]"!;1!CYRJ &8A&/CH
M(5#%1JD^Y"-<]M8_QW.L1I1P?>ZPG>6"%]G ,5H_M-A]B:^!XDPSGBWC<.HQ
MJ]DS+R@-#L80#0BB>(;MXN03\*3D[$!B3=_<<A&/M[!,N^HI+'_5?!RQ6/I0
M.RA4R)Y/&62%M7QH6,N_K["65:GA5U%J2!"4CFI6&^TRQ#(@,Z%.M"2G.;=%
MC9?=9T./(G-?RW_/M/SW3ZT]S#E*,4<N:4SGLM(EA47J'W3.JJ3A4AB+NLJ]
MMMBZH/D;['62)5.[_)7\44%!65:&J8FU7[I:V3W@)VU?$*0!.ZHZZ( 9F#6#
M7*1'=Y.1N7WE]Q@<FV<A$ZL'C).IL-+M#RW5XB!J'YGW04))%+ADQO*1@-18
MW'"@&\ZAHZFV=VUSAI -'@L++/H\].14$\7 1%(@S)YPC$__B@#,<!UF=M%)
MS*P6Z?JY7N4]R?>JY!&]7NQ<9<+]4DZ[7*8_S(P"PWF\MBUBM(G$N9WZB3N_
M/_1M-]DZCC.6F2>^ONS9O-ZGF#FL=#];U4=13!>G-2CQHZ&]X@["^G9,C&OJ
MU="BE7+44!38)7\PQ. MS<<Q"M<3@>=TBC_O9!C* Y@ *5*4 CN?9)QTR#0:
MW%O!\\>_W*O'$.>;F)[BJHN4G::*1BVLB\0<(#@L.,=#T-HA>"GF:6>N*SV&
M;T>I%),'T"Q6$TV<<+I^;:&-[+(9T:=U<1->R(Q2)ETM?E?)BKF1G'Q ]8&>
M^0/]\N>3&;TDL-,_PQR6JZPXR-[4$,33Z8&E[B[5]\*1M\T>L: E/AO9%?/J
MHDGT5D*T2XC5V?WA/%9/N-"Q9QV6?)OE DAZM?O.TZ'C<\:U$9I2]!V%&,?V
MKHVZLT2(ME,2J*?7%=:KVS]/P+2?%8-D^CEAG^7KNAJ2Z)J7I'8=L3+C#$OU
M)%5>1J L3F$]35XC02OJ,,]5F,CXKXL3>0%NH-QT:A&=CF;=1^/$<UQX!?J9
MD+O(LWMT4K*1("(J,.]P\+L+)V/V2 +/1?'7\"/TBH*/8V(2"]UVZ7<O?M41
M@"%157H&TH7U*H!ZE)^@=BIV<L@=QJ?". *HK2MZD+@M/%YOB8!;?!"%L-A<
M/&."3MT.>I3KB\#.QZ-WPF'_2N]?PPQW,;=:_/@L%M_D_$BL0:+<=S)2JV#I
MQ+7C V.0YS-+<W2#CRE@_6>T'$F$=U]<G:78=^2!UVV\7Z4K8>N*[NOO  _]
M#[+/R@<T!6:ETF X>F<,?()[SI\W+LX02!D:_SG4>"LP[U^]C/=@A6;N;R4(
MXQEPU4Q/?#':T?W0=S>DLWYF-7B3AE_F \TE-=?JWO,\O/\9)%S'HR=[I;GR
M9V& /]%42D*!>Y$(HAB[NR%U<ZL_P9F.,T(P$@.H.A!")#,EK1B>O[,R,R.3
M0/5CN,.9I+W&TOUP4W<L+Y3"F;ESF#%@0ZDD9<E&]<A.1 )A=+%NPK'=(?"@
MG<XIY^OR=K.\XZ=NNNB0P6?#.Z)!/"?7<:23ZR?L1SC,9BQ8R;(]M1(S.2[:
M)Y<&IH3(=E8;H%F0AQEIK^'J':+^*SI'&R+5%?"(W@ 6?&8U'0I8B;%<>%[G
M!1Z98J7[%DDS'?#BCG]6IML'%$QDDX'UBFO%;VX1O(^]:DIPERZ7J+S$=>N'
M4S]PZ %LV3!* 9 B0:HDM,W)=$5QUS_:D Q6I(6S5*01?_P6I(EH" 85M^:3
M(1D)L.:OGO,9RJ#$AGX#PS.'0TNZ>3W:C!*#G7W"G?4HV#T1WA$[_X"ZA;MI
M1VEBW$+NHB9%]0NWJ3&NM]E*%XIU#X9@5Z*M0G3VC.*N%0GP@1?\LT]6),"*
M!/A5>)<[[ %1''1&Y/YEG,)QK(R TN"X2RVYWB2;T849[]$8Z@'+*AI,Y4[X
MB[]_ __[Y=??>%) "?8D^AO2DE$U<\1PC&#_!OT_ C-YV/$BY0H>==QAL+1F
M)\\X.Z&IF<=9&_=,$7$.*&> =DN,32!X%\FX5$#M'.:>:R#(8*4YC"\9K$@_
M$[)V&.,'>F@C0ZQD([]VN-][E5*LDC$5!RA9!PE& I0 8?)6^..&NAN/**ZV
M$-1_Y-4%BE'< E["!W<*2717]MD3/KX*.,@NKA(\YSB=FU;T%F>S.49OF-[_
MQR*)NH,Q9/R&Z,S2I-0LRFSZS=C3S"YN:)1K[,) LI \&,LE85TR9N6)L>&
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M+T1KT%8?QW8;/8#U>A:+OB^P;\)@H7J*+N5$PP(!F,9=?9Z EC]I0GQ <1U
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MN'[;O;QP'F7C/Q95:.-][/FO\G\MO^QVGYU+@?_NYV?;<G470^SVN10% TT
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MY,NP:3]/K&J@"20E=%Y?GK"__-E"6"??D&EPJMP$E7D5E"P7;>)+6ZH<]*!
M;"<0:&G+6J*L<EVNL[TL Z-Q? &+THU-[GAUBM*8(=[2P/G2P5SI7YN:+ "/
M(/%*\;M-LK4@],EMAM=&O'ON%F#R0 X^.?W)Z1-9J!3I[AF+H51L$%R=>VC1
MC\Z954!/M>'%1<4,066ST +AX<QO#+N)B4LJGO*;3(F5=DL\S"H;=/1C&+:9
M]I%SN6SGB.[%?0:!&13>3D,V&D5BSLP]A)HI,@E,=A/2G>6.=D:,8W(],NW
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MIQX8+8)#1<#>BIG>>01^!3/#+S?Q.7*@R SI.KU^Z&VNV3M4H2HAKES:!Q0
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M'36K"QFM0;<+F9&$*;?@;SG8>DJA%5^H\OAFSMN1.+'ZK(V>Q!1[<9C45?_
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M_G<6W \8.U5%B;%)0E&64B#F.:SI!ZW7/!$9M@N*13WIV]"E8./0EW13J$B
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M'4U\HN1XF[9;O[3C?/7ZS;MOKG[\_ALWTK^D<6_F9>]N"%)#ZCL!_0NY-7J
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MM[HA"QKQNX%Y'1@FWGJ\U+HB'<WZ6&SV1W<=(MG#2I/<!NN?<EH8T\*PG42
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MU\(-V=ZD6L] TL0,]HBR:,W$RVK7S$ _L,M/:=(CW5Q^DKAHQ<-8[T/7(EO
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MIH)F2K-'K!Q>$VQ4RZ3AIMBLY]*DQN^'R&L<^TYBW*&CI^>13*BK/^6G72F
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MH'JL>DHE."I#4[U-AZK;F?:'? #;]H0B)W.:S(DA4:IAT]D]V?$4RQL>W!S
M=DPJ89,5J141@HT-"(5PZII0"6. #'F2G1(H=&(-'@ RS=T@&$/MDN2!@7J4
MEGC3I]S@L:["N(U1&&,21F%T>CSEA:?TXC/&$VS0!NP4 %A.;TWIPRHL*>%(
MG6WT[PE'>J+1*97<L>(E [&-?U8GIWEX9YLSUC^,!%LN_Y=:-48;'ZR^)N
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M_46MLHA:(A_9FSF.(O9NO=8 BP CWUX'60VRRGE-'#IV@?L\G^( SHKF/T&
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M@[2IQ+:D8@FF N&W!?:E-C E=HR0'=N^8!!&ESX7D ,R]8MU@CNRMMX/HDO
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MM84KO@S^<.#8>,K U)SWDE*HHRCA<SI-\^6)*A9PXQ5K%UL6;39_GJA3IN"
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M2(2)O2/S#=G-1,\43= 3>0!UOJVU*L"J(%>32938OB29$E@;+TK0 :WWS1D
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M ,I.>BVF_F;O@3RY#1)7G2F[ERI-I/@\7PMSN_D7)0)LQJ_6YFF;.Q^R4XJ
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M@D/DI"I%LCXEFXCR^;I>=:[7BR3U-Y 2+C^;/Y'!!?,GT?/OG "?X_OT#J:
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MD\,=3C>6.!'%-3[EYH]'&U 5#.(J8KZ "E=1Z^?C^0WH]=+BZ\A],YY%*;L
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M$ 6T%I=K*<484+C%DN[O<MW]&2IK=5@YD0ZMQLN5DF&,@Z(\V\!2-/=B%;I
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M?H[]-,7AS>X^\-WE>HW!)S/\G:G21HPX$M2/2JB@71X[1@'=@A7+(:@";IF
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MHU^I#"+*X:A#W/M-I\[-;L,>1L*"_7-$U!BZ=6^).L,/P?$>=?GI$LS.,A=
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M;UD>R*Z,XO3!><!7D1,FD+OE!!<):(L*?NN*$%FNR8F]Q7$ZQ T)U!$C/T-
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M;[$37"10A0'*(POX=< *&I3= F01HVL%OL>P5/DBYE(T\X[_^S3#^YT_.7X
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MO4$2+:_ORILWN[]F2'8J+F0&E&+]J3W"$.6>V+Q[>&.K#+"* %4Z#K #7O"
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MK.Q.<.S[$DS24\$D>= ?1,OAC+L978^QW>C&:8^G,#>P>%48KPMUO$HAK3"
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MN60_,$ ZZF*BN7&LP-.81GT1QEF_\EE"5+/12F<9I*=4ODZ$L3<T+5S\$5,
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M@$'\:*(#NCQY@6-UA)G3D$Z*K#U?Y]5ARK@$"<,2Z&=#JD;I%G#>N[Q:3L+
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M[N^OI!$]XH;V22@0H?$[N0A@N%AN?/1&%JIT']3]JVT'<.(@/.]WNX"\6[P
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MMT;A)6GK!"$44#W)$-4YTX JMU_=QPG"*BYT@=.<'(/:J2D?FLL#Z4ZJ-FK
M!!O^EGTU43]<6%6^J=,H3NPB+B9<[FNM-;*_;OD+.RO"D^ORF7(+$0_1P0N
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M7/>MLR8?Q/J;@KH;;K8H?L73Q5??>[J!EYX7ED1+0U,W5M ,]F@!OD^0F^X
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M5TF02:N.3I HAHRO;].7ZC;ET[,S[*1<<T+Q5E@Z9KBO.6(=N5BM8G#IT?_
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M^_N!@CU!:2A\K[X<*G6,:_M"W=R)_2&)"9&;>I0=G""I>QE)G4I,I42V3B?
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MC**G6T1R )FW,<D!7AXT0L;DW9P@C[C.BY"94H";3,@W]7&"L)H/4^J!T?*
M2GO;-PF4WQ(0<(+W&%7'.J1>-/9W8G6'BQVAJ=MVXE;*WW:#T>*B!-0T\8#>
MR4]"&:_7TPDB,SP5YD/C!)H"H*>QDWW)\(2W8W[[S-=*BQG62,D_?XE6_MJG
ML2RB0-*>(SJQWAFV$I'MS+ MT50D39T@0UBC1XKU(6OL!"E\.@4\C/!=\P4
MGK&\G*^UPY;:#N($Z0*#D^I5H&CN!#E:51]5!+8:H$KR__Y303%^_?V#^X7\
ML,-W#Y9<&5[E/]CW2^2#H/L1,QF3_NG//_W\\\<_I=[W*(RVAS\1)CSA_\N3
M [+_@DI(8AKOPG44;\N1&P!R]I]_J'[[#Z7U0-]3!$7@_B!8OZB\=*3\190K
M<IL8K>GD$SQ[LG )6O[X&KW]:85\H.)G^,,/\(<?OR>K_P$!F%?1&XJKRT#8
M1@,TR[^+-M4 DQ)EC7%S*OT\TI0N\ =7Y/$6>*^".95_'YE/5*.Z"5=\TJV
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MB)U$%1G2]O9(*";RX&WQ'Q>Q%R98=F"1J3P(&AWM;S$L]-$=_F/COBH:3JK
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MX=;S8Y)5@)^II3KB#?ILJ_ZNB1.!):FW*<JFBIYLX']PZ-^PHD/NT"P-%'[
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M#>6O:SDDKJ"A&\^(YF4H&7,%](YW=]D[9L_[[=:+#_/UL_\:$HMJF-8Y=SZ
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M3J/E/RB_KO<Q!-NBV(]69$Y7T78;A;1%!7Y)ASA30YN6]]HZL&'EM^&X$N:
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M>WW!.PZ2Q_^./#&[6@XQJJRY"U=[?#)\+\C$@GC=54W'6_4KX:I?C;CJ-\0
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M'$<6_943\]XSW3W[Q#TWPFNU(FS+X:4K^JF#)B&+MRA2P\4N]==?@)NX8*5
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M8X#5*&;=B5P](<*J^.]749@#F3G!"XIW/_,0//%. #@9SS'H=2(K-4X:R[\
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M*S2@YSS/ L&R>D;+GF-?Y6/@#*!O90(M72Q'*"]USI%6A^M?&D5UI;J<Q3F
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ML&F0PW2+^EBPPT-TRO'_ZKA%_IN5D)\D"6@J;!<-=CR]/X4 L!GCQ'Z?].V
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MR/&FE3;"?$, ^T 7G_ABD"N'Q)X#\CZIG_*2-T:Y>?(2546<CJ^PBE)^C$?
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MU-0/H?-*HUG7(ZB72\T&@1$^U"N_05>D5I^:=F:"2Q+CCW780'?J,B<05/'
M+T0^;'>/^^PEME$)EOH6EQN6($-.<"%K#YK(N IWE9MR%5:K]'.]7,96RVBH
MQ\AA8+XJG&7.SL[?%E^'K']$4O'V8%VZ;D:L9I=+,B2!!3*PU&.^"W\4J0:X
M>"H@M1!YA%#?)7<<>% R4NH(QK#5HI'KSSY2P4$G%62/>E[:H:'<5%ZM.Z.-
MJ+O9IP]4EY%__?"4S^:<HD6+_#Z(A.J2T5HG1R%#'+=X^!J,M+-\ R*A1UU&
MJ"1!FY1"P3URDB+Y;/Z$[ I/D7*[S1S%'QFYI8I9P&(ITAIH*=9BJL^8;Y/8
MO6:T1YI=!OVS2'%'DHKO9)(C6HI0<LL\VJ>"$8 )88P42)<^@H$ 9 3.;(,V
M(%21_/$%N:?<)PT%:D&ER WMM01W.PP!'\GF<R=Y<F ASR+5K6!,Y$J+Z-*@
M/B77/%#,Z?HPA,X@M4O\F+NX(&5R[0%+LA%/_G"2S:9(@U$%EG6*?"J1RXM<
MUDZ^1/I;P)<9HAD!F5/+)Z2]8&TF!',1&,*.5PA?YT0_H';^R-T(-/8 E1BU
M46$]4*$&R5-9DQ<^Z1EE:0AFJ8Y'DG$FDR>:%8:W979.G3E<44_::D];1JY/
M +8839"74WJ7QUL*]1@CFLU MG(?I*OJ@BISF%"(K%;9X"GB L!V2<U108L)
MDCO5ID+.6E.A)CBP#_56NQ&V#\) 4:$* U*"H3!%_FFO2 Y73C!8(T/X7R+
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M?'-=C%%!\$,[@H> AYUX\^K);RFD8H5Q8IKBIPJZ&J6S_/A?7=,0KU@"(C\
M4B 5_4Q;T:#Q[\!JQ8NV_<__6V;T6NF-?;7Z2OLDC1>F=7XR\O[-!CCW21JO
M1E!K;K1(2+E7JN13I5DM-QKDTX=RO5Q[;\OM%1Q_U@8A %<P(UM@G[JF:+%#
M=6%DC4JG;ZL]P<:K;L...QN9P@;N<D%<O$&81JH+YCD68!8LQ LY?4719)4(
M-V(D,0?]IZO]V1"B3E3+;C7O0^E[3!:$A7-OB[$TPY&@< /Y@XW3H&J#")0F
M?V)NT7SH\C*3';5W,-822E:0+*0"5M3(5/C62/@BMFQQCZM!8=@Z;@2MW&E@
M?YK-Y/-OD4A'REW2YN0R<WXQU0;^(F:_.I392, ^C-6(_X)1 OC#BD#;M-2=
M'<54F"&;R9ZCFGADL!$=ZL7O K>,P(GN9]1PB:K(OY"J>$&!N8RU=)"NJ>_3
M91%,6@*0=3)?PA:O/,&%4WJ^BK-S29:NP*! CN01^27H^J3\2'VY<"Y3,;+C
M;.8,)C3%O/%ON[=*]LUL@]6L@F5>V*^E/3/;8"V;7'FL\.:F7%LXUTF=NTO3
M(E/FP +-_'?7B3I'XIH'XTOK4WNMF)!6;"@&UL4'*L2.R)N])%VJ%?=K:<W,
MMJ053S.YUYG6LYV27^$8F[$_X?]H-%MY@&1_(>>WZL"^.FH%[N#==U='7=7S
MWOT?4$L#!!0    ( *N"J%B6<]8>^@@  !@^   /    <V%N82UE>#,Q7S$N
M:'1M[5MM4QLY$OZ^OT*7K=Q!E<?X-1";H\H!YT+5+F3!5&4_:D8:6\>,-"MI
M;'R__KJE&=L8$PPL!4Y,50*>:;5:/<^C?AGY<&33Y.@7<CCBE,%O<FB%3?A1
M_UO0K%?KAWO^(PCL%1*'H6)38NPTX?]^EU(]%+)#:&[5/T2:*6VIM-V,,B;D
ML$,.LION.Z>6B7$YJ+@;6)5U:M6VD-U4R&#$Q7!DBPNAN@F,^!_J")5F7 =P
M!30=9J626$F+(KQ3KV6VZPWQ*KON7DQ3D4P[ Y%R0\[XA%RHE,I2,%36JA1D
M+;^Q 4W$4'82'EN< X>7TTQ&PO+ 9#3BG4SS8*)IUEV:^[O3P5P3P>RH$PL;
M1"#))4[RSU_K'VK=PST<>W2XE\$_\)#SU$LN4:./E]<8J43ISJ\U]].]?\43
M_X1"E;"_PP7]FY$(A24>9S-'K.F"^L%#T][OA0@,X/J-N.&X?S$X_7QZW!N<
MGI^1KU<7EU>]LP$9G#_>)T^&Q9MRR,75;_U+4F_2H-[:H;ND=W9"ZFU6?+HZ
M.^E?D,&7/KGL'U]=G Y.0;C_[?A+[^P_?=(['I#SSZ3^L=FJ_*S^ZUV2WLGY
MUT'_9!%-Z"Z'L&:M@2YR'NQ=?.J=]2^#\V^_]?\LG=>HU1I/X&/CZ7Q<M?&N
MZ[SG^>JT0BXM'W-)3JKD"]6Z0GZOGE0K).+:BGA*[(C:SI(W%D(9$R9+Z+03
M)_SFCC?^FQO444[GA )CJ;9=M^X UI2:3D@-3X3D=SPT-[I5;3?WW[^6RXK9
MR[4*B=8&;LG?6>*[HWJU=-R"Q[S*>JVVK/"5 $!&=,R)YF/!)YS!\Q:&_)7#
M KA.IG =4QJB)/FL=$KJM> /HF)R224EGX2R/!I)L',XK9!3&57G 1V#^3RD
M;Q&S'F(:&X"83^!\AHA(I^1:JDG"V9!7/' *N# %FJ2R!$=1(0F54Y)+JW,.
MME)XAJ *<41)"I^TH F):027-%$II$16>;D[ I)'W!BJIRB2TFL.\R[H-'"-
M@3$P98(Q!>= @4CH*$]!3,)PL 02:@+^B4;$Y/C??/R$:UXHP06DPB20]D,>
M3B;"CF"!)N.1,Q#U9F":8K#,,0QC))PNNF%+AN>1H;G)9. D%A+@ALB=PZL"
M3 !QN*T7[@L9P^9*K0 ]0D9)SD G0'@!2Q6 O\ -&8PW2!XD59+,V5$ TRQ-
M#98R@8HK*)$G( "44(!;-YUQ]D34C$B<J(DI^:+Y4!BKH90E%"]ZN\'*R@+L
M36G,'6NWR'\>\EL;@/S!+9C\RQ2H+O)&W#!5' OXN&-V'7I."=7<X11P)\*$
M(YX(AS6'B3 C'(%B*<0+C!GX&=89)<KD, XGUBKQ@,VTBCB#RX;L #X9!\![
M$/9OHA&50TYZL$E?Y E(N$*JO<.]%:Z0PD_^H\"Z17JBH'Z"._D"?SR>T9:U
M)XIO313#1+C.95:!!"9>G8>94H ;<8N :AS,G_\/3I[]=J.^?_"A];'1W&_M
M-]I/8!)4S&^?2B?<@',!5RX9>1CT%<R3(IJ;]8=@PA)R ' QDT^!5*Y! >SF
M8V%<C  I+IT>K/OFT64Q0FF>4,>((@>:H[I21"^\*2#2@"U&)8)1ZPP-C6""
M:H$+$#Y3<S%3HJ;<8/;D]A#C4BT7493A8)"%"(:#,GBF(LH3BH$0EN6,F&=A
M,,+G=(NI*/P5<A2$!P;C.5LC-FT9]QS&A1O'N+6#P!WBK1\^UN8?<'8L&-**
M&B4IQDEJ@))8NB#7J&8E[H&)@H8B$7:*B=NJ:7$7<!1QZ/<$OB6Z4/JX<'Q3
M+"C+=0;L,R[1C"*EF3/ %4%#+B%_3("$<(=GR&X4@0+/$PUV 9%!1-Q2[86I
M%FT U?ICFN0N B .>1Q#E2+&@""SHMJ -'*-6.8_KBX]'*=@(,0AXPN<4.7V
M_KG7B;9T)LVQ>HL?+OU)6-:%;IO@W@=@3Q>5;VGQLK1@&T"+$X^[N_C%5EE1
M6K@[2_1X1,3!#$Y%4:X1GPOITBU]J3(6KN +'-!B(E!1='_)SAWA&,@%^_^2
M7&%F!.!R/3UL]\E\9LNNMV1$S2R?Q,CAR,B9"ZEN]46XFY)$7/.D:/ MR5>>
MX9 UJ?>3\.QIC8GVC]F8<*] 6,G(RGSWQF"RR)#Y1HY(?T3>>*=6 KLH5$I6
M:3-+TMP%4):FPEK.5X;'4$$"B'>8 )O<\!U@$$0C@]$.?F.E5E*=_Y4+,-F1
M.Y>1:_GM;GL.VY[#42^!W!_<*X *V)#"UE8D. "W2+!FM?^$TVO,F'PMX'(F
M5\6XES5E(_E1="C*=-\.7+'M4P8##9_M^BNH4U0]( PL@.*DXA,V ]F:R5.
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M^"_D* @/#/ISMD%LVC'N.8P+MXYQ&P>!>\3;/'QLS#_@[%@PI!4U2E*,D]0
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MYA'^OU!+ 0(4 Q0    ( *N"J%AK\.Q9FD$$ %K^!0 2              "
M 0    !I;6<Q,3(V-S8Y-S-?,"YJ<&=02P$"% ,4    " "K@JA8T['+5N-^
M P#8KR, $0              @ '*000 <V%N82TR,#(T,#,S,2YH=&U02P$"
M% ,4    " "K@JA8$:0))<)' 0 +-Q0 $0              @ '<P < <V%N
M82TR,#(T,#,S,2YX<V102P$"% ,4    " "K@JA8D>/!05 0   0I0  #P
M            @ '-" D <V%N82UE>#$P7S$N:'1M4$L! A0#%     @ JX*H
M6)9SUA[Z"   &#X   \              ( !2AD) '-A;F$M97@S,5\Q+FAT
M;5!+ 0(4 Q0    ( *N"J%B8D: OY0@  & Y   /              "  7$B
M"0!S86YA+65X,S%?,BYH=&U02P$"% ,4    " "K@JA8BP%[[$\%  "V(
M#P              @ &#*PD <V%N82UE>#,R7S$N:'1M4$L! A0#%     @
MJX*H6&>1P/E-!0  R1\   \              ( !_S ) '-A;F$M97@S,E\R
:+FAT;5!+!08     "  ( .\!  !Y-@D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>sana-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sana="http://sana.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sana-20240331.xsd" xlink:type="simple"/>
    <context id="C_86a65137-2789-4d83-b804-3ef4fd1ebe47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3b656889-79bb-4672-bcb3-fd154c164adf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3f674985-b139-480d-b274-2a0503c4dce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dfb83220-389a-46ef-9749-8c6f3606deb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e77f8e79-8380-4173-9ea0-6fd155040616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_beb5b16b-6471-404e-aa6d-b2a7573c831a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_584f9a41-0e9d-44db-a47d-1be5d9acba98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_81ea7889-0580-4531-870a-0c65974ac802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_29744a16-e164-4459-bf1b-bc4cbfe6916d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sana:InProcessResearchAndDevelopmentIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_18f3293e-df26-43da-a598-50ac321fdc65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c6027cc1-7afb-4fa9-88e4-4c01cce1cb2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_f8a9dedd-06c5-4477-a6bb-e88883200c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_42aa39ff-3900-4c5e-985b-ace73bd8d9af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_3cf9a87b-eed3-43a3-93f1-c8d0035536c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_784cd865-32af-4b9e-9a2d-1283b79c0fb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1ff8bdde-18f8-4091-bad9-c22cba67895c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0650284f-37cc-47aa-8b3e-b08472cfc282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68a01da0-f0b5-45cd-b4fe-aae17edbf123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_cca9dd29-2dba-4680-84e1-d43e2ddb90e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">sana:Rule10B51TradingPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="C_e2d83e1b-1262-4dec-b6d4-df0a5108f32b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_aa78a347-b2c3-4998-92a1-ff2191d35b80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_2f9d4e78-b28f-45b8-a7ec-c2b98459dfc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9c74da5e-db6b-4240-81f6-b1cc19323032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0cd2c1c8-63b2-4e43-b354-bbe68ce2f425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c7d54ad9-1d5e-4031-8013-d956752e48dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f1fcce66-212c-4a70-9718-133d1c668a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_55131829-499c-4826-bd23-4f67ee1ace9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_50195858-336e-4ba8-93a6-442d74800d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d058c627-dfd8-4eb4-89d4-e773af8d23b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e5f766dc-31ca-402b-9dbd-c586a549b71f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4600a476-bff3-4417-9572-0fce0dfac06c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cfb14b1e-3ce3-4211-b44b-454387680bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_c8e330e6-05d0-41c5-9f40-ed43cee976e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ad091749-d991-4041-9e16-79d0ac453e20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_00b71411-02d1-4dbc-842b-d19a3cff2367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_6091c139-f87a-4c94-9bf8-6b84025b7ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_86dab90d-c97a-4375-b478-9bef336bc6ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e6ce25b6-c626-470d-b450-ff463c8d2c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_729027ec-b0b4-4b18-87f2-8db8ae9bdd77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d90fc972-dfb8-47f8-aecb-c44ba7bfe28d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_94f4df8f-7b42-4c68-be26-534736b5d5f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sana:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cdc2c79f-6027-47c6-b3d8-4dec37b42493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_2cc9980e-3cae-4e1d-8847-36113c44cfb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95b79823-dbbd-4370-9127-b27adbac303b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_65f65e05-e779-44e5-ae6f-7877d20cf158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c347a70d-0102-4f86-9df2-224e9dde7027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dafa944e-950c-499e-8b37-2dbf29453f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5fe7817f-a59d-4ee9-8d11-4a174e824ba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_06a0dace-22c9-49b4-b126-d21eae97f669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_823c66ba-b506-4ca6-9d31-5351ec2592d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5a55ce09-f176-4fab-a2e9-e04a6400a283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_be1d75be-894d-4c8e-a248-7743778c933d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_63e6b918-5acf-48a9-b764-d3dbe3d981fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9cce18b1-5b05-469a-898d-954d3e894e00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_49111c32-8c42-46ee-b4fc-28fe251ba44f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3855180a-7d90-426b-9874-03499729f15a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_3e115f01-d2f7-4c57-aad5-86133c460620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bbf6b029-0470-4e87-9590-c00f1975ad8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_70fd08ab-41b6-404e-b0b7-355ae3c53fbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_60a4c997-ab06-4f9e-8db8-c507524ec994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_18571269-31c5-4f70-a45a-3ef776d6eb61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:UnderwritersOptionToPurchaseAdditionalSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_5b0a8034-8cf2-4c3d-a6c4-dc826a8a63fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_a6da32b5-4e8e-4f22-b11e-b496dd2352a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_223e6244-4447-479e-a802-dff78ea29aef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7b455bc1-d635-49ad-bf86-120e8cdbf8b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_546c0313-0f3f-4820-bf29-21b1e0968e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_91e4e70f-95ff-409e-9dca-3d8f020d91b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8a8fc778-052c-4707-bdea-05eb75e7228d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cbe6df99-60ae-4f68-a843-401a8a497361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_995d9eee-7d60-4997-aedf-118f7f6b649d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_147c1909-b56c-4e45-bb6a-2f58c5972a51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e852dc08-0bf7-4b90-9f2e-d291734160a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_e95d768c-3dca-4fa7-ad61-ee5856361683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0ca9ade4-b42f-4a4e-999d-db79e5fb7206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_d3ae50f3-372a-4d53-b386-1eaa80038130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_9e464808-fafe-40f7-96bf-047d5e9dfd51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_1bd66b24-e325-40b8-abb1-65a998714668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a57b1903-cab8-45b9-8d74-c152b19c7eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_06e3eb5f-e863-49fa-8563-0e30982ae5cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c57b0ce6-633b-46bf-af84-70d41e43de5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_16202469-4333-43bd-8ab0-185f07269735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b81110b3-94ea-476b-8d47-6401255ca2bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7135efce-efcb-4461-a247-176eda4a968d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34f78daa-46b2-4c59-83f1-782cdc0c0849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a337850-011f-419d-9b96-9745a28abc2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_55b234fc-e689-4f6e-ade4-f2280aca3981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2ab6eba0-d3c4-442f-bc85-efd0ea497f3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_d7611f40-5b1f-46ae-8564-b1292748318e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_3bf2bbd7-4ee7-4371-8586-07b289dc7983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_04c586a3-4616-447f-9140-209061d79050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_50ec5c72-5617-4171-8d33-f4ac6315d6f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:RochesterNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7474455a-fc6d-4cd3-90d2-70280da1b89f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d60103d-6496-453b-beb9-76e3514ed534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a1033bd7-dfcc-4e46-b61c-7521a50f2305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_06a89b0d-46d1-4a51-939b-a06edc10c59b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b65933e-d17e-4f72-8dde-db3186b43c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9ef92338-838e-468e-a513-56d2d714ed59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_80adbfa4-77b0-4c43-8085-8ee94b655983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_eb5073c6-93d6-4f52-8309-895c393ef41f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_5baaaa87-fae6-4ea1-8c7f-c6624c122de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_a197803e-4cdd-43c1-9127-6f070156a3c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="C_a379388d-c2de-4807-a894-cff2e4a56b6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_12ff06ef-947f-4808-a33d-0ff97573bdf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8f3c4803-a059-4ebb-ae2b-4ac87f86d07d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc66556d-71cc-4a9b-ab52-0e7d6815bf7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_bd00d5a3-324d-497b-a8e2-82db2e6edc2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_4f29e181-ea6c-400a-8ba7-6bea7dba7a7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_50f28a60-d008-4a0e-9e96-e1ccac671344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_43cb099f-cefc-4cc9-beab-28440d03eebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_c5046514-fcb5-4d24-b1c8-fa4729ff4c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sana:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1e125326-33fa-46ec-a521-b916a2ec4dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sana:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_643555c3-2807-4634-8e1c-203532b68dd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_928be825-e134-4309-ace3-ac7914760235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3e731ce1-98f4-4819-a7ad-0f95050b9b55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0b0fcd89-81c1-4b90-a9c4-cb1922157bbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e48bacc4-19a5-4b6d-bd4a-f5ea9f59378a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:MrHardyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">sana:Rule10B51TradingPlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b931ac74-0689-4fcf-9fd6-7716f8afe0a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_9b2f8dd4-c615-4c6b-b326-f49621a6eb03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_70cd5777-3e29-4131-aad9-ba09ce7c693d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_641277e3-749d-4eb9-a24e-d5fc027e6183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sana:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7de50755-31cf-4120-a7ad-64811d98119c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a9d7d6d-eeb7-46e6-b7d4-e0b5c139fee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a51b0686-423c-43e8-94c5-8d8eb699f340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9fdca39a-64d6-45fd-a2b0-60576cb81cf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_b4ec08c5-443c-43d4-9292-a4247d9af712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sana:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1ccf1cdd-58e0-4408-a0fa-022aac193bde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sana:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0b964641-c572-4eb4-ad43-aaa271ec731c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeLaboratoryAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sana:BothellWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_dfd47a7d-8c14-4eb8-8032-56ab21cc27b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9ef25fb2-65c6-460a-a441-dd847f65b914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_586b0056-75c6-4ab5-8d42-c2f9ab46e617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c12ea39b-aeb0-4f12-b248-2e617e0f6530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a16970d7-1af4-4067-88b3-324a3854a541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sana:NathanHardyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="C_1df77845-a1de-4f4e-81f7-0609b3956c1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e53ea5e6-c436-4396-b07d-aa29105b61ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_25947cd9-a663-4cab-b957-bc7138703866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88402e74-7150-43da-a733-2aff3a7e03cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12fdc9e8-0ca8-4874-b926-71ede412b36f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_4650afc1-9af0-49d7-a045-02b7cc48e08a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:LongTermFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4a1f55ec-17f1-42c1-b4cf-309cd1fd5eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e1998177-1c58-4e27-be53-21c13d9ca1d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f0806d70-bf3c-4907-8e95-1d6b45653b32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_25788be5-71c6-4519-9446-0a103addacb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17283059-11e9-44c9-8c95-9b47afc70185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7ec8e97a-eeb9-43b9-a3d4-79634fa4152c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_dfdf28a6-c13c-4877-a638-bd86f15aca04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">sana:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fb2f913c-2539-43df-900b-bd15d965ab34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:HarvardCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sana:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_fec33127-b46e-468d-bbde-9835085b612c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">sana:CobaltContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_70a725dd-e57a-4033-8f99-adf5043341f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sana:CobaltBiomedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sana:MarketCapitalizationTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_ae90f9dc-f66e-4ca7-9990-7e8b027d5fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sana:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_65e2a512-f26e-46ac-8ba3-43bba960b76f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sana:BeamTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_6118355a-f762-4887-9f8b-16f2afbc5567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94d2ec2c-37d2-474c-abc6-bc8a607c98a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_bad0c086-6e01-4d43-9445-ceaacc421516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:HarvardSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5d2713f5-18c1-46f4-a590-7d2440ecea25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:CobaltSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1c1f3354-a6f1-4f78-9017-287f0a19140e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">sana:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_03b3791a-af07-4998-800e-8084e61f8a12">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_06f5dfe0-bd7e-472d-b74d-02623451c999">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_e07fcceb-2d04-43f0-bf54-bc5fa7bd2e81">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_dd90f8af-8f09-48bf-8318-19f8252188a3">0001770121</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      id="F_89418f0f-6984-4348-b8ec-9c99d5c63b1a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      id="F_0d6428fa-d4da-42b6-8df5-341dae7d687e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      id="F_c6d507a7-6a7d-44db-b8c6-e6984e181cbc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      id="F_76611905-94cf-4a23-a199-66b620c77ee6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_1ede2c8d-756e-40dc-8c8a-ee6a66e7752d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_53a20183-aca1-42fc-96ad-318f0bd6815c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_323d185e-d271-4dc5-8663-9340bef4638d">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_fa7333e1-1be7-4c77-9841-cd36b0d7d1ec">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_b38b945b-7d1f-413d-87af-402c1f5e8491">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_d4a8171d-0e81-43cd-8bd9-d9d44c3be49e">001-39941</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_ca645344-af45-4842-93a0-1d7937bacdf9">Sana Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_fb1820b6-55a7-4b87-aa4c-26bcaeb004d3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_de92aece-ba39-4d0b-88e9-af8d8b5c509d">83-1381173</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_37bd5347-37ec-4303-ab8e-e709ba817645">188 East Blaine Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_d1861d24-9553-44a4-9525-be4bad843074">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_15bfb468-fb94-4910-b80c-41bbb49f1077">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_1ab40ed1-4daa-431c-b73f-3cfa38155d13">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_c0518b9b-f777-473e-b351-5b168704c49e">98102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_ec43f76d-50e4-46b8-9d98-64df478257b9">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_4634815b-ff16-46c7-be9f-919e9581ff9a">701-7914</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_7786d7ac-5ac9-47b1-8154-d4dcf0235b7b">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_bc3706f1-5edc-49ca-9c4d-079ed9b24de8">SANA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_7e807241-31a0-459e-9e91-c76283cc2353">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_65110dfa-4c37-42bf-9f98-281ce9643de6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_2620dae0-ee24-408c-ba89-22aef5ab3d1f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_e7845687-e7e5-477f-9cb5-a71ee1ea780b">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_8ce8518a-89c5-41fd-922d-d11fe5c704af">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_a596f406-937d-46ba-80ee-abbcfc6e4165">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_1f9a07dc-a942-417a-8799-54aa8728cf7e">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_7755ccde-eea3-4447-bfe7-52aceb405538">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_91e4e70f-95ff-409e-9dca-3d8f020d91b0"
      decimals="INF"
      id="F_85e2e2fb-b472-47c8-8c5e-96e65682e8b9"
      unitRef="U_shares">221502908</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_53c17e3e-475a-469d-b972-6afcfaa93949"
      unitRef="U_USD">177054000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_1b5abbaf-1d9d-4315-bb97-5e5a2d1cb6b7"
      unitRef="U_USD">133517000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_5c8c09c8-c191-4f82-a637-ac8e3775f819"
      unitRef="U_USD">134028000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_3eb53fe4-924f-4a21-a76b-079b7d7ef0fc"
      unitRef="U_USD">71678000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_b78548a1-9f81-4a63-9181-7ec0a8fee7f8"
      unitRef="U_USD">3832000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_ebc6ea81-a7c1-4686-8d6b-5433925999b3"
      unitRef="U_USD">3832000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_ad8af7ab-564d-4d52-842b-d837124dac8c"
      unitRef="U_USD">6349000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_0ca36da6-4fce-4ab8-b64c-c919d5db3dd9"
      unitRef="U_USD">4488000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_3f7d16da-3e9c-44a1-a3c7-2f0415177cea"
      unitRef="U_USD">321263000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_ae69d7a8-e86f-43ce-9750-3c02685fb23c"
      unitRef="U_USD">213515000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_2b301c4e-1abd-4a9b-a435-b3f46162a12b"
      unitRef="U_USD">81649000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_584c370c-8184-4e92-9df7-8a4d421a6d5a"
      unitRef="U_USD">70689000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_8a89ccc9-f7ed-49cd-9dad-642c4ec65974"
      unitRef="U_USD">71565000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_7f34448d-1dc6-4fd3-8a0d-c9f7693b52b2"
      unitRef="U_USD">74903000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_754c02ef-b905-4dec-8f44-75c7c034ccf1"
      unitRef="U_USD">59195000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_4d80183a-72d1-4d61-885a-d8f8c0dd64a6"
      unitRef="U_USD">59195000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_e341bd40-5808-4e58-9151-4939295e8a55"
      unitRef="U_USD">140627000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_6ecbf232-29b1-4e98-8b73-8ce672bd989e"
      unitRef="U_USD">140627000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_17e1f16d-e9d9-409d-8178-47a1b859baaa"
      unitRef="U_USD">7078000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_ff6f362f-03a8-4a5a-837a-2bc283c28a6b"
      unitRef="U_USD">6370000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_d0a2bb30-5d36-43e3-a7ab-ef0c1776c57e"
      unitRef="U_USD">681377000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_4b255846-20fe-4bd3-85e8-7fc1c3444c0d"
      unitRef="U_USD">565299000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_2cab6506-adf6-4ecc-b9aa-4c1c30c59b6b"
      unitRef="U_USD">6095000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_5776d78f-b9d1-46b4-ab0e-b0a28821f6f1"
      unitRef="U_USD">4108000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_d879e358-6081-472a-a72e-fdfe8d2a194a"
      unitRef="U_USD">13965000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_114ae177-b2cb-45e7-ab8e-4d6346206571"
      unitRef="U_USD">23722000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_f086dc00-2346-4e2f-bdae-3cec7b3a6389"
      unitRef="U_USD">19674000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_3932d3ad-b554-4f99-909c-98b5f8f7069e"
      unitRef="U_USD">23462000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_11bebba3-c5aa-424b-9195-585a6c6510b4"
      unitRef="U_USD">13167000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_044825fb-e278-4e05-a975-40b0bba297ac"
      unitRef="U_USD">13195000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_5be915f3-8249-4646-b59f-86a2b692a7ae"
      unitRef="U_USD">52901000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_27722f3e-6325-47d1-912e-31675d137bdb"
      unitRef="U_USD">64487000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_77441a53-4d61-4639-aab0-4555192605ed"
      unitRef="U_USD">92922000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_5d3278d0-d2aa-4e06-938f-646df1793c3d"
      unitRef="U_USD">90901000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_c87c608d-c0a2-43fc-a432-aeda4b47102f"
      unitRef="U_USD">114990000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_a621436b-4744-470a-8fd2-3e54dc360d2d"
      unitRef="U_USD">109606000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <sana:SuccessPaymentLiabilitiesNoncurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_e4baff81-0d84-4912-b151-d7798ba015a1"
      unitRef="U_USD">45422000</sana:SuccessPaymentLiabilitiesNoncurrent>
    <sana:SuccessPaymentLiabilitiesNoncurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_78978f6d-f6fb-4c6a-97df-3033a27227c5"
      unitRef="U_USD">12799000</sana:SuccessPaymentLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_00c4f4bf-dfb2-47c6-97be-69d561401015"
      unitRef="U_USD">306235000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_96284bf2-b58c-4957-9386-6bf1671478ea"
      unitRef="U_USD">277793000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="INF"
      id="F_50c7c6c2-3287-4368-b4b4-81687e83610d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="INF"
      id="F_893f503b-b705-4d44-b399-2ef95bb168b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="INF"
      id="F_d71344d8-a889-418c-9389-7f9903c56947"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="INF"
      id="F_bc6d6d16-5e39-4f58-9c57-c110a1ad9cf5"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_1deb4767-931e-4a36-978b-3a82f0c9feb6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_d7027eab-50ef-4af6-b935-0ef636ececa5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_082f62d3-5782-4cc9-9924-ec025842dc3f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_decd702e-76fd-4937-97a8-8e61b11a07c7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="INF"
      id="F_928c76cb-fa0b-4001-859f-c5bd78a3aba2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="INF"
      id="F_03d2e8cd-fce9-4726-865b-25a7093cf3d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="INF"
      id="F_082662f6-c08b-45e8-a599-7fe80b52a771"
      unitRef="U_shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="INF"
      id="F_4d6a6f44-fc6c-4ff9-8edc-edbaae84b5c1"
      unitRef="U_shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_515cd990-c564-44d2-a7c8-6c207fea5f09"
      unitRef="U_shares">221286000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_ebf95dba-b7a5-44ce-864b-a5504979bf2e"
      unitRef="U_shares">221286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_47a650a2-874b-4aec-810f-7710554cfbe9"
      unitRef="U_shares">197857000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_056948e1-4cad-4616-a5f7-10f4f2094db0"
      unitRef="U_shares">197857000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_1d42ee6f-6136-44a5-b3fc-7ba411272f13"
      unitRef="U_USD">22000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_944217ce-a4f3-4a1f-83c5-d6dd0708475e"
      unitRef="U_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_eb05ad87-ff5e-4193-92e4-340ff894fff9"
      unitRef="U_USD">1820701000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_05b420e9-d81b-407a-ba7e-f36ea2fa0a0a"
      unitRef="U_USD">1625637000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_cbea4d00-18f5-4e0c-8ad0-346c2ba8c2a8"
      unitRef="U_USD">-15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_86152fa0-6ebf-4986-85d6-b5a7f74bb764"
      unitRef="U_USD">-60000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_28b1cb26-7f44-478a-9859-f9aa4bc13e42"
      unitRef="U_USD">-1445566000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_3bf1a3e7-d7bf-4b09-8535-1c4277748ca3"
      unitRef="U_USD">-1338091000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_421ab790-3a6e-4530-b85f-487de2e329f0"
      unitRef="U_USD">375142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_3876553a-ce6a-44f3-aa11-5dce4babc29f"
      unitRef="U_USD">287506000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_cfef2d73-b435-49ca-9eb2-665b7f6f6447"
      unitRef="U_USD">681377000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_e17a9de6-e7b8-49e0-9542-2684ece63869"
      unitRef="U_USD">565299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_4c57f2af-8fb4-4c40-a3ee-b70f7cd460cc"
      unitRef="U_USD">56448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_086a84ae-58fc-4c50-ad46-da70d1a71e73"
      unitRef="U_USD">67166000</us-gaap:ResearchAndDevelopmentExpense>
    <sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_f2e53b67-5d52-44e8-bc4f-03865ce2a25c"
      unitRef="U_USD">38007000</sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration>
    <sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_e579455d-6e32-47a7-8a0e-f2288e0f5d84"
      unitRef="U_USD">120000</sana:ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_a70203dd-b82f-44cc-95d6-617e3c31bda7"
      unitRef="U_USD">16269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_ae8a2fd9-01dd-46fc-85f8-c62826f44a35"
      unitRef="U_USD">16766000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_a5569b1a-64a3-4b78-8505-f1b5ba40a241"
      unitRef="U_USD">110724000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_be52b09a-f413-4994-8324-430944dc4f8e"
      unitRef="U_USD">84052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_960d1734-1465-4b37-a3b5-9a3ff0249ddd"
      unitRef="U_USD">-110724000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_8fc08c65-c8c5-45e6-bae9-d78d1126c996"
      unitRef="U_USD">-84052000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_717639fb-b43a-4a77-a74a-28de57cbb8d7"
      unitRef="U_USD">3034000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_dd0f8121-6c31-43dc-8894-c65338d319af"
      unitRef="U_USD">1976000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_2a5d5bb9-922f-46f2-9044-6616bba7b4a5"
      unitRef="U_USD">215000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_ad0385ea-58b3-45e5-8ed9-359c9617b25f"
      unitRef="U_USD">-47000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_7e92cf91-1104-469f-baed-3ce20370ecbb"
      unitRef="U_USD">-107475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_79e0efef-7080-42fd-8827-c926eb3ec731"
      unitRef="U_USD">-82123000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_06a00c5d-1d85-488e-b79c-8295f4a5e5f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_0c040662-7ef4-4f8b-b137-5ad17d72ea95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="2"
      id="F_d627e4b3-1845-47c1-a824-9cc25ba16198"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="2"
      id="F_1a6e4c64-a02e-4d09-94c8-46f9e9ec9245"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_3b1b7768-da41-4817-a57d-6ae380a8ae57"
      unitRef="U_shares">217290000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_c9fd1bf8-1120-4488-b819-e2021a4c158e"
      unitRef="U_shares">217290000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_cd03d08e-7720-4a8c-86da-9bd42af54740"
      unitRef="U_shares">191228000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_bef0dab7-4f5b-4459-ab5a-2c6ca754da5d"
      unitRef="U_shares">191228000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_79fc240c-9fb3-471b-a488-0495fc2043a8"
      unitRef="U_USD">-107475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_a804fa7c-20e6-4e47-b2b2-41dd142b095b"
      unitRef="U_USD">-82123000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_2bef461a-f177-43b3-89df-f395ba44fce2"
      unitRef="U_USD">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_7a71e55c-ba28-485d-85be-025ddb5ba507"
      unitRef="U_USD">2188000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_3560b61f-06cc-437c-9fa8-5be45ea0f4cd"
      unitRef="U_USD">-107430000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_05313b80-f74c-4170-8f9d-6254638ce8a7"
      unitRef="U_USD">-79935000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7474455a-fc6d-4cd3-90d2-70280da1b89f"
      decimals="-3"
      id="F_a586d17d-36c3-4347-8c26-832692be3774"
      unitRef="U_shares">197857000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7474455a-fc6d-4cd3-90d2-70280da1b89f"
      decimals="-3"
      id="F_fab2b8fa-a3f5-415a-852f-f68d5ef4513b"
      unitRef="U_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2cc9980e-3cae-4e1d-8847-36113c44cfb5"
      decimals="-3"
      id="F_894ee2ee-396e-427f-9fa1-4e72a981a53b"
      unitRef="U_USD">1625637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_34f78daa-46b2-4c59-83f1-782cdc0c0849"
      decimals="-3"
      id="F_799b79e1-bffb-4731-873b-a2655f019e72"
      unitRef="U_USD">-60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9ef92338-838e-468e-a513-56d2d714ed59"
      decimals="-3"
      id="F_9ae9eaff-c684-4e32-bb88-fad93ffe0b78"
      unitRef="U_USD">-1338091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_2b013ffd-2225-4c00-a380-6cbe131490ba"
      unitRef="U_USD">287506000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495"
      decimals="-3"
      id="F_edaf6df8-b7b9-47ee-922c-b98cf511f8e1"
      unitRef="U_USD">113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6091c139-f87a-4c94-9bf8-6b84025b7ad0"
      decimals="-3"
      id="F_c9e6fbc3-6742-4e65-854f-1c11346c0586"
      unitRef="U_shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9c74da5e-db6b-4240-81f6-b1cc19323032"
      decimals="-3"
      id="F_5ca5fcf7-0f86-47d8-83fa-6c49c4fcb642"
      unitRef="U_USD">1037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8ab6bb89-d0fa-44eb-aff4-0bfc8ebc4495"
      decimals="-3"
      id="F_98c5026f-3709-4c09-bf89-397df73cc121"
      unitRef="U_USD">1037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_4f29e181-ea6c-400a-8ba7-6bea7dba7a7f"
      decimals="-3"
      id="F_ac055fb9-2d28-4054-a137-76e608382c62"
      unitRef="U_USD">9741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e"
      decimals="-3"
      id="F_4dd1f496-6527-4a9a-8f90-75b5e9519fc6"
      unitRef="U_shares">21773000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e"
      decimals="-3"
      id="F_a54aff0c-cdd2-4ac3-9125-5e83d1cc3b49"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3855180a-7d90-426b-9874-03499729f15a"
      decimals="-3"
      id="F_0df6390b-cfb8-4db1-96a9-882e835aba21"
      unitRef="U_USD">180006000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_f2eeab11-9d67-4033-b058-b83469e0382b"
      unitRef="U_USD">180008000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e"
      decimals="-3"
      id="F_ce386e64-982f-4fce-9fd6-2d5542827212"
      unitRef="U_shares">386000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d7611f40-5b1f-46ae-8564-b1292748318e"
      decimals="-3"
      id="F_ca448d7e-d61c-46d5-a3c6-53b5aa263464"
      unitRef="U_shares">1120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3855180a-7d90-426b-9874-03499729f15a"
      decimals="-3"
      id="F_973e129c-341b-42b6-86e1-2fbbb49d4c73"
      unitRef="U_USD">4929000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_b233d0c1-3b08-4158-ade4-961a761033ee"
      unitRef="U_USD">4929000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3855180a-7d90-426b-9874-03499729f15a"
      decimals="-3"
      id="F_37e1f731-3898-4010-81b7-7aca351cb971"
      unitRef="U_USD">9092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_41c28b30-f544-4f0d-9656-eb473a747263"
      unitRef="U_USD">9092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_50195858-336e-4ba8-93a6-442d74800d39"
      decimals="-3"
      id="F_43b9eef7-28cb-419d-8684-a4e2a200e6bb"
      unitRef="U_USD">45000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_6c74c197-a61d-4cc8-ab65-348bcb049909"
      unitRef="U_USD">45000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b964641-c572-4eb4-ad43-aaa271ec731c"
      decimals="-3"
      id="F_aae59333-aff3-427d-bbd7-9aaab9107ffa"
      unitRef="U_USD">-107475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_8d8f2eb8-3de6-461b-95a9-33177502ff00"
      unitRef="U_USD">-107475000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd"
      decimals="-3"
      id="F_110faeb5-d8aa-41d9-af21-383aa79ff1a1"
      unitRef="U_shares">221286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_de0b0267-e232-4cd8-a74c-3ba26f83bedd"
      decimals="-3"
      id="F_c2cd3578-40f8-4f14-b5de-90fa980bbff8"
      unitRef="U_USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a9d7d6d-eeb7-46e6-b7d4-e0b5c139fee0"
      decimals="-3"
      id="F_f09c9a88-e2ae-43b2-a277-cfeb2310dcba"
      unitRef="U_USD">1820701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d058c627-dfd8-4eb4-89d4-e773af8d23b4"
      decimals="-3"
      id="F_0063670f-1edd-4325-9583-2447802a771a"
      unitRef="U_USD">-15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_12ff06ef-947f-4808-a33d-0ff97573bdf9"
      decimals="-3"
      id="F_b2b9a6c3-f285-4a59-8dda-b62f58f40c24"
      unitRef="U_USD">-1445566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_93aa2dff-fd23-44ba-b58a-d49c190ec8c7"
      unitRef="U_USD">375142000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4600a476-bff3-4417-9572-0fce0dfac06c"
      decimals="-3"
      id="F_0b24f823-fd56-450f-80d2-ecfb04ed3179"
      unitRef="U_shares">191022000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4600a476-bff3-4417-9572-0fce0dfac06c"
      decimals="-3"
      id="F_b4d7a17e-409d-4f5b-b92b-8b64cf652497"
      unitRef="U_USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70fd08ab-41b6-404e-b0b7-355ae3c53fbf"
      decimals="-3"
      id="F_6c4e875c-ed89-4a56-a703-681557477cf6"
      unitRef="U_USD">1558459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e2d83e1b-1262-4dec-b6d4-df0a5108f32b"
      decimals="-3"
      id="F_3e931f44-5850-4770-a854-61631330a5ca"
      unitRef="U_USD">-4327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50ec5c72-5617-4171-8d33-f4ac6315d6f5"
      decimals="-3"
      id="F_53f77737-e9ea-4891-984e-75c4acb7c4bf"
      unitRef="U_USD">-1054836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7135efce-efcb-4461-a247-176eda4a968d"
      decimals="-3"
      id="F_087b45e6-e680-4cfd-b2e5-9740d4022d9e"
      unitRef="U_USD">499315000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2"
      decimals="-3"
      id="F_f476bf7b-ff45-41cd-abf8-6ec61eede583"
      unitRef="U_USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_f2d2f21e-1837-450d-822d-92479f7e6b84"
      unitRef="U_USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7"
      decimals="-3"
      id="F_47fa6da4-7de1-49eb-b12b-81e656acaee3"
      unitRef="U_shares">154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c68255b0-d18e-4f5a-afe3-9b641ba752f7"
      decimals="-3"
      id="F_9ca3fe4f-c5fa-4b28-998b-4eafd7033705"
      unitRef="U_shares">233000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2"
      decimals="-3"
      id="F_4fdf0f60-d6a0-423b-81d2-b1bb6a66b129"
      unitRef="U_USD">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_e4ad866d-3cfc-4d95-a862-6fe158e68a36"
      unitRef="U_USD">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0d8d7cce-a911-4d25-ad6b-dcba0d1374b2"
      decimals="-3"
      id="F_9a620017-59dd-446a-938f-6092777b97bb"
      unitRef="U_USD">8751000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_cc18e823-60df-4ab6-bc47-8fb66aac2a45"
      unitRef="U_USD">8751000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_eb5073c6-93d6-4f52-8309-895c393ef41f"
      decimals="-3"
      id="F_a1cd6fd9-d684-48e6-9736-0cd16d3a47f4"
      unitRef="U_USD">2188000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_5c4aa1f5-818d-4a1b-b23c-624d3acc30c0"
      unitRef="U_USD">2188000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b0fcd89-81c1-4b90-a9c4-cb1922157bbb"
      decimals="-3"
      id="F_29a540d6-2250-4afa-8c54-d4646cc490f1"
      unitRef="U_USD">-82123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_f2a4bf33-c270-4ae7-9fe3-178a91c2172b"
      unitRef="U_USD">-82123000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3b656889-79bb-4672-bcb3-fd154c164adf"
      decimals="-3"
      id="F_c255f73f-4928-41d2-8deb-3b4b41fcb551"
      unitRef="U_shares">191409000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3b656889-79bb-4672-bcb3-fd154c164adf"
      decimals="-3"
      id="F_673b9a12-9f86-418d-b3ae-4e83ec52fa9f"
      unitRef="U_USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a6da32b5-4e8e-4f22-b11e-b496dd2352a2"
      decimals="-3"
      id="F_51a4fa71-f01f-4407-b3be-41c3c1ef4bad"
      unitRef="U_USD">1567341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bc66556d-71cc-4a9b-ab52-0e7d6815bf7c"
      decimals="-3"
      id="F_f5dccf6e-91f1-4c6f-9a89-bc17c825fabb"
      unitRef="U_USD">-2139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_68a01da0-f0b5-45cd-b4fe-aae17edbf123"
      decimals="-3"
      id="F_29d0f388-d236-40ef-bfca-b02b1d1f5871"
      unitRef="U_USD">-1136959000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d"
      decimals="-3"
      id="F_cf45b6bd-f3b3-42c6-9846-01a74bedc5b9"
      unitRef="U_USD">428262000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_0ca72e03-fccd-497f-93c0-85b1b77dee9b"
      unitRef="U_USD">-107475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_c487d193-a03e-421b-96e5-973210281719"
      unitRef="U_USD">-82123000</us-gaap:ProfitLoss>
    <sana:DepreciationAndImpairmentOfLongLivedAssets
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_3338d0d9-58b9-4046-97d0-7858c5810632"
      unitRef="U_USD">3746000</sana:DepreciationAndImpairmentOfLongLivedAssets>
    <sana:DepreciationAndImpairmentOfLongLivedAssets
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_312f29b5-b1f6-4a6c-8a4a-fa250359943e"
      unitRef="U_USD">4346000</sana:DepreciationAndImpairmentOfLongLivedAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_12c1ab98-788e-4ca8-b76b-123d81deeea5"
      unitRef="U_USD">9092000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_5353b4f5-afae-482c-a81d-b8b81c17c693"
      unitRef="U_USD">8751000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_70f11d6b-7b3d-4947-bbab-17a63a270713"
      unitRef="U_USD">5384000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_49879107-7928-4c0d-a18f-e0ad21417bb2"
      unitRef="U_USD">5460000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <sana:ChangeInFairValueOfSuccessPaymentLiabilities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_07f63c25-0446-4f6d-9ddb-648f1a77c724"
      unitRef="U_USD">32623000</sana:ChangeInFairValueOfSuccessPaymentLiabilities>
    <sana:ChangeInFairValueOfSuccessPaymentLiabilities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_1cf1268c-0be0-41af-a036-a8d70b938c24"
      unitRef="U_USD">-5340000</sana:ChangeInFairValueOfSuccessPaymentLiabilities>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_95ce682f-7a36-4efb-9afc-e455fdfe0487"
      unitRef="U_USD">3338000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_6eb45cab-379a-42ac-9093-037f95f71c66"
      unitRef="U_USD">3354000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_019bfc5f-72d2-4de4-ba30-22a214a69f78"
      unitRef="U_USD">4879000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_d0efa6e2-2cae-4378-b2eb-6c11d86c3280"
      unitRef="U_USD">2913000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_f6ebe65d-15e8-466e-9020-c37ee2f0b962"
      unitRef="U_USD">2380000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_f59c29db-c7c6-49d7-8989-5b1fa4e38b3b"
      unitRef="U_USD">106000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_7d75109d-c6c2-4e21-9490-56d89ae98158"
      unitRef="U_USD">-5804000</sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_34e28ea3-f446-4a17-b0f2-feb26271d525"
      unitRef="U_USD">8000</sana:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_d0ad801b-fcc2-411e-b0bc-d8acbf8ac78b"
      unitRef="U_USD">-1064000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_7f43f9ce-09e6-4989-a046-8305c41f1d5c"
      unitRef="U_USD">-354000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_a2c9db16-3c37-40ea-8bb2-c0854dcfc13f"
      unitRef="U_USD">-9821000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_7081f2df-1c28-4843-8d78-41c38d441c88"
      unitRef="U_USD">-10339000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_95007e06-d987-4734-9e83-df6e2fa0c023"
      unitRef="U_USD">-65632000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_6f6143dd-7bb4-49d3-b8fc-c8248e83f3d6"
      unitRef="U_USD">-79272000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_19b55dad-55d2-4bf6-87d2-b51c4da19967"
      unitRef="U_USD">114393000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_7e2b0e83-79d3-42cf-aaaa-bb49074f71cd"
      unitRef="U_USD">20431000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_f24472c1-70be-4200-b6e8-28a8d23a6af3"
      unitRef="U_USD">53010000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_57e12ef9-7d84-4e63-b5fa-bc3b1bf585f6"
      unitRef="U_USD">85334000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_903585bb-5e72-4750-b6b7-52d14be41089"
      unitRef="U_USD">15845000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_f94ccf5a-0ff7-47c5-90bd-553f6702a22a"
      unitRef="U_USD">2176000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_06d32fcd-0b62-4f78-b65b-29b7731e1423"
      unitRef="U_USD">-77228000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_51f8bec1-9264-4707-aa48-bfbf13fdd8b3"
      unitRef="U_USD">62727000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_60e2b902-e528-4291-aa6f-a4a787465e98"
      unitRef="U_USD">4929000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_7f1dbce3-2424-41ad-94b6-da56917574f2"
      unitRef="U_USD">236000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <sana:ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_48e014cf-d4c7-4b3b-a01c-3d917cb68d8d"
      unitRef="U_USD">181468000</sana:ProceedsFromIssuanceOfCommonStockFromEquityFinancingsNet>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_c23cf31d-0054-41ad-8b6a-33dd13c72509"
      unitRef="U_USD">186397000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_a2541dd2-fc75-4ade-8f13-81b66b0f14b4"
      unitRef="U_USD">236000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_1953d698-7ebc-4a8f-abc8-30e1c3442a33"
      unitRef="U_USD">43537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_bed8ad88-25c1-428a-be40-bca263f833fb"
      unitRef="U_USD">-16309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_869eef38-c888-4d0a-b911-d7d6e55dc743"
      unitRef="U_USD">137349000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7135efce-efcb-4461-a247-176eda4a968d"
      decimals="-3"
      id="F_c028e25c-55af-46ee-93a4-356fdac645b4"
      unitRef="U_USD">187273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_fabf3876-e407-46e0-ad28-592ee44e34e2"
      unitRef="U_USD">180886000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c75aafa0-70be-460e-88a9-9fc3d2f1a68d"
      decimals="-3"
      id="F_8f67effa-584b-4336-aa86-1bbf266826ec"
      unitRef="U_USD">170964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_f0090257-9d6d-4d01-bd0d-75362e3c057a"
      unitRef="U_USD">8984000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_6f0d4ddb-9080-45b2-8d3e-91ed983100b5"
      unitRef="U_USD">8375000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_60177e28-8aed-490c-91f5-1b561c7172f7"
      unitRef="U_USD">968000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <sana:CashReceivedForTenantImprovementAllowances
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_47e436ac-a208-470d-88ac-df4baa763c71"
      unitRef="U_USD">6121000</sana:CashReceivedForTenantImprovementAllowances>
    <us-gaap:NatureOfOperations
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_af4b53e3-3a56-46f4-9a8b-6c23113ef649">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sana Biotechnology, Inc. (the Company or Sana) is a biotechnology company focusing on utilizing engineered cells as medicines. The Company&#x2019;s operations to date have included identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, preparing for and executing clinical trials of its product candidates and supporting clinical trials of product candidates developed using its technologies, acquiring technology, organizing and staffing the Company, business planning, establishing and maintaining the Company&#x2019;s intellectual property portfolio, raising capital, and providing general and administrative support for these operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and capital resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to a number of risks and uncertainties similar to other biotechnology companies in the development stage, including, but not limited to, those related to the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, building out internal and external manufacturing capabilities, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products, the need to protect the Company&#x2019;s intellectual property and proprietary technologies, and the need to attract and retain key scientific and management personnel. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations with the proceeds from additional equity or debt financings or capital obtained in connection with strategic collaborations or licensing or other arrangements. In the event that additional financing is required, the Company may not be able to raise it on terms acceptable to it or at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company completed an underwritten public offering pursuant to which it sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of its common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2022, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), acting as sales agent, pursuant to which it may offer and sell through Cowen up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of the Company&#x2019;s common stock from time to time in a series of one or more at the market equity offerings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(collectively, the ATM facility). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the Company has sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of the Company's common stock under the ATM facility for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting commissions and expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred operating losses each year since inception and expects such losses to continue for the foreseeable future. As of March 31, 2024, the Company had cash, cash equivalents, and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, which includes cumulative non-cash charges related to the revaluation of the success payment liabilities and contingent consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_641277e3-749d-4eb9-a24e-d5fc027e6183"
      decimals="-5"
      id="F_08cf3f95-f30e-4501-9ecf-ebeae320c3f0"
      unitRef="U_shares">21800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_18571269-31c5-4f70-a45a-3ef776d6eb61"
      decimals="-5"
      id="F_ccd05363-ad8e-4a05-9749-2dd63bef6e8e"
      unitRef="U_shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_55131829-499c-4826-bd23-4f67ee1ace9e"
      decimals="-5"
      id="F_23003e58-667c-455f-843e-2c5aa7dfcc8f"
      unitRef="U_shares">12700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_43cb099f-cefc-4cc9-beab-28440d03eebf"
      decimals="-5"
      id="F_e5c76193-6abb-45f4-a1f9-0f19d042e23f"
      unitRef="U_USD">180000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sana:CommonStockMaximumOfferingAmount
      contextRef="C_643555c3-2807-4634-8e1c-203532b68dd5"
      decimals="INF"
      id="F_e1c0a772-0a61-4035-a43f-4450e906e654"
      unitRef="U_USD">150000000</sana:CommonStockMaximumOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08"
      decimals="-5"
      id="F_13a9b362-1622-4d30-9a95-8e5859f07c69"
      unitRef="U_shares">4900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08"
      decimals="-5"
      id="F_f956a0e7-9443-4047-9a15-19ab5fcf731c"
      unitRef="U_USD">28700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:InvestmentsAndCash
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-5"
      id="F_374bc4d5-6bb5-4380-86b5-df44375ef10a"
      unitRef="U_USD">311100000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-8"
      id="F_fd9b3963-439f-4d8b-a34c-30d6710c6070"
      unitRef="U_USD">-1400000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <sana:SuccessPaymentLiabilities
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-5"
      id="F_00761bfe-018b-49b5-84e7-8fa77e2d6722"
      unitRef="U_USD">43000000</sana:SuccessPaymentLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-5"
      id="F_af2b6ee2-5d4a-4c30-a8a4-79a141f23903"
      unitRef="U_USD">63700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_fa5c64ef-77eb-41bb-8c3f-2e69c8c88e12">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of significant accounting policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 29, 2024 (2023 Annual Report).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Significant accounting policies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies used in the preparation of these condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 are consistent with those discussed in Note 2 in the 2023 Annual Report.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, and operating lease right-of-use assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures that requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU is effective for the Company's fiscal year 2025. Early adoption is permitted. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_cfad2021-4a03-407c-a82f-ce2ff0b61158">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 29, 2024 (2023 Annual Report).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <sana:SignificantAccountingPoliciesPolicyTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_fbf6bf23-277e-4ca8-a4ad-de7ba20a4cf8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Significant accounting policies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies used in the preparation of these condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 are consistent with those discussed in Note 2 in the 2023 Annual Report.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sana:SignificantAccountingPoliciesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_20abdb1a-75e6-4909-b748-cefc10ad8d3e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, and operating lease right-of-use assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_78db7f19-cecd-4529-8b72-d4c60185b0d5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures that requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU is effective for the Company's fiscal year 2025. Early adoption is permitted. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_855c8e2a-27fc-4fd8-a168-877a38cef2a1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Acquisitions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cobalt Biomedicine, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2019, the Company acquired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding equity of Cobalt Biomedicine, Inc. (Cobalt), a privately held early-stage biotechnology company developing a platform technology using its fusogen technology to specifically and consistently deliver various biological payloads to cells (the Cobalt acquisition).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the Cobalt acquisition, the Company recorded an intangible asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which consists of in-process research and development that is classified as indefinite-lived until the successful completion of the associated research and development technology, at which point it becomes a finite-lived asset and will be amortized over its estimated useful life. If the research and development technology is abandoned, an impairment charge will be recorded. The Company is actively developing the fusogen technology and, accordingly, the intangible asset is not complete. Amortization will begin when regulatory approval of a product candidate developed using the fusogen technology is obtained in a major market, typically either the United States or the European Union.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of goodwill as a result of the Cobalt acquisition, which is primarily attributable to the value the acquisition provides the Company by complementing the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; portfolio with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; fusogen cell engineering technology and furthering the Company&#x2019;s research in using engineered cells as medicines. The goodwill is not deductible for income tax purposes. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments of the intangible asset or goodwill since the acquisition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the terms and conditions in the Cobalt acquisition agreement, the Company has an obligation to pay to certain former Cobalt stockholders contingent consideration (Cobalt Contingent Consideration) of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of certain specified development milestones and a success payment (Cobalt Success Payment) of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, each of which is payable in cash or stock. The Cobalt Success Payment is payable if, at pre-determined valuation measurement dates, the Company&#x2019;s market capitalization equals or exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, and the Company is advancing a program based on the fusogen technology in a clinical trial pursuant to an investigational new drug (IND) application, or has filed, or received approval for, a biologics license application or new drug application for a product developed using the fusogen technology. The Cobalt Success Payment can be achieved over a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the date of the acquisition, but this period could be shorter upon the occurrence of certain events. A valuation measurement date would also be triggered upon a change of control of the Company if at least one of the Company&#x2019;s programs based on the fusogen technology is an active research program at the time of such change of control. If the Company&#x2019;s market capitalization is below $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion as of the date of a change of control, the amount of the potential Cobalt Success Payment will decrease, and the amount of potential Cobalt Contingent Consideration will increase. As of March 31, 2024, a Cobalt Success Payment had not been triggered.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth various thresholds for the Company&#x2019;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.887%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Sana market capitalization upon a change of control and resulting impact to Cobalt Success&lt;br/&gt;Payment and additional potential Cobalt Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt Success&lt;br/&gt;Payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Additional&lt;br/&gt;potential Cobalt&lt;br/&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion, but less than $8.1 billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion, but less than $7.4 billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less than $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Cobalt Success Payment and Cobalt Contingent Consideration liabilities are carried at fair value, with changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Success Payment liability was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Success Payment, the Company recognized an expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and a gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024 and December 31, 2023, the estimated fair value of the Cobalt Contingent Consideration was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Cobalt Contingent Consideration, the Company recognized expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5"
      decimals="INF"
      id="F_1a775300-6b77-4728-8fe5-71f501f21618"
      unitRef="U_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_29744a16-e164-4459-bf1b-bc4cbfe6916d"
      decimals="-5"
      id="F_7100acfa-0b69-47c7-9440-401f3dc18b6c"
      unitRef="U_USD">59200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="C_ec49a133-cfe9-4f3d-9b5e-fff07bcd1ba5"
      decimals="-5"
      id="F_159810e0-be69-4f5e-9eca-957e61087ea1"
      unitRef="U_USD">140600000</us-gaap:Goodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d"
      decimals="INF"
      id="F_33110ebc-84ef-4156-af47-bee7d34f8ef3"
      unitRef="U_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <sana:MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones
      contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d"
      decimals="INF"
      id="F_77a523ca-af06-458b-bff0-1cfb340095c7"
      unitRef="U_USD">500000000.0</sana:MaximumContingentConsiderationUponAchievementOfCertainPreSpecifiedDevelopmentMilestones>
    <sana:MaximumPotentialSuccessPayments
      contextRef="C_3a337850-011f-419d-9b96-9745a28abc2f"
      decimals="-5"
      id="F_702dbac6-39c4-4051-9eef-64871108974a"
      unitRef="U_USD">500000000.0</sana:MaximumPotentialSuccessPayments>
    <sana:ThresholdMarketCapitalization
      contextRef="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e"
      decimals="INF"
      id="F_e45a0cc0-22e2-417f-9eba-693b2e48e16e"
      unitRef="U_USD">8100000000</sana:ThresholdMarketCapitalization>
    <sana:BusinessAcquisitionMaximumTermForSuccessPayment
      contextRef="C_dd9c3b1c-6453-46ab-85c1-051c526b1e0d"
      id="F_242abe60-c925-4ed9-b181-943ecdce42a2">P20Y</sana:BusinessAcquisitionMaximumTermForSuccessPayment>
    <sana:ThresholdMarketCapitalization
      contextRef="C_fafef7ce-5638-4834-9bcd-01b7dab7d03e"
      decimals="INF"
      id="F_2aeeca27-1e90-42c4-9592-f677b525ccbe"
      unitRef="U_USD">8100000000</sana:ThresholdMarketCapitalization>
    <sana:ScheduleOfMarketCapitalizationsTableTextBlock
      contextRef="C_bea2b4c5-cc6b-48f1-a2d0-ee8940a4e55f"
      id="F_2714ebe6-41c4-40ff-a8ae-9872d4b0aca3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth various thresholds for the Company&#x2019;s market capitalizations as of the date of a change of control and the resulting potential Cobalt Success Payment and additional potential Cobalt Contingent Consideration:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.887%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Sana market capitalization upon a change of control and resulting impact to Cobalt Success&lt;br/&gt;Payment and additional potential Cobalt Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt Success&lt;br/&gt;Payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Additional&lt;br/&gt;potential Cobalt&lt;br/&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion, but less than $8.1 billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equal to or exceeds $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion, but less than $7.4 billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less than $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;billion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sana:ScheduleOfMarketCapitalizationsTableTextBlock>
    <sana:ThresholdMarketCapitalization
      contextRef="C_ce5d2745-fdcb-4e7c-8c2b-84309b60bf11"
      decimals="-8"
      id="F_a6564e5f-7114-4cd6-858c-e5401916196f"
      unitRef="U_USD">8100000000</sana:ThresholdMarketCapitalization>
    <sana:PotentialSuccessPayment
      contextRef="C_e6ce25b6-c626-470d-b450-ff463c8d2c46"
      decimals="-6"
      id="F_6cf1e72a-02b9-4b52-bf44-ab3eea4d2a39"
      unitRef="U_USD">500000000</sana:PotentialSuccessPayment>
    <sana:ThresholdMarketCapitalization
      contextRef="C_42aa39ff-3900-4c5e-985b-ace73bd8d9af"
      decimals="-8"
      id="F_a49ff2e7-ca05-47b7-ada2-d01f0c333b2e"
      unitRef="U_USD">7400000000</sana:ThresholdMarketCapitalization>
    <sana:PotentialSuccessPayment
      contextRef="C_70a725dd-e57a-4033-8f99-adf5043341f3"
      decimals="-6"
      id="F_ede4c08f-8537-4224-bb13-08ac5a6fd8ad"
      unitRef="U_USD">150000000</sana:PotentialSuccessPayment>
    <sana:AdditionalPotentialContingentConsideration
      contextRef="C_c6027cc1-7afb-4fa9-88e4-4c01cce1cb2d"
      decimals="-6"
      id="F_44885445-83ef-4dc1-a138-aab6b1da3f88"
      unitRef="U_USD">350000000</sana:AdditionalPotentialContingentConsideration>
    <sana:ThresholdMarketCapitalization
      contextRef="C_cbe6df99-60ae-4f68-a843-401a8a497361"
      decimals="-8"
      id="F_daa40623-cc92-4db9-8cf5-cfde6f07f531"
      unitRef="U_USD">6800000000</sana:ThresholdMarketCapitalization>
    <sana:PotentialSuccessPayment
      contextRef="C_9cce18b1-5b05-469a-898d-954d3e894e00"
      decimals="-6"
      id="F_f4d93089-30f0-4943-929d-2f3fd8e6ae55"
      unitRef="U_USD">100000000</sana:PotentialSuccessPayment>
    <sana:AdditionalPotentialContingentConsideration
      contextRef="C_9fdca39a-64d6-45fd-a2b0-60576cb81cf0"
      decimals="-6"
      id="F_23e1af54-ba6c-43dc-8e92-622fbd832615"
      unitRef="U_USD">400000000</sana:AdditionalPotentialContingentConsideration>
    <sana:ThresholdMarketCapitalization
      contextRef="C_12fdc9e8-0ca8-4874-b926-71ede412b36f"
      decimals="-8"
      id="F_1d9fee9b-1c1c-426d-9469-8844783c2b36"
      unitRef="U_USD">6800000000</sana:ThresholdMarketCapitalization>
    <sana:AdditionalPotentialContingentConsideration
      contextRef="C_bd00d5a3-324d-497b-a8e2-82db2e6edc2b"
      decimals="-6"
      id="F_2de1a582-367c-4496-83a2-891567e53e41"
      unitRef="U_USD">500000000</sana:AdditionalPotentialContingentConsideration>
    <sana:EstimatedFairValueOfSuccessPaymentLiability
      contextRef="C_5a55ce09-f176-4fab-a2e9-e04a6400a283"
      decimals="-5"
      id="F_f6063f06-64d5-489a-bdaa-d7f33c96b55e"
      unitRef="U_USD">39100000</sana:EstimatedFairValueOfSuccessPaymentLiability>
    <sana:EstimatedFairValueOfSuccessPaymentLiability
      contextRef="C_8a8fc778-052c-4707-bdea-05eb75e7228d"
      decimals="-5"
      id="F_9a3c11b0-c0c6-49b4-ba59-e8032ccb1609"
      unitRef="U_USD">11200000</sana:EstimatedFairValueOfSuccessPaymentLiability>
    <sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities
      contextRef="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef"
      decimals="-5"
      id="F_36035de1-bafa-404d-95f0-5c060a70eb23"
      unitRef="U_USD">27900000</sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities>
    <sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities
      contextRef="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203"
      decimals="-5"
      id="F_d08241e3-752b-4f0f-801b-49d9f514547f"
      unitRef="U_USD">4800000</sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities>
    <sana:EstimatedFairValueOfContingentConsideration
      contextRef="C_49111c32-8c42-46ee-b4fc-28fe251ba44f"
      decimals="-5"
      id="F_1950e763-bcfb-4dd5-9399-d8dd5d2a5a2c"
      unitRef="U_USD">115000000.0</sana:EstimatedFairValueOfContingentConsideration>
    <sana:EstimatedFairValueOfContingentConsideration
      contextRef="C_3e731ce1-98f4-4819-a7ad-0f95050b9b55"
      decimals="-5"
      id="F_532f5651-6d64-47d6-89a5-cf7aa38e45b4"
      unitRef="U_USD">109600000</sana:EstimatedFairValueOfContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_5aba9b50-a3b8-471c-8cdb-6651eaf7b9ef"
      decimals="-5"
      id="F_b06722b4-8592-485c-bff4-45184667ab51"
      unitRef="U_USD">5400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_c9f2002a-aba0-4446-aeaf-a4d784cbb203"
      decimals="-5"
      id="F_2ee61d09-b593-4ceb-9b84-6c4994d001bf"
      unitRef="U_USD">5500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_6a3962f1-0eb4-43fa-a548-a7a09261591a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. License and collaboration agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Beam Therapeutics Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the Company entered into an option and license agreement with Beam Therapeutics Inc. (Beam), pursuant to which the Company was granted a non-exclusive license to use Beam&#x2019;s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products that (i) are directed to certain antigen targets, with respect to the Company&#x2019;s allogeneic T cell programs, or (ii) comprise certain human cell types, with respect to the Company&#x2019;s stem cell-derived programs. The Company made an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Beam, which was recorded in research and development expense for the year ended December 31, 2021. Additionally, under the terms of the agreement, the Company may be obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in specified developmental and commercial milestone payments and royalties on licensed products&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each licensed product. At the time of the entry into the option and license agreement, a member of the Company&#x2019;s board of directors was a beneficial owner of greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares of Beam. This director is also affiliated with a member of the board of directors of Beam.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;President and Fellows of Harvard College&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2019, the Company entered into an exclusive license agreement with the President and Fellows of Harvard College (Harvard) to access certain intellectual property for the development of hypoimmune-modified cells.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the agreement, the Company paid to Harvard aggregate consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, comprising $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash. Additionally, the Company may be required to pay to Harvard up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in success payments, payable in cash, based on increases in the fair value of the Company&#x2019;s common stock (Harvard Success Payments). The potential Harvard Success Payments are based on multiples of increased value ranging from 5x to 40x, based on a comparison of the fair market value of the Company&#x2019;s common stock relative to the original issuance price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share at ongoing pre-determined valuation measurement dates. The Harvard Success Payments can be achieved over a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the effective date of the agreement. If a higher success payment tier is first met at the same time a lower tier is first met, both tiers will be owed. Any previous success payments made to Harvard would be credited against the success payment owed as of any valuation measurement date so that Harvard does not receive multiple success payments in connection with the same threshold. As of March 31, 2024, a Harvard Success Payment had not been triggered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the potential success payments and common stock price required for payment:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Multiple of Equity Value at Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;5x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;10x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;20x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;30x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;40x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment(s) (in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Harvard Success Payment liabilities are carried at fair value, with the initial value and changes in fair value recognized in research and development related success payments and contingent consideration. As of March 31, 2024 and December 31, 2023, the estimated fair value of the Harvard Success Payment liability was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and was recorded in long-term liabilities. In connection with the change in the estimated fair value of the Harvard Success Payment liability, the Company recognized an expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and a gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2024 and 2023 respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sana:UpfrontPaymentToCollaborators
      contextRef="C_fe99b6ea-bd16-45cf-96dc-6c01fd8e050e"
      decimals="-5"
      id="F_b8d36da5-5ebc-4443-9f37-5a1e4a1149f8"
      unitRef="U_USD">50000000</sana:UpfrontPaymentToCollaborators>
    <sana:PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable
      contextRef="C_65e2a512-f26e-46ac-8ba3-43bba960b76f"
      decimals="-5"
      id="F_ef56406a-bf04-440d-a6ab-27a3f5e49915"
      unitRef="U_USD">65000000.0</sana:PotentialAmountOfMilestonePaymentsAndRoyaltiesPayable>
    <sana:BeneficialOwnershipPercentage
      contextRef="C_17283059-11e9-44c9-8c95-9b47afc70185"
      decimals="INF"
      id="F_e4d93890-d6b9-4c75-b5f2-548403860c83"
      unitRef="U_pure">0.10</sana:BeneficialOwnershipPercentage>
    <sana:TotalValueOfConsiderationPaidUnderLicenseAgreement
      contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983"
      decimals="-5"
      id="F_fbe18a0c-eb97-4099-b28c-04d74552d9c0"
      unitRef="U_USD">12000000.0</sana:TotalValueOfConsiderationPaidUnderLicenseAgreement>
    <sana:StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement
      contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983"
      decimals="-5"
      id="F_46ad2af4-0258-4d03-857c-872bc8abde1a"
      unitRef="U_USD">9000000.0</sana:StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement>
    <sana:PaymentToCollaborators
      contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983"
      decimals="-5"
      id="F_f6fa04e4-6e45-4d97-b34b-3896a9bbf32f"
      unitRef="U_USD">3000000.0</sana:PaymentToCollaborators>
    <sana:MaximumPotentialSuccessPayments
      contextRef="C_b931ac74-0689-4fcf-9fd6-7716f8afe0a5"
      decimals="INF"
      id="F_102a93ff-7241-4934-ae2b-1e0cea1371dd"
      unitRef="U_USD">175000000.0</sana:MaximumPotentialSuccessPayments>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cdc2c79f-6027-47c6-b3d8-4dec37b42493"
      decimals="INF"
      id="F_3697b1fe-5379-4c27-a826-3545390ae076"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.00</us-gaap:SharesIssuedPricePerShare>
    <sana:MaximumPeriodExpectedToAchieveForSuccessPayments
      contextRef="C_80adbfa4-77b0-4c43-8085-8ee94b655983"
      id="F_c53a4903-045f-49f3-80ac-11217a0ebd04">P12Y</sana:MaximumPeriodExpectedToAchieveForSuccessPayments>
    <sana:SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_3d21b129-5405-4646-bdab-6528bea0e6a1">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the potential success payments and common stock price required for payment:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Multiple of Equity Value at Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;5x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;10x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;20x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;30x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;40x&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment(s) (in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</sana:SummaryOfPotentialSuccessPaymentsHarvardTableTextBlock>
    <sana:CommonStockPricePerShareRequiredForPayment
      contextRef="C_d3ae50f3-372a-4d53-b386-1eaa80038130"
      decimals="INF"
      id="F_80d726c6-43d2-43ab-bf6e-608fc39bf5c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.00</sana:CommonStockPricePerShareRequiredForPayment>
    <sana:CommonStockPricePerShareRequiredForPayment
      contextRef="C_f1fcce66-212c-4a70-9718-133d1c668a44"
      decimals="INF"
      id="F_e92b542c-b8c7-4bcf-8e0d-546ff2adeb39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">40.00</sana:CommonStockPricePerShareRequiredForPayment>
    <sana:CommonStockPricePerShareRequiredForPayment
      contextRef="C_fb2f913c-2539-43df-900b-bd15d965ab34"
      decimals="INF"
      id="F_0d7d2425-f45c-4a38-8349-f1a88a14d0d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">80.00</sana:CommonStockPricePerShareRequiredForPayment>
    <sana:CommonStockPricePerShareRequiredForPayment
      contextRef="C_546c0313-0f3f-4820-bf29-21b1e0968e55"
      decimals="INF"
      id="F_953479b4-d50e-4584-b4ce-2fe9b8f0b233"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">120.00</sana:CommonStockPricePerShareRequiredForPayment>
    <sana:CommonStockPricePerShareRequiredForPayment
      contextRef="C_06a0dace-22c9-49b4-b126-d21eae97f669"
      decimals="INF"
      id="F_28c15ee6-9894-4c78-841b-36acf22022b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">160.00</sana:CommonStockPricePerShareRequiredForPayment>
    <sana:PotentialSuccessPayments
      contextRef="C_aa78a347-b2c3-4998-92a1-ff2191d35b80"
      decimals="-5"
      id="F_16f0c711-7e8b-4053-9a05-922455f172e5"
      unitRef="U_USD">5000000.0</sana:PotentialSuccessPayments>
    <sana:PotentialSuccessPayments
      contextRef="C_3cf9a87b-eed3-43a3-93f1-c8d0035536c6"
      decimals="-5"
      id="F_ad98775a-be7c-45bb-bfc8-d1a62e87a57e"
      unitRef="U_USD">15000000.0</sana:PotentialSuccessPayments>
    <sana:PotentialSuccessPayments
      contextRef="C_cfb14b1e-3ce3-4211-b44b-454387680bb3"
      decimals="-5"
      id="F_dee65e79-bae0-4f94-a383-64ee9cafb74f"
      unitRef="U_USD">30000000.0</sana:PotentialSuccessPayments>
    <sana:PotentialSuccessPayments
      contextRef="C_2ab6eba0-d3c4-442f-bc85-efd0ea497f3a"
      decimals="-5"
      id="F_b8c047bf-5fc4-45de-9a05-effd0dc88622"
      unitRef="U_USD">50000000.0</sana:PotentialSuccessPayments>
    <sana:PotentialSuccessPayments
      contextRef="C_04c586a3-4616-447f-9140-209061d79050"
      decimals="-5"
      id="F_a1de764e-92ad-4d9c-a0de-fc97066cb848"
      unitRef="U_USD">75000000.0</sana:PotentialSuccessPayments>
    <sana:EstimatedFairValueOfSuccessPaymentLiability
      contextRef="C_ad091749-d991-4041-9e16-79d0ac453e20"
      decimals="-5"
      id="F_36196e0b-d4a2-4214-a519-08c8ced93d44"
      unitRef="U_USD">6300000</sana:EstimatedFairValueOfSuccessPaymentLiability>
    <sana:EstimatedFairValueOfSuccessPaymentLiability
      contextRef="C_86dab90d-c97a-4375-b478-9bef336bc6ff"
      decimals="-5"
      id="F_4c7fefa8-511a-4e86-9375-cfcf1128c721"
      unitRef="U_USD">1600000</sana:EstimatedFairValueOfSuccessPaymentLiability>
    <sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities
      contextRef="C_1bd66b24-e325-40b8-abb1-65a998714668"
      decimals="-5"
      id="F_88372381-6bfe-43d7-86d6-c67d3a7d90e7"
      unitRef="U_USD">4700000</sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities>
    <sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities
      contextRef="C_e852dc08-0bf7-4b90-9f2e-d291734160a9"
      decimals="-5"
      id="F_d246bcaa-6d00-43df-a026-9d4baed25483"
      unitRef="U_USD">600000</sana:GainExpenseInConnectionWithChangeInEstimatedFairValueOfSuccessPaymentLiabilities>
    <us-gaap:RestrictedAssetsDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_7246052a-57d9-4425-973b-c1847b9e5f49">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Restricted cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;standby letters of credit that are collateralized with a bank account at a financial institution in accordance with certain lease agreements. The aggregate amount of such standby letters of credit was&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of each of March 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_a668ec0c-db2d-4470-8ee5-e59d6f89b92f">standby letters of credit that are collateralized with a bank account at a financial institution in accordance with certain lease agreements. The aggregate amount of such standby letters of credit was</us-gaap:RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription>
    <us-gaap:RestrictedCash
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-5"
      id="F_33f7ad58-8076-46e1-adbf-76619dd3be2d"
      unitRef="U_USD">3800000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-5"
      id="F_6bb4bea3-4218-42f3-9726-0e2d4283cae0"
      unitRef="U_USD">3800000</us-gaap:RestrictedCash>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_4a19df60-eb90-4d0f-91e0-193c7106a282">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Fair value measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.193%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.193%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level 2 marketable securities include U.S. government and agency securities and corporate debt securities and are valued based on either recent trades of securities in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.366%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.4879999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 months or greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that there was no material change in the credit risk of the above investments during the three months ended March 31, 2024. As such, an allowance for credit losses has not been recognized. As of March 31, 2024, the Company does not intend to sell such securities, and it is not more-likely-than-not that the Company will be required to sell the securities prior to the recovery of the amortized cost basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, all marketable securities had an effective maturity date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or less. Investments in securities with maturities of less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or those for which management intends to use to fund current operations, are included in current assets and classified as available-for-sale. As of March 31, 2024, the balance in accumulated other comprehensive loss included net unrealized gains related to the Company&#x2019;s available-for-sale debt securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3 financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.091%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt &lt;br/&gt;Success Payment&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard &lt;br/&gt;Success Payment&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value &#x2013; expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes significant estimates and assumptions it believes would be made by a market participant in determining the estimated fair value of the Cobalt Contingent Consideration at each balance sheet date. The fair value of the Cobalt Contingent Consideration was determined by calculating the probability-weighted estimated value of the pre-specified development milestone payments based on the assessment of the likelihood and estimated timing that the milestones would be achieved and the applicable discount rates. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. The Company assesses these estimates on an ongoing basis as additional data impacting the assumptions are obtained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the Cobalt Contingent Consideration was calculated using the following unobservable inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.906%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Probability of milestone achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average unobservable inputs were calculated based on the relative value of the pre-specified development milestones. The estimated fair value of the Cobalt Contingent Consideration may change significantly as development progresses and additional data are obtained, impacting the assumptions regarding probabilities of successful achievement of the milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value assumptions, judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions, inputs and/or different valuation techniques could result in materially different fair value estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Success payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes significant estimates and assumptions in determining the estimated fair value of the success payment liabilities and the associated expense or gain at each balance sheet date. The estimated fair value of the Cobalt Success Payment and Harvard Success Payment liabilities was determined using a Monte Carlo simulation methodology, which models the estimated fair value of the liability based on several key assumptions, including the expected volatility, remaining term, risk-free interest rate, estimated number and timing of valuation measurement dates on the basis of which payment may be triggered, and, for the Cobalt Success Payment, the Company&#x2019;s market capitalization, and, for the Harvard Success Payments, the per share fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the Cobalt Success Payments and Harvard Success Payments were calculated using the following unobservable inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.906%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_b3d9af53-f9d3-4bd8-b057-7e3429dfa1cf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.193%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;299,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.193%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Success payment liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f"
      decimals="-3"
      id="F_36019788-a2e3-4db0-a64f-b493fd87ce9e"
      unitRef="U_USD">85137000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f683baa9-075c-4ebe-a723-0d7db30bfa1f"
      decimals="-3"
      id="F_5d79a7b1-c10a-46bb-88fe-3002433842f7"
      unitRef="U_USD">85137000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67"
      decimals="-3"
      id="F_2ac0420f-8eb3-4eb9-9294-6e92b8736fc1"
      unitRef="U_USD">79179000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67"
      decimals="-3"
      id="F_b8c228b8-9ef5-4921-a7d7-6af096e7678d"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67"
      decimals="-3"
      id="F_51043ba3-f09a-4d2d-8e39-7eb17c62b3bf"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a9b5da00-c2fb-4c39-b852-726b57ee6d67"
      decimals="-3"
      id="F_d837ae5d-7425-4869-89ce-f826ef4ace62"
      unitRef="U_USD">79179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f"
      decimals="-3"
      id="F_10166b3f-7bc3-435e-97ff-3212afbac2ea"
      unitRef="U_USD">514000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7c7fe089-a10c-450e-8f7f-75aa8066a27f"
      decimals="-3"
      id="F_3ab1c460-e882-4848-9e81-052402093e4b"
      unitRef="U_USD">514000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf"
      decimals="-3"
      id="F_dc56632c-e7d0-474c-9a0b-9cb0b455fe05"
      unitRef="U_USD">164830000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf"
      decimals="-3"
      id="F_2e2c0475-0901-47bf-9b30-9cc98cf688b0"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf"
      decimals="-3"
      id="F_3e2b1c1a-f34f-49a9-a778-436a728d7f17"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b81110b3-94ea-476b-8d47-6401255ca2bf"
      decimals="-3"
      id="F_fa4fce04-3261-4aef-b4f3-990029785bec"
      unitRef="U_USD">164830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7"
      decimals="-3"
      id="F_db89c9c8-9d96-4296-9852-360aebf2f0ed"
      unitRef="U_USD">122671000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7"
      decimals="-3"
      id="F_7d60236f-a756-487c-b819-3237f0fd2518"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7"
      decimals="-3"
      id="F_40270e8a-2f3b-429e-89e2-19119e14195c"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_34f2cdb6-3833-4e88-880b-1f2e49a79dc7"
      decimals="-3"
      id="F_bfadbebd-b546-41a2-87a9-9b795de75648"
      unitRef="U_USD">122657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47"
      decimals="-3"
      id="F_b8e9118e-8681-44f9-8158-d24dcdb8822f"
      unitRef="U_USD">11372000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47"
      decimals="-3"
      id="F_7506b4f2-3801-4d17-954a-e4d4e4950d81"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47"
      decimals="-3"
      id="F_692054b4-59b5-49f2-ac15-dae4c24a2b72"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_86a65137-2789-4d83-b804-3ef4fd1ebe47"
      decimals="-3"
      id="F_1848d1d3-bafb-43f4-ae36-d0a69596e21c"
      unitRef="U_USD">11371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff"
      decimals="-3"
      id="F_afd5f43b-1630-43f7-8be6-caadf186e533"
      unitRef="U_USD">134043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff"
      decimals="-3"
      id="F_42bab626-6b9a-42fd-94b5-b422f88f0bb5"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff"
      decimals="-3"
      id="F_0406b1a9-8601-4066-82a1-9ac0e0d4b75e"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c2fb6c57-21f5-4c06-a1f4-3fc46d7bafff"
      decimals="-3"
      id="F_ab00c7b8-b852-4df1-88d2-601000ff62c0"
      unitRef="U_USD">134028000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9"
      decimals="-3"
      id="F_11170fda-ecfd-472e-bfe2-c84e3c27fe49"
      unitRef="U_USD">381000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7f19c3d4-1663-4261-8f9d-fdfa8caeabf9"
      decimals="-3"
      id="F_8dd71a39-c29f-4849-8c98-8cb48d3ef3cb"
      unitRef="U_USD">381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529"
      decimals="-3"
      id="F_9186e794-8fb3-4985-8687-9a7693d8e5fd"
      unitRef="U_USD">299254000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529"
      decimals="-3"
      id="F_4254d478-fbc0-412d-8cc9-35b88e8465f9"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529"
      decimals="-3"
      id="F_73681776-eb86-41f5-863b-dfa20b334ba8"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d45c221a-befc-4a56-bb9d-3ba4f87bb529"
      decimals="-3"
      id="F_39d7feed-7a31-4c89-8642-07282aa96bee"
      unitRef="U_USD">299239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8d60103d-6496-453b-beb9-76e3514ed534"
      decimals="-3"
      id="F_8e2f8169-10f8-4562-b285-2f1f5d077706"
      unitRef="U_USD">114990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8d60103d-6496-453b-beb9-76e3514ed534"
      decimals="-3"
      id="F_b8c4edd8-1be8-4975-86f7-a68e682d91a7"
      unitRef="U_USD">114990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7"
      decimals="-3"
      id="F_af124d01-0e33-47ce-b5ff-8df8bc435618"
      unitRef="U_USD">45422000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dfb5e233-b4e3-44e2-a1ec-3eaea1018dc7"
      decimals="-3"
      id="F_b9e4e0fe-f633-4e0d-923b-5896af1ffe8e"
      unitRef="U_USD">45422000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4650afc1-9af0-49d7-a045-02b7cc48e08a"
      decimals="-3"
      id="F_8b6c4b02-fa8c-4490-98c3-2bc24584888f"
      unitRef="U_USD">160412000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4650afc1-9af0-49d7-a045-02b7cc48e08a"
      decimals="-3"
      id="F_9c1fd164-90f8-44c3-9632-e4b5ac5c9fcd"
      unitRef="U_USD">160412000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f0806d70-bf3c-4907-8e95-1d6b45653b32"
      decimals="-3"
      id="F_6b32a626-0ed0-4025-8ef2-27b847a7665d"
      unitRef="U_USD">160412000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f0806d70-bf3c-4907-8e95-1d6b45653b32"
      decimals="-3"
      id="F_a7089bf3-80b2-479b-9579-ea8a16f71f3b"
      unitRef="U_USD">160412000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4"
      decimals="-3"
      id="F_14034f09-bf8f-45d1-9b73-118301f17858"
      unitRef="U_USD">70315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_94b55f6e-19e2-4875-b7b4-0404f3b189d4"
      decimals="-3"
      id="F_dcabe9b9-69fd-43b3-8db9-9e5302f08e94"
      unitRef="U_USD">70315000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1"
      decimals="-3"
      id="F_27ff6939-f5f9-43ab-a2b0-64d43135918a"
      unitRef="U_USD">33091000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1"
      decimals="-3"
      id="F_6bd9e2fe-8775-4ce6-bc26-77cc0eceb725"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_73ef30a6-13f6-433f-aed5-ee58ebb059d1"
      decimals="-3"
      id="F_2115fdb6-3645-4705-ae2d-226fb05f9937"
      unitRef="U_USD">33094000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e53ea5e6-c436-4396-b07d-aa29105b61ad"
      decimals="-3"
      id="F_e30b6f2e-c7b1-4f3b-ab13-f5ef44b3291f"
      unitRef="U_USD">1062000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e53ea5e6-c436-4396-b07d-aa29105b61ad"
      decimals="-3"
      id="F_875bcdab-a397-46cc-a9a2-3bff258ff6b0"
      unitRef="U_USD">1062000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92"
      decimals="-3"
      id="F_66587589-4bcb-4c20-946b-984cc93439a7"
      unitRef="U_USD">104468000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92"
      decimals="-3"
      id="F_adf2eb4a-7033-4886-a1e2-186922932e53"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8b65933e-d17e-4f72-8dde-db3186b43c92"
      decimals="-3"
      id="F_d1f371bf-4157-48d8-b927-1699ed6bbcc0"
      unitRef="U_USD">104471000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd"
      decimals="-3"
      id="F_b05615c5-6238-43fc-87db-43fb0071cbfd"
      unitRef="U_USD">57924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd"
      decimals="-3"
      id="F_91c09dd9-23e7-4a2d-9d71-3d18db5eadb6"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd"
      decimals="-3"
      id="F_bf29fb2f-4470-46bb-9cb3-57d4ff564eb2"
      unitRef="U_USD">78000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8663c3a6-b6f8-4c37-ab2c-e8426dec34bd"
      decimals="-3"
      id="F_2b9c72a4-2fe3-4d68-b53f-a2593e4b9201"
      unitRef="U_USD">57853000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc"
      decimals="-3"
      id="F_ac0e7e94-1045-4242-a4b5-8a972ffe8adc"
      unitRef="U_USD">13817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc"
      decimals="-3"
      id="F_5436931e-6c61-4042-9977-91b8e8197e31"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc"
      decimals="-3"
      id="F_226b74c3-6825-46e4-a459-6996d0fc5b5f"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c7d54ad9-1d5e-4031-8013-d956752e48dc"
      decimals="-3"
      id="F_5308ea36-c4c2-46b8-84ed-45ac9d78e069"
      unitRef="U_USD">13825000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b"
      decimals="-3"
      id="F_cb3fcf0b-740d-4136-a82a-35cec7a33691"
      unitRef="U_USD">71741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b"
      decimals="-3"
      id="F_3a7b66c2-c37d-4474-9254-820e8b028afc"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b"
      decimals="-3"
      id="F_317fec0a-1914-4b71-996d-f0397f14f1d9"
      unitRef="U_USD">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_06a89b0d-46d1-4a51-939b-a06edc10c59b"
      decimals="-3"
      id="F_98a599d1-4c8b-45f3-9f14-1e874d742218"
      unitRef="U_USD">71678000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd"
      decimals="-3"
      id="F_e5796ac3-36ac-4999-9f32-83a95a240d46"
      unitRef="U_USD">359000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fe19a7f0-f8aa-4de6-b696-009eccea77bd"
      decimals="-3"
      id="F_a8dbda5c-f95c-49b2-b00c-088fb375df16"
      unitRef="U_USD">359000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea"
      decimals="-3"
      id="F_e4bed30e-1ee9-46f8-bde9-d90b3ca6c55e"
      unitRef="U_USD">176568000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea"
      decimals="-3"
      id="F_61d91c7f-2de2-429a-b742-8bb77d8c6350"
      unitRef="U_USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea"
      decimals="-3"
      id="F_a13ce842-4b5b-4970-ba76-a5945ad8eba6"
      unitRef="U_USD">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8a2f152-54a4-47e8-b7ff-3667247dc7ea"
      decimals="-3"
      id="F_ae1bdab5-d881-492b-9540-eb3bc41b36ba"
      unitRef="U_USD">176508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb"
      decimals="-3"
      id="F_dff58693-171e-42ac-b932-7158cd9f6e74"
      unitRef="U_USD">109606000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9cf19fdd-5c70-4c5c-8cd2-a4cb4c728abb"
      decimals="-3"
      id="F_88f5af5e-80e8-4954-ac3f-9b266abdb2f8"
      unitRef="U_USD">109606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0650284f-37cc-47aa-8b3e-b08472cfc282"
      decimals="-3"
      id="F_eb763d02-6e92-4c82-a792-b11c2dd4a64d"
      unitRef="U_USD">12799000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0650284f-37cc-47aa-8b3e-b08472cfc282"
      decimals="-3"
      id="F_ef9dcb14-e76c-4b50-a1f7-43461e7a3fa4"
      unitRef="U_USD">12799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_55b234fc-e689-4f6e-ade4-f2280aca3981"
      decimals="-3"
      id="F_5870ea3f-a1c7-4c8e-8fd5-13e4b4abca0d"
      unitRef="U_USD">122405000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_55b234fc-e689-4f6e-ade4-f2280aca3981"
      decimals="-3"
      id="F_28c7b9ce-5c7a-42b3-b156-5d27bdea1a79"
      unitRef="U_USD">122405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12"
      decimals="-3"
      id="F_d3750b5a-011e-4409-b2d8-170f19d90210"
      unitRef="U_USD">122405000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_63e38a6c-e3e0-4dbd-b56e-ce632748ab12"
      decimals="-3"
      id="F_a11177e9-7e5d-4224-bcde-e484c8572486"
      unitRef="U_USD">122405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_80d67667-6d5e-4f5c-b8dc-e7aa2080845b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.366%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.068%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.4879999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 months or greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_0a9daac1-f211-42cd-9fb0-c6264548aa3b"
      unitRef="U_USD">111511000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_3dc00502-27cf-41d8-9e95-e72894aabfbe"
      unitRef="U_USD">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_37b7ea51-325f-498d-9dc1-53945dce35c1"
      unitRef="U_USD">5984000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_474936e9-4581-4e2d-9479-025626ddd1be"
      unitRef="U_USD">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_ca0bd08d-25f9-4455-82d1-2ebee66577fc"
      unitRef="U_USD">117495000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_dffe3d68-d060-4f1e-9ced-8bb8def7858d"
      decimals="-3"
      id="F_b0c49ee1-cd2f-42fc-80ed-c4d54bdfbd19"
      unitRef="U_USD">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6"
      decimals="-3"
      id="F_308ef987-e8ab-47c8-9cfd-64e774986bb3"
      unitRef="U_USD">7858000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6"
      decimals="-3"
      id="F_41633f10-ed7f-46b0-a53b-11151090a6c1"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6"
      decimals="-3"
      id="F_687ad711-0e13-4427-9b03-c360021748a5"
      unitRef="U_USD">7858000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_1fe38b28-27f0-41c8-a1ff-5a7abb0495d6"
      decimals="-3"
      id="F_043abc2a-e750-49a9-bdc4-cf629e5d8b10"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_f54867e2-58dd-4e02-a0c0-3029e6cbbea7"
      unitRef="U_USD">119369000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_486fcd91-e49a-487f-882f-4f5cb90c5331"
      unitRef="U_USD">11000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_5acd689d-4a21-4838-bdde-f5867739c694"
      unitRef="U_USD">5984000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_c7d0e781-f93c-49b5-849d-75ae9fa1f59a"
      unitRef="U_USD">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_e30e9e77-8f58-44e1-8cba-e874078c5787"
      unitRef="U_USD">125353000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_50dc67f9-a566-456d-b0a2-dc6271a5a36b"
      unitRef="U_USD">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_89665812-1e4f-43aa-adcb-57e7281945e1"
      unitRef="U_USD">9186000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_8f8b29e7-08ae-4647-8ea3-e3e6ecacd8ef"
      unitRef="U_USD">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_aa422555-1e05-48cf-b05a-abbdea653fb9"
      unitRef="U_USD">10386000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_4df62a84-301a-4703-9a5e-aa0a9f088f3a"
      unitRef="U_USD">75000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_4cbbb529-9cab-4079-8647-6a0288e024bf"
      unitRef="U_USD">19572000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_efe79fba-b895-4c6f-a87e-18eb7fa4d53b"
      decimals="-3"
      id="F_927c574e-13d0-4d9a-aa2a-7d59a8b6ebc8"
      unitRef="U_USD">78000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd"
      decimals="-3"
      id="F_fe9d120a-9a74-4f88-a96c-9996f4de18fd"
      unitRef="U_USD">1396000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd"
      decimals="-3"
      id="F_f296384d-0993-44f9-a4a4-2e5c6f670870"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd"
      decimals="-3"
      id="F_36bfb3a0-80cf-48e5-a59f-6df5158d538b"
      unitRef="U_USD">1396000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_88402e74-7150-43da-a733-2aff3a7e03cd"
      decimals="-3"
      id="F_7461c982-2631-4353-99ee-c6273c8d41f6"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_951ee1cd-d8b9-4975-aaa8-110b08ff119f"
      unitRef="U_USD">10582000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_2381a936-c335-4586-8f2c-b189cb1d1371"
      unitRef="U_USD">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_0331f0f3-0b3c-4a57-8b69-3cf64f85a1d4"
      unitRef="U_USD">10386000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_96f7eff0-bf1b-4963-86c5-7b096346ed3b"
      unitRef="U_USD">75000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_c7042ee5-e2f8-4de0-893f-6601e9667903"
      unitRef="U_USD">20968000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_e6249957-fb99-4aeb-a664-edea6d918b2e"
      unitRef="U_USD">79000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <sana:MarketableSecuritiesMaturityPeriod
      contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f"
      id="F_eb5cd8c1-b9af-42a9-b2b5-d0bb5027c297">P2Y</sana:MarketableSecuritiesMaturityPeriod>
    <sana:InvestmentsSecuritiesMaturitiesPeriod
      contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f"
      id="F_ba026c8a-174c-4a49-8eb6-c67e3cf66021">P1Y</sana:InvestmentsSecuritiesMaturitiesPeriod>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_2e11f6bb-55d4-4720-b46d-2e328cb744a7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3 financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.091%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt &lt;br/&gt;Success Payment&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard &lt;br/&gt;Success Payment&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value &#x2013; expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1c1f3354-a6f1-4f78-9017-287f0a19140e"
      decimals="-3"
      id="F_2bf7bfba-6102-41e8-bb23-1946328665d3"
      unitRef="U_USD">109606000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_dafa944e-950c-499e-8b37-2dbf29453f70"
      decimals="-3"
      id="F_e452a598-e86b-4dd9-ae5b-bc67a9ce7c8a"
      unitRef="U_USD">11160000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_3f674985-b139-480d-b274-2a0503c4dce6"
      decimals="-3"
      id="F_1d37d7de-89e3-477f-9f1b-ac3a2e290cc4"
      unitRef="U_USD">1639000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_9b2f8dd4-c615-4c6b-b326-f49621a6eb03"
      decimals="-3"
      id="F_acb3350c-5d59-4829-a4f9-0b6f699905d2"
      unitRef="U_USD">-5384000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_06e3eb5f-e863-49fa-8563-0e30982ae5cd"
      decimals="-3"
      id="F_36230086-736a-4208-b15c-692f305f704a"
      unitRef="U_USD">-27920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_bad0c086-6e01-4d43-9445-ceaacc421516"
      decimals="-3"
      id="F_413bde9e-76ec-4847-8b73-cf7c20139da1"
      unitRef="U_USD">-4703000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f8a9dedd-06c5-4477-a6bb-e88883200c61"
      decimals="-3"
      id="F_381d5c4b-0c0e-4a89-bbe6-5369f10dfce3"
      unitRef="U_USD">114990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a51b0686-423c-43e8-94c5-8d8eb699f340"
      decimals="-3"
      id="F_e24fb00a-f6ce-4ea5-8a62-f5055b8630c9"
      unitRef="U_USD">39080000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_81ea7889-0580-4531-870a-0c65974ac802"
      decimals="-3"
      id="F_227c8d62-07f0-439d-92e7-2e5a8cc0fe3f"
      unitRef="U_USD">6342000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_9ef25fb2-65c6-460a-a441-dd847f65b914"
      id="F_61350f4f-189e-4526-aa52-5d9c099603e6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the Cobalt Contingent Consideration was calculated using the following unobservable inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.906%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Probability of milestone achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_33ce4ada-7ce3-43bc-bd74-e90240b2eb28"
      decimals="INF"
      id="F_0e29e905-d7da-45a9-b6a9-16dbfd1567a1"
      unitRef="U_pure">0.109</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_0cd2c1c8-63b2-4e43-b354-bbe68ce2f425"
      decimals="INF"
      id="F_8399e3a1-df61-491c-8c08-8ed94f645bdd"
      unitRef="U_pure">0.113</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_fec33127-b46e-468d-bbde-9835085b612c"
      decimals="3"
      id="F_84b52fa7-ba92-4fd4-86e4-9a16aaa8b4dd"
      unitRef="U_pure">0.11</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_16202469-4333-43bd-8ab0-185f07269735"
      decimals="INF"
      id="F_d22a3bcc-229f-4fed-9df6-47d84db7bba8"
      unitRef="U_pure">0.117</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_25947cd9-a663-4cab-b957-bc7138703866"
      decimals="INF"
      id="F_c01d9739-3bf5-47e2-b32a-49c9f9023700"
      unitRef="U_pure">0.124</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_3e115f01-d2f7-4c57-aad5-86133c460620"
      decimals="3"
      id="F_e02c3345-ae70-4170-ab4d-374645bc8940"
      unitRef="U_pure">0.119</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_7de50755-31cf-4120-a7ad-64811d98119c"
      decimals="INF"
      id="F_d03b4a98-7e76-4a3e-bb93-cf234681a497"
      unitRef="U_pure">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_50f28a60-d008-4a0e-9e96-e1ccac671344"
      decimals="INF"
      id="F_010094b1-b8d7-4a16-b585-dc5370fdb6b7"
      unitRef="U_pure">0.55</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_beb5b16b-6471-404e-aa6d-b2a7573c831a"
      decimals="3"
      id="F_61d0307e-ef4e-453b-a2ea-2dbce05d62aa"
      unitRef="U_pure">0.257</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_e77f8e79-8380-4173-9ea0-6fd155040616"
      decimals="INF"
      id="F_9d0f5442-13f0-4aa9-b505-2a619f85a851"
      unitRef="U_pure">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_2f9d4e78-b28f-45b8-a7ec-c2b98459dfc6"
      decimals="INF"
      id="F_a22718c5-48b3-4508-b2e6-2b14884ff6ce"
      unitRef="U_pure">0.55</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_1ccf1cdd-58e0-4408-a0fa-022aac193bde"
      decimals="3"
      id="F_c4fcb343-b02a-4154-b9de-bd36743fd679"
      unitRef="U_pure">0.257</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_7b455bc1-d635-49ad-bf86-120e8cdbf8b4"
      id="F_19b9ddd7-ce1c-4183-95c5-c98ee130c697">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of the Cobalt Success Payments and Harvard Success Payments were calculated using the following unobservable inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.906%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.954%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.519%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.054%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cobalt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <sana:SuccessPaymentLiabilityMeasurementInput
      contextRef="C_5d2713f5-18c1-46f4-a590-7d2440ecea25"
      decimals="3"
      id="F_d790ba18-efc0-4e8f-b0cf-f9aaf39f0951"
      unitRef="U_pure">0.725</sana:SuccessPaymentLiabilityMeasurementInput>
    <sana:SuccessPaymentLiabilityMeasurementInput
      contextRef="C_d90fc972-dfb8-47f8-aecb-c44ba7bfe28d"
      decimals="3"
      id="F_b71846ea-0f69-4469-9bec-67f20cf670f1"
      unitRef="U_pure">0.725</sana:SuccessPaymentLiabilityMeasurementInput>
    <sana:SuccessPaymentLiabilityMeasurementInput
      contextRef="C_c8e330e6-05d0-41c5-9f40-ed43cee976e6"
      decimals="3"
      id="F_659326f4-05a9-4b7e-b6c0-112a31377c31"
      unitRef="U_pure">0.725</sana:SuccessPaymentLiabilityMeasurementInput>
    <sana:SuccessPaymentLiabilityMeasurementInput
      contextRef="C_dfb83220-389a-46ef-9749-8c6f3606deb9"
      decimals="3"
      id="F_8e669bcf-956f-4625-adf4-f4fe0ab8d094"
      unitRef="U_pure">0.725</sana:SuccessPaymentLiabilityMeasurementInput>
    <sana:SuccessPaymentLiabilityExpectedTerm
      contextRef="C_18f3293e-df26-43da-a598-50ac321fdc65"
      id="F_34f34f4f-d74c-46f4-a8e9-eeaf3858ce7d">P14Y10M24D</sana:SuccessPaymentLiabilityExpectedTerm>
    <sana:SuccessPaymentLiabilityExpectedTerm
      contextRef="C_dfd47a7d-8c14-4eb8-8032-56ab21cc27b6"
      id="F_06eccc21-ca86-4751-9a15-9e195234872f">P7Y</sana:SuccessPaymentLiabilityExpectedTerm>
    <sana:SuccessPaymentLiabilityExpectedTerm
      contextRef="C_586b0056-75c6-4ab5-8d42-c2f9ab46e617"
      id="F_3bdad3f2-edf9-421e-8b8e-bb527efa3718">P15Y1M6D</sana:SuccessPaymentLiabilityExpectedTerm>
    <sana:SuccessPaymentLiabilityExpectedTerm
      contextRef="C_4a1f55ec-17f1-42c1-b4cf-309cd1fd5eda"
      id="F_87eec537-dd7a-4c99-88ae-1e04b175ebc7">P7Y2M12D</sana:SuccessPaymentLiabilityExpectedTerm>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_d91a4fa2-9762-4177-9065-2401d6591984">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Property and equipment, net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment, software, and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_7af7e458-b589-486e-8f68-bac7d376916f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment, software, and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c5046514-fcb5-4d24-b1c8-fa4729ff4c0a"
      decimals="-3"
      id="F_ed34c559-2e83-420e-b4d8-917cb05d0970"
      unitRef="U_USD">53447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_94f4df8f-7b42-4c68-be26-534736b5d5f9"
      decimals="-3"
      id="F_3babd502-a9f5-4f5f-acf7-8e377e6d2077"
      unitRef="U_USD">51643000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a379388d-c2de-4807-a894-cff2e4a56b6e"
      decimals="-3"
      id="F_2e3b6d4f-4c0d-49f7-8c0d-7a4a4aaa9e7d"
      unitRef="U_USD">33848000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f3c4803-a059-4ebb-ae2b-4ac87f86d07d"
      decimals="-3"
      id="F_73062964-b8b0-4cbc-8e37-34e48cb6828e"
      unitRef="U_USD">31361000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_823c66ba-b506-4ca6-9d31-5351ec2592d4"
      decimals="-3"
      id="F_62bd69e9-71be-46c3-abed-415a7e316abc"
      unitRef="U_USD">35028000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_60a4c997-ab06-4f9e-8db8-c507524ec994"
      decimals="-3"
      id="F_70eb55ea-b39c-45b1-8a58-5fa2fde325d6"
      unitRef="U_USD">26332000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a57b1903-cab8-45b9-8d74-c152b19c7eae"
      decimals="-3"
      id="F_7255910a-58cc-4510-b01d-e9628a1af6f9"
      unitRef="U_USD">4843000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_25788be5-71c6-4519-9446-0a103addacb4"
      decimals="-3"
      id="F_f302e7ec-21a4-48ba-9d81-97b2e849176e"
      unitRef="U_USD">3124000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_f7c0e121-76e5-4d2d-8107-52e3f9ff4b41"
      unitRef="U_USD">127166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_aba53209-6af2-4115-b1fa-5567f416327e"
      unitRef="U_USD">112460000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_2820c459-79e3-481e-8753-847c6dd0e044"
      unitRef="U_USD">45517000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_0ac92247-1cc6-4b59-8b6b-8ec45013656f"
      unitRef="U_USD">41771000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_cdd2a4f6-cec3-4834-8515-d7f0ea98dbba"
      unitRef="U_USD">81649000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_7d0164b0-39b8-4f64-a7ff-ba60ab3f6b7d"
      unitRef="U_USD">70689000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-5"
      id="F_4e149a09-abcc-47a3-8b8a-e617a707434a"
      unitRef="U_USD">3700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-5"
      id="F_b2dc9cc4-f200-4dfa-9c5d-37fc24d7a2f6"
      unitRef="U_USD">4300000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_50c566b3-f72b-44ed-b9b8-6297fc043f08">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Accrued liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation and accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued bonuses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued paid time off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_b394d44d-f76e-47a8-bf48-749ebb765808">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation and accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued bonuses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued paid time off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_33685f69-c922-4180-b480-574cfcdf75e3"
      unitRef="U_USD">3957000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_c818d6cc-db65-4b2c-82e4-f68ad129d2d8"
      unitRef="U_USD">14379000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_a7c55258-dae5-406c-8519-d03a3d581e8a"
      unitRef="U_USD">5398000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_4da0eeb3-f7fb-4d4b-9400-e5d7ec925691"
      unitRef="U_USD">4731000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_d50ab3b8-5a80-4b2c-a8f9-992ad88175a1"
      unitRef="U_USD">4065000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_4dec071e-d2ad-469f-b470-fcee16cda728"
      unitRef="U_USD">3936000</us-gaap:AccruedSalariesCurrent>
    <sana:AccruedCompensationOther
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_04f7e7b1-a7c6-4d93-92d8-a154e8f0e375"
      unitRef="U_USD">545000</sana:AccruedCompensationOther>
    <sana:AccruedCompensationOther
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_93c6d397-f0e2-471f-9391-7ce1516dbb56"
      unitRef="U_USD">676000</sana:AccruedCompensationOther>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_1eec4786-9c05-427e-ba45-592585edc1cb"
      unitRef="U_USD">13965000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_d5692c9b-d140-4387-8986-72c0b78bb0bd"
      unitRef="U_USD">23722000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sana:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_a23ac715-99ce-47b4-b6c6-ef31965bc5b1"
      unitRef="U_USD">9749000</sana:AccruedResearchAndDevelopmentServicesCurrent>
    <sana:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_7a932373-f310-45fb-a16b-c68626b42787"
      unitRef="U_USD">10110000</sana:AccruedResearchAndDevelopmentServicesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_41ded248-912a-4b2b-9bbf-5f08187fc241"
      unitRef="U_USD">3509000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_2dfdb457-ba0c-446d-9782-ed9e2622029e"
      unitRef="U_USD">1470000</us-gaap:AccruedProfessionalFeesCurrent>
    <sana:AccruedPropertyAndEquipmentCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_b9ffc065-3e41-4395-aa75-c8f097404f65"
      unitRef="U_USD">5053000</sana:AccruedPropertyAndEquipmentCurrent>
    <sana:AccruedPropertyAndEquipmentCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_4acc6f12-3687-4b88-949d-00c64d621f89"
      unitRef="U_USD">9200000</sana:AccruedPropertyAndEquipmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_b29a9bdc-5296-455c-9d07-990ef7d17ed1"
      unitRef="U_USD">1363000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_2e2535ab-4318-42e8-b53a-43e599fe6eb4"
      unitRef="U_USD">2682000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_ea45e8c2-c1dd-4097-83f1-941c4b93571d"
      unitRef="U_USD">19674000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_071347fa-fcd5-49b5-a639-2dd896181807"
      unitRef="U_USD">23462000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_cb4bc8f4-511d-4cd4-9030-4abb2f839535">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Commitments and contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lease commitments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s lease portfolio primarily comprises operating leases for office, laboratory, and manufacturing space. These leases contain various rent abatement periods, after which they require monthly lease payments that may be subject to annual increases throughout the lease term. Certain leases include options to extend the term. The renewal option is considered in the remaining lease term for the lease only when the Company is reasonably certain it will renew the lease. Certain leases provide the Company with the right to make tenant improvements, including the addition of laboratory space or build-out of manufacturing capabilities, and include a lease incentive allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company entered into a lease agreement for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,565&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office, laboratory, and manufacturing space located in Bothell, Washington (the Bothell facility). The initial term of the lease expires in February 2039, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;with the option to extend the lease for up to three additional five-year terms.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The lease agreement also provides for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for reimbursement of tenant improvements, as well as an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for tenant improvements, available at the Company&#x2019;s election, which the Company would be obligated to repay to the landlord monthly over the initial term of the lease with interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per year.  The Company is obligated to pay base rent of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the initial term of the lease. In accordance with the lease agreement, the Company has obtained a letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company recognized the right-of-use asset and lease liability in the three months ended March 31, 2023, when the lease commenced.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table contains additional information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.14%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Approximate &lt;br/&gt;Square Footage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Commencement Dates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Expiration Dates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Seattle, WA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cambridge, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;November 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;February 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;South San Francisco, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rochester, NY&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Bothell, WA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory/Manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2039&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Throughout the term of the lease agreements, the Company is responsible for paying, in addition to base rent, certain operating costs, such as common area maintenance, taxes, utilities, and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s lease costs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.112%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the weighted-average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years, and the weighted-average incremental borrowing rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the Company&#x2019;s undiscounted operating lease cash flows by fiscal year to the present value of the operating lease liabilities as of March 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024 (remaining 9 months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: tenant improvement allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sana:AreaOfLeasedSpace
      contextRef="C_00b71411-02d1-4dbc-842b-d19a3cff2367"
      decimals="0"
      id="F_1f856708-f51a-42d3-bb1a-71e81aa3934c"
      unitRef="U_sqft">79565</sana:AreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_3bf2bbd7-4ee7-4371-8586-07b289dc7983"
      id="F_35beea1b-8e7f-49ee-b9b4-455c7e9aed0c">with the option to extend the lease for up to three additional five-year terms.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <sana:ReimbursementOfTenantImprovements
      contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"
      decimals="-5"
      id="F_f581b282-5c2f-4b2e-893d-7f2499d782ae"
      unitRef="U_USD">19900000</sana:ReimbursementOfTenantImprovements>
    <sana:OptionalTenantImprovementAllowance
      contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"
      decimals="-5"
      id="F_69bbe27f-9b8b-4a71-8be4-b01d220766f3"
      unitRef="U_USD">8000000.0</sana:OptionalTenantImprovementAllowance>
    <sana:OptionalTenantImprovementAllowanceInterestRate
      contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"
      decimals="3"
      id="F_b1370d6f-af75-46fb-81e6-22fcae5905c5"
      unitRef="U_pure">0.065</sana:OptionalTenantImprovementAllowanceInterestRate>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"
      decimals="-5"
      id="F_c27730ed-46fa-4486-9214-10e12314e772"
      unitRef="U_USD">68800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_9e464808-fafe-40f7-96bf-047d5e9dfd51"
      decimals="-5"
      id="F_ff72fad0-5b1b-48ec-9d00-16622e184a1b"
      unitRef="U_USD">1600000</us-gaap:LettersOfCreditOutstandingAmount>
    <sana:OperatingLeasesAdditionalInformationTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_4fa71e3d-abed-4fef-9662-27fc368c0ad5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table contains additional information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.14%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Approximate &lt;br/&gt;Square Footage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Commencement Dates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Expiration Dates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Seattle, WA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cambridge, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;November 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;February 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;South San Francisco, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;April 2030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rochester, NY&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cef0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Bothell, WA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office/Laboratory/Manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 2039&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sana:OperatingLeasesAdditionalInformationTableTextBlock>
    <sana:AreaOfLeasedSpace
      contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"
      decimals="0"
      id="F_9e1795a6-29d6-4d55-9a2d-67573f232883"
      unitRef="U_sqft">48000</sana:AreaOfLeasedSpace>
    <sana:OperatingLeaseCommencementBeginningMonthAndYear
      contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"
      id="F_05e7777b-6404-4c18-8a54-ca5574fc5fc7">2019-03</sana:OperatingLeaseCommencementBeginningMonthAndYear>
    <sana:OperatingLeaseCommencementEndingMonthAndYear
      contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"
      id="F_00628e6f-8177-4bdc-a730-a9e88e2ed86d">2020-09</sana:OperatingLeaseCommencementEndingMonthAndYear>
    <sana:OperatingLeaseExpirationBeginningMonthAndYear
      contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"
      id="F_872c322a-6c36-4355-a4a4-559806c10890">2026-12</sana:OperatingLeaseExpirationBeginningMonthAndYear>
    <sana:OperatingLeaseExpirationEndingMonthAndYear
      contextRef="C_e5f7082a-ec2c-4a8e-bfb1-2e0e6297e616"
      id="F_6f552f07-4d25-42b9-bc6a-381232a70ea3">2028-04</sana:OperatingLeaseExpirationEndingMonthAndYear>
    <sana:AreaOfLeasedSpace
      contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"
      decimals="0"
      id="F_715a6668-23cc-452e-97ac-29d11f517fd7"
      unitRef="U_sqft">60000</sana:AreaOfLeasedSpace>
    <sana:OperatingLeaseCommencementBeginningMonthAndYear
      contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"
      id="F_42ab5218-eb0b-4680-9dc6-fa6d0cb0d095">2019-03</sana:OperatingLeaseCommencementBeginningMonthAndYear>
    <sana:OperatingLeaseCommencementEndingMonthAndYear
      contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"
      id="F_1881a911-81ac-412f-810a-434a7ca976dc">2022-01</sana:OperatingLeaseCommencementEndingMonthAndYear>
    <sana:OperatingLeaseExpirationBeginningMonthAndYear
      contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"
      id="F_5f59419c-752e-4b60-8df0-6d760a59fc7e">2025-11</sana:OperatingLeaseExpirationBeginningMonthAndYear>
    <sana:OperatingLeaseExpirationEndingMonthAndYear
      contextRef="C_dfdf28a6-c13c-4877-a638-bd86f15aca04"
      id="F_35a66299-941e-4d8d-87ba-4967549dc769">2028-02</sana:OperatingLeaseExpirationEndingMonthAndYear>
    <sana:AreaOfLeasedSpace
      contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712"
      decimals="0"
      id="F_82faed73-9733-45b5-a56e-1398cfd4f79b"
      unitRef="U_sqft">100000</sana:AreaOfLeasedSpace>
    <sana:OperatingLeaseCommencementBeginningMonthAndYear
      contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712"
      id="F_2705ffc2-ed4d-4986-8320-72df97b86687">2019-12</sana:OperatingLeaseCommencementBeginningMonthAndYear>
    <sana:OperatingLeaseCommencementEndingMonthAndYear
      contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712"
      id="F_1170012a-8e63-4015-aaae-1ce9a5acf713">2022-04</sana:OperatingLeaseCommencementEndingMonthAndYear>
    <sana:OperatingLeaseExpirationBeginningMonthAndYear
      contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712"
      id="F_d39aa45b-8f2a-48e9-83f3-8e3773ff88c8">2024-04</sana:OperatingLeaseExpirationBeginningMonthAndYear>
    <sana:OperatingLeaseExpirationEndingMonthAndYear
      contextRef="C_b4ec08c5-443c-43d4-9292-a4247d9af712"
      id="F_73477c37-9905-45e4-9ed8-0777ded4d9e9">2030-04</sana:OperatingLeaseExpirationEndingMonthAndYear>
    <sana:AreaOfLeasedSpace
      contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa"
      decimals="0"
      id="F_b3bd111f-ee19-4f17-94ea-71da21508045"
      unitRef="U_sqft">3000</sana:AreaOfLeasedSpace>
    <sana:OperatingLeaseCommencementBeginningMonthAndYear
      contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa"
      id="F_2570310d-b476-4946-810d-da62296ef0e6">2022-01</sana:OperatingLeaseCommencementBeginningMonthAndYear>
    <sana:OperatingLeaseExpirationEndingMonthAndYear
      contextRef="C_125ebb9c-fd0d-4db7-b372-178d07ccfffa"
      id="F_c176c879-4813-490a-9e0d-e95198d7a3fe">2025-01</sana:OperatingLeaseExpirationEndingMonthAndYear>
    <sana:AreaOfLeasedSpace
      contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc"
      decimals="0"
      id="F_2a501a3b-025f-4d4b-8ef8-a368c8d01269"
      unitRef="U_sqft">80000</sana:AreaOfLeasedSpace>
    <sana:OperatingLeaseCommencementBeginningMonthAndYear
      contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc"
      id="F_ec9102d9-08eb-42f3-a356-112a627acae7">2023-01</sana:OperatingLeaseCommencementBeginningMonthAndYear>
    <sana:OperatingLeaseExpirationEndingMonthAndYear
      contextRef="C_25c2ec8b-27b4-41ab-a2ca-9cd7f5a482cc"
      id="F_bff69047-5480-408c-9d37-3390b756f0e5">2039-01</sana:OperatingLeaseExpirationEndingMonthAndYear>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_dca8f3fd-9c94-4ff1-823c-8664d4b9864e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s lease costs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.112%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_d365ba3b-6971-42b7-915f-d4fe4c9b5014"
      unitRef="U_USD">5981000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_e2f66391-3386-4f6b-aacf-41c7416e03fc"
      unitRef="U_USD">7061000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_c8942148-6ffc-44bf-9df6-469eeea10345"
      unitRef="U_USD">2014000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_058a0cc0-26a8-4686-98d8-232fc2336c96"
      unitRef="U_USD">1982000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_78f67632-2a47-4054-80e7-2e12a2f730b4"
      unitRef="U_USD">7995000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_c39fef41-0419-4270-ada5-c485ff0d6bcb"
      unitRef="U_USD">9043000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      id="F_72890691-af76-4311-a9c9-ff314e9044b9">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="3"
      id="F_9936e71b-fd88-4fe6-aa9d-95f304367bdc"
      unitRef="U_pure">0.112</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_c4552a84-d535-48d7-a4a7-bb79cc8486ff">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the Company&#x2019;s undiscounted operating lease cash flows by fiscal year to the present value of the operating lease liabilities as of March 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024 (remaining 9 months)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: tenant improvement allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cef0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_544fa7d9-68b2-4d61-9c46-2ba6d920d1f0"
      unitRef="U_USD">16971000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_d91afa56-1dcb-4d71-8731-577901f55ddd"
      unitRef="U_USD">25394000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_17432a4a-4cd7-485f-a162-2b0b2bb2148e"
      unitRef="U_USD">22472000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_45172f7c-adf0-4cec-b680-4032dc6a6590"
      unitRef="U_USD">19899000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_7ae0b75a-de4c-4f8f-9f16-de8b2416df47"
      unitRef="U_USD">15226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <sana:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_0f505193-69f0-490a-8ae6-bfd99927d76a"
      unitRef="U_USD">93495000</sana:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_e2a790c9-32c7-4a8a-ba11-06781b06a5f9"
      unitRef="U_USD">193457000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_dd215489-c1bb-44c1-8c9d-3016c5a64630"
      unitRef="U_USD">85980000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <sana:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_c26a9f4b-42b8-442a-8777-5da9afa96bb6"
      unitRef="U_USD">1388000</sana:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_146355d6-a2e4-48e7-b03d-3e1aa9871874"
      unitRef="U_USD">106089000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_7f317852-38d2-4a8a-8b86-169a68fc437c"
      unitRef="U_USD">13167000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_00e03f72-7e95-488e-bc03-a273a55f3ff9"
      unitRef="U_USD">92922000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_324af212-363d-4915-be35-4c7da52cdae5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Stockholders&#x2019; equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company completed an underwritten public offering pursuant to which it sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares pursuant to the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of its common stock, for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses. The pre-funded warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of common stock. As the pre-funded warrants are indexed to the Company&#x2019;s common stock and otherwise meet the requirements to be classified in equity, the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The pre-funded warrants are exercisable at any time; however, the holders of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of pre-funded warrants may increase or decrease such percentages not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% by providing at least 61 days&#x2019; prior notice to the Company.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The pre-funded warrants do not expire. During the three months ended March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants were exercised.&lt;/span&gt;&lt;span style="color:#0070c0;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2022, the Company entered into a sales agreement with Cowen, acting as sales agent, pursuant to which it may offer and sell through Cowen up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of the Company&#x2019;s common stock from time to time in a series of one or more at the market equity offerings. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, the Company has sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of the Company's common stock under the ATM facility for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting commissions and expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_641277e3-749d-4eb9-a24e-d5fc027e6183"
      decimals="-5"
      id="F_c7a6f46b-1e34-4422-ab1d-f4c7af859761"
      unitRef="U_shares">21800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_18571269-31c5-4f70-a45a-3ef776d6eb61"
      decimals="-5"
      id="F_dc397cf4-9fb3-41af-a0c8-4e0d01825ef2"
      unitRef="U_shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5baaaa87-fae6-4ea1-8c7f-c6624c122de2"
      decimals="-5"
      id="F_74b6cc72-010a-46ac-8b84-267694c45934"
      unitRef="U_shares">12700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_995d9eee-7d60-4997-aedf-118f7f6b649d"
      decimals="-5"
      id="F_036e289e-c625-4bac-bfab-06e91438e85f"
      unitRef="U_USD">180000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_223e6244-4447-479e-a802-dff78ea29aef"
      decimals="4"
      id="F_4abcabde-7354-485c-83fb-78ff214c19d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sana:DescriptionOfPreFundedWarrantsExerciable
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_b41404ae-80b6-454d-9945-9dfe96cf4f42"> The pre-funded warrants are exercisable at any time; however, the holders of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. The holders of pre-funded warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#x2019; prior notice to the Company.</sana:DescriptionOfPreFundedWarrantsExerciable>
    <sana:PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="4"
      id="F_e1deb8e8-d0da-4c33-b928-1cdbaa571c37"
      unitRef="U_pure">0.0499</sana:PreFundedWarrantsNotExerciseIfHolderTogetherOwnsMaximumPercentageOfNumberOfCommonStockOutstanding>
    <sana:MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="4"
      id="F_37faadb4-6766-4f22-9401-33e877a1bbe8"
      unitRef="U_pure">0.1999</sana:MaximumPercentageOfPreFundedWarrantsIncreaseDecreaseByProvidingAtleastSixtyOneDaysPriorNotice>
    <sana:PreFundedWarrantsExercised
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="INF"
      id="F_afa891f3-db9f-4dd2-b173-bbddfdffeac4"
      unitRef="U_shares">0</sana:PreFundedWarrantsExercised>
    <sana:CommonStockMaximumOfferingAmount
      contextRef="C_643555c3-2807-4634-8e1c-203532b68dd5"
      decimals="INF"
      id="F_4888984c-7a23-4264-8762-7302493c5a94"
      unitRef="U_USD">150000000</sana:CommonStockMaximumOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08"
      decimals="-5"
      id="F_e0e69ea6-9d2f-4986-aad9-e59a47ef78a9"
      unitRef="U_shares">4900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8963df71-f8ac-4c02-a298-9bc1a3dbec08"
      decimals="-5"
      id="F_b4aa861e-8f26-4e23-8b3d-8ec277ff97dd"
      unitRef="U_USD">28700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_cc600275-638b-4519-a26d-61acac3ba9f4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity incentive plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2021, the Company adopted the 2021 Incentive Award Plan (2021 Plan) and the 2021 Employee Stock Purchase Plan (2021 ESPP), both of which became effective on the completion of the Company&#x2019;s initial public offering. The 2021 Plan provides for a variety of stock-based compensation awards, including stock options, restricted stock awards (RSAs), and restricted stock units (RSUs). The 2021 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees may purchase shares at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering period or on the purchase date. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares were available for future issuance under the 2021 Plan and the 2021 ESPP, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense is recognized in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.006%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.918000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.918000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of March 31, 2024 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized stock-based compensation expense (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average period costs expected to be recognized (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.283%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.283%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes additional information related to stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.674%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average grant date fair value per share for options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Aggregate intrinsic value of stock options exercised (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted stock&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.244%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs&lt;br/&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested shares as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested shares as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of RSUs that vested during the three months ended March 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_ae90f9dc-f66e-4ca7-9990-7e8b027d5fe0"
      decimals="INF"
      id="F_03d3d11c-b986-4f2c-ba21-81a2b1b70dac"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="C_7ec8e97a-eeb9-43b9-a3d4-79634fa4152c"
      decimals="2"
      id="F_8ff4c9b4-70f7-4421-80f9-73915fb4bcfe"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_729027ec-b0b4-4b18-87f2-8db8ae9bdd77"
      decimals="INF"
      id="F_9e35091c-1557-4376-8dcd-c2330e1e237d"
      unitRef="U_shares">20900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5fe7817f-a59d-4ee9-8d11-4a174e824ba6"
      decimals="INF"
      id="F_805092e9-3d26-453d-9565-bb05ed500f84"
      unitRef="U_shares">6500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_4635fec7-340a-41c2-9b93-ece0dc456af7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense is recognized in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.006%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.918000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.918000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_65f65e05-e779-44e5-ae6f-7877d20cf158"
      decimals="-3"
      id="F_f6ec1583-266e-4ddc-b9d9-6242f3be6c6f"
      unitRef="U_USD">5848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_584f9a41-0e9d-44db-a47d-1be5d9acba98"
      decimals="-3"
      id="F_7baf52e6-1640-4d68-bc00-f559393ffb61"
      unitRef="U_USD">5972000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_70cd5777-3e29-4131-aad9-ba09ce7c693d"
      decimals="-3"
      id="F_879ebc93-2da1-48ce-b29d-ee7d22885e16"
      unitRef="U_USD">3244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e95d768c-3dca-4fa7-ad61-ee5856361683"
      decimals="-3"
      id="F_195ca3e0-e7dd-4505-a6c3-141547f7b1e4"
      unitRef="U_USD">2779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_1952ee66-1bce-4349-a8bd-6d28883c954c"
      unitRef="U_USD">9092000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_cf928ab8-3d46-43d5-a1c9-23124df61d7c"
      unitRef="U_USD">8751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_47b101f5-8958-47f7-acf7-78cd836bbecb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of March 31, 2024 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized stock-based compensation expense (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average period costs expected to be recognized (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_147c1909-b56c-4e45-bb6a-2f58c5972a51"
      decimals="-3"
      id="F_85b27bfe-77d3-4e25-bbdd-2967f67ca2e8"
      unitRef="U_USD">75911000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b"
      decimals="-3"
      id="F_33fe7388-b966-4cc6-ab14-071b0d359126"
      unitRef="U_USD">27876000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_784cd865-32af-4b9e-9a2d-1283b79c0fb7"
      id="F_12282d14-50c0-4bae-bd2a-233516871cad">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      id="F_82ef70e4-244b-4818-bbc5-1cbf3fc9d96e">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_a6310310-c9ba-496b-9511-bfe8a894de72">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_19974386-d3e7-4e48-8f7b-5e9bfb532c46"
      unitRef="U_shares">26849000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="2"
      id="F_e2b13ba7-767e-4b08-999e-e3d92e0c8c3f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1df77845-a1de-4f4e-81f7-0609b3956c1c"
      id="F_2c3da09d-8af9-4bb6-9901-616541a9c859">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_1ff8bdde-18f8-4091-bad9-c22cba67895c"
      decimals="-3"
      id="F_41b66762-e476-42c7-8bca-926450254ba3"
      unitRef="U_USD">11235000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_ce4e579a-6dd8-4afb-9280-304262f31c13"
      unitRef="U_shares">5551000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_4ad51445-b516-4ed7-8e22-d6bf8e0c12ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_4784e1c4-88ce-4d1e-8d10-4e427ee77aa4"
      unitRef="U_shares">1120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_0527c461-a237-48da-a999-0d026205d0f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_598f0659-9607-4268-96c7-96dbe8245c7b"
      unitRef="U_shares">1048000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_c8f8d9bf-f812-4a52-9e2c-80d6dbacd47d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_71c4c4b5-03cf-47f6-8ac7-91ce2c0ae0b3"
      unitRef="U_shares">30232000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="2"
      id="F_46091c0c-6d87-4aa4-959d-d0b216a5ad0f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_c1ae660d-4a06-4a31-8e67-0f1dc6bc4fde">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_5c315bb7-a9b3-4d02-b31c-5089443c73f3"
      unitRef="U_USD">113377000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_363aa8de-a4ce-47d4-b656-46bb61fbaa85"
      unitRef="U_shares">13187000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="2"
      id="F_379352d1-d53b-4358-9d79-7625f1307b91"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_a913226d-22d6-4b00-8610-3dee17a8cd0b">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_e1998177-1c58-4e27-be53-21c13d9ca1d7"
      decimals="-3"
      id="F_03f54541-a667-4f02-ae89-5ebbdbd86a1b"
      unitRef="U_USD">57144000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_6f8ec7d3-622b-405f-b262-9af716141515">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.283%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.283%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="INF"
      id="F_89f3a77d-668f-4351-9080-d0631ed22447"
      unitRef="U_pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="INF"
      id="F_04b5bb9c-7aef-4829-a5df-dadcd8d96258"
      unitRef="U_pure">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="INF"
      id="F_8f19a0a8-b258-4375-8e09-dcddd21d7ab0"
      unitRef="U_pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="INF"
      id="F_e7def24c-4704-4921-bf3a-a61a6b993470"
      unitRef="U_pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="3"
      id="F_b8331a06-4acd-4968-9a96-063767305fa5"
      unitRef="U_pure">0.725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="3"
      id="F_b0bfca63-ea74-43a2-9a72-b978910059c4"
      unitRef="U_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_cb05e12b-2d6d-4df0-9d7a-c596f9921fe0">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a1033bd7-dfcc-4e46-b61c-7521a50f2305"
      id="F_5fb2807a-8e33-49f9-955a-a20be8964c8b">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_94d2ec2c-37d2-474c-abc6-bc8a607c98a5"
      id="F_a75215c2-26d7-4a74-ae7b-d5deb1db2b62">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_c5038f89-0c83-46c5-8561-3e614568eed7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="2"
      id="F_a6eab7f3-a8fb-4b9e-9d9f-ddf0334aa420"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_2685d842-5650-4197-a643-d542786cb919">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes additional information related to stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.674%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average grant date fair value per share for options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Aggregate intrinsic value of stock options exercised (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="2"
      id="F_68a79f47-bb8c-44e6-b4dd-1eecc582e063"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="2"
      id="F_5fe95310-058f-4ef2-b7e9-e1b64039c4c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_9633b417-1ced-48c6-bebb-494ec1355193"
      unitRef="U_USD">3586000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_adf37f2c-038d-43b5-859c-36e7f16605af"
      unitRef="U_USD">561000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_1672d5fc-b374-4603-97fa-b53d1b74fa51">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the Company&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.244%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;RSUs&lt;br/&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested shares as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested shares as of March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6118355a-f762-4887-9f8b-16f2afbc5567"
      decimals="-3"
      id="F_013a9e2f-fe48-416a-8744-5fbfb82ccbb3"
      unitRef="U_shares">2341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6118355a-f762-4887-9f8b-16f2afbc5567"
      decimals="2"
      id="F_2e936ea6-0a8a-41de-ac78-b0491b832e6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="-3"
      id="F_63ba9815-d884-4d4b-8b8d-e985e985646a"
      unitRef="U_shares">2461000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="2"
      id="F_995a0090-82eb-4b34-b6be-89c10e6ab3b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="-3"
      id="F_987535fa-824a-449c-bc36-6172ad42a216"
      unitRef="U_shares">388000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="2"
      id="F_24b77dc3-cea3-45cf-86b3-5c430ea2b131"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="-3"
      id="F_6efd6572-eabf-40d5-8863-f91aab021836"
      unitRef="U_shares">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="2"
      id="F_0fbf3291-5ce7-4d3a-a040-237e0668954d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b"
      decimals="-3"
      id="F_96819c65-396b-4c0a-86df-28e928e053f0"
      unitRef="U_shares">4226000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c57b0ce6-633b-46bf-af84-70d41e43de5b"
      decimals="2"
      id="F_5ece6b7f-6197-44dc-8cc9-45c33d99914f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_928be825-e134-4309-ace3-ac7914760235"
      decimals="-5"
      id="F_1f4f8683-07b9-46ae-968c-45714fa1617e"
      unitRef="U_USD">4100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_5b0a8034-8cf2-4c3d-a6c4-dc826a8a63fb"
      decimals="-5"
      id="F_06fa1dd6-d192-4417-b369-c30a1c9ab077"
      unitRef="U_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_83579e20-7b95-4307-9ae3-97804b7db75e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Income taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax provision for interim periods is determined using an estimate of the Company&#x2019;s annual effective tax rate, adjusted for discrete items arising in the quarter. The Company&#x2019;s effective tax rate differs from the U.S. statutory tax rate primarily due to a valuation allowance on the deferred tax assets. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies judgment in its determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of March 31, 2024 and December 31, 2023, the Company&#x2019;s uncertain tax positions were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_4b642d79-a973-4f5a-b894-040d30d500da">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Net loss per share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per common share are calculated by dividing net loss by the weighted-average number of common shares outstanding during the relevant period, including the pre-funded warrants given their nominal exercise price. The Company was in a loss position for all periods presented, and basic net loss per share and diluted net loss per share are therefore the same for all periods, as the inclusion of all potential common securities outstanding would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following securities were excluded from the computation of net loss per diluted share of common stock for periods presented as their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_63df13a5-167d-483f-8df2-56b7a71351f9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following securities were excluded from the computation of net loss per diluted share of common stock for periods presented as their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_63e6b918-5acf-48a9-b764-d3dbe3d981fe"
      decimals="-3"
      id="F_98cd472e-13f3-4e6e-b021-831a7010392e"
      unitRef="U_shares">30232000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c347a70d-0102-4f86-9df2-224e9dde7027"
      decimals="-3"
      id="F_fa2cfcd8-e594-474a-830d-e049cf01d7cb"
      unitRef="U_shares">29202000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c12ea39b-aeb0-4f12-b248-2e617e0f6530"
      decimals="-3"
      id="F_5754a3b8-7b8f-4865-93ac-601e384d2afa"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_95b79823-dbbd-4370-9127-b27adbac303b"
      decimals="-3"
      id="F_594414be-6da6-4974-a7cc-d76cebddd76a"
      unitRef="U_shares">5000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bbf6b029-0470-4e87-9590-c00f1975ad8c"
      decimals="-3"
      id="F_ec80eea1-53bd-4a85-b7a2-3f1c6173b47b"
      unitRef="U_shares">4226000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0ca9ade4-b42f-4a4e-999d-db79e5fb7206"
      decimals="-3"
      id="F_5b580e94-0064-47b6-a0cc-d8f7bd84b037"
      unitRef="U_shares">1891000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      decimals="-3"
      id="F_c9fac4aa-ee4d-46c8-b6d6-a9bc7931b1bc"
      unitRef="U_shares">34458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_51a400fc-4b58-4aa1-9459-3c9f19c825dc"
      decimals="-3"
      id="F_b0f7528b-78fc-421c-b805-abc63570ff95"
      unitRef="U_shares">31098000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_209ac247-f4da-48ad-b38e-54a110a57637">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Employee benefit plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2019, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The Company matches each participant&#x2019;s 401(k) contributions, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per year per participant.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_e5f766dc-31ca-402b-9dbd-c586a549b71f"
      decimals="INF"
      id="F_70d87741-addf-4332-b8c8-4b2cc9c5d8c5"
      unitRef="U_USD">4000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_083ca282-bf9a-4088-a941-827319b84476">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During our last fiscal quarter, the following officer, as defined in Rule 16a-1(f), adopted a &#x201c;Rule 10b5-1 trading arrangement&#x201d; as defined in Regulation S-K Item 408, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 5, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nathan Hardy&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, adopted a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; providing for the sale from time to time of an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,813&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of options. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 15, 2026, or earlier if all transactions under the trading arrangement are completed. On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 13, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Mr. Hardy&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; terminated a separate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; providing for the sale from time to time of an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,236&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,692&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of options. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until April 20, 2024, or earlier if all transactions under the trading arrangement were completed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No other officers or directors, as defined in Rule 16a-1(f), &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and/or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or a &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as defined in Regulation S-K Item 408, during the last fiscal quarter.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee"
      id="F_2401d043-3f35-4948-8ac9-ab5e79176758">March 5, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee"
      id="F_b31e089e-8d14-4c76-bbe7-c168c079645f">Nathan Hardy</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee"
      id="F_4bd5bf51-b897-4e00-bd50-8f3517d68ac2">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_1e125326-33fa-46ec-a521-b916a2ec4dee"
      id="F_905f05bb-4a08-4af7-bfdd-abcd94c9fb0f">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_a16970d7-1af4-4067-88b3-324a3854a541"
      decimals="0"
      id="F_1e159c8e-110c-4ff4-a9a7-5d0c043aa225"
      unitRef="U_shares">76125</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_cca9dd29-2dba-4680-84e1-d43e2ddb90e4"
      decimals="0"
      id="F_49d244dc-3c73-4276-bd7e-2ab995077f9a"
      unitRef="U_shares">23813</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrTerminationDate
      contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1"
      id="F_a7ded5a1-850d-4887-a3cb-599c2e843352">March 13, 2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName
      contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1"
      id="F_27a21dc0-e46a-4241-b993-8d3bb8e70fec">Mr. Hardy</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_71c59ec2-dfdf-4a24-8476-db61ff9189b1"
      id="F_76df8f33-9e07-41b8-b08c-4d6e475d50b1">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_a197803e-4cdd-43c1-9127-6f070156a3c2"
      decimals="0"
      id="F_63506a92-35e0-4738-9dbe-ef7a0efb7ba6"
      unitRef="U_shares">140236</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_e48bacc4-19a5-4b6d-bd4a-f5ea9f59378a"
      decimals="0"
      id="F_6889dbac-0135-40a6-bd8b-140f64c3c3ff"
      unitRef="U_shares">76692</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_fc720b9c-2813-4524-8f2b-b68213d1eb88">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_d7fb71d1-e00f-4e2b-920e-57ea32147f7d">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_5f3ea77d-2d6a-4ade-bbcb-e13b9f227713">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_be1d75be-894d-4c8e-a248-7743778c933d"
      id="F_3e4f0726-cc83-44c3-9186-8346c32b80e7">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
